
--- Fim da P√°gina 1 ---


--- Fim da P√°gina 2 ---

P O C K E T
NOTEBOOK
Pocket
MEDICINE
Fourth Edition
Edited by
MARC S. SABATINE, M.D., M.P.H.
ASSOCIATE PROFESSOR OF MEDICINE
HARVARD MEDICAL SCHOOL
The Massachusetts General Hospital
Handbook of Internal Medicine

--- Fim da P√°gina 3 ---

Acquisitions Editor: Sonya Seigafuse
Product Manager: Kerry Barrett
Production Manager: Bridgett Dougherty
Senior Manufacturing Manager: Benjamin Rivera
Marketing Manager: Kim Schonberger
Design Coordinator: Doug Smock
Production Service: Aptara
¬© 2011 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER
business
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103 USA
LWW.com
All rights reserved.This book is protected by copyright. No part of this book may 
be reproduced in any form by any means, including photocopying, or utilized by any
information storage and retrieval system without written permission from the copyright
owner, except for brief quotations embodied in critical articles and reviews. Materials
appearing in this book prepared by individuals as part of their official duties as U.S.
government employees are not covered by the above-mentioned copyright.
Printed in China
Library of Congress Cataloging-in-Publication Data
Pocket medicine / edited by Marc S. Sabatine.‚Äì4th ed.
p. ; cm.
‚ÄúThe Massachusetts General Hospital Handbook of Internal Medicine.‚Äù
Includes bibliographical references and index.
ISBN-13: 978-1-60831-905-3 (domestic : alk. paper)
ISBN-10: 1-60831-905-9 (domestic : alk. paper)
ISBN-13: 978-1-4511-0335-9 (international : alk. paper)
ISBN-10: 1-4511-0335-2 (international : alk. paper)
1. Internal medicine‚ÄìHandbooks, manuals, etc. I. Sabatine, Marc S.
II. Massachusetts General Hospital.
[DNLM: 1. Internal Medicine‚ÄìHandbooks. 2. Clinical
Medicine‚ÄìHandbooks.
WB 39 P7394 2011]
RC55.P63 2011
616‚Äìdc22
2010024523
DISCLAIMER Care has been taken to confirm the accuracy of the information presented
and to describe generally accepted practices. However, the authors, editors, and publisher
are not responsible for errors or omissions or for any consequences from application of the
information in this book and make no warranty, expressed or implied, with respect to
the currency, completeness, or accuracy of the contents of the publication. Application
of the information in a particular situation remains the professional responsibility of the
practitioner.
The authors, editors, and publisher have exerted every effort to ensure that drug
selection and dosage set forth in this text are in accordance with current recommenda-
tions and practice at the time of publication.However,in view of ongoing research,changes
in government regulations, and the constant flow of information relating to drug therapy
and drug reactions, the reader is urged to check the package insert for each drug for any
change in indications and dosage and for added warnings and precautions.This is particu-
larly important when the recommended agent is a new or infrequently employed drug.
Some drugs and medical devices presented in the publication have Food and Drug
Administration (FDA) clearance for limited use in restricted research settings. It is the
responsibility of the health care provider to ascertain the FDA status of each drug or
device planned for use in their clinical practice.
To purchase additional copies of this book, call our customer service department at
(800) 638-3030 or fax orders to (301) 223-2320. International customers should call
(301) 223-2300.
Visit Lippincott Williams & Wilkins on the Internet: at LWW.com. Lippincott Williams
& Wilkins customer service representatives are available from 8:30 am to 6 pm, EST.
10 9 8 7 6 5 4 3 2 1

--- Fim da P√°gina 4 ---

CONTENTS
Contributing Authors
vi
Foreword
ix
Preface
x
CARDIOLOGY
Rajat Gupta,Viviany R.Taqueti, David M. Dudzinski, Rory B.Weiner,
Michelle O‚ÄôDonoghue, Marc S. Sabatine
Electrocardiography
1-1
Chest Pain
1-3
Noninvasive Evaluation of CAD
1-4
Coronary Angiography and Revascularization
1-5
Acute Coronary Syndromes
1-6
PA Catheter and Tailored Therapy
1-12
Heart Failure
1-14
Cardiomyopathies
1-17
Valvular Heart Disease
1-20
Pericardial Disease
1-25
Hypertension
1-28
Aortic Aneurysm
1-30
Acute Aortic Syndromes
1-31
Arrhythmias
1-32
Atrial Fibrillation
1-35
Syncope
1-37
Intracardiac Devices
1-39
Cardiac Risk Assessment for Noncardiac Surgery
1-40
PULMONARY
Mary Berlik Rice, Kathryn A. Hibbert,Atul Malhotra
Dyspnea
2-1
Pulmonary Function Tests (PFTs)
2-1
Asthma
2-2
Chronic Obstructive Pulmonary Disease
2-5
Hemoptysis
2-7
Solitary Pulmonary Nodule
2-7
Obstructive Sleep Apnea (OSA)
2-8
Interstitial Lung Disease
2-9
Pleural Effusion
2-11
Venous Thromboembolism (VTE)
2-13
Pulmonary Hypertension (PHT)
2-16
Respiratory Failure
2-18
Mechanical Ventilation
2-19
Acute Respiratory Distress Syndrome
2-22
Sepsis
2-23
GASTROENTEROLOGY
Louis J. Cohen,Andrew S. de Lemos, Lawrence S. Friedman
Esophageal and Gastric Disorders
3-1
Gastrointestinal Bleeding
3-3
Diarrhea, Constipation, and Ileus
3-5
Diverticular Disease
3-9
Inflammatory Bowel Disease
3-10

--- Fim da P√°gina 5 ---

Intestinal Ischemia
3-12
Pancreatitis
3-13
Abnormal Liver Tests
3-15
Hepatitis
3-17
Acute Liver Failure
3-20
Cirrhosis
3-21
Hepatic Vascular Disease
3-25
Ascites
3-26
Biliary Tract Disease
3-27
NEPHROLOGY
Andrew L. Lundquist, Eugene P. Rhee, Hasan Bazari
Acid-Base Disturbances
4-1
Sodium and Water Homeostasis
4-6
Potassium Homeostasis
4-10
Renal Failure
4-12
Glomerular Disease
4-16
Urinalysis
4-18
Nephrolithiasis
4-19
HEMATOLOGY-ONCOLOGY
Andrew J. Aguirre, Franklin W. Huang, David B. Sykes, David T. Ting,
Daniel J. DeAngelo, David P. Ryan
Anemia
5-1
Disorders of Hemostasis
5-6
Platelet Disorders
5-7
Coagulopathies
5-10
Hypercoagulable States
5-11
Disorders of Leukocytes
5-12
Transfusion Therapy
5-13
Myelodysplastic Syndromes (MDS)
5-14
Myeloproliferative Neoplasms (MPN)
5-15
Leukemia
5-17
Lymphoma
5-21
Plasma Cell Dyscrasias
5-24
Hematopoietic Stem Cell Transplantation (HSCT)
5-26
Lung Cancer
5-28
Breast Cancer
5-30
Prostate Cancer
5-32
Colorectal Cancer (CRC)
5-33
Pancreatic Tumors
5-35
Oncologic Emergencies
5-36
Cancer of Unknown Primary Site
5-37
INFECTIOUS DISEASES
Roby P. Bhattacharyya, Rachel P. Simmons, Nesli Basgoz
Pneumonia
6-1
Fungal Infections
6-3
Infections in Susceptible Hosts
6-4
Urinary Tract Infections (UTI)
6-5
Soft Tissue and Bone Infections
6-6
Infections of the Nervous System
6-9
Bacterial Endocarditis
6-12
Tuberculosis
6-15

--- Fim da P√°gina 6 ---

HIV/AIDS
6-17
Tick-Borne Diseases
6-21
Fever of Unknown Origin (FUO)
6-23
ENDOCRINOLOGY
Alaka Ray, Geoffrey A.Walford, Michael Mannstadt
Pituitary Disorders
7-1
Disorders of Multiple Endocrine Systems
7-2
Thyroid Disorders
7-3
Adrenal Disorders
7-7
Calcium Disorders
7-11
Diabetes Mellitus
7-13
Lipid Disorders
7-16
RHEUMATOLOGY
Gwen C. Crevensten, Katherine P. Liao, Robert P. Friday
Arthritis‚ÄîOverview
8-1
Rheumatoid Arthritis (RA)
8-3
Relapsing Polychondritis
8-4
Crystal Deposition Arthritides
8-5
Seronegative Spondyloarthritis
8-7
Infectious Arthritis & Bursitis
8-9
Connective Tissue Diseases
8-11
Systemic Lupus Erythematosus (SLE)
8-15
Vasculitis
8-17
Cryoglobulinemia
8-21
Amyloidosis
8-22
NEUROLOGY
David Y. Hwang,Atul Maheshwari, Mikael L. Rinne, David M. Greer
Change in Mental Status
9-1
Seizures
9-3
Alcohol Withdrawal
9-5
Stroke
9-6
Weakness & Neuromuscular Dysfunction
9-8
Headache
9-10
Back and Spinal Cord Disease
9-11
APPENDIX
ACLS Algorithms
10-1
ICU Medications
10-4
Antibiotics
10-6
Formulae and Quick Reference
10-7
ABBREVIATIONS
11-1
INDEX
I-1
PHOTO INSERTS
Radiology
P-1
Echocardiography
P-9
Coronary Angiography
P-13
Peripheral Blood Smears
P-13
Leukemias
P-14
Urinalysis
P-15

--- Fim da P√°gina 7 ---

CONTRIBUTING AUTHORS
Andrew J. Aguirre, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
Nesli Basgoz, MD
Associate Chief and Clinical Director, Infectious Disease Division,
Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
Hasan Bazari, MD
Attending Physician, Nephrology Unit, Massachusetts General Hospital
Program Director, Internal Medicine Residency, Massachusetts 
General Hospital
Associate Professor of Medicine, Harvard Medical School
Roby P. Bhattacharyya, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
Louis J. Cohen, MD
Internal Medicine Resident, Massachusetts General Hospital
Gwen C. Crevensten, MD
Internal Medicine Resident, Massachusetts General Hospital
Andrew S. de Lemos, MD
Gastroenterology Fellow, Massachusetts General Hospital
Daniel J. DeAngelo, MD, PhD
Clinical Director, Adult Leukemia Program, Dana-Farber Cancer
Institute & Brigham and Women‚Äôs Hospital
Associate Professor of Medicine, Harvard Medical School
David M. Dudzinski, MD, JD
Cardiology Fellow, Massachusetts General Hospital
Robert P. Friday, MD, PhD
Attending Physician, Rheumatology Unit, Massachusetts General Hospital
Associate Director, Rheumatology Fellowship Program, Massachusetts
General Hospital
Instructor in Medicine, Harvard Medical School
Lawrence S. Friedman, MD
Chair, Department of Medicine, Newton-Wellesley Hospital
Assistant Chief of Medicine, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
Professor of Medicine,Tufts University School of Medicine
David M. Greer, MD, MA
Director, Neurological Consultation Service, Massachusetts General
Hospital
Program Director, Partners Neurology Residency Program
Associate Professor of Neurology, Harvard Medical School

--- Fim da P√°gina 8 ---

Rajat Gupta, MD
Internal Medicine Resident, Massachusetts General Hospital
Kathryn A. Hibbert, MD
Pulmonary and Critical Care Fellow, Harvard Medical School
Franklin W. Huang, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
David Y. Hwang, MD
Neurology Resident, Partners Neurology Residency
Katherine P. Liao, MD, MPH
Rheumatology Fellow, Brigham and Women‚Äôs Hospital
Andrew L. Lundquist, MD
Internal Medicine Resident, Massachusetts General Hospital
Atul Maheshwari, MD
Neurology Resident, Partners Neurology Residency
Atul Malhotra, MD
Associate Physician, Divisions of Pulmonary & Critical Care and Sleep
Medicine, Brigham and Women‚Äôs Hospital
Medical Director of the Brigham Sleep Disorders Program
Associate Professor of Medicine, Harvard Medical School
Michael Mannstadt, MD
Assistant Physician, Endocrine Unit, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Michelle O‚ÄôDonoghue, MD, MPH
Investigator,TIMI Study Group and Associate Physician, Cardiovascular
Division, Brigham and Women‚Äôs Hospital
Affiliate Physician, Cardiology Division, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Alaka Ray, MD
Internal Medicine Resident, Massachusetts General Hospital
Eugene P. Rhee, MD
Nephrology Fellow, BWH/MGH Joint Nephrology Fellowship Program
Mary Berlik Rice, MD
Internal Medicine Resident, Massachusetts General Hospital
Mikael L. Rinne, MD, PhD
Neurology Resident, Partners Neurology Residency
David P. Ryan, MD
Clinical Director, Massachusetts General Hospital Cancer Center
Associate Chief of Hematology/Oncology, Massachusetts General
Hospital
Associate Professor of Medicine, Harvard Medical School

--- Fim da P√°gina 9 ---

Marc S. Sabatine, MD, MPH
Vice Chair,TIMI Study Group and Associate Physician, Cardiovascular
Division, Brigham and Women‚Äôs Hospital
Affiliate Physician, Cardiology Division, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
Rachel P. Simmons, MD
Infectious Disease Fellow, Massachusetts General Hospital and Brigham
and Women‚Äôs Hospital
David B. Sykes, MD, PhD
Hematology-Oncology Fellow, Dana-Farber/Partners CancerCare
Hematology/Oncology Program
Viviany R.Taqueti, MD
Internal Medicine Resident, Massachusetts General Hospital
David T.Ting, MD
Hematology-Oncology Fellow, Dana-Farber/Partners CancerCare
Hematology/Oncology Program
Geoffrey A.Walford, MD
Endocrinology Fellow, Massachusetts General Hospital
Rory B.Weiner, MD
Cardiology Fellow, Massachusetts General Hospital

--- Fim da P√°gina 10 ---

FOREWORD
To the 1st Edition
It is with the greatest enthusiasm that I introduce Pocket Medicine. In an
era of information glut, it will logically be asked,‚ÄúWhy another manual
for medical house officers?‚Äù Yet, despite enormous information readily
available in any number of textbooks, or at the push of a key on a com-
puter, it is often that the harried house officer is less helped by the
description of differential diagnosis and therapies than one would wish.
Pocket Medicine is the joint venture between house staff and faculty
expert in a number of medical specialties.This collaboration is designed
to provide a rapid but thoughtful initial approach to medical problems
seen by house officers with great frequency. Questions that frequently
come from faculty to the house staff on rounds, many hours after the
initial interaction between patient and doctor, have been anticipated and
important pathways for arriving at diagnoses and initiating therapies are
presented.This approach will facilitate the evidence-based medicine dis-
cussion that will follow the workup of the patient.This well-conceived
handbook should enhance the ability of every medical house officer to
properly evaluate a patient in a timely fashion and to be stimulated to
think of the evidence supporting the diagnosis and the likely outcome of
therapeutic intervention. Pocket Medicine will prove to be a worthy addi-
tion to medical education and to the care of our patients.
DENNIS A. AUSIELLO, MD
Physician-in-Chief, Massachusetts General Hospital
Jackson Professor of Clinical Medicine, Harvard Medical School

--- Fim da P√°gina 11 ---

PREFACE
For Jenny, Matteo, and Natalie with love
Written by residents, fellows, and attendings, the mandate for Pocket
Medicine was to provide,in a concise a manner as possible,the key infor-
mation a clinician needs for the initial approach to and management of
the most common inpatient medical problems.
The tremendous response to the previous editions suggests we
were able to help fill an important need for clinicians.With this fourth
edition come several major improvements including: a thorough updat-
ing of every topic; the addition of several new topics (including acute
aortic syndromes, sepsis, obstructive sleep apnea, hepatic vascular dis-
ease, optimal use of diuretics, viral respiratory infections, infections in
susceptible hosts, intensive glycemic control, approach to the patient
with joint pain, and alcohol withdrawal); incorporation of references to
the most recent reviews and important studies published through the
middle of 2010; and the addition of high-resolution chest radiographs,
chest and abdominal CTs, and echocardiograms, and photomicrographs
of peripheral blood smears and urinalyses.We welcome any suggestions
for further improvement.
Of course medicine is far too vast a field to ever summarize in a
textbook of any size. Long monographs have been devoted to many of
the topics discussed herein. Pocket Medicine is meant only as a starting
point to guide one during the initial phases of diagnosis and management
until one has time to consult more definitive resources. Although the
recommendations herein are as evidence-based as possible, medicine is
both a science and an art.As always, sound clinical judgement must be
applied to every scenario.
I am grateful for the support of the house officers, fellows, and
attendings at the Massachusetts General Hospital.It is a privilege to work
with such a knowledgeable,dedicated,and compassionate group of physi-
cians. I always look back on my time there as Chief Resident as one of
the best experiences I have ever had. I am grateful to several outstanding
clinical mentors, including Hasan Bazari, Denny Ausiello, Larry Friedman,
Nesli Basgoz, Mort Swartz, Eric Isselbacher, Bill Dec, Mike Fifer, and
Roman DeSanctis, as well as the late Charlie McCabe and Peter Yurchak.
Special thanks to my parents for their perpetual encouragement and love
and, of course, to my wife, Jennifer Tseng, who, despite being a surgeon, is
my closest advisor, my best friend, and the love of my life.
I hope that you find Pocket Medicine useful throughout the arduous
but incredibly rewarding journey of practicing medicine.
MARC S. SABATINE, MD, MPH

--- Fim da P√°gina 12 ---

ELECTROCARDIOGRAPHY
Approach (a systematic approach is vital) 
‚Ä¢ Rate (? tachy, brady) and rhythm (? relationship between P and QRS)
‚Ä¢ Intervals (PR, QRS, QT) and axis (? LAD or RAD)
‚Ä¢ Chamber abnormality (? LAA and/or RAA, ? LVH and/or RVH)
‚Ä¢ QRST changes (? Q waves, poor R-wave progression V1‚ÄìV6, ST c/T, or T-wave s)
Left axis deviation (LAD)
‚Ä¢ Definition: axis beyond ‚Äì30 (S  R in lead II)
‚Ä¢ Etiologies: LVH, LBBB, inferior MI,WPW
‚Ä¢ Left anterior fascicular block: LAD (‚Äì45 to
‚Äì90) and qR in aVL and QRS 120 msec and
no other cause of LAD (eg, IMI)
Right axis deviation (RAD)
‚Ä¢ Definition: axis beyond 90 (S  R in lead I)
‚Ä¢ Etiologies: RVH, PE, COPD (usually not 110),
septal defects, lateral MI,WPW
‚Ä¢ Left posterior fascicular block: RAD (90‚Äì180)
and rS in I & aVL and qR in III & aVF and
QRS 120 msec and no other cause of RAD
Bundle Branch Blocks (Circ 2009;119:e235)
Initial depol. is left-to-right across septum (r in V1 & q in V6;
Normal
nb, absent in LBBB) followed by LV & RV free wall, with LV
dominating (nb, RV depol. later and visible in RBBB).
RBBB
1. QRS 120 msec (110‚Äì119  incomplete)
2. rSR‚Äô in R precordial leads (V1,V2)
3. Wide S wave in I and V6
4.
	 STT or TWI in R precordial leads
LBBB
1. QRS 120 msec (110‚Äì119  incomplete)
2. Broad, slurred, monophasic R in I, aVL,V5‚ÄìV6 (	 RS in 
V5‚ÄìV6 if cardiomegaly)
3. Absence of Q in I,V5, and V6 (may have narrow q in aVL)
4. Displacement of ST & Tw opposite major QRS deflection
5.
	 PRWP, LAD, Qw‚Äôs in inferior leads
Bifascicular block: RBBB  LAFB/LPFB
Prolonged QT interval (JAMA 2003;289:2120; NEJM 2004;350:1013; www.torsades.org)
‚Ä¢ QT measured from beginning of QRS complex to end of T wave (measure longest QT)
‚Ä¢ QT varies w/ HR S correct w/ Bazett formula: QTc  QT/
(in sec),
formula inaccurate at very high and low HR (nl QTc 450 msec  and 460 msec )
‚Ä¢ Etiologies:
Antiarrhythmics: class Ia (procainamide, disopyramide), class III (amiodarone, sotalol)
Psych drugs: antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI,TCA
Antimicrobials: macrolides, quinolones, voriconazole, pentamidine, atovaquone,
chloroquine, amantadine, foscarnet, atazanavir, ? TMP-SMX
Other: antiemetics (droperidol, 5-HT3 antagonists), alfuzosin, methadone, ranolazine
Electrolyte disturbances: hypoCa, ? hypoK, ? hypoMg
Autonomic dysfxn: ICH (deep TWI), stroke, carotid endarterectomy, neck dissection
Congenital (long QT syndrome): K, Na, Ca channelopathies (Lancet 2008;372:750)
Misc: CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia
Left Atrial Abnormality (LAA)
Right Atrial Abnormality (RAA)
ECG
P wave
Criteria
Left ventricular hypertrophy (LVH) (Circ 2009;119:e251)
‚Ä¢ Etiologies: HTN,AS/AI, HCMP, coarctation of aorta
‚Ä¢ Criteria (all w/ Se 50%, Sp 85%)
Romhilt-Estes point-score system: 4 points  probable, 5 points  definite
cAmplitude (any of the following):largest R or S in limb leads 20 mm or S in V1 or V2
30 mm or R in V5 or V6 30 mm (3 points)
1RR
V
V
I  0¬∞
II
+60¬∞
III
+120¬∞
aVL
‚àí30¬∞
aVF
+90¬∞
aVR
‚àí150¬∞
‚àí90¬∞
¬±180¬∞
LAD
RAD
normal
axis
Figure 1-1 QRS axis
>120 msec
>40 msec
II
V
or
>1 mm
II
V1
or
>1.5 mm
>2.5 mm
ECG
1-1

--- Fim da P√°gina 13 ---

ST displacement opposite to QRS deflection: w/o dig (3 points); w/ dig (1 point)
LAA (3 points); LAD (2 points); QRS duration 90 msec (1 point)
Intrinsicoid deflection (QRS onset to peak of R) in V5 or V6 50 msec (1 point)
Sokolow-Lyon: S in V1  R in V5 or V6 35 mm
Cornell: R in aVL  S in V3 28 mm in men or 20 mm in women
Other: R in aVL 11 mm (or, if LAD/LAFB, 13 mm and S in III 15 mm)
Right ventricular hypertrophy (RVH) (Circ 2009;119:e251)
‚Ä¢ Etiologies: cor pulmonale, congenital (tetralogy,TGA, PS,ASD,VSD), MS,TR
‚Ä¢ Criteria (all tend to be insensitive, but highly specific, except in COPD)
R  S in V1 or R in V1 7 mm, S in V5 or V6 7 mm, drop in R/S ratio across precordium
RAD 110 (LVH  RAD or prominent S in V5 or V6 S biventricular hypertrophy)
Ddx of dominant R wave in V1 or V2
‚Ä¢ Ventricular enlargement: RVH (RAD, RAA, deep S waves in I,V5,V6); HCMP
‚Ä¢ Myocardial injury: true posterior MI (often IMI); Duchenne muscular dystrophy
‚Ä¢ Abnormal depolarization: RBBB (QRS 120 msec, rSR‚Äô);WPW (T PR, 
 wave, c QRS)
‚Ä¢ Other: dextroversion; lead misplacement; normal variant
Poor R-wave progression (PRWP) (Archives 1982;142:1145)
‚Ä¢ Definition: loss of anterior forces w/o frank Q waves (V1‚ÄìV3); R wave in V3 3 mm
‚Ä¢ Etiologies:
old anteroseptal MI (usually R wave V3 1.5 mm, 	 persistent ST c or TWI V2 & V3)
cardiomyopathy 
LVH (delayed RWP with prominent left precordial voltage)
RVH/COPD (small R wave and prominent S wave in lead I)
LBBB;WPW; clockwise rotation of the heart; lead misplacement
Pathologic Q waves
‚Ä¢ Definition: 30 msec or 25% height of the R wave in that complex
‚Ä¢ Small (septal) q waves in I, aVL,V5 & V6 are normal, as can be isolated Qw in III, aVR,V1
‚Ä¢ ‚ÄúPseudoinfarct‚Äù pattern may be seen in LBBB, infiltrative disease, HCMP, COPD, PTX,WPW
ST elevation (STE) (NEJM 2003;349:2128; Circ 2009;119:e241, e262)
‚Ä¢ Acute MI (upward convexity 	 TWI) or prior MI with persistent STE
‚Ä¢ Coronary spasm (Prinzmetal‚Äôs angina; transient STE in a coronary distribution)
‚Ä¢ Myopericarditis (diffuse, upward concavity STE; a/w PR T;Tw usually upright)
‚Ä¢ HCMP, Takotsubo CMP, ventricular aneurysm, cardiac contusion 
‚Ä¢ Pulmonary embolism (occ. STE V1‚ÄìV3; typically associated TWI V1‚ÄìV4, RAD, RBBB)
‚Ä¢ Repolarization abnormalities
LBBB (c QRS duration, STE discordant from QRS complex)
dx of STEMI in setting of LBBB: 1 mm STE concordant w/ QRS (Se 73%, Sp 92%)
or 5 mm discordant (Se 31%, Sp 92%) (‚ÄúSgarbossa criteria,‚Äù NEJM 1996;334:481)
LVH (c QRS amplitude); Brugada syndrome (rSR‚Äô, downsloping STE V1‚ÄìV2)
Hyperkalemia (c QRS duration, tall Ts, no Ps)
‚Ä¢ Early repolarization: most often seen in leads V2‚ÄìV5 and in young adults 
J point c 1‚Äì4 mm; notch in downstroke of R wave; upward concavity of ST; large Tw;
ratio of STE / T wave amplitude 25%; pattern may disappear with exercise
early repol in inf leads may be a/w c risk of VF, but absolute risk low (NEJM 2009;361:2529)
ST depression (STD)
‚Ä¢ Myocardial ischemia (	 Tw abnl) or acute true posterior MI (V1‚ÄìV3)
‚Ä¢ Digitalis effect (downsloping ST 	 Tw abnl, does not correlate w/ dig levels)
‚Ä¢ Hypokalemia (	 U wave)
‚Ä¢ Repolarization abnl in a/w LBBB or LVH (usually in leads V5,V6, I, aVL)
T wave inversion (TWI; generally 1 mm; deep if 5 mm) (Circ 2009;119:e241)
‚Ä¢ Ischemia or infarct;Wellens‚Äô sign (deep early precordial TWI) S proximal LCA lesion
‚Ä¢ Myopericarditis; CMP (incl Takotsubo & ARVD); MVP; PE (especially if TWI V1‚ÄìV4)
‚Ä¢ Repolarization abnl in a/w LVH/RVH (‚Äústrain pattern‚Äù), BBB
‚Ä¢ Post-tachycardia or post-pacing
‚Ä¢ Electrolyte, digoxin, PaO2, PaCO2, pH, or core temperature disturbances
‚Ä¢ Intracranial bleed (‚Äúcerebral T waves,‚Äù usually w/ c QT)
‚Ä¢ Normal variant in children (V1‚ÄìV4) and leads in which QRS complex predominantly ;
profound TWI in young athletes may predict future risk of CMP (NEJM 2008;358:152)
Low voltage
‚Ä¢ QRS amplitude (R  S) 5 mm in all limb leads & 10 mm in all precordial leads
‚Ä¢ Etiologies: COPD (precordial leads only), pericardial effusion, myxedema, obesity,
pleural effusion, restrictive or infiltrative CMP, diffuse CAD
ECG
1-2

--- Fim da P√°gina 14 ---

CHEST PAIN
1-3
CHEST PAIN
Cardiac Causes
Disorder
Typical Characteristics & Diagnostic Studies
Unstable 
Substernal pressure S neck, jaw, L arm; 30. 	 Dyspnea, diaphoresis,
angina
N/V. c w/ exertion; T w/ NTG or rest; however, relief by NTG in ED not 
reliable indicator of angina (Annals EM 2005;45:581). 	 ECG s (ST T/c,TWI).
MI
Same as angina but c intensity & duration.  troponin or CK-MB.
Pericarditis
Sharp pain S trapezius, c w/ respiration, T w/ sitting forward. 	 Pericardial
& Myo-
friction rub. ECG s (diffuse STE & PR T). 	 Pericardial effusion.
pericarditis
If myocarditis, same as above  c Tn and 	 s/s CHF and T EF.
Aortic
Abrupt onset severe tearing, knifelike pain (absence LR 0.3), ant or post 
dissection
mid-scapular. HTN or HoTN. 	 Asymmetric (20 mmHg) BP or pulse 
deficit (LR 5.7), focal neuro deficit (LR 6), AI, widened mediastinum 
on CXR (absence LR 0.3); false lumen on imaging. (JAMA 2002;287:2262)
Pulmonary Causes
Disorder
Typical Characteristics & Diagnostic Studies
Pneumonia
Pleuritic; dyspnea, fever, cough, sputum. c RR, crackles. CXR infiltrate.
Pleuritis
Sharp, pleuritic pain. 	 Pleuritic friction rub.
PTX
Sudden onset, sharp pleuritic pain. Hyperresonance, T BS. PTX on CXR.
PE
Sudden onset pleuritic pain. c RR & HR, T SaO2, ECG s (RAD, RBBB,
TWI V1‚ÄìV4, occ STE V1‚ÄìV3).  CTA.
PHT
Exertional pressure, dyspnea. T SaO2, loud P2, right-sided S3 and/or S4.
GI Causes
Disorder
Typical Characteristics & Diagnostic Studies
Esophageal
Substernal burning, acid taste in mouth, water brash. c by meals,
reflux
recumbency; T by antacids. EGD, manometry, pH monitoring.
Esoph spasm
Intense substernal pain. c by swallowing, T by NTG/CCB. Manometry.
Mallory-Weiss
Precipitated by vomiting. EGD.
Boerhaave
Precipitated by vomiting. Severe pain, c w/ swallowing. Palpable SC
syndrome
emphysema; mediastinal air on chest CT.
PUD
Epigastric pain, relieved by antacids. 	 GIB. EGD, 	 H. pylori test.
Biliary dis.
RUQ pain, nausea/vomiting. c by fatty foods. RUQ U/S, LFTs.
Pancreatitis
Epigastric/back discomfort. c amylase & lipase; abd CT.
Musculoskeletal and Miscellaneous Causes
Disorder
Typical Characteristics & Diagnostic Studies
Chostochondritis
Localized sharp pain. c w/ movement. Reproduced by palpation.
Herpes zoster
Intense unilateral pain. Dermatomal rash & sensory findings.
Anxiety
‚ÄúTightness‚Äù
Initial approach
‚Ä¢ Focused history: quality & severity of pain; location & radiation; provoking & palliating 
factors; duration, frequency & pattern; setting in which it occurred; associated sx
‚Ä¢ Targeted exam: VS (including BP in both arms), cardiac gallops, murmurs, or rubs;
signs of vascular disease (carotid or femoral bruits, T pulses), signs of heart failure;
lung & abdominal exam; chest wall exam for reproducibility of pain
‚Ä¢ 12-lead ECG: obtain w/in 10 min; c/w priors & obtain serial ECGs; consider posterior
leads (V7‚ÄìV9) to reveal isolated posterior MI if hx c/w ACS but ECG unrevealing
‚Ä¢ Cardiac biomarkers (Tn, CK-MB): serial testing at presentation, 6‚Äì12 h after sx onset
troponin (I/T): most Se & Sp marker; level 99th %ile in approp. clinical setting is dx of MI
detectable 3‚Äì6 h after injury, peaks 24 h, may remain elevated for 7‚Äì10 d in STEMI
high-sens. assays: 90‚Äì95% Se & Sp; 85% Se w/in 3 h of sx onset (NEJM 2009;361:858, 868)
‚Äúfalse ‚Äù (non-ACS myonecrosis): myocarditis/toxic CMP, severe CHF, HTN crisis, PE
or severe resp. distress, cardiac trauma/cardioversion, sepsis, SAH, demand ischemia;
? renal failure (T clearance, skeletal myopathy vs. true microinfarctions)
CK-MB: less Se & Sp (skel. muscle, tongue, diaphragm, intestine, uterus, prostate)
‚Ä¢ CXR; other imaging (echo, PE CTA, etc.) as indicated based on H&P and initial testing
‚Ä¢ Coronary CT angiography: 1‚ÅÑ2 free of CAD S 0% w/ ACS; 1‚ÅÑ2 w/ plaque S 17% w/ ACS;
even with signif stenosis, only 35% w/ ACS (JACC 2009;53:1642). ‚à¥good for r/o not r/i.

--- Fim da P√°gina 15 ---

STRESS TEST
1-4
NONINVASIVE EVALUATION OF CAD
Test
Sens
Spec
Pros
Cons
ETT
60%
75%
Exercise capacity; no 
Limited Sens (50% for 1VD,
(w/ ECG only)
radiation; low cost
but 85% for 3VD/LM)
SPECT/PET
85%
90%
Localizes ischemia; LV fxn Radiation; cost
Echo
85%
95%
Localizes ischemia; LV fxn Operator dependent; cost
& valve data, no radiation
CT Angio
90%
88%
High NPV to r/o CAD
Radiation; contrast; cost 
Exercise tolerance test (stress test) (NEJM 2001;344:1840)
‚Ä¢ Indications: dx CAD, evaluate if known CAD &  in clinical status, risk stratify s/p
ACS, evaluate exercise tolerance, localize ischemia (imaging required)
‚Ä¢ Contraindications
Absolute: AMI w/in 48 h, high-risk UA, acute PE, severe AS, uncontrolled CHF,
uncontrolled arrhythmias, myopericarditis, acute aortic dissection
Relative: left main CAD, mod valvular stenosis, severe HTN, HCMP, high-degree
AVB, severe electrolyte abnl, inability to exercise
‚Ä¢ Exercise: standard Bruce (c speed/incline q3min), modified Bruce (begins w/o tread-
mill incline), submax (if 3 wk post-MI), or sx-limited; hold antianginals if trying to
dx CAD, give if assessing if Pt ischemic on meds
‚Ä¢ Pharmacologic: if unable to exer., low exer. tol or recent MI. Se & Sp  exercise;
Preferred if LBBB. Requires imaging since ECG not specific in this setting. Coronary
vasodilators (will reveal CAD, but not tell you if Pt ischemic): regadenoson, dipyri-
damole, or adenosine (may precipitate bradycardia and bronchospasm).
Chronotropes/inotropes (physiologic): dobutamine (may precipitate tachyarrhythmias).
‚Ä¢ Imaging: used if uninterpretable ECG (paced, LBBB, resting STT 1 mm, dig., LVH,
WPW), after indeterminate ECG test, pharmacologic tests, or localization of ischemia
SPECT (eg, 99mTc-sestamibi), PET (rubidium-82; usually w/ pharm test), echo, MRI
Test results
‚Ä¢ HR (must achieve 85% of max predicted HR [220-age] for exercise test to be dx), BP
response, peak double product (HR  BP), HR recovery (HRpeak‚Äì HR1 min later; nl 12)
‚Ä¢ Max exercise capacity achieved (METS or min)
‚Ä¢ Occurrence of symptoms (at what level of exertion and similarity to presenting sx)
‚Ä¢ ECG changes: downsloping or horizontal ST T (1 mm) predictive of CAD (but dis-
tribution of ST T do not localize ischemic territory); STE highly predictive
‚Ä¢ Duke treadmill score  exercise min ‚Äì (5  max ST dev) ‚Äì (4  angina index) [0 none, 1
nonlimiting, 2 limiting]; score 5 S 1% 1-y mort; ‚Äì10 to 4 S 2‚Äì3%;  ‚Äì11 S 5%
‚Ä¢ Imaging: radionuclide defects or echocardiographic regional wall motion abnormalities
reversible defect  ischemia; fixed defect  infarct
false : breast S ant ‚Äúdefect‚Äù and diaphragm S inf ‚Äúdefect‚Äù
false  may be seen if balanced (eg, 3VD) ischemia (global T perfusion w/o regional s)
ECG-gating allows assessment of LV systolic function
High-risk test results (PPV 50% for LM or 3VD, ‚à¥consider coronary angiography)
‚Ä¢ ECG: ST T 2 mm or 1 mm in stage 1 or in 5 leads or 5 min in recovery; ST c; VT
‚Ä¢ Physiologic: T BP, exercise 4 METS, angina during exercise, Duke score  ‚Äì11; EF 35%
‚Ä¢ Radionuclide: 1 lg or 2 mod. reversible defects, transient LV cavity dilation, c lung uptake
Myocardial viability
‚Ä¢ Goal: identify hibernating myocardium that could regain fxn after revascularization
‚Ä¢ Options: MRI (Se 95%, Sp 70%), PET (Se 90%, Sp 75%), dobutamine stress
echo (Se 70%, Sp 85%); rest-redistribution thallium (Se 90%, Sp 55%)
CT & MR coronary angiography (NEJM 2008;369:2324; Circ 2010;121:2509)
‚Ä¢ Image quality best at slower & regular HR (give B if possible, goal HR 55‚Äì60)
‚Ä¢ Calcium generates artifact for CT angiography
‚Ä¢ MRI being studied: angiography, perfusion, LV fxn, hyperenhancement (Circ 2009;119:1671)
Coronary artery calcium score (CACS, NEJM 2008;358:1336; JAMA 2010;303:1610)
‚Ä¢ Quantitative evaluation of extent of calcium and thus estimate of plaque burden
‚Ä¢ Not able to assess % stenosis of coronary arteries (no IV contrast)
‚Ä¢ ? value in asx Pts w/ intermediate Framingham risk score (10‚Äì20% 10-y risk) w/ CACS of
0, 1‚Äì100, 101‚Äì300, and 300 corresponding to low, average, moderate, and high risk
‚Ä¢ May be of value as screening text to r/o CAD in sx Pt (CACS 100 S 3% probability
of signif CAD; but high scores have poor specificity)

--- Fim da P√°gina 16 ---

ANGIO/PCI
1-5
CORONARY ANGIOGRAPHY AND REVASCULARIZATION
Indications for coronary angiography in stable CAD or asx Pts
‚Ä¢ CCS class III-IV angina despite medical Rx or angina  systolic dysfxn
‚Ä¢ High-risk stress test findings (see prior topic)
‚Ä¢ Uncertain dx after noninvasive testing (& compelling need to determine dx), occupational
need for definitive dx (eg, pilot), or inability to undergo noninvasive testing
‚Ä¢ Systolic dysfxn with unexplained cause
‚Ä¢ Survivor of SCD, polymorphic VT, sustained monomorphic VT
‚Ä¢ Suspected spasm or nonatherosclerotic cause of ischemia (eg, anomalous coronary)
Pre-cath checklist
‚Ä¢ Document peripheral arterial exam (femoral, DP, PT pulses; femoral bruits); NPO 6 h
‚Ä¢ ‚úìCBC, PT, & Cr; give IVF (	 bicarb, acetylcysteine; see ‚ÄúCIAKI‚Äù); blood bank sample
‚Ä¢ ASA 325 mg; consider clopidogrel preRx (300‚Äì600 mg 2‚Äì6 h before) vs. prasugrel
at time of PCI (if ACS)
Coronary revascularization in stable CAD (JACC 2004;44:e213 & 2006;47:e1)
‚Ä¢ CABG: T mortality c/w med Rx (albeit pre statins & ACEI/ARB) in Pts w/ 3VD, LM,
or 2VD w/ critical prox LAD, and espec. if T EF (but viable myocardium); T repeat
revasc and trend toward T D/MI but c stroke c/w PCI in LM/3VD (NEJM 2009;360:961);
CABG vs. PCI being studied in DM (FREEDOM trial)
‚Ä¢ PCI: T angina c/w med Rx; does not T D/MI (COURAGE, NEJM 2007;356:1503); prompt
revasc (PCI or CABG) did not T mortality vs. med Rx in DM (NEJM 2009;360:2503)
‚Ä¢ PCI comparable to CABG in Pts w/o 3VD, w/o DM, and nl EF (Lancet 2009;373:1190)
‚Ä¢ For stable CAD w/o critical anatomy and w/o T EF, initial focus on optimal med Rx
‚Ä¢ If revasc deemed necessary, PCI if limited # of discrete lesions, nl EF, no DM, poor oper-
ative candidate; CABG if extensive or diffuse disease, T EF, DM, or valvular disease
‚Ä¢ Fractional flow reserve [ratio of maximal flow (induced by IV or IC adenosine) distal vs.
proximal to a stenosis]: PCI only if 0.8 S T # stents & T D/MI/revasc (NEJM 2009;360:213)
PCI
‚Ä¢ Balloon angioplasty (POBA): effective, but c/b dissection & elastic recoil & neointimal
hyperplasia S restenosis; now reserved for small lesions & ? some SVG lesions
‚Ä¢ Bare metal stents (BMS): T elastic recoil S 33‚Äì50% T restenosis & repeat revasc (to 
10% by 12 mos) c/w POBA; requires ASA lifelong & clopidogrel  4 wks
‚Ä¢ Drug-eluting stents (DES): T neointimal hyperplasia S 75% T restenosis, 50% T repeat
revasc (to 5% by 1 y), no c D/MI c/w BMS (NEJM 2008;359:1330); 2nd gen. everolimus DES
promising (NEJM 2010;362:1728); require ASA lifelong & clopidogrel  1 y (Circ 2007;115:813)
‚Ä¢ Anticoagulant: UFH (short-acting, rapidly reversible, but need to ‚úìPTT/ACT), LMWH (no
need for monitoring, but t1/2 8‚Äì12 h), bivalirudin (T bleeding, but 	c MI; NEJM 2009;359:688)
Post-PCI complications
‚Ä¢ Postprocedure ‚úìvascular access site, distal pulses, ECG, CBC, Cr, CK-MB
‚Ä¢ Bleeding
hematoma/overt bleeding: manual compression, reverse/stop anticoag
retroperitoneal bleed: may present with T Hct 	 back pain; c HR & T BP late;
Dx: abd/pelvic CT (I‚Äì); Rx: reverse/stop anticoag, IVF/PRBC as required
if bleeding uncontrolled, consult performing interventionalist or surgery
‚Ä¢ Vascular damage
pseudoaneurysm: triad of pain, expansile mass, systolic bruit; Dx: U/S; Rx: manual
compression, U/S-directed compression or thrombin injection, or surgical repair
AV fistula: continuous bruit; Dx: U/S; Rx: surgical repair
T perfusion to LE (embolization, dissection, thrombus): loss of distal pulse; Dx: angio;
Rx: percutaneous or surgical repair
‚Ä¢ Peri-procedural MI: 3 ULN of CK-MB occurs in 5‚Äì10%; Qw MI in 1%
‚Ä¢ Renal failure: contrast-induced manifests w/in 24 h, peaks 3‚Äì5 d (see ‚ÄúCIAKI‚Äù)
‚Ä¢ Cholesterol emboli syndrome (typically in middle-aged & elderly and w/ Ao atheroma)
renal failure (late and progressive, eos in urine); mesenteric ischemia (abd pain,
LGIB, pancreatitis); intact distal pulses but livedo pattern and toe necrosis
‚Ä¢ Stent thrombosis: mins to yrs after PCI, typically p/w AMI. Often due to mechanical
prob. (stent underexpansion or unrecognized dissection, typically presents early) or
d/c of antiplt Rx (espec if d/c both ASA & ADP blocker; JAMA 2005;293: 2126). Risk of
late stent thrombosis may be higher with DES than BMS (JACC 2006;48:2584).
‚Ä¢ In-stent restenosis: mos after PCI, typically p/w gradual c angina (10% p/w ACS).
Due to combination of elastic recoil and neointimal hyperplasia; T w/ DES vs. BMS.

--- Fim da P√°gina 17 ---

ACS
1-6
ACUTE CORONARY SYNDROMES
Myocardial ischemia typically due to atherosclerotic plaque rupture S coronary thrombosis
Spectrum of Acute Coronary Syndromes
Dx
UA
NSTEMI
STEMI
Coronary thrombosis
Subtotal
Total
History
angina that is new-onset, crescendo, or
angina at rest
at rest; usually 30 min
usually 30 min
ECG
	 ST depression and/or TWI
ST elevations
Troponin/CK-MB


 
Ddx (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)
‚Ä¢ Nonatherosclerotic coronary artery disease
Spasm: Prinzmetal‚Äôs variant, cocaine-induced (6% of CP  cocaine use r/i for MI)
Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde
extension (usually involving RCA S IMI), or mechanical (catheter, surgery, trauma)
Embolism: endocarditis, prosthetic valve, mural thrombus, myxoma; thrombosis
Vasculitis: Kawasaki syndrome,Takayasu arteritis, PAN, Churg-Strauss, SLE, RA
Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)
‚Ä¢ Fixed CAD but c myocardial O2 demand (eg, c HR, anemia,AS) S ‚Äúdemand‚Äù ischemia
‚Ä¢ Myocarditis (myocardial necrosis, but not caused by CAD); toxic CMP; cardiac contusion
Clinical manifestations (JAMA 2005;294:2623)
‚Ä¢ Typical angina: retrosternal pressure/pain/tightness 	 radiation to neck, jaw, or arms
precip. by exertion, relieved by rest or NTG; in ACS, new-onset, crescendo, or at rest
‚Ä¢ Associated symptoms: dyspnea, diaphoresis, N/V, palpitations, or lightheadedness
‚Ä¢ Many MIs (20% in older series) are initially unrecognized b/c silent or atypical sx
Physical exam
‚Ä¢ Signs of ischemia: S4, new MR murmur 2 papillary muscle dysfxn, paradoxical S2
‚Ä¢ Signs of heart failure: c JVP, crackles in lung fields,  S3, HoTN, cool extremities
‚Ä¢ Signs of other areas of atherosclerotic disease: carotid or femoral bruits, T distal pulses
Diagnostic studies
‚Ä¢ ECG: ST deviation (depression or elevation),TWI, LBBB not known to be old
Qw or PRWP suggest prior MI and ‚à¥CAD
‚úìECG w/in 10 min of presentation, with any  in sx, and at 6‚Äì12 h; c/w baseline
dx of STEMI in setting of LBBB: 1 mm STE concordant w/ QRS (Se 73%, Sp 92%)
or 5 mm discordant (Se 31%, Sp 92%) in any lead (NEJM 1996;334:481)
Localization of MI
Anatomic Area
ECG Leads w/ STE
Coronary Artery
Septal
V1‚ÄìV2
Proximal LAD
Anterior
V3‚ÄìV4
LAD
Apical
V5‚ÄìV6
Distal LAD, LCx, or RCA
Lateral
I, aVL
LCx
Inferior
II, III, aVF
RCA (85%), LCx (15%)
RV
V1‚ÄìV2 & V4R (most Se)
Proximal RCA
Posterior
ST depressionV1‚ÄìV3
RCA or LCx
If ECG non-dx and suspicion high, consider addt‚Äôl lateral (posterior) leads (V7‚ÄìV9) to further assess LCx territory.
Check right-sided precordial leads in patients with IMI to help detect RV involvement (STE in V4R most Se).
STE in III  STE in II and lack of STE in I or aVL suggest RCA rather than LCx culprit in IMI.
‚Ä¢ Cardiac biomarkers (Tn or CK-MB): serial testing at presentation, 6‚Äì12 h after sx onset;
rise to 99th %ile of reference limit in approp. clinical setting dx of MI (see ‚ÄúChest Pain‚Äù);
nb, in Pts w/ ACS & T CrCl, c Tn S poor prognosis (NEJM 2002;346:2047)
‚Ä¢ CT angiography: ‚àÖsignif stenosis 98% NPV;  only 35% PPV (JACC 2009;53:1642)
‚Ä¢ Echocardiogram: new wall motion abnormality (operator & reader dependent)
Prinzmetal‚Äôs (variant) angina
‚Ä¢ Coronary spasm S transient STE usually w/o MI (but MI,AVB,VT can occur)
‚Ä¢ Pts usually young, smokers, 	 other vasospastic disorders (eg, migraines, Raynaud‚Äôs)
‚Ä¢ Angiography S nonobstructive CAD, focal spasm w/ hyperventilation, acetylcholine
‚Ä¢ Treatment: high-dose CCB, nitrates (SL NTG prn), ? -blockers; d/c smoking
‚Ä¢ Cocaine-induced vasospasm: avoid B as unopposed -stimulation can worsen spasm

--- Fim da P√°gina 18 ---

Likelihood of ACS
Feature
High
Intermediate
Low
(any of below)
(no high features,
(no high/inter. features,
any of below)
may have below)
History
chest or L arm pain
chest or L arm pain
atypical sx (eg, pleuritic,
like prior angina
age 70 y
sharp, or positional pain)
h/o CAD (incl MI)
male, diabetes
Exam
HoTN, diaphoresis,
PAD or CVD
pain reproduced on palp.
CHF, transient MR
ECG
new STD (1 mm)
old Qw, STD (0.5‚Äì0.9 
TWF/TWI (1 mm) in 
TWI in mult leads
mm),TWI (1 mm)
leads w/ dominant R wave
Biomarkers
 Tn or CK-MB
Normal
Normal
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
Approach to triage
‚Ä¢ If hx and initial ECG & biomarkers non-dx, repeat ECG & biomarkers 12 h later
‚Ä¢ If remain nl and low likelihood of ACS, search for alternative causes of chest pain
‚Ä¢ If remain nl & Pt pain-free, have r/o MI, but if suspicion for ACS based on hx, then still
need to r/o UA w/ stress test to assess for inducible ischemia (or CTA to r/o CAD);
if low risk (age 70; √ò prior CAD, CVD, PAD; √ò rest angina) can do as outPt w/in 72 h
(0% mortality, 0.5% MI, Ann Emerg Med 2006;47:427);
if not low risk, admit and evaluate for ischemia (stress test or cath)
‚Ä¢ If ECG or biomarker abnl or high likelihood of ACS, then admit and Rx as per below
UA/NSTEMI (NSTE ACS)
Anti-Ischemic and Other Treatment
Nitrates (SL, PO, topical, or IV)
T anginal sx, no T in mortality
-blockers: PO; IV if ongoing pain,
13% T in progression to MI (JAMA 1988;260:2259)
HTN or c HR (w/o s/s CHF)
Contraindicated if HR 50, SBP 90,
eg, metoprolol 5 mg IV q5 min  3
moderate or severe CHF, 2/3 AVB, severe 
then 25‚Äì50 mg PO q6h
bronchospasm
titrate to HR 50‚Äì60
CCB (nondihydropyridines)
If cannot tolerate B b/c bronchospasm
ACEI or ARB
Especially if CHF or EF 0.40 and if SBP 100
Morphine
Consider if persistent sx or pulmonary edema
Should not be used to mask persistent CP
Oxygen
Use if necessary to keep SaO2 90%
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
Antiplatelet Therapy
Aspirin
50‚Äì70% T D/MI (NEJM 1988;319:1105)
162‚Äì325 mg  1 (1st dose crushed/chewed) If ASA allergy, use clopidogrel instead
then 75‚Äì325 mg/d
(and desensitize to ASA)
Clopidogrel (ADP receptor blocker)
Give in addition to ASA. 20% T CVD/MI/stroke
300 mg  1 S 75 mg/d 
c benefit if given upstream prior to PCI 
(requires 6 h to steady-state)
but need to wait 5 d after d/c clopi prior
600 mg  1 S 150 mg/d  7d may T
to CABG (NEJM 2001;345:494; Lancet 2001;358:257)
D/MI/stroke by 15% in PCI Pts
30% pop have T fxn CYP2C19 allele S T plt 
(CURRENT/OASIS-7, ESC 2009)
inhib & c ischemic events (NEJM 2009;360:354)
Prasugrel (ADP receptor blocker)
More rapid (30 min) and potent plt inhib c/w clopi.
60 mg  1 S 10 mg/d
19% T CVD/MI/stroke in ACS w/ planned PCI vs 
(? 5 mg/d if 60 kg)
clopi, but c bleeding (NEJM 2007;359:2001).
Particularly efficacious in DM (Circ 2008;118:1626).
Avoid if 75 y; contraindic. if h/o TIA/CVA.
Ticagrelor (ADP receptor blocker)
More rapid (30 min) and potent plt inhib c/w clopi.
180 mg  1 S 90 mg bid
16% T CVD/MI/stroke & 22% T death c/w clopi, but 
reversible (nl plt fxn after 72 h)
with c non-CABG bleeding (NEJM 2009;361;1045).
under review at FDA
c frequency of dyspnea.
GP IIb/IIIa inhibitors (GPI)
May be given in addition to oral antiplt Rx(s)
abciximab; eptifibatide; tirofiban
No clear benefit for starting GPI prior to PCI and c
infusions given 2‚Äì24 h post-PCI
risk of bleeding (NEJM 2009;360:2176)
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
ACS
1-7

--- Fim da P√°gina 19 ---

Anticoagulant Therapy
UFH
24% T D/MI (JAMA 1996;276:811)
60 U/kg IVB (max 4000 U)
titrate to aPTT 1.5‚Äì2x cntl (50‚Äì70 sec)
12 U/kg/h (max 1000 U/h)
Enoxaparin (low-molecular-weight heparin)
Consider instead of UFH. 10% T D/MI (JAMA
1 mg/kg SC bid  2‚Äì8 d ( 	 30 mg IVB)
2004;292:89). Benefit greatest if conservative 
(qd if CrCl 30)
strategy. Can perform PCI on enoxaparin.
Bivalirudin (direct thrombin inhibitor)
Use instead of heparin for Pts w/ HIT.
0.75mg/kg IVB at time of PCI S 1.75 
With invasive strategy, bival alone noninferior to
mg/kg/h
heparin  GPI (non-signif 8% c D/MI/UR) w/
47% T bleeding (NEJM 2006;355:2203).
Fondaparinux (Xa inhibitor)
C/w enox, 17% T mortality & 38% T bleeding by
2.5 mg SC qd
30 d (NEJM 2006;354:1464). However, c risk of
cath thromb.; ‚à¥must supplement w/ UFH if PCI.
Coronary angiography (Circ 2007;116:e148 & 2009;120:2271)
‚Ä¢ Conservative approach  selective angiography
medical Rx with pre-d/c stress test; angio only if recurrent ischemia or strongly  ETT
‚Ä¢ Early invasive approach  routine angiography w/in 24‚Äì48 h
Indicated if high risk: recurrent ischemia,  Tn, ST,TRS 3, CHF, T EF, recent PCI 6
mos, sustained VT, prior CABG, hemodynamic instability
32% T rehosp for ACS, nonsignif 16% T MI, no  in mortality c/w cons. (JAMA 2008;300:71)
c peri-PCI MI counterbalanced by TT in spont. MI
Long-term mortality benefit likely only if c/w cons. strategy with low rate of angio/PCI
T D/MI/refractory ischemia if cath w/in 24 h c/w 36 h (NEJM 2009;360:2165);
‚à¥reasonable to cath high-risk Pts (GRACE score 140) w/ 12‚Äì24 of admission
TIMI Risk Score for UA/NSTEMI (JAMA 2000;284:825)
Calculation of Risk Score
Application of Risk Score
Characteristic
Point
Score
D/MI/UR by 14 d
Historical
0‚Äì1
5%
Age 65 y
1
2
8%
3 Risk factors for CAD
1
3
13%
Known CAD (stenosis 50%)
1
4
20%
ASA use in past 7 d
1
5
26%
Presentation
6‚Äì7
41%
Severe angina (2 episodes w/in 24 h)
1
Higher risk Pts (TRS 3) derive c
ST deviation 0.5 mm
1
benefit from LMWH, GP IIb/IIIa 
 cardiac marker (troponin, CK-MB)
1
inhibitors, and early angiography
RISK SCORE  Total points
(0‚Äì7)
(JACC 2003;41:89S)
Figure 1-2 Approach to UA/NSTEMI
ACS
1-8
CONS strategy
LOW RISK
HIGH RISK
‚äïTn, ST ‚Üì ‚â•0.5 mm, TRS ‚â•3, s/s CHF
ASA; clopidogrel (upstream or at time of PCI)
UFH, ENOX, or bival (depending on pref of cath lab)
¬± GP IIb/IIIa inhibitor
Angiography
‚Üì 
Stress test
once stabilized and before d/c
recurrent
ischemia
Med Rx
PCI (w/ GPI unless bival;
consider prasugrel vs. dopi) CABG
add
GPI
Long-term medical Rx
Med Rx
high risk
treadmill score    ‚Äì11
large perfusion defect (espec. ant)
multiple perfusion defects
low risk
w/in ~24 h
ASA & clopidogrel
ENOX, fonda, or UFH
INV strategy
EF
recent PCI
prior CABG
 Tn, no ST ‚Üì, and TRS 0‚Äì2,    CHF

--- Fim da P√°gina 20 ---

STEMI
Reperfusion
‚Ä¢ Immediate reperfusion (ie, opening occluded culprit coronary artery) is critical
‚Ä¢ In PCI-capable hospital, goal should be primary PCI w/in 90 min of 1st medical contact
‚Ä¢ In non-PCI-capable hospital, consider transfer to PCI-capable hospital (see below), o/w
fibrinolytic therapy w/in 30 min of hospital presentation
‚Ä¢ Do not let decision regarding method of reperfusion delay time to reperfusion
Primary PCI (NEJM 2007;356:47)
‚Ä¢ Superior to lysis: 27% T death, 65% T reMI, 54% T stroke, 95% T ICH (Lancet 2003;361:13)
‚Ä¢ Thrombus aspiration during angio prior to stenting T mortality (Lancet 2008;371:1915)
‚Ä¢ Transfer to center for 1 PCI may also be superior to lysis (NEJM 2003;349:733), see below
Fibrinolysis vs. Hospital Transfer for Primary PCI
Assess Time and Risk
1. Time required for transport to skilled PCI lab: door-to-balloon 90 min &
[door-to-balloon]-[door-to-needle] 1 h favors transfer for PCI
2. Risk from STEMI: high-risk Pts (eg, shock) fare better with mechanical reperfusion
3. Time to presentation: efficacy of lytics T w/ c time from sx onset, espec. 3 h
4. Risk of fibrinolysis: if high risk of ICH or bleeding, PCI safer option
Adapted from ACC/AHA 2004 STEMI Guidelines (Circ 2004;110:e82)
Fibrinolysis
‚Ä¢ Indications: sx 12 h and either STE 0.1 mV (1 mm) in 2 contig. leads or LBBB not
known to be old; benefit if sx 12 h less clear; reasonable if persistent sx & STE
‚Ä¢ Mortality T 20% in anterior MI or LBBB and 10% in IMI c/w ‚àÖreperfusion Rx
‚Ä¢ Prehospital lysis (ie, ambulance): further 17% T in mortality (JAMA 2000;283:2686)
‚Ä¢ 1% risk of ICH; high-risk groups include elderly (2% if 75 y), women, low wt
‚Ä¢ Although age not contraindic., c risk of ICH in elderly (75 y) makes PCI more attractive
Contraindications to Fibrinolysis
Absolute Contraindications
Relative Contraindications
‚Ä¢ Any prior ICH
‚Ä¢ Hx of severe HTN or SBP 180 or DBP 110 on
‚Ä¢ Intracranial neoplasm, aneurysm,
presentation (? absolute contra. if low-risk MI)
AVM
‚Ä¢ Ischemic stroke 3 mos prior
‚Ä¢ Nonhemorrhagic stroke or closed
‚Ä¢ Prolonged CPR (10 min)
head trauma w/in 3 mo
‚Ä¢ Trauma or major surgery w/in 3 wk
‚Ä¢ Active internal bleeding or known
‚Ä¢ Recent internal bleed (w/in 2‚Äì4 wk); active PUD
bleeding diathesis
‚Ä¢ Noncompressible vascular punctures
‚Ä¢ Suspected aortic dissection
‚Ä¢ Prior SK exposure (if considering SK)
‚Ä¢ Pregnancy
‚Ä¢ Current use of anticoagulants
Nonprimary PCI
‚Ä¢ Facilitated PCI: upstream lytic, GPI, or GPI  1‚ÅÑ2 dose lytic before PCI of no benefit
‚Ä¢ Rescue PCI if shock, unstable, failed reperfusion or persistent sx (NEJM 2005;353:2758)
‚Ä¢ Routine angio 	 PCI w/in 24 h of successful lysis: T D/MI/Revasc (Lancet 2004;364:1045) and
w/in 6 h T reMI, recurrent ischemia & CHF c/w w/in 2 wk (NEJM 2009;360:2705);
‚à¥if lysed at non-PCI capable hospital, consider transfer to PCI-capable hospital ASAP
espec if high-risk presentation (eg, anterior MI, inferior MI w/ low EF or RV infarct,
extensive STE or LBBB, HF, T BP or c HR)
‚Ä¢ Late PCI (median day 8) of occluded infarct-related artery: no benefit (NEJM 2006;355:2395)
Antiplatelet Therapy
Aspirin 162‚Äì325 mg (crushed/chewed)
23% T in death (Lancet 1988;ii:349)
ADP receptor blocker
Lysis: clopidogrel 41% c in patency, 7% T mort., no 
Clopidogrel: 600 mg pre-PCI, 300 mg
 in major bleed or ICH (NEJM 2005;352:1179; Lancet
if lysis (not if 75 y) S 75 mg/d
2005;366:1607); no data for prasugrel or ticagrelor
Prasugrel & ticagrelor as above
PCI: prasugrel and ticagrelor T CV events c/w clopi 
GP IIb/IIIa inhibitors
Lysis: no indication (Lancet 2001;357:1905)
abciximab, eptifibatide, tirofiban
Peri-PCI: 60% T D/MI/UR (NEJM 2001;344:1895)
Adapted from ACC/AHA 2009 STEMI Guidelines Focused Update (Circ 2009;120:2271)
ACS
1-9

--- Fim da P√°gina 21 ---

Anticoagulant Therapy
UFH
No demonstrated mortality benefit
60 U/kg IVB (max 4000 U)
c patency with fibrin-specific lytics
12 U/kg/h (max 1000 U/h)
Titrate to aPTT 1.5‚Äì2x cntl (50‚Äì70 sec)
Enoxaparin
Lysis: 17% T D/MI w/ ENOX  7 d vs. UFH  2 d
30 mg IVB  1 S 1 mg/kg SC bid
(NEJM 2006;354;1477)
(75 y: no bolus, 0.75 mg/kg SC bid)
PCI: acceptable alternative to UFH (age & CrCl
(CrCl  30 mL/min: 1 mg/kg SC qd)
adjustments untested in 1 PCI)
Bivalirudin
PCI: T death & T bleeding but c acute stent 
0.75 mg/kg IVB S 1.75 mg/kg/hr IV
thrombosis c/w heparin  GPI (NEJM 2008;358:2218)
Fondaparinux
Lysis: superior to placebo & to UFH, with less
2.5 mg SC QD
bleeding (JAMA 2006;295;1519)
PCI: risk of cath thromb.; should not be used
Immediate Adjunctive Therapy
-blockers
20% T arrhythmic death or reMI, 30% c cardiogenic
eg, metoprolol 25 mg PO q6h
shock, & no  overall mortality when given to Pts
titrate to HR 55‚Äì60
incl. those w/ mod CHF (Lancet 2005;366:1622)
IV only if HTN & no s/s CHF
Contraindic. if HR 60 or 110, SBP 120, mod/severe 
CHF, late present., 2/3 AVB, severe bronchospasm
Nitrates
? 5% T mortality (Lancet 1994;343:1115;1995;345:669)
SL or IV
Use for relief of sx, control of BP, or Rx of CHF
Contraindic. in hypovolemia, sx RV infarcts, sildenafil
Oxygen
Use if necessary to keep SaO2 90%.
Morphine
Relieves pain, T anxiety, venodilation S T preload
ACE inhibitors
10% T mortality (Lancet 1994;343:1115 & 1995;345:669)
eg, captopril 6.25 mg tid,
Greatest benefit in ant. MI, EF 40%, or prior MI
titrate up as tolerated
Contraindicated in severe hypotension or renal failure
ARBs
Appear  ACEI (VALIANT, NEJM 2003;349:20)
Insulin
Treat hyperglycemia 180 mg/dL while avoiding 
hypoglycemia, no clear benefit for intensive control
Adapted from ACC/AHA 2007 STEMI Guidelines Focused Update (Circ 2008;117:296)
LV failure (25%)
‚Ä¢ Diurese to achieve PCWP 15‚Äì20 S T pulmonary edema, T myocardial O2 demand
‚Ä¢ T Afterload S c stroke volume & CO, T myocardial O2 demand
can use IV NTG or nitroprusside (risk of coronary steal) S short-acting ACEI
‚Ä¢ Inotropes if CHF despite diuresis & T afterload; use dopamine, dobutamine, or milrinone
‚Ä¢ Cardiogenic shock (7%)  MAP 60 mmHg, CI 2 L/min/m2, PCWP 18 mmHg
inotropes, IABP, percutaneous VAD to keep CI  2; pressors (eg, norepinephrine) to keep
MAP 60; if not done already, coronary revascularization ASAP (NEJM 1999;341:625)
IMI complications (Circ 1990;81:401; Annals 1995;123:509)
‚Ä¢ Heart block (20%, occurs because RCA typically supplies AV node)
40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly
Rx: atropine, epi, aminophylline (100 mg/min  2.5 min), temp wire
‚Ä¢ Precordial ST T (15‚Äì30%): anterior ischemia vs. true posterior STEMI vs. reciprocal s
‚Ä¢ RV infarct (30‚Äì50%, but only 1‚ÅÑ2 of those clinically significant)
hypotension; c JVP,  Kussmaul‚Äôs; 1 mm STE in V4R; RA/PCWP 0.8; prox RCA occl.
Rx: optimize preload (RA goal 10‚Äì14, BHJ 1990;63:98); c contractility (dobutamine);
maintain AV synchrony (pacing as necessary); reperfusion (NEJM 1998;338:933);
mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)
Mechanical complications (incid.1% for each; typically occur a few days post-MI)
‚Ä¢ Free wall rupture: c risk w/ fibrinolysis, size of MI, age; p/w PEA or hypoTN, peri-
cardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, surgery
‚Ä¢ VSD: large MI in elderly;AMI S apical VSD, IMI S basal septum; 90% w/ harsh murmur 	
thrill (NEJM 2002;347:1426); Rx: diuretics, vasodil., inotropes, IABP, surgery, perc. closure
‚Ä¢ Papillary muscle rupture: small MI; more likely in IMI S PM pap. muscle (supplied by
PDA) than AMI S AL pap. muscle (supplied by diags & OMs); 50% w/ new murmur,
rarely a thrill, c v wave in PCWP tracing; asymmetric pulmonary edema. Rx: diuretics,
vasodilators, IABP, surgery.
Arrhythmias post-MI
‚Ä¢ Treat as per ACLS for unstable or symptomatic bradycardias & tachycardias
‚Ä¢ AF (10‚Äì16% incidence): -blocker, amiodarone, digoxin (particularly if CHF), heparin
ACS
1-10

--- Fim da P√°gina 22 ---

ACS
1-11
‚Ä¢ VT/VF: lido or amio  6‚Äì24 h, then reassess; c B as tol., replete K & Mg, r/o ischemia;
early monomorphic (48 h post-MI) does not carry bad prognosis
‚Ä¢ Accelerated idioventricular rhythm (AIVR): slow VT (100 bpm), often seen after
successful reperfusion; typically self-terminates and does not require treatment
‚Ä¢ Consider backup transcutaneous pacing (TP) if: 2 AVB type I, BBB
‚Ä¢ Backup TP or initiate transvenous pacing if: 2 AVB type II; BBB  AVB
‚Ä¢ Transvenous pacing (TV) if: 3 AVB; new BBB  2 AVB type II; alternating LBBB/RBBB
(can bridge w/ TP until TV, which is best accomplished under fluoro guidance)
Other Post-MI Complications
Complication
Clinical features
Treatment
LV thrombus
30% incid. (esp. lg antero-apical MI)
Anticoagulate  3‚Äì6 mo
Ventricular
Noncontractile outpouching of LV;
Surgery if recurrent CHF,
aneurysm
8‚Äì15% incid.; persistent STE.
thromboemboli, arrhythmia
Ventricular
Rupture S sealed by thrombus and
Surgery
pseudoaneurysm
pericardium
Pericarditis
10‚Äì20% incid.; 1‚Äì4 d post-MI
High-dose aspirin, NSAIDs
 pericardial rub; ECG s rare
Minimize anticoagulation
Dressler‚Äôs
4% incid.; 2‚Äì10 wk post-MI
High-dose aspirin, NSAIDs
syndrome
Fever, pericarditis, pleuritis
Prognosis
‚Ä¢ In registries, in-hospital mortality is 6% w/ reperfusion Rx (lytic or PCI) and 20% w/o
‚Ä¢ Predictors of mortality: age, time to Rx, anterior MI or LBBB, heart failure (Circ 2000;102:2031)
Killip Class
Class
Definition
Mort.
I
no CHF
6%
II
 S3 and/or basilar rales
17%
III
pulmonary edema
30‚Äì40%
IV
cardiogenic shock
60‚Äì80%
(Am J Cardiol 1967;20:457)
Forrester Class Mortality
PCWP (mmHg)
18
18
CI
2.2
3%
9%
2.2
23%
51%
(NEJM 1976;295:1356)
PREDISCHARGE CHECKLIST AND LONG-TERM POST-ACS MANAGEMENT
Risk stratification
‚Ä¢ Stress test if anatomy undefined or significant residual CAD after PCI of culprit vessel
‚Ä¢ Echocardiogram to assess EF; EF c 6% in STEMI over 6 mos (JACC 2007;50:149)
Medications (barring contraindications)
‚Ä¢ Aspirin: 162‚Äì325 mg/d for 1 mo (BMS) or 3‚Äì6 mos (DES); 75‚Äì162 mg/d thereafter
‚Ä¢ ADP receptor blocker (eg, clopidogrel): 12 mos (? longer if DES); some PPIs may
interfere with biotransformation of clopidogrel and ‚à¥plt inhibition, but no convincing
evidence to date of impact on clinical outcomes (Lancet 2009;374:989; COGENT, TCT 2009) 
‚Ä¢ -blocker: 23% T mortality after acute MI
‚Ä¢ Statin: high-intensity lipid-lowering (eg, atorvastatin 80 mg, NEJM 2004;350:1495)
‚Ä¢ ACEI: life-long if CHF, T EF, HTN, DM; 4‚Äì6 wks or at least until hosp. d/c in all STEMI
? long-term benefit in CAD w/o CHF (NEJM 2000;342:145 & 2004;351:2058; Lancet 2003;362:782)
‚Ä¢ Aldosterone antagonist: if EF 40% & signs of HF (see ‚ÄúHeart Failure‚Äù)
‚Ä¢ Nitrates: standing if symptomatic; SL NTG prn for all
‚Ä¢ Oral anticoagulants: beyond indic. for AF and LV thrombus, comb. of warfarin (goal
INR 2‚Äì2.5)  ASA T D/MI/CVA c/w ASA alone, but c bleeding (NEJM 2002;347:969);
addition of oral Xa or IIa inhibitors post-ACS under study (Lancet 2009;374:29)
ICD (NEJM 2008;359:2245)
‚Ä¢ If sust.VT/VF 2 d post-MI not due to reversible ischemia
‚Ä¢ Indicated in 1 prevention of SCD if post-MI w/ EF 30‚Äì40% (NYHA II‚ÄìIII) or
30‚Äì35% (NYHA I); need to wait 40 d after MI (NEJM 2004;351:2481 & 2009; 361;1427)
Risk factors and lifestyle modifications
‚Ä¢ Low chol. (200 mg/d) & low fat (7% saturated) diet; LDL goal 70 mg/dL; ? fish oil
(BMJ 2008;337:a2931)
‚Ä¢ BP 140/90 mmHg, 130/80 if diabetes or chronic kidney disease, consider 120/80
‚Ä¢ Smoking cessation
‚Ä¢ If diabetic, HbA1c 7% (avoid TZDs if CHF)
‚Ä¢ Exercise (30 mins 3‚Äì4  per wk);Weight loss with BMI goal 18.5‚Äì24.9 kg/m2
‚Ä¢ Influenza vaccination (Circ 2006;114:1549)

--- Fim da P√°gina 23 ---

PAC
1-12
PA CATHETER AND TAILORED THERAPY 
Rationale
‚Ä¢ Cardiac output (CO)  SV  HR; SV depends on LV end-diastolic volume (LVEDV)
‚à¥manipulate LVEDV to optimize CO while minimizing pulmonary edema
‚Ä¢ Balloon at tip of catheter inflated S floats into ‚Äúwedge‚Äù position. Column of blood extends
from tip of catheter, through pulmonary circulation, to a point just proximal to LA. Under
conditions of no flow, PCWP  LA pressure  LVEDP, which is proportional to LVEDV.
‚Ä¢ Situations in which these basic assumptions fail:
1) Catheter tip not in West lung zone 3 (and ‚à¥PCWP  alveolar pressure Z LA
pressure); clues include lack of a & v waves and if PA diastolic pressure  PCWP
2) PCWP  LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)
3) Mean LA pressure  LVEDP (eg, MR, MS)
4)  LVEDP-LVEDV relationship (ie, abnl compliance, ‚à¥‚Äúnl‚Äù LVEDP may not be optimal)
Indications (JACC 1998;32:840 & Circ 2009;119:e391)
‚Ä¢ Diagnosis and evaluation
Ddx of shock (cardiogenic vs. distributive; espec. if trial of IVF failed / high-risk) and
of pulmonary edema (cardiogenic vs. not; espec. if trial of diuretic failed / high-risk)
Evaluation of CO, intracardiac shunt, pulmonary HTN, MR, tamponade
‚Ä¢ Therapeutics
Tailored therapy to optimize PCWP, SV, SvO2 in heart failure/shock
Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in pulmonary HTN
Guide to perioperative management in some high-risk Pts, pre-transplantation
‚Ä¢ Contraindications
Absolute: right-sided endocarditis, thrombus, or mechanical R-sided valve
Relative: coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB
(5% risk of RBBB S CHB, place under fluoro), bioprosthetic R-sided valve
Efficacy concerns
‚Ä¢ No benefit to routine PAC in high-risk surgery or ARDS (NEJM 2006;354:2213)
‚Ä¢ No benefit in decompensated CHF (JAMA 2005;294:1625); untested in cardiogenic shock
‚Ä¢ But: 1‚ÅÑ2 of CO & PCWP clinical estimates incorrect; CVP & PCWP not well correl.; ‚à¥use
PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock
Placement
‚Ä¢ Insertion site: R internal jugular or L subclavian veins for ‚Äúanatomic‚Äù flotation into PA 
‚Ä¢ Inflate balloon (max 1.5 mL) when advancing and to measure PCWP
‚Ä¢ Use resistance to inflation and pressure tracing to avoid overinflation
‚Ä¢ Deflate the balloon when withdrawing and at all other times
‚Ä¢ CXR should be obtained after bedside placement to assess for catheter position and PTX
‚Ä¢ If catheter cannot be successfully floated (typically if severe TR or RV dilatation) or if
another relative contraindication exists, consider fluoroscopic guidance
Complications
‚Ä¢ Central venous access: pneumo/hemothorax (1‚Äì3%), arterial puncture, air embolism
‚Ä¢ Advancement: atrial or ventricular arrhythmias (3% VT), RBBB (5%), catheter knot-
ting, cardiac perforation/tamponade, PA rupture
‚Ä¢ Maintenance: infection (especially if catheter 3 d old), thrombus, pulmonary
infarction (1%), PA rupture/pseudoaneurysm (esp. w/ PHT), balloon rupture
Intracardiac pressures
‚Ä¢ Transmural pressure ( preload)  measured intracardiac pressure-intrathoracic pressure
‚Ä¢ Intrathoracic pressure (usually slightly ) is transmitted to vessels and heart
‚Ä¢ Always measure intracardiac pressure at end-expiration, when intrathoracic pressure
closest to 0; (‚Äúhigh point‚Äù in spont. breathing Pts;‚Äúlow point‚Äù in Pts on  pressure vent.)
‚Ä¢ If c intrathoracic pressure (eg, PEEP), measured PCWP overestimates true transmural
pressures. Can approx by subtracting 1‚ÅÑ2 PEEP (convert cmH2O to mmHg by  3‚ÅÑ4).
‚Ä¢ PCWP: LV preload best estimated at a wave; risk of pulmonary edema from avg PCWP 
Cardiac output
‚Ä¢ Thermodilution: saline injected in RA.  in temp over time measured at thermis-
tor (in PA) is integrated  1/CO. Inaccurate if T CO, sev TR, or shunt.
‚Ä¢ Fick method: O2 consumption (L/min)  CO (L/min)  arteriovenous O2 difference.
CO derived by dividing O2 consumption by observed AV O2 difference [10  1.34 ml
O2/g Hb  Hb g/dl  (SaO2 ‚Äì SvO2)].
Can estimate O2 consumption using wt-based formula, but best to measure (espec
if c metabolism, eg, sepsis).
If SVO2 80%, consider wedged (ie, pulm vein) sat, LSR shunt, impaired O2 utiliza-
tion (severe sepsis, cyanide, carbon monoxide), cc O2 delivery.

--- Fim da P√°gina 24 ---

PA Catheter Waveforms
Location
RA
RV
PA
PCWP
Distance
20 cm
30 cm
40 cm
50 cm
Pressure
mean 6
syst 15‚Äì30
syst 15‚Äì30
mean 12
(mmHg)
diast 1‚Äì8
mean 9‚Äì18
diast 6‚Äì12
Waves
a  atrial contraction,
RVEDP occurs
Waveform should
Similar to RA except
occurs in PR interval
right before
contain notch (closure dampened and delayed.
c  bulging of TV back into
upstroke and 
of pulmonic valve).
a wave after QRS,
RA at start of systole
 mean RA
Peak during T wave
	 distinct c wave,
x  atrial relaxation and
pressure unless
PA systolic  RV
v wave after T
Comment
descent of base of heart
there is TS or TR
systolic unless there
(helps distinguish
v  blood entering RA, occurs
is a gradient (eg, PS).
PCWP w/ large v
mid T wave
waves 2 MR from 
y  blood exiting RA after TV
PA).
opens at start of diastole
PCWP waveform abnormalities: large a wave S ? mitral stenosis; large v wave S ? mitral regurgitation;
blunted y descent S ? tamponade; steep x & y descents S ? constriction.
Hemodynamic Profiles of Various Forms of Shock
RA
PCWP
CO
SVR
Type of shock
(JVP)
(CXR)
(UOP)
(Cap refill)
Hypovolemic
T
T
T
c
Cardiogenic
nl or c
c
T
c
Distributive
variable
variable
usually c
T
(but can be T in sepsis)
RV Infarct / Massive PE
c
nl or T
T
c
Tamponade
c
c
T
c
(Surrogates for hemodynamic parameters shown below parameter in parentheses.)
Tailored therapy in cardiogenic shock (Circ 2009;119:e391)
‚Ä¢ Goals: optimize both MAP and CO while T risk of pulmonary edema
MAP  CO  SVR; CO  HR  SV (which depends on preload, afterload, and contractility)
pulmonary edema when PCWP 20‚Äì25 (higher levels may be tolerated in chronic HF)
‚Ä¢ Optimize preload  LVEDV  LVEDP  LAP  PCWP (NEJM 1973;289:1263)
goal PCWP 14‚Äì18 in acute MI, 10‚Äì14 in chronic heart failure
optimize in individual Pt by measuring SV w/ different PCWP to create Starling curve
c by giving NS (albumin w/o clinical benefit over NS; PRBC if significant anemia)
T by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics 
‚Ä¢ Optimize afterload ‚âàwall stress during LV ejection  [(SBP  radius) / (2  wall thick.)]
and ‚à¥‚àùMAP and ‚àùSVR  (MAP ‚Äì CVP / CO); goals: MAP 60, SVR 800‚Äì1200
MAP 60 & SVR c: vasodilators (eg, nitroprusside, NTG,ACEI, hydral.) or wean pressors
MAP 60 & SVR c (& ‚à¥CO T): temporize w/ pressors until can c CO (see below)
MAP 60 & SVR low/nl (& ‚à¥inappropriate vasoplegia): vasopressors (eg, norepineph-
rine [, ], dopamine [D, , ], phenylephrine [], or vasopressin [V1] if refractory)
‚Ä¢ Optimize contractility ‚àùCO for given preload & afterload; goal CI  (CO/ BSA) 2.2
if too low despite optimal preload & vasodilators (as MAP permits):  inotropes 
eg, dobutamine (moderate inotrope & mild vasodilator), milrinone (strong 
inotrope & vasodilator, incl pulmonary artery), both proarrhythmic, or epinephrine 
(strong inotrope and vasopressor); also consider mechanical assistance with 
IABP or percutaneous or surgical LVAD 	 RVAD
PAC
1-13
0
5
10
15
20
25
30
mm
Hg
simultaneous
ECG
a
c
x
y
v
a
x
y
v

--- Fim da P√°gina 25 ---

HF
1-14
HEART FAILURE
Definitions (Braunwald‚Äôs Heart Disease, 8th ed., 2008)
‚Ä¢ Failure of heart to pump blood forward at sufficient rate to meet metabolic demands of
peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures
‚Ä¢ Low output (T cardiac output) vs. high output (c stroke volume 	 c cardiac output)
‚Ä¢ Left-sided (pulmonary edema) vs. right-sided (c JVP, hepatomegaly, peripheral edema)
‚Ä¢ Backward (c filling pressures, congestion) vs. forward (impaired systemic perfusion)
‚Ä¢ Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)
Figure 1-3 Approach to left-sided heart failure
History
‚Ä¢ Low output: fatigue, weakness, exercise intolerance,  MS, anorexia
‚Ä¢ Congestive: left-sided S dyspnea, orthopnea, paroxysmal nocturnal dyspnea
right-sided S peripheral edema, RUQ discomfort, bloating, satiety
Functional classification (New York Heart Association class)
‚Ä¢ Class I: no sx w/ ordinary activity; class II: sx w/ ordinary activity;
Class III: sx w/ minimal activity; class IV: sx at rest
Physical exam (‚Äú2-minute‚Äù hemodynamic profile; JAMA 2002;287:628)
‚Ä¢ Congestion (‚Äúdry‚Äù vs. ‚Äúwet‚Äù)
c JVP (80% of the time JVP 10 S PCWP 22; J Heart Lung Trans 1999;18:1126)
 hepatojugular reflux: 1 cm c in JVP for 15 sec with abdominal pressure
73% Se & 87% Sp for RA 8 and 55% Se & 83% Sp for PCWP 15 (AJC 1990;66:1002)
Valsalva square wave (c SBP thru strain) (JAMA 1996;275:630)
S3 (in Pts w/ HF S 40% c risk of HF hosp. or pump failure death; NEJM 2001;1345:574)
rales, dullness at base 2 pleural effus. (often absent due to lymphatic compensation)
	 hepatomegaly, ascites and jaundice, peripheral edema
‚Ä¢ Perfusion (‚Äúwarm‚Äù vs. ‚Äúcold‚Äù)
narrow pulse pressure (25% of SBP) S CI 2.2 (91% Se, 83% Sp; JAMA 1989;261:884)
pulsus alternans, cool & pale extremities, T UOP, muscle atrophy
‚Ä¢ 	 Other: Cheyne-Stokes resp., abnl PMI (diffuse, sustained, or lifting depending on cause of
HF), S4 (diast. dysfxn), murmur (valvular dis., c MV annulus, displaced papillary muscles)
Evaluation for the presence of heart failure
‚Ä¢ CXR (see Radiology insert): pulm edema, pleural effusions 	 cardiomegaly, cephaliza-
tion, Kerley B-lines
‚Ä¢ BNP / NT-proBNP: can help exclude HF as cause of dyspnea if low; predicts risk of rehosp
‚Ä¢ Evidence of T perfusion to vital organs: c BUN, c Cr, T serum Na, abnormal LFTs
‚Ä¢ Echo (see inserts): T EF & c chamber size S systolic dysfxn; hypertrophy, abnl MV inflow,
abnl tissue Doppler S ? diastolic dysfxn; abnl valves or pericardium; estimate RVSP
‚Ä¢ PA catheterization: c PCWP, T CO and c SVR (low-output failure)
Left-sided Heart Failure
‚ÜëAfterload
AS, HCMP
HTN crisis
Coarctation
r/o mitral valve disease
consider myxoma, pulmonary VOD
‚ÜëLVEDP
‚ÜëLVEDV
‚ÜìContractility
Ischemia/MI
DCMP
Chronic AI/MR
High Output
AV fistula
Paget‚Äôs
Sepsis
Beriberi
Anemia
Thyrotoxicosis
or
‚ÜìForward Flow
MR, AI, VSD
Systolic
Dysfunction
High SV
Failure
LVH
1¬∞ HCMP
2¬∞ to HTN, AS
or
Ischemia
or
RCMP
Myocardial
Endomyocardial
Pericardial
Disease
(usually right-
sided failure)
Tamponade
Constriction
normal LVEDV
Diastolic
Dysfunction
‚ÜëSV
‚ÜëESV

--- Fim da P√°gina 26 ---

Evaluation of the causes of heart failure
‚Ä¢ ECG: evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCMP) 
‚Ä¢ Coronary angiography (or ? CT coronary angiography)
‚Ä¢ If no CAD, w/u for nonischemic DCMP, HCMP, or RCMP (see ‚ÄúCardiomyopathies‚Äù)
Precipitants of acute heart failure
‚Ä¢ Myocardial ischemia or infarction; myocarditis
‚Ä¢ Renal failure (acute, progression of CKD, or insufficient dialysis) S c preload
‚Ä¢ Hypertensive crisis (incl. from RAS), worsening AS S c left-sided afterload
‚Ä¢ Dietary indiscretion or medical nonadherence
‚Ä¢ Drugs (B, CCB, NSAIDs,TZDs) or toxins (EtOH, anthracyclines)
‚Ä¢ Arrhythmias; acute valvular dysfxn (eg, endocarditis), espec. mitral or aortic regurgitation 
‚Ä¢ COPD or PE S c right-sided afterload
‚Ä¢ Anemia, systemic infection, thyroid disease
Treatment of acute decompensated heart failure 
‚Ä¢ Assess degree of congestion & adequacy of perfusion
‚Ä¢ For congestion: ‚ÄúLMNOP‚Äù
Lasix w/ monitoring of UOP; high-dose
(IVB 2.5 PO dose) vs. low-dose (IVB  
1 PO dose) S c UOP but transient 
c in renal dysfxn; ‚àÖclear diff between
cont vs. intermittent (DOSE,ACC 2010) 
Morphine (T sx, venodilator, T afterload)
Nitrates (venodilator)
Oxygen 	 noninvasive ventilation (see ‚ÄúMechanical Ventilation‚Äù)
Position (sitting up & legs dangling over side of bed S T preload)
‚Ä¢ For low perfusion, see below 
Treatment of advanced heart failure (Circ 2009;119:e391)
‚Ä¢ Tailored Rx w/ PAC (qv); goals of MAP 60, CI 2.2 (MVO2 60%), SVR 800, PCWP 18
‚Ä¢ IV vasodilators: NTG, nitroprusside (risk of coronary steal in Pts w/ CAD;
prolonged use S cyanide/thiocyanate toxicity); nesiritide (rBNP) T PCWP & sx,
but may c Cr & mortality (JAMA 2002;287:1531 & 2005;293:1900)
‚Ä¢ Inotropes (properties in addition to c inotropy listed below)
dobutamine: vasodilation at doses 5 g/kg/min; mild T PVR; desensitization over time
dopamine: splanchnic vasodil. S c GFR & natriuresis; vasoconstrict. at 5 g/kg/min
milrinone: prominent systemic & pulmonary vasodilation; T dose by 50% in renal failure
‚Ä¢ Ultrafiltration: 1 L fluid loss at 48 h and 50% T in rehosp. (JACC 2007;49:675)
‚Ä¢ Mechanical circulatory support
intraaortic balloon pump (IABP): deflates in diastole & inflates in systole to T impe-
dence to LV ejection of blood & c coronary perfusion
ventricular assist device (LVAD 	 RVAD): as bridge to recovery (NEJM 2006;355:1873) or
transplant (some temporary types can be placed percutaneously  PVAD), or as
destination therapy (45‚Äì50% T mort. vs. med Rx; NEJM 2001;345:1435 & 2009;361:2241)
‚Ä¢ Cardiac transplantation: 15‚Äì20% mort. in 1st y, median survival 10 y
Recommended Chronic Therapy by CHF Stage (Circ 2009;119: e391)
Stage (Not NYHA Class)
Pt Characteristics
Therapy
High risk for HF
HTN, DM, CAD
Treat HTN, lipids, DM, SVT
 Structural heart dis.
Cardiotoxin exposure
Stop smoking, EtOH
A
Asx
FHx of CMP
Encourage exercise
ACEI if HTN, DM, CVD, PAD
B
 Structural heart dis.
Prior MI, T EF, LVH
All measures for stage A
Asx
or asx valvular dis.
ACEI & B if MI/CAD or T EF
 Structural heart dis.
All measures for stage A
 Symptoms of HF
ACEI, B, diuretics, Na restrict
C
(prior or current) 
Overt HF
Consider aldactone, ICD, CRT
Consider nitrate/hydral, digoxin
Refractory HF
Sx despite maximal 
All measures for stage A‚ÄìC
requiring specialized
medical Rx
IV inotropes,VAD, transplant
D
interventions
4 yr mortality 50%
End-of-life care
(Circ 2009;119:e391)
‚Ä¢ No clear evidence that BNP-guided Rx results in superior clinical outcomes outside
of encouraging intensification of established therapies (JAMA 2009;301:383)
‚Ä¢ Implantable PA pressure sensor may T risk of hosp (CHAMPION, HF Congress 2010)
HF
1-15
Congestion?
No
Yes
Warm & Dry Warm & Wet
OutPt Rx
Diuresis 	
vasodilator
Cold & Dry
Cold & Wet
	 Inotropes
Tailored Rx 
(CCU)
(CCU)
Low perfusion?
Yes
No

--- Fim da P√°gina 27 ---

Treatment of Chronic Heart Failure with Reduced Ejection Fraction
Diet, exercise
Na 2 g/d, fluid restriction, exercise training in ambulatory Pts
ACEI
T mortality: 40% in NYHA IV, 16% in NYHA II/III, 20% in asx,
post-MI, EF 40% (NEJM 1987;316:1429; 1991;325:293; 1992;327:669)
20% T reMI; 20‚Äì30% T rehosp for HF (c amt of benefit w/ T EF)
30% T HF in asx Pts w/ EF 35% (SOLVD-P, NEJM 1992;327:685)
High-dose ACEI more efficacious than low-dose 
Watch for azotemia, c K (can ameliorate by low-K diet, diuretics,
kayexalate), cough, angioedema
ATII receptor
Consider as alternative if cannot tolerate ACEI (eg, b/c cough)
blockers (ARBs)
Noninferior to ACEI (VALIANT, NEJM 2003;349:1893)
Good alternative if ACEI intol (CHARM-Alternative, Lancet 2003;362:772)
As with ACEI, higher doses more efficacious (Lancet 2009;374:1840)
? T HF (Val-HEFT, NEJM 2001;345:1667) and T mort. when added to 
ACEI (CHARM-Added, Lancet 2003;362:767), but c risk of c K and c Cr
Hydralazine  nitrates
Consider if cannot tolerate ACEI/ARB or in blacks w/ Class III/IV
25% T mort. (NEJM 1986;314:1547); infer. to ACEI (NEJM 1991;325:303)
40% T mort. in blacks on standard Rx (A-HEFT, NEJM 2004;351:2049)
-blocker
EF will transiently T, then c. Contraindic. in decompensated HF.
(data for carvedilol,
35% T mort. & 40% T rehosp. in NYHA II‚ÄìIV (JAMA 2002;287:883)
metoprolol, bisoprolol)
Carvedilol superior to low-dose metoprolol (Lancet 2003;362:7)
Aldosterone
Consider if HF severe or post-MI, adeq. renal fxn; watch for c K
antagonists
30% T mort. in NYHA III/IV & EF 35% (RALES, NEJM 1999;341:709)
15% T mort. in HF post-MI, EF 40% (EPHESUS, NEJM 2003;348:1309)
Cardiac
Consider if EF 35%, QRS 120 ms, and symptomatic
resynchronization
36% T mort. & c EF in NYHA III‚ÄìIV (CARE-HF, NEJM 2005;352:1539)
therapy (CRT)
T HF if EF30% & NYHA I/II, espec if QRS 150 ms, no  in 
mortality (NEJM 2009;361:1329)
No single measure of dyssynchrony on echo improves Pt 
selection for CRT (Circ 2008;117:2608)
ICD
Use for 1 prevention if sx & EF 35% or for 2 prevention
T mort. in Pts w/ MI & EF 30% (NEJM 2002;346:877); no  mort.
early post-MI (NEJM 2004;351:2481; 2009;361:1427), ‚à¥wait 40 d
23% T mort. in all DCMP, EF 35% (SCD-HeFT, NEJM 2005;352:225)
T arrhythmic death in nonisch DCMP (DEFINITE, NEJM 2004;350:2151)
Diuretics
Loop 	 thiazides diuretics (sx relief; no mortality benefit)
Digoxin
23% T HF hosp., no  mortality (NEJM 1997;336:525)
? c mort. in women, ? related to c levels (NEJM 2002;347:1403)
? optimal dig concentration 0.5‚Äì0.8 ng/mL (JAMA 2003;289:871)
-3 fatty acids
9% T mortality (Lancet 2008;372:1223)
Anticoagulation
Consider if AF, LV thrombus, large akinetic LV segment, EF 30%
Heart rhythm
Catheter ablation of AF S c in EF, T sx (NEJM 2004;351:2373)
No mortality benefit to AF rhythm vs. rate cntl (NEJM 2008;358:2667)
For sx AF, pulm vein isolation improves sx c/w AVN ablation & 
CRT (NEJM 2008;359:1778)
(Lancet 2009;373:941; Circ 2009;119:e391; NEJM 2010;362:228)
Heart failure with preserved EF (‚ÄúDiastolic HF‚Äù) (JACC 2009;53:905)
‚Ä¢ 40‚Äì60% of Pts w/ HF have normal or only min. impaired systolic fxn (EF 40%) (NEJM
2006;355:251, 260), w/ mortality rates similar to those w/ systolic dysfxn
‚Ä¢ 30% of population 45 y w/ diastolic dysfxn on echo, 20% mild, 10% mod/sev,
but only 50% of severe and 5% of moderate cases were symptomatic (JAMA 2003;289:194)
‚Ä¢ Etiologies (impaired relaxation and/or c passive stiffness): ischemia, prior MI, LVH,
HCMP, infiltrative CMP, RCMP, aging, hypothyroidism
‚Ä¢ Precipitants of pulmonary edema: volume overload (poor compliance of LV S sensitive
to even modest c in volume); ischemia (T relaxation); tachycardia (T filling time in
diastole),AF (loss of atrial boost to LV filling); HTN (T afterload S T stroke volume) 
‚Ä¢ Dx w/ clinical s/s of HF w/ preserved systolic and impaired diastolic fxn on echo:
abnormal MV inflow: E/A reversal and s in E wave deceleration time
T myocardial relax.: c isovol relax. time & T early diastole tissue Doppler vel
LVH, LAE
‚Ä¢ Treatment: diuresis for volume overload, BP control, prevention of tachycardia and
ischemia. No clear benefit of ACEI/ARB in Pts with isolated diastolic HF (Lancet
2003;362:777; NEJM 2008;359:2456). May underscore heterogeneity of Pt population.
HF
1-16

--- Fim da P√°gina 28 ---

CMP
1-17
CARDIOMYOPATHIES
Diseases with mechanical and/or electrical dysfunction of the myocardium
DILATED CARDIOMYOPATHY (DCMP)
Definition and epidemiology (Circ 2006;113:1807)
‚Ä¢ Ventricular dilatation and T contractility 	 T wall thickness,
‚Ä¢ Incidence: 5‚Äì8 cases/100,000 population per y; prevalence: 1 in 2500
Etiologies (NEJM 1994;331:1564 & 2000;342:1077)
‚Ä¢ Ischemia: systolic dysfxn & dilation out of proportion to CAD (poor remodeling post-MI)
‚Ä¢ Valvular disease: systolic dysfxn due to chronic volume overload in MR & AI
‚Ä¢ Familial (25%): mutations in cytoskeletal, nuclear, and filament proteins (NEJM 1992;362:77)
‚Ä¢ Idiopathic (25% of DCMP, ? undiagnosed infectious, alcoholic, or genetic cause)
‚Ä¢ Infectious myocarditis (10‚Äì15%, autoimmune response to infxn; NEJM 2009;360:1526)
Viruses (coxsackie, adeno, echovirus, CMV): ranging from subacute (dilated LV w/ mild-
mod dysfxn) to fulminant (nondilated, thickened, edematous LV w/ severe dysfxn)
Bacterial, fungal, rickettsial,TB, Lyme (mild myocarditis, often with AVB)
HIV: 8% of asx HIV ; due to HIV vs. other viruses vs. meds (NEJM 1998;339:1093)
Chagas: apical aneurysm 	 thrombus, RBBB, megaesophagus or colon (NEJM 1993;329:639)
‚Ä¢ Toxic
Alcohol (5%) typically 7‚Äì8 drinks/d  5 y, but much interindividual variability
Anthracyclines (risk c 550 mg/m2, may manifest late), cyclophosphamide, trastuzumab 
Cocaine, antiretrovirals, lead, carbon monoxide poisoning, radiation
‚Ä¢ Infiltrative (5%): often mix of DCMP  RCMP (qv) with thickened wall
amyloidosis, sarcoidosis, hemochromatosis, tumor
‚Ä¢ Autoimmune
Collagen vascular disease (3%): polymyositis, SLE, scleroderma, PAN, RA,Wegener‚Äôs
Peripartum (last month S 5 mo postpartum): 0.1% of preg.; c risk w/ multiparity &
c age; 50% will improve; ? c risk w/ next preg. (JAMA 2000;283:1183)
Idiopathic giant cell myocarditis (GCM): avg age 42 y, fulminant,VT (NEJM 1997;336:1860)
Eosinophilic (variable peripheral eosinophilia): hypersensitivity (mild CHF) or
acute necrotizing (ANEM; STE, effusion, severe CHF)
‚Ä¢ Stress-induced (Takotsubo apical ballooning): mimics MI (pain, 	 STE & c Tn; deep TWI
& c QT; mid/apical dyskinesis; ? Rx w/ ACEI; usually improves over wks (NEJM 2005;352:539)
‚Ä¢ Tachycardia-induced: likelihood proportional to rate and duration
‚Ä¢ Arrhythmogenic right ventricular cardiomyopathy (ARVC): fibrofatty replacement
of RV S dilation (dx w/ MRI); ECG: 	 RBBB,TWI V1‚ÄìV3,  wave; risk VT (Circ 2004;110:1879)
‚Ä¢ Metabolic & other: hypothyroidism, acromegaly, pheo, thiamine, sleep apnea
Clinical manifestations
‚Ä¢ Heart failure: both congestive & poor forward flow sx; signs of L- & R-sided HF
diffuse, lat.-displaced PMI, S3, 	 MR or TR (annular dilat., displaced pap. muscle)
‚Ä¢ Embolic events (10%), arrhythmias & palpitations
‚Ä¢ Chest pain can be seen w/ some etiologies (eg, myocarditis)
Diagnostic studies and workup
‚Ä¢ CXR: moderate to marked cardiomegaly, 	 pulmonary edema & pleural effusions
‚Ä¢ ECG: may see PRWP, Q waves, or BBB; low voltage; AF (20%)
‚Ä¢ Echocardiogram: LV dilatation, T EF, regional or global LV HK, 	 RV HK, 	 mural thrombi
‚Ä¢ Laboratory evaluation:TFTs, iron studies, HIV, SPEP, ANA; others per clinical suspicion
‚Ä¢ Family hx (20‚Äì35% w/ familial dis.), genetic counseling 	 genetic testing (JAMA 2009;302:2471)
‚Ä¢ Stress test: completely  test useful to r/o ischemic etiology (low false  rate), but
 test does not rule in ischemic etiology (high false  rate, even w/ imaging)
‚Ä¢ Coronary angiography to r/o CAD if risk factors, h/o angina, Qw MI on ECG,
equivocal ETT; consider CT angiography (JACC 2007;49:2044) 
‚Ä¢ ? Endomyocardial biopsy (JACC 2007;50:1914): yield 10% (of these, 75% myocarditis, 25% 
systemic disease); 40% false  rate (patchy dis.) & false  (necrosis S inflammation)
no proven Rx for myocarditis; ‚à¥biopsy if: acute & hemodyn compromise (r/o GCM,
ANEM); arrhythmia or RCMP features (r/o infiltrative); or suspect toxic, allergic, tumor
‚Ä¢ Cardiac MRI: detect myocarditis or infiltrative disease, but nonspecific (EHJ 2005;26:1461)
Treatment (see ‚ÄúHeart Failure‚Äù for standard HF Rx)
‚Ä¢ Implantation of devices may be tempered by possibility of reversibility of CMP
‚Ä¢ Immunosuppression: for giant cell myocarditis (prednisone  AZA), collagen vascular
disease, peripartum (? IVIg), & eosinophilic; no proven benefit for viral myocarditis
‚Ä¢ Prognosis differs by etiology (NEJM 2000;342:1077): postpartum (best), ischemic (worst)

--- Fim da P√°gina 29 ---

HYPERTROPHIC CARDIOMYOPATHY (HCMP)
Definition and epidemiology
‚Ä¢ LV (usually 15 mm) and/or RV hypertrophy disproportionate to hemodynamic load
‚Ä¢ Prevalence: 1 case/500 population; 50% sporadic, 50% familial
‚Ä¢ Differentiate from 2 LVH: hypertension (espec. elderly women; NEJM 1985;312:277),AS,
elite athletes (wall thickness usually 13 mm & symmetric and nl/c rates of tissue
Doppler diastolic relaxation; NEJM 1991;324:295), Fabry dis. (c Cr, skin findings)
Pathology
‚Ä¢ Autosomal dominant mutations in cardiac sarcomere genes (eg, -myosin heavy chain) 
‚Ä¢ Myocardial fiber disarray with hypertrophy
‚Ä¢ Morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical
Pathophysiology
‚Ä¢ Subaortic outflow obstruction: narrowed tract 2 hypertrophied septum  systolic
anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and
papillary muscle displacement. Gradient (‚àá) worse w/ c contractility
(digoxin, -agonists), T preload, or T afterload.
‚Ä¢ Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and abnormal
mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)
‚Ä¢ Diastolic dysfunction: c chamber stiffness  impaired relaxation
‚Ä¢ Ischemia: small vessel dis., perforating artery compression (bridging), T coronary perfusion
‚Ä¢ Syncope: s in load-dependent CO, arrhythmias
Clinical manifestations (70% are asymptomatic at dx)
‚Ä¢ Dyspnea (90%): due to c LVEDP, MR, and diastolic dysfunction
‚Ä¢ Angina (25%) even w/o epicardial CAD; microvasc. dysfxn (NEJM 2003;349:1027)
‚Ä¢ Arrhythmias (AF in 20‚Äì25%;VT/VF) S palpitations, syncope, sudden cardiac death
Physical exam
‚Ä¢ Sustained PMI, S2 paradox. split if severe outflow obstruction,  S4 (occ. palpable)
‚Ä¢ Systolic crescendo-decrescendo murmur at LLSB: c w/ Valsalva & standing
‚Ä¢ 	 mid-to-late or holosystolic murmur of MR at apex
‚Ä¢ Bisferiens carotid pulse (brisk rise, decline, then 2nd rise); JVP w/ prominent a wave
‚Ä¢ Contrast to AS, which has murmur that T w/ Valsalva and T carotid pulses
Diagnostic studies
‚Ä¢ CXR: cardiomegaly (LV and LA)
‚Ä¢ ECG: LVH, anterolateral and inferior pseudo-Qw, 	 apical giant TWI (apical variant)
‚Ä¢ Echo: no absolute cutoffs for degree of LVH but septum / post wall 1.3 suggestive,
as is septum 15 mm; other findings include dynamic outflow obstruction, SAM, MR
‚Ä¢ MRI: hypertrophy  patchy delayed enhancement (useful for dx & prognosis) 
‚Ä¢ Cardiac cath: subaortic pressure ‚àá; Brockenbrough sign  T pulse pressure post-
extrasystolic beat (in contrast to AS, in which pulse pressure c postextrasystole)
Treatment (NEJM 2004;350:1320)
‚Ä¢ Heart failure
 inotropes/chronotropes: -blockers, CCB (verapamil), disopyramide.
Careful use of diuretics.Vasodilators only if systolic dysfxn.Avoid digoxin.
If refractory to drug therapy and there is obstructive physiology (‚àá50 mmHg):
a) Alcohol septal ablation (NEJM 2002;347:1326)
triphasic ‚àáresponse: acute T S 	 partial c back to 50% of baseline S T over months
by 1 y resting ‚àá15 mmHg & stress-induced ‚àá31 mmHg (J Interv Card 2006;19:319)
complications: transient (& occ. delayed) 3 AVB w/ 10‚Äì20% req. PPM;VT
b) Surgical myectomy: long-term sx improvement in 90% (Circ 2005;112:482)
c) ? Dual-chamber pacing, but largely placebo effect (JACC 1997;29:435; Circ 1999;99:2927)
If refractory to drug therapy and there is nonobstructive pathophysiology: transplant
‚Ä¢ Acute HF: can be precip. by dehydration or tachycardia; Rx w/ fluids, B, phenylephrine 
‚Ä¢ AF: rate control with -blockers, maintain SR with disopyramide, amiodarone
‚Ä¢ Sudden cardiac death: ICD (JACC 2003;42:1687). Major risk factors include history of VT/VF,
 FHx SCD, unexplained syncope, NSVT, T SBP or relative HoTN (c SBP 20
mmHg) w/ exercise, LV wall 30 mm; risk 4%/y in high-risk Pts (JAMA 2007;298:405)
‚Ä¢ Counsel to avoid dehydration, extreme exertion
‚Ä¢ Endocarditis prophylaxis no longer recommended (Circ 2007;16:1736)
‚Ä¢ First-degree relatives: periodic screening w/ echo (as timing of HCMP onset variable)
CMP
1-18

--- Fim da P√°gina 30 ---

RESTRICTIVE CARDIOMYOPATHY (RCMP)
Definition
‚Ä¢ Impaired ventricular filling due to T compliance in absence of pericardial disease
Etiology (NEJM 1997;336:267; JACC 2010;55:1769)
‚Ä¢ Myocardial processes
autoimmune (scleroderma, polymyositis-dermatomyositis)
infiltrative diseases (see primary entries for extracardiac manifestations, Dx, Rx)
amyloidosis (JACC 2007;50:2101): age at presentation 60 y; male:female  3:2
AL (MM, light-chain, MGUS,WM); familial (transthyretin,TTR);AA/senile (TTR, ANP)
ECG: T QRS amplitude (50%), pseudoinfarction pattern (Qw),AVB (10‚Äì20%),
hemiblock (20%), BBB (5‚Äì20%)
Echo: biventricular wall thickening, granular sparkling texture (30%), biatrial
enlargement (40%), thickened atrial septum, valve thickening (65%), diastolic 
dysfxn, small effusion
normal voltage & normal septal thickness has NPV 90%
MRI: distinct late gadolinium enhancement pattern (JACC 2008;51:1022)
sarcoidosis: age at present. 30 y; more common in blacks, N. Europeans, women
5% of those with sarcoid w/ overt cardiac involvement; cardiac w/o systemic in 10%
ECG:AVB (75%), RBBB (20‚Äì60%),VT
Echo: regional WMA (particularly basal septum) with thinning or mild hypertrophy
nuclear imaging: gallium uptake in areas of sestaMIBI perfusion defects
hemochromatosis: presents in middle-aged men (particularly N. European)
storage diseases: Gaucher‚Äôs, Fabry, Hurler‚Äôs, glycogen storage diseases
diabetes mellitus
‚Ä¢ Endomyocardial processes
chronic eosinophilic: L√∂ffler‚Äôs endocarditis (temperate climates; c eos.; mural thrombi
that embolize); endomyocardial fibrosis (tropical climates; var. eos.; mural thrombi)
toxins: radiation, anthracyclines
serotonin: carcinoid, serotonin agonists, ergot alkaloids
metastatic cancer
Pathology & pathophysiology
‚Ä¢ Path: normal or c wall thickness 	 infiltration or abnormal deposition
‚Ä¢ T myocardial compliance S nl EDV but c EDP S c systemic & pulm. venous pressures
‚Ä¢ T ventricular cavity size S T SV and T CO
Clinical manifestations (Circ 2000;101:2490)
‚Ä¢ Right-sided  left-sided heart failure with peripheral edema  pulmonary edema
‚Ä¢ Diuretic ‚Äúrefractoriness‚Äù
‚Ä¢ Thromboembolic events
‚Ä¢ Poorly tolerated tachyarrhythmias;VT S syncope/sudden cardiac death
Physical exam
‚Ä¢ c JVP, 	 Kussmaul‚Äôs sign (classically seen in constrictive pericarditis)
‚Ä¢ Cardiac: 	 S3 and S4, 	 murmurs of MR and TR
‚Ä¢ Congestive hepatomegaly, 	 ascites and jaundice, peripheral edema
Diagnostic studies
‚Ä¢ CXR: normal ventricular chamber size, enlarged atria, 	 pulmonary congestion
‚Ä¢ ECG: low voltage, pseudoinfarction pattern (Qw), 	 arrhythmias
‚Ä¢ Echo: symmetric wall thickening, biatrial enlarge., 	 mural thrombi, 	 cavity oblit.
w/ diast dysfxn: c early diast (E) and T late atrial (A) filling, c E/A ratio, T decel. time
‚Ä¢ Cardiac MRI: may reveal inflammation or evidence of infiltration (although nonspecific)
‚Ä¢ Cardiac catheterization
atria: M‚Äôs or W‚Äôs (prominent x and y descents)
ventricles: dip & plateau (rapid T pressure at onset of diastole, rapid c to early plateau)
concordance of LV and RV pressure peaks during respiratory cycle (vs. discor-
dance in constrictive pericarditis; Circ 1996;93:2007)
‚Ä¢ Endomyocardial biopsy if suspect infiltrative process
‚Ä¢ Restrictive cardiomyopathy vs. constrictive pericarditis: see ‚ÄúPericardial Disease‚Äù
Treatment (in addition to Rx‚Äôing underlying disease)
‚Ä¢ Gentle diuresis. May not tolerate CCB or other vasodilators.
‚Ä¢ Control HR and maintain SR (important for diastolic filling). Dig proarrhythmic in amyloid.
‚Ä¢ Anticoagulation (particularly with AF or low CO)
‚Ä¢ Transplantation for refractory cases
CMP
1-19

--- Fim da P√°gina 31 ---

VALVES
1-20
VALVULAR HEART DISEASE
AORTIC STENOSIS (AS)
Etiology
‚Ä¢ Calcific: predominant cause in Pts 70 y; risk factors include HTN, c chol., ESRD
‚Ä¢ Congenital (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts 70 y
‚Ä¢ Rheumatic heart disease (AS usually accompanied by AI and MV disease)
‚Ä¢ AS mimickers: subvalvular (HCMP, subAo membrane), supravalvular
Clinical manifestations (usually indicates AVA 1 cm2 or concomitant CAD)
‚Ä¢ Angina: c O2 demand (hypertrophy)  T O2 supply (T cor perfusion pressure) 	 CAD
‚Ä¢ Syncope (exertional): peripheral vasodil. w/ fixed CO S T MAP S T cerebral perfusion
‚Ä¢ Heart failure: outflow obstruct  diastolic dysfxn S pulm. edema; precip. by AF (T LV filling)
‚Ä¢ Acquired von Willebrand disease (20% of sev.AS): destruction of vWF (NEJM 2003;349:343)
‚Ä¢ Natural hx: usually slowly progressive (AVA T 0.1 cm2 per y, but varies; Circ 1997;95:2262),
until sx develop; mean survival based on sx: angina  5 y; syncope  3 y; CHF  2 y 
Physical examination
‚Ä¢ Midsystolic crescendo-decrescendo murmur at
RUSB, harsh, high-pitched, radiates to carotids, apex
(holosystolic  Gallavardin effect) c w/ passive leg raise,
T w/ standing & Valsalva
‚Ä¢ In contrast, dynamic outflow obstruction (eg, HCMP) T
w/ passive leg raise & c w/ standing & Valsalva
‚Ä¢ Ejection click after S1 sometimes heard with bicuspid AoV
‚Ä¢ Signs of severity: late-peaking murmur, paradoxically split S2
or inaudible A2, small and delayed carotid pulse (‚Äúpulsus
parvus et tardus‚Äù), LV heave,  S4 (occasionally palpable)
Diagnostic studies
‚Ä¢ ECG: LVH, LAE, LBBB,AF (in late disease)
‚Ä¢ CXR: cardiomegaly,AoV calcification, poststenotic dilation of
ascending Ao, pulmonary congestion
‚Ä¢ Echo: valve morphology, estim pressure gradient & calculate AVA, EF 
‚Ä¢ Cardiac cath: pressure gradiant (‚àá) across AoV,AVA, r/o CAD (in 50% of calcific AS)
‚Ä¢ Dobutamine challenge during echo or cath if low EF and ‚àá30 to differentiate:
afterload mismatch: 20% c SV & c ‚àá, no  AVA (implies contractile reserve & c EF post-AVR) 
pseudostenosis: 20% c SV, no  in ‚àá, c AVA (implies low AVA artifact of LV dysfxn)
limited contractile reserve: no  SV, ‚àá, or AVA (implies EF prob. will not improve w/ AVR)
Classification of Aortic Stenosis
Stage
Mean Gradient (mmHg)
Jet Vel. (m‚ÅÑs)
AVA (cm2)
LVEF
Normal
0
1
3‚Äì4
normal
Mild
25
3
1.5
normal
Moderate
25‚Äì40
3‚Äì4
1.0‚Äì1.5
normal
Severe, compensated
40
4
1.0*
normal
Severe, decompensated
Variable
Variable
1.0*
T
*AVA index (AVA relative to BSA) 0.6 cm2/m2 also qualifies for severe AS.
Treatment (Circ 2008;118:e523 & Lancet 2009;373:956)
‚Ä¢ Management decisions are based on symptoms: once they develop surgery is needed.
If asx, HTN can be cautiously Rx‚Äôd; statins have not been proven to T progression.
‚Ä¢ AVR: only effective Rx for severe AS. Indicated in sx AS (almost invariably severe; if
not, look for another cause of sx) & asx sev. AS  EF 50%. Consider if asx
sev. AS and AVA 0.6 cm2, mean gradient 60 mmHg, aortic jet 5 m/s, T
BP w/ exercise (can carefully exercise asx AS to uncover sx, do not exercise sx
AS), high likelihood of rapid prog. or asx mod sev AS and undergoing CV surgery.
‚Ä¢ Medical therapy: used in sx Pts who are not operative candidates
careful diuresis, control HTN, maintain SR; digoxin if low EF or AF 
avoid venodilators (nitrates) and  inotropes (-blockers & CCB) in severe AS
avoid vigorous physical exertion once AS moderate-severe
? nitroprusside if p/w CHF w/ sev.AS, EF 35%, CI 2.2, & nl BP (NEJM 2003;348:1756)
‚Ä¢ IABP: stabilization, bridge to surgery
‚Ä¢ Balloon Ao valvotomy (BAV): 50% c AVA & T peak ‚àá, but 50% restenosis by 6‚Äì12 mo &
c risk of peri-PAV stroke/AI (NEJM 1988;319:125), ‚à¥bridge to AVR or palliation
‚Ä¢ Transcatheter AoV implantation (TAVI); bioprosthetic valve mounted on balloon-
expandable stent (JACC 2009;53:1829); AVA c 1 cm2 (JACC 2010;55:1080); RCTs ongoing
ECG 
50 
110 
130 
150 
30 
10 
Pathophysiology of Heart
Disease, 4th ed., 2006, for
this and subseq graphics.

--- Fim da P√°gina 32 ---

AORTIC INSUFFICIENCY (AI)
Etiology (Circ 2006;114:422)
‚Ä¢ Valve disease (43%)
rheumatic heart disease (usually mixed AS/AI and concomitant MV disease)
bicuspid AoV: natural hx: 1/3 S normal, 1/3 S AS, 1/6 S AI, 1/6 S endocarditis S AI
infective endocarditis
valvulitis: RA, SLE; anorectics (fen/phen) & other serotoninergics (NEJM 2007;356:29,39)
‚Ä¢ Root disease (57%)
HTN
aortic aneurysm or dissection, annuloaortic ectasia, Marfan syndrome
aortic inflammation: giant cell,Takayasu‚Äôs, ankylosing spond., reactive arthritis, syphilis
Clinical manifestations
‚Ä¢ Acute: sudden T forward SV and c LVEDP (noncompliant ventricle) S pulmonary edema
	 hypotension and cardiogenic shock
‚Ä¢ Chronic: clinically silent while LV dilates (to c compliance to keep LVEDP low) more
than it hypertrophies S chronic volume overload S LV decompensation S CHF
‚Ä¢ Natural hx: variable progression (unlike AS, can be fast or slow); once decompensation
begins, prognosis poor w/o AVR (mortality 10%/y)
Physical examination
‚Ä¢ Early diastolic decrescendo murmur at LUSB
(RUSB if dilated Ao root); c/ sitting forward, expir,
handgrip; severity of AI  duration of murmur (except in 
acute and severe late); Austin Flint murmur:mid-to-late diastolic 
rumble at apex (AI jet interfering w/ mitral inflow) 
‚Ä¢ Wide pulse pressure due to c stroke volume, hyperdy-
namic pulse S many of classic signs (see table); pulse
pressure narrows in late AI with T LV fxn; bisferiens
(twice-beating) arterial pulse
‚Ä¢ PMI diffuse and laterally displaced; soft S1 (early closure of
MV); 	 S3 (Z T EF but rather just volume overload in AI) 
Classic Eponymous Signs in Chronic AI (South Med J 1981;74:459)
Sign
Description
Corrigan‚Äôs pulse
‚Äúwater hammer‚Äù pulse (ie, rapid rise/fall or distention/collapse)
Hill‚Äôs sign
(popliteal SBP ‚Äì brachial SBP) 60 mmHg
Duroziez‚Äôs sign
to-and-fro murmur heard over femoral artery w/ light compression
Pistol shot sounds
pistol shot sound heard over femoral artery
Traube‚Äôs sound
double sound heard over femoral artery when compressed distally
de Musset‚Äôs sign
head-bobbing with each heartbeat (low Se)
M√ºller‚Äôs sign
systolic pulsations of the uvula
Quincke‚Äôs pulses
subungual capillary pulsations (low Sp)
Diagnostic studies
‚Ä¢ ECG: LVH, LAD, abnl repolarization; CXR: cardiomegaly 	 ascending Ao dilatation
‚Ä¢ Echo: severity of AI (severe  width of regurgitant jet 65% LVOT, vena contracta
0.6 cm, regurg fraction 50%, regurg orifice 0.3 cm2, flow reversal in descending
Ao); LV size & fxn
Treatment (Circ 2008;118:e523)
‚Ä¢ Acute decompensation (consider ischemia and endocarditis as possible precipitants)
surgery usually urgently needed for acute severe AI which is poorly tolerated by LV
IV afterload reduction (nitroprusside) and inotropic support (dobutamine)
	 chronotropic support (c HR S T diastole S T time for regurgitation)
pure vasoconstrictors and IABP contraindicated
‚Ä¢ In chronic AI, management decisions based on LV size and fxn (and before sx occur) 
‚Ä¢ Surgery (AVR, replacement or repair if possible)
sx (if equivocal, consider stress test) severe AI (if not severe, unlikely to be cause of sx)
asx severe AI and EF 50% or LV dilation (end syst. diam. 55 mm or end diast. diam.
75 mm, or 50 & 70, respectively, if progression) or undergoing cardiac surgery
‚Ä¢ Medical therapy: vasodilators (nifedipine,ACEI, hydralazine) if severe AI w/ sx or LV
dysfxn & Pt not operative candidate or to improve hemodynamics before AVR;
no clear benefit on clinical outcomes or LV fxn when used to try to prolong compen-
sation in asx severe AI w/ mild LV dilation & nl LV fxn (NEJM 2005;353:1342)
VALVES
1-21
ECG

--- Fim da P√°gina 33 ---

MITRAL REGURGITATION (MR)
Etiology (Lancet 2009;373:1382) 
‚Ä¢ Leaflet abnormalities: myxomatous degeneration (MVP), endocarditis, calcific
RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs
‚Ä¢ Functional: inferoapical papillary muscle displacement due to ischemic LV
remodeling or other causes of DCMP; LV annular dilation due to LV dilation 
‚Ä¢ Ruptured chordae tendinae: myxomatous, endocarditis, spontaneous, trauma
‚Ä¢ Acute papillary muscle dysfxn b/c of ischemia or rupture during MI [usu. posteromedial
papillary m. (supplied by PDA only) vs. anterolateral (suppl. by diags & OMs)]
‚Ä¢ HCMP: (see ‚ÄúCardiomyopathy‚Äù)
Clinical manifestations
‚Ä¢ Acute: pulmonary edema, hypotension, cardiogenic shock (NEJM 2004;351:1627)
‚Ä¢ Chronic: typically asx for yrs, then as LV fails S progressive DOE, fatigue,AF, PHT
‚Ä¢ Prognosis: 5-y survival w/ medical therapy is 80% if asx, but only 45% if sx
Physical examination
‚Ä¢ High-pitched, blowing, holosystolic murmur at apex;
radiates to axilla; 	 thrill; c w/ handgrip (Se 68%, Sp 92%),
T w/ Valsalva (Se 93%) (NEJM 1988;318:1572)
ant. leaflet abnl S post. jet heard at spine 
post. leaflet abnl S ant. jet heard at sternum
‚Ä¢ Lat. displ. hyperdynamic PMI, obscured S1, widely split S2
(A2 early b/c T LV afterload, P2 late if PHT); 	 S3
‚Ä¢ Carotid upstroke brisk (vs. diminished and delayed in AS)
Diagnostic studies
‚Ä¢ ECG: LAE, LVH, 	 atrial fibrillation
‚Ä¢ CXR: dilated LA, dilated LV, 	 pulmonary congestion
‚Ä¢ Echo: MV anatomy (ie, cause of MR); MR severity: jet area
(can underestimate eccentric jets), jet width at origin (‚Äúvena
contracta‚Äù), or effective regurgitant orifice (ERO; predicts survival,
NEJM 2005;352:875); LV fxn (EF should be supranormal if compensated, ‚à¥EF 60% w/ sev.
MR  LV dysfxn);TEE if TTE inconclusive or pre/intraop to guide repair vs. replace
‚Ä¢ Cardiac cath: prominent PCWP cv waves (not spec. for MR), LVgram for MR severity & EF
Classification of Mitral Regurgitation
Severity
Regurg.
Jet Area
Jet width
ERO
Angio
fraction
(% of LA)
(cm)
(cm2)
(see footnote)
Mild
30%
20
0.3
0.2
1
Moderate
30‚Äì49%
20‚Äì40
0.3‚Äì0.69
0.2‚Äì0.39
2
Severe
50%
40
0.70
0.40
3/4
1  LA clears w/ each beat; 2  LA does not clear, faintly opac. after several beats; 3  LA & LV opac. equal
Treatment (Circ 2008;118:e523; NEJM 2009;361:2261)
‚Ä¢ Acute decompensation (consider ischemia and endocarditis as precipitants)
IV afterload reduction (nitroprusside), 	 inotropes (dobuta), IABP, avoid vasoconstrictors 
surgery usually needed for acute severe MR as prognosis is poor w/o MVR
‚Ä¢ Surgery (repair [preferred if feasible] vs. replacement w/ preservation of mitral apparatus)
sx severe MR, asx severe MR and EF 30‚Äì60% or LV sys. diam.  40 mm
consider MV repair for asx severe MR w/ preserved EF, esp. if new AF or PHT
if in AF, Maze procedure or pulm vein isolation may S NSR and prevent future stroke
‚Ä¢ In Pts undergoing CABG w/ mod/sev fxnal ischemic MR, consider annuloplasty ring
‚Ä¢ Percutaneous MV repair: edge-to-edge clip may be noninferior to surgery (EVEREST II,
ACC 2010); annuloplasty band placed in coronary sinus (Circ 2006;113:851) under study 
‚Ä¢ Medical: ‚àÖbenefit (incl ACEI) in asx Pts; indicated if sx but not an operative candidate 
T preload (T CHF and MR by T MV orifice): diuretics, nitrates (espec if ischemic/fxnal MR)
if LV dysfxn:ACEI, B (carvedilol), 	 biV pacing; maintain SR
MITRAL STENOSIS (MS)
Etiology
‚Ä¢ Rheumatic heart disease (RHD): fusion of commissures S ‚Äúfish mouth‚Äù valve
from autoimmune rxn to  strep infxn; seen largely in developing world today
‚Ä¢ Mitral annular calcification (MAC): encroachment upon leaflets S functional MS
‚Ä¢ Congenital, infectious endocarditis w/ large lesion, myxoma, thrombus 
‚Ä¢ Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)
VALVES
1-22
Tall v
wave
ECG 

--- Fim da P√°gina 34 ---

Clinical manifestations (Lancet 2009;374:1271)
‚Ä¢ Dyspnea and pulmonary edema (if due to RHD, sx usually begin in 30s)
precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia,AF
‚Ä¢ Atrial fibrillation: onset often precipitates heart failure in Pts w/ MS
‚Ä¢ Embolic events: commonly cerebral, especially in AF or endocarditis
‚Ä¢ Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure
‚Ä¢ Ortner‚Äôs syndrome: hoarseness from LA compression of recurrent laryngeal nerve
Physical examination
‚Ä¢ Low-pitched mid-diastolic rumble at apex
w/ presystolic accentuation (if not in AF); best
heard in L lat decubitus position during expi-
ration, c w/ exercise; severity proportional to
duration (not intensity) of murmur 
‚Ä¢ Opening snap (high-pitched early diastolic
sound at apex) from fused leaflet tips;
MVA proportional to S2‚ÄìOS interval (tighter 
valve S c LA pressure S shorter interval)
‚Ä¢ Loud S1 (unless MV calcified)
Diagnostic studies
‚Ä¢ ECG: LAE (‚ÄúP mitrale‚Äù), 	 AF, 	 RVH
‚Ä¢ CXR: dilated LA (straightening of left heart border, double density on right, left
mainstem bronchus elevation)
‚Ä¢ Echo: estimate pressure gradient (‚àá), RVSP, valve area, valve echo score (0‚Äì16, based on
leaflet mobility & thickening, subvalvular thickening, Ca; exercise TTE if discrepancy
between sx and severity of MS at rest;TEE to assess for LA thrombus before PMV 
‚Ä¢ Cardiac cath: ‚àáfrom simultaneous PCWP & LV pressures, calculated MVA; LA
pressure tall a wave and blunted y descent; c PA pressures
Classification of Mitral Stenosis
Stage
Mean gradient (mmHg)
MV area (cm2)
PA Systolic (mmHg)
Normal
0
4‚Äì6
25
Mild
5
1.5‚Äì2
30
Moderate
5‚Äì10
1‚Äì1.5
30‚Äì50
Severe
10
1
50
Treatment (Circ 2008;118:e523)
‚Ä¢ Medical: Na restriction, cautious diuresis, -blockers, sx-limited physical stress
‚Ä¢ Anticoagulation if AF, prior embolism, LA thrombus, or large LA
‚Ä¢ Indications for mechanical intervention: heart failure sx w/ MVA 1.5 or
heart failure sx w/ MVA 1.5 but c PASP, PCWP, or MV ‚àáw/ exercise, or
asx Pts w/ MVA 1.5 and PHT (PASP 50 or 60 mmHg w/ exercise) or new-onset AF
‚Ä¢ Percutaneous mitral valvotomy (PMV): preferred Rx if RHD; MVA doubles, ‚àáT by 50%;
MVR if valve score 8,  mild MR, √ò AF or LA clot (NEJM 1994;331:961; Circ 2002;105:1465)
‚Ä¢ Surgical (MV repair if possible, o/w replacement): consider in sx Pts w/ MVA 1.5
if PMV unavailable or contraindicated (mod. MR, LA clot), or valve morphology unsuitable
‚Ä¢ Pregnancy: if NYHA class III/IV S PMV, o/w medical Rx w/ low-dose diuretic & B
MITRAL VALVE PROLAPSE (MVP)
Definition and Etiology
‚Ä¢ Billowing of MV leaflet 2 mm above mitral annulus in parasternal long axis echo view
‚Ä¢ Leaflet redundancy from myxomatous proliferation of spongiosa of MV apparatus 
‚Ä¢ Idiopathic, familial, and a/w connective tissue diseases (eg, Marfan‚Äôs, Ehlers-Danlos)
‚Ä¢ Prevalence 1‚Äì2.5% of gen. population,  (NEJM 1999;341:1), most common cause of MR
Clinical manifestations (usually asymptomatic)
‚Ä¢ MR (from leaflet prolapse or ruptured chordae); infective endocarditis; embolic events
‚Ä¢ Arrhythmias, rarely sudden cardiac death
Physical exam
‚Ä¢ High-pitched, midsystolic click 	 mid-to-late systolic murmur
T LV volume (standing) S click earlier; c LV volume or afterload S click later, softer
Treatment
‚Ä¢ Endocarditis prophylaxis no longer recommended (Circ 2007:116:1736)
‚Ä¢ Aspirin or anticoagulation if prior neurologic event or atrial fibrillation
VALVES
1-23
ECG 
OS

--- Fim da P√°gina 35 ---

PROSTHETIC HEART VALVES
Mechanical (60%)
‚Ä¢ Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball
‚Ä¢ Characteristics: very durable (20‚Äì30 y), but thrombogenic and ‚à¥require anticoagulation
consider if age 65 y or if anticoagulation already indicated (JACC 2010;55:2413)
Bioprosthetic (40%)
‚Ä¢ Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft 
‚Ä¢ Characteristics: less durable, but minimally thrombogenic
consider if age 65 y, lifespan 20 y, or contraindication to anticoagulation
Physical examination
‚Ä¢ Normal: crisp sounds, 	 soft murmur during forward flow (normal to have small ‚àá)
‚Ä¢ Abnormal: regurgitant murmurs, absent mechanical valve closure sounds
Anticoagulation (Circ 2008;118:e523)
‚Ä¢ Warfarin
low-risk mech AVR: INR 2‚Äì3 (consider 2.5‚Äì3.5 for 1st 3 mo)
mech MVR or high-risk (defined below) mech AVR: INR 2.5‚Äì3.5
high-risk bioprosthetic: INR 2‚Äì3 (and consider for 1st 3 mo in low-risk)
high-risk features: prior thromboembolism,AF, T EF, hypercoagulable 
‚Ä¢ ASA (75‚Äì100 mg) indicated for all Pts with prosthetic valves; avoid adding to 
warfarin if h/o GIB, uncontrolled HTN, erratic INR, or 80 y
Periprocedural ‚ÄúBridging‚Äù of Anticoagulation in Pts with Mechanical Valve(s)
AVR w/o risk factors
d/c warfarin 48‚Äì72 h before surg; restart 24 h after surg
MVR or AVR w/ risk factors
Preop: d/c warfarin, start UFH when INR 2
4‚Äì6 h preop: d/c UFH; postop: restart UFH & warfarin ASAP
Procedures include noncardiac surgery, invasive procedures, and major dental work (Circ 2008;118:e523)
Correction of overanticoagulation (Circ 2008;118:e626)
‚Ä¢ Risk from major bleeding must be weighed against risk of valve thrombosis
‚Ä¢ Not bleeding & INR 5: withhold warfarin, do not give vit K, ‚úìserial INRs
‚Ä¢ Not bleeding & INR 5‚Äì10: withhold warfarin, vit K 1‚Äì2.5 mg PO, ‚úìserial INRs
‚Ä¢ Bleeding or INR 10: FFP 	 low-dose (1 mg) vit K IV
Endocarditis prophylaxis (see ‚ÄúEndocarditis‚Äù)
‚Ä¢ Indicated for all prosthetic valves to T IE risk during transient bacteremia
Complications 
‚Ä¢ Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley;
bioprosthetic valves: up to 30% fail rate w/in 10‚Äì15 y, mitral  aortic
‚Ä¢ Paravalvular leak (r/o endocarditis); small central jet of regurg is normal in mech. valves
‚Ä¢ Obstruction from thrombosis or pannus ingrowth: ‚úìTTE,TEE and/or fluoroscopy if ? clot
significantly sx pannus ingrowth: remove w/ surgery
thrombosis: surgery if left-sided valve & either severe sx or lg (? 1 cm) clot burden;
fibrinolytic Rx often ineffective for left-sided thrombosis & 12‚Äì15% risk of stroke;
consider UFH 	 lytic if mild sx and small clot burden or poor surg candidate;
fibrinolytic therapy reasonable for right-sided thrombosis 
‚Ä¢ Infective endocarditis 	 valvular abscess and conduction system disruption
‚Ä¢ Embolization (r/o endocarditis); risk 1%/y w/ warfarin (vs. 2% w/ ASA, or 4% w/o meds)
mech MVR 2 risk of embolic events vs. mech AVR (Circ 1994:89:635)
‚Ä¢ Bleeding (from anticoag), hemolysis (especially w/ caged-ball valves or paravalvular leak)
HEART VALVES (superior view, JAMA 1976;235:1603)
AV  aortic valve
AVN  AV node
B His  bundle of His
CS  coronary sinus
Cx  circumflex artery
LAD  left anterior descending artery
LAF  left anterior fascicle
LCA  left coronary artery
LPF  left posterior fascicle
MV  mitral valve
RB  right bundle
RC/LC/NC  right/left/noncoronary cusp
RCA  right coronary artery
TV  tricuspid valve
VALVES
1-24

--- Fim da P√°gina 36 ---

PERICARDIAL
1-25
PERICARDIAL DISEASE
GENERAL PRINCIPLES
Anatomy
‚Ä¢ 2-layered (parietal & visceral) tissue sac surrounding heart & proximal great vessels
Disease states
‚Ä¢ Inflammation (w/ or w/o fluid accumulation) S pericarditis
‚Ä¢ Fluid accumulation (usually in setting of inflammation) S effusion 	 tamponade
‚Ä¢ Change in compliance (sequela of inflammation) S constriction
‚Ä¢ Tamponade and constriction characterized by increased ventricular interdependence
PERICARDITIS AND PERICARDIAL EFFUSION
Etiologies of Pericarditis (Lancet 2004;363:717)
Infectious
Viral: Coxsackie, echo, adeno, EBV,VZV, HIV, influenza
(50%)
Bacterial (from endocarditis, pneumonia, or s/p cardiac surgery):
S. pneumococcus, N. meningitidis, S. aureus, Borrelia (Lyme)
Tuberculous (extension from lung or hematogenous)
Fungal: Histo, Coccidio, Candida; Parasitic: Entamoeba, Echino
Neoplastic
Common: metastatic (lung, breast, lymphoma, leukemia, renal cell)
(35%)
Rare: primary cardiac & serosal tumors (mesothelioma)
Autoimmune
Connective tissue diseases: SLE, RA, scleroderma, Sj√∂gren‚Äôs
Vasculitides: PAN, Churg-Strauss,Wegener‚Äôs
Drug-induced: procainamide, hydralazine, INH, CsA
Uremia
Develops in 20% of Pts, especially if on HD. May be transudative.
Cardiovascular
Acute transmural MI (5‚Äì20%); late post-MI (Dressler‚Äôs syndrome)
Proximal aortic dissection (up to 45%)
Chest trauma or s/p cardiac procedure or surgery
Radiation
4,000 cGy to mediastinum; acute or delayed; may be transudative
Idiopathic
Most presumed to be undiagnosed viral
Effusions w/o
CHF, cirrhosis, nephrotic syndrome, hypothyroidism, amyloidosis.;
pericarditis
Transudative.
Clinical manifestations (NEJM 2004;351:2195)
‚Ä¢ Pericarditis: chest pain that is pleuritic, positional (T by sitting forward), radiates to
trapezius; may be absent in tuberculous, neoplastic, post-XRT, and uremic pericarditis;
	 fever; 	 s/s of systemic etiologies
‚Ä¢ Effusion: ranges from asx to tamponade (see below)
Physical exam
‚Ä¢ Pericarditis: multiphasic friction rub best heard at LLSB w/ diaphragm of stethoscope
(leathery sound w/ up to 3 components: atrial contraction, ventricular contraction,
ventricular relaxation) that is notoriously variable and evanescent
‚Ä¢ Effusion: distant heart sounds, dullness over left posterior lung field due to 
compressive atelectasis from pericardial effusion (Ewart‚Äôs sign)
Diagnostic studies (EHJ 2004;25:587; Circ 2006;113:1622)
‚Ä¢ ECG: may show diffuse STE (concave up) & PR depression (except in aVR: ST T & PR c),
TWI; classically and in contrast to STEMI,TWI do not occur until STs normalize
Stages: STE & PR T (I); ST & PR normalize (II); diffuse TWI (III);Tw normalize (IV).
May show evidence of large effusion w/ low voltage & electrical alternans (beat-to-
beat  in QRS amplitude and/or axis).
‚Ä¢ CXR: if large effusion (250 mL of fluid) S c cardiac silhouette w/ ‚Äúwater-bottle‚Äù
heart and epicardial halo
‚Ä¢ Echocardiogram: presence, size, & location of effusion; presence of tamponade
physiology; pericarditis itself w/o spec. abnl (‚à¥echo can be nl), although can see
pericardial stranding (fibrin or tumor); can also detect asx myocarditis
‚Ä¢ CT will reveal pericardial effusions, often appearing larger than on echocardiography
‚Ä¢ CK-MB or troponin ( in 30%, JACC 2003;42:2144) if myopericarditis
Workup for effusion
‚Ä¢ r/o infxn: usually apparent from Hx & CXR; ? ‚úìacute and convalescent serologies
‚Ä¢ r/o noninfectious etiologies: BUN, Cr, ANA, RF, screen for common malignancies

--- Fim da P√°gina 37 ---

‚Ä¢ Pericardiocentesis if suspect infxn or malignancy or if effusion large (2 cm)
‚úìcell counts,TP, LDH, glc, gram stain & Cx,AFB, cytology
ADA, PCR for MTb, and specific tumor markers as indicated by clinical suspicion
‚Äúexudate‚Äù criteria:TP 3 g/dL,TPeff/TPserum 0.5,LDHeff/LDHserum 0.6,or glc 60 mg/dL
high Se (90%) but very low Sp (20%); overall low utility (Chest 1997;111:1213)
‚Ä¢ Pericardial bx if suspicion remains for malignancy or tuberculosis
Treatment of pericarditis (EHJ 2004;25:587; Circ 2006;113:1622)
‚Ä¢ NSAIDs (eg, ibuprofen 600‚Äì800 mg tid) 	 colchicine 0.5 mg bid (Circ 2005;112:2012) 
sx usually subside in 1‚Äì3 d, continue Rx for 7‚Äì14 d (JAMA 2003;289:1150)
‚Ä¢ Steroids (usually systemic; occ. intrapericardial) for systemic rheum or autoimmune
disorder, uremic, preg., contraindication to NSAID, or refractory idiopathic dis.
Risks of steroids: ? c rate of relapse, and c osteoporosis, Cushing‚Äôs (Circ 2008;118:667).
‚Ä¢ Avoid anticoagulants
‚Ä¢ Infectious effusion S pericardial drainage (preferably surgically)  systemic antibiotics
‚Ä¢ Acute idiopathic effusion self-limited in 70‚Äì90% of cases
‚Ä¢ Recurrent effusion S consider pericardial window (percutaneous vs. surgical)
PERICARDIAL TAMPONADE
Etiology
‚Ä¢ Any cause of pericarditis but especially malignancy, uremia, idiopathic,
proximal aortic dissection with rupture, myocardial rupture
‚Ä¢ Rapidly accumulating effusions most likely to cause tamponade as no time for 
pericardium to stretch (c compliance) and accommodate fluid
Pathophysiology (NEJM 2003;349:684)
‚Ä¢ c intrapericardial pressure, compression of heart chambers, T venous return S T CO
‚Ä¢ Diastolic pressures c & equalize in all cardiac chambers S minimal flow of blood from
RA to RV when TV opens S blunted y descent
‚Ä¢ c ventricular interdependence S pulsus paradoxus (pathologic exaggeration of nl physio) 
Inspiration S T intrapericardial & RA pressures S c venous return S c RV size S
septal shift to left.Also, c pulmonary vascular compliance S T pulm venous return.
Result is T LV filling S T LV stroke volume & blood pressure.
Clinical manifestations
‚Ä¢ Cardiogenic shock (hypotension, fatigue) without pulmonary edema
‚Ä¢ Dyspnea (seen in 85%) may be due to c respiratory drive to augment venous return
Physical exam (JAMA 2007;297:1810)
‚Ä¢ Beck‚Äôs triad (present in minority): distant heart sounds, c JVP, hypotension
‚Ä¢ c JVP (76%) w/ blunted y descent
‚Ä¢ Reflex tachycardia (77%), hypotension (26%; occasionally hypertensive), cool extremities
‚Ä¢ Pulsus paradoxus (Se 82%, Sp 70%)  T SBP 10 mmHg during inspiration
LR 3.3 (5.9 if pulsus 12), LR 0.03
Ddx  PE, hypovolemia, severe obstructive lung disease, constriction (1/3), CHF
Can be absent if pre-existing c LVEDP, cardiac arrhythmia, or regional tamponade
‚Ä¢ Distant heart sounds (28%), 	 pericardial friction rub (30%)
‚Ä¢ Tachypnea but clear lungs
Diagnostic studies
‚Ä¢ ECG: T voltage (seen in 42%), electrical alternans, 	 signs of pericarditis
‚Ä¢ CXR: c cardiac silhouette (89%)
‚Ä¢ Echocardiogram:  effusion, IVC plethora, septal shift with inspiration,
diastolic collapse of RA (Se 85%, Sp 80%) and/or RV (Se 80%, Sp 90%)
respirophasic ‚Äôs in transvalvular velocities (c across TV & T across MV w/ inspir.)
postsurgical tamponade may be localized and not easily visible 
‚Ä¢ Cardiac cath (right heart and pericardial): elevation (15‚Äì30 mmHg) and equalization of
intrapericardial and diastolic pressures (RA, RV, PCWP), blunted y descent in RA
c in stroke volume postpericardiocentesis ultimate proof of tamponade
if RA pressure remains elevated after drainage, may have effusive-constrictive disease
(NEJM 2004;350:469) or myocardial dysfxn (eg, from concomitant myocarditis)
Treatment
‚Ä¢ Volume (but be careful as overfilling can worsen tamponade) and  inotropes (avoid B)
‚Ä¢ Pericardiocentesis (except if due to aortic or myocardial rupture, in which cases 
consider removing just enough fluid to reverse PEA while awaiting surgery)
PERICARDIAL
1-26

--- Fim da P√°gina 38 ---

PERICARDIAL
1-27
CONSTRICTIVE PERICARDITIS
Etiology
‚Ä¢ Any cause of pericarditis but especially postviral, radiation, uremia, TB, post-
cardiac surgery, and idiopathic
Pathophysiology
‚Ä¢ Rigid pericardium limits diastolic filling S c systemic venous pressures
‚Ä¢ Venous return is limited only after early rapid filling phase; ‚à¥rapid T in RA pressure with
atrial relaxation and opening of tricuspid valve and prominent x and y descents
‚Ä¢ Kussmaul‚Äôs sign: JVP does not decrease with inspiration (c venous return with inspi-
ration, but negative intrathoracic pressure not transmitted to heart because of
rigid pericardium)
Clinical manifestations
‚Ä¢ Right-sided  left-sided heart failure
Physical exam
‚Ä¢ c JVP with prominent y descent,  Kussmaul‚Äôs sign (Ddx:TS, acute cor pulmonale,
RV infarct, RCMP)
‚Ä¢ Hepatomegaly, ascites, peripheral edema
‚Ä¢ PMI usually not palpable, pericardial knock, usually no pulsus paradoxus
Diagnostic studies
‚Ä¢ ECG: nonspecific,AF common in advanced cases
‚Ä¢ CXR: calcification (MTb most common cause), especially in lateral view (although does
not necessarily  constriction)
‚Ä¢ Echocardiogram: 	 thickened pericardium, ‚Äúseptal bounce‚Äù  abrupt posterior dis-
placement of septum during rapid filling in early diastole
‚Ä¢ Cardiac catheterization
atria: Ms or Ws (prominent x and y descents)
ventricles: dip-and-plateau or square-root sign (rapid T pressure at onset of
diastole, rapid c to early plateau)
discordance between LV & RV pressure peaks during respiratory cycle (Circ 1996;93:2007)
‚Ä¢ CT or MRI: thickened pericardium (4 mm on CT) with tethering
Treatment
‚Ä¢ Diuresis for intravascular volume overload, surgical pericardiectomy
Constrictive Pericarditis vs. Restrictive Cardiomyopathy
Evaluation
Constrictive pericarditis
Restrictive cardiomyopathy
 Kussmaul‚Äôs sign
	 Kussmaul‚Äôs sign
Physical exam
Absent PMI
Powerful PMI, 	 S3 and S4
 Pericardial knock
	 Regurg murmurs of MR,TR
ECG
	 Low voltage
Low voltage
	 Conduction abnormalities
Normal wall thickness
	 c wall thickness
Septal bounce during
Biatrial enlargement
early diastole
Inspir. S T flow across TV & MV
Echocardiogram
Inspir. S c flow across
Slower peak filling rate
TV and T flow across MV
Longer time to peak filling rate
E (tissue velocity) nl/c
E T
Expir. hepatic vein flow reversal
Inspir. hepatic vein flow reversal
CT/MRI
Thickened pericardium
Normal pericardium
Prominent x and y descents
Dip-and-plateau sign
LVEDP  RVEDP
LVEDP  RVEDP (espec. w/ vol.)
RVSP 55 (Se 90%, Sp 29%)
RVSP 55 mmHg
Cardiac
RVEDP 1‚ÅÑ3 RVSP (Se 93%, Sp 46%)
RVEDP 1‚ÅÑ3 RVSP
catheterization
Discordance of LV & RV
Concordance of LV & RV pressure 
pressure peaks during 
peaks during respiratory cycle
respiratory cycle
Systolic area index (ratio of RV to Systolic area index 1.1
LV pressure‚Äìtime area in inspir
(JACC 2008;51:315)
vs. expir) 1.1 (Se 97%, Sp 100%)
Endomyocardial
Usually normal
 Specific etiology of RCMP
biopsy

--- Fim da P√°gina 39 ---

HYPERTENSION
1-28
HYPERTENSION
JNC VII Classification
Category
Systolic (mmHg)
Diastolic (mmHg)
Normal
120
80
Pre-HTN
120‚Äì139
80‚Äì89
Stage 1 HTN
140‚Äì159
90‚Äì99
Stage 2 HTN
160
100
Epidemiology (JAMA 2003;290:199)
‚Ä¢ Prevalence 30% in U.S. adults; 65 million affected (29% in whites, 33.5% in blacks)
‚Ä¢ 60% of those w/ HTN are on Rx, only half of whom are adequately controlled
Etiologies
‚Ä¢ Essential (95%): onset 25‚Äì55 y;  FHx. Unclear mechanism but ? additive microvasc 
renal injury over time w/ contribution of hyperactive sympathetics (NEJM 2002;346:913)
genetic loci under investigation (Nat Genet 2009;41:666 & 677)
‚Ä¢ Secondary: Consider if Pt 20 or 50 y or if sudden onset, severe, refractory or c HTN
Secondary Causes of Hypertension
Diseases
Suggestive Findings
Initial Workup
Renal parenchymal
h/o DM, polycystic kidney 
CrCl, albuminuria
(2‚Äì3%)
disease, glomerulonephritis
See ‚ÄúRenal Failure‚Äù
Renovascular (1‚Äì2%)
ARF induced by ACEI/ARB
MRA (90% Se & Sp),
Athero (90%)
Recurrent flash pulm edema
CTA, duplex U/S, angio,
FMD (10%, young women)
Renal bruit; hypokalemia
plasma renin (low Sp)
PAN, scleroderma
(NEJM 2009;361:1972)
Hyperaldo or
Hypokalemia
See ‚ÄúAdrenal Disorders‚Äù
Cushing‚Äôs (1‚Äì5%)
Metabolic alkalosis
Pheochromocytoma (1%)
Paroxysmal HTN, H/A, palp.
Myxedema (1%)
See Thyroid Disorders
TFTs
Hypercalcemia (1%)
Polyuria, dehydration,  MS
ICa
Obstructive sleep apnea (qv)
Medications: OCP, steroids, licorice; NSAIDs (espec. COX-2); Epo; cyclosporine
Coarctation of aorta: T LE pulses, systolic murmur, radiofemoral delay; abnl TTE, CXR
Polycythemia vera: c Hct
Standard workup
‚Ä¢ Goals: (1) identify CV risk factors or other diseases that would modify prognosis or Rx;
(2) reveal 2 causes of hypertension; (3) assess for target-organ damage
‚Ä¢ History: CAD, CHF,TIA/CVA, PAD, DM, renal insufficiency, sleep apnea;  FHx for HTN
diet, Na intake, smoking, alcohol, prescription and OTC medications, OCP
‚Ä¢ Physical exam: ‚úìBP in both arms; funduscopic, cardiac (LVH, murmurs), vascular,
abdominal (masses or bruits), neurologic
‚Ä¢ Laboratory tests: K, BUN, Cr, Ca, glc, Hct, U/A, lipids,TSH, ECG (for LVH), CXR,
urinary albumin:creatinine (if appropriate) 
Complications of HTN
‚Ä¢ Each c 20 mmHg SBP or 10 mmHg DBP S 2 c CV complications (Lancet 2002;360:1903)
‚Ä¢ Neurologic: TIA/CVA, ruptured aneurysms
‚Ä¢ Retinopathy: I  arteriolar narrowing, II  copper-wiring,AV nicking, III  hemorrhages
and exudates, IV  papilledema
‚Ä¢ Cardiac: CAD, LVH, CHF
‚Ä¢ Vascular: aortic dissection, aortic aneurysm
‚Ä¢ Renal: proteinuria, renal failure
Treatment (NEJM 2003;348:610)
‚Ä¢ Goal: 140/90 mmHg; if DM or renal disease goal is 130/80 mmHg
‚Ä¢ Treatment results in 50% T CHF, 40% T stroke, 20‚Äì25% T MI (Lancet 2000;356:1955);
benefits of Rx‚Äôing stage II HTN extend to Pts 80 y (NEJM 2008;358:1887)
‚Ä¢ Lifestyle modifications (each T SBP 5 mmHg)
weight loss: goal BMI 18.5‚Äì24.9; aerobic exercise: 30 min exercise/d, 5 d/wk
diet: rich in fruits & vegetables, low in saturated & total fat (DASH, NEJM 2001;344:3)
sodium restriction: 2.4 g/d and ideally 1.5 g/d (NEJM 2010;362:2102)
limit alcohol consumption: 2 drinks/d in men; 1 drink/d in women & lighter-wt Pts
BP should be determined by
making 2 measurements
separated by 2 min.
Confirm stage 1 w/in 2 mo;
can Rx stage 2 immediately.
(JAMA 2003;289:2560;
JNC VIII forthcoming)
OTHER
ENDO
RENAL

--- Fim da P√°gina 40 ---

‚Ä¢ Pharmacologic options (if HTN or pre-HTN  diabetes or renal disease)
Pre-HTN: ARB prevents onset of HTN, no T in clinical events (NEJM 2006;354:1685)
HTN: choice of therapy controversial, concomitant disease may help guide
uncomplicated: ? thiazide better than ACEI or CCB in preventing CVD (JAMA
2002;288:2981; NEJM 2009;361:2153); -blockers not first line (Lancet 2005;366:1545)
 high-risk CAD:ACEI (NEJM 2000;342;145) or ARB (NEJM 2008;358:1547);ACEI  CCB
superior to ACEI  thiazide (NEJM 2008;359:2417) or B  diuretic (Lancet 2005;366:895)
 angina: -blockers, CCB 
 post-MI: B (JAMA 1982;247:1707),ACEI (NEJM 1992;327:669), 	 aldosterone antagonist
 HF:ACEI/ARB, -blockers, diuretics, aldosterone antagonist (see ‚ÄúHeart Failure‚Äù)
 recurrent stroke prevention:ACEI (Lancet 2001;358:1033); benefit of ARB unclear
(Lancet 2002;359:995; NEJM 2008;359:1225).
 diabetes mellitus: ACEI or ARB; can also consider diuretic, BB, or CCB
 chronic kidney disease:ACEI/ARB (NEJM 1993;329:1456 & 2001;345:851, 861)
most will require 2 drugs; if not at goal S optimize doses or add drug 
‚Ä¢ Secondary causes
Renovasc: control BP w/ diuretic  ACEI/ARB (watch for c Cr w/ bilat. RAS) or CCB
Atherosclerosis risk-factor modification: quit smoking, T chol.
If refractory HTN, recurrent HF, UA, or worse CKD, revasc. indicated (JACC 2006;47:1)
For atherosclerosis: stenting T restenosis vs. PTA alone, but no clear improvement in
BP or renal function vs. med Rx alone (NEJM 2009;361:1953; Annals 2009;150:840)
For FMD (usually more distal lesions): PTA 	 bailout stenting
Surgery for complex lesions or aortic involvement
Renal parenchymal: salt and fluid restriction, 	 diuretics
Endocrine etiologies: see ‚ÄúAdrenal Disorders‚Äù
‚Ä¢ Pregnancy: methyldopa, labetalol; other B and CCB probably safe
HYPERTENSIVE CRISES
‚Ä¢ Hypertensive emergency: c BP S acute target-organ ischemia and damage
neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema
cardiac damage:ACS, HF/pulmonary edema, aortic dissection
renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis
microangiopathic hemolytic anemia; preeclampsia-eclampsia
‚Ä¢ Hypertensive urgency: SBP 180 or DBP 120 (?110) w/ min./no target-organ damage
Precipitants
‚Ä¢ Progression of essential HTN 	 medical noncompliance (especially clonidine)
‚Ä¢ Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia
‚Ä¢ Endocrine: pheochromocytoma, Cushing‚Äôs
‚Ä¢ Sympathomimetics: cocaine, amphetamines, MAO inhibitors  foods rich in tyramine
‚Ä¢ Cerebral injury (do not treat HTN in acute ischemic stroke unless Pt getting lysed, extreme,
BP, ie, 220/120, or Ao dissection, active ischemia, or CHF; Stroke 2003;34:1056)
Treatment (Chest 2007;131:1949)
‚Ä¢ Tailor goals to clinical context (eg, more rapid lowering for Ao dissection)
‚Ä¢ Emergency: T MAP by 25% in mins to 2 h w/ IV agents (may need arterial line for
monitoring); goal DBP 110 w/in 2‚Äì6 h, as tolerated
‚Ä¢ Urgency: T BP in hours using PO agents; goal normal BP in 1‚Äì2 d
‚Ä¢ Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated
Drugs for Hypertensive Crises
Intravenous agents
Oral agents
Agent
Dose
Agent
Dose
Nitroprusside*
0.25‚Äì10 g/kg/min
Captopril
12.5‚Äì100 mg tid
Nitroglycerin
17‚Äì1000 g/min
Labetalol
200‚Äì800 mg tid
Labetalol
20 mg load S 20‚Äì80 mg IVB
Clonidine
0.2 mg load S
q10min or 0.5‚Äì2 mg/min
0.1 mg qh
Hydralazine
10‚Äì20 mg q20‚Äì30min
Hydralazine
10‚Äì75 mg qid
Esmolol
500 g/kg load S 25‚Äì300 g/kg/min
Fenoldopam
0.1‚Äì1.6 g/kg/min
Nicardipine
5‚Äì15 mg/h
Phentolamine
5‚Äì15 mg bolus q5‚Äì15min
*Metabolized to cyanide S  MS, lactic acidosis, death. Limit use of very high doses (8‚Äì10 g/kg/min) to 10 min.
Monitor thiocyanate levels. Hydroxocobalamin or sodium thiosulfate infusion for treatment of cyanide toxicity.
HYPERTENSION
1-29

--- Fim da P√°gina 41 ---

AORTA
1-30
AORTIC ANEURYSM
Definitions
‚Ä¢ True aneurysm (involves all 3 layers of aorta) vs. false (rupture contained in adventitia)
‚Ä¢ Location: root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoab-
dominal aortic aneurysm, abdominal aortic aneurysm (AAA)
‚Ä¢ Type: fusiform (circumferential dilation) vs. saccular (localized dilation)
Epidemiology (Circ 2005;111:816 & 2008;117:242)
‚Ä¢ Aortic aneurysms 13th leading cause of death in U.S. (15,000 deaths/y from ruptures)
‚Ä¢ TAA: : 1.7:1; usually involves root/asc Ao or descending Ao (arch & thoracoabd rare)
Risk factors: HTN; atherosclerosis; aortitis (Takayasu‚Äôs, GCA, spondyloarthritis,
syphilis); congenital (bicuspid AoV,Turner‚Äôs); connective tissue diseases
(Marfan, Ehlers-Danlos type IV); familial; chronic Ao dissection; trauma
‚Ä¢ AAA: 5% prev. in individuals 65 y; 5‚Äì10 more common in  than ; most infrarenal
Risk factors  risk factors for atherosclerosis: smoking, HTN, hyperlipidemia, age, FHx
Pathophysiology (NEJM 2009;361:1114; Nat Med 2009;15:649)
‚Ä¢ LaPlace‚Äôs law: tension across a cylinder ‚àù[(P  r) / (wall thickness)]
‚Ä¢ TAA: cystic medial necrosis (medial degeneration, mucoid infiltration, apoptosis) 
‚Ä¢ AAA: atherosclerosis & inflammation S matrix degeneration S medial weakening
‚Ä¢ Inflammatory and infectious (‚Äúmycotic‚Äù) aneurysms rare
Screening (JAMA 2009;302:2015)
‚Ä¢ TAA: no established population screening guidelines
‚Ä¢ AAA: ‚úìfor pulsatile abdominal mass in all Pts; U/S for all men 60 y w/ FHx of AAA
and all men 65‚Äì75 y w/ prior tobacco use ( J Vasc Surg 2004;39:267; Annals 2005;142:203;)
Diagnostic studies (Circ 2005;111:816)
‚Ä¢ Contrast CT: quick, noninvasive, good Se & Sp for all aortic aneurysms
‚Ä¢ CXR: often abnormal, but not definitive in TAA
‚Ä¢ Abdominal ultrasound: screening and surveillance test of choice for AAA
‚Ä¢ TTE/TEE: useful for root and rest of TAA
‚Ä¢ MRI: preferred for aortic root imaging for TAA, but also useful in AAA
Treatment (Circ 2006;113;e463; 2008;177:1883; 2010;121:1544)
‚Ä¢ Risk factor modification: smoking cessation, LDL-C 70 mg/dL; ? macrolides or
tetracyclines (inhibit MMPs, anti-Chlamydia)
‚Ä¢ BP control: -blockers (T dP/dt) T aneurysm growth (NEJM 1994;330:1335); ACEI a/w T
risk of rupture (Lancet 2006;368:659),ARB may T rate of aortic root growth in Marfan (NEJM
2008;358:2787);no burst activity/exercise requiring Valsalva maneuvers (eg,heavy lifting)
‚Ä¢ Surgery
TAA: symptomatic, ascending 5.5 cm; descending 6 cm; Marfan Pt 4.0‚Äì4.5 cm;
growing 0.5 cm/y; aneurysm 4.5 cm and planned AoV surgery
AAA: 5 cm; rapidly growing; infrarenal/juxtarenal 5.5 cm (NEJM 2002;346:1437)
‚Ä¢ Endovascular aneurysm repair (EVAR) (NEJM 2008;358:494)
T short-term mortality, bleeding, and length of stay, but, long-term graft complica-
tions (2‚Äì5%/y; leak, rupture) necessitating periodic surveillance and no  in
overall mortality (JAMA 2009;302:1535; NEJM 2010;362:1863 & 1881). Consider for high-
risk operative Pts or in descending thoracic aneurysms 5.5 cm (JACC 2010;55:986).
In Pts unfit for surgery: T aneurysm mortality but no  in overall mortality over
medical Rx (NEJM 2010;362:1872). EVAR noninferior (? superior) to open repair in
ruptured AAA w/ favorable anatomy (Ann Surg 2009;250:818).
Complications
‚Ä¢ Pain: gnawing chest, back, or abdominal pain
‚Ä¢ Rupture: risk c w/ diameter, female sex, current smoking, HTN
TAA: 2.5%/y if 6 cm vs. 7% if 6 cm; AAA: 1%/y if 5 cm vs. 6.5% if 5‚Äì5.9 cm
may be heralded by c pain; once occurs, usually fatal or Pt may p/w severe constant
pain and in hemorrhagic shock; 90% mortality
‚Ä¢ Aortic Dissection (see following section)
‚Ä¢ Thromboembolic ischemic events
‚Ä¢ Compression of adjacent structures (eg, SVC, trachea, esophagus)
Follow-up
‚Ä¢ Expansion rate 0.1 cm/y for TAA, 0.4 cm/y for AAA
‚Ä¢ Serial imaging first 3, 6, 9, & 12 mo, then annually
‚Ä¢ Screening for CAD, PAD, and aneurysms elsewhere, espec. popliteal. 25% of Pts w/
TAA will also have AAA.

--- Fim da P√°gina 42 ---

AORTA
1-31
ACUTE AORTIC SYNDROMES
Definitions (Circ 2003;108:628)
‚Ä¢ Classic dissection: intimal tear S extravasation of blood into aortic media
‚Ä¢ Incomplete dissection: intimomedial tear without significant intramural extravasation
‚Ä¢ Intramural hematoma (IMH): vasa vasorum rupture S medial hemorrhage
‚Ä¢ Penetrating ulcer: ulceration of plaque penetrating intima S medial hemorrhage
Classification
‚Ä¢ Proximal: involves ascending Ao, regardless of origin (  Stanford A, DeBakey I & II)
‚Ä¢ Distal: involves descending Ao only, distal to subclavian art. (  Stanford B, DeBakey III)
Risk factors 
‚Ä¢ Hypertension (h/o HTN in 70% of dissections); male sex (70% male)
‚Ä¢ Connective tissue disease: Marfan (fibrillin): arachnodactyly, joint disloc., pectus,
ectopia lentis, MVP; Ehlers-Danlos type IV (type III procollagen): translucent skin; bowel
or uterine rupture; Loeys-Dietz; annuloaortic ectasia, familial AoD; PCKD
‚Ä¢ Congenital aortic anomaly: bicuspid aortic valve or coarctation (eg, in Turner‚Äôs)
‚Ä¢ Aortitis:Takayasu‚Äôs, giant cell arteritis, Beh√ßet‚Äôs, syphilis
‚Ä¢ Pregnancy: typically in 3rd trimester; can also see spont. coronary artery dissections
‚Ä¢ Trauma: blunt, IABP, cardiac or aortic surgery, cardiac catheterization
Clinical Manifestations and Physical Examination (JAMA 2000;283:897)
Feature
Proximal
Distal
‚ÄúAortic‚Äù pain (often severe, tearing or ripping 
94%
98%
pain, maximal at onset [vs. crescendo for ACS])
(chest, back)
(back, chest, abd)
Syncope (often due to tamponade)
13%
4%
CHF (usually AI)
9%
3%
CVA
6%
2%
Hypertension
35%
70%
Hypotension/shock (tamponade,AI, MI, rupture)
25%
4%
Pulse deficit
19%
9%
AI murmur
44%
12%
Diagnostic studies (Circ 2005;112:3802)
‚Ä¢ Check bilateral BP and radial pulses for symmetry
‚Ä¢ CXR: abnormal in 60‚Äì90% (c mediastinum, effusion), but cannot be used to r/o dissection
‚Ä¢ CT: quick, noninvasive, good Se (80% for proximal; 90‚Äì95% for distal); multidetector CT
may improve Se; however, if  & high clin. suspicion S additional studies
‚Ä¢ TEE: Se 95% for proximal, 80% for distal; can assess coronaries, pericardium,AI
‚Ä¢ MRI: Se & Sp 98%, but time-consuming & not readily available
‚Ä¢ Aortography: Se 90%, time-consuming, cannot detect IMH; can assess branch vessels
‚Ä¢ D-dimer 500 ng/mL may help r/o dissection when sx 24 h (Circ 2009;119:2702)
Treatment (Lancet 2008;372:55; Circ 2010;121:1544)
‚Ä¢ Medical: T dP/dt targeting HR 60 and SBP 100‚Äì120
first with IV -blockers (eg, propranolol, esmolol, labetalol) to blunt reflex c HR &
inotropy that will occur in response to vasodilators
then T SBP with IV vasodilators (eg, nitroprusside)
control pain with MSO4 prn
‚Ä¢ Surgery
proximal (root replacement): all acute; chronic if c/b progression,AI or aneurysm
distal: if c/b progression, signif. branch artery involvement, uncontrolled HTN, aneurysm
‚Ä¢ Endovascular options: covered stent to seal entry; bare-metal stent to restore
flow down compromised branches; fenestration of false lumen
Complications
‚Ä¢ Rupture: pericardial sac S tamponade (avoid pericardiocentesis unless shock/PEA);
pleural space; mediastinum; retroperitoneum
‚Ä¢ Obstruction of branch artery
can be static (avulsed/thrombosed) or dynamic (s in pressure in true vs. false lumen)
coronary S MI (usually RCA S IMI, since dissection often occurs along outer curvature)
innominate/carotid S CVA, Horner; intercostal/lumbar S spinal cord ischemia/paraplegia
innominate/subclavian S upper extremity ischemia; iliac S lower extremity ischemia
celiac/mesenteric S bowel ischemia; renal S acute renal failure
‚Ä¢ AI: due to annular dilatation or disruption or displacement of leaflet by false lumen
‚Ä¢ Mortality: 1‚Äì2%/h  48 h for acute proximal; 10% at 30 d for acute distal 

--- Fim da P√°gina 43 ---

ARRHYTHMIAS
1-32
ARRHYTHMIAS
BRADYCARDIAS, AV BLOCK, AND AV DISSOCIATION
Sinus bradycardia (SB) (NEJM 2000;342:703)
‚Ä¢ Etiologies: meds (incl B, CCB, amio, Li, dig), c vagal tone (incl. athletes, sleep, IMI),
metabolic (hypoxia, sepsis, myxedema, hypothermia, T glc), OSA, c ICP
‚Ä¢ Treatment: usually none required; atropine or pacing if symptomatic
‚Ä¢ Most common cause of sinus pause is blocked premature atrial beat
Sick sinus syndrome (SSS) 
‚Ä¢ Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial
tachyarrhythmias (‚Äútachy-brady‚Äù syndrome), chronotropic incompetence w/ ETT
‚Ä¢ Treatment: meds alone usually fail (adeq. control tachy S unacceptable brady); usually
need combination of meds (B, CCB, dig) for tachy & PPM for brady
AV Block
Type
Features
1	
Prolonged PR (200 ms), all atrial impulses conducted (1:1).
2	 Mobitz I
Progressive c PR until impulse not conducted (S ‚Äúgrouped beating‚Äù).
(Wenckebach)
Abnl AV node due to ischemia (IMI), inflammation (myocarditis, MV 
surgery), high vagal tone (athletes), drug-induced.
Classically (50%), absolute c in PR decreases over time (S T RR
intervals, duration of pause 2 preceding RR interval).
AVB usually worsens w/ carotid sinus massage, improves w/ atropine.
Often paroxysmal/asx, no Rx required.
2	 Mobitz II
Occasional or repetitive blocked impulses w/ consistent PR interval.
Abnl His-Purkinje system due to ischemia (AMI), degeneration of
conduction system, infiltrative disease, inflammation/AoV surgery.
AVB usually improves w/ carotid sinus massage, worsens w/ atropine.
Often progresses to 3 AVB. Pacing wire or PPM often required.
3	 (complete)
No AV conduction. Escape, if present, narrow (jxnal) or wide (vent.)
Nb, if 2:1 block, cannot distinguish Type I vs. II 2 AVB (no chance to observe PR prolongation); usually catego-
rize based on other ECG & clinical data. High-grade AVB usually refers to block of 2 successive impulses.
AV dissociation 
‚Ä¢ Default: slowing of SA node allows subsidiary pacemaker (eg,AV junction) to take over
‚Ä¢ Usurpation: acceleration of subsidiary pacemaker (eg,AV junctional tach,VT)
‚Ä¢ 3 AV block: atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges
distinguish from isorhythmic dissociation (A V rate, ‚à¥some P‚Äôs non-conducting)
SUPRAVENTRICULAR TACHYCARDIAS (SVTS)
Arise above the ventricles, ‚à¥narrow QRS unless aberrant conduction or pre-excitation.
Etiologies of SVT (NEJM 1995;332:162; 2006;354:1039)
Type
Features
Sinus tachycardia (ST)
Caused by pain, fever, hypovolemia, hypoxia,
anemia, anxiety, -agonists, etc.
SA node reentrant tachycardia
Rare. Reentrant loop w/in SA node, discern
(SANRT)
from ST by rapid onset & termination.
Atrial tachycardia (AT)
Originate at site in atria other than SA node.
Seen w/ CAD, COPD, c catechols, EtOH, dig.
Multifocal atrial tachycardia (MAT)
c automaticity at multiple sites in the atria
Atrial flutter (AFL)
Macroreentry, usually w/in tricuspid annulus
Atrial fibrillation (AF)
Wavelets irregularly passing down AVN, often
originate from the pulmonary veins
AV nodal reentrant tach (AVNRT)
Reentrant circuit using dual pathways w/in AVN
Atrioventricular reciprocating
Reentrant circuit using AVN and accessory
tachycardia (AVRT)
pathway. Orthodromic (conducts down AVN;
usually narrow QRS) vs. antidromic (conducts 
down accessory path; wide QRS).
Nonparoxysmal junctional
c automaticity at AV junction
tachycardia (NPJT)
May see retrograde P waves or AV dissociation
Seen in myo/endocarditis, cardiac surg, IMI, dig.
AV Jxn
Atrial

--- Fim da P√°gina 44 ---

Treatment of SVT
Rhythm
Acute treatment
Long-term treatment
Unstable
Cardioversion per ACLS
n/a
ST
Treat underlying stressor(s)
n/a
AT
-blockers, CCB, or amiodarone
-blockers or CCB, 	 antiarrhythmics
? Radiofrequency ablation
AVNRT
Vagal maneuvers
For AVNRT (see next section for AVRT):
or AVRT
Adenosine (caution in AVRT*)
Radiofrequency ablation
CCB or -blockers
CCB or -blockers (chronic or prn)
	 Class IC antiarrhythmics (if nl heart)
NPJT
CCB, -blockers, amiodarone
Rx underlying dis. (eg, dig tox, ischemia)
AF
-blockers, CCB, digoxin, AAD
See ‚ÄúAtrial Fibrillation‚Äù
AFL
-blockers, CCB, digoxin, AAD
Radiofrequency ablation
-blockers or CCB 	 antiarrhythmics
MAT
CCB or -blockers if tolerated
Treat underlying disease process
? AVN ablation  PPM
*Avoid adenosine & nodal agents if accessory pathway  preexcited tachycardia, see below. (JACC 2003;42:1493)
‚Ä¢ Catheter ablation has high overall success rate (AFL/AVNRT 95%, AF 80%)
Complications: stroke, MI, bleeding, perforation, conduction block (JAMA 2007;290:2768)
ACCESSORY PATHWAYS (WOLFF-PARKINSON-WHITE)
Definitions
‚Ä¢ Accessory pathway (bypass tract) of conducting myocardium connect-
ing atria & ventricles, allowing impulses to bypass normal AVN delay
‚Ä¢ Preexcitation (WPW) pattern: T PR interval, c QRS width w/ 
wave (slurred onset, can be subtle), ST & Tw abnl (can mimic old IMI);
only seen w/ pathways that conduct antegrade (if pathway only conducts
retrograde then ECG will be normal during SR;‚Äúconcealed‚Äù bypass tract)
‚Ä¢ WPW syndrome: accessory pathway  paroxysmal tachycardia
Diagnosis of SVT Type (NEJM 2006;354:1039)
Onset
Abrupt onset/offset suggests reentry (AVNRT,AVRT, SANRT)
Rate
Not diagnostic as most SVTs can range from 140‚Äì250 bpm, but:
ST usually 150 bpm;AFL often conducts 2:1 S ventricular rate 150 bpm
AVNRT & AVRT are usually 150 bpm
Rhythm
Irregular S AF,AFL w/ variable block, or MAT
P wave
Before QRS S ST, AT (P different from sinus), MAT (3 morphologies)
morphology
After QRS & inverted in inf. leads S retrograde atrial activation via AVN
AVNRT: buried in or distort terminal portion of QRS (pseudo RSR‚Äô in V1)
AVRT: slightly after but usually distinct from QRS
Usually short RP interval (1/2 RR), but can be long RP 
Fibrillation or no P waves S AF
Saw-toothed ‚ÄúF‚Äù waves (best seen in inferior leads & V1) S AFL
Response to
c automaticity rhythms (ST,AT, MAT) S slow rate or c AV block
vagal stim.
AVN reentry (AVNRT,AVRT) S abruptly terminate (classically with a P
or adenosine
wave after last QRS) or no response
AFL S c AV block S unmasking of ‚ÄúF‚Äù waves
Figure 1-4 Approach to SVT
ARRHYTHMIAS
1-33
upright
  QRS
ST
SANRT
SVT
Regular
Irregular
P wave morphology
‚â† sinus
   QRS
a
ATAC
retrograde
p QRS
AVNRT
AVRT, NPJT
none or
distorts QRS
‚â•3 morph.
a QRS
AVNRT
F waves
@ 300 bpm
AFL
none or
fibrillation
AF
MAT
P wave morphology
a
Œ¥ wave

--- Fim da P√°gina 45 ---

Tachycardias
‚Ä¢ Orthodromic AVRT: narrow-complex SVT (typically), conducting T AVN & c accessory
pathway; requires retrograde conduction and ‚à¥can occur w/ concealed bypass tracts
‚Ä¢ Antidromic AVRT: wide-complex SVT, conducting T accessory pathway & c AVN;
requires antegrade conduction and ‚à¥should see WPW pattern during SR
‚Ä¢ AF with rapid conduction down accessory pathway, ‚à¥wide-complex irregular SVT;
requires antegrade conduction and ‚à¥should see WPW pattern during SR
Treatment
‚Ä¢ AVRT: vagal maneuvers, B, ? CCB; caution w/ adenosine (can precip. AF); have defib-
rillator ready
‚Ä¢ AF/AFL w/ conduction down accessory pathway: need to Rx arrhythmia and c pathway
refractoriness; use procainamide, ibutilide, flecainide or cardiovert; avoid CCB & B
(ineffective) and dig/adenosine (can T refractoriness of pathway S c vent. rate SVF)
‚Ä¢ Long term: Rx tachycardias w/ radiofrequency ablation or antiarrhythmics (IA, IC)
consider pathway ablation if asx but AVRT or AF inducible on EPS (NEJM 2003;349:1803)
risk of SCD related to how short R-R interval is in AF and if SVT inducible w/ exercise
WIDE-COMPLEX TACHYCARDIAS (WCTS)
Etiologies
‚Ä¢ Ventricular tachycardia (VT)
‚Ä¢ SVT conducted with aberrancy: either fixed BBB, rate-dependent BBB (usually
RBBB), conduction via an accessory pathway, or atrially-triggered ventricular pacing 
Monomorphic ventricular tachycardia (MMVT)
‚Ä¢ All beats look similar; predominantly upward in V1  RBBB-type vs. downward  LBBB-type
‚Ä¢ Etiologies in a structurally abnormal heart: prior MI (scar); CMP; myocarditis;
arrhythmogenic RV CMP (ARVC): incomplete RBBB,
 wave (terminal notch in QRS) & TWI in V1‚Äì3 on resting
ECG, LBBB-type VT, dx w/ MRI (Lancet 2009;373:1289)
‚Ä¢ Etiologies in a structurally normal heart:
RVOT VT: normal resting ECG, LBBB-type VT w/ inferior axis;
idiopathic LV VT (responds to verapamil)
Polymorphic ventricular tachycardia (PMVT)
‚Ä¢ QRS morphology changes from beat to beat
‚Ä¢ Etiologies: ischemia; CMP; catecholaminergic;
torsades de pointes (TdP, ‚Äútwisting of the points‚Äù, PMVT  c QT): c QT acquired
(eg, meds, lytes, see ‚ÄúECG‚Äù) or congenital (K/Na channelopathies; Tw abnl; TdP trig-
gered by sympathetic stim [exercise, emotion, sudden loud noises]; Lancet 2008;372:750) 
Brugada syndrome (Na channelopathy): pseudo-RBBB
w/ STE in V1‚Äì3 (provoked w/ IA or IC) on resting ECG
Diagnostic clues that favor VT (assume until proven o/w)
‚Ä¢ Prior MI, CHF, or LV dysfunction best predictors that WCT is VT (Am J Med 1998;84:53)
‚Ä¢ Hemodynamics and rate do not reliably distinguish VT from SVT
‚Ä¢ MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy;
grossly irregularly irregular rhythm suggests AF w/ aberrancy
‚Ä¢ ECG features that favor VT (Circ 1991;83:1649)
AV dissociation (independent P waves, capture or fusion beats) proves VT
very wide QRS (140 ms in RBBB-type or 160 in LBBB-type); extreme axis deviation
QRS morphology atypical for BBB
RBBB-type: absence of tall R‚Äô (or presence of monophasic R) in V1, r/S ratio 1 in V6
LBBB-type: onset to nadir 60‚Äì100 ms in V1, q wave in V6
concordance (QRS in all precordial leads w/ same pattern/direction)
Long-term management (JACC 2006;48:1064)
‚Ä¢ Workup: echo to ‚úìLV fxn, cath or stress test to r/o ischemia, ? MRI and/or RV bx to
look for infiltrative CMP or ARVC, ? EP study to assess inducibility
‚Ä¢ ICD: 2 prevention after documented VT/VF arrest (unless due to reversible cause)
1 prevention if high-risk, eg, EF 30‚Äì35% (see ‚ÄúHeart Failure‚Äù), ? ARVD, ? Brugada,
? certain long QT syndromes, severe HCMP
‚Ä¢ Medications: -blockers (espec for LQTS), antiarrhythmics (eg, amiodarone) to suppress
recurrent VT, triggering ICD firing, or if not ICD candidate, anti-tachycardic pacing
‚Ä¢ If med a/w TdP S QT 500 	VPBs: d/c med, replete K, give Mg, 	 pacing (JACC 2010;55:934)
‚Ä¢ Radiofrequency ablation if isolated VT focus, or if recurrent VT triggering ICD 
firing; ablation before ICD implantation T discharge rate by 40% (Lancet 2010;375:31)
ARRHYTHMIAS
1-34
Epsilon
V2

--- Fim da P√°gina 46 ---

AF
1-35
(Adapted from NEJM 2004;351:2408; & JACC 2006;48:e149)
Rate Control for AF (Goal HR 60‚Äì80, 90‚Äì115 with exertion)
Agent
Acute (IV)
Maint. (PO)
Comments
Verapamil
5‚Äì10 mg over 2
120‚Äì360 mg/d
T BP (Rx w/ Ca gluc)
may repeat in 30
in divided doses
Watch for CHF
0.25 mg/kg over 2
120‚Äì360 mg/d
Preferred if COPD
Diltiazem
may repeat after 15
in divided doses
Can c dig levels
5‚Äì15 mg/h infusion
Metoprolol
5 mg over 2
25‚Äì100 mg bid
T BP (Rx w/ glucagon)
may repeat q5  3
or tid
Watch for CHF &
Propranolol
1 mg q2
80‚Äì240 mg/d in
bronchospasm
divided doses
Preferred if CAD
Digoxin
0.25 mg q2h
0.125‚Äì0.375 mg
Consider in HF or low BP
(takes hrs)
up to 1.5 mg
qd (adj for CrCl)
Poor exertional HR ctrl
Amiodarone
150 mg over 10 S 0.5‚Äì1 mg/min
IV B, CCB, and digoxin contraindicated if evidence of WPW (.e., pre-excitation or WCT) since may
facilitate conduction down accessory pathway leading to VF; ‚à¥procainamide 1st line Rx
ATRIAL FIBRILLATION
Classification (JACC 2006;48:e149)
‚Ä¢ Paroxysmal (self-terminating) vs. persistent (sustained 7 d) vs. permanent (typically
1 y and when cardioversion has failed or is foregone)
‚Ä¢ Valvular (rheumatic MV disease, prosthetic valve, or valve repair) vs. nonvalvular
‚Ä¢ Lone AF  age 60 y and w/o clinical or echo evidence of cardiac disease (including HTN)
Epidemiology and Etiologies (Annals 2008;149:ITC5-2)
‚Ä¢ 1% of population has recurrent AF (8% of elderly); mean age at presentation 75 y 
‚Ä¢ Acute (up to 50% w/o identifiable cause)
Cardiac: CHF, myo/pericarditis, ischemia/MI, hypertensive crisis, cardiac surgery
Pulmonary: acute pulmonary disease or hypoxia (eg, COPD flare, pneumonia), PE
Metabolic: high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis
Drugs: alcohol (‚Äúholiday heart‚Äù), cocaine, amphetamines, theophylline, caffeine
Neurogenic: subarachnoid hemorrhage, ischemic stroke
‚Ä¢ Chronic: c age, HTN, ischemia, valve dis. (MV,TV,AoV), CMP, hyperthyroidism, obesity
Pathophysiology (NEJM 1998;339:659; & Circ 1995;92:1954)
‚Ä¢ Commonly originates from ectopic foci in atrial ‚Äúsleeves‚Äù in the pulmonary veins
‚Ä¢ Loss of atrial contraction S HF; LA stasis S thromboemboli; tachycardia S CMP
Evaluation
‚Ä¢ H&P, ECG, CXR, echo (LA size, ? thrombus, valves, LV fxn, pericardium), K, Mg, FOBT
before anticoag,TFTs, ? r/o ischemia (AF unlikely due to ischemia in absence of other sx)
Figure 1-5 Approach to acute AF
B
CCB
New or Recent-Onset AF
1. Rate Control
2. Anticoagulate
Œ≤B or CCB
(see Table)
AF <48 hrs &
low risk of stroke
unstable
Urgent
cardioversion
stable
IV UFH if admitting & cardioverting
o/w oral anticoag
Spont. cardioversion
(occurs w/in 24 hrs in 50-67% acute AF)
3. Cardiovert
Cardioversion
(electrical and/or pharmacologic)
Cardioversion
anticoag √ó ‚â•4‚Äì12 wks
oral
Empiric oral
anticoag √ó ‚â•3 wks
TEE
AF >48 hrs (or unknown)
or high risk of stroke 
  LA
thromb.
+
re
‚Üì
  LA
thromb.
‚àí

--- Fim da P√°gina 47 ---

Strategies for recurrent AF
‚Ä¢ Rate control: goal HR typically 60‚Äì80 at rest (although no clear benefit vs. goal
110, NEJM 2010;362:1363) and 90‚Äì115 w/ exertion (see above table for options) 
AV node ablation  PPM as a last resort (NEJM 2001;344:1043; NEJM 2002;346:2062)
‚Ä¢ Rhythm control: no clear survival benefit vs. rate ctrl (NEJM 2002;347:1825 & 2008;358:2667)
‚Ä¢ Anticoag (if indicated) to prevent thromboemboli, whether rate or rhythm strategy
Antiarrhythmic Drugs (AAD) for AF
Agent
Conversion
Maintenance
Comments
Amiodarone
5‚Äì7 mg/kg IV over
200‚Äì400 mg qd
c QT but TdP rare
30‚Äì60‚Äô S 1 mg/min
(most effective
Pulm, liver, thyroid toxicity
to achieve 10-g load drug)
‚úìPFTs, LFTs,TFTs
Dronedarone
n/a
400 mg bid
c QT, contraindic severe CHF
T side effects c/w amio
T efficacy but also T CV mort
Ibutilide
1 mg IV over 10‚Äô
n/a
Contraindic. if T K or c QT
may repeat  1
c QT, 3‚Äì8% risk of TdP
Mg 1‚Äì2 g IV to T risk TdP
Dofetilide
0.5 mg PO bid
0.5 mg bid
c QT, c risk of TdP
Renally adjust dose
Sotalol
n/a
90‚Äì160 mg bid
‚úìfor T HR, c QT
Renally adjust dose
Flecainide
300 mg PO  1
100‚Äì150 mg bid PreRx w/ AVN blocker
Propafenone
600 mg PO  1
150‚Äì300 mg tid Contraindic. if structural or
ischemic heart disease
Procainamide
10‚Äì15 mg/kg IV
1‚Äì2 g bid of
T BP; c QT
over 1 h
slow release
	 PreRx w/ AVN blocker
(JACC 2006;48:e149; NEJM 2007;357:987 & 2009;360:668; JACC 2009;54:1089)
‚Ä¢ Lone AF S class IC drugs or sotalol, ? statins
‚Ä¢ CAD S class III drugs
‚Ä¢ CHF S dofetilide or amiodarone (NEJM 2007;356:935)
Cardioversion
‚Ä¢ Consider pharm or DC cardioversion w/ 1st AF episode of if sx;
if AF 48 h, 2‚Äì5% risk stroke w/ cardioversion (pharm. or electric)
‚à¥either TEE to r/o thrombus or therapeutic anticoagulation for 3 wks prior
‚Ä¢ Likelihood of success dependent on AF duration (better 7 d) and atrial size
‚Ä¢ Consider pre-Rx w/ antiarrhythmic drugs (especially if 1st attempt fails)
‚Ä¢ For pharmacologic cardioversion, class III and IC drugs have best proven efficacy
‚Ä¢ Even if SR returns, atria mechanically stunned.Also, greatest likelihood of recurrent AF
in first 3 mos after return to SR, ‚à¥must anticoagulate postcardioversion 4‚Äì12 wks.
‚Ä¢ ‚ÄúPill-in-pocket‚Äù: if IC drugs have been safely tolerated in Pts w/o ischemic or
structural heart disease, can take as outPt prn if recurrent sx AF (NEJM 2004;351:2384)
Nonpharmacologic therapy
‚Ä¢ Radiofrequency ablation (circumferential pulm. vein isolation): 80% success; consider
if T EF or AADs failed/contraindic (NEJM 2006;354:934; JAMA 2005;293:2634 & 2010;303:333)
‚Ä¢ Surgical ‚Äúmaze‚Äù procedure (70‚Äì95% success rate) option if undergoing cardiac surgery
‚Ä¢ Left atrial appendage closure if undergoing cardiac surgery T risk of stroke; percuta-
neous closure may be comparable to warfarin and w/ T risk of ICH (Lancet 2009;374:534)
Anticoagulation (JACC 2006;48:e149; Chest 2008;133:546S)
‚Ä¢ Risk of stroke 4.5% per year in nonvalvular AF; risk factors include:
CHADS2: CHF (1 point), HTN (1), Age 75 y (1), DM (1), prior Stroke/TIA (2)
echo: EF 35%, dense spontaneous echo contrast in LAA, ? c LA size, ? Ao athero
‚Ä¢ Risk of stroke cc in valvular AF,  anticoagulate all
‚Ä¢ Rx options: warfarin (INR 2‚Äì3) S 68% T stroke (heparin S warfarin bridge if h/o stroke) 
ASA (81‚Äì325 mg/d): better than placebo (21% T stroke) but inferior to warfarin
ASAclopi inferior to warfarin but T stroke (& c bleed) c/w ASA alone (NEJM 2009;360:2066)
? dabigatran (oral direct thrombin inhib): 100 mg bid ‚âàefficacy & T bleeding and 150 mg
bid T stroke and ‚âàbleeding c/w warfarin (w/o need to ‚úìINR; RE-LY, NEJM 2009;361:1139) 
‚Ä¢ Whom to Rx: valvular AF, prior stroke/TIA, or 
2 risk factors S warfarin
1 risk factor S warfarin or ASA; 0 risk factors S ASA 
if not good candidate for warfarin (c risk of bleeding) S ASA  ? clopidogrel
if require ASAclopiwarfarin (eg,AF & s/p recent stenting): INR 2‚Äì2.5,ASA 75‚Äì81 mg/d 
AF
1-36
III
IC
IA

--- Fim da P√°gina 48 ---

SYNCOPE
1-37
SYNCOPE
Definition
‚Ä¢ Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion
‚Ä¢ If CPR or cardioversion required, then SCD and not syncope (different prognosis)
Etiologies (NEJM 2002;347:878; JACC 2006;47:473; Eur Heart J 2009;30:2631)
‚Ä¢ Neurocardiogenic (a.k.a. vasovagal, 20%; NEJM 2005;352:1004): c sympathetic tone S
vigorous contraction of LV S mechanoreceptors in LV trigger c vagal tone (hyperactive
Bezold-Jarisch reflex) S T HR (cardioinhibitory) and/or T BP (vasodepressor)
cough, deglutition, defecation & micturition S c vagal tone and thus can be precipitants
related disorder: carotid sinus hypersensitivity
‚Ä¢ Orthostatic hypotension (10%)
hypovolemia, diuretics, deconditioning
vasodilators (espec. if combined w/  chronotropes)
autonomic neuropathy (1  Parkinson‚Äôs, Shy-Drager, Lewy body dementia, POTS;
2  diabetes, EtOH, amyloidosis, renal failure) (NEJM 2008;358:615)
‚Ä¢ Cardiovascular
Arrhythmia (15%)
Bradyarrhythmias: SSS, high-grade AV block,  chronotropes, PPM malfunction
Tachyarrhythmias:VT, SVT (syncope rare unless structural heart disease or WPW)
Mechanical (5%)
Endocardial:AS, MS, PS, prosthetic valve thrombosis, myxoma
Myocardial: pump dysfxn from MI or outflow obstruction from HCMP (but usually VT)
Pericardial: tamponade
Vascular: PE, PHT, aortic dissection, ruptured AAA, subclavian steal
‚Ä¢ Neurologic (10%): seizure (technically not syncope),TIA/CVA, vertebrobasilar
insufficiency, dissection of cerebral arteries, migraine, narcolepsy
‚Ä¢ No cause identified in 40% of cases
‚Ä¢ Misc. causes of LOC (but not syncope): hypoglycemia, hypoxia, anemia, psychogenic
Workup (etiology cannot be determined in 40% of cases)
‚Ä¢ H&P incl. orthostatic VS have highest yield and most cost effective (Archives 2009;169:1299)
‚Ä¢ History (from Pt and witnesses if available)
activity and posture before the incident
precipitating factors: exertion (AS, HCMP, PHT), positional  (orthostatic hypotension),
stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing,
warm environment, N/V, cough/micturition/defecation/swallowing (neurocardiogenic),
head turning or shaving (carotid sinus hypersens.); arm exercise (subclavian steal)
prodrome (eg, diaphoresis, nausea, blurry vision): cardiac 5 sec, vasovagal 5 sec
associated sx: chest pain, palp., neurologic, post-ictal, bowel or bladder incontinence
(convulsive activity for 10 sec may occur with transient cerebral hypoperfusion)
‚Ä¢ PMH: prior syncope, previous cardiac or neurologic dis.; no CV disease at baseline S 5%
cardiac, 25% vasovagal; CV disease S 20% cardiac, 10% vasovagal (NEJM 2002;347:878)
‚Ä¢ Medications
vasodilators: -blockers, nitrates,ACEI/ARB, CCB, hydralazine, phenothiazines, antidep.
diuretics;  chronotropes (eg, -blockers and CCB)
proarrhythmic or QT prolonging: class IA, IC or III antiarrhythmics, et al. (see ‚ÄúECG‚Äù)
psychoactive drugs: antipsychotics,TCA, barbiturates, benzodiazepines, EtOH
‚Ä¢ Family history: CMP, SCD
‚Ä¢ Physical exam
VS including orthostatics ( if supine S standing results in 20 mmHg T SBP,
10 mmHg T DBP, or 10‚Äì20 bpm c HR), BP in both arms
cardiac: HF (c JVP, displ. PMI, S3), murmurs, LVH (S4, LV heave), PHT (RV heave, c P2)
vascular exam: ‚úìfor asymmetric pulses, carotid bruits, carotid sinus massage
neurologic exam: focal findings, evidence of tongue biting; fecal occult blood test
‚Ä¢ ECG (abnormal in 50%, definitively identifies cause of syncope in 10%)
sinus bradycardia, sinus pauses,AVB, BBB, SVT,VT
ischemic changes (new or old); atrial or ventricular hypertrophy
markers of arrhythmia: ectopy, c QT, preexcitation (WPW), Brugada,  wave (ARVC)
Other diagnostic studies (consider ordering based on results of H&P and ECG)
‚Ä¢ Ambulatory ECG monitoring: if suspect arrhythmogenic syncope
Holter monitoring (continuous ECG 24‚Äì48 h): useful if frequent events
arrhythmia  sx (4%); asx but signif. arrhythmia (13%); sx but no arrhythmia (17%)
Event recorder (activated by Pt to record rhythm strip): useful for infrequent events, but
problematic if no prodrome; yield 20‚Äì50% over 30‚Äì60 d of monitoring

--- Fim da P√°gina 49 ---

Loop recorders (continuously save rhythm strip and ‚à¥can be activated after an
event): useful for infrequent events including w/o prodrome (Mayo Clin Proc 2008;83:1280).
Implantable loop recorders (inserted SC; can record up to 3 y): useful for very
infrequent events; yield 90% after 1 y (AJC 2003;92:1231)
‚Ä¢ Echo: r/o structural heart disease (eg, CMP [incl HCMP & ARVD], valvular disease
[incl AS, MS, MVP], myxoma, amyloid, PHT, 	 anomalous coronaries)
‚Ä¢ ETT: esp. w/ exertional syncope; r/o ischemia- or catecholamine-induced arrhythmias
‚Ä¢ Cardiac catheterization: consider if noninvasive tests suggest ischemia
‚Ä¢ Electrophysiologic studies (EPS)
consider if arrhythmia detected, if structural heart disease, or if CAD (esp. with low EF)
50% abnl (inducible VT, conduction abnormalities) if heart disease, but ? significance
3‚Äì20% abnl if abnl ECG; 1% abnl if normal heart and normal ECG (Annals 1997;127:76)
‚Ä¢ Tilt table testing (provocative test for vasovagal syncope): r/o other causes first
 in 50% w/ recurrent unexplained syncope; Se 26‚Äì80%, Sp 90%; reprod. 80%
‚Ä¢ Cardiac MRI: helpful to dx ARVC if suggestive ECG, echo (RV dysfxn), or  FH of SCD
‚Ä¢ Neurologic studies (cerebrovascular studies, CT, MRI, EEG): if H&P suggestive; low yield
Figure 1-6 Approach to syncope
SYNCOPE
1-38
Syncope
Cardiac
Mechanical
History, Physical Exam (incl. orthostatics), 12-lead ECG
? Neuro-
cardiogenic
? Neurologic
? Arrhythmia
Orthostatic
hypotension
Arrhythmia
negative
abnl neuro
exam
situational or
   prodrome
diagnostic
suggestive
echo ¬± ETT
(¬± CTA to r/o
PE or AoD)
orthostatics
abnl rhythm
on ECG
? tilt table
if recurs
EEG, cerebrovasc,
CT/MRI
EP study
structurally abnl
heart or ischemia
ambul. ECG
if recurs
valve, tamp.,
PE,PHT
normal
abnl heart
or ECG,
exertional or
    prodrome
+
‚àí
+
(Adapted from JACC 2006;47:473)
High-risk features (usually warrant admission with telemetry & further testing)
‚Ä¢ Age 60 y, h/o CAD, CMP, valvular disease, congenital heart disease, arrhythmias
‚Ä¢ Syncope c/w cardiac cause (lack of prodrome, exertional, resultant trauma)
‚Ä¢ Recurrent syncope
‚Ä¢ Abnormal cardiac exam or ECG
Treatment
‚Ä¢ Arrhythmia, cardiac mechanical, or neurologic syncope: treat underlying disorder
‚Ä¢ Vasovagal syncope: ? midodrine, fludrocortisone, disopyramide, SSRI 
? 16 oz of H2O before at-risk situations (Circ 2003;108:2660)
no proven benefit w/ -blockers (Circ 2006;113:1164) or PPM (JAMA 2003;289:2224)
‚Ä¢ Orthostatic syncope: volume replete (eg, 500 mL PO q a.m.); if chronic S rise from supine
to standing slowly, compressive stockings, midodrine, fludrocortisone, high Na diet
Prognosis (Ann Emerg Med 1997;29:459; NEJM 2002;347:878)
‚Ä¢ 22% overall recurrence rate if idiopathic, else 3% recurrence
‚Ä¢ Cardiac syncope: 2-fold c in mort., 20‚Äì40% 1-y SCD rate, median survival 6 y
‚Ä¢ Unexplained syncope w/ 1.3-fold c in mort., but noncardiac or unexplained syncope w/ nl
ECG, no h/o VT, no HF, age 45 S low recurrence rate and 5% 1-y SCD rate
‚Ä¢ Vasovagal syncope: Pts not at increased risk for death, MI, or stroke
‚Ä¢ ‚úìstate driving laws and MD reporting requirements. Consider appropriateness of Pt
involvement in exercise/sport, operating machinery, high-risk occupation (eg, pilot).

--- Fim da P√°gina 50 ---

PPM/ICD
1-39
INTRACARDIAC DEVICES
Pacemaker Code
A, atrial;V, vent.;
1st letter
2nd letter
3rd letter
4th letter
I, inhibition; D, dual;
Chamber
Chamber
Response to
Program
R, rate-adaptive
paced
sensed
sensed beat
features
Common Pacing Modes
VVI
Ventricular pacing on demand w/ single lead in RV. Sensed ventricular
beat inhibits V pacing. Used in chronic AF with symptomatic bradycardia.
DDD
A & V sensing & pacing (RA & RV leads). Sensed A beat inhibits A pacing &
triggers V pacing S tracking of intrinsic atrial activity. Maintains AV synchrony.
Magnet
Pacing at fixed rate regardless of intrinsic activity. Use to ‚úìability to capture
(place over 
when output inhibited by intrinsic rhythm. Use if Pt hemodynamically 
generator)
unstable due to inappropriate PPM inhibition or PPM-induced tachycardia.
Indications for Pacing (Circ 2008;117:2820)
AV block
Symptomatic 3 or 2 AVB; ? asx 3 or type II 2 AVB
HR 40; pauses 3 sec while awake; alternating L and R BBB
Sinus node
SB or pauses a/w sxs or ? if sx w/o clear assoc. Chronotropic incompet.
Acute MI
See ‚ÄúSTEMI‚Äù
Tachy-
Sx recurrent SVT that can be term. by pacing after failing drugs & ablation
arrhythmia
Sustained pause-dependent VT; ? high-risk Pts w/ congenital long QT
Syncope
Carotid sinus hypersensitivity with asystole 3 sec
? Neurocardiogenic syncope w/ prominent cardioinhib. response
? Syncope with bi- or trifascicular block and not likely 2 to other causes
CMP
Sx DCMP (BiV pacing); ? refractory sx HCMP w/ signif outflow obstruction
Permanent Pacemaker (PPM) Complications
Issue
Manifestation
Description
Failure to
Bradycardia
Battery depletion, lead fracture/dislodgment,
pace
c pacing threshold due to local tissue rxn/injury, or
myopotential sensing S inappropriate inhibition
Failure to sense
Inapprop. pacing
Lead dislodgment or sensing threshold too high
PM-mediated
Tachycardia
Seen w/ DDD.V depol. S retrograde A activation S
tachycardia
sensed by A lead S triggers V pacing S etc.
PM syndrome
Palpit, HF
Seen w/ VVI. Due to loss of AV synchrony.
Cardiac Resynch Therapy (CRT) / Biventricular (BiV) Pacing (JACC 2008;51:2085)
‚Ä¢ 3-lead pacemaker (RA, RV, coronary sinus); R S in V1 suggests appropriate LV capture
‚Ä¢ Goal: enhance synch RV & LV fxn (c CO, T remodeling, even if nl EF, NEJM 2009;361:2123)
‚Ä¢ Pt selection: NYHA III/IV HF despite med Rx  LVEF 35%  QRS 120 ms;
no clear benefit if QRS 120 ms w/ echo dyssynchrony (NEJM 2007;357:2461);
? lesser benefit if chronic AF
‚Ä¢ Benefits: T HF sx, T HF hosp., c survival (NEJM 2004;350:2140 & 2005;352:1539); T HF events
compared w/ ICD alone in NYHA I/II & QRS 150 ms (MADIT-CRT, NEJM 2009;361:1329)
Implantable Cardiac Defibrillator (ICD) (NEJM 2003;349:1836; JACC 2006;48:1064)
‚Ä¢ RV lead capable of defibrillation & pacing ( 	 antitachycardia pacing,ATP); 	 RA lead
‚Ä¢ Goal: terminate VT/VF w/ shock or burst of pacing, prevent sudden cardiac death (SCD)
‚Ä¢ Patient selection (JACC 2008;51:2085)
2 prevention: survivors of VF arrest, unstable VT w/o reversible cause (NEJM
1997;337:1576); structural heart disease & spontaneous sustained VT (even if asx) 
1 prevention: life expectancy 1 y, LVEF 30% or LVEF 30‚Äì35% & NYHA II-III or
LVEF 35‚Äì40% & inducible VT/VF (wait 40 d if post-MI or 9 mos for non-
ischemic CMP; NEJM 2009;361:1427); for HCMP,ARVD, Brugada, sarcoid, LQTS,
Chagas, or congenital heart, ICD if risk factors for SCD
‚Ä¢ Benefits: T mortality from SCD c/w antiarrhythmics or placebo
‚Ä¢ ICD discharge: ‚úìdevice to see if appropriate; r/o ischemia; 6 mos driving ban; if recur-
rent VT, ? drug Rx (eg, amio  B, JAMA 2006;295:165) or VT ablation (NEJM 2007;357:2657).
Nb, ablation at time of ICD T risk of VT by 40% (Lancet 2010;375:31).
Device infection (Circ 2010;121:458)
‚Ä¢ Presents as pocket infection (warmth, erythema, tenderness) and/or sepsis w/ bacteremia
‚Ä¢ Infection in 1‚ÅÑ2 of Pts w/ S. aureus bacteremia (even w/o s/s and w/  TTE/TEE)
‚Ä¢ Treatment: abx and removal of system

--- Fim da P√°gina 51 ---

PREOP EVAL
1-40
CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY
Clinical Assessment
Active Cardiac Conditions
Clinical Risk Factors
‚Ä¢ MI w/in 30 d or current unstable or severe angina 
‚Ä¢ h/o CAD
‚Ä¢ Decompensated HF
‚Ä¢ h/o HF
‚Ä¢ Significant arrhythmia (eg, high-grade AVB, Mobitz II,
‚Ä¢ h/o Cerebrovascular dis.
3 AVB, new or sx VT, SVT w/ HR 100, sx brady)
‚Ä¢ Diabetes mellitus
‚Ä¢ Severe AS or sx MS
‚Ä¢ Renal insuffic. (Cr 2 mg/dL)
Surgery-Specific Risk
High (5% risk)
Intermediate (1‚Äì5%)
Low (1%)
‚Ä¢ Aortic or other major
‚Ä¢ Intrathoracic; intraperitoneal; 
‚Ä¢ Endoscopic
vascular
prostate
‚Ä¢ Breast; superficial
‚Ä¢ Peripheral vasc.
‚Ä¢ CEA; head & neck
‚Ä¢ Cataract; ambulatory
‚Ä¢ Orthopedic
Functional Capacity
1‚Äì4 METs
4‚Äì10 METs
10 METs
‚Ä¢ ADLs
‚Ä¢ Climb a flight of stairs/hill
‚Ä¢ Strenuous sports
‚Ä¢ Walk indoors
‚Ä¢ Walk briskly; heavy housework
‚Ä¢ Walk 1‚Äì2 level blocks
‚Ä¢ Golf, doubles tennis
Noninvasive Testing Result
High risk
Intermediate risk
Low risk
Ischemia at 4 METs manifested 
Ischemia at 4‚Äì6 METs
No ischemia or
by 1 of:
manifested by 1 of:
at 7 METs w/
‚Ä¢ Horiz/down ST T 1 mm or STE
‚Ä¢ Horiz/down ST T 1 mm
‚Ä¢ ST T 1 mm or
‚Ä¢ 5 abnl leads or 3 min after exert
‚Ä¢ 3‚Äì4 abnl leads
‚Ä¢ 1‚Äì2 abnl leads
‚Ä¢ SBP T 10 mmHg or typical angina
‚Ä¢ 1‚Äì3 min after exert
Preoperative evaluation
Figure 1-7 ACC/AHA approach to preoperative cardiovascular evaluation for non‚Äìcardiac surgery
Peri-op surveillance;
post-op risk stratification
& risk factor mgmt
Step 1
Need for emergency
non-cardiac surgery?
yes
no
Further evaluation
prior to OR;
Rx as indicated
Step 2
Active cardiac
conditions?
yes
no
Consider periop Œ≤B if CAD or
>1 clinical risk factors.
Step 4
Fxnal capacity
‚â•4 METs w/o sx?
yes
no or unknown
Consider periop Œ≤B.
? Non-inv test if will Œî mgmt.
intermed
risk surgery
high risk
surgery
Step 5
Presence of
clinical
risk
factors?
Consider non-inv
test if will Œî mgmt.
1‚Äì2
‚â•3
Operating
Room
Step 3
Low-risk surgery?
none
yes
no
Periop Œ≤B
if to OR
(Circ 2009;120:e169)

--- Fim da P√°gina 52 ---

PREOP EVAL
1-41
Pre-operative testing and therapy
‚Ä¢ ECG if 1 risk factor and planned vascular surgery, or if known vascular disease and
intermediate risk surgery. ? prior to any vascular surgery.
‚Ä¢ TTE if dyspnea of unknown origin or if HF w/ c dyspnea and no TTE in past 12 mo
‚Ä¢ Stress test if active cardiac issues (see above), or vascular surgery w/ 3 risk factors
& it will  mgmt. Overall low PPV to predict periop CV events.
‚Ä¢ Coronary revascularization should be based on standard indications (eg,ACS,
refractory sx, lg territory at risk). Has not been shown to  risk of death or
postop MI when done prior to elective vasc. surgery based on perceived cardiac
risk (NEJM 2004;351:2795) or documented extensive ischemia (AJC 2009;103:897), but sys-
tematic angiography T 2‚Äì5 y mortality in one vascular surgery trial (JACC 2009;54:989).
‚Ä¢ Given need for dual antiplatelet Rx after stenting, wait 4 wk after BMS and ideally
12 mo after DES before discontinuing ADP receptor blockade; continue ASA
‚Ä¢ If possible, wait 4‚Äì6 wk after MI (even if  ETT or  ETT & revascularized). If no
revasc, wait 6 mo before elective surgery.
‚Ä¢ Preop statins: T ischemia & CV events in Pts undergoing vascular surg (NEJM 2009;361:980)
Perioperative -blocker use (Circ 2009;120:2123; JAMA 2010;303:551)
‚Ä¢ Conflicting evidence regarding efficacy of B for T periop events. Some studies have
shown T cardiac death & MI (NEJM 1996;335:1713 & 1999;341:1789) whereas another T MI
but c death & stroke and c bradycardia/HoTN (Lancet 2008;371;1839).
‚Ä¢ Consider periop B if CAD,  stress test, or 1 cardiac risk factor, espec if vascular surgery  
‚Ä¢ Ideally initiate 1 wk prior to surgery and titrate during preop, intraop, and postop peri-
ods to achieve HR 55‚Äì65 bpm and BP control. Avoid bradycardia and hypotension.
Postoperative monitoring
‚Ä¢ ‚úìPostop ECG if known CAD or high-risk surgery. Consider if 1 risk factor for CAD.
‚Ä¢ ‚úìPostop troponin only if new ECG s or chest pain suggestive of ACS

--- Fim da P√°gina 53 ---

NOTES
NOTES
1-42

--- Fim da P√°gina 54 ---

DYSP/PFTS
2-1
DYSPNEA
Pathophysiology
Etiologies
Airway obstruction
Asthma, COPD, bronchiectasis (dilated, collapsible 
(c resistance to airflow)
airways, impaired clearance of secretions,  hemoptysis;
infxn #1 cause; Rx: mucolytics, bronchodilators,  abx),
CF (chronic resp infxns, bronchiectasis, infertility,
pancreatitis), tumor or foreign body
Parenchymal disease
Pulmonary edema: cardiogenic (LV systolic or diastolic 
(c resistance to expansion)
dysfxn) or noncardiogenic (ALI/ARDS)
ILD
Vascular
Large vessel: PE, tumor emboli
(V/Q mismatch)
Small vessel: PHT, vasculitis, ILD, emphysema
Bellows
Pleural disease: effusion, fibrosis
(c resistance to CW/diaphragm
Chest wall/diaphragm: kyphoscoliosis, c abd girth
expansion; weakness of
Neuromuscular disorders
respiratory muscles)
Hyperinflation (COPD, asthma)
Stimulation of receptors
Chemoreceptors: hypoxemia, metabolic acidosis
Mechanoreceptors: ILD, pulmonary edema, PHT, PE
T O2 carrying cap. (but nl PaO2)
Anemia, methemoglobinemia, CO poisoning
Psychological
Anxiety, panic attack, depression, somatization
Evaluation
‚Ä¢ Cardiopulmonary exam, SaO2, CXR (see Appendix & Radiology inserts), ECG
predictors of CHF: h/o CHF, PND, S3, CXR w/ venous congestion, AF (JAMA 2005;294:1944)
dyspnea w/ nl CXR S CAD, asthma, PE, PHT, early ILD, anemia, acidosis, NM disease
‚Ä¢ Based on results of initial evaluation: PFTs, chest CT,TTE, cardiopulmonary testing
‚Ä¢ BNP & NT-proBNP c in CHF (but also c in AF, RV strain from PE, COPD flare, PHT)
BNP 100 pg/mL: 90% Se, 76% Sp for CHF causing dyspnea (NEJM 2002;347:161)
NT-proBNP: 300 pg/mL S 99% Se, 60% Sp for CHF (‚à¥use 300 to rule out) 
to rule in use age-related cut points: 450 pg/mL if 50 y, 900 if 50‚Äì75 y,
1,800 if 75 y S 90% Se, 84% Sp (EHJ 2006;27:330)
c in chronic heart failure, ‚à¥need to compare to known ‚Äúdry BNP‚Äù
PULMONARY FUNCTION TESTS (PFTs)
‚Ä¢ Spirometry: evaluate for obstructive disease
Flow-volume loops: diagnose and/or localize obstruction
Bronchodilator: indicated if obstruction at baseline or asthma clinically suspected
Methacholine challenge: helps dx asthma if spirometry nl, 20% T FEV1 S asthma
‚Ä¢ Lung volumes: evaluate for restrictive disease including NM causes
‚Ä¢ DLCO: evaluates functional surface area for gas exchange; helps differentiate causes of
obstructive and restrictive diseases and screens for vascular disease & early ILD
Figure 2-1 Approach to abnormal PFTs
Approach to abnormal PFTs
OBSTRUCTIVE PATTERN
Asthma or
asthmatic
bronchitis
COPD
RESTRICTIVE PATTERN
NM
disease
Pleural
disease?
ILD
CHF
‚Üì Pimax
‚Üì RV
Emphysema
Chronic
bronchitis
FEV1 response to bronchodil.
minimal
>12% and
200 cc ‚Üë 
Abnl DLCO w/
normal spirometry
PE, PHT
Vasculitis
Early ILD
Anemia
Asthma
Hemorrhage
Polycythemia
‚Üë Pulm blood vol.
(eg, obesity, mild
CHF, L‚ÜíR shunts)
‚Üì DLCO
‚Üì DLCO
nl DLCO
‚Üì DLCO
‚Üë DLCO
FEV1/FVC <0.75
TLC <80% predicted

--- Fim da P√°gina 55 ---

ASTHMA
2-2
ASTHMA
Definition and epidemiology
‚Ä¢ Chronic inflam. disorder w/ airway hyperrespons.  var. airflow obstruction
‚Ä¢ Affects 5% population; 85% of cases by age 40 y
Clinical manifestations (NEJM 2001;344:350)
‚Ä¢ Classic triad  wheezing, cough, and dyspnea; others include chest tightness,
sputum; symptoms typically chronic with episodic exacerbation
‚Ä¢ Precipitants (triggers)
respiratory irritants (smoke, perfume, etc.) & allergens (pets, dust mites, pollen, etc.)
infections (URI, bronchitis, sinusitis)
drugs (eg, ASA & NSAIDs via leukotrienes, B via bronchospasm, MSO4 via histamine)
emotional stress, cold air, exercise
‚Ä¢ Exacerbations: important to note frequency, severity, duration, and required treatment
(need for steroids, ED visits, hospitalizations, and intubations)
Physical examination
‚Ä¢ Wheezing and prolonged expiratory phase
‚Ä¢ Presence of nasal polyps, rhinitis, rash S allergic component
‚Ä¢ Exacerbation S c RR, c HR, accessory muscle use, diaphoresis, pulsus paradoxus
Diagnostic studies
‚Ä¢ Peak exp flow (PEF): 60 L/min c after bronchodil or 20% diurnal variation sug-
gests asthma. 80% personal best c/w poor control, 50% c/w severe exacerbation.
‚Ä¢ Spirometry: T FEV1, T FEV1/FVC, coved flow-volume loop; lung volumes:  c RV & TLC
 bronchodilator response (c FEV1 12%) strongly suggestive of asthma
methacholine challenge (T FEV1 20%) if PFTs nl: Se 90% (AJRCCM 2000;161:309)
‚Ä¢ Sputum: eos 3% has 86% Se, 88% Sp; can also see Curschmann‚Äôs spirals (mucus casts
of distal airways) and Charcot-Leyden crystals (eosinophil lysophospholipase);
 in sputum eos count may guide outPt Rx (Lancet 2002;360:1715)
‚Ä¢ Allergy suspected S consider ‚úìserum IgE, eos, skin testing/RAST 
Ddx (‚Äúall that wheezes is not asthma‚Äù)
‚Ä¢ Hyperventilation & panic attacks
‚Ä¢ Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2	 to GERD)
‚Ä¢ COPD, bronchiectasis; ILD (including sarcoidosis); vasculitis; PE
‚Ä¢ CHF
‚ÄúAsthma plus‚Äù syndromes (Lancet 2002;360:1313)
‚Ä¢ Atopy 
 asthma  allergic rhinitis  atopic dermatitis
‚Ä¢ ASA-sensitive asthma (Samter‚Äôs syndrome) 
 asthma  ASA sensitivity  nasal polyps
‚Ä¢ ABPA 
 asthma  pulmonary infiltrates  allergic rxn to Aspergillus
‚Ä¢ Churg-Strauss 
 asthma  eosinophilia  granulomatous vasculitis
‚ÄúReliever‚Äù medications (used prn to quickly relieve sx)
‚Ä¢ Short-acting inhaled 2-agonists: albuterol Rx of choice; levoalbuterol (R-isomer) 2x
potency, no outcome benefit, ? less tachycardia (J Allergy Clin Immunol 2008;122:544)
‚Ä¢ Inhaled anticholinergics (ipratropium) improve 2-agonist delivery S c bronchodilation
‚ÄúController‚Äù meds (taken daily to keep control) (NEJM 2009;360:1002)
‚Ä¢ Inh corticosteroids: Rx of choice (JAMA 2001;285:2583). PRN ? as good as daily for mild
asthma (NEJM 2005;352:1519 & 2007;356:2040). PO steroids may be needed for severely
uncontrolled asthma, but avoid if possible b/c systemic side effects.
‚Ä¢ Long-acting inh 2-agonists (eg, salmeterol): improves PEF when added to inh steroid
(Lancet 2009;374:1754). Except for control of exercise-induced asthma, should not be
used w/o inh steroid (may c mortality; Chest 2006;129:15 & Annals 2006;144:904). Clinical
relevance of 2-receptor pharmacogenetic interaction not validated 
(Lancet 2009;374:1754).
‚Ä¢ Nedocromil/cromolyn: limited use in adults. Useful in young Pts, exercise-induced
bronchospasm; ineffective unless used before trigger or exercise exposure.
‚Ä¢ Theophylline: useful in hard to control Pts, PO convenience, but high side effect pro-
file
‚Ä¢ Leukotriene modifiers: some Pts very responsive, especially aspirin-sensitive
(AJRCCM 2002;165:9) and exercise-induced  asthma (Annals 2000;132:97).Transcription of
genes for 5-lipoxygenase pathway predicts response (Nat Genet 1999;22:168).
‚Ä¢ Anti-IgE: allergic asthma (c IgE) uncontrolled on inh steroids (NEJM 2006;354:2689), not
cost-effective for most cases of severe asthma (JACI 2007;120:1146)

--- Fim da P√°gina 56 ---

Other
‚Ä¢ Behavior modification: identify and avoid triggers
‚Ä¢ Immunotherapy (eg, desensitization): may be useful if significant allergic component
‚Ä¢ TNF antagonists may be helpful in Pts w/ refractory asthma (NEJM 2006;354:697)
‚Ä¢ Anti-IL5 found to spare steroids in uncontrolled Pts w/ sputum eos (NEJM 2009;360:985)
‚Ä¢ Bronchial thermoplasty (exp‚Äôtal): radiofrequency destruction of airway smooth muscle
no  in FEV1, but T in sx and # of exacerbations (NEJM 2007;356:1327)
‚Ä¢ PPI: not found to improve asthma sx, even if asx GERD (NEJM 2009;360:1487)
Principles of treatment
‚Ä¢ Education and avoidance of environmental triggers for all Pts
‚Ä¢ Use quick-relief rescue medication as needed for all Pts
‚Ä¢ Goal is to achieve complete control 
 daily sx 2/wk, ‚àÖnocturnal sx or limitation
of activity, reliever med 2/wk, nl PEF or FEV1; partly controlled 
 1‚Äì2 of the
above present in a wk; uncontrolled 
 3 of the above present in a wk
‚Ä¢ Step up treatment as needed to gain control, step down as tolerated
‚Ä¢ If PEF T 15%  2 d or T 30%, quadrupling inh steroid dose S T need for PO steroids
(AJRCCM 2009;180:598)
Asthma Stepwise Therapy
Step 1
Step 2
Step 3
Step 4
Step 5
Rapid-acting 2-agonists prn
Select one
Select one
Do one or more
Add one or both
Low-dose
Low-dose ICS 
 low-dose ICS to
Oral steroids
ICS
LABA
med/high dose (w/LABA)
(lowest dose)
LTA
Med/high-dose ICS
Add LTA
Anti-IgE Rx
Low-dose ICS  LTA
Add Theo
Low-dose ICS  Theo
ICS, inh corticosteroid; LABA, long-acting 2-agonist; LTA, leukotriene antag.;Theo, sustained-rel. theophylline
Boldfaced Rx preferred options. (Adapted from Global Initiative for Asthma [GINA] 2009)
EXACERBATION
Direct evaluation
‚Ä¢ History
Asthma Hx: baseline PEF, steroid requirement, ED visits, hospital admissions;
previous need for intubation a good predictor of risk of death (Thorax 1986;41:833)
Current exacerbation: duration, severity, potential precipitants, meds used
‚Ä¢ Physical exam
Signs of severity: tachypnea, tachycardia, diaphoresis, cyanosis, fragmented speech,
absent breath sounds, accessory muscle use, pulsus paradoxus, abdominal paradox
Assess for barotrauma: asymmetric breath sounds, tracheal deviation, subcutaneous
air S pneumothorax, precordial (Hamman‚Äôs) crunch S pneumomediastinum
‚Ä¢ Diagnostic studies
ABG: not always considered essential because exam and SaO2 provide equivalent info;
low PaCO2 initially; nl or high PaCO2 may signify tiring; may respond to bronchodilator
PEF: used to follow clinical course; CXR: not essential unless suspicion for PNA or PTX
Severity of Asthma Exacerbation
Feature
Mild
Moderate
Severe
Breathless w/ . . .
Walking
Talking
At rest
Talking in . . .
Sentences
Phrases
Words
Mental status
 Agitated
Agitated
Agitated
RR
c
c
30
Accessory muscles
‚àÖ


Wheeze
Moderate, end-expir
Loud
Usually loud
HR
100
100‚Äì120
120
Pulsus paradoxus
Normal (10)
10‚Äì25
25
PEF
80%
60‚Äì80%
60%
SaO2
95%
91‚Äì95%
90%
PaO2
Normal
60
60
PaCO2
45
45
45
Presence of several parameters (not necessarily all) indicates classification (GINA 2009)
Resp arrest imminent: drowsy, abdominal paradox, wheezes inaudible (b/c ‚àÖair movement), bradycardia,
loss of abdominal paradox (respiratory muscle fatigue).
ASTHMA
2-3
Controller options

--- Fim da P√°gina 57 ---

Acute Pharmacologic Treatment
Agent
Dose
Comments
Oxygen
Titrate to achieve SaO2 90%
Albuterol
MDI 4‚Äì8 puffs q20min or
First-line therapy
nebulizer 2.5‚Äì5 mg q20min
continuous nebulizer if severe
Corticosteroids
prednisone 60 mg PO or
IV not superior to PO (JAMA
methylprednisolone 80 mg IV
1988;260:527)
Ipratropium
MDI 4‚Äì8 puffs q30min or
c bronchodilation when
nebulizer 0.5 mg q30min  3
combined w/ albuterol
(Chest 2002;121:1977)
Magnesium
2 g IV over 20 min (Lancet 2003;361:2114)
c PEF & FEV1
Figure 2-2 Initial assessment of asthma exacerbation
ASTHMA
2-4
Initial Assessment of Severity (as above)
Oxygen to maintain SaO2 ‚â•90%
Inhaled Œ≤2-agonists ¬± anticholinergic
Steroids PO or IV (if severe)
Magnesium IV (if severe)
Reassess after 1‚Äì2 h
Good response
PEF >70%
SaO2 >90%
normal exam
response sustained 60‚Ä≤after Rx
Discharge home
Inh Œ≤2-agonists
Oral steroid taper
Close follow-up
Admit to hospital ward
Inh Œ≤2-agonists ¬± antichol
Steroids PO/IV
Magnesium IV
Admit to ICU
Inh Œ≤2-agonists + antichol
Steroids IV
¬± Œ≤2-agonist IV & theo IV
¬± intubation
Incomplete response
PEF <60%
SaO2 not
mild/mod signs or exam
RFs for near-fatal asthma
Poor response
PEF <30%
PaO2 <60 or PaCO2 >45
severe sx
RFs for near-fatal asthma
Reassess periodically at intervals
Incomplete after 6‚Äì12 h
or poor response
(Adapted from GINA 2009.) Risk factors for near-fatal asthma: h/o near-fatal asthma, ED visit or hosp for
asthma in past 1 y, current or recent use of PO steroids, not using inh steroids, overdependent on rapid-
acting 2-agonists, psych issues, h/o noncompliance.
Other treatments
‚Ä¢ Epinephrine (0.3‚Äì0.5 mL SC of 1:1000 dilution): no advantage over inhaled 2-agonists
‚Ä¢ Abx: not needed w/o evidence of bacterial infection. Evidence of improved sx & FEV1
may be related to anti-inflammatory effect (NEJM 2006;354:1589; Chest 2009;136:498).
ICU-level care
‚Ä¢ High-dose steroids: methylprednisolone 125 mg IV q6h (Archives 1983;143:1324)
‚Ä¢ Noninvasive ventilation: likely improves obstruction (Chest 2003;123:1018), but con-
troversial. Consider if mod distress, resp failure not imminent (Resp Care 2008;53:740).
‚Ä¢ Invasive ventilation:
large ET tube, keep Pplat 30 cm H2O (predicts barotrauma better than PIP), maxi-
mize exp time, and use no PEEP to avoid hyperinflation (Resp Care 2008;53:740)
paralysis, inhalational anesthetics, bronchoalveolar lavage w/ mucolytic, heliox
(need 60‚Äì80% helium), and ECMO have been used with success

--- Fim da P√°gina 58 ---

CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Definition and epidemiology (NEJM 2004;350:26)
‚Ä¢ Progressive airflow limitation caused by airway and parenchymal inflammation
Emphysema vs. Chronic Bronchitis
Emphysema
Chronic Bronchitis
Definition
Dilation/destruction of 
Productive cough 3 mo/y
parenchyma (path definition)
 2 y (clinical definition)
Pathophysiology
Tissue destruction
Small airways affected
Matched V/Q defects
V/Q mismatch
Mild hypoxemia
Severe hypoxemia, hypercapnia
PHT, cor pulmonale
Clinical
Severe, constant dyspnea
Intermittent dyspnea
manifestations
Mild cough
Copious sputum production
Physical exam
‚ÄúPink puffer‚Äù
‚ÄúBlue bloater‚Äù
Tachypneic, noncyanotic, thin
Cyanotic, obese, edematous
Diminished breath sounds
Rhonchi & wheezes
Pathogenesis (Lancet 2003;362:1053)
‚Ä¢ Cigarette smoke (centrilobular emphysema, affects 15‚Äì20% of smokers)
‚Ä¢ Recurrent airway infections
‚Ä¢ 1-antitrypsin defic.: early-onset panacinar emphysema, 1‚Äì3% of COPD cases. Suspect
if age 45, lower lungs affected, extrathoracic manifestations (liver disease [not if
MZ subtype], FMD, pancreatitis). ‚úìserum AAT level (nb, acute phase reactant).
Clinical manifestations
‚Ä¢ Chronic cough, sputum production, dyspnea; later stages S freq exac., a.m. HA, wt loss
‚Ä¢ Exacerbation triggers: infxn, other cardiopulmonary disease, incl. PE (Annals 2006;144:390)
Infxn: overt tracheobronchitis/pneumonia from viruses, S. pneumoniae, H. influenzae,
M. catarrhalis, or triggered by changes in strain of colonizers (NEJM 2002;347:465)
‚Ä¢ Physical exam: c AP diameter of chest (‚Äúbarrel-chest‚Äù), hyperresonance, T diaphragmatic
excursion, T breath sounds, c expiratory phase, rhonchi, wheezes
during exacerbation: tachypnea, accessory muscle use, pulsus paradoxus, cyanosis
Diagnostic studies
‚Ä¢ CXR (see Radiology inserts): hyperinflation, flattened diaphragms,  interstitial markings
and bullae
‚Ä¢ PFTs: Obstruction: TT FEV1, T FVC, T FEV1/FVC, expir scooping of flow-volume loop
Hyperinflation: cc RV, c TLC, c RV/TLC
Abnormal gas exchange: T DLCO (in emphysema)
‚Ä¢ ABG: T PaO2,  c PaCO2 (in chronic bronchitis, usually only if FEV1 1.5 L) and T pH
‚Ä¢ ECG: PRWP, S1S2S3, R-sided strain, RVH, c P waves in lead II (‚ÄúP pulmonale‚Äù)
Chronic treatment (Annals 2007;147:633; NEJM 2010;362:1407)
‚Ä¢ Bronchodilators (first-line therapy): anticholinergics, 2-agonists, theophylline
LA anticholinergic (tiotropium): T exac, T admit, T resp failure (NEJM 2008;359:1543),
better than ipratropium (Cochrane 2005;CD002876) or LABA as mono Rx (Chest 2004;125:249)
LABA: 15% T in exacerbations, T FEV1 decline, trend toward T mort. (NEJM 2007;356:775)
LABA  inh steroid: ? T mort (NEJM 2007;356:775; AJRCCM 2008;177:19)
Tiotropium  LABA  inh steroid: c FEV1, T COPD admits (Annals 2007;146:545)
‚Ä¢ Corticosteroids (inhaled): 20% T in exacerbations if FEV1 2.0 L (Chest 2009;136:1029)
may slow FEV1 loss, but more so in combo with 2-agonist (NEJM 2007;356:775)
c in pneumonia (not seen w/ budesonide, Lancet 2009;374:712)
no  in mortality with inh steroids alone (NEJM 2007;356:775)
‚Ä¢ Mucolytics: no  FEV1, but ? T exacerbation rate (Lancet 2008;371:2013)
‚Ä¢ Oxygen: if PaO2 55 mm Hg or SaO2 89% (during rest, exercise, or sleep) to prevent cor
pulmonale and T mortality (Annals 1980;93:391 & Lancet 1981;i:681)
‚Ä¢ Prevention: Flu/Pneumovax; smoking cessation (eg, varenicline, buproprion) S 50%
T in lung function decline (AJRCCM 2002;166:675) and T long-term mortality (Annals 2005;142:223)
‚Ä¢ Rehabilitation: T dyspnea and fatigue, c exercise tolerance, c QoL (Chest 2007;131:4S)
‚Ä¢ Experimental
Lung volume reduction surgery: c exer. capacity, T mort. if FEV1 20%, upper-lobe, low
exer. capacity (NEJM 2003;348:2059); ? bronchoscopic (Chest 2006;129:518)
Bronchoscopic opening of extra-anatomical airway passages to c exp collateral flow
Roflumilast (PDE-4 inhibitor): c FEV1 when added to standard Rx (Lancet 2009;374:685&695)
Nocturnal BiPAP: may improve survival, ? decrease QoL (Thorax 2009;64:561)
‚Ä¢ Lung transplant: c QoL and T sx (Lancet 1998;351:24), ? survival benefit (Am J Transplant 2009;9:1640)
COPD
2-5

--- Fim da P√°gina 59 ---

Prognosis
‚Ä¢ FEV1: 60% predicted S 5-y mort 10%; 40% S 50%; 20% S 90%
‚Ä¢ BODE 10-pt scale (Lancet 2009;374:704); HR 1.62 for resp. mort, 1.34 mort for each 1-pt c
BMI: 21 (1)
Obstruction (FEV1): 50‚Äì64% (1), 36‚Äì49 (2), 35 (3)
Dyspnea (MMRC scale): walking level (1), after 100 yds (2), with ADL (3)
Exs capacity (6-min walk): 250‚Äì349 m (1), 150‚Äì249 (2), 149 (3)
superior to FEV1 (NEJM 2004;350:1005); can predict survival from LVRS (Chest 2006;129:873)
COPD Staging and Recommended Therapies by GOLD Criteria
Stage
PFTs (of predicted)
Therapies
I: Mild
FEV1 80%
Bronchodilator prn
II: Mod
FEV1 50‚Äì80%
Standing LA dilator (tiotropium  ag)
Rehabilitation
III: Severe
FEV1 30‚Äì50%
Above  inh steroid if c exacerbations
IV:Very 
FEV1 30% or FEV1
Above  O2 if chronic resp failure
Severe
50% and chronic
Experimental as indicated
respiratory failure
(Adapted from Global Initiative for Chronic Obstructive Pulmonary Disease, 2009)
EXACERBATION
COPD Exacerbation Treatment (NEJM 2002;346:988)
Agent
Dose
Comments
Ipratropium
MDI 4‚Äì8 puffs q1‚Äì2h or
First-line therapy
Nebulizer 0.5 mg q1‚Äì2h
Albuterol
MDI 4‚Äì8 puffs q1‚Äì2h or
Benefit if component of
Nebulizer 2.5‚Äì5 mg q1‚Äì2h
reversible bronchoconstriction
Corticosteroids No consensus for optimal dose & 
T treatment failure, T hospital stay,
duration (Cochrane 2009:CD001288).
c FEV1 but no mortality benefit,
Consider:
c complications (Cochrane 
Methylprednisolone 125 mg IV
2009:CD001288)
q6h  72 h then:
Prednisone 60 mg PO qd w/ 20 mg 
OutPt Rx after ED visit T
taper q3‚Äì4d (NEJM 1999;340:1941)
relapse (NEJM 2003;348:2618)
or prednisone 40 mg x 10d or 
prednisone 30 mg qd  2 wks 
if pH 7.26 (Lancet 1999;354:456)
Antibiotics
Amoxicillin,TMP-SMX,
H. flu, M. catarrhalis, S. pneumo 
doxycycline, clarithromycin,
freq. precipitants.
anti-pneumococcal FQ, etc., all
Dyspnea, c sputum production,
reasonable (no single abx proven
c purulence S abx may improve
superior). Consider local flora and 
outcome (Annals 1987;106:196)
avoid repeat courses of same 
c PEF & chance of clinical
antibiotic.
resolution (JAMA 1995;273:957)
T subseq exacerbation (Thorax
2008;63:96)
5d course likely enough for 
mild-mod exacerbation (Thorax
2008;63:41; JAMA 2010;303:2035)
Oxygenation
c FiO2 to achieve PaO2 55‚Äì60
Watch for CO2 retention
or SaO2 90‚Äì93%
(due to cV/Q mismatch, loss of
hypoxemic resp. drive,
Haldane effect)
but must maintain oxygenation!
Noninvasive
Initiate early if mod/severe dyspnea, T pH / c PaCO2, RR 25
positive-
Results in 58% T intubation, T LOS by 3.2 d, 59% T mortality
pressure
Contraindications:  MS, inability to cooperate or clear secretions,
ventilation
hemodynamic instability, UGIB
(NEJM 1995;333:817; Annals 2003;138:861; Cochrane 2004;CD004104; ERJ 2005;25:348)
Endotracheal
Consider if PaO2 55‚Äì60, c‚Äôing PaCO2, T‚Äôing pH, c RR, respiratory
intubation
fatigue,  MS, or hemodynamic instability
Other measures
Mucolytics overall not supported by data (Chest 2001;119:1190)
Monitor for cardiac arrhythmias
COPD
2-6
FEV1/FVC 70%
RF reduction,
Flu vaccine

--- Fim da P√°gina 60 ---

HEMOP/SPN
2-7
HEMOPTYSIS
Definition and pathophysiology
‚Ä¢ Expectoration of blood or blood-streaked sputum
‚Ä¢ Massive hemoptysis: 600 mL/24‚Äì48 h;gas exchange more important than blood loss
‚Ä¢ Massive hemoptysis usually from tortuous or invaded bronchial arteries
Etiologies
Infection/
Bronchitis (most common cause of trivial hemoptysis)
Inflammation
Bronchiectasis incl. CF (common cause of massive hemoptysis)
Tuberculosis or aspergilloma (can be massive)
Pneumonia or lung abscess
Neoplasm
Usually primary lung cancer, sometimes metastasis (can be massive)
Cardiovascular
PE (can be massive), pulmonary artery rupture (2	 to instrumentation),
CHF, mitral stenosis, trauma/foreign body, bronchovascular fistula
Other
Vasculitis (Wegener‚Äôs, Goodpasture‚Äôs, Beh√ßet‚Äôs; can be massive),
AVM, anticoagulation (w/ underlying lung disease), coagulopathy,
cocaine, idiopathic pulmonary hemosiderosis, catamenial (lung 
endometriosis)
(Crit Care Med 2000;28:1642)
Diagnostic workup
‚Ä¢ Localize bleeding site
Rule out GI or ENT source by exam, history; may require endoscopy
Pulmonary source: determine whether unilateral or bilateral, localized or
diffuse, parenchymal or airway by CXR or chest CT, bronchoscopy if necessary
‚Ä¢ PT, PTT, CBC to rule out coagulopathy
‚Ä¢ Sputum culture/stain for bacteria, fungi, and AFB; cytology to r/o malignancy
‚Ä¢ ANCA, anti-GBM, urinalysis to ‚úìfor vasculitis or pulmonary-renal syndrome
Treatment
‚Ä¢ Mechanism of death is asphyxiation not exsanguination; maintain gas exchange, reverse
coagulation and treat underlying condition; cough supp. may c risk of asphyxiation
‚Ä¢ Massive hemoptysis: put bleeding side dependent; selectively intubate nl lung if needed
Angiography: used for Dx & Rx (vascular occlusion balloons or selective embolization
of bronchial circulation)
Rigid bronchoscopy: allows more interventional options (electrocautery, laser) than flex.
Surgical resection
SOLITARY PULMONARY NODULE
Principles
‚Ä¢ Definition: single, 3 cm, surrounded by normal lung, no LAN or pleural effusion
‚Ä¢ Often ‚Äúincidentalomas,‚Äù but may represent early potentially curable localized malignancy
Etiologies
Benign (70%)
Malignant (30%)
Granuloma (80%):TB, histo, coccidio
Bronchogenic carcinoma (75%):
Hamartoma (10%)
adeno & large cell (peripheral)
Bronchogenic cyst,AVM, pulm infarct
squamous & small cell (central)
Echinococcosis, ascariasis, aspergilloma
Metastatic (20%): breast, head & neck,
Wegener‚Äôs, rheumatoid nodule
colon, testicular, renal, sarcoma, melanoma
Lipoma, fibroma, amyloidoma, pneumonitis
Carcinoid, primary sarcoma
Risk of Cancer
Feature
Low
Intermediate
High
Diameter (cm)
1.5
1.5‚Äì2.2
2.3
Nodule shape
smooth
scalloped
spiculated
Age (y)
45
45‚Äì60
60
Smoking
never
current (1 ppd)
current (1 ppd)
Smoking cessation
none, quit 7 y
quit 7 y ago
never quit
(NEJM 2003;348:2535)

--- Fim da P√°gina 61 ---

Initial evaluation
‚Ä¢ History: h/o cancer, smoking, age (30 y 
 2% malignant, 15% ea. decade 30)
‚Ä¢ CT: size/shape, Ca, LAN, effusions, bony destruction, c/w old studies
‚àÖCa S c likelihood malignant; laminated S granuloma; ‚Äúpopcorn‚Äù S hamartoma
Diagnostic studies
‚Ä¢ PET: detects metab. activity of tumors, 97% Se & 78% Sp for malig. (espec if 8 mm)
also useful for surgical staging b/c may detect unsuspected mets (Lancet 2001;2:659)
useful in deciding which lesions to bx vs. follow w/ serial CT (J Thor Oncol 2006;1:71)
‚Ä¢ Transthoracic needle biopsy: if tech. feasible, 97% will obtain definitive tissue dx
(AJR 2005;185:1294); if noninformative or malignant S resect
‚Ä¢ Video-assisted thorascopic surgery (VATS): for percutaneously inaccessible lesions;
highly sensitive and allows resection; has replaced thoracotomy
‚Ä¢ Transbronchial bx: most lesions too small to reliably sample w/o endobronchial
U/S (Chest 2003;123:604); bronch w/ brushings low-yield unless invading bronchus
‚Ä¢ PPD, fungal serologies,ANCA
Management
‚Ä¢ Low-risk: serial CT (q3mo  4, then q6mo  2); shared decision w/ Pt regarding bx
‚Ä¢ Intermediate-risk: PET, transthoracic needle bx or transbronchial bx depending on
location, comorbidities and Pt preference; if noninformative S VATS
‚Ä¢ High-risk (and surgical candidate): VATS S lobectomy if malignant
OBSTRUCTIVE SLEEP APNEA (OSA)
Definition and pathophysiology
‚Ä¢ Repetitive pharyngeal collapse during sleep causing apnea (10 s) or hypopnea (airflow
reduction)  desaturation, arousals from sleep S daytime sleepiness
‚Ä¢ Apnea-hypopnea index (AHI) 
 avg # apneas and hypopneas per hr of sleep
‚Ä¢ Sleep-induced loss of activity of pharyngeal dilator muscles S pharyngeal collapse S
arousal S activation of sympathetic nervous system; phenotypes vary across OSA Pts
‚Ä¢ Apnea S negative intrathoracic pressure S c preload, c afterload S HTN, CV sequelae
‚Ä¢ Risk factors: obesity (present in 70%), male, age, alcohol, smoking, black race
Clinical manifestations (Lancet 2002;360:237)
‚Ä¢ Snoring, witnessed apneas/gasping, daytime sleepiness
‚Ä¢ Cardiovascular
HTN (JAMA 2000;283:1829; NEJM 2000;342:1378)
Associated with c risk of stroke and death (NEJM 2005;353:2034) and possibly CAD and
CHF (AJRCCM 2001;163:19)
‚Ä¢ Neurocognitive
T cognitive performance, T QOL
c MVA and work accidents (NEJM 1999;340:847; AJRCCM 2001;164:2031)
Diagnosis and treatment
‚Ä¢ Polysomnography (sleep study); can do home-testing. If , trial of CPAP.
‚Ä¢ CPAP: TT apnea/hypopnea, T BP (Lancet 2002;359:204), T sleepiness, c performance (AJRCCM
2001;164:608), c EF in Pts with heart failure (NEJM 2003;348:1233)
‚Ä¢ Oral appliances can prevent retroglossal collapse. Offer if refusing CPAP.
‚Ä¢ Avoid alcohol and sedatives
‚Ä¢ Surgery (eg, uvulopalatopharyngoplasty, UPPP) of limited benefit (Chest 1997;111:265)
OSA
2-8

--- Fim da P√°gina 62 ---

ILD
2-9
INTERSTITIAL LUNG DISEASE
WORKUP OF ILD
Rule out mimickers of ILD
‚Ä¢ Congestive heart failure (‚úìBNP, trial of diuresis)
‚Ä¢ Infection: viral, atypical bacterial, fungal, mycobacterial, parasitic
‚Ä¢ Malignancy: lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma
History and physical exam
‚Ä¢ Occupational, travel, exposure, medications, precipitating event
‚Ä¢ Tempo (acute S infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)
‚Ä¢ Extrapulmonary s/s (skin s, arthralgias/arthritis, clubbing, neuropathies, etc.)
Diagnostic studies (see Appendix & Radiology inserts)
‚Ä¢ CXR and high-resolution chest CT: reticular, nodular, or ground glass pattern
upper S coal, silicon, hypersens., sarcoid,TB, RA; lower S IPF, asbestos, scleroderma
adenopathy S sarcoidosis, berylliosis, silicosis, malignancy, fungal infections
pleural disease S collagen-vascular diseases, asbestosis, infections, XRT
‚Ä¢ PFTs: restrictive pattern (T volumes), T DLCO, T PaO2 (especially w/ exercise); if also
obstructive, consider sarcoid
‚Ä¢ Serologies: ‚úìACE,ANA, RF, ANCA, anti-GBM, HIV
‚Ä¢ Bronchoalveolar lavage: dx infxn, hemorrhage, eosinophilic syndromes, PAP
‚Ä¢ Biopsy (transbronch, CT-guided,VATS, open) if no clear precipitant and w/u unrevealing
ETIOLOGIES OF ILD
Sarcoidosis (NEJM 2007;357:2153 & Clin Chest Med 2008;29:533)
‚Ä¢ Prevalence: African Americans, northern Europeans, and females; onset in 3rd‚Äì4th decade
‚Ä¢ Pathophysiology: depression of cellular immune system peripherally, activation centrally
Clinical Manifestations
Organ system 
Manifestations
Pulmonary
Hilar LAN; fibrosis; pulm hypertension. Stages: I 
 bilat hilar 
LAN; II 
 LAN  ILD; III 
 ILD only; IV 
 diffuse fibrosis
Cutaneous (25‚Äì33%)
Waxy skin plaques
Lupus pernio (violaceous indurated lesions on face)
Erythema nodosum (red tender nodules due to panniculitis,
typically on shins). Ddx: idiopathic (34%), infxn (33%,
strep,TB), sarcoid (22%), drugs (OCP, PCNs), vasculitis 
(Beh√ßet‚Äôs), IBD, lymphoma.
Ocular (25‚Äì80%)
Anterior  posterior uveitis; c lacrimal gland 
Endo & renal (10%)
Nephrolithiasis, hypercalcemia (10%), hypercalciuria (40%)
Due to vitamin D hydroxylation by M
Neuro (10% clin, 25% path)
CN VII palsy, periph neuropathies, CNS lesions, seizures
Cardiac (5% clin, 25% path)
Conduction block,VT, CMP
Liver, spleen, BM
Granulomatous hepatitis (25%), splenic & BM gran. (50%)
Constitutional
Fever, night sweats, anorexia & wt loss (a/w hepatic path)
Musculoskeletal
Arthralgias, periarticular swelling, bone cysts
‚Ä¢ L√∂fgren‚Äôs syndrome: erythema nodosum  hilar adenopathy  arthritis (good prognosis)
‚Ä¢ Diagnostic studies: LN bx S noncaseating granulomas  multinucleated giant cells
18FDG PET can be used to identify extent and potentially targets for dx bx
c ACE (Se 60%, 90% w/ active dis., Sp 80%, false  in granulomatous diseases)
‚Ä¢ To assess extent: CXR, PFTs, full ophtho exam, ECG, CBC (lymphopenia, c eos), Ca,
24-h urine for Ca, LFTs;  Holter, echo, cardiac MRI, brain MRI, etc., based on s/s
‚Ä¢ Rx:steroids (eg,prednisone 20‚Äì40 mg/d) if sx or extrathoracic organ dysfxn (improves sx,
but doesn‚Äôt  long-term course);hydroxychloroquine for extensive skin disease;anti-TNF,
MTX, AZA, mycophenolate, or cyclophosphamide for chronic/refractory disease
‚Ä¢ Prognosis: 2‚ÅÑ3 spontaneously remit w/in 10 y (60‚Äì80% of stage I, 50‚Äì60% stage II,
30% stage III), w/ relapses uncommon; 1‚ÅÑ3 have progressive disease
Iatrogenic
‚Ä¢ Amiodarone (10%; dose & duration depend.): chronic interstitial pneumonia 4
ARDS; bx S vacuolized M w/ lamellar inclusions on EM; Rx: d/c amio, give steroids
‚Ä¢ Other drugs: nitrofurantoin, sulfonamides, thiazides, INH, hydralazine, gold
‚Ä¢ Chemo: bleomycin (triggered by hyperoxia), busulfan, cyclophosphamide, MTX, etc.
‚Ä¢ XRT: COP/BOOP w/ sharply linear, nonanatomic boundaries; DAH

--- Fim da P√°gina 63 ---

Idiopathic interstitial pneumonias (IIPs) (AJRCCM 2005;172:268)
‚Ä¢ Definition: ILD of unknown cause; dx by radiographic, histologic, and clinical features
IIPs
Type
Imaging/Histology
Clinical
UIP/IPF
Reticular opacities, honeycombing, traction 
Sx 12 mos
bronchiectasis; periph, subpl., & basal
5-y mort 80%
NSIP
Homogenous ground glass opacities or consolid.,
Sx mos‚Äìy
reticular irreg lines; symmetric, periph., basal,
5-y mort 10% (fibrotic
subpl. Mimics CTD ILD. Cellular and fibrotic

 UIP) 
subtypes, latter similar to UIP but homogenous.
COP/BOOP
Patchy bilat consolid., nodules; subpl. & 
Can be post-infxn,
peribronchial. Prolif of granulation tissue in small 
HSCT, XRT, rxn to
bronchioles & inflam of surrounding alveoli.
drugs. 5-y mort 5%.
AIP
Diffuse ground glass opacities, consolid. w/ lobular 
Sx 3 wks.
sparing. Path similar to DAD.
6-mo mort 60%
DIP
Diffuse ground glass opacities, reticular lines;
30‚Äì50-yo smokers.
lower zones, periph. M in alveoli.
Sx wks‚Äìmos.
RB-ILD
Bronchial thickening, centrilobular nodules, patchy 
Death rare.
ground glass opacities. M in alveoli.
(AJRCCM 2002;165:277; Archives 2001;161:158). UIP, usual interstitial PNA (IP); IPF, idiopathic pulm fibrosis; NSIP,
nonspecific IP; COP, cryptogenic organizing PNA; BOOP, bronchiolitis obliterans w/ organizing PNA; AIP,
acute IP (Hamman-Rich syndrome); DIP, desquamative IP; RB-ILD, resp bronchiolitis-assoc ILD.
‚Ä¢ Rx for UIP/IPF: steroids  AZA; NAC 600 tid may slow T lung fxn (NEJM 2005;353:2229)
‚Ä¢ Steroids for other IIPs: NSIP (espec. cellular type) and COP (AJRCCM 2000;162:571); 
? benefit for AIP and DIP/RB-ILD (for which Pts should stop smoking)
Environmental & occupational exposures (NEJM 2000;342:406)
‚Ä¢ Pneumoconioses (inorganic dusts)
Coal worker‚Äôs: upper lobe coal macules; may progress to massive fibrosis
Silicosis: upper lobe opacities  eggshell calcification of lymph nodes; c risk of TB
Asbestosis: lower lobe fibrosis, calcified pleural plaques, DOE, dry cough, rales on
exam.Asbestos exposure also S pleural plaques, benign pleural effusion, diffuse
pleural thickening, rounded atelectasis, mesothelioma, lung Ca (esp in smokers).
Berylliosis: multisystemic granulomatous disease that mimics sarcoidosis
‚Ä¢ Hypersensitivity pneumonitides (organic dusts): loose, noncaseating granulomas
Antigens: farmer‚Äôs lung (spores of thermophilic actinomyces); pigeon fancier‚Äôs lung
(proteins from feathers and excreta of birds); humidifier lung (thermophilic bacteria)
Pathophysiology: immunologic rxn; either acute (6 h after exposure) or chronic
Collagen vascular diseases (ERJ 2001;18:69S; NEJM 2006;355:2655)
‚Ä¢ Rheumatologic disease
Scleroderma: fibrosis in 67%; PHT seen in 10% of CREST Pts 
PM-DM: ILD & weakness of respiratory muscles; MCTD: PHT & fibrosis
SLE & RA: pleuritis and pleural effusions more often than ILD; SLE can cause DAH
‚Ä¢ Vasculitis (can p/w DAH)
Wegener‚Äôs granulomatosis ( c-ANCA) w/ necrotizing granulomas
Churg-Strauss syndrome ( c- or p-ANCA) w/ eosinophilia & necrotizing granulomas
Microscopic polyangiitis ( p-ANCA) w/o granulomas
‚Ä¢ Goodpasture‚Äôs syndrome 
 DAH  RPGN; typically in smokers;  anti-GBM in 90%
‚Ä¢ Idiopathic pulmonary hemosiderosis (IPH): a rare disease and dx of exclusion
Pulmonary infiltrates w/ eosinophilia (PIE) 
 eos on BAL  periph. blood
‚Ä¢ Allergic bronchopulmonary aspergillosis (ABPA): allergic reaction to Aspergillus
Criteria: asthma, pulm infiltrates (transient or fixed), skin rxn & serum precipitins
to Aspergillus, c IgE to Aspergillus & total (1,000), c eos, central bronchiectasis
Rx: steroids  itraconazole for refractory cases (NEJM 2000;342:756)
‚Ä¢ L√∂ffler‚Äôs syndrome: parasites/drugs S transient pulm infilt  cough, fever, dyspnea, eos 
‚Ä¢ Acute eosinophilic pneumonia (AEP): acute hypoxic febrile illness; Rx: steroids
‚Ä¢ Chronic eosinophilic pneumonia (CEP):‚Äúphotonegative‚Äù of CHF, typically in women
‚Ä¢ Other: Churg-Strauss syndrome; hypereos syndrome
Miscellaneous
‚Ä¢ Pulm alveolar proteinosis (PAP): accum of surfactant-like phospholipids;  smokers; white
& gummy sputum; BAL milky fluid (NEJM 2003;349:2527); Rx w/ lung lavage & anti-GMCSF 
‚Ä¢ Langerhans cell granulomatosis (LCG): young  smokers; apical cysts; PTX (25%)
‚Ä¢ Lymphocytic interstitial pneumonia (LIP): polyclonal B-cell lung infiltration (? lymphoma) w/
retic. & ground glass opacities and septal/bronchovasc thickening; sx 1 y; Rx: steroids
ILD
2-10

--- Fim da P√°gina 64 ---

PLEURAL EFF
2-11
PLEURAL EFFUSION
Pathophysiology
‚Ä¢ Systemic factors (eg, c PCWP, T oncotic pressure) S transudative effusion
‚Ä¢ Local factors (ie,  pleural surface permeability) S exudative effusion
Transudates
‚Ä¢ Congestive heart failure (40%): 80% bilateral,  cardiomegaly on CXR
occasionally exudative (especially after aggressive diuresis or if chronic), but 75% of
exudative effusions in CHF Pts found to have non-CHF cause (Chest 2002;122:1518)
‚Ä¢ Constrictive pericarditis (knock on exam, calcification or thickening on imaging)
‚Ä¢ Cirrhosis (‚Äúhepatic hydrothorax‚Äù): diaphragmatic defect w/ passage of ascitic fluid
often right-sided (2‚ÅÑ3) & massive (even w/o marked ascites)
‚Ä¢ Nephrotic syndrome: usually small, bilateral, asymptomatic (r/o PE b/c hypercoag)
‚Ä¢ Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD
Exudates
‚Ä¢ Lung parenchymal infection (25%)
bacterial (parapneumonic): can evolve along spectrum of exudative (but sterile) S
fibropurulent (infected fluid) S organization (fibrosis & formation of rigid pleural peel).
Common causes: Strep pneumo, Staph aureus, Strep milleri, Klebsiella, Pseudomonas,
Haemophilus, Bacteroides, Peptostreptococcus, mixed flora in aspiration pneumonia.
mycobacterial: 50% lymphs 80% of the time, ADA 40, pleural bx 70% Se
fungal, viral (usually small), parasitic (eg, amebiasis, echinococcosis, paragonimiasis)
‚Ä¢ Malignancy (15%): primary lung cancer most common, metastases (especially breast,
lymphoma, etc.), mesothelioma (‚úìserum osteopontin levels; NEJM 2005;353:15)
‚Ä¢ Pulmonary embolism (10%): effusions in 40% of PEs; exudate (75%)  transudate
(25%); hemorrhagic‚Äîmust have high suspicion b/c presentation highly variable
‚Ä¢ Collagen vascular disease: RA (large), SLE (small),Wegener‚Äôs, Churg-Strauss
‚Ä¢ Gastrointestinal diseases: pancreatitis, esophageal rupture, abdominal abscess
‚Ä¢ Hemothorax (Hcteff/Hctblood 50%): trauma, PE, malignancy, coagulopathy, leaking aortic
aneurysm, aortic dissection, pulmonary vascular malformation
‚Ä¢ Chylothorax (triglycerides 110): thoracic duct damage due to trauma, malignancy, LAM
‚Ä¢ Other: post-CABG: left-sided; initially bloody, clears after several wks
Dressler‚Äôs syndrome (pericarditis & pleuritis post-MI), uremia, post-radiation therapy
Asbestos exposure: benign;  eosinophils
Drug-induced (eg, nitrofurantoin, methysergide, bromocriptine, amiodarone):  eos
Uremia; post-XRT; sarcoidosis
Meigs‚Äô syndrome 
 benign ovarian tumor S ascites & pleural effusion
Yellow-nail syndrome: yellow nails, lymphedema, pleural effusion, bronchiectasis
Diagnostic studies
‚Ä¢ Thoracentesis (NEJM 2006;355:e16)
Indications: all effusions 1 cm in decubitus view
if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h) 
asymmetry, fever, chest pain, or failure to resolve S thoracentesis
parapneumonics should be tapped ASAP (cannot exclude infxn clinically)
Diagnostic studies: ‚úìtotal protein, LDH, glucose, cell count w/ differential, gram stain &
culture, pH; remaining fluid for additional studies as dictated by clinical scenario
Complications: PTX (5‚Äì10%), hemothorax (1%), re-expansion pulm. edema (if 1.5 L
removed), spleen/liver lac.; post-tap CXR not routinely needed (Annals 1996;124:816)
‚Ä¢ Transudate vs. exudate (Annals 1972;77:507)
Light‚Äôs criteria: exudate 
 TPeff/TPserum 0.5 or LDHeff/LDHserum 0.6 or LDHeff
2‚ÅÑ3 ULN of LDHserum; 98% Se, 83% Sp; best Se of all methods (Chest 1995;107:1604);
however, will misidentify 25% of transudates as exudates;  if clinically suspect
transudate but meets criterion for exudate, confirm w/ test w/ higher Sp
exudative criteria w/ better Sp: serum-effusion alb gradient 1.2, Se 87%, Sp 92%;
serum-effusion TP gradient 3.1, Se 84%, Sp 91%; choleff 45 mg/dL and LDHeff
200, 90% Se, 98% Sp (no serum required)
CHF effusions: TP may c with diuresis or chronicity S ‚Äúpseudoexudate‚Äù; use albumin
gradient 1.2, choleff 60 mg/dL (Se 54%, Sp 92%), or clinical judgment to help
distinguish (Chest 2002;122:1524)
‚Ä¢ Complicated vs. uncomplicated parapneumonic (Chest 1995;108:299)
complicated 
  gram stain or culture or pH 7.2 or glucose 60
complicated parapneumonic effusions usually require drainage to achieve resolution
empyema 
 frank pus, also needs drainage to achieve resolution

--- Fim da P√°gina 65 ---

PLEURAL EFF
2-12
‚Ä¢ Additional pleural fluid studies (NEJM 2002;346:1971)
NT-proBNP 1,500 pg/mL has 91% Se & 93% Sp for CHF (Am J Med 2004;116:417)
WBC & diff.: exudates tend to have c WBC vs. transudates but nonspecific
neutrophils S parapneumonic, PE, pancreatitis
lymphocytes (50%) S cancer,TB, rheumatologic
eos (10%) S blood, air, drug rxn, asbestos, paragonimiasis, Churg-Strauss, PE
RBC: Hcteff 1‚Äì20% S cancer, PE, trauma; Hcteff/Hctblood 50% S hemothorax
AFB: yield in TB 0‚Äì10% w/ stain, 11‚Äì50% w/ culture, 70% w/ pleural bx
adenosine deaminase (ADA): seen w/ granulomas, 70 suggests TB, 40 excludes TB
cytology: ideally 150 mL and at least 60 mL should be obtained (Chest 2010;137:68)
glucose: 60 mg/dL S malignancy, infection, RA
amylase: seen in pancreatic disease and esophageal rupture (salivary amylase)
rheumatoid factor, CH50,ANA: limited utility in dx collagen vascular disease
triglycerides: 110 S chylothorax, 50‚Äì110 S ‚úìlipoprotein analysis for chylomicrons
cholesterol: 60; seen in chronic effusions (eg, CHF, RA, old TB)
creatinine: effusion/serum ratio 1 S urinothorax
‚Ä¢ Chest CT; pleural biopsy; VATS
‚Ä¢ Undiagnosed persistent pleural effusions (Clin Chest Med 2006;27:309)
Transudative: most commonly CHF or hepatic hydrothorax. ‚úìs/s CHF or cirrhosis,
NT-proBNPeff; consider intraperitoneal injection of technetium-99m sulfur colloid
Exudative (ensure using Sp test listed above): most commonly malig, empyema,TB,
PE. ‚úìs/s malig, chest CT (I), ADA or IFN- release assay; consider thoracoscopy.
Characteristics of Pleural Fluid (not diagnostic criteria)
Etiology
Appear
WBC diff
RBC
pH
Glc
Comments
CHF
clear, straw
1,000
5,000
normal
 serum
bilateral,
lymphs
cardiomegaly
Cirrhosis
clear, straw
1,000
5,000
normal
 serum
right-sided
Uncomplicated
turbid
5‚Äì40,000
5,000
normal
 serum
parapneumonic
polys
to T
(40)
Complicated
turbid to
5‚Äì40,000
5,000
TT
TT
need drainage
parapneumonic
purulent
polys
(40)
Empyema
purulent
25‚Äì100,000
5,000
TTT
TT
need drainage
polys
Tuberculosis
serosang.
5‚Äì10,000
10,000
normal
normal
 AFB
lymphs
to T
to T
 ADA
Malignancy
turbid to
1‚Äì100,000
100,000
normal
normal
 cytology
bloody
lymphs
to T
to T
Pulmonary
sometimes
1‚Äì50,000
100,000
normal
 serum
no infarct S
embolism
bloody
polys
transudate
Rheumatoid
turbid
1‚Äì20,000
1,000
T
RA TTT
c RF, T CH50
arthritis/SLE
variable
SLE nl
c imm. complex
Pancreatitis
serosang.
1‚Äì50,000
10,000
normal
 serum
left-sided,
to turbid
polys
c amylase
Esophageal
turbid to
5,000
10,000
TTT
TT
left-sided,
rupture
purulent
50,000
c amylase
Treatment
‚Ä¢ Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process
‚Ä¢ Parapneumonic effusion (Chest 2000;118:1158)
uncomplicated S antibiotics for pneumonia
1‚ÅÑ2 hemithorax or complicated or empyema S tube thoracostomy
(o/w risk of organization and subsequent need for surgical decortication)
loculated S tube thoracostomy or VATS; intrapleural lytics w/o clear benefit
(although largest trial used lytics late and w/ small-bore chest tubes; NEJM 2005;352:865)
‚Ä¢ Malignant effusion: serial thoracenteses vs. tube thoracostomy  pleurodesis (success rate
80‚Äì90%) vs. indwelling pleural catheter for outPts (Cochrane database 2004;CD002916);
choice of specific pleurodesis agent (talc, bleo, doxy) controversial; systemic steroids
and pH 7.2 a/w c likelihood to fail pleurodesis
‚Ä¢ TB effusions: effusion will often resolve spontaneously; however, treat Pt for active TB
‚Ä¢ Hepatic hydrothorax
Rx:  pressure gradient (ie, T ascitic fluid volume, NIPPV)
avoid chest tubes; prn thoracenteses, pleurodesis,TIPS or VATS closure of diaphragmatic
defects if medical Rx fails; NIPPV for acute short-term management
spontaneous bacterial empyema (SBEM) can occur (even w/o SBP being present),
‚à¥thoracentesis if suspect infection
transplant is definitive treatment and workup should begin immediately

--- Fim da P√°gina 66 ---

VTE
2-13
VENOUS THROMBOEMBOLISM (VTE)
Definitions
‚Ä¢ Proximal deep venous thrombosis (DVT): thrombosis of popliteal, femoral, or iliac veins
(nb,‚Äúsuperficial‚Äù femoral vein part of deep venous system)
‚Ä¢ Pulmonary embolism (PE): thrombosis originating in venous system and embolizing
to pulmonary arterial circulation; 1 case/1,000 person y; 250,000/y (Archives 2003;163:1711)
Risk factors 
‚Ä¢ Virchow‚Äôs triad for thrombogenesis
stasis: bed rest, inactivity, CHF, CVA w/in 3 mo, air travel 6 h (NEJM 2001;345:779)
injury to endothelium: trauma, surgery, prior DVT, inflammation
thrombophilia:APC resistance, protein C or S deficiency, APS, prothrombin gene
mutation,c factor VIII, hyperhomocysteinemia, HIT, OCP, HRT, tamoxifen, raloxifene
‚Ä¢ Malignancy (12% of ‚Äúidiopathic‚Äù DVT/PE)
‚Ä¢ History of thrombosis (greater risk of recurrent VTE than genetic thrombophilia)
‚Ä¢ Statin therapy T risk (NEJM 2009;360:1851)
Thromboprophylaxis (Chest 2008;133:381S)
Risk
Patient & situation
Prophylaxis
Low
Minor surgery in mobile Pt;
Early, aggressive ambulation
VTE 10%
fully mobile medical Pt
Moderate
Most surgery Pts; sick or
UFH 5,000 U SC bid or tid; LMWH, fonda
VTE 10‚Äì40%
bedrest medical Pts 
(if HIT ); mechanical Ppx if high bleed risk
High
Ortho surgery, trauma,
LMWH, fondaparinux, warfarin (INR 2‚Äì3);
VTE 40‚Äì80%
spinal cord injury
mechanical Ppx if high bleed risk
Rivaroxaban (oral anti-Xa; NEJM 2008;358:2765 & 2776) and dabigatran (oral anti-IIa) under study.
Clinical manifestations‚ÄîDVT
‚Ä¢ Calf pain, lower extremity swelling (3 cm c/w unaffected side), venous distention,
pain, erythema, warmth, tenderness, palpable cord,  Homan‚Äôs sign (calf pain on
dorsiflexion, seen in 5% of Pts), phlegmasia cerulea dolens: stagnant blood S
edema, cyanosis, pain
‚Ä¢ 50% of Pts with sx DVT have asx PE
Pretest Probability of DVT
Major points
Minor points
‚Ä¢ Active cancer
‚Ä¢ Trauma to symptomatic leg w/in 60 d
‚Ä¢ Paralysis, paresis, immobilization of foot
‚Ä¢ Pitting edema in symptomatic leg
‚Ä¢ Bed rest  3 d or major surg. w/in 4 wk
‚Ä¢ Dilated superficial veins (nonvaricose)
‚Ä¢ Localized tenderness along veins
in symptomatic leg only
‚Ä¢ Swelling of thigh and calf
‚Ä¢ Hospitalization w/in previous 6 mo
‚Ä¢ Swelling of calf 3 cm c/w asx side
‚Ä¢ Erythema
‚Ä¢  FHx of DVT (2 1	 relatives)
High probability (85%  DVT)
Low probability (5%  DVT)
3 major  no alternative dx
1 major  2 minor  alternative dx
2 major  2 minor  no alternative dx
1 major  1 minor  no alternative dx
Intermediate prob (33%  DVT)
0 major  3 minor  alternative dx
neither high nor low probability
0 major  2 minor  no alternative dx
(Lancet 1995;345:1326; NEJM 1996;335:1816)
Diagnostic studies‚ÄîDVT
‚Ä¢ Compression U/S 95% Se & Sp for sx DVT (lower for asx DVT); survey whole leg
rather than just proximal (JAMA 2010;303:438)
‚Ä¢ D-dimer: 500 helps r/o DVT (see later for details);Venography: CT, MR, or angiography
Figure 2-3 Approach to suspected DVT
Pretest probability
Low
D-Dimer
DVT excluded 
Ultrasound
DVT
confirmed
‚â•500 ng/mL
<500 ng/mL 
Intermediate
or High
High
clin prob
Intermed
clin prob
repeat U/S in 1 wk
if D-dimer ‚äï
Venography (CT, MR, angio)
_
‚äï
‚äï
_
(Lancet 1995;345:1326 & 1997;350:1795; NEJM 1996;335:1816 & 2003;349:13; Archives 2002;162:907.)

--- Fim da P√°gina 67 ---

Clinical manifestations‚ÄîPE
‚Ä¢ Dyspnea (73%), pleuritic chest pain (66%), cough (37%), hemoptysis (13%)
‚Ä¢ c RR (70%), crackles (51%), c HR (30%), fever, cyanosis, pleural friction rub, loud P2
‚Ä¢ Massive: syncope, HoTN, PEA; c JVP, R-sided S3, Graham Steell (PR) murmur
‚ÄúModified Wells‚Äù Pretest Probability Scoring of PE
Variable
Point Score
‚Ä¢ PE as likely or more likely than alternate dx; clin. s/s of DVT
3 each
‚Ä¢ HR 100 bpm; prior DVT or PE
1.5 each
‚Ä¢ Immobilization (bed rest 3 d) or surgery w/in 4 wk
1.5
‚Ä¢ Hemoptysis; malignancy
1 each
‚ÄúModified Wells‚Äù Pretest Probability Assessment (Use for V/Q)
Score 2
Score 2‚Äì6
Score 6
Low probability
Intermediate probability
High probability
‚ÄúDichotomized Wells‚Äù Pretest Probability Assessment* (Use for CTA)
Score 4: PE ‚ÄúUnlikely‚Äù
Score 4: PE ‚ÄúLikely‚Äù
(Annals 2001;135:98) (*JAMA 2006;295:172)
Diagnostic studies‚ÄîPE
‚Ä¢ CXR (limited Se & Sp): 12% nl, atelectasis, effusion, c hemidiaphragm, Hampton hump,
(wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)
‚Ä¢ ECG (limited Se & Sp): sinus tachycardia, AF; signs of RV strain S RAD, P pulmonale,
RBBB, SIQIIITIII & TWI V1‚ÄìV4 (McGinn-White pattern, Chest 1997;111:537)
‚Ä¢ ABG: hypoxemia, hypocapnia, respiratory alkalosis, c A-a gradient (Chest 1996;109:78)
18% w/ room air PaO2 85‚Äì105 mm Hg, 6% w/ nl A-a gradient (Chest 1991;100:598)
‚Ä¢ D-dimer: high Se, poor Sp (25%);  ELISA has 99% NPV and can be used to r/o PE in
Pts w/ ‚Äúunlikely‚Äù pretest prob. (JAMA 2006;295:172)
‚Ä¢ Echocardiography: useful for risk stratification (RV dysfxn), but not dx (Se 50%)
‚Ä¢ V/Q scan: high Se (98%), low Sp (10%). Sp improves to 97% for high prob VQ.
Use if pretest prob of PE high and CT not available or contraindicated. Can also
exclude PE if low pretest prob, low prob VQ, but 4% false  (JAMA 1990;263:2753).
‚Ä¢ CT angiography (CTA; see Radiology inserts): Se. 90% & Sp 95% w/ MDCT, 
CTV, good quality scans and experienced readers (NEJM 2006;354:2317); PPV & NPV
95% if imaging concordant w/ clinical suspicion, 80% if discordant ( need to
consider both); CT may also provide other dx
‚Ä¢ Lower extremity compression U/S shows DVT in 9%, sparing CTA, but when added
to CTA, does not  outcomes (Lancet 2008;371:1343)
‚Ä¢ Pulmonary angio: ? gold standard (morbidity 5%, mortality 0.5%), infrequently performed
‚Ä¢ MR angiography: Se 84% (segmental) to 100% (lobar) (Lancet 2002;359:1643)
Figure 2-4 Approach to suspected PE using CTA
VTE
2-14
‚ÄúDichotomized Wells‚Äù
clinical PE probability
Unlikely
D-Dimer
PE excluded
Spiral CTA & CTV
If poor cardiopulm. reserve or
‚Äúhigh‚Äù clin prob., consider V/Q
or angiogram before excluding.
PE confirmed
‚äï
_
‚â•500 ng/mL
<500 ng/mL
Likely
Based on data from NEJM 2005;352:1760 & 2006;354:22; JAMA 2005;293:2012 & 2006;295:172
Workup for Idiopathic VTE
‚Ä¢ Thrombophilia workup: ‚úìif  FH, consider if age 50 y or on OCP/HRT. Send
panel 2 wk after complete anticoagulation, as thrombus, heparin, and warfarin 
results. Nb, does not change management after 1st idiopathic DVT if plan for long-
term anticoagulation (JAMA 2005;293:2352; Blood 2008;112:4432; Am J Med 2008;121:458).
‚Ä¢ Malignancy workup: 12% Pts w/ ‚Äúidiopathic‚Äù DVT/PE will have malignancy; age-
appropriate screening adequate; avoid extensive w/u (NEJM 1998;338:1169)

--- Fim da P√°gina 68 ---

Risk stratification for Pts with PE
‚Ä¢ Clinical: hypotension and/or tachycardia (30% mortality), hypoxemia
‚Ä¢ CTA: RV / LV dimension ratio 0.9 (Circ 2004;110:3276)
‚Ä¢ Biomarkers: c troponin (Circ 2002;106:1263), c BNP (Circ 2003;107:1576) a/w c mortality
‚Ä¢ Echocardiogram: RV dysfxn (controversial in absence of hypotension)
Treatment of VTE (Chest 2008;133;454S; NEJM 2008;359:2804)
‚Ä¢ LE DVT: calf or proximal S anticoagulate (even if asx)
‚Ä¢ UE DVT: anticoagulate (same guidelines as LE). If catheter-associated, need not
remove if catheter fxnal and ongoing need for catheter
‚Ä¢ Superficial venous thrombosis: anticoagulate (especially if extensive clot) as 10%
experience thromboembolic event w/in 3 mo (Annals 2010;152:218)
‚Ä¢ Acute anticoagulation (initiate immediately if high clinical suspicion!)
IV UFH: 80 U/kg bolus S 18 U/kg/h S titrate to goal PTT 1.5‚Äì2.3  cntl (eg,
60‚Äì85 sec), or
LWMH (eg, enoxaparin 1 mg/kg SC bid or dalteparin 200 IU/kg SC qd)
LWMH preferred over UFH except: renal failure (CrCl 25),? extreme obesity,
hemodynamic instability, or bleed risk (Cochrane 2004;CD001100)
No need to monitor anti-factor Xa unless concern re: dosing (eg, renal insuffic)
Attractive option as outPt bridge to long-term oral anticoagulation
Fondaparinux: 5‚Äì10 mg SC qd  UFH (NEJM 2003;349:1695), used in HIT  Pts
Direct thrombin inhibitors (eg, argatroban, lepirudin) used in HIT  Pts
‚Ä¢ Early ambulation
‚Ä¢ Thrombolysis (eg,TPA 100 mg over 2 h)
Use if PE a/w hemodynamic compromise (‚Äúmassive PE‚Äù)
Consider if PE w/o hemodynamic compromise, but high-risk (‚Äúsubmassive PE,‚Äù eg,
marked dyspnea, severe hypoxemia, RV dysfxn on echo, RV enlargement on
CTA) and low bleed risk. Risk of ICH 3% and no proven mortality benefit
(NEJM 2002;347:1143; Cochrane 2006:CD004437).
Consider if extensive (eg, iliofemoral) acute DVT and catheter-directed Rx not available 
‚Ä¢ Catheter-directed therapy (fibrinolytic & thrombus fragmentation/aspiration)
Consider if extensive (eg, iliofemoral) acute DVT
Consider if PE w/ hemodynamic compromise or high-risk and not candidate for
systemic fibrinolytic therapy or surgical thrombectomy
‚Ä¢ Thrombectomy: if large, proximal PE  hemodynamic compromise  contra. to lysis;
consider in experienced ctr if large prox. PE  RV dysfxn (J Thorac CV Surg 2005;129:1018)
‚Ä¢ IVC filter: if anticoagulation contraindication, failure, or bleed, or ? T CP reserve; temp.
filter if risk time-limited; adding filter to anticoagulation S PE T 1/2, DVT c 2, no
mort. diff. (NEJM 1998;338:409; Circ 2005;112:416)
‚Ä¢ Long-term anticoagulation
Warfarin (goal INR 2‚Äì3): start same day as heparin unless instability and ? need for
lytic, catheter-based Rx, or surgery; overlap 5 d w/ heparin & until INR 2  24 h
Superficial venous thrombosis: 4 wk
1st prox DVT or PE 2	 reversible/time-limited risk factor or distal DVT: 3 mo
1st unprovoked prox DVT or PE: 3 mo, then reassess; if low bleed risk S indefinite Rx
2nd VTE event: indefinite warfarin (NEJM 1997;336:393 & 2003;348:1425)
VTE a/w cancer: LMWH  3‚Äì6 mo, then LMWH/warfarin indefinitely or until can-
cer cured (NEJM 2003;349:146); ‚úìhead CT for brain mets if melanoma, renal cell,
thyroid, chorioCA
Complications & Prognosis
‚Ä¢ Postthrombotic syndrome (25%): pain, swelling; T with compression stockings  3 mo
‚Ä¢ Recurrent VTE: 1%/y (after 1st VTE) to 5%/y (after recurrent VTE)
after only 6 mo of Rx: 5%/y & 10%/y, respectively
predictors: abnl D-dimer 1 month after d/c anticoag (NEJM 2006;355:1780);  U/S after 3
mo of anticoag (Annals 2002;137:955); thrombin generation 400 nM (JAMA 2006;296:397)
‚Ä¢ Chronic thromboembolic PHT after acute PE 3.8% (NEJM 2004;350:2257), consider
thromboendarterectomy
‚Ä¢ Mortality: 10% for DVT and 15% for PE at 6 mo (Circ 2003;107:1‚Äì4)
VTE
2-15

--- Fim da P√°gina 69 ---

PHT
2-16
PULMONARY HYPERTENSION (PHT)
PA mean pressure 25 mm Hg at rest or 30 mm Hg with exertion
Pathobiology (NEJM 2004;35:1655)
‚Ä¢ Smooth muscle & endothelial cell proliferation: c VEGF, ET-1, 5-HT; T PGI2, NO,VIP;
mutations in bone morphogenic protein receptor 2 (BMPR2; gene involved in prolif. &
apoptosis) seen in 50% familial and 26% sporadic cases of PPH (NEJM 2001;345:319) 
‚Ä¢ Imbalance between vasoconstrictors and vasodilators
c vasoconstrictors: thromboxane A2 (TXA2), serotonin (5-HT), endothelin-1 (ET-1)
T vasodilators: prostacyclin (PGI2), nitric oxide (NO), vasoactive peptide (VIP)
‚Ä¢ In situ thrombosis: c TXA2, 5-HT, PAI-1; T PGI2, NO,VIP, tissue plasminogen activator
Etiologies of Pulmonary Hypertension (Revised WHO Classification)
Pulmonary arterial
‚Ä¢ Idiopathic (IPAH): mean age of onset 36 y ( older than );
HTN (PAH)
: 
 2:1, usually mild c in PAP
‚Ä¢ Familial (FPAH)
‚Ä¢ Associated conditions (APAH)
Connective tissue disorders: CREST, SLE, MCTD, RA, PM, Sj√∂gren
Congenital LSR shunts:ASD,VSD, PDA
Portopulmonary HTN (? 2	 vasoactive substances not filtered in
ESLD; Z hepatopulmonary syndrome)
HIV; drugs & toxins: anorexic agents, rapeseed oil, L-tryptophan
Other: thyroid dis., glycogen storage dis., Gaucher disease, HHT,
hemoglobinopathies, chronic myeloprolif d/o, splenectomy
‚Ä¢ Pulmonary veno-occlusive disease: ? 2	 chemo, BMT; orthopnea,
CHF, pl eff, nl PCWP; art vasodil. worsen CHF (AJRCCM 2000;162:1964)
‚Ä¢ Pulmonary capillary hemangiomatosis
Left heart disease
‚Ä¢ Left atrial or ventricular (diastolic or systolic) dysfunction    
‚Ä¢ Left-sided valvular heart disease (eg, MS/MR)
Lung diseases and/ 
‚Ä¢ COPD
‚Ä¢ Alveolar hypoventilation (eg, NM disease)
or chronic
‚Ä¢ ILD
‚Ä¢ Chronic hypoxemia (eg, high altitude)
hypoxemia
‚Ä¢ Sleep apnea
‚Ä¢ Developmental abnormalities
Chronic thrombotic ‚Ä¢ Obstruction of proximal or distal pulmonary arteries
or embolic disease
‚Ä¢ Nonthrombotic emboli (tumor, foreign body, parasites)
Miscellaneous
‚Ä¢ Sarcoidosis, histiocytosis X, lymphangiomatosis, schistosomiasis
‚Ä¢ Compression of pulm vessels (adenopathy, tumor, fibrosing
mediastinitis)
(Circulation 2009;28:119:2250)
Clinical manifestations
‚Ä¢ Dyspnea, exertional syncope (hypoxia, T CO), exertional chest pain (RV ischemia)
‚Ä¢ Symptoms of R-sided CHF (eg, peripheral edema, RUQ fullness, abdominal distention)
Physical exam
‚Ä¢ PHT: prominent P2, R-sided S4, RV heave, PA tap & flow murmur, PR (Graham Steell),TR
‚Ä¢  RV failure: c JVP, hepatomegaly, peripheral edema
Diagnostic studies & workup (Circ 2009;119:2250)
‚Ä¢ IPAH yearly incidence 1‚Äì2 per million, ‚à¥r/o 2	 causes
‚Ä¢ CXR and high-resolution chest CT: dilatation & pruning of pulmonary arteries,
enlargement of RA and RV; r/o parenchymal lung disease
‚Ä¢ ECG: RAD, RBBB, RAE (‚ÄúP pulmonale‚Äù), RVH (Se 55%, Sp 70%)
‚Ä¢ PFTs: T DLCO, mild restrictive pattern; r/o obstructive and restrictive lung disease
‚Ä¢ ABG & polysomnography: T PaO2 and SaO2 (especially w/ exertion), T PaCO2, c A-a
gradient; r/o hypoventilation and OSA
‚Ä¢ TTE: c RVSP (but over or under by 10 mm Hg in 1‚ÅÑ2 of PHT Pts; AJRCCM 2009;179:615),
flattened (‚ÄúD‚Äù) septum,TR, PR; r/o LV dysfxn, MV disease, and congenital heart disease
‚Ä¢ RHC: c RA, RV, & PA pressures, nl PCWP (unless due to L-sided heart disease),
c transpulm gradient (PAP-PCWP 12‚Äì15, but can be nl if due to LV or valvular dis.),
c PVR, T CO; r/o c L-sided pressures shunt
‚Ä¢ CTA (large/med vessel),V/Q scan (small vessel),  pulmonary angiogram: r/o PE and
chronic thromboembolic disease
‚Ä¢ Vasculitis labs: ANA (commonly  in PPH), RF, anti-Scl-70, anti-centromere, ESR
‚Ä¢ LFTs & HIV: r/o portopulmonary and HIV-associated PAH
‚Ä¢ 6-min walk test (6MWT) or cardiopulmonary exercise testing to establish fxnl capacity
Treatment (NEJM 2004;351:1425; JIM 2005;258:199; Circ 2009;119:2250)
‚Ä¢ Principles
1) prevent and reverse vasoactive substance imbalance and vascular remodeling
2) prevent RV failure: T wall stress (T PVR, PAP, RV diam); ensure adeq. systemic DBP

--- Fim da P√°gina 70 ---

‚Ä¢ Supportive
Oxygen: maintain SaO2 90‚Äì92% (reduces vasoconstriction)
Diuretics: T RV wall stress and relieve RHF sx; gentle b/c RV is preload dependent
Digoxin: control AF, ? counteract neg. inotropic effects CCB
Dobutamine and inhaled NO for decompensated PHT
Anticoagulation: TVTE risk of RHF; ? prevention of in situ microthrombi; ? mort. benefit
(Circ 1984;70:580; Chest 2006;130:545)
‚Ä¢ Vasodilators
acute vasoreactivity test: use inhaled NO, adenosine, or prostacyclin to identify Pts likely
to have a long-term response to oral CCB ( vasoreactive response defined as T PAP
10 mm Hg to a level 40 mm Hg with c or stable CO); 10% Pts are acute
responders; no response S still candidates for other vasodilators (NEJM 2004;351:1425)
Vasodilators
Comments
Oral CCB
If  acute vasoreactive response; 1‚ÅÑ2 will be long-term responder
Nifedipine, diltiazem
(NYHA I/II & near-nl hemodynamics) & have T mortality. Side effects:
HoTN, lower limb edema. (NEJM 1992;327:76, Circ 2005;111:3105)
IV Prostacyclin
Vasodilation, T plt agg, T smooth muscle proliferation; benefits c
Epoprostenol; Flolan
w/ time (? vascular remodeling). c 6MWT, c QoL, T mortality. Side 
effects: HA, flushing, jaw/leg pain, abd cramps, nausea, diarrhea,
catheter infxn. (NEJM 1996;334:296 & 1998:338:273; Annals 2000;132:425)
Prostacyclin
Same mechanism as prostacyclin IV, but easier to take, T side effects,
analogues
and w/o risk of catheter infxn. T sx, c 6MWT; trend to T clinical events 
Iloprost (inhaled)
w/ iloprost but not treprostinil. Beraprost w/o sustained outcome 
Treprostinil (IV or SC)
improvement (n/a in U.S.). (NEJM 2002;347:322; AJRCCM 2002;165:800)
Beraprost (PO)
Endothelin receptor
T Smooth muscle remodeling, c vasodilation, T fibrosis. T sx, c 6MWT, T
antagonists (ERAs)
clinical events. Side effects: c LFTs, headache, anemia, edema,
Bosentan, ambrisentan
teratogen. (NEJM 2002;346:896; JACC 2005;46:529; Circ 2008;117:3010)
PDE-5 Inhibitor
c cGMP S c NO S vasodilation, T smooth muscle proliferation
Sildenafil, tadalafil
T sx, c 6MWT, no  clinical outcomes. Low side effect profile: HA,
vision ‚Äòs, sinus congestion. (NEJM 2009;361:1864)
‚Ä¢ Treat underlying causes of 2	 PHT; can use vasodilators, although little evidence
‚Ä¢ Refractory PHT
balloon atrial septostomy: RSL shunt causes c CO, T SaO2, net c tissue O2 delivery
lung transplant (single or bilateral); heart-lung needed if Eisenmenger physiology
Figure 2-5 Treatment of PAH
PHT
2-17
Acute vasoreactivity testing
sustained
response?
Anticoag ¬± diuretics ¬± O2 ¬± dig  
Oral CCB
ERA or PDE-5 inhib
Epoprostenol or
treprostinil (IV)
Iloprost
Treprostinil (SC)
Epoprostenol
or treprostinil (IV)
Iloprost
ERA or PDE-5 inhib
Treprostinil (SC)
Continue
CCB
inadequate 
response
yes
‚äï
& lower risk
 & higher risk
Combination Rx
Investigational protocols
Atrial septostomy
Lung transplantation
inadequate 
response
inadequate 
response
no
Higher risk: presence of any of the poor prognostic risk factors listed below. Modified from Circ 2009;119:2250.
Management of ICU patient
‚Ä¢ Avoid overly aggressive volume resuscitation
‚Ä¢ Caution with vasodilators if any L-sided dysfunction
‚Ä¢ May benefit from inotropes/chronotropes
‚Ä¢ Consider fibrinolysis if acute, refractory decompensation
Prognosis
‚Ä¢ Median survival after dx 2.8 y; PAH (all etiologies): 2-y 66%, 5-y 48% (Chest 2004;126:78-S)
‚Ä¢ Poor prognostic factors: clinical evidence of RV failure, rapidly progressive sx,WHO
(modified NYHA) class IV, 6MWT 300 m, peak VO2 10.4 mL/kg/min, c RA or RV
or RV dysfxn, RA 20 or CI 2.0, c BNP (Chest 2006;129:1313)
‚Ä¢ Lung transplant: 1-y survival 66‚Äì75%; 5-y survival 45‚Äì55% (Chest 2004;126:63-S)

--- Fim da P√°gina 71 ---

RESPIRATORY FAILURE
‚Ä¢ A-a gradient  PAO2 ‚Äì PaO2: normal (on room air) 
 ‚Äú4  age/4‚Äù or ‚Äú2.5  (0.2  age)‚Äù
hypoxemia  normal A-a gradient S problem is excess PaCO2 (ie, hypoventilation)
‚Ä¢ SvO2 (mixed venous O2 sat, nl 60‚Äì80%): measure O2 consumption vs. delivery; low
SvO2 S T O2 delivery (T SaO2, nl SaO2 but T CO or anemia) or excessive O2 consump.
‚Ä¢ V/Q mismatch and shunt represent spectrum w/ both coexisting in alveolar disease
100% O2 can overcome V/Q mismatch but not large shunt b/c sigmoidal Hg-O2 curve
Figure 2-6 Workup of acute hypoxemia
Hypoxemia S PAO2
FiO2
(760 ‚Äì 47)
PaCO2
R
RESP FAILURE
2-18
‚Üì SaO2
‚Üë PaCO2
Hypoventilation
True shunt
V/Q mismatch
Other causes of hypoxemia:
‚Ä¢ ‚Üì FiO2 (eg, empty O2 tank, tubing pb)
‚Ä¢ ‚Üì PiO2 (eg, high altitude)
sedation
COPD, OSA
diaphragm or NM disease
administer
100% O2
  ABG
alveolar collapse (atelectasis)
alveolar filling (PNA, CHF)
R ‚Üí L intracardiac shunt
intrapulmonary shunt (AVM)
airway (asthma, COPD)
alveolar (PNA, CHF)
vascular (PE)
hypoxemia
does not
correct
hypoxemia
corrects
‚Üë A-a gradient
nl PaCO2
Chemical Causes of Cellular Hypoxia
Condition
Causes
Classic 
PaO2
Pulse 
CO-
Treatment
Features
Ox Sat
Ox Sat
( 100% O2)
Carbon 
Fires, portable
Cherry-red skin
nl
nl
T
Hyperbaric O2
monoxide
heaters, auto exhaust
(COHb color)
Methemo-
Nitrates, sulfonamide, Chocolate brown 
nl
mild T
T
Methylene blue
globinemia
benzocaine, dapsone
blood
Cyanide
Nitroprusside, fires, 
Bitter almond 
nl
nl
nl
Hydroxy-
industrial
odor; pink skin
(c SvO2)
cobalamin
CO binds to Hb more avidly than does O2. Pulse ox misreads COHb as HbO2 S falsely nl sat.
Oxidizing drugs  Hb (ferrous) to MetHb (ferric), which cannot carry O2. Pulse ox misreads MetHb as HbO2.
Cyanide inhibits mitochondrial O2 use S cellular hypoxia but pink skin and c venous O2 sat.
c PaCO2
‚ÄúWon‚Äôt breathe‚Äù
‚ÄúCan‚Äôt breathe‚Äù
Respiratory Drive
NM System
Lung/Airways
CW/Pleura
T RR
TVT
TVT and/or cVD
TVT
T P100
T PImax
Abnl PFTs
Abnl PEx
Voluntary hypervent.
T PEmax
Abnl CXR/CT
Nl PImax & A-a gradient
Chemoreceptors
Neuropathies
Lung parenchyma
Chest wall
metab. alkalosis
cervical spine
emphysema
obesity
1 neurologic
phrenic nerve
ILD/fibrosis
kyphosis
brainstem stroke
GBS, ALS, polio
CHF, PNA
scoliosis
tumor
NMJ
Airways
Pleura
1	 alveolar hypovent
MG, LE, botulism
asthma, COPD
fibrosis
2 neurologic
Myopathies
bronchiectasis
effusion
sedatives
diaphragm
CF
CNS infection
PM/DM; T PO4
OSA
hypothyroidism
musc dystrophies
c VCO2 typically transient cause of c PaCO2; Ddx: exercise, fever, hyperthyroidism, c work of breathing, c carbs.
Hypercapnia S PaCO2
k
Vco2
RR
VT
a1
VD
VT
b
.

--- Fim da P√°gina 72 ---

MECHANICAL VENTILATION
Indications
‚Ä¢ Improve gas exchange
c oxygenation
c alveolar ventilation and/or reverse acute respiratory acidosis
‚Ä¢ Relieve respiratory distress
T work of breathing (can account for up to 50% of total oxygen consumption)
T respiratory muscle fatigue
‚Ä¢ Apnea, airway protection, pulmonary toilet
Choosing settings (NEJM 2001;344:1986)
1. Choose method (including potentially noninvasive ventilation, see later)
2. Pick ventilator mode, and (if appropriate) volume targeted or pressure targeted
3. Set or ‚úìremaining variables (eg, FiO2, PEEP, I:E time, flow, airway pressures)
Step 1: Pick Ventilator Mode
Mode
Description
Assist control
Vent delivers a minimum number of supported breaths
(AC)
Additional Pt-initiated breaths trigger fully-assisted vent breaths
‚à¥Vent-triggered breaths identical to Pt-triggered breaths
Tachypnea S ? respiratory alkalosis, breath-stacking, & auto-PEEP
May be pressure targeted or volume targeted
Synchronized
Vent delivers min. # supported breaths (synch. to Pt‚Äôs efforts)
intermittent
Additional Pt-initiated breaths S VT determined by Pt‚Äôs efforts
mandatory vent
‚à¥Vent-assisted breaths Z spontaneous breaths
(SIMV)
Must overcome resp. circuit during spont. breaths S c fatigue
SIMV 
 AC in Pts who are not spontaneously breathing
Pressure support
Support Pt-initiated breaths w/ a set inspiratory pressure & PEEP
vent (PSV)
A mode of partial vent support because no set rate
Continuous
Pt breathes spont. at his/her own rate while vent maintains constant
positive airway
positive airway pressure throughout respiratory cycle
pressure (CPAP)
(7 cm H2O overcomes 7 Fr ETT)
T piece
No airway pressure, no rate set; patient breathes through ETT
Other
High-frequency vent (AJRCCM 2002;166:801; CCM 2003;S-31:S-317)
ECMO and ECCO2R (Ann Surg 2004;240:595)
Step 2: Choose Volume Targeted or Pressure Targeted
Volume 
Vent delivers a set VT
targeted
Airway pressures depend on airway resist. & lung/chest wall compliance
Benefit: c control over ventilation (ideal initial ventilator setting);
evidence-based benefit in ALI/ARDS; easy to measure mechanical
respiratory properties (PIP, Pplat, airway resistance, compliance)
Risk: Patient at risk for c pressures S barotrauma (and volutrauma if set
volume too high!)
Volume control (VC) : in AC or SIMV mode, vent delivers variable pressure 
(depending on real-time lung compliance) to achieve set VT. Volume support 
(VS) sample principle in spontaneous mode.
Pressure 
Vent delivers a fixed inspiratory pressure regardless of VT
targeted
VT depends on airway resistance and lung/chest wall compliance
Benefit: May c patient comfort (PSV) requiring less sedation
Risk: Pt at risk for T volumes S inadequate VE
Other
Proportional assist ventilation (PAV): vent delivers variable pressure 
(depending on real-time lung mech.) to achieve targeted % of work of 
breathing
Airway pressure release ventilation (APRV): vent keeps lungs inflated at high 
pressure w/ intermittent release to allow for exhalation via passive recoil
Neurally adjusted ventilator assist (NAVA): vent support proportional to 
diaphragmatic electrical activity sensed using esophageal electrode
General 
Institutional/practitioner preference and patient comfort usually
principles
dictate ventilator strategy; no strategy has proven superior
Common reasons for  include: dyssynchrony, poor gas exchange,  mech.
resp properties, goals of care (eg, sedation, weaning, lung protection)
Alarms can be set for c volumes and c airway pressures in pressure-
targeted and volume-targeted strategies, respectively
MECH VENT
2-19

--- Fim da P√°gina 73 ---

Step 3: Set or ‚úìRemaining Variables
FiO2
Fraction of inspired air that is oxygen
Positive
Positive pressure applied during exhalation via resistor in exhalation port
end-
Benefits: prevents alveoli collapse, T intrapulmonary shunt, c O2
expiratory
Cardiac effects: T preload by c intrathoracic pressure S T venous return;
pressure
T afterload by T cardiac transmural pressure; may c or T CO and may c or 
(PEEP)
T oxygen delivery based on the above
Auto-PEEP or intrinsic PEEP: inadequate exhalation time S lungs
unable to completely empty before the next breath (ie,‚Äúbreath
stacking‚Äù); if flow at end-expiration, there must be pressure 
 auto-PEEP
Will T preload and may T CO, especially if hypovolemic
Will c work of breathing as must be overcome by Pt to trigger breaths;
can prevent Pt from successfully triggering ventilator
Can be detected if end-expiratory flow Z 0 before next breath
Can measure by occluding expiratory port of vent at end-expiration
Can T by: c exp time, T RR, TVT, Rx bronchospasm and secretions
Inspiratory
Normally I:E ratio is 1:2; however, can alter I time (and consequently
time
flow rate, see later); use in pressure-control mode
Inspiratory
c flow rate S T I time S c E time S ‚à¥may improve ventilation in obstructive
flow rates
disease, but may affect resp rate and bronchodilation/constriction
Peak
Dynamic measurement during inspiration; set in pressure-targeted mode
inspiratory
Determined by airway resistance and lung/chest wall compliance
pressure
c PIP w/o c Pplat S c airway resist (eg, bronchospasm, plugging)
(PIP)
T PIP S T airway resistance or air leak in the system
Plateau
Static measurement at the end of inspiration when there is no flow
pressure
Determined by resp system compliance (resist. not a factor since ‚àÖflow)
(Pplat)
c Pplat S T lung or chest wall compliance (eg, PTX, pulmonary edema,
pneumonia, atelectasis), c PEEP, or auto-PEEP
Pplat 30 cm H2O T barotrauma (TVT, T PEEP or c compl [eg, by diuresis])
Initial Settings
Mode
Tidal volume
Respiratory rate
FiO2
PEEP
Assist control 
4‚Äì8* mL/kg
12‚Äì14
1.0 (ie, 100%)
? 5 cm H2O
volume-targeted
IBW
breaths/min
*Goal for ARDS; ventilation at VT 8 mL/kg may be injurious in other types of ventilated Pts as well.
Noninvasive Ventilation
Conditions
Cardiogenic pulmonary edema: may T intub. & mortality (JAMA
2005;294:3124; Lancet 2006;367:1155) although recent trial (w/ high 
crossover) did not show any benefit (NEJM 2008;359:142)
COPD exacerbation w/ hypercapnia: T intub. & mortality (Lancet
2000;355:1931), but if pH 7.3 S intubate
High-risk extubation (age 65, CHF,APACHE II 12): NIV  24 h 
directly after extubation S T reintub and, if PaCO2 45 during 
SBT, T mortality (AJRCCM 2006;173:164). However, if used as 
rescue after failed extubation S c mortality (NEJM 2004;350:2452).
End-of-life care (Resp Care 2009;54:223)
Immunosupp. w/ infiltrates: T complic & mort (NEJM 2001;344:481)
Indications
Clinical: mod-severe dyspnea, RR 24‚Äì30, signs of c work of 
(Lancet 2009;374:250)
breathing, accessory muscle use, abd paradox
Gas exchange: PaCO2 45 (& significantly worse than baseline),
hypoxemia, PaO2/FiO2 200
Contraindications
Claustrophobia, inability to fit mask,  MS, vomiting, unable to 
(JAMA 2002;288:932)
protect airway, extrapulm organ failure, hemodyn instab, sev UGIB
Continuous positive
PEEP
airway pressure
No limit on O2 delivered (ie, can give hi-flow S FiO2 1.0)
(CPAP)
Used if primary problem hypoxemia (eg, CHF)
NPPV/bilevel
PSV  PEEP.Able to set both inspiratory (usually 8‚Äì10 cm H2O) 
positive airway
and expiratory pressures (usually 5 cm H2O).
pressure (BiPAP)
Used if primary problem hypoventilation; FiO2 delivery limited
Mask ventilation
Tight-fitting mask connecting patient to a standard ventilator
Can receive PS 20‚Äì30 cm H2O, PEEP 10 cm H2O, FiO2 1.0
Used for short-term support (24 h) for a reversible process
MECH VENT
2-20

--- Fim da P√°gina 74 ---

Tailoring the ventilator settings
‚Ä¢ To improve oxygenation: options include c FiO2, c PEEP
First, c FiO2. If 0.6 and oxygenation remains suboptimal, then try c PEEP:
If c PaO2/FiO2 and Pplat stable, suggests recruitable lung (ie, atelectasis). Continue to
c PEEP until either can  T FiO2 to 0.6 or Pplat 30 cm H2O. If PEEP 20 & FiO2 1.0
and oxygenation remains suboptimal, consider rescue/expt strategies (see ARDS).
If c PEEP S ‚àÖ or T PaO2/FiO2 or c PaCO2, suggests additional lung not recruitable
and instead overdistending lung S c shunt & dead space; ‚à¥T PEEP
‚Ä¢ To improve ventilation: c VT or inspiratory pressure, c RR (may need to T I time). Nb,
tolerate c PaCO2 (permissive hypercapnia) in ALI/ARDS (qv) as long as pH 7.15.
Acute ventilatory deterioration (usually c PIP)
‚Ä¢ Response to c PIP: disconnect Pt from vent., bag, auscultate, suction, ‚úìCXR & ABG
Figure 2-7 Approach to acute ventilatory deterioration
MECH VENT
2-21
PIP
increased (eg, >40)
P
air leak
‚Üìairway resistance
‚Üìlung compliance
asynch breathing
auto-PEEP
pneumothorax, R-mainstem intub
atelectasis, PNA, pulmonary edema
PE
PE
extrathoracic process
normal
decreased
‚Üëairway resistance
bronchospasm
secretions
aspiration
(ventilator tubing problem)
normal
increased (eg, >30)
=
VT
P
-PEEP
[nl >60]
P
= PIP ‚Äì
[nl <10]
(Adapted from Marino PL. The ICU Book, 3rd ed., Philadelphia: Lippincott Williams & Wilkins, 2007:467)
Weaning from the ventilator
‚Ä¢ Weaning strategy: spontaneous breathing trial (SBT) for Pts who meet screening 
criteria (qv) better than gradual weaning of PSV or SIMV (NEJM 1995;332:345). Daily
awakening (d/c all sedation; pass if open eyes & w/o: agitation, RR 35, SaO2
88%, resp distress or arrhythmias) followed by SBT better than SBT alone 
(Lancet 2008;371:126).
‚Ä¢ Identify Pts who can breathe spontaneously (NEJM 1991;324:1445 & 1996;335:1864)
screening criteria: sedation reversed, VS stable, minimal secretions, adequate cough,
cause of respiratory failure or previously failed SBT reversed
vent parameters: PaO2/FiO2 200, PEEP 5, f/VT 105, VE 12 L/min, VC 10 mL/kg
rapid shallow breathing index (f/VT) 105 predicts failure; NPV 0.95 (NEJM 1991;324:1445)
‚Ä¢ SBT 
 CPAP or T piece  30‚Äì120 min (AJRCCM 1999;159:512)
failure if: deteriorating ABGs, c RR, c or T HR, c or T BP, diaphoresis, anxiety
‚Ä¢ Tolerate SBT S extubation. Fail SBT S ? cause S work to correct S retry SBT qd
Complications
‚Ä¢ Barotrauma and volutrauma (eg, PTX, pneumomediastinum)
high PIPs usually safe unless c Pplat (30 cm H2O, but lower better) S alveolar damage
‚Ä¢ Oxygen toxicity (theoretical); proportional to duration  degree of c oxygen (FiO2 0.6)
‚Ä¢ Alterations in cardiac output (eg, PEEP can T preload S hypotension)
‚Ä¢ Ventilator-associated pneumonia (1%/day, mortality rate 30%)
typical pathogens: MRSA, Pseudomonas, Acinetobacter, and Enterobacter species
preventive strategies (AJRCCM 2005;171:388): wash hands, semirecumbent position, 
non-nasal intub, enteral nutrition rather than TPN, routine suction of subglottic
secretions, avoid unnecessary abx & transfusions, routine oral antiseptic, 
stress-ulcer prophylaxis w/ ? sucralfate (TVAP, c GIB) vs. H2RA/PPI, ? silver-coated
tubes (JAMA 2008;300:805)
‚Ä¢ Laryngeal
edema: for Pts vent 36 h; ? predicted by  cuff leak test. Methylprednisolone 20 mg IV
q4h starting 12 h pre-extub S TT edema and 50% T in reintubation (Lancet 2007;369:1003)
ulceration: consider tracheostomy for patients in whom expect 14 d of mech. vent S
T duration mech. vent, T # ICU days (BMJ 2005;330:1243); no benefit to performing at
1 wk vs. waiting until 2 wk (JAMA 2010;303:1483)

--- Fim da P√°gina 75 ---

ARDS
2-22
ACUTE RESPIRATORY DISTRESS SYNDROME
Definition & Presentation (NEJM 2000;342:1334; American-Euro Consensus Conf 1994)
‚Ä¢ Acute onset (24 h)
‚Ä¢ Bilateral patchy airspace disease (need not be diffuse)
‚Ä¢ Noncardiogenic pulmonary edema (PCWP 18 or no clinical evidence of c LAP)
‚Ä¢ Severe hypoxemia: PaO2/FiO2 200 S ARDS; PaO2/FiO2 300 S ALI (acute lung injury)
‚Ä¢ Chest CT: heterogeneous lung with densities greater in dependent areas
‚Ä¢ Lung bx: classically shows diffuse alveolar damage (DAD); bx not required but often
provides useful dx information (Chest 2004;125:197)
Pathophysiology
‚Ä¢ c intrapulmonary shunt S hypoxemia (‚à¥Rx w/ PEEP to prevent derecruitment)
‚Ä¢ c increased dead space fraction (see appendix), predicts c mort. (NEJM 2002;346:1281)
‚Ä¢ T compliance: VT/(Pplat ‚Äì PEEP) 50 mL/cm H2O
Etiologies
Direct Injury
Indirect Injury
‚Ä¢ Pneumonia (40%)
‚Ä¢ Inhalation injury
‚Ä¢ Sepsis (25%) ‚Ä¢ Pancreatitis
‚Ä¢ Aspiration (15%)
‚Ä¢ Lung contusion
‚Ä¢ Shock
‚Ä¢ Trauma/multiple fractures
‚Ä¢ Near drowning
‚Ä¢ DIC
‚Ä¢ Transfusion (TRALI)
Treatment (primarily supportive) (Lancet 2007;369:1553 & NEJM 2007;357:1113)
‚Ä¢ Goal is to maintain gas exchange, sustain life, & avoid ventilator-induced lung injury (VILI)
Mechanisms of VILI
Ventilator Strategies*
Barotrauma/volutrauma:
VT 6 mL/kg, Pplat 30 cm H2O, tolerate c PaCO2
alveolar overdistention S
(but keep pH 7.15), T mortality (NEJM 2000;342:1301).
mechanical damage 
Weight risk/benefit of sedation & paralysis.
Biotrauma S SIRS
Low VT, open lung strategy w/ high PEEP
Atelectrauma: repetitive alveoli 
Titrate PEEP to prevent tidal alveolar collapse
recruitment & decruitment
Variable benefit in different studies, Pt subgps. No 
benefit at given VT if titrated to PaO2 alone (NEJM
2004;351:327; JAMA 2008;299:637). If titrated to Pplat 28‚Äì30 
cm H2O S T time on vent, better lung mechanics 
(JAMA 2008;299:646), ? T mortality (JAMA 2010;303:865).
If able to c PEEP w/o c Pplat, suggests ‚Äúrecruitability.‚Äù
‚à¥c PEEP if S c SaO2; target SaO2 88‚Äì90% & Pplat 30
Hyperoxia: ? injury;
c PEEP rather than FiO2 (keep 0.60)
worsened V/Q matching
O2 -induced injury only theoretical in humans
*See ARDSnet.org for ventilator protocol.
‚Ä¢ Fluid balance: target CVP 4‚Äì6 cm H2O (if nonoliguric & normotensive) S c
vent/ICU-free days, but no mortality difference (NEJM 2006;354:2564)
‚Ä¢ PA catheter for fluid management S c complications vs. CVP only (NEJM 2006;354:2213)
‚Ä¢ Steroids: debate continues. Adverse effects include neuromuscular weakness, poor
glc control, ? infection. Benefit may vary by time since ARDS onset:
72 h: older studies w/o benefit (NEJM 1987;317:1565); ? T mort, c vent/ICU-free days
in recent, controversial study (Chest 2007;131:954)
7‚Äì13 d: ? benefit S c vent/ICU-free days, no mortality difference (NEJM 2006;354:1671)
14 d: c mortality (NEJM 2006;354:1671)
‚Ä¢ Experimental:
Inhaled nitric oxide: no proven T PAP, can c PaO2/FiO2, no T mort or vent-free days
(BMJ 2007;334:779); inhaled prostacyclins similar physiologically, similar effect
Prone ventilation: c PaO2, but c complications and no T mortality (JAMA 2009;302:1977)
High-frequency oscillatory ventilation: no mort benefit (AJRCCM 2002;166:801), can tran-
siently c PaO2 (Chest 2007;131:1907)
Lung recruitment: apply CPAP 40‚Äì45 cm H2O  2 min to recruit lung and then c
PEEP to maintain; sicker Pts had c recruitable lung (NEJM 2006;354:1775, 1839)
ECMO: may be useful in refractory ARDS, but no good trial c/w protocolized, low-
VT ARDS ventilation (Ann Surg 2004;240:595; Chest 1997;112:759; Lancet 2009;374:1351)
Esoph manometry: adjust PEEP according to esoph pressure (pleural pressure) to
maintain positive transpulm pressure S c PaO2/FiO2, c compliance and possible
outcome benefit (NEJM 2008;359:2095)
Prognosis
‚Ä¢ Mortality: 40% overall in clinical trials; 9‚Äì15% resp. causes, 85‚Äì91% extrapulm (MODS)
‚Ä¢ Survivors: PFTs normal, T DLCO, muscle wasting, weakness persists (NEJM 2003;348:683)

--- Fim da P√°gina 76 ---

SEPSIS
2-23
SEPSIS
Definitions
Systemic 
2 or more of the following:
Inflammatory Response 
(1) Temp 38 or 36	C,
Syndrome (SIRS)
(2) HR 90,
(3) RR 20 or PaCO2 32,
(4) WBC 12,000 or 4000 or 10% bands
Sepsis
SIRS  suspected infection
Severe Sepsis
Sepsis  organ dysfunction, hypoperfusion or hypotension
Signs of hypoperfusion may incl. lactic acidosis, oliguria, MS
Septic Shock
Sepsis-induced hypotension despite adequate fluid 
resuscitation, along with signs of hypoperfusion
(Chest 1992;101;1644)
Fluids & Vasoactive Drugs
‚Ä¢ Early goal-directed therapy (‚ÄúRivers Protocol‚Äù, NEJM 2001;345:1368)
Insert arterial & central venous lines (NEJM 2007;356:e21; PAC not needed) and ‚úìMAP,
CVP, & central venous (no need for mixed venous) O2 sat
Target MAP 65 mm Hg, CVP 8‚Äì12 mm Hg, & UOP 0.5 mL/kg/h using fluid (eg,
500 mL NS q30min) and vasopressors as needed
Target ScvO2 70% using PRBCs & inotropes (dobutamine, c dose as needed q15min)
When done w/in first 6 h for severe sepsis & septic shock, 42% T mortality
‚Ä¢ Normal saline as good as albumin for resuscitation (NEJM 2004;350:2247)
‚Ä¢ Norepinephrine preferred to dopamine (T arrhythmias & trend T mort.; NEJM 2010;362:779)
‚Ä¢ Vasopressin added to low-dose norepinephrine not superior to high-dose norepineph-
rine (NEJM 2008;358:877); consider if HoTN refractory to catecholamine vasopressors
‚Ä¢ Use PRBC w/ caution, may c mortality/morbidity, c risk of ARDS (Crit Care Med
2005;33:1191); ‚à¥goal Hb 7 unless active cardiac ischemia (NEJM 1999;340:409)
‚Ä¢ After early resuscitation, if ALI/ARDS, target CVP 4‚Äì6 mm Hg as additional fluids
may be harmful S c ventilator/ICU days (NEJM 2006;354:2564; Chest 2008;133:252)
‚Ä¢ Pulse pressure variation 13% with respiration S likely volume-responsive (Chest
2008;133:252); only validated in passive, intubated Pts
Antibiotics
‚Ä¢ If possible, obtain 2 sets of BCx before starting abx
‚Ä¢ Start empiric IV abx w/in 1 h of recognition of severe sepsis or septic shock
‚Ä¢ Typically want broad gram-positive and gram-negative coverage, including MRSA and
highly resistant gram-negative bacilli  anaerobes
Steroids (NEJM 2003;348:727; JAMA 2009;301:2362)
‚Ä¢ ACTH stimulation test helps predict mortality in sepsis, does not predict benefit
from corticosteroid therapy (JAMA 2000;283:1038; NEJM 2008;358:111)
‚Ä¢ Earlier study showed possible mortality benefit w/in 8 h of severe septic shock (SBP 90 for
1 h despite fluids & pressors) if post ACTH stim cortisol   9 g/dL (JAMA 2002;288:862)
‚Ä¢ No mortality benefit to early (72 h) empiric corticosteroids in all Pts w/ septic
shock, regardless of ACTH stim; faster resolution of shock, more superinfection
(NEJM 2008;358:111)
‚Ä¢ ? hydrocortisone 50‚Äì100 q6‚Äì8h  fludrocortisone 50 g daily in septic shock refrac-
tory to fluids & pressors, regardless of ACTH stim (Crit Care Med 2008;36:296)
Activated Protein C
‚Ä¢ Remains controversial: 6% absolute T mort., but c bleeding (NEJM 2001;344:699); no mort.
benefit if low risk of death (APACHE 25 or single organ failure, NEJM 2005;353:1332)
‚Ä¢ ? if APACHE 25 or multi-organ failure w/o contraindic. (Crit Care Med 2008;36:296)
Intensive Glycemic Control
‚Ä¢ No evidence of improved outcomes in MICU population w/ intensive glycemic control
‚Ä¢ Intensive glycemic control to goal 80‚Äì110 mg/dL in surgical ICU population S
mortality benefit, greatest if 3-d ICU stay (NEJM 2001;345:1359)
‚Ä¢ More recently, intensive glycemic control S either no  or c increased mortality, and
definite c hypoglycemia (JAMA 2008;300:933; NEJM 2006;354:449; 2008;358:125; 2009;360:1283)
‚Ä¢ Reasonable to keep glc 150 mg/dL in severe sepsis, using validated protocol (Crit Care
Med 2008;36:296)

--- Fim da P√°gina 77 ---

NOTES
NOTES
2-24

--- Fim da P√°gina 78 ---

ESOPHAGEAL
3-1
ESOPHAGEAL AND GASTRIC DISORDERS
DYSPHAGIA
Definitions
‚Ä¢ Oropharyngeal: inability to propel food from mouth through UES into esophagus
‚Ä¢ Esophageal: difficulty swallowing & passing food from esophagus into stomach
Figure 3-1 Etiologies of and approach to dysphagia (NCP Gastrohep 2008;5:393)
Dysphagia
Mechanical Obstruction
difficulty w/ solids only
Ring, Web
Eos esophagitis
Peptic 
stricture
Motility Disorder
difficulty w/ solids & liquids
Esophageal 
cancer
Spasm & related 
disorders
Scleroderma, 
Amyloid, DM
Achalasia
prog sx
chronic GERD
intermittent
sx
prog
sx
intermittent sx
¬± chest pain
prog sx
prog sx / GERD
Manometry
Manometry 
abnl
normal
EGD ¬± barium
swallow
EGD ¬± barium
swallow
Modified barium swallow, 
ENT eval, ¬± EGD
Modified barium swallow, 
ENT eval, ¬± EGD
Oral cancer, 
XRT, Zenker‚Äôs
Stroke, PD, ALS, 
Myopathies
pb
struct
NM prob
Dysphagia
Oropharyngeal
sensation of food
getting stuck
Esophageal Dysphagia
struct
abnl
inflam
Esophagitis
normal
diffinitiating swallow, drooling, 
dysarthria, cough, nasalregurg
Achalasia
‚Ä¢ Etiologies: idiopathic (most common), pseudoachalasia (due to GE jxn tumor), Chagas
‚Ä¢ Sx: dysphagia (solid & liquid), chest pain (1‚ÅÑ3 of Pts), regurgitation
‚Ä¢ Dx: barium swallow S dilated esophagus w/ distal ‚Äúbird‚Äôs beak‚Äù narrowing; manometry S
simultaneous, low amplitude contractions of esophageal body, incomplete relaxation of 
lower esophageal sphincter ( LES hypertension); EGD S r/o pseudoachalasia (retroflex)
‚Ä¢ Rx: Heller myotomy; balloon dilatation (2% eso perf); botulinum toxin (poor surg cand)
Other Esophageal Disorders 
‚Ä¢ Webs (upper or mid esoph; congenital, GVHD, Fe-defic anemia); Rings (lower; ? due
to GERD); Zenker‚Äôs diverticulum (pharyngoesoph jxn); dx w/ barium swallow; Rx
endo/surg
‚Ä¢ Infx esophagitis: odynophagia  dysphagia; often immunosupp w/ Candida, HSV, CMV
‚Ä¢ Pill esophagitis: odynophagia  dypshagia; NSAID, KCl, bisphosp., doxy & tetracycline
‚Ä¢ Eos esophagitis: EGD w/ ringed, corrugated eso, stricture, 15 eos/hpf on bx; Rx steroids
GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Pathophysiology
‚Ä¢ Excessive transient relaxations of lower esophageal sphincter (LES) or incompetent LES
‚Ä¢ Mucosal damage (esophagitis) due to prolonged contact w/ acid can evolve to stricture
‚Ä¢ Risk factors: hiatal hernia, obesity, gastric hypersecretory states, delayed emptying 
‚Ä¢ Precipitants: supine position, fatty foods, caffeine, alcohol, cigarettes, CCB, pregnancy
Clinical manifestations
‚Ä¢ Esophageal: heartburn, atypical chest pain, regurgitation, water brash, dysphagia
‚Ä¢ Extraesophageal: cough, asthma (often poorly controlled), laryngitis, dental erosions
Diagnosis (Gastro 2008;135:1383)
‚Ä¢ Based on hx and empiric trial of PPI (Se & Sp: 78% & 54%) (Annals 2004;140:518)
‚Ä¢ EGD if failure to respond to BID PPI or alarm features: dysphagia, odynophagia, vomit-
ing, wt loss, Fe-defic anemia,  FOBT, palpable mass or adenopathy, age 55 y
‚Ä¢ If dx uncertain & EGD nl S high res manometry w/ 24-h esophageal pH monitoring
Treatment (NEJM 2008;359:1700)
‚Ä¢ Lifestyle: avoid precipitants, lose weight, avoid large & late meals, elevate head of bed
‚Ä¢ Medical: PPI (up to BID)  H2RA, espec. if esophagitis (Coch 2007;2:003244), antacids
PPI achieve relief in 80‚Äì90%; side effects: diarrhea, H/A, c risk of C. diff & hip fx
‚Ä¢ Surgical: fundoplication if refractory sx on meds: success 90%, but 1‚ÅÑ2 on meds
after 10 y

--- Fim da P√°gina 79 ---

Complications (NEJM 2009;361:2548)
‚Ä¢ Barrett‚Äôs esophagus: 10‚Äì15% of Pts w/ GERD, compared w/ 5‚Äì6% w/o GERD 
‚Ä¢ Esophageal adenocarcinoma: risk 0.5%/y if Barrett‚Äôs, 1.6%/y if low-grade dysplasia,
6%/y if high-grade dysplasia 
‚Ä¢ Management: surveillance EGD w/ bx (or high-res imaging w/ narrow-band or OCT)  
Barrett‚Äôs w/ no dysplasia: surveillance q 3 y; low-grade dysplasia: q 6 mos
High-grade: endoscopic mucosal resection to r/o cancer, then RFA or other ablative Rx
DYSPEPSIA (‚ÄúINDIGESTION‚Äù)
Definition
‚Ä¢ Upper abdominal sx: discomfort, pain, fullness, bloating, burning
Etiologies
‚Ä¢ Functional (‚Äúnonulcer dyspepsia‚Äù or NUD 60%): some combination of visceral
afferent hypersensitivity & abnormal gastric motility (Rome III criteria in Gastro 2006;130:1377)
‚Ä¢ Organic (40%): GERD, PUD, rarely gastric cancer, other (meds, diabetic gastro-
paresis, lactose intolerance, biliary pain, chronic pancreatitis, mesenteric ischemia)
‚Ä¢ Alarm features that suggest organic cause & warrant EGD: see list above under GERD
Treatment of functional dyspepsia (NUD) (Gastro 2005;129:1756)
‚Ä¢ H. pylori eradication S empiric Rx if  serology, NNT  14 (Cochrane 2006(2) CD002096)
‚Ä¢ PPI effective in some (? misdx GERD), other S prokinetics,TCA
PEPTIC ULCER DISEASE (PUD)
Epidemiology & Etiologies (Lancet 2009;374:1449)
‚Ä¢ Lifetime prevalence 10%, but incidence T‚Äôing b/c T incidence of H. pylori and potent acid
suppression Rx. However, incidence of hospitalization for complications un‚Äôd (in fact c
in elderly; likely 2 to c NSAID use).
‚Ä¢ H. pylori infection: 80% of duodenal ulcers (DU) and 60% of gastric ulcers (GU)
50% of population colonized w/ H. pylori, but only 5‚Äì10% will develop PUD
‚Ä¢ ASA & NSAIDs: 45% erosions, 15‚Äì30% GU, 0.1‚Äì4% UGIB
‚Ä¢ Hypersecretory states (often mult. recurrent ulcers): gastrinoma (Zollinger-Ellison
syndrome, also p/w diarrhea, 1% of PUD), carcinoid, mastocytosis 
‚Ä¢ Malignancy: 5‚Äì10% of GU
‚Ä¢ Other: smoking, stress ulcers (if CNS process  ‚ÄúCushing‚Äôs‚Äù; if burn  ‚ÄúCurling‚Äôs‚Äù),
XRT, chemo, CMV or HSV (immunosupp), bisphosphonates; steroids alone not a
risk factor, but may exacerbate NSAID-induced ulceration
Clinical manifestations
‚Ä¢ Epigastric abdominal pain: relieved with food (DU) or worsened by food (GU)
‚Ä¢ Complications: UGIB, perforation & penetration, gastric outlet obstruction
Diagnostic studies
‚Ä¢ Test for H. pylori
Serology: Se 80%, Sp 90%; not useful to confirm erad. as can stay  wks to y
Stool antigen: Se & Sp 90%; use to confirm erad.; high false  in acute GIB
EGD  rapid urease test (Se & Sp 95%) or histo: false  if on abx, bismuth, PPI 
‚Ä¢ EGD req to def make dx; consider if fail empiric Rx or alarm features; bx GUs to r/o malig;
relook in 6‚Äì12 wks if apparently benign ulcer is lg or complicated or sx persist despite Rx
Treatment (NEJM 2010;362:1597)
‚Ä¢ If H. pylori , eradicate:
Triple Rx: clarith 500 bid  amox 1 g bid  PPI bid 	 10‚Äì14 d (but c clarith resist rates) 
Quadruple Rx: MNZ TCN  bismuth  PPI (H. pylori resist to clarith or amox allergy)
Sequential Rx (PPI  abx 	 5 d S PPI  2 different abx 	 5 d): erad. rates 90%
emerging as poss 1st-line Rx (Annals 2008;148:923)
Besides PUD, test & Rx if: gastric MALT lymphoma, atrophic gastritis, FHx gastric ca 
‚Ä¢ If H. pylori : gastric acid suppression w/ PPI
‚Ä¢ Discontinue ASA and NSAIDs; add PPI
‚Ä¢ Lifestyle changes: d/c smoking and probably EtOH; diet does not seem to play a role
‚Ä¢ Surgery: if refractory to med Rx (1st r/o NSAID use) or for complications (see above)
Prophylaxis if ASA/NSAID required (JACC 2008;52:1502)
‚Ä¢ PPI if (a) h/o PUD/UGIB; (b) also on clopidogrel (although ? T antiplt effect); (c) 
2 of
the following: age 60, steroids, or dyspepsia; prior to start test & Rx H. pylori
‚Ä¢ Consider misoprostol; consider H2RA if ASA monotherapy (Lancet 2009;374:119)
‚Ä¢ Consider  to COX-2 inhibit (T PUD & UGIB but c CV events) if low CV risk & not on ASA
‚Ä¢ Stress ulcer: risk factors  ICU & coagulopathic, mech vent, h/o GIB, steroid use; Rx w/ PPI
ESOPHAGEAL
3-2

--- Fim da P√°gina 80 ---

GIB
3-3
GASTROINTESTINAL BLEEDING
Definition
‚Ä¢ Intraluminal blood loss anywhere from the oropharynx to the anus
‚Ä¢ Classification: upper  above the ligament of Treitz; lower  below the ligament of Treitz
‚Ä¢ Signs: hematemesis  blood in vomitus (UGIB); hematochezia  bloody stools
(LGIB or rapid UGIB); melena  black, tarry stools from digested blood (usually
UGIB, but can be anywhere above and including the right colon)
Etiologies of upper GI bleed (UGIB)
‚Ä¢ Peptic ulcer disease (50%): H. pylori, NSAIDs, gastric hypersecretory states
‚Ä¢ Varices (10‚Äì30%): esophageal  gastric, 2 to portal HTN. If isolated gastric S r/o
splenic vein thrombosis.
‚Ä¢ Gastritis/gastropathy/duodenitis (15%): NSAIDs,ASA, alcohol, stress, portal
hypertensive 
‚Ä¢ Erosive esophagitis/ulcer (10%): GERD, XRT, infectious (CMV, HSV, or Candida if
immunosuppressed), pill esophagitis (bisphosphonate, NSAIDs;  odynophagia)
‚Ä¢ Mallory-Weiss tear (10%): GE junction tear due to retching against closed glottis
‚Ä¢ Vascular lesions (5%)
Dieulafoy‚Äôs lesion: superficial ectatic artery usually in cardia S sudden, massive UGIB
AVMs, angioectasias, hered. hemor. telangectasia: submucosal, anywhere in GI tract
Gastric antral vascular ectasia (GAVE): ‚Äúwatermelon stomach,‚Äù tortuous, dilated ves-
sels; a/w cirrhosis, atrophic gastritis, CREST
Aorto-enteric fistula: AAA or aortic graft erodes into 3rd portion of duodenum;
p/w ‚Äúherald bleed‚Äù; if suspected, diagnose by endoscopy or CT
‚Ä¢ Neoplastic disease: esophageal or gastric carcinoma, GIST
‚Ä¢ Oropharyngeal bleeding and epistaxis S swallowed blood
Etiologies of lower GI bleed (LGIB)
‚Ä¢ Diverticular hemorrhage (33%): 60% of diverticular bleeding localized to right colon
‚Ä¢ Neoplastic disease (19%): usually occult bleeding, rarely severe
‚Ä¢ Colitis (18%): infectious, ischemic, radiation, inflammatory bowel disease (UC  CD)
‚Ä¢ Angiodysplasia (8%): most commonly located in ascending colon and cecum
‚Ä¢ Anorectal (4%): hemorrhoids, anal fissure, rectal ulcer
‚Ä¢ Other: post-polypectomy, vasculitis 
Clinical manifestations
‚Ä¢ UGIBLGIB: N/V, hematemesis, coffee-ground emesis, epigastric pain, vasovagal, melena
‚Ä¢ LGIBUGIB: diarrhea, tenesmus, BRBPR, hematochezia (11% UGIB; Gastro 1988;95:1569)
Initial Management
‚Ä¢ Assess severity: tachycardia suggests 10% volume loss, orthostatic hypotension 
20% loss, shock 30% loss
‚Ä¢ Resuscitation: placement of 2 large-bore (18-gauge or larger) intravenous lines
Volume replacement: NS or LR to achieve normal VS, UOP, & mental status
‚Ä¢ Transfuse: blood bank sample for type & cross; use O-neg if emergent 
Transfuse 2‚Äì8 U and target Hct 25‚Äì30 depending on comorbidities
‚Ä¢ Reverse coagulopathy: FFP & vit K to normalize PT; plts to keep count 50,000
‚Ä¢ Triage: consider ICU if unstable VS or poor end organ perfusion
Intubation for emergent EGD, if ongoing hematemesis, shock, poor resp status,  MS
? OutPt management if SBP 
110, HR 100, Hb 
13 () or 
12 (), BUN 18,
‚àÖmelena, syncope, heart failure, liver disease (Lancet 2009;373;42)
Workup
‚Ä¢ History: where (anatomic location) & why (etiology)
acute or chronic, prior GIB, # of episodes, other GI dx 
hematemesis, vomiting prior to hematemesis (Mallory-Weiss), melena, hematochezia
abdominal pain, wt loss, anorexia,  in stool caliber
ASA/NSAIDs, clopidogrel, anticoagulants, known coagulopathy
alcohol (gastritis, varices), cirrhosis, known liver disease, risk factors for liver disease
abdominal/rectal radiation, history of cancer, prior GI or aortic surgery
‚Ä¢ Physical exam: VS most important, orthostatic s, JVP
localizable abd tenderness, peritoneal signs, masses, LAN, signs of prior surgery
signs of liver disease (hepatosplenomegaly, ascites, etc.)
rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color, occult blood 
pallor, jaundice, telangiectasias (alcoholic liver disease or hered. hemor. telangectasia)
‚Ä¢ Laboratory studies: Hct (may be normal in first 24 h of acute GIB before equilibration) 
T 2‚Äì3% S 500 mL blood loss; low MCV S Fe deficient and chronic blood loss; plt, PT,
PTT; BUN/Cr (ratio 36 in UGIB b/c GI resorption of blood  prerenal azotemia); LFTs

--- Fim da P√°gina 81 ---

Diagnostic studies
‚Ä¢ Nasogastric tube can help for localization: fresh blood S active UGIB; coffee 
grounds S recent UGIB (can be confused w/ bile); nonbloody bile S ? lower source,
but does not exclude active UGIB (15% missed);  occult blood testing of no value
‚Ä¢ UGIB: EGD for dx and potential Rx, consider erythro 250 mg IV 30 min prior S empty
stomach of blood S c Dx/Rx yield (Am J Gastro 2006;101:1211)
‚Ä¢ LGIB: first r/o UGIB before attempting to localize presumed LGIB, then colonoscopy
(identifies cause in 70%), consider rapid purge w/ PEG solution 4 L over 2 h
‚Ä¢ Unstable or recurrent UGIB & LGIB:
arteriography: can localize if bleeding rates 
0.5 mL/min and can Rx (coil, vaso, glue)
tagged RBC scan: can localize bleeding rates 
0.1 mL/min for surg but unreliable
emergent exploratory laparotomy (last resort)
Etiology
Treatment Options
Varices
Pharmacologic
(Hep 2007;46:922;
octreotide 50 g IVB S 50 g/h infusion (84% success). Usually 
NEJM 2010;362:823)
	 5 d, but most benefit w/in 24‚Äì48 h.
Abx: cirrhotics w/ any GIB should receive prophylaxis: Cftx IV vs.
norfloxacin PO (Hep 2004;39:746 & Gastro 2006;131;1049)
Nonpharmacologic
endoscopic band ligation (90% success)
arteriography with coiling/glue occasionally for gastric varices
balloon tamponade (Sengstaken-Blakemore) if bleeding severe;
mainly used as rescue procedure and bridge to TIPS 
TIPS for esophageal variceal hemorrhage refractory to above, or
for gastric varices; c/b encephalopathy, shunt occlusion
surgery (portocaval/splenorenal shunts) rarely used now
PUD
If active bleeding or non-bleeding visible vessel (NBVV) on EGD
(NEJM 2000;343:310;
PPI (eg, omeprazole 80 mg IVB S 8 mg/h)
2007;356:1631;
before EGD S T need for endoscopic Rx and T LOS
2008;359:928; Annals 
continue IV dose 	 72 h following EGD: T rebleed rate
2010;152:101)
convert to PO after 72 h
? Octreotide if no access to EGD
Endoscopic therapy (ET): epi inj  either bipolar cautery or 
hemoclip; rebleeding risk: 43% (NBVV) to 85% (active bleed) 
w/o ET vs. 15‚Äì20% w/ ET vs. 7% w/ ET PPI (most w/in 48 h)
Clear liquids 6 h after ET if hemodynamically stable
Arteriography w/ vasopressin or embolization; surgery (last resort)
If adherent clot
PPI as above  endo removal of clot (if experienced ctr) to r/o 
NBVV; rebleeding risk 22% w/o ET vs. 5% w/ ET
If flat, pigmented spot or clean base
No endo Rx indicated; rebleed risk 10%: oral PPI BID
Consider early hospital d/c (see criteria in NEJM 2008;359:928)
If Pt on ASA for CV disease and PUD GIB endoscopically 
controlled, resume ASA when CV risk  rebleeding risk, typically 
7 d following index bleed (Annals 2010;152:101)
Mallory-Weiss
Usually stops spontaneously; endoscopic Rx if active
Esophagitis 
PPI, H2-receptor antagonists
Gastritis
Diverticular 
Usually stops spontaneously (75%)
disease
Endoscopic Rx (eg, epinephrine injection, cautery, banding, or
hemoclip), arterial vasopressin or embolization, surgery
Angiodysplasia
Usually stops spontaneously (85%)
Endo Rx (cautery or argon plasma), arterio w/ vasopressin, surgery
Obscure GIB (Gastro 2007;133;1694) 
‚Ä¢ Definition: continued bleeding (melena, hematochezia) despite  EGD & colo; 5% of GIB
‚Ä¢ Etiologies: Dieulafoy‚Äôs lesion, small bowel angiodysplasia or cancer, Crohn‚Äôs disease,
aortoenteric fistula, Meckel‚Äôs diverticulum (2% of pop., remnant of vitelline duct w/
ectopic gastric mucosa), hemobilia
‚Ä¢ Diagnosis: repeat EGD w/ push enteroscopy/colon‚Äîperform when bleeding is active 
If  perform video capsule to evaluate small intestine (Gastro 2009;137:1197) 
If still  consider 99mTc-pertechnetate scan (‚ÄúMeckel‚Äôs scan‚Äù), double-balloon
enteroscopy, tagged RBC scan, and arteriography
GIB
3-4

--- Fim da P√°gina 82 ---

DIARRHEA, CONSTIPATION, AND ILEUS
ACUTE DIARRHEA (4 WK)
Acute Infectious Etiologies
Pathogen
Epidemiology & Clinical Sx
Noninflammatory
Predom. disruption small intestine absorp. & secretion.
Voluminous diarrhea, N/V.  fecal WBC & FOB.
Preformed toxin
‚ÄúFood poisoning,‚Äù 24 h dur. S. aureus (meats & dairy),
B. cereus (fried rice), C. perfringens (rewarmed meats).
Viral
Rotavirus
Outbreak person to person (PTP), daycare; lasts 4‚Äì8 d.
Norovirus
50% of all diarrhea. Winter outbreaks; PTP & food/water;
no immunity. Lasts 1‚Äì3 d. Vomiting prominent.
Bacterial E. coli (toxigenic)
50% of traveler‚Äôs diarrhea; cholera-like toxin; 7 d.
Vibrio cholerae
Contam H2O, fish, shellfish; 50 cases/y in U.S. gulf coast.
Severe dehydration & electrolyte depletion.
Parasitic
Giardia
Streams/outdoor sports, travel, outbreaks. Bloating.
( malab 
Cryptosporidia
Water-borne outbreak; typically self-limited, can cause
for mos 
chronic infxn if immunosupp. Abd pain (80%), fever (40%).
after Rx)
(NEJM 2002;346:1723)
Cyclospora
Contaminated produce
Inflammatory
Predom. colonic invasion. Small vol diarrhea. LLQ 
cramps, tenesmus, fever, typically  fecal WBC or FOB.
Bacterial Campylobacter
Undercooked poultry, unpasteurized milk, travel to Asia;
carried by puppies & kittens. Prodrome; abd pain S
‚Äúpseudoappendicitis‚Äù; c/b GBS, reactive arthritis.
Salmonella
Eggs, poultry, milk. Bacteremia in 5‚Äì10%. 10‚Äì33% of 
(nontyphoidal)
bacteremic Pts 50 y develop aortitis.
Shigella
Low inoculum; PTP spread. Abrupt onset; often gross 
blood & pus in stool; cc WBC.
E. coli (O157:H7 
Undercooked beef, unpasteurized milk, raw produce; PTP.
& inv/ hemorrhagic
O157 & non-O157 sp. (40%) produce Shiga toxin S HUS
non-O157:H7)
(typically in children). Gross blood in stool.
C. difficile
See later
Vibrio parahaem.
Undercooked seafood 
Salmonella typhi
Travel to Asia. Systemic toxicity, relative bradycardia, rose
spot rash, ileus S pea-soup diarrhea, bacteremia.
Other
Yersinia: undercooked pork; unpasteurized milk, abd pain 
S ‚Äúpseudoappendicitis‚Äù (aka mesenteric adenitis)
Aeromonas, Pleisomonas, Listeria (meats & cheeses)
Parasitic
E. histolytica
Contaminated food/water, travel (rare in U.S.); liver abscess 
Viral
CMV
Immunosuppressed; dx by shell vial cx of colon bx
Evaluation (NEJM 2009;361:1560 & Gastro 2009;136:1874)
‚Ä¢ Hx: stool freq, bloody, abd pain, duration of sxs [1 wk for viral & bacterial 
(except C. diff), 1 wk for parasitic], travel, food, recent abx
‚Ä¢ PEx: vol depletion (VS, UOP, axillae, skin turgor, MS), fever, abd tenderness, ileus, rash
‚Ä¢ Further evaluation if warning signs: fever, signific abd pain, blood or pus in stools, 6
stools/d, severe dehydration, immunosupp., elderly, duration 7 d, hosp-acquired
‚Ä¢ Etiology established in only 3% of community-acquired diarrhea
‚Ä¢ Laboratory: fecal WBC (high false  & ; ‚úìfecal calprotectin or lactoferrin), stool cx,
BCx, lytes, C. diff (if recent hosp or abx), stool O & P (if 10 d, travel to endemic area,
exposure to unpurified H2O, community outbreak, daycare, HIV  or MSM)
 stool ELISAs (viruses, Crypto, Giardia), serologies (E. histolytica), special stool cx
‚Ä¢ Imaging/endoscopy: CT/KUB if ? toxic megacolon; sig/colo if immunosupp or cx 
‚Ä¢ Ddx: infxn vs. preformed toxin vs. med-induced vs. initial presentation of chronic diarrhea
Treatment
‚Ä¢ If none of the above warning signs and Pt able to take POs S supportive Rx only:
oral hydration, loperamide, bismuth subsalicylate (avoid anticholinergics)
‚Ä¢ If moderate dehydration: 50‚Äì200 mL/kg/d of oral solution (1‚ÅÑ2 tsp salt, 1 tsp baking soda,
8 tsp sugar, & 8 oz OJ diluted to 1 L w/ H2O) or Gatorade, etc. If severe, LR IV.
‚Ä¢ For traveler‚Äôs diarrhea, bismuth or rifaximin useful for prophylaxis & empiric Rx
DIARRHEA
3-5

--- Fim da P√°gina 83 ---

‚Ä¢ Empiric abx for non‚Äìhospital-acquired inflammatory diarrhea reasonable: FQ 	 5‚Äì7 d
abx rec for Shigella, cholera, C. diff, Giardia, amebiasis, Salmonella if Pt 50 y or
immunosupp. or hospitalized, ? Campylobacter (if w/in 4 d of sx onset, Rx w/ azithro)
avoid abx if suspect E. coli O157:H7 as may c risk of HUS
CLOSTRIDIUM DIFFICILE
Pathogenesis
‚Ä¢ Ingestion of C. difficile spores S colonization when colonic flora d by abx or 
chemo S release of toxin A/B S colonic mucosal necrosis & inflammation 
S pseudomembranes
‚Ä¢ c toxigenic strain (NAP-1/027) c mort. & length of hosp. (esp in elderly) (NEJM 2008;359:1932)
‚Ä¢ Additional risk factors: elderly, nursing home residents, IBD, ? PPI exposure
Clinical manifestations (a spectrum of disease)
‚Ä¢ Asx colonization: 3% healthy adults; 20% in hospitalized patients on antibiotics
‚Ä¢ Acute watery diarrhea (occ bloody)  mucus, often w/ lower abd pain, fever, ccc WBC
‚Ä¢ Pseudomembranous colitis: above sx  pseudomembranes  bowel wall thickening
‚Ä¢ Fulminant colitis (2‚Äì3%): toxic megacolon (colon dilatation 
6 cm on KUB, colonic
atony, systemic toxicity) and/or bowel perforation
Diagnosis
‚Ä¢ Stool ELISA: detects toxin A and/or B; fast (2‚Äì6 h); Se 90‚Äì95% if AB tested. If high
clinical suspicion and 1st test  consider repeating 	 1 (CID 2008;46:S12).
‚Ä¢ Stool cytotoxin assay: gold standard, highly Se & Sp, but takes 24‚Äì48 h
‚Ä¢ Consider flex sig if dx uncertain and/or evidence of no improvement w/ standard Rx
Treatment (Gastro 2009;136:1899)
‚Ä¢ In everyone: start contact precautions, if possible d/c abx ASAP; stop antimotility agents
‚Ä¢ Mild (6 BM/d, temp 101F, WBC 15 k, no peritoneal sx or SIRS, and age 65 y)
Rx: MNZ 500 mg PO tid 	 10‚Äì14 d; IV equal efficacy, use if poor PO or ileus
‚Ä¢ Moderate (6‚Äì12 BM/d, temp 101‚Äì103F, WBC 15‚Äì25 k, visible LGIB, or age 65 y)
Rx: vanco 125‚Äì500 mg PO qid 	 10‚Äì14 d; add MNZ 500 IV tid if not improved by 48 h
‚Ä¢ Severe (12 BM/d, temp 103F, WBC 25k, c abd pain, sepsis, or no bowel sounds)
Rx: vanco PO  MNZ IV; PR vancomycin available if ileus, though avoid if evidence of
toxic megacolon; ? tigecycline (CID 2009;48:1732);Ab CT, urgent surgery consult re:
colectomy; consider IVIG
‚Ä¢ If Pt needs to stay on original abx, continue C. diff. Rx for 
7 d post-abx cessation
‚Ä¢ Stool carriage may persist 3‚Äì6 wk postcessation of sx and should not trigger further Rx
‚Ä¢ Recurrent infection: 15‚Äì30% risk after d/c of abx, most w/in 2 wk of stopping abx
1st relapse: if mild; repeat 14-d course of MNZ or vanco
2nd relapse: PO vanco taper for 6 wk
2 relapses: vanco taper & adjunctive Rx such as S. boulardii, probiotics, rifaximin,
nitazoxanide, or cholestyramine (will bind vanco so cannot take concurrently)
Antitoxin A/B Ab to prevent recurrent infxn under study (NEJM 2010:362:197)
CHRONIC DIARRHEA (4 WK; Gastro 2004;127:287)
Medications (cause c secretion, c motility,  flora, c cell death, or inflammation)
‚Ä¢ PPI, colchicine, abx, H2RA, SSRIs,ARBs, NSAIDs, chemo, caffeine
Osmotic (c osmotic gap,  fecal fat, T diarrhea with fasting)
‚Ä¢ Lactose intolerance: seen in 75% nonwhites & in 25% whites; can be acquired
after gastroenteritis, med illness, GI surgery. Clinical: bloating, flatulence, discom-
fort, diarrhea. Dx: hydrogen breath test or empiric lactose-free diet. Rx: lactose-
free diet, use of lactaid milk and lactase enzyme tablets.
‚Ä¢ Other: lactulose, laxatives, antacids, sorbitol, fructose
Malabsorption (c osmotic gap, c fecal fat, T diarrhea with fasting)
‚Ä¢ Celiac disease (NEJM 2007;357:1731)
Immune rxn in genetically predisposed Pts (1% pop) to gliadin, a component of
gluten (wheat protein) S small bowel inflammatory infiltrate S crypt hyperplasia,
villus atrophy S impaired intestinal absorption
Other s/s: Fe/folate defic anemia; osteoporosis; dermatitis herpetiformis (pruritic
papulovesicular); c AST/ALT
DIARRHEA
3-6

--- Fim da P√°gina 84 ---

Dx: IgA antitissue transglutaminase or anti-endomysial Ab has 90% Se & 98% Sp
(JAMA 2010;303:1738). Small bowel bx and response to gluten-free diet definitive.
Rx: gluten-free diet; 7‚Äì30% do not respond to diet S ? wrong dx or noncompliant
Complic: 5% refractory (sx despite strict dietary adherence), risk of T-cell lym-
phoma, and small bowel adenocarcinoma
‚Ä¢ Whipple‚Äôs disease: infxn w/ T. whipplei (NEJM 2007;365:55)
Other s/s: fever, LAN, edema, arthritis, CNS s, gray-brown skin pigmentation, AI &
MS, oculomasticatory myorhythmia (eye oscillations  mastication muscle contract.)
Rx: (PCN  streptomycin) or 3rd-gen ceph 	 10‚Äì14 d S Bactrim for 
1 y
‚Ä¢ Bacterial overgrowth: c small intestinal bacteria from incompetent/absent ileoce-
cal valve, s/p RYGB, scleroderma, diabetes, s/p vagotomy S fat & CHO malabsorp-
tion. Dx:  14C-xylose & H breath tests; Rx: cycled abx (eg, MNZ, FQ, rifaximin)
‚Ä¢ Pancreatic insufficiency: most commonly from chronic pancreatitis or pancreatic cancer
‚Ä¢ T bile acids due to T synthesis (cirrhosis) or cholestasis (PBC) S malabsorption
‚Ä¢ Other: s/p short bowel resection (short bowel syndrome), Crohn‚Äôs disease, chronic
mesenteric ischemia, eosinophilic gastroenteritis, intestinal lymphoma, tropical sprue
Inflammatory ( fecal WBC or lactoferrin or calprotectin,  FOB, fever, abd pain)
‚Ä¢ Infections: particularly parasitic (incl above pathogens & Strongyloides), CMV, TB
‚Ä¢ Inflammatory bowel disease
‚Ä¢ Radiation enteritis, ischemic colitis, neoplasia (colon cancer, lymphoma)
Secretory (normal osmotic gap, no  diarrhea after NPO, nocturnal diarrhea freq described)
‚Ä¢ Hormonal:VIP (VIPoma,Verner-Morrison), serotonin (carcinoid), thyroxine, calcitonin
(medullary cancer of the thyroid), gastrin (Zollinger-Ellison), glucagon, substance P 
‚Ä¢ Laxative abuse
‚Ä¢ Neoplasm: carcinoma, lymphoma, villous adenoma
‚Ä¢ T bile acids absorption (s/p ileal resection, Crohn‚Äôs) S colonic exposure & c secretion
‚Ä¢ Lymphocytic colitis, collagenous colitis (often a/w meds, including NSAIDs)
Motility (normal osmotic gap)
‚Ä¢ Irritable bowel syndrome (10‚Äì15% of adults; NEJM 2008;358:1692)
Due to altered intestinal motility/secretion in response to luminal or environmental
stimuli w/ enhanced pain perception and dysregulation of the brain-gut axis
Rome III criteria: recurrent abd pain 
3 d/mo over last 3 mo plus 
2 of following: (i)
improvement w/ defecation, (ii) onset w/  freq of stool, (iii) onset w/  in form of stool
Rx sx-guided (AJG 2009;104:51). Pain: antispasmodics,TCA, SSRI. Bloating: rifaximin,
probiotics. Diarrhea: loperamide, alosetron (5-HT3 antagonist) for women (c risk
of ischemic colitis). Constipation: c fiber 25 g/d, lubiprostone (Cl channel activa-
tor); tegaserod (5-HT4 agonist) withdrawn due to CV risk.
‚Ä¢ Scleroderma; diabetic autonomic neuropathy; hyperthyroidism; amyloidosis; s/p vagotomy
Figure 3-2 Workup of chronic diarrhea
DIARRHEA
3-7
Chronic diarrhea
Secretory/Motility
Med-induced
stool osmotic gap = Osmstool (usu 290) ‚Äì [2 √ó (Nastool + Kstool)]
<50
Malabsorption
Based on hx ‚úì anti-tissue
transglut, stool elastase,
14C-xylose & H+
 breath
tests, EGD w/ bx, EUS
‚äï FOB ‚äï WBC
‚äï lactoferrin
‚äï calpotectin
Inflammatory
‚úìstool cx
colonoscopy
‚úìCT scan, colonoscopy,
hormone levels
‚úìH+ breath test or empiric
lactose-free diet, laxative screen
>50
Osmotic
culprit meds
‚äï fecal fat

--- Fim da P√°gina 85 ---

CONSTIPATION & ADYNAMIC ILEUS
Constipation (NEJM 2003;349:1360)
‚Ä¢ Definition (Rome III): 
2 of the following during last 3 mo at least 25% of time:
straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction,
manual maneuvers to facilitate defecation, stool frequency 3 per wk
‚Ä¢ Etiology
Functional: normal transit, slow transit, pelvic floor dysfunction, constipation-predom IBS
Meds: opioids, anticholinergics (TCAs & antipsychotics), Fe, CCB, diuretics, NSAIDs
Obstruction: cancer, stricture, rectocele, anal stenosis, extrinsic compression
Metabolic/endo: DM, hypothyroid, uremia, preg, panhypopit, porphyria, c Ca, T K, T Mg
Neuro: Parkinson‚Äôs, Hirschsprung‚Äôs, amyloid, MS, spinal injury, autonomic neuropathy
‚Ä¢ Diagnosis: H&P w/ DRE. Labs: consider CBC, electrolytes w/ Ca,TSH
Colonoscopy if alarm sx: wt loss,  FOBT, fevers, FHx of IBD or colon cancer.
Sigmoidoscopy if no alarm sx & 50 y/o.
For functional constipation: sitzmark study, anorectal manometry, defecography
‚Ä¢ Treatment: Bulk laxatives (fiber 20 g/d) S osmotic laxative S stimulant laxative
Bulk laxatives (psyllium, methylcellulose, polycarbophil): c colonic residue, c peristalsis 
Osmotic laxatives (Mg, sodium phosphate (avoid if CKD), lactulose): c water in colon 
Stimulant laxatives (senna, castor oil, bisacodyl, docusate sodium): c motility & secretion
Enema/suppository (phosphate, mineral oil, tap water, soapsuds, bisacodyl) 
Lubiprostone (see IBS). Methylnaltrexone for opioid-induced (NEJM 2008;358:2332).
Adynamic ileus
‚Ä¢ Definition: loss of intestinal peristalsis in absence of mechanical obstruction
Ogilvie‚Äôs  acute colonic adynamic ileus in presence of competent ileocecal valve
‚Ä¢ Precipitants: intra-abd process (surgery, pancreatitis, peritonitis); severe medical illness
(eg, PNA, sepsis); intestinal ischemia; meds (opiates, anticholinergics); electrolyte abnl
‚Ä¢ Clinical manifestations: abd. discomfort, N/V, hiccups, abd. distention, T or absent bowel
sounds, no peritoneal signs (unless perforation); cecum 
10‚Äì12 cm S c rupture
‚Ä¢ Dx: supine & upright KUB vs. CTS gas-filled loops of small & large intestine. Must
exclude mechanical obstruction (absence of gas in rectum).
‚Ä¢ Treatment: NPO, mobilize (walk, roll), d/c drugs that T intestinal motility, enemas;
decompression (NGT, rectal tubes, colonoscope); erythromycin, neostigmine
CONSTIPATION
3-8

--- Fim da P√°gina 86 ---

DIVERTICULAR DISEASE
DIVERTICULOSIS
Definition and Pathobiology (Lancet 2004;363:631)
‚Ä¢ Acquired herniations of colonic mucosa and submucosa through the colonic wall 
‚Ä¢ May be a consequence of low-fiber diet S c stool transit time and T stool volume S
c intraluminal pressure S herniation at site of relative muscle weakness where
vasa recta penetrate to supply blood to colonic mucosa and submucosa
Epidemiology 
‚Ä¢ Prevalence higher w/ c age (10% if 40 y; 50‚Äì66% if 80 y);‚ÄúWesternized‚Äù societies 
‚Ä¢ Left side (90%, mostly sigmoid)  right side of colon (except in Asia, where RL)
Clinical manifestations
‚Ä¢ Usually asx, but 5‚Äì15% develop diverticular hemorrhage and 10‚Äì25% diverticulitis 
‚Ä¢ Nuts/seeds/popcorn intake in asx diverticulosis does not c risk of 1st case of diverticulitis
or diverticular bleeding (JAMA 2008;300:907)
DIVERTICULITIS
Pathophysiology (NEJM 2007;357:2057)
‚Ä¢ Retention of undigested food and bacteria in diverticulum S fecalith formation S
obstruction S compromise of diverticulum‚Äôs blood supply, infection, perforation
‚Ä¢ Uncomplicated: microperforation S localized infection
‚Ä¢ Complicated (25%): macroperforation S abscess, peritonitis, fistula (65% w/ bladder),
obstruction, stricture
Clinical manifestations
‚Ä¢ LLQ abdominal pain, fever, nausea, vomiting, constipation
‚Ä¢ PEx ranges from LLQ tenderness  palpable mass to peritoneal signs & septic shock
‚Ä¢ Ddx includes IBD, infectious colitis, PID, tubal pregnancy, cystitits, colorectal cancer
Diagnostic studies
‚Ä¢ Plain abdominal radiographs to r/o free air, ileus, or obstruction
‚Ä¢ Abdominal CT (IO): 95% Se & Sp; assess complicated disease (abscess, fistula)
‚Ä¢ Colonoscopy contraindicated acutely c risk of perforation; do 6 wks after to r/o neoplasm
Treatment (Am J Gastro 2008;103:1550)
‚Ä¢ Mild: outPt Rx indicated if Pt has few comorbidities and can tolerate POs
PO abx: (MNZ  FQ) or amox/clav for 7‚Äì10 d; liquid diet until clinical improvement
‚Ä¢ Severe: inPt Rx if cannot take POs, narcotics needed for pain, or complications
NPO, IV fluids, NGT (if ileus)
IV abx (GNR & anaerobic coverage): amp/gent/MNZ or piperacillin-tazobactam
‚Ä¢ Abscesses 4 cm should be drained percutaneously or surgically
‚Ä¢ Surgery: if progression despite med Rx, undrainable abcess, free perforation, or
recurrent disease (2 severe episodes)
‚Ä¢ Colonic stricture: late complication of diverticulitis; Rx w/ endoscopic dilation vs. resection
Prevention
‚Ä¢ Low-fiber diet immediately after acute episode; high-fiber diet when 6 wks w/o sx
‚Ä¢ Consider mesalamine  rifaximin if multiple episodes
‚Ä¢ Risk of recurrence 10‚Äì30% w/in 10 y of 1st episode; more likely 2nd episode complicated
DIVERTICULAR HEMORRHAGE (also see ‚ÄúGastrointestinal Bleeding‚Äù)
Pathophysiology
‚Ä¢ Intimal thickening and medial thinning of vasa recta as it courses over dome of diver-
ticulum S weakening of vascular wall S arterial rupture
‚Ä¢ Diverticula more common in left colon; but bleeding diverticula more often in right colon
Clinical manifestations
‚Ä¢ Painless hematochezia/BRBPR, but can have abdominal cramping
‚Ä¢ Usually stops spontaneously (75%) but resolution may occur over hrs‚Äìdays; 20% recur
Diagnostic studies
‚Ä¢ Colonoscopy: rapid prep w/ Go-Lytely via NGT (4‚Äì6 L over 2‚Äì4 h)
‚Ä¢ Arteriography  tagged RBC scan if severe bleeding
Treatment
‚Ä¢ Colonoscopy: epinephrine injection  electrocautery (NEJM 2000;342:78), hemoclip, banding
‚Ä¢ Arteriography: intra-arterial vasopressin infusion or embolization
‚Ä¢ Surgery: if above modalities fail & bleeding is persistent & hemodynamically significant
DIVERTICULAR
3-9

--- Fim da P√°gina 87 ---

INFLAMMATORY BOWEL DISEASE
Definition
‚Ä¢ Ulcerative colitis (UC): idiopathic inflammation of the colonic mucosa
‚Ä¢ Crohn‚Äôs disease (CD): idiopathic transmural inflammation of the GI tract, skip areas
‚Ä¢ Indeterminate colitis: in 5‚Äì10% of chronic colitis, cannot distinguish UC vs. CD even w/ bx 
Epidemiology & Pathophysiology (Lancet 2007;369:1627 & NEJM 2009;361:2066)
‚Ä¢ 1.4 million people in US; prev 1:1000 UC and 1:3000 CD; c incidence in Caucasians, Jews
‚Ä¢ Age of onset 15‚Äì30 y in UC and CD; CD is bimodal and has second peak at 50‚Äì70 y
‚Ä¢ Smokers at c risk for CD, whereas nonsmokers & former smokers at c risk for UC
‚Ä¢ Genetic predisposition  disruption of intestinal barrier (epithelial or T immune)   in gut
microbiome S acute inflam w/o immune downregulation or tolerance S chronic inflam
ULCERATIVE COLITIS (Lancet 2007;369:1641)
Clinical manifestations
‚Ä¢ Grossly bloody diarrhea, lower abdominal cramps, urgency, tenesmus
‚Ä¢ Severe colitis (15%): progresses rapidly over 1‚Äì2 wks with T Hct, c ESR, fever,
hypotension, 6 bloody BMs per day, distended abdomen with absent bowel sounds
‚Ä¢ Extracolonic (25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers,
uveitis, episcleritis, thromboembolic events (espec during a flare; Lancet 2010;375:657),
AIHA, seroneg arthritis, chronic hepatitis, cirrhosis, PSC (c risk of cholangiocarcinoma)
Diagnosis
‚Ä¢ Colonoscopy: involves rectum (95%) & extends proximally and contiguously within colon
‚Ä¢ Classify by location: proctitis (25‚Äì55%), left-sided colitis (ie, sigmoid  descending
colon, 50‚Äì70%), and pancolitis (20%)
‚Ä¢ Appearance: granular, friable mucosa with diffuse ulceration; pseudopolyps
‚Ä¢ Microscopy: superficial chronic inflammation; crypt abscess and architectural distortion
Complications
‚Ä¢ Toxic megacolon (5%): colon dilatation (
6 cm on KUB), colonic atony, systemic
toxicity, & c risk of perf. Rx w/ IV steroids & broad-spectrum abx; surgery if fail to
improve w/in 48‚Äì72 h
‚Ä¢ Stricture (5%): occurs in rectosigmoid after repeated episodes of inflammation
Prognosis
‚Ä¢ 50% of Pts in remission at any given time; intermittent exacerbations in 90%; contin-
ual active disease in 18%. Rate of colectomy at 10 y is 24%.
‚Ä¢ Mortality rate of severe UC flare is 2%, & overall life expectancy in UC  non-UC Pts 
CROHN‚ÄôS DISEASE (Lancet 2007;369:1641)
Clinical manifestations
‚Ä¢ Smoldering disease with abd pain, fevers, malaise, wt loss
‚Ä¢ Mucus-containing, non-grossly bloody diarrhea; n/v, bloating, obstipation
‚Ä¢ T albumin, c ESR/CRP, T Hct (due to Fe, B12, folate deficiency; chronic inflammation)
‚Ä¢ Extracolonic as in UC 
Diagnosis
‚Ä¢ EGD/Colonoscopy  small bowel imaging (eg, video capsule endoscopy or CT
enterography); CD can affect any portion of GI tract with skip lesions
‚Ä¢ Classify by location: small bowel (47%), ileocolonic (21%), colonic (28%); upper tract rare
‚Ä¢ Appearance: nonfriable mucosa, cobblestoning, aphthous ulcers, deep & long fissures 
‚Ä¢ Microscopy: transmural inflammation with mononuclear cell infiltrate, noncaseat-
ing granulomas (seen in 25% of mucosal biopsies), fibrosis, ulcers, fissures
Complications
‚Ä¢ Perianal disease: fissures, fistulas, perirectal abscesses (up to 30% of Pts)
‚Ä¢ Stricture: small bowel, postprandial abd pain; can lead to complete SBO
‚Ä¢ Fistulas: perianal, enteroenteric, rectovaginal, enterovesicular, enterocutaneous
‚Ä¢ Abscess: fever, tender abd mass, c WBC; steroids mask sx, ‚à¥need high-level suspicion
‚Ä¢ Malabsorption: illeal disease/resection: T bile acids abs S gallstones; T fatty acid abs S
Ca oxalate kidney stones; T fat soluble vitamin abs SVit D deficiency S osteopenia
Prognosis
‚Ä¢ Highly variable: 1 y following dx, 55‚Äì65% in remission, 10‚Äì30% have flared, 15‚Äì25%
have low activity, and 13‚Äì20% have chronic active course 
‚Ä¢ At 20 y, majority will have required some surgery; overall life expectancy is slightly T
IBD
3-10

--- Fim da P√°gina 88 ---

MANAGEMENT (Lancet 2007;369:1641 & Gastro 2007;133:1670)
Initial Evaluation 
‚Ä¢ H&P (‚úìfor intestinal & extraintestinal manifestations) and endoscopy as above
‚Ä¢ Laboratory: ESR, CRP, CBC, LFTs, Fe, B12, folate, Vit D. Anti-Saccharomyces cerevisiae
Abs (ASCA) for CD & p-ANCA for UC have low Se, higher Sp; ‚à¥not dx.
‚Ä¢ Exclude other etiologies: infectious/ischemic colitis, med adverse effect, intestinal 
lymphoma/carcinoma, colon cancer, IBS, vasculitis, Behcet‚Äôs, sprue, bacterial overgrowth
‚Ä¢ Rule out infection before treating with immunosuppressants and biologics
Goals of Treatment 
‚Ä¢ Avoid NSAIDs (both UC and CD)
‚Ä¢ Induce remission of acute flare S maintain remission; mucosal healing 1 goal
‚Ä¢ Convention has been step-up Rx (least S most toxic). Recent shift to early and/or combined
immunomodulation to improve disease outcome (Lancet 2008;371:660 & NEJM 2010;362:1383).
Induction of Remission (Acute Flare Treatment)
Ulcerative Colitis
5-ASA
For mild dis. (4 BMs/d w/o systemic toxicity). PR if disease distal to splenic 
flexure. PO if more extensive: 2.4‚Äì4.8 g/d mesalamine (released in 
ileum/colon), olsalazine (colon), sulfasalazine (avoid if sulfa allergy).
Steroids
Mod dis. (6 BMs/d w/ minimal systemic tox) S PO prednisone. Severe dis.
(6 BMs/d w/ systemic tox) S IV. PR only in mild distal dis.
Anti-TNF
Mod/Severe flare unresponsive to steroids, flare on immunomodulators.
Infliximab: 20% remission by 30 wks (NEJM 2005;353:2462) 
CsA
Severe flare: 2 mg/kg infusion 	 24 h; ‚úìMg; avoid if low chol (seizures)
Surgery
J pouch anal anastamosis; 6% fail; pouchitis: Rx w/ abx, probiotics
Crohn‚Äôs Disease
Abx
FQ/MNZ or amox/clav; best for perianal disease, limited data for colonic CD
Steroids
Mild dis. (tolerating POs, w/o 10% wt loss): consider budesonide w/ ileal dis.
(1st-pass metabolism limits systemic adverse effects)
Mod dis. (wt loss, abd pain, nausea, anemia): PO prednisone
Severe dis. (fever, obstruction, cachexia): IV pred 1 mg/kg
w/o immunomod at 1 y 30% remission, 30% steroid-depend, 40% surgery
Anti-TNF
Indic as above for UC, though early Rx prior to steroid failure gaining favor.
Infliximab (chimeric), adalimumab (humanized), or certolizumab (pegylated).
Inflixi  AZA S 60% steroid-free clin remission by 6 mos (NEJM 2010;362:1383).
Other
Surgery: diverting ileostomy, especially good for perineal disease
anti-41 integrin (natalizumab): rare risk of PML, restricted use in CD
In clinical trials: anti-IL12/23 (ustekinamab), anti-47 integrin (vedolizumab)
Maintenance of Remission (Chronic Treatment)
Ulcerative Colitis
5-ASA
Effective in maintaining remission in mild/mod UC
6MP/AZA
Takes 2‚Äì4 mos before treatment response
Anti-TNF
Infliximab: T colectomy rates & c mucosal healing
Crohn‚Äôs Disease
6MP/AZA
As above w/ UC; also effective for maintenance in Pts w/ fistulae
Anti-TNF
T surg, T hosp, cmucosal healing; 30% remission at 1 y 
If flare on infliximab: c dose, c freq, or  to adalimumab (Annals 2007;146:829)
MTX
15‚Äì25 mg IM/SC or PO qwk; 1‚Äì2 mos to take effect (NEJM 2000;342:1627)
Complications of therapy (Clin Gastro Hep 2009:7:874)
‚Ä¢ Anti-TNF: reactivation TB; must doc  PPD prior to Rx. If c LFTs, must exclude viral
hepatitis. Small c‚Äôd risk of NHL. Other: infusion rxn; lupus-like rxn, psoriasis, MS, CHF.
‚Ä¢ 6MP/AZA: BM suppression, lymphoma, pancreatitis, hepatitis; ‚úìTPMT genotype
prior to dosing to T risk of generation of toxic metabolites 
‚Ä¢ 5-ASA: diarrhea, abd pain, pancreatitis
Cancer screening (Gastro 2010;138:738)
‚Ä¢ Colon cancer: risk in UC 2% at 10 y, 8% at 20 y, 18% at 30 y. Similar for colonic
CD, except risk of small bowel cancer as well. Dysplasia best marker for risk. Other
risk factors include: PSC,  FHx, greater extent of disease, stricture, & pseudopolyps.
‚Ä¢ Surveillance: colonoscopy with random bxs 8 y after dx to eval for dysplasia, q1‚Äì3y
thereafter based on risk factors. If high-grade dysplasia or dysplasia assoc. lesion/mass
S colectomy. Chemoprophylaxis: 5-ASA & ursodeoxycholic acid (if PSC) beneficial.
IBD
3-11

--- Fim da P√°gina 89 ---

INTEST ISCHEM
3-12
INTESTINAL ISCHEMIA
ACUTE MESENTERIC ISCHEMIA (25%)
Etiologies
‚Ä¢ SMA embolism (50%): from LA (AF), LV (T EF), or valves; SMA most prone to embolism
‚Ä¢ Nonocclusive mesenteric ischemia (25%): transient intestinal hypoperfusion due to
T CO, atherosclerosis, sepsis, drugs that T gut perfusion (pressors, cocaine, dig, diuretic)
‚Ä¢ SMA thrombosis (10%): usually at site of atherosclerosis, often at origin of artery
‚Ä¢ Venous thrombosis (10%): hypercoagulable states, portal hypertension, IBD,
malignancy, inflammation (pancreatitis, peritonitis), pregnancy, trauma, surgery
‚Ä¢ Focal segmental ischemia of the small bowel (5%): vascular occlusion to small
segments of the small bowel (vasculitis, atheromatous emboli, strangulated hernias, XRT)
Clinical manifestations
‚Ä¢ Occlusive: sudden abd pain out of proportion to abdominal tenderness on exam
at least initially (2‚Äì4 h) until severe ischemia S frank infarction w/ peritoneal signs 
‚Ä¢ Nonocclusive: abd distension & pain, though up to 25% may be pain-free,  N/V;
often in setting of CHF  h/o chronic mesenteric ischemia sx
‚Ä¢ Hematochezia due to mucosal sloughing (right colon supplied by SMA)
‚Ä¢ ‚ÄúIntestinal angina‚Äù: postprandial abd pain, early satiety, & T wt from gastric vascular ‚Äústeal‚Äù;
may occur wks to mos before onset of acute pain in pts w/ chronic mesenteric ischemia
Physical exam
‚Ä¢ May be unremarkable, or may only show abdominal distention;  FOBT 75% of Pts
‚Ä¢ Bowel infarction suggested by peritoneal signs (diffuse tenderness, rebound, guarding)
Diagnostic studies
‚Ä¢ Dx relies on high level of suspicion; rapid dx essential to avoid infarction (occurs w/in h)
‚Ä¢ Laboratory: often nl; 75% c WBC; c amylase & LDH; 50% acidosis w/ c lactate (late)
‚Ä¢ KUB: nl early before infarct;‚Äúthumbprinting,‚Äù ileus, pneumatosis in later stages
‚Ä¢ CT angiogram (arterial phase imaging): non-invasive test of choice; can detect
thrombi in mesenteric vessels, colonic dilatation, bowel wall thickening, pneumatosis/
portal venous gas; venous phase imaging for dx of mesenteric vein thrombosis
‚Ä¢ Angiography: gold standard; potentially therapeutic; indicated if suspect occlusion
Treatment
‚Ä¢ Fluid resuscitation, optimize hemodynamics (minimize pressors); broad-spectrum abx
‚Ä¢ Emergent surgery for prompt resection of necrotic bowel if evidence of peritonitis
‚Ä¢ Anticoagulation for arterial & venous thrombosis and embolic disease
‚Ä¢ Papaverine (vasodilator) catheter-directed infusion into SMA, typically in nonocclu-
sive ischemia when spasm is considered the primary cause of the ischemia
‚Ä¢ SMA embolism: consider fibrinolytics; if no quick improvement S surgical
embolectomy if possible, o/w aortomesenteric bypass
‚Ä¢ SMA thrombosis: percutaneous or surgical revascularization (J Vasc Surg 2009;50:341)
‚Ä¢ Nonocclusive: correct underlying cause (especially cardiac)
‚Ä¢ Consider angioplasty/stent vs. surg revasc in cases of chronic mesenteric ischemia if:

2 vessels or occl SMA, supportive clinical hx, & other etiologies for abd pain excluded
Prognosis
‚Ä¢ Mortality 20 to 70% if bowel infarcted; dx prior to infarction strongest predictor of survival
ISCHEMIC COLITIS (75%)
Definition and pathophysiology
‚Ä¢ Non-occlusive disease 2 to s in systemic circulation or anatomic/fxnal s in local
mesenteric vasculature; often underlying etiology unknown, frequently seen in elderly 
‚Ä¢ ‚ÄúWatershed‚Äù areas (splenic flexure & recto-sigmoid) most susceptible, 25% involve R side
Clinical manifestations, diagnosis, and treatment
‚Ä¢ Disease spectrum: reversible colopathy (35%), transient colitis (15%), chronic ulcerating
colitis (20%), stricture (10%), gangrene (15%), fulminant colitis (5%)
‚Ä¢ Usually p/w cramping LLQ pain w/  FOBT or overtly bloody stool; fever
and peritoneal signs should raise clinical suspicion for infarction
‚Ä¢ Dx: r/o infectious colitis; consider flexible sig/colonoscopy if sx persist and no alternative
etiology identified (only if peritonitis not present, o/w avoid overdistension of colon)
‚Ä¢ Treatment: bowel rest, IV fluids, broad-spectrum abx, serial abd exams; surgery for
infarction, fulminant colitis, hemorrhage, failure of medical Rx, recurrent sepsis, stricture
‚Ä¢ Resolution w/in 48 h w/ conservative measures occurs in 50% of cases

--- Fim da P√°gina 90 ---

PANCREATITIS
Pathogenesis
‚Ä¢ Acinar injury via direct or indirect toxicity S release or impaired secretion (ie, duct
obstruction) of enzymes S autodigestion S fat necrosis
‚Ä¢ Profound acute inflammatory response
Etiologies
‚Ä¢ Gallstones (40%): , usually small stones (5 mm) are culprit, also microlithiasis
‚Ä¢ Alcohol (30%): , usually chronic, w/ acute flares
‚Ä¢ Drugs (occur via hypersensitivity, toxic metab, or direct toxicity): furosemide, thiazides,
sulfa, DDI, asparaginase, estrogen, 6-MP/AZA,ACEI, dapsone, 5-ASA, valproic acid 
‚Ä¢ Obstructive: panc/ampullary tumors, mets (breast, lung), annular pancreas, divisum w/
concurrent minor papilla stenosis, and ascaris 
‚Ä¢ Metabolic: hypertriglyceridemia (TG need to be 1000 and usually 4500; seen w/
type I and type V familial hypertriglyceridemia), hypercalcemia
‚Ä¢ Infections: coxsackie, mumps, EBV, CMV, HAV, HBV, mycoplasma,TB, candida/toxo/crypto
‚Ä¢ Autoimmune: can p/w chronic disease or panc mass; c IgG4,  ANA, duct abnl
‚Ä¢ Ischemia: vasculitis, cholesterol emboli, hypovolemic shock, cardiopulmonary bypass
‚Ä¢ Post ERCP: 5% w/ clinical, overt pancreatitis; 35‚Äì70% with asx c amylase
‚Ä¢ Post trauma: blunt abd trauma, pancreatic/biliary surgery
‚Ä¢ Familial: autosomal dominant w/ variable penetrance (PRSS1, CFTR, SPINK1 genes)
‚Ä¢ Scorpion sting (in Trinidad): mechanism believed to be hyperstimulation of pancreas
Clinical manifestations
‚Ä¢ Epigastric abdominal pain, radiating to back, constant, some relief w/ leaning forward
‚Ä¢ Nausea and vomiting
‚Ä¢ Ddx: acute cholecystitis, perforated viscus such as DU, intestinal obstruction, mesen-
teric ischemia, IMI,AAA leak, distal aortic dissection, ruptured ectopic pregnancy
Physical exam
‚Ä¢ Abdominal tenderness and guarding, T bowel sounds (adynamic ileus) 
 palpable abdominal mass;  jaundice if biliary obstruction
‚Ä¢ Signs of retroperitoneal hemorrhage (Cullen‚Äôs  periumbilical; Grey Turner‚Äôs  flank) rare
‚Ä¢ Fever, tachycardia, hypotension  shock
Diagnostic studies (Gastro 2007;132:2022)
‚Ä¢ Laboratory
c amylase: levels 3 	 ULN suggestive of pancreatitis; level Z severity
false : acute on chronic (eg, alcoholic); hypertriglyceridemia (T amylase activity)
false : other abd or salivary gland process, acidemia, renal failure, macroamylasemia 
(amylase binds to other proteins in serum, cannot be filtered out)
c lipase: more specific than amylase
false : renal failure, other abd process, diabetic ketoacidosis, HIV, macrolipasemia
ALT 3 	 ULN suggests gallstone pancreatitis (Am J Gastro 1994;89:1863); A, bili not helpful
Other labs (see Prognosis): c WBC, c or T Hct, c BUN, T Ca, c glc
‚Ä¢ Imaging studies
KUB/CXR: can see ‚Äúsentinel loop‚Äù air in small bowel in LUQ, atelectasis, effusion
Abd CT: not required for dx, but test of choice to make dx. Helps exclude other
dx, stage severity, & r/o complications. CT w/ IV contrast on day 3 of presenta-
tion in severe cases to evaluate for pancreatic necrosis (avoid on presentation
b/c theoretical concern of c necrosis w/ IV contrast; defer if concomitant ARF).
Abd U/S: typically not useful to visualize pancreas (obscured by bowel gas), but help-
ful to investigate biliary etiology, ie, gallstones and BD dilatation; can see pseudocyst
MRI/MRCP: can detect necrosis; also used to assess for stones & ductal disruption
Endoscopic U/S (EUS):limited role acutely;useful for occult biliary disease (microlithiasis)
Treatment (Lancet 2008;371:143)
‚Ä¢ Supportive therapy: in mild cases, bowel rest is usually sufficient
Fluid resuscitation (may need up to 10 L/d if hemodynamically severe pancreatitis)
Nutrition: enteral preferred over TPN if NPO 7 d; T infectious complications &
disease severity, & trend toward T mortality (BMJ 2004;328:1407). Ideally NJ tube, but NG okay.
Analgesia: IV meperidine, morphine (theoretical risk of sphincter of Oddi spasm,
but has not been shown to adversely affect outcome), hydromorphone
‚Ä¢ Prophylactic systemic abx (eg, imipenem) to T mortality & prevent conversion of
sterile necrosis to infected necrosis remains controversial (Am J Surg 2009;197:806 &
Gastro 2007; 132:2022); ? reserve for severe pancreatitis w/ 30% necrosis by CT, & no
more than 14 d
‚Ä¢ Surgery: infected necrosis (qv) nearly always requires debridement. Improved outcomes by
delaying (if possible) surgery 
2 wks to allow organization of necrosis. Cholecystectomy
if gallstones (w/in 48 h if mild, o/w w/in 14 d; Surg 2009;145:260; Ann Surg 2010;251:615)
PANCREATITIS
3-13

--- Fim da P√°gina 91 ---

‚Ä¢ ERCP  sphincterotomy: in acute setting, reserved for severe cholangitis/sepsis and T
bili 5 (ie., presumptive obstructive BD stone). Otherwise, early ERCP does not
reduce risk of local or systemic pancreatitis complications (Ann Surg 2007;245:10).
Complications
‚Ä¢ Systemic: shock, ARDS, renal failure, GI hemorrhage, DIC
‚Ä¢ Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia
‚Ä¢ Acute fluid collection (30‚Äì50%): seen early, no capsule, no Rx required
‚Ä¢ Pseudocyst (10‚Äì20%): fluid collection, persists for 4‚Äì6 wks, encapsulated
suggested by persistent pain & elevation of amylase or lipase, or mass on exam
most resolve spont.; if 6 cm or persists 6 wks  pain S endo/perc/surg drainage
‚Ä¢ Sterile pancreatic necrosis (20%): area of nonviable pancreatic tissue
? prophylactic abx (see above); supportive measures, surgery if Pt unstable
‚Ä¢ Infection (5% of all cases, 30% of severe): usually 2 enteric GNR
infected pancreatic necrosis: fever & c WBC not specific; ‚à¥FNA in deteriorating Pt
w/ necrosis (small risk of seeding sterile necrosis); if gram stain/cx  S abx  evacu-
ation (percutaneously, followed by surgical debridement after 4 wks; NEJM 2010;362:1491)
pancreatic abscess: circumscribed collection of pus (usually w/o pancreatic tissue)
treat with abx  drainage (CT-guided if possible), usually seen 
4 wks into course
‚Ä¢ Ascites or pleural effusion: occurs due to disrupted pancreatic duct; consider early ERCP
w/ stent across duct; can also occur from draining pseudocyst
Prognosis (Gastro 2007;132:2022)
‚Ä¢ Severe pancreatitis (20%)  organ failure or local complications (necrosis, pseudocyst) 
‚Ä¢ Scoring systems: HAPS, BISAP,APACHE II, Ranson‚Äôs criteria, CT Severity Index
HAPS: no abd tenderness or rebound on exam plus nl Hct and Cr on admission
predicts non-severe course w/ 98% accuracy (Clin Gas Hep 2009;6:702)
BISAP: 5-point scoring system on admission (BUN 25, GCS 15, SIRS, age 60,
and pleural effusion) identifies Pts at risk for c‚Äôd mortality (Am J Gastro 2009;104:966)
APACHE II (www.mdcalc.com/apache-ii-score-for-icu-mortality): severe if score 
8
Ranson‚Äôs Criteria
Prognosis
At diagnosis
At 48 hours
# of criteria
Mortality
age 55
Hct T 10%
2
5%
WBC 16,000/mm3
BUN c 5 mg/dL
3‚Äì4
15‚Äì20%
glucose 200 mg/dL
base deficit 4 mEq/L
5‚Äì6
40%
AST 250 U/L
Ca 8 mEq/L

7
99%
LDH 350 U/L
PaO2 60 mmHg
fluid sequestration 6 L
(Am J Gastro 1982;77:633)
CT 
Description
Points
Necrosis
Points
Total
Mortality
Grade
Index
A
Normal pancreas c/w mild 
0
33%
2
0‚Äì3
3%
pancreatitis
B
Enlarged pancreas but w/o 
1
33‚Äì50%
4
4‚Äì6
6%
inflammation
C
Pancreatic or peripancreatic 
2
50%
6
7‚Äì10
17%
inflammation
D
Single peripancreatic fluid 
3
collection
E

2 Peripancreatic fluid 
4
collections or gas in 
pancreas/retroperitoneum
(Radiology 1990;174: 331)
Chronic pancreatitis
‚Ä¢ 70‚Äì80% due to alcohol, also consider autoimmune pancreatitis
‚Ä¢ Often, but not always, recurrent acute attacks S inflammatory infiltrate S fibrosis S
exocrine then endocrine insufficiency
‚Ä¢ Sxs include epigastric pain, N/V; over time will be painless and p/w steatorrhea and wt loss
‚Ä¢ Amylase/lipase c early, but may be nl later.  fecal fat, T‚Äôd stool elastase & 
chymotrypsin, Ca2 in pancreas on KUB/CT
‚Ä¢ ERCP/MRCP/EUS high Se for dx: stricture, dil ducts, honeycombing of parenchyma
‚Ä¢ Treatment is low-fat diet and enzyme replacement
PANCREATITIS
3-14

--- Fim da P√°gina 92 ---

LFTS
3-15
ABNORMAL LIVER TESTS
Tests of hepatocellular injury or cholestasis
‚Ä¢ Aminotransferases (AST,ALT): intracellular enzymes released 2 necrosis/inflammation
ALT more specific for liver than is AST (heart, skeletal muscle, kidney, brain, RBC/WBC)
ALT  AST S viral hepatitis or fatty liver/nonalcoholic steatohepatitis (pericirrhotic)
AST:ALT 2:1 S alcoholic hepatitis, cirrhosis, NAFLD; nonhepatic source
ALT/AST 15	 ULN S etiologies of acute liver failure (ccc LDH S ischemia/toxic)
‚Ä¢ Alkaline phosphatase (A): enzyme bound in hepatic canicular membrane
besides liver, also found in bone, intestines, kidney, and placenta
confirm liver origin with: c 5‚Äô-NT, c GGT, or A heat fractionation
c levels seen with biliary obstruction or intrahepatic cholestasis (eg, hepatic infiltration)
Tests of hepatic function
‚Ä¢ Albumin: marker for liver protein synthesis, T slowly in liver failure (t1/2 20 d)
‚Ä¢ Prothrombin time (PT): depends on synthesis of coag factors by the liver (except FVIII);
b/c t1/2 of some of these factors (eg,V,VII) is short, c PT can occur w/in hrs of liver dysfxn
‚Ä¢ Bilirubin: product of heme metabolism carried by albumin to liver where it must be
taken up for conjugation (to make soluble) and then excreted into bile (most sensitive
to detect parenchymal disease); either conjugated (direct) or unconjugated (indirect)
Patterns of liver injury
‚Ä¢ Hepatocellular: cc aminotransferases,  c bilirubin or A
ccc ALT & AST (1000): severe viral hepatitis, acetaminophen, ischemia, Wilson‚Äôs, AIH 
‚Ä¢ Cholestasis: cc A and bilirubin,  c aminotransferases
‚Ä¢ Isolated hyperbilirubinemia: cc bilirubin (direct or indirect), nl A and aminotransferases
‚Ä¢ Infiltrative: c A,  c bilirubin or aminotransferases
‚Ä¢ Jaundice is a clinical sign seen when bilirubin 2.5 mg/dL (especially in sclera or under
tongue); if hyperbilirubinemia conjugated S c urine bilirubin
Figure 3-3 Approach to abnormal liver tests with hepatocellular pattern
Hepatocellular injury
(predom ‚Üë AST & ALT, ¬± ‚Üë bili and AœÜ)
Viral
hepatitis
HAV, HBV, HCV,
HDV, HEV,
CMV, EBV, HSV,
VZV
alcohol
acetaminophen
meds, toxins
ischemic
congestive
Budd-Chiari
SOS
hemochrom.
Œ±1-AT defic.
Wilson‚Äôs
celiac sprue
Auto-
immune
Drugs &
Toxins
Vascular
Hereditary
NAFLD
autoAbs
tox screen
hypotension
CHF
systemic
disease
obesity, DM
hyperlipidemia
viral markers
Cholestasis
(predom ‚Üë AœÜ and bili, ¬± ‚Üë AST & ALT)
Biliary
obstruction
Hepatocellular dysfunction
ductal dilatation
ductal dilatation
Intrahepatic
cholestasis
Biliary epithelial
damage
meds
(e.g., sex hormones, erythro)
sepsis, postop.
PBC
hepatitis (‚Üë ALT)
cirrhosis (‚ÜëPT, ‚Üìalb)
¬± ‚Üë AœÜ
choledocholithiasis
cholangiocarcinoma
pancreatic cancer
sclerosing cholangitis
‚Üë‚Üë AœÜ
‚àí
+
‚Ä¢ Acute workup: toxins (EtOH, acetaminophen) & vascular abnl (U/S w/ Doppler)
viral tests: HAV IgM, HBV sAg, HCV RNA, HEV Ab,  EBV, CMV, HSV,VZV
autoimmune (ANA, ASMA, ALKM) & ceruloplasmin
‚Ä¢ Chronic workup: HBV sAg, HCV Ab; Fe,TIBC; glc, HbA1c,TG;ANA, ASMA, ALKM; anti-
tissue transglutaminase; ceruloplasmin & 1-AT;TSH; vascular abnl (U/S w/ Doppler) 
Figure 3-4 Approach to abnormal liver tests with cholestatic pattern

--- Fim da P√°gina 93 ---

Abnormal liver tests in asymptomatic patients (Gastro 2002;123:1364)
‚Ä¢ Careful review of history (meds, ETOH/drug use, exposures, risk factors for liver disease)
and physical exam. Evaluate for any clues to etiology 1st (eg, d/c med and repeat LFTs).
‚Ä¢ Confirm hepatic source: if primarily c A (‚úì GGT) or ASTALT (‚úì CK, aldolase,TFT)
‚Ä¢ Hepatocellular
Evaluate for most common causes: hepatitis A/B/C, hemochromatosis; screen for
evidence of chronic liver disease (platelets, PT/INR, albumin)
If  evaluation S lifestyle modification (wt loss, DM control)  repeat test 6 mo 
If evidence of chronic liver disease or persistent lab abnl, screen for less common
causes:AIH,Wilson‚Äôs, celiac, 1-AT; ‚úìU/S & consider liver bx
If still  S liver bx if ALT or AST 2	 ULN for 6 mo; o/w observe
‚Ä¢ Cholestatic: ‚úìRUQ U/S, AMA
if biliary dilatation or obstruction S MRCP 
if AMA  and U/S , or AMA  and U/S w/ abnl parenchyma S liver bx
if AMA & U/S : A 1.5	 ULN S consider bx; A 1.5	 ULN S observe
‚Ä¢ Isolated hyperbilirubinemia: ‚úìconjugated vs. unconjugated
conjugated S perform abdominal U/S S MRCP if dilatation or obstruction; if nl 
ultrasound ‚úìAMA and consider MRCP or liver bx
unconjugated S ‚úìHct, retic count, smear, LDH, haptoglobin
Common medications that cause abnormal liver tests
Hepatocellular
Cholestatic
Mixed
Acarbose
Methotrexate
Amox/Clav
Estrogens
Amitriptyline
Acetaminophen
NSAID
Anabolic
Irbesartan
Azathioprine
Allopurinol
Omeprazole
Steroids
Mirtazapine
Captopril
Amiodarone
Paroxetine
Chlorpromazine
Phenothiazine
Carbamazepine
Baclofen
Pyrazinamide
Clopidogrel
Terbinafine
Clindamycin
Bupropion
Rifampin
OCP
Tricyclics
Enalapril
Fluoxetine
Risperidone
Erythromycins
Nitrofurantoin
HAART
Sertraline
Phenobarbital
Isoniazid
Statins
Phenytoin
Ketoconazole
Tetracyclines
Sulfonamides
Lisinopril
Trazodone
Trazodone
Losartan
Valproic Acid
Verapamil
Does not include herbal supplements or toxins (NEJM 2006;354:731)
LFTS
3-16
Isolated hyperbilirubinemia
(predom ‚Üë bili, near normal AœÜ, AST & ALT)
Defective
excretion
unconjugated
Defective
conjugation
Overproduction
Dubin-Johnson
Rotor‚Äôs
Abnl biliary transport protein
Gilbert‚Äôs (<5 mg/dL)
Crigler-Najjar
Hemolysis (<4 mg/dL)
Ineffective erythropoiesis
Hematoma reabsorption
PE
conjugated
Infiltrative pattern
(predom ‚Üë AœÜ, near normal bili, AST & ALT)
Malignancy
HCC
Metastatic
Lymphoma
Granulomas
Abscess
Other
TB
Sarcoidosis
Histoplasmosis
Amoebic
Bacterial
Medications
Idiopathic
Figure 3-5 Approach to abnormal liver tests with isolated hyperbilirubinemia
Figure 3-6 Approach to abnormal liver tests with infiltrative pattern

--- Fim da P√°gina 94 ---

HEPATITIS
3-17
(Adapted from Friedman LS, Keeffe EB. Serologic course of HBV. Handbook of Liver Disease 2004; Hoofnagle JH,
DiBisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991;11:73.)
Diagnosis
HbsAg anti-HBs
anti-HBc HBeAg
anti-HBe HBV DNA
Acute hepatitis


IgM



Window period


IgM



Recovery


IgG



Immunization






Chronic hepatitis


IgG



HBeAg 
Chronic hepatitis


IgG


*
HBeAg 
*Precore mutant: HBeAg not generated, but anti-HBe can develop due to cross-reactivity w/ HBcAg;
a/w high serum HBV DNA levels
HEPATITIS
VIRAL
Hepatitis A (ssRNA; accounts for 30‚Äì45% of acute viral hepatitis)
‚Ä¢ Transmission: fecal-oral route; contaminated food, water, shellfish; day-care ctr outbreaks
‚Ä¢ Incubation: 2‚Äì6 wks; no chronic carrier state
‚Ä¢ Sx: T appetite, malaise, fever, N/V, RUQ pain,  jaundice; rarely fulminant
‚Ä¢ Diagnosis: acute hepatitis   IgM anti-HAV; past exposure   IgG anti-HAV ( IgM)
‚Ä¢ Treatment for acute HAV supportive. Prevention: vaccinate children & Pts w/ chronic
HBV, HCV, or other chronic liver disease (2 doses at 0, 6‚Äì12 mos)
‚Ä¢ Postexposure ppx: age 1‚Äì40 y S vaccine; age 1 or 40 y or immunosupp S Ig
Hepatitis B (dsDNA; accounts for 45% of acute viral hepatitis; Lancet 2009;373:582) 
‚Ä¢ Transmission: blood, sexual, perinatal
‚Ä¢ Incubation: 6 wks‚Äì6 mos (mean 12‚Äì14 wks)
‚Ä¢ Acute infxn: 70% subclinical, 30% jaundice, 1% fulminant hepatitis (up to 60% mortality)
‚Ä¢ Chronic infxn: 5% (adult-acquired; higher if immunosupp), 90% (perinatally acquired);
40% chronic carriers S cirrhosis; c risk of cirrhosis if HCV, HDV, or HIV coinfection
‚Ä¢ Risk of hepatocellular carcinoma: 25‚Äì40%; highest risk w/ perinatal transmission & c‚Äôd HBV
DNA; risk of HCC w/ or w/o concurrent cirrhosis. Screen w/ AFP & US vs MRI q6mo.
‚Ä¢ Extrahepatic syndromes: PAN (1%), MPGN, arthritis, dermatitis, PMR
‚Ä¢ Serologic and virologic tests
HBsAg: appears before sx; used to screen blood donors; persists 6 mo  chronic HBV
HBeAg: evidence of viral replication and c infectivity
IgM anti-HBc: first Ab to appear; indicates acute infection
window period  HBsAg become , anti-HBs not yet , anti-HBc only clue to infection
IgG anti-HBc: indicates previous (HBsAg ) or ongoing (HBsAg ) HBV infection
anti-HBe: indicates waning viral replication, T infectivity
anti-HBs: indicates resolution of acute disease & immunity (sole marker after vac)
HBV DNA: presence in serum correlates w/ active viral replication in liver
Figure 3-7 Serologic course of acute HBV infection with resolution
Jaundice
Symptoms
‚Üë ALT
HBeAg
HBsAg
IgG anti-HBc
anti-HBs
anti-HBe
IgM anti-HBc
‚Äúwindow period‚Äù
1
2
3
4
5
6
7
8
9
10
11
12
Months after exposure
Titer
HBV DNA

--- Fim da P√°gina 95 ---

‚Ä¢ Treatment for acute HBV: supportive; hospitalize for  MS or c INR (liver transplant ctr)
‚Ä¢ Treatment for chronic HBV if: (1) HBeAg  w/ DNA 20,000 IU/mL & elevated ALT;
(2) HBeAg  w/ DNA 2,000 IU/mL & elevated ALT or liver bx demonstrates
stage 2 fibrosis (NEJM 2008;359:1486 & Hep 2009;50;661)
‚Ä¢ PEG IFN-2a: best rate of HBeAg seroconversion at 1 y (27%), low tolerability limits use
‚Ä¢ 1st line is entecavir or tenofovir; well-tolerated & low resistance, HBeAg sero-
conversion at 1 yr is 21%; seroconversion at 3 y for entecavir is 39%; lamivudine
15‚Äì30% resis at 1 y; telbivudine c CK & neuropathy; adefovir (add to lamivudine-
resistant Pts) nephrotoxic & resistance occurs, too
‚Ä¢ Goal: if HBeAg  S HBeAg , anti-HBe ; if HBeAg  or ‚àÖseroconversion S
indefinite
‚Ä¢ If undergo liver transplant: HBIG  nucleoside analog effective in preventing reinfection
‚Ä¢ HIV/HBV coinfection: Rx w/ 2 drugs active against both HBV & HIV (NEJM 2007;356:1445)
‚Ä¢ If inactive carrier scheduled to receive immunosuppresion/chemotherapy S Rx
‚Ä¢ Prevention: vaccinate high-risk Pts (3 doses 0, 1 & 6 mos)
‚Ä¢ Postexposure (risk infxn 30%) ppx: HBIG S vaccine (if unvac. or known nonresponder)
Hepatitis C (RNA; accounts for 10‚Äì30% of acute viral hepatitis; Lancet 2008;372:321)
‚Ä¢ Transmission: blood  sexual; 20% w/o clear precipitant
‚Ä¢ Incubation: 1‚Äì5 mos; mean 6‚Äì7 wks
‚Ä¢ Natural hx
acute infection: 80% subclinical; 10‚Äì20% symptomatic hepatitis w/ jaundice; fulminant
hepatitis very rare; spontaneous clearance in up to 30%
chronic:up to 80% S chronic hepatitis,20‚Äì30% of whom develop cirrhosis (after 20 y)
c risk of cirrhosis in men, EtOH, HIV; HCC in 2‚Äì5% of cirrhotics/y
‚Ä¢ Extrahepatic syndromes: cryoglobulinemia, porphyria cutanea tarda (blistering rash in sun-
exposed areas), MPGN, MGUS, IPF, NHL, and DM
‚Ä¢ Serologic and virologic tests
anti-HCV (ELISA):  in 6 wks,does not  recovery or immunity;can be  after recovery
HCV RNA:  w/in 2 wks, marker of active infection
HCV RIBA: used to confirm  anti-HCV ELISA in Pts w/ undetectable HCV RNA
HCV genotype (1‚Äì4): guides duration & predicts response to Rx (genotype 2,3  1,4)
‚Ä¢ Diagnosis: acute hepatitis   HCV RNA,  anti-HCV 
resolved hepatitis   HCV RNA,  anti-HCV
chronic hepatitis   HCV RNA,  anti-HCV
‚Ä¢ Treatment indications (Hep 2009;49:1335)
Acute: if no spont clearance at 8‚Äì12 wks, consider PEG-IFN	-2a/b 
 12‚Äì24 wks 
Chronic:RNA ,plus bx w/ either chronic hepatitis & fibrosis stage 1 or compensated
liver disease (in genotype 2 or 3, may proceed to Rx w/o bx b/c high response rate)
‚Ä¢ Drugs: PEG-IFN-2a  ribavirin (Gastro 2010;138:108). Goal is sustained virologic
response (SVR)  absence of viremia 24 wks after completion of Rx. PIs (telaprevir,
boceprevir) promising (NEJM 2009;360:1827 & 1839; 2010;362:1292).
‚Ä¢ Genotypes 1 or 4: Rx 48 wks. If early vir resp (EVR) not achieved by wk 12 (ie, RNA
T 2 log) stop Rx, as EVR best predictor of lack of SVR. If partial EVR (RNA T 2
log at 12 wks & undetectable at 24 wks), consider prolonging Rx to 72 wks.
Overall SVR rate 50‚Äì60%.
‚Ä¢ Genotypes 2 or 3: Rx 24 wks; SVR rate 80%
‚Ä¢ Predictors of response: RNA 400k IU/mL, rapid vir resp (‚àÖRNA at wk 4),
‚àÖcirrhosis, , age 40 y, wt 75 kg, white/Hispanic, ‚àÖHIV, SNPs in IL28B
(Nat Gen 2009;41:1100; Gastro 2010;138:2307)
‚Ä¢ Risks of Rx: flu-like sx, psych sx (if depressed can give SSRI), thyroid dysfxn, marrow
suppression (can give EPO & GCSF), hemolysis (ribavirin), sexual dysfxn
‚Ä¢ Contraindic.: decompensated cirrhosis, preg., severe psych illness, active substance
abuse, severe cardiac/pulm disease, uncontrolled DM, seizure d/o, autoimmune disease
‚Ä¢ Vaccinate all chronic HCV patients against HBV and HAV if not immune
‚Ä¢ Postexposure (needlestick risk 3%) ppx: none; if HCV RNA S , consider Rx w/in 3 mos
Hepatitis D (RNA)
‚Ä¢ Transmission: blood or sexual; endemic in Africa & E. Europe
‚Ä¢ Pathogenesis: requires HBV to cause either simultaneous or superimposed infection
‚Ä¢ Natural hx: in HBV c severity of infxn and c progression to cirrhosis; clears w/ HBV 
‚Ä¢ Serologic/virologic tests: anti-HDV; follow HDV RNA during Rx (high relapse rate)
Hepatitis E (RNA)
‚Ä¢ Transmission: fecal-oral; travelers to Pakistan, India, SE Asia, Africa, and Mexico
‚Ä¢ Natural hx: acute hepatitis w/ c mortality (10‚Äì20%) if pregnant; rare chronic in transplant Pts
‚Ä¢ Diagnosis: IgM anti-HEV (through CDC)
Other viruses (CMV, EBV, HSV, VZV)
HEPATITIS
3-18

--- Fim da P√°gina 96 ---

AUTOIMMUNE HEPATITIS (AIH)
Classification (NEJM 2006;354:54)
‚Ä¢ Type 1: anti‚Äìsmooth muscle Ab (ASMA), ANA; anti‚Äìsoluble liver antigen (anti-SLA)
a/w more severe disease and relapsing disease
‚Ä¢ Type 2: anti‚Äìliver/kidney microsome type 1 (anti-LKM1); children (age 2‚Äì14 y);
Mediterranean
‚Ä¢
Overlap syndrome: autoimmune hepatitis  PBC or PSC
Diagnosis and Treatment 
‚Ä¢
3‚ÅÑ4 female; 40% present acutely (occ fulminant); 34% asymptomatic; ALT can be 1,000 
‚Ä¢ Extrahepatic syndromes: thyroiditis, arthritis, UC, Sj√∂gren‚Äôs, Coombs,  hemolytic anemia
‚Ä¢ Dx: scoring system combining serologies, c IgG, ‚àÖviral hepatitis, & characteristic liver bx
(lymphoplasmocytic infiltrate & interface hepatitis) has high Sp & mod Se (Hep 2008;48:169)
‚Ä¢ Rx: if LFTs 10	 ULN, or if 5	 ULN w/ IgG 2	 ULN, or bridging/multiacinar necrosis on bx
‚Ä¢ Prednisone  azathioprine S 65% remission w/in 3 y; 50% relapse on withdrawal
of meds at 6 mos; up to 90% by 3 y; ‚à¥most will require long-term Rx
‚Ä¢ Liver transplant for ESLD; recurs in 40% of Pts, but generally easily treated
OTHER CAUSES OF HEPATITIS OR HEPATOTOXICITY
Alcoholic hepatitis (NEJM 2009;360:2758)
‚Ä¢ Sxs: can range from asx hepatomegaly to decompensation w/ ascites, encephalopathy,
and death. AST & ALT usually 300‚Äì500 w/ AST:ALT 2:1, in part b/c concomitant
B6 defic (ALT can be normal); T plt, c iron sat, c‚Äôd Tbili & INR indicate severe hepatitis.
‚Ä¢ Rx: if discriminant fxn ( 4.6 	 [PT-control]  Tb in mg/dL) 32 or encephalopathy
methylprednisolone 32 mg/d 	 4 wks S 4‚Äì6 wk taper; T death (NEJM 1992;326:507)
contraindications: GIB, chronic HBV, sepsis 
pentoxifylline 400 mg tid T mortality due to reduction in HRS (Coch 2009;4:CD007339)
‚Ä¢ Lille model predicts nonresponse to corticosteroids & mortality, powered by Tb from
day 1S7; nonresponders have 6-mo survival of 25% (www.lillemodel.com & Hep
2007;45:1348)
Acetaminophen hepatotoxicity (Clin Liv Dis 2007;11:525 & NEJM 2008;359:285)
‚Ä¢ Normal metabolism via glucuronidation and sulfation S nontoxic metabolites
‚Ä¢ Overdose (usually 10 g): CYP2E1 hydroxylation S reactive electrophilic species
(NAPQI) that are scavenged by glutathione until reserves exhausted S hepatotoxicity
‚Ä¢ CYP2E1 induced by fasting and alcohol allowing for ‚Äútherapeutic misadventure‚Äù in
malnourished alcoholics taking even low doses (2‚Äì6 g) of acetaminophen
‚Ä¢ Liver dysfunction may not be apparent for 2‚Äì6 d
‚Ä¢ Rx: NG lavage, activated charcoal if w/in 4 h. Consider early transfer to transplant ctr.
N-acetylcysteine: administer up to 72 h after ingestion, if time of ingestion
unknown, or if chronic ingestion 4 g per day
Rumack-Matthew nomogram predicts risk of hepatotoxicity from a given
serum level of acetaminophen when time of ingestion is known (see Appendix) 
Low threshold to start NAC even w/ low or undetectable serum acetaminophen levels
PO NAC (preferred): 140 mg/kg loading dose S 70 mg/kg q4h 	 17 additional doses
IV NAC: 150 mg/kg over 1h S 50 mg/kg over 4 h S 100 mg/kg over 16 h;
risk of anaphylaxis; use if unable to tolerate POs, GIB, preg, fulminant hepatic failure
Ischemic hepatitis
‚Ä¢ ‚ÄúShock liver‚Äù w/ AST & ALT 1000  cc LDH; delayed cc Tbili
‚Ä¢ Often requires c venous pressure  T portal/arterial pressure  hypoxia
‚Ä¢ Typically seen in hypotension, sepsis, CHF
Nonalcoholic fatty liver disease (NAFLD) (Gastro 2008;134:1682)
‚Ä¢ Fatty infiltration of the liver and absence of EtOH or other cause of liver disease.
Nonalcoholic steatohepatitis (NASH)  NAFLD  inflammation  fibrosis on liver bx
‚Ä¢ Prevalence: 20‚Äì30% of U.S. population. Risk factors: DM & metabolic syndrome
(hyperinsulinemia, obesity, c TGs), HAART, tamoxifen, amiodarone,TPN, rapid wt loss.
Variants in apolipoprotein C3 gene a/w c TG & risk of NAFLD (NEJM 2010;362:1082).
‚Ä¢ Clinical: 80% asx,ALT AST; NAFLD can progress to cirrhosis in 1‚Äì3% of Pts w/
NAFLD and up to 25% of Pts w/ NASH
‚Ä¢ Dx: U/S, MRI, CT suggest fatty infiltration but liver bx only way to dx NASH vs.
NAFLD
‚Ä¢ Rx: wt loss, glycemic/lipid control; both pioglitazone and vitamin E T steatosis &
inflammation, but not fibrosis (NEJM 2010;362:1675)
HEPATITIS
3-19

--- Fim da P√°gina 97 ---

LIVER FAILURE
3-20
ACUTE LIVER FAILURE
Definition
‚Ä¢ Acute hepatic disease  coagulopathy  encephalopathy; w/o known pre-existing liver dis.
‚Ä¢ Fulminant  develops w/in 8 wks; subfulminant  develops between 8 wks and 6 mos
Etiology (Hep 2008;47:1401)
‚Ä¢ Viral
HAV, HBV, HCV (rare), HDV  HBV, HEV (especially if pregnant)
HSV (immunosupp. Pt), EBV, CMV, adenovirus, paramyxovirus, parvovirus B19
‚Ä¢ Drugs/Toxins
Drugs: acetaminophen (most common cause; 40% of all cases), phenytoin, INH,
rifampin, sulfonamides, tetracycline, telithromycin, amiodarone, PTU, valproate
Toxins: fluorinated hydrocarbons, CCl4, Amanita phalloides
‚Ä¢ Vascular: ischemic hepatitis, Budd-Chiari syndrome, hepatic SOS, malignant infiltration
‚Ä¢ Autoimmune hepatitis (usually initial presentation)
‚Ä¢ Misc.: Wilson‚Äôs, acute fatty liver of pregnancy (HELLP, Reye‚Äôs), idiopathic (20%)
Clinical manifestations
‚Ä¢ Initial presentation usually nonspecific, w/ nausea, vomiting, malaise, followed by jaundice
‚Ä¢ Neurologic
encephalopathy: stage I  MS; stage II  lethargy, confusion; stage III  stupor;
stage IV  coma
asterixis in stage I/II/III encephalopathy; hyperreflexia, clonus, rigidity in stage III/IV
cerebral edema S c ICP, T CPP S cerebral hypoxia, uncal herniation, Cushing‚Äôs reflex
(hypertension  bradycardia), pupillary dilatation, decerebrate posturing, apnea
‚Ä¢ Cardiovascular: hypotension with low SVR
‚Ä¢ Pulmonary: respiratory alkalosis, impaired peripheral O2 uptake, pulm edema, ARDS
‚Ä¢ Gastrointestinal: GIB (T clotting factors, T plt, DIC), pancreatitis (? due to ischemia)
‚Ä¢ Renal:ATN, hepatorenal syndrome, hyponatremia, hypokalemia, hypophosphatemia
‚Ä¢ Hematology: coagulopathy (due to T synthesis of clotting factors  DIC)
‚Ä¢ Infection (90% of Pts): especially with Staph, Strep, GNRs, and fungi (T immune fxn,
invasive procedures); SBP in 32% of Pts; fever and c WBC may be absent
‚Ä¢ Endocrine: hypoglycemia (T glc synthesis), metabolic acidosis (c lactate), adrenal insuf.
Workup
‚Ä¢ Viral serologies (HBV DNA, HCV RNA)
‚Ä¢ Autoimmune hepatitis serologies, ceruloplasmin & urine copper
‚Ä¢ Toxicology screen (acetaminophen levels q1-2h until peak determined)
‚Ä¢ Imaging studies (RUQ U/S or abd CT, Doppler studies of portal and hepatic veins)
‚Ä¢ Liver biopsy (unless precluded by coagulopathy S in which case consider transjugular)
Treatment (Hep 2005;41;1179 & Nat Rev Gastro Hep 2009;6:542) 
‚Ä¢ ICU care at liver transplant ctr for hemodynamic & ventilatory support; CVVH for ARF
‚Ä¢ IV N-acetylcysteine (same dose as for acetaminophen): all Pts w/ hepatic failure and
grade 1‚Äì2 enceph: c cerebral blood flow and c transplant-free survival (Gastro 2009;137:856)
‚Ä¢ Cerebral edema: CT Se only 60%, ‚à¥consider ICP monitoring if stage III/IV enceph; head of
bed 30o and hypertonic saline for goal Na 145‚Äì155 mEq/L; other potential measures:
hyperventilation, mannitol, barbiturates, ? induction of hypothermia, IV indomethacin
‚Ä¢ Encephalopathy: intubate for grade III or IV; ? lactulose, but no efficacy data
‚Ä¢ Coagulopathy: vit K; FFP/plts/cryo if active bleeding; ? recomb. factor VIIa; PPI prophylaxis
‚Ä¢ Infection: low threshold for abx (broad spectrum, eg, vancomycin & 3rd-gen ceph.),
albeit no proven mortality benefit to empiric abx
‚Ä¢ Treatment of specific causes: nucleosides for HBV; corticosteroids for autoimmune
hepatitis; chelation Rx for Wilson‚Äôs; IV acyclovir for HSV; gastric lavage and 
charcoal  penicillin and silymarin for Amanita phalloides; delivery of child for 
pregnancy-related;TIPS and anticoagulation for Budd-Chiari
‚Ä¢ Liver transplantation if poor prognosis w/ grade II or III encephalopathy (see below)
‚Ä¢ Extracorporeal liver assist devices (cell-based vs. non) under study as bridge to transplant
Prognosis
‚Ä¢ Non-acetaminophen ALF mortality 80%, acetaminophen-induced ALF mortality 30%
‚Ä¢ Predictors of poor outcome
acetaminophen-induced: pH 7.3 after fluids or INR 6.5, Cr 3.4, or grade III/IV enceph.
non‚Äìacetaminophen-induced: INR 6.5 or 3 of the following: non-A/B viral hep;
non-acetaminophen drug toxicity; time from jaundice to enceph. 7 d; age 10 or
40 y; INR 3.5;T bili 17.4
‚Ä¢ 25‚Äì30% of Pts w/ ALF undergo liver transplantation w/ 5-y survival rate of 70%

--- Fim da P√°gina 98 ---

CIRRHOSIS
Definition (Lancet 2008;371:838)
‚Ä¢ Definition: fibrosis and nodular regeneration resulting from hepatocellular injury
‚Ä¢ Decompensated  jaundice, variceal bleed, encephalopathy, ascites; worse prognosis
Etiologies
‚Ä¢ Alcohol (60‚Äì70%): Laennec‚Äôs cirrhosis; micronodular 
‚Ä¢ Viral hepatitis (10%): chronic HBV, HCV, HDV infection
‚Ä¢ Autoimmune hepatitis: female, c IgG,  ANA, anti‚Äìsmooth muscle Ab
‚Ä¢ Metabolic diseases (5%): hemochromatosis,Wilson‚Äôs disease, 1-antitrypsin deficiency
‚Ä¢ Biliary tract diseases (5%): primary biliary cirrhosis, secondary biliary cirrhosis
(calculus, neoplasm, stricture, biliary atresia), primary sclerosing cholangitis
‚Ä¢ Vascular diseases: Budd-Chiari syndrome, R-sided CHF, constrictive pericarditis
‚Ä¢ Nonalcoholic fatty liver disease (NAFLD, 10‚Äì15%) cause of most ‚Äúcryptogenic
cirrhosis‚Äù 
Clinical manifestations
‚Ä¢ Subclinical or may p/w liver dysfunction (jaundice, coagulopathy, encephalopathy) and/or
portal HTN (ascites, varices); 35% p/w fever (SBP, acute EtOH); 25% p/w hematemesis
Physical exam
‚Ä¢ Liver: initially enlarged, palpable (L lobe predom), firm; eventually shrunken and 
nodular
‚Ä¢ Signs of liver failure: jaundice (bili 2), spider angiomata & palmar erythema (c estra-
diol), Dupuytren‚Äôs contractures, white nail lines (Muehrcke‚Äôs lines) & proximal nail
beds (Terry‚Äôs nails), c parotid & lacrimal glands, gynecomastia, testicular atrophy,
asterixis, encephalopathy, fetor hepaticus, clubbing, hypertrophic osteoarthropathy
‚Ä¢ Signs of portal hypertension: splenomegaly, ascites, dilated superficial abdominal veins
(caput medusae), epigastric Cruveilhier-Baumgarten venous hum
Laboratory studies
‚Ä¢ c bilirubin, c PT (poor correlation w/ bleeding; factor VIII nl as not synthesized by liver),
T alb,  c aminotransferases (AST  ALT if late) and c A (variable), T Na, c gamma glob
‚Ä¢ Anemia (marrow suppression, hypersplenism, Fe and/or folate deficiencies), neutropenia
(hypersplenism), thrombocytopenia (hypersplenism, TTpo production by liver, EtOH tox)
Workup
‚Ä¢ Abdominal U/S w/ Doppler: liver size (c L & caudate lobe), r/o HCC, ascites,
‚úìpatency of portal, splenic, and hepatic veins 
‚Ä¢ Assess fibrosis: biomarkers (FibroSURE  panel of 6 markers, c score predictive of
fibrosis, esp in Hep C); US/MR elastography 
‚Ä¢ Determine etiology: hepatitis serologies (HBsAg, anti-HBs, anti-HCV), autoimmune
hepatitis studies (IgG,ANA, anti‚Äìsmooth muscle Ab), Fe and Cu studies, 1-AT, AMA
‚Ä¢  Liver bx: percutaneous or transjugular (consider if ascites or coagulopathy) used
to dx etiology and presence of cirrhosis
Ascites (see ‚ÄúAscites‚Äù for details on dx eval)
‚Ä¢ Due to portal HTN (defined as hepatic venous pressure gradient [HVPG] 5 mmHg)
‚Ä¢ Develops in 60% w/in 10 y; 50% mortality at 5 y (Hepatology 2009;29:2087)
‚Ä¢ Treatment (Am J Gastro 2009;104:1802): T Na intake (1‚Äì2 g/d) in all
free H2O restriction only if Na 125
Diuretics: goal 1 L/d; urine Na/K 1 implies effective aldo block
spironolactone (100 mg PO qd)  furosemide (40 mg PO qd); c doses in proportion
‚àÖNSAID as interferes w/ diuretic action (common cause of refractory ascites)
‚Ä¢ Refractory ascites  ascites despite med/diet compliance; 20% mortality at 3 mo
Large-volume paracentesis (LVP) remove 4‚Äì6 L per session until dry or T sx
? albumin replacement: T chemical abnl; no  mortality (Gastro 1988;94:1493)
Beware LVP if SBP as c risk of ARF S consider dx tap to r/o SBP first
Transjugular intrahepatic portosystemic shunt (TIPS)
T ascites in 75%, c CrCl, c transplant-free survival (NEJM 2000;342:1701)
c encephalopathy (‚à¥TIPS contraindic. if  mild at baseline), no  quality of life
(Gastro 2003;124:634); by 1 y 40% occlude (metal stent); new coated stent T (20%)
occlusion and ? T mortality (Gastro 2004;126:469)
LVP 1st line Rx b/c TIPS complications (metal stent), but TIPS T mort (Gastro 2007;133:825) 
‚Ä¢ Hepatic hydrothorax: 2 diaphragmatic defect; often unilateral, R L,  ascites
Treatment: ‚àÖchest tube due to c complications; Rx same as ascites
Spontaneous bacterial empyema can occur (even w/o SBP) S consider dx thora-
centesis; Rx same as for SBP (see later)
CIRRHOSIS
3-21

--- Fim da P√°gina 99 ---

Spontaneous bacterial peritonitis (SBP; see ‚ÄúAscites‚Äù for details on dx)
‚Ä¢ Develops in 20% of cirrhotics; risk factors  AFTP 1 g/dL, h/o prior SBP, current GIB 
‚Ä¢ Can p/w encephalopathy, abd pain, fever, but often (25%) asx; ‚à¥consider paracentesis
in all hospitalized cirrhotics w/ ascites
‚Ä¢ Micro: 70% GNR (E. coli, Klebs), 30% GPC (Enterococcus, S. pneumo), nosocomial
(fungi, Pseud)
‚Ä¢ Rx: cefotaxime 2 gm IV q8h (or amox/clav) 	 5 d; if ‚àÖenceph/ARF can use ofloxacin PO
IV albumin 1.5 g/kg at time of dx and 1 g/kg on day 3 c survival (NEJM 1999;341:403) 
If not improving consider repeat paracentesis at 48 h: 25% T PMN count  Rx success
20% mortality during hospitalization
‚Ä¢ Ppx: if h/o SBP or AFTP 1.5  Na 130, Cr 1.2 or Child-Pugh B (Am J Gastro 2009;4:993)
norfloxacin 400 mg PO qd or Bactrim DS qd; beware quinolone resistance
Gastroesophageal varices  UGIB (see also ‚ÄúGIB‚Äù; NEJM 2010;362:823)
‚Ä¢ At risk if HVPG 12 mmHg; screen all cirrhotics at time of dx
‚Ä¢ 1 prevention of UGIB: consider if mod-large varices or ‚Äúred wale‚Äù marks or Child-Pugh B/C
nonselective -blockers: 50% T risk of bleeding  T mortality 
no benefit in preventing varices (NEJM 2005;353:2254), but do T progression in size
nadolol or propanolol (ideally titrate to HVPG; often titrate to 25% T HR)
EGD not req. to document improvement 
endoscopic band ligation (EBL): T bleeding & mortality ‚âàB (Am J Gastro 2007;102:2842)
q1‚Äì2wk until gone S survey EGD at 3 mo S q6‚Äì12mo; adding B only c side effects
B vs EBL: choice based on Pt/physican preference, B often 1st (Hep 2008;47:1764)
‚Ä¢ 2 prevention: for all Pts after 1st bleed b/c 50% rebleed & 30% mortality 
B  EBL  either alone (Annals 2008;149:109); if refractory S TIPS or liver transplant
Portosystemic (hepatic) encenphalopathy (PSE)
‚Ä¢ Pathogenesis: failure of liver to detoxify NH3  other substances that cause cerebral
edema and/or act as false neurotrasmitters (GABA-like)
‚Ä¢ Preciptants: c dietary protein, constipation, GIB, med noncompliance, infection, azotemia,
TK,  volume/water, hypoxia, HCC, portosystemic shunt, meds, portal vein thrombosis
‚Ä¢ Stages: (1) confusion; (2) drowsiness; (3) stupor; (4) coma
‚Ä¢ Dx: asterixis can be seen; NH3 poor Se for dx & monitoring Rx; remains a clinical dx
‚Ä¢ Acute treatment: identify/correct precipitants, restrict dietary protein acutely (60‚Äì80 g/d),
lactulose (acidification of colon: NH3 S NH4
); goal 2‚Äì4 stools/d or rifaximin 400 mg
tid (T gut bacteria S T NH3 prod); rifaximin and lactulose similar efficacy ( J Hep 2003;38:51)
‚Ä¢ 2 prevention: lactulose  rifaximin 550 bid (Gastro 2009;137:885 NEJM 2010;362:1071)
Hepatorenal syndrome (NEJM 2009;361:1279)
‚Ä¢ Pathobiology unknown, though kidney is pathologically normal; ? vascular s
‚Ä¢ Definition: progressive azotemia (Cr 1.5 or 1.5 	 base) despite volume challenge
(1 g/kg/d of albumin 	 2 d), and exclusion of other causes (drugs, ATN, obstruction);
(nb, often overestimate renal fxn in cirrhotics b/c T muscle mass [‚à¥less creatine], c Cr
renal tubular secretion, and T conversion of creatine S creatinine) 
Type I: Cr 2.5 or 1.5	 baseline in 2 wk; usually occurs in severe liver failure,
often following precipitating event (see later); median survival 2 wk
Type II: more indolent course, median survival 6 mo; liver failure present but  type I
Both a/w ascites (usually h/o refractory ascites), oliguria, UNa 10 mEq/L and T Na 
‚Ä¢ Precipitants: GIB, overdiuresis, infection, paracentesis, drugs (aminoglycosides, NSAIDs) 
‚Ä¢ Rx: octreotide (200 mcg SC tid)  midodrine (12.5 mg PO tid)  albumin (Hep 1999;29:1690);
albumin  terlipressin (Gastro 2008;134:1352 & 1360); ? TIPS; definitive Rx  liver transplant
Other complications
‚Ä¢ Hepatopulmonary syndrome (NEJM 2008;358:2378)
Defintion/etiology: abnl pulm gas exchange (A-a gradient 
15 or PaO2 80)
 intrapulm vascular shunting w/o intrinsic pulm disease; ? due to c pulmonary NO
S/S: platypnea-orthodeoxia, clubbing, cyanosis
Dx w/ contrast echo showing pulm A-V shunt (opac. in LA 3‚Äì6 cycles after RA)
Rx: O2; potential embolization if large vessel on CT, liver transplant only definitive Rx
‚Ä¢ Portopulmonary hypertension: c PAP; unclear pathogenesis though some
response to prostacyclin or to endothelin antagonists; poor prognosis
‚Ä¢ ‚ÄúCirrhotic‚Äù cardiomyopathy: T inotopic & chronotropic response, T systolic and
diastolic fxn, prolonged QT, hyperkinetic circulation; c troponin, BNP (Gut 2008;57:268)
‚Ä¢ Infxns: Kuppfer cell (hepatic m) dysfxn, T opsonic activity; vaccinate for HAV &
HBV, influenza yearly, pneumonia
‚Ä¢ Hepatocellular carcinoma: incidence 3.5%/y (c risk if HBV or hemochromatosis)
Sx: c liver size, ascites, encephalopathy, wt loss; screen all cirrhotics w/ U/S  AFP
q6‚Äì12 mo S T mortality (Clin Gastro Hep 2007;5:508), though CT/MRI more sensitive
‚Ä¢ Diabetes (15‚Äì30%): due to altered glc & insulin metabolism
CIRRHOSIS
3-22

--- Fim da P√°gina 100 ---

Prognosis
Modified Child-Turcotte-Pugh Scoring System
Points scored
1
2
3
Ascites
None
Easily controlled
Poorly controlled
Encephalopathy
None
Grade I or II
Grade III or IV
Bilirubin (mg/dL)
2
2‚Äì3
3
Albumin (g/dL)
3.5
2.8‚Äì3.5
2.8
PT (sec  control)
4
4‚Äì6
6
or INR
1.7
1.8‚Äì2.3
2.3
Classification
A
B
C
Total points
5‚Äì6
7‚Äì9
10‚Äì15
1-y survival
100%
80%
45%
‚Ä¢ MELD (Model for End-Stage Liver Disease): used to stratify Pts on liver transplant
list & to predict 3-mo survival in Pts w/ various underlying forms of liver disease &
complications. Based on Cr, INR, & total bili. Calculator:
www.mayoclinic.org/meld/mayomodel6.html. If MELD 21 additional predictors of
mortality include Na 130 (NEJM 2008;359:1018 & Clin Gastro Hep 2009;7:1236), refractory
ascites, c HVPG, and low quality of life.
Liver transplantation
‚Ä¢ Evaluate when Child class B and MELD 
10
‚Ä¢ Indications: recurrent or severe encephalopathy, refractory ascites, SBP, recurrent variceal
bleeding, hepatorenal or hepatopulmonary syndrome, hepatocellular carcinoma (if no
single lesion is 5 cm or 3 lesions with largest 3 cm), fulminant hepatic failure
‚Ä¢ Contraindic.: advanced HIV, active substance abuse (EtOH w/in 6 mo), sepsis, severe comor-
bidity (cardiopulm in particular), extrahepatic malignancy, persistent noncompliance
‚Ä¢ Survival: 1-y survival up to 90%, 5-y survival up to 80%; autoimmune hepatitis, hep
B/C and some forms of Budd-Chiari may recur posttransplant
OTHER ETIOLOGIES OF CIRRHOSIS
Hereditary hemochromatosis (Lancet 2007;370:1855; Hepatology 2008;48:991)
‚Ä¢ Recessive disorders of iron sensing (hepcidin) and transport (transferrin) 
S tissue iron overload; nonhereditary: ineffect. erythropoiesis  transfusions
‚Ä¢ HFE mutations (85% of cases), typically C282Y homozygotes (0.5% of N. European
Caucasians), rarely C282Y/H63D compound heterozygotes; HJV mut. S juvenile onset.
C282Y homozygotes: 28% of  develop sx (88% lab abnl), and 1% of  develop sx
(due to menses T Fe load S later presentation). C282Y/H63D: only 1.5% manifest dis.
‚Ä¢ Sx: fatigue & arthralgias. In advanced disease (rare): bronze skin (melanin  iron),
hypogonadism (espec. in juvenile onset), DM, arthropathy (MCP), CHF, infxns (Vibrio,
Listeria, Yersinia), cirrhosis (c risk if EtOH/fatty liver disease; 15% risk of HCC). Disease
also a/w ALS & porphyria.
‚Ä¢ Dx: iron sat 45% (iron/TIBC 	 100%; most Se & Sp), c ferritin (acute phase reactant,
so poor Sp; often nl in young Pts); MRI (shows ‚Äúblack liver‚Äù and can ‚úìiron stores).
If c iron saturation S ‚úìHFE gene mutation (C282Y/C282Y or C282Y/H63D are ).
Liver bx to assess damage if: HFE  and: ferritin 1000 ng/ml, c LFTs, or c liver size.
‚Ä¢ Treatment: phlebotomy (500 mL  1 unit) qwk until Fe sat 50% and ferritin 50, then prn;
PPI (T intestinal iron transport); deferoxamine if phleb. contraindic.; genetic counseling
Wilson‚Äôs disease (Lancet 2007;369:397 & Hepatology 2008;6:2089)
‚Ä¢ Recessive disorder of copper transport (mutation in ATP7B) S copper overload;
primarily affects liver, but also other tissues (brain, eye)
‚Ä¢ Epidemiology: 1 in 40,000, usually manifests before age 30 y; almost always before 40 y
‚Ä¢ Extrahepatic s/s: neuro  disease, parkinsonism and movement disorder (hepatolen-
ticular disease), Kayser-Fleischer rings ( in 99% w/ neuro  but in 50% w/
hepatic disease), hemolytic anemia, renal disease
‚Ä¢ Dx: c 24-h urine Cu, T serum ceruloplasmin (Se 90%), penicillamine challenge w/ c urine Cu
excretion. In acute liver failure, A/bili 4  AST/ALT 2 better Se & Sp than urine Cu
or ceruloplasmin (Hepatology 2008;4:1167). Gold standard  liver bx w/ hepatic Cu content.
‚Ä¢ Treatment: chelation therapy w/ penicillamine  pyridoxine; 2nd line trientine (T tox-
icity w/ similar efficacy). Zinc: T intestinal Cu transport and can help delay disease;
best used if asx or in conjuction w/ chelation (must give 4‚Äì5 h apart from chelators).
CIRRHOSIS
3-23

--- Fim da P√°gina 101 ---

1-antitrypsin deficiency (1-AT) (NEJM 2009;360:2749)
‚Ä¢ Abnl 1-AT S polymerization in liver (cirrhosis) & uninhibited protease activity in
lung (emphysema). Affects 1/3000 of European ancestry; 1% of all COPDers
(onset before 40 y)
‚Ä¢ Extrahepatic disease: emphysema, necrotizing panniculitis, ANCA vasculitis (Wegener)
‚Ä¢ Dx: absence of 1-AT globulin on SPEP,  PAS inclusion bodies on liver bx
gold standard  protein phenotyping of protease inhibitor (Pi); ZZ, null/null, or null/Z S
clinical sx; null/null makes no 1-AT, ‚à¥only COPD and not liver dz (no polymerization)
‚Ä¢ Treatment: standard Rx for cirrhosis/chronic liver dis.; 1-AT replacement for emphysema
Primary biliary cirrhosis (PBC) (NEJM 2005;353:1261; Hepatology 2009;50:291)
‚Ä¢ Autoimmune destruction of intrahepatic bile ducts; may be triggered by certain infections
or toxins; a/w X monosomy, variants in IL12 & IL12 receptor genes (NEJM 2009;360:2544)
‚Ä¢ Epidemiology: middle-aged women; a/w Sj√∂gren‚Äôs, Raynaud‚Äôs, scleroderma, celiac dis.
‚Ä¢ Sx: fatigue, pruritus, jaundice, steatorrhea, xanthelasma, autonomic and cognitive dysfxn
‚Ä¢ Ddx: biliary stricture/cancer, PSC, autoimmune hepatitis (overlap syndrome), sarcoid,
meds, idiopathic adult ductopenia, eosinophilic cholangitis, AIDS cholangiopathy,
ischemic damage. Imaging of biliary tree (MRCP, CT, ERCP)  serology can help.
‚Ä¢ Dx: c A, c bili, c chol,  anti-mitochondrial Ab (AMA) in 95%. If  AMA, liver bx not needed
due to high Se & Sp. 0.5% gen pop  AMA & normal LFTs S 10% develop PBC at 6 y.
If AMA , liver bx (Pts often  ANA, anti‚Äìsmooth muscle; same prognosis as  AMA).
‚Ä¢ Rx: ursodeoxycholic acid (13‚Äì15 mg/kg/d) regardless of stage, 25% complete response
c survival & T histologic change and complications (eg, varices) (Gastro 2005;128:297)
? colchicine, methotrexate, budesonide if refractory 
Pruritus: cholestyramine (give 2‚Äì4 h after UDCA); if refractory sx: naltrexone, sertraline
Fat-soluble vitamins; screen/Rx osteoporosis (risk indepedent of vit D deficiency) 
Liver transplant: 20% recur but no impact on long-term survival
Primary sclerosing cholangitis (PSC) (Liver Transpl 2008;14:735)
‚Ä¢ Idiopathic cholestasis w/ fibrosis, stricturing, and dilatation of intrahepatic and extra-
hepatic bile ducts; a/w HLA types, autoantibodies but poor response to
immunomodulator Rx suggesting nonautoimmune pathogenesis
‚Ä¢ Epidemiology: young men (age 20‚Äì50 y), 70% a/w ulcerative colitis (rarely Crohn‚Äôs disease)
‚Ä¢ Clinical manifestations: fatigue, pruritus, jaundice, fevers, RUQ pain, cholangiocarcinoma
‚Ä¢ Ddx: same as PBC, may also have overlap w/ autoimmune hepatitis and similar pre-
sentation to IgG4 autoimmune cholangitis (steroid responsive) (Gastro 2008;134:706)
‚Ä¢ Dx: c bilirubin, c A,  p-ANCA in 70% but nonspecific
MRCP S multifocal beaded bile duct strictures, but may miss dx if confined to small
intrahepatic ducts (2% ‚Äúsmall duct PSC‚Äù: better prognosis, ? different disease) 
ERCP w/ liver bx gold standard:‚Äúonion-skin‚Äù fibrosis around bile ducts
‚Ä¢ Treatment: supportive care, fat-soluble vitamins; no meds have improved survival
Ursodeoxycholic acid may T colon CA risk in Pts w/ UC and improve LFTs in Pts w/o UC
Dominant stricture: endoscopic dilation, short-term stenting, or surgical resection
Cholangiocarcinoma (20%): ? annual surveillance w RUQ U/S and CA 19-9; ? PET
Liver transplantation: 30% recurrence, though if UC, colectomy may T recurrence
CIRRHOSIS
3-24

--- Fim da P√°gina 102 ---

HEP VASC
3-25
HEPATIC VASCULAR DISEASE
Portal vein thrombosis (PVT) (Al Phar Ther 2009;30:881)
‚Ä¢ Definition: thrombosis, constriction, or invasion of portal vein S portal HTN S varices.
Isolated splenic vein thrombosis (eg, 2 to pancreatitis) S isolated gastric varices.
‚Ä¢ Etiologies: cirrhosis, neoplasm (pancreas, HCC), abdominal infxn S pylephlebitis (infected
thrombosis of PVT), hypercoag state (incl MPS), panceatitis, IBD, surgery, trauma
‚Ä¢ Clinical manifestations
acute PVT: can p/w pain; often asx and dx as incidental finding on U/S or CT 
if mesenteric vein involved may p/w intestinal infarct; if fevers consider pylephlebitis 
chronic PVT: asx/incidental finding; may p/w s/s of portal HTN S hematemesis 2
variceal bleeding, splenomegaly, mild encephalopathy; ascites rare unless cirrhosis
‚Ä¢ Diagnostic studies: LFTs usually normal; U/S w/ Doppler, MRA, CT (I), angiography;
‚Äúportal cavernoma‚Äù network of hepatopedal collaterals in chronic PVT‚Äîcan rarely cause
biliary obstruction and cholestatic LFT  portal cholangiopathy (may require surgery)
‚Ä¢ Treatment: eval for underlying cause (cirrhosis, MDS, hypercoag); if cirrhotic, Rx less clear
acute: anticoagulation 6 mo unless irreversible etiology (not cirrhosis), then indefinite
chronic: anticoagulation if hypercoag. state (not cirrhosis); unclear if benefit  bleed risk 
Varices: screen at dx; no evidence for 1 ppx of bleed; if bleed endoscopic Rx and B.
If refractory bleed consider TIPS, shunt. Isolated gastric varices 2 splenic vein
thrombosis: splenectomy is curative.
Budd-Chiari syndrome (NEJM 2004;350:578)
‚Ä¢ Occlusion of hepatic veins or IVC S sinusoidal congestion and portal HTN
‚Ä¢ Etiologies: 50% due to myeloproliferative disorder a/w JAK2 mutations (esp P. vera),
hypercoag. state, tumor invasion (HCC, renal, adrenal), IVC webs, trauma, 1‚ÅÑ4 idiopathic
‚Ä¢ Symptoms: hepatomegaly, RUQ pain, ascites, dilated venous collaterals
‚Ä¢ Dx:  c aminotransferases & A; Doppler U/S of hepatic veins (85% Se & Sp); CT (I)
or MRI/MRA S vein occlusion or c caudate lobe (separate venous drainage);‚Äúspider-
web‚Äù pattern on hepatic venography; liver bx showing congestion (r/o right-sided CHF)
‚Ä¢ Treatment: anticoagulation (heparin S warfarin), thrombolysis if acute clot;TIPS preferred
over surgical shunt; angioplasty w/ metallic stent if web or small clot; liver transplant
Sinusoidal obstruction syndrome (SOS) (Mayo 2003;78:589)
‚Ä¢ Occlusion of hepatic venules and sinusoids (formerly veno-occlusive disease)
‚Ä¢ Etiologies: HSCT, chemo (esp cyclopho), XRT, Jamaican bush tea
‚Ä¢ Clinical manifestations: hepatomegaly, RUQ pain, ascites, weight gain, c bilirubin
‚Ä¢ Dx: U/S w/ reversal of portal flow, but often not helpful; dx made clinically (c bili, wt
gain/ascites, and RUQ pain) or, if necessary, by liver bx or HVPG (10 mmHg)
‚Ä¢ Treatment (20% mortality): supportive; ? defibrotide (adenosine agonist c TPA levels)
‚Ä¢ Ppx: ursodeoxycholic acid for high risk HSCT pop; ? use of low-dose heparin
Figure 3-8
A
B
Inferior vena cava
Left hepatic vein
Hepatic
artery
Portal vein
Liver
Right hepatic vein
Central
vein
To hepatic vein,
then to inferior
vena cava 
Plates of
hepatocytes
Blood mixes
in sinusoids
Lobule
Portal triad
Bile duct
Portal vein
from bowel
Hepatic
artery from
aorta
 
Bile canaliculi
Modified from The Nature of Disease Pathology for the Health Professions, 2007. Hepatology 2009;49:1729.

--- Fim da P√°gina 103 ---

ASCITES
3-26
ASCITES
Pathophysiology
‚Ä¢ ‚ÄúUnderfill‚Äù theory: portal hypertension S transudation of fluid into peritoneum S
T plasma volume S renal Na retention
‚Ä¢ ‚ÄúOverflow‚Äù theory: hepatorenal reflex S Na retention
‚Ä¢ Peripheral vasodilatation theory (favored): portal hypertension S systemic vasodilatation
(? due to release of NO) S T effective arterial volume S renal Na retention
‚Ä¢ Other: T serum oncotic pressure from hypoalbuminemia; c hepatic lymph production
Etiologies
Portal hypertension related
Nonportal hypertension related
SAAG 1.1
SAAG 1.1
Sinusoidal
Peritonitis: TB, ruptured viscus (c amy)
cirrhosis (81%), including SBP
Peritoneal carcinomatosis
acute hepatitis
Pancreatitis
extensive malignancy (HCC or mets)
Vasculitis
Postsinusoidal
Hypoalbuminemic states: nephrotic
right-sided CHF incl. constriction & TR
syndrome, protein-losing enteropathy
Budd-Chiari syndrome, SOS
Meigs‚Äô syndrome (ovarian tumor)
Presinusoidal (a/w varices  ascites)
Bowel obstruction/infarction
portal or splenic vein thrombosis, schisto
Postoperative lymphatic leak
Symptoms
‚Ä¢ c abd girth, wt gain, new abd hernia, abd pain, dyspnea, nausea, early satiety
Evaluation (JAMA 2008;299:1166; Hepatology 2009;29:2087)
‚Ä¢ Physical exam: flank dullness (NPV 90%; 1500 mL needed), shifting dullness (Se 83%)
‚Ä¢ Radiologic: U/S detects 100 mL; MRI/CT scan (also help with Ddx)
‚Ä¢ Paracentesis (NEJM 2006;355:e21; Dig Dis Sci 2007;52:3307): perform in all Pts w/ new ascites and
consider in all hospitalized cirrhotics w/ ascites; complic. 1% (bleeding, but risk not
related to PT or plt count; Hepatology 2004;40:484); U/S c success but does not T complic.
‚Ä¢ Serum-ascites albumin gradient (SAAG): 95% acc. for portal HTN (Annals 1992;117:215)

1.1 g/dL S portal hypertension related; 1.1 g/dL S non‚Äìportal hypertension related
if portal HTN  another cause (seen in 5% of cases) SAAG still 
1.1
if known cirrhosis and SAAG 1.1 but no other readily identifiable cause, likely
just cirrhosis (Am J Gastro 2009;104:1401) 
‚Ä¢ Ascites fluid total protein (AFTP): useful when SAAG 
1.1 to distinguish cirrhosis
(AFTP 2.5 g/dL) from cardiac ascites (AFTP 2.5 g/dL)
‚Ä¢ Rule out infection: cell count w/ diff  gram stain/cx define bacterial peritonitis
(see later); bedside inoculation of cx bottles c yield to 90% (Gastro 1988;95:1351)
fungal cx if prolonged hosp., abx use;AFB cx  adenosine deaminase to r/o TB
‚Ä¢ Other tests: amylase (pancreatitis, gut perforation); triglycerides (chylous ascites); cytology
(peritoneal carcinomatosis, 95% Se w/ 3 samples); LDH, glc, CEA, A (perforation) 
Treatment
‚Ä¢ If 2 to portal HTN (see ‚ÄúCirrhosis‚Äù for details): T Na intake  diuretics (spirono-
lactone  lasix); if refractory S large-volume paracentesis or TIPS 
‚Ä¢ If non‚Äìportal HTN related: depends on underlying cause (TB, malignancy, etc.)
Bacterial peritonitis
Type
Ascites cell 
Ascites
count/mm3
culture
Sterile
250 polys

Spontaneous bacterial peritonitis (SBP)

250 polys
 (1 organism)
Culture- neutrocytic ascites (CNNA)

250 polys

Nonneutrocytic bacterascites (NNBA)
250 polys
 (1 organism)
Secondary

250 polys
 (polymicro)
Peritoneal dialysis-associated

100, poly predom.

‚Ä¢ SBP/CNNA: seen in cirrhosis (qv) b/c ascites have T opsonins; rare in other causes
‚Ä¢ NNBA: often resolves w/o Rx; follow closely S Rx only if sx or persistently culture 
‚Ä¢ Secondary intraabdominal abscess or perforation so often polymicrobial 
ascitic fluid TP 1 g/dL, glc 50 mg/dL, LDH 225 U, CEA 5,A 240
Rx: 3rd-gen. ceph  metronidazole; urgent abdominal imaging  ex lap
‚Ä¢ Peritoneal dialysis-associated: cloudy fluid, abd pain, fever, nausea
pathogens: 70% GPC, 30% GNR; Rx: vanc  gent (IV load, then administer in PD)

--- Fim da P√°gina 104 ---

BILIARY TRACT DISEASE
CHOLELITHIASIS (GALLSTONES)
Epidemiology & Pathogenesis (J Hep 2008;48:S124)
‚Ä¢ 10% adults in the U.S. have gallstones
‚Ä¢ Bile  bile salts, phospholipids, cholesterol; c cholesterol saturation in bile  accelerated
nucleation  gallbladder hypomotility S gallstones
‚Ä¢ Risk factors: female; South, Central, Native American, c age (40 y), obesity, pregnancy,
TPN, rapid T wt, drugs (OCPs, estrogen, clofibrate, octreotide, ceftriaxone), ileal disease
‚Ä¢ ? statin use 1 y T risk of sx gallstones & cholecystectomy ( JAMA 2009;302:2001)
Types of gallstones
‚Ä¢ Cholesterol (90%): 2 subtypes
mixed: contain 50% cholesterol; typically smaller, multiple stones
pure: 100% cholesterol; larger, yellow, white appearance
‚Ä¢ Pigment (10%)
Black: unconjugated bilirubin (chronic hemolysis, cirrhosis) and calcium
Brown: stasis & infection in bile ducts S bacteria deconjugate bilirubin S precipitates w/
calcium; seen w/ duodenal diverticula, biliary strictures, parasites 
Clinical manifestations
‚Ä¢ May be asx; biliary colic in 2%/y; once sx, rate of complications 2%/y
‚Ä¢ Biliary colic  episodic RUQ or epigastric abd pain that begins abruptly, is con-
tinuous, resolves slowly, and lasts for 30 min to 3 h;  radiation to scapula; nausea
‚Ä¢ May be precipitated by fatty foods
‚Ä¢ Physical exam: afebrile,  RUQ tenderness or epigastric pain
Diagnostic studies
‚Ä¢ RUQ U/S: Se & Sp 95% for stones 5 mm; can show complications (cholecystitis);
should be performed only after fasting 
8 h to ensure distended, bile-filled gallbladder
Treatment
‚Ä¢ Cholecystectomy (CCY), usually laparoscopic, if symptomatic
‚Ä¢ CCY in asx Pts w/: selective mucosal GB calcification (7% risk of ca) (Surgery
2001;129:699), GB polyps 10 mm, Native American, stones 3 cm
‚Ä¢ Ursodeoxycholic acid (rare) for cholesterol stones w/ uncomplicated biliary pain or if
poor surgical candidate; also reduces risk of gallstone formation with rapid weight loss
Complications
‚Ä¢ Cholecystitis: 20% of sx biliary pain S cholecystitis w/in 2 y
‚Ä¢ Choledocholithiasis S cholangitis or gallstone pancreatitis
‚Ä¢ Mirizzi‚Äôs syndrome: common hepatic duct compression by cystic duct stone S jaundice,
biliary obstruction
‚Ä¢ Cholecystoenteric fistula: stone erodes through gallbladder into bowel
‚Ä¢ Gallstone ileus: SBO (usually at term ileum) due to stone in intestine that passed thru fistula
‚Ä¢ Gallbladder carcinoma (1% in U.S.)
CHOLECYSTITIS (NEJM 2008;358:2804)
Pathogenesis
‚Ä¢ Acute cholecystitis: stone impaction in cystic duct S inflammation behind 
obstruction S GB swelling  secondary infection (50%) of biliary fluid
‚Ä¢ Acalculous cholecystitis: gallbladder stasis and ischemia S inflammatory response; occurs
mainly in critically ill, hosp. Pts (postop major surgery, TPN, sepsis, trauma, burns,
opiates, immunosuppression, infxn [eg, CMV, Crypto, Campylobacter, typhoid fever])
Clinical manifestations
‚Ä¢ History: RUQ/epigastric pain  radiation to R shoulder/back, nausea, vomiting, fever 
‚Ä¢ Physical examination: RUQ tenderness, Murphy‚Äôs sign  c RUQ pain and inspiratory
arrest with deep breath during palpation of R subcostal region,  palpable gallbladder
‚Ä¢ Laboratory evaluation: c WBC,  mild c bilirubin, A,ALT/AST, and amylase;
AST/ALT 500 U/L, bili 4 mg/dL, or amylase 1,000 U/L S choledocholithiasis
Diagnostic studies
‚Ä¢ RUQ U/S: high Se & Sp for stones, but need specific signs of cholecystitis: GB wall
thickening 5 mm, pericholecystic fluid, and a sonographic Murphy‚Äôs sign
BILIARY
3-27

--- Fim da P√°gina 105 ---

‚Ä¢ HIDA scan: most Se test (80‚Äì90%) for acute cholecystitis. IV inj of HIDA, which is
selectively secreted into biliary tree. In acute cholecystitis, HIDA enters BD but
not GB. 10‚Äì20% false  (cystic duct obstructed from chronic cholecystitis, lengthy
fasting, liver disease).
Treatment
‚Ä¢ NPO, IV fluids, nasogastric tube if intractable vomiting, analgesia
‚Ä¢ Antibiotics (E. coli, Klebsiella, and Enterobacter sp. are usual pathogens) 
([2nd- or 3rd-generation cephalosporin or FQ]  MNZ) or piperacillin-tazobactam
‚Ä¢
Early CCY (usually w/in 72 h). Delaying surgery 2‚Äì3 mos T operative time w/o 
rate of complications or conversion to open procedure (Am J Surg 2008;194:40).
‚Ä¢ Cholecystostomy and percutaneous drainage if too sick for surgery
‚Ä¢ Intraoperative cholangiogram or ERCP to r/o choledocholithiasis in Pts w/ jaundice,
cholangitis, or stone in BD on U/S
Complications
‚Ä¢ Gangrenous cholecystitis: necrosis w/ risk of empyema and perforation
‚Ä¢ Emphysematous cholecystitis: infection by gas-forming organisms (air in GB wall)
‚Ä¢ Post CCY: bile duct leak, BD injury or retained stones, cystic duct remnant, sphincter of
Oddi dysfxn
CHOLEDOCHOLITHIASIS
Definition
‚Ä¢ Gallstone lodged in bile duct (BD)
Epidemiology
‚Ä¢ Occurs in 15% of Pts w/ gallbladder stones; can form de novo in BD
Clinical manifestations
‚Ä¢ Asymptomatic (50%)
‚Ä¢ RUQ/epigastric pain due to obstruction of bile flow S c BD pressure, jaundice, pruritis,
nausea
Diagnostic studies
‚Ä¢ Labs: c bilirubin,A; transient spike in ALT or amylase suggests passage of stone
‚Ä¢ RUQ U/S: BD stones seen 50% of cases; usually inferred from dilated BD (6 mm)
‚Ä¢ ERCP preferred dx modality; cholangiogram (percutaneous, operative) when ERCP
unavailable or unsuccessful; EUS/MRCP to exclude BD stones when suspicion low
Treatment
‚Ä¢ ERCP & papillotomy w/ stone extraction
‚Ä¢ CCY typically w/in 6 wks unless contraindication (15% Pts will develop indication
for CCY if left unRx‚Äôd)
Complications
‚Ä¢ Cholangitis, cholecystitis, pancreatitis, stricture
CHOLANGITIS
Definition and Etiologies
‚Ä¢ BD obstruction S infection proximal to the obstruction
‚Ä¢ Etiologies: BD stone (85%)
Malignant (biliary, pancreatic) or benign stricture
Infiltration w/ flukes (Clonorchis sinensis, Opisthorchis viverrini)
Clinical manifestations
‚Ä¢ Charcot‚Äôs triad: RUQ pain, jaundice, fever/chills; present in 70% of Pts
‚Ä¢ Reynold‚Äôs pentad: Charcot‚Äôs triad  shock and  MS; present in 15% of Pts
Diagnostic studies
‚Ä¢ RUQ U/S
‚Ä¢ Labs: c WBC, bilirubin, A, amylase;  BCx
‚Ä¢ ERCP; percutaneous transhepatic cholangiogram (if ERCP unsuccessful) 
Treatment
‚Ä¢ Antibiotics (broad spectrum) to cover common bile pathogens (see above)
ampicillin  gentamicin (or levofloxacin)  MNZ (if severe); carbapenems; pip/tazo
‚Ä¢ 80% respond to conservative Rx and abx S biliary drainage on elective basis
‚Ä¢ 20% require urgent biliary decompression via ERCP (papillotomy, stone extrac-
tion, and/or stent insertion). If sphincterotomy cannot be performed (larger stones),
decompression by biliary stent or nasobiliary catheter can be done; otherwise 
percutaneous transhepatic biliary drainage or surgery.
BILIARY
3-28

--- Fim da P√°gina 106 ---

ACID-BASE
4-1
ACID-BASE DISTURBANCES
GENERAL
Definitions
‚Ä¢ Acidemia S pH 7.36, alkalemia S pH 7.44
‚Ä¢ Acidosis S process that increases [H]; alkalosis S process that decreases [H]
‚Ä¢ Primary disorders: metabolic acidosis or alkalosis, respiratory acidosis or alkalosis
‚Ä¢ Compensation
respiratory: hyper- or hypoventilation alters PaCO2 to counteract 1 metabolic process
renal: excretion/retention of H/HCO3 to counteract 1 respiratory process
respiratory compensation occurs in min; renal compensation takes hrs to days
compensation never fully corrects pH; if pH normal, consider mixed disorder
Consequences of Severe Acid-Base Disturbances
Organ System
Acidemia (pH 7.20)
Alkalemia (pH 7.60)
Cardiovascular
T contractility, arteriolar vasodilation
Arteriolar vasoconstriction
T MAP & CO; T response to catecholamines
T coronary blood flow
c risk of arrhythmias
c risk of arrhythmias
Respiratory
Hyperventilation, T resp muscle strength
Hypoventilation
Metabolic
c K
T K, ICa, Mg, PO4
Neurologic
 MS
 MS, seizures
(NEJM 1998;338:26 & 107)
Workup
‚Ä¢ Determine primary disorder: ‚úìpH, PaCO2, HCO3
‚Ä¢ Determine if degree of compensation is appropriate
Primary Disorders
Primary disorder
Problem
pH
HCO3
PaCO2
Metabolic acidosis
gain of H or loss of HCO3
T
‚áì
T
Metabolic alkalosis
gain of HCO3 or loss of H
c
‚áë
c
Respiratory acidosis
hypoventilation
T
c
‚áë
Respiratory alkalosis
hyperventilation
c
T
‚áì
Compensation for Acid/Base Disorders
Primary disorder
Expected compensation
Metabolic acidosis
T PaCO2  1.25  HCO3
or PaCO2  (1.5  HCO3)  8 	 2
(also, PaCO2  last two digits of pH)
Metabolic alkalosis
c PaCO2  0.75  HCO3
Acute respiratory acidosis
c HCO3  0.1  PaCO2
(also, T pH  0.008  PaCO2)
Chronic respiratory acidosis
c HCO3  0.4  PaCO2
(also, T pH  0.003  PaCO2)
Acute respiratory alkalosis
T HCO3  0.2  PaCO2
(also, c pH  0.008  PaCO2)
Chronic respiratory alkalosis
T HCO3  0.4  PaCO2
Mixed disorders (more than one primary disorder at the same time)
‚Ä¢ If compensation less or greater than predicted, may be 2 disorders:
PaCO2 too low S concomitant 1 resp. alk.
PaCO2 too high S concomitant 1 resp. acid.
HCO3 too low S concomitant 1 met. acid.
HCO3 too high S concomitant 1 met. alk.
‚Ä¢ Normal pH but . . .
c PaCO2  c HCO3 S resp. acid.  met. alk.
T PaCO2  T HCO3 S resp. alk.  met. acid.
normal PaCO2 & HCO3, but c AG S AG met. acid.  met. alk.
normal PaCO2, HCO3, & AG S no disturbance or non-AG met. acid.  met. alk.
‚Ä¢ Cannot have resp. acid. (hypoventilation) and resp. alk. (hyperventilation) simultaneously

--- Fim da P√°gina 107 ---

Figure 4-1 Acid-Base nomogram
ACID-BASE
4-2
NB, If ABG not available, can use VBG, but note that pH 0.04 T, PaCO2 8 mm Hg c, and
HCO3 2 mEq c. (Adapted from Brenner BM, ed. Brenner & Rector‚Äôs The Kidney, 8th ed., 2007; Ferri F, ed.
Practical Guide to The Care of the Medical Patient, 7th ed., 2007)
METABOLIC ACIDOSIS
Initial workup
‚Ä¢ ‚úìanion gap (AG)  Na 
 (Cl  HCO3)  unmeasured anions 
 unmeasured cations
if c glc, use measured not corrected Na
expected AG is [albumin]  2.5 (ie, 10 if albumin is 4 g/dL, 7.5 if albumin is 3 g/dL)
c AG S c unmeasured anions such as organic acids, phosphates, sulfates
T AG S T alb or c unmeasured cations (Ca, Mg, K, Li, bromine, immunoglobulin)
‚Ä¢ If c AG, ‚úìdelta-delta (  AG/HCO3) to assess if there is an additional metabolic
acid-base disturbance; AG  (calculated AG 
 expected AG), HCO3  (24 
 HCO3)
  1‚Äì2 S pure AG metabolic acidosis
  1 S AG metabolic acidosis and simultaneous non-AG acidosis
  2 S AG metabolic acidosis and simultaneous metabolic alkalosis
Etiologies of AG Metabolic Acidosis
Ketoacidosis
Diabetes mellitus, alcoholism, starvation
Lactic
Type A: impairment in tissue oxygenation, eg, circulatory or
acidosis
respiratory failure, sepsis, ischemic bowel, carbon monoxide, cyanide
Type B: no impairment in tissue oxygenation, eg, malignancy, alcoholism,
meds (metformin, NRTIs, salicylates, propylene glycol)
D-lactic acidosis: short bowel syndrome S precip by glc ingest S metab by 
colonic bacteria to D-lactate; not detected by standard lactate assay
Renal failure
Accumulation of organic anions such as phosphates, sulfates, urate, etc.
Ingestions
Methanol (windshield fluid, antifreeze, solvents, fuel): metab to formic acid
Ethylene glycol (antifreeze): metab to glycolic and oxalic acids
Propylene glycol (pharmaceutical solvent, eg, IV diazepam & lorazepam;
antifreeze): lactic acidosis
Salicylates: metabolic acidosis (from lactate, ketones)  respiratory
alkalosis due to stimulation of CNS respiratory center
Acetaminophen: glutathione depletion S c endogenous organic acid 5-
oxoproline in susceptible host (malnourished, female, renal failure)
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
7.00
7.10
7.20
7.30
7.40
7.50
7.60
7.70
7.80
Metabolic
Alkalosis
Mixed
Resp. Acid.
& Met. Alk.
Acute Resp. Alk.
Mixed
Resp. & Met.
Alkalosis
Met. Alk.
w/o
expected
resp.
comp.
Normal
Chronic
Resp. Alk.
Mixed
Met. Acid.
& Resp. Alk.
Acute Resp. Acid.
Chronic
Resp.
Acidosis
Mixed
Resp. & Met.
Acidosis
Met. Acid. w/o
expected resp. comp.
Acute on
Chronic
Resp. Alk.
Acute on
Chronic
Resp. Acid.
Arterial Blood pH
Arterial Plasma [HCO3] (mEq/L)
Metabolic Acidosis
40
35
30
25
20
15
10
50
60
70
80
90
100
110
120
PaCO2 (mm Hg)

--- Fim da P√°gina 108 ---

Workup for AG metabolic acidosis
‚Ä¢ ‚úìfor ketonuria (dipstick acetoacetate) or plasma -hydroxybutyrate (OHB)
nb, urine acetoacetate often not present in early ketoacidosis due to shunting to
OHB; ‚à¥acetoacetate may later turn , but does not signify worsening disease
‚Ä¢ If  ketones, ‚úìrenal function, lactate, toxin screen, and osmolal gap
‚Ä¢ Osmolal gap (OG)  measured osmoles 
 calculated osmoles
calculated osmoles  (2  Na)  (glucose/18)  (BUN/2.8)
(can  [EtOH/4.6] if have EtOH level and want to test if other ingestions)
OG 10 S suggests ingestion (see below)
Ingestions
AG
OG
Ingestion
Other manifestations
c
nl
Acetaminophen
Hepatitis
Salicylates
Fever, tachycardia, tinnitus; met. acid.  resp. alk.
Ethanol
Alcoholic fetor, MS, hepatitis; keto  lactic acid. 	
met. alk. (vomiting)
Methanol
MS, blurred vision, pupillary dilation, papilledema
c
c
Ethylene glycol
MS, cardiopulmonary failure, hypocalcemia, Ca oxalate 
crystals S renal failure; urine fluoresces under UV light
Propylene glycol
AKI
nl
c
Isopropyl alcohol
MS, fruity breath (acetone)
Etiologies of Non-AG Metabolic Acidosis
GI losses of HCO3
Diarrhea, intestinal or pancreatic fistulas or drainage
RTAs
See section on renal tubular acidoses below
Early renal failure
Impaired generation of ammonia
Ingestions
Acetazolamide, sevelamer, cholestyramine, toluene
Dilutional
Due to rapid infusion of bicarbonate-free intravenous fluids
Post-hypocapnia
Respiratory alkalosis S renal wasting of HCO3; rapid correction
of resp. alk. S transient acidosis until HCO3 regenerated
Ureteral diversion
Colonic Cl‚Äì/HCO3
‚Äì exchange, ammonium reabsorption
Workup for non-AG metabolic acidosis
‚Ä¢ Evaluate history for causes (see above)
‚Ä¢ ‚úìurine anion gap (UAG)  (UNa  UK) 
 UCl
UAG  unmeasured anions 
 unmeasured cations; as NH4
 is primary unmea-
sured cation, UAG is indirect assay for renal NH4
 excretion (NEJM 1988;318:594)
‚Ä¢  UAG S c renal NH4
 excretion S appropriate renal response to acidemia
Ddx: GI causes, type II RTA, ingestions or dilutional
‚Ä¢  UAG S failure of kidneys to secrete NH4

Ddx: type I or IV RTA, early renal failure 
nb, plasma K usually T in type I and c in type IV
‚Ä¢ UAG evaluation assumes Pt not volume deplete (UNa 25) & w/o AG met. acid. S  UAG
Renal tubular acidoses (RTAs)
‚Ä¢ Proximal (Type II): T proximal reabsorption of HCO3
1 (Fanconi‚Äôs syndrome  T proximal reabsorption of HCO3, PO4, glc, amino
acids), paraprotein (multiple myeloma, amyloidosis), meds (acetazolamide, heavy
metals, ifosfamide), renal transplant, T Vit D, NRTIs
‚Ä¢ Distal (Type I): defective distal H secretion
1, autoimmune (Sj√∂gren‚Äôs, RA), nephrocalcinosis, meds (ampho, Li, ifosfamide);
normally a/w T K; if with c K S sickle cell, obstruction, SLE, renal transplant
‚Ä¢ Hypoaldo (Type IV): c K S T NH3 synthesis/delivery S T urine acid carrying capacity
T renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, HIV
normal renin, T aldo synthesis: 1 adrenal disorders, ACEI,ARBs, heparin
T response to aldosterone
meds: K-sparing diuretics,TMP-SMX, pentamidine, calcineurin inhibitors
tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes
ACID-BASE
4-3

--- Fim da P√°gina 109 ---

Renal Tubular Acidosis
Location
Type
Acidosis
UAG
U pH
FeHCO3
b
Serum K
Proximal
II
moderate
	
5.3a
15%
T
Distal
I
severe

5.3
3%
Tc
Hypoaldo
IV
mild

5.3
3%
c
aurine pH will rise above 5.3 in the setting of HCO3 load
bFeHCO3 should be checked after an HCO3 load
csee above for causes of distal RTA (Type I) associated with hyperkalemia
Figure 4-2 Approach to metabolic acidosis
ACID-BASE
4-4
Treatment of severe metabolic acidoses (pH 7.2) (NEJM 1998;338:26)
‚Ä¢ DKA: insulin & IVF;AKA: dextrose, IVF, replete K, Mg, PO4 as needed
‚Ä¢ Lactic acidosis: treat underlying condition, avoid vasoconstrictors
‚Ä¢ Renal failure: hemodialysis
‚Ä¢ Methanol & ethylene glycol: early fomepizole, vit. B6 (ethylene glycol), folate
(methanol), hemodialysis (especially if late presentation) (NEJM 2009;360:2216)
‚Ä¢ Alkali therapy: NaHCO3 (eg, 3 50-mmol amp in 1 L D5W) to get serum HCO3 8
and pH 7.2 (estimate mmol of HCO3 needed as 8-[HCO3]serum  wt  0.5)
side effects: volume overload, hypernatremia, T ICa, c PaCO2 (and ‚à¥possibly
intracellular acidosis), overshoot; no proven benefit in lactic acidosis (Annals 1990;112:492)
METABOLIC ALKALOSIS
Pathophysiology
‚Ä¢ Saline-responsive etiologies require initiating event and maintenance factors, whereas
saline-resistant etiologies develop from various causes
‚Ä¢ Initiating event
loss of H from GI tract or kidneys
exogenous alkali
contraction alkalosis: diuresis S excretion of HCO3-poor fluid S extracellular fluid
‚Äúcontracts‚Äù around fixed amount of HCO3 S c HCO3 concentration
posthypercapnia: respiratory acidosis S renal compensation with HCO3 retention;
rapid correction of respiratory disorder (eg, with intubation) S transient excess HCO3
‚Ä¢ Maintenance factors
volume depletion S c proximal reabsorption of NaHCO3 and c aldosterone (see next)
hyperaldosteronism (either 1 or 2) S distal Na reabsorption in exchange for K and
H excretion (and consequent HCO3 retention)
hypokalemia S transcellular K/H exchange; intracellular acidosis in renal proximal
tubular cells promotes bicarbonate reabsorption and ammoniagenesis
Metabolic Acidosis
AG Metabolic Acidosis
DKA
AKA
Starvation
(Salicylates)
Lactic
acidosis
Non-AG Metabolic Acidosis
Renal
failure
Proximal RTA
(Type II)
Distal RTA
(Type I)
‚äïketones
‚äïUAG
‚ÜëAG
normal AG
Salicylates
5-oxoprolinuria
Ethanol
Methanol
Ethylene glycol
Propylene glycol
Ingestions
ketones
‚äï
‚àí
lactate
uremia
OG <10
OG >10
‚äïtox screen
Hypoaldo RTA
(Type IV)
Renal causes
Diarrhea
Fistulas
Ingestions
Dilutional
Post-hypocapnia
‚àíUAG
Fe
<3%
urine pH >5.3
Fe
>15%
urine pH var.
hypokalemia
hyperkalemia
urine pH <5.3
clinical hx
Early
Late
GI & misc.
causes

--- Fim da P√°gina 110 ---

Etiologies of Metabolic Alkalosis
Saline-responsive
GI loss of H: vomiting, NGT drainage, villous adenoma
Diuretic use
Posthypercapnia, laxatives, cystic fibrosis
Saline-resistant
Hypertensive (mineralocorticoid excess)
1 hyperaldosteronism (eg, Conn‚Äôs)
2 hyperaldosteronism (eg, renovascular dis., renin-secreting tumor)
non-aldo (Cushing‚Äôs, Liddle‚Äôs, exogenous mineralocorticoids, licorice)
Normotensive
severe hypokalemia
exogenous alkali load
Bartter‚Äôs syndrome (loop-like), Gitelman‚Äôs syndrome (thiazide-like)
Workup
‚Ä¢ Check volume status and UCl
UCl 20 mEq/L S saline-responsive
UCl 20 mEq/L S saline-resistant (unless currently receiving diuretics)
(UNa unreliable determinant of volume status as alkalemia S c HCO3 excretion S
c Na excretion; negatively charged HCO3 ‚Äúdrags‚Äù Na along)
If UCl 20 and volume replete, ‚úìblood pressure
Figure 4-3 Approach to metabolic alkalosis
Treatment of severe metabolic alkalosis (pH 7.6)
‚Ä¢ If volume depletion: d/c diuretics and correct volume deficit with isotonic saline
If cardiopulmonary disease precludes hydration, can use KCl, acetazolamide, HCl
‚Ä¢ If NGT drainage that cannot be d/c: PPI
‚Ä¢ Hyperaldosteronism: treat underlying condition
RESPIRATORY ACIDOSIS
Etiologies
‚Ä¢ CNS depression: sedatives, CNS trauma, O2 in chronic hypercapnia (T hypoxemic drive)
‚Ä¢ Neuromuscular disorders: myasthenia gravis, Guillain-Barr√©, poliomyelitis, ALS,
muscular dystrophy, severe hypophosphatemia
‚Ä¢ Upper airway abnormalities: acute airway obstruction, laryngospasm, obstructive
sleep apnea, esophageal intubation
‚Ä¢ Lower airway abnormalities: asthma, COPD
‚Ä¢ Lung parenchyma abnormalities (often cause hypoxia S c RR S resp. alk., but eventual
muscle fatigue S resp. acid.): pneumonia, pulmonary edema, restrictive lung disease
‚Ä¢ Thoracic cage abnormalities: pneumothorax, flail chest, kyphoscoliosis
‚Ä¢ Post infusion of bicarbonate in acidemic Pt w/ limited ability to c minute ventilation
RESPIRATORY ALKALOSIS
Etiologies (NEJM 2002;347:43)
‚Ä¢ Hypoxia S hyperventilation: pneumonia, pulm. edema, PE, restrictive lung disease
‚Ä¢ Primary hyperventilation
CNS disorders, pain, anxiety
drugs: salicylates, progesterone, methylxanthines
pregnancy, sepsis, hepatic failure
ACID-BASE
4-5
Metabolic Alkalosis
Saline-Responsive
GI losses
vomiting
NGT drainage
villous adenoma
Prior diuretics
Vol. deplete
Saline-Resistant
Post-
hypercapnia
laxatives
cystic fibrosis
U <20
1¬∞ hyperaldo
2¬∞ hyperaldo
non-mineralocorticoid
Current diuretics
severe ‚ÜìK
exogenous alkali
Bartter‚Äôs
Gitelman‚Äôs
U >20
Hypertensive
Hypo- or 
normotensive

--- Fim da P√°gina 111 ---

SODIUM
4-6
SODIUM AND WATER HOMEOSTASIS
OVERVIEW
General
‚Ä¢ Disorders of serum sodium are generally due to s in total body water, not sodium
‚Ä¢ Hyper- or hypoosmolality S rapid water shifts S s in brain cell volume S  MS, seizures
Key hormones
‚Ä¢ Antidiuretic hormone (ADH): primary hormone that regulates sodium concentration
stimuli for secretion: hyperosmolality, TT effective arterial volume (EAV)
action: insertion of aquaporin-2 channels in collecting ducts S passive water reabsorption
urine osmolality is an indirect functional assay of the ADH-renal axis
Uosm range: 60 mOsm/L (no ADH) to 1200 mOsm/L (maximal ADH)
‚Ä¢ Aldosterone: primary hormone that regulates total body sodium (and ‚à¥volume)
stimuli for secretion: hypovolemia (via renin and angiotensin II), hyperkalemia
action: iso-osmotic reabsorption of sodium in exchange for potassium or H
HYPONATREMIA
Pathophysiology
‚Ä¢ Excess of water relative to sodium; almost always due to c ADH
‚Ä¢ c ADH may be appropriate (eg, hypovolemia or hypervolemia with T EAV)
‚Ä¢ c ADH may be inappropriate (SIADH)
‚Ä¢ Rarely, T ADH (appropriately suppressed), but kidneys unable to maintain nl [Na]serum
primary polydipsia: ingestion of massive quantities (usually 12 L/d) of free H2O
overwhelms diluting ability of kidney (normal solute load 750 mOsm/d, min Uosm
 60 mOsm/L S excrete in 12 L; if H2O ingestion exceeds this, H2O retention)
‚Äútea & toast‚Äù and ‚Äúbeer potomania‚Äù: TT daily solute load, c free H2O S insufficient
solute to excrete H2O intake (eg, if only 250 mOsm/d, minimum Uosm  60
mOsm/L S excrete in 4 L; if H2O ingestion exceeds this, H2O retention)
Workup (NEJM 2000;342:1581)
‚Ä¢ Measure plasma osmolality
Hypotonic hyponatremia most common scenario; true excess of free H2O relative to Na
Hypertonic hyponatremia: excess of another effective osmole (eg, glc, mannitol) that
draws H2O intravascularly; each 100 mg/dL c glc 100 mg/dL S T [Na] by 2.4 mEq/L
Isotonic hyponatremia: rare lab artifact from hyperlipidemia or hyperproteinemia
‚Ä¢ For hypotonic hyponatremia, ‚úìvolume status (vital signs, orthostatics, JVP, skin
turgor, mucous membranes, peripheral edema, BUN, Cr, uric acid)
‚Ä¢ Uosm diagnostically useful in limited circumstances, because almost always 300
exceptions: Uosm 100 in 1 polydipsia & T solute intake
moreover, Uosm 300 Z SIADH; must determine if c ADH appropriate or inappropriate
however, Uosm important when deciding on treatment (see below)
‚Ä¢ If euvolemic and c Uosm, evaluate for glucocorticoid insufficiency and hypothyroidism
Figure 4-4 Approach to hyponatremia
Hypotonic Hyponatremia
Hypovolemic
Hyponatremia
Renal losses
mineralocorticoid
def.
Extra-renal
losses
hypovolemic
Hypervolemic
Hyponatremia
CHF
Cirrhosis
Nephrosis
Renal
failure
Euvolemic
Hyponatremia
SIADH
hypothyroidism
glucocorticoid def.
1¬∞ polydipsia
low solute
Reset
osmostat
hypervolemic
euvolemic
Pt‚Äôs clinical history

--- Fim da P√°gina 112 ---

Hypovolemic hypotonic hyponatremia (ie, TT total body Na, T TBW)
‚Ä¢ Renal losses (UNa 20 mEq/L, FENa 1%): diuretics (espec. thiazides, as loop diuretics
T tonicity of medullary interstitium and impair urine concentrating ability), salt-
wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency
‚Ä¢ Extrarenal losses (UNa 10 mEq/L, FENa 1%): GI losses (eg, diarrhea), third-spacing
(eg, pancreatitis), inadequate intake, insensible losses
Euvolemic hypotonic hyponatremia (ie, nl total body Na, c TBW)
‚Ä¢ SIADH (eu- or mild hypervolemia, inapprop c UOsm, normal UNa, T BUN & UA)
malignancy: lung, brain, GI, GU, lymphoma, leukemia, thymoma, mesothelioma
pulmonary: pneumonia, asthma, COPD, PTX,  pressure ventilation
intracranial: trauma, stroke, hemorrhage, infxn, hydrocephalus
drugs: antipsychotics, antidepressants, chemotherapy, vasopressin, dDAVP, MDMA
miscellaneous: pain, nausea, postoperative state
‚Ä¢ Endocrinopathies: c ADH activity seen in glucocorticoid deficiency (co-secretion of
ADH & CRH) and hypothyroidism (T CO & T GFR)
‚Ä¢ Psychogenic polydipsia (Uosm 100, T uric acid): usually requires intake 12 L/d
‚Ä¢ Low solute:‚Äútea & toast‚Äù;‚Äúbeer potomania‚Äù
‚Ä¢ Reset osmostat: chronic malnutrition (T intracellular osmoles) or pregnancy (hormonal
effects) S ADH physiology reset to regulate a lower [Na]serum
Hypervolemic hypotonic hyponatremia (ie, c total body Na, cc TBW)
‚Ä¢ CHF (T CO S T EAV; UNa 10 mEq/L, FENa 1%)
‚Ä¢ Cirrhosis (splanchnic arterial vasodilation and ascites S T EAV; UNa 10 mEq/L,
FENa 1%)
‚Ä¢ Nephrotic syndrome (hypoalbuminemia S edema S T EAV; UNa 10 mEq/L,
FENa 1%)
‚Ä¢ Advanced renal failure (diminished ability to excrete free H2O; UNa 20 mEq/L)
Treatment
‚Ä¢ Goals of treatment
Asymptomatic hyponatremia: correct [Na]serum at rate of 0.5 mEq/L/h
Symptomatic hyponatremia: initial rapid correction of Na (2 mEq/L/h for the first 
2‚Äì3 h) until sx resolve
Rate of c Na should not exceed 10‚Äì12 mEq/L/d to avoid osmotic demyelination 
syndrome (spastic quadriplegia, dysarthria, dysphagia), espec if hypoNa chronic
‚Ä¢ Effect of IV fluids
initial [Na]serum per L infusate 
eg, 1 L hypertonic saline (513 mEq Na) given to 70-kg man w/ [Na]  110 mEq/L
will c [Na]serum by 9.4 mEq
however, above assumes entire infusate retained without any output of Na or H2O
if Pt is euvolemic, as in SIADH, then infused Na will be excreted
eg, 1 L NS (154 mEq of Na or 308 mOsm of solute in 1 L free H2O) given to Pt with
SIADH with Uosm  616 S 308 mOsm solute excreted in 0.5 L H2O S
net gain 0.5 L H2O S T [Na]serum
‚à¥normal saline can worsen hyponatremia 2 SIADH if Uosm  infusateosm
‚Ä¢ Hypovolemic hyponatremia: volume repletion with normal saline
once volume replete S stimulus for ADH removed S kidneys will excrete free H2O S
serum Na will correct rapidly
‚Ä¢ SIADH (NEJM 2007;356:2064): free water restrict  treat underlying cause
hypertonic saline (	 loop diuretic) if sx or Na fails to c w/ free H2O restriction
1 L hypertonic saline will raise [Na]serum by 10 mEq (see above)
50 mL/h will c [Na] by 0.5 mEq/L/h; 100‚Äì200 mL/h will c [Na] by 1‚Äì2 mEq/L/h
formula only provides estimate; ‚à¥recheck serum Na frequently
salt tabs: particularly if chronic and no CHF
aquaresis: conivaptan (IV V1a & V2 vasopressin receptor antag) or tolvaptan (oral V2
antag); used for symptomatic SIADH resistant to above Rx
demeclocycline: causes nephrogenic DI, T Uosm
‚Ä¢ Hypervolemic hyponatremia: free water restrict
mobilize excess Na & H2O (loop diuretics) & c EAV (vasodilators to c CO in CHF,
colloid infusion in cirrhosis)
aquaresis: tolvaptan (NEJM 2006;355:2099), consider in symptomatic hyponatremia
resistant to above Rx, monitor for overcorrection 
TBW  wt (kg)  0.6 () or 0.5 ();
if elderly use 0.5 () or 0.45 ()
[Na]infusate 
 [Na]serum

TBW  1
SODIUM
4-7

--- Fim da P√°gina 113 ---

HYPERNATREMIA
Pathophysiology (NEJM 2000;342:1493)
‚Ä¢ Deficit of water relative to sodium; by definition, all hypernatremic Pts are hypertonic 
‚Ä¢ Usually loss of hypotonic fluid; occasionally infusion of hypertonic fluid
‚Ä¢ And impaired access to free water (eg, intubation,  MS, elderly): hypernatremia
is a powerful thirst stimulus, ‚à¥usually only develops in Pts w/o access to H2O
Workup
‚Ä¢ ‚úìUosm, UNa, volume status (vital signs, orthostatics, JVP, skin turgor, BUN, Cr)
Uosm 700‚Äì800 S extrarenal loss or Na overload; ‚úìUNa to differentiate
Uosm 700‚Äì800 S renal loss; differentiate DI vs. diuresis based on Uosm and clinical hx 
Figure 4-5 Approach to hypernatremia
SODIUM
4-8
Extrarenal H2O loss (Uosm 700‚Äì800)
‚Ä¢ GI H2O loss: vomiting, NGT drainage, osmotic diarrhea, fistula
‚Ä¢ Insensible loss: fever, exercise, ventilation 
Renal H2O loss (Uosm 700‚Äì800)
‚Ä¢ Diuresis: osmotic (glc, mannitol, urea), loop diuretics
‚Ä¢ Diabetes insipidus:ADH deficiency (central) or resistance (nephrogenic)
Central: hypothalamic or posterior pituitary disease (congenital, trauma/surgery,
tumors, infiltrative); also idiopathic, hypoxic encephalopathy, anorexia, EtOH
Nephrogenic (Annals 2006;144:186)
congenital (ADH receptor V2 mutation, aquaporin-2 mutation)
drugs: Li, amphotericin, demeclocycline, foscarnet, cidofovir
metabolic: hypercalcemia, severe hypokalemia, protein malnutrition, congenital
tubulointerstitial: postobstruction, recovery phase of ATN, PKD, sickle cell,
Sj√∂gren‚Äôs, amyloid, pregnancy (placental vasopressinase)
DI usually presents as severe polyuria and mild hypernatremia
Other (Uosm 700‚Äì800)
‚Ä¢ Na overload: hypertonic saline (eg, resuscitation w/ NaHCO3), mineralocorticoid excess
‚Ä¢ Seizures, cexercise: c intracellular osmoles S H2O shifts S transient c [Na]serum
Treatment
‚Ä¢ Restore access to H2O or supply daily requirement of H2O (1 L/d)
‚Ä¢ Replace free H2O deficit (also replace concurrent volume deficit if appropriate):
Free H2O deficit (L) 
 TBW
shortcut: for typical 70-kg man, free H2O deficit (L)  ([Na]serum ‚Äì 140)/3
 [Na]serum per L infusate 
eg, 1 L D5W given to 70-kg man w/ [Na]  160 mEq/L will T [Na]serum by 3.7 mEq
‚Ä¢ Rate of T of Na should not exceed 0.5 mEq/L/h to avoid cerebral edema
shortcut: in 70-kg man, 125 mL/h of free H2O will T [Na] by 0.5 mEq/L/h
‚Ä¢
1‚ÅÑ2 NS (77 mEq/L) or 1‚ÅÑ4 NS (38 mEq/L) provides both volume & free H2O (500 or
750 mL of free H2O per L, respectively); can give free H2O via NGT/OGT
‚Ä¢ Formulas provide only estimates; ‚à¥recheck serum Na frequently
‚Ä¢ DI and osmotic diuresis: see ‚ÄúPolyuria‚Äù section below
‚Ä¢ Na overload: D5W  loop diuretic
[Na]serum 
 [Na]infusate

TBW  1
TBW  wt (kg)  0.6 () or 0.5 ();
if elderly use 0.5 () or 0.45 ()
[Na]serum 
 140

140
Hypernatremia
Extrarenal H2O loss
‚Üë Intracellular Osmoles
or
Renal H2O loss
Na Overload
NaCl/NaHCO3 IVF
Mineralocorticoids
GI H2O loss
Insensible loss
Seizure, Exercise
Complete DI
Partial DI
Osmotic diuresis
Loop diuretics

--- Fim da P√°gina 114 ---

POLYURIA
Definition and pathophysiology
‚Ä¢ Polyuria defined as 3 L UOP per day
‚Ä¢ Due to an osmotic or a water diuresis; almost always due to osmotic diuresis in inpatients
Workup
‚Ä¢ Perform a timed urine collection (6 h sufficient) and measure Uosm
‚Ä¢ 24-h osmole excretion rate  24-h UOP (actual or estimate)  Uosm
1000 mOsm/d S osmotic diuresis
800 mOsm/d S water diuresis
Osmotic diuresis
‚Ä¢ Etiologies
Glucose (uncontrolled diabetes mellitus)
Mannitol
Urea: recovering ARF, c protein feeds, hypercatabolism (burns, steroids), GI bleed
NaCl administration
Propylene glycol
Water diuresis
‚Ä¢ Etiologies: diabetes insipidus (DI) (Naserum 140) or 1 polydipsia (Naserum 140)
see ‚ÄúHypernatremia‚Äù above for list of causes of central and nephrogenic DI
‚Ä¢ Workup of DI: Uosm 300 (complete) or 300‚Äì600 (partial)
water deprivation test (start in a.m., ‚úìNaserum, Posm, Uosm, UOP q1‚Äì2h)
Deprive until Posm 295, then ‚úìUosm. If Uosm 300, then administer vasopressin (5 U SC)
or dDAVP (10 g intranasal), then check Uosm in 1‚Äì2 hrs:
Uosm c by 50%  central DI
Uosm unchanged  nephrogenic DI
‚úìADH level before and after water deprivation to evaluate proper response 
Figure 4-6 Approach to polyuria
Treatment
‚Ä¢ 1 polydipsia: treat psychiatric illness, check meds, restrict access to free H2O
‚Ä¢ Osmotic diuresis: address underlying cause, replace free H2O deficit (see
‚ÄúHypernatremia‚Äù for formula to calculate) and ongoing losses
‚Ä¢ DI:
central DI: desmopressin (dDAVP)
nephrogenic DI: treat underlying cause if possible; Na restriction  thiazide (mild volume
depletion S T delivery of filtrate to dysfxnal diluting segment of kidney)
pregnancy-induced DI: due to vasopressinase from placenta, ‚à¥ Rx w/ dDAVP
SODIUM
4-9
Polyuria
Osmotic Diuresis
Water Diuresis
Water
deprivation
>1000 mOsm/d
Glucose, Mannitol
Urea
NaCl IVF
Propylene glycol
1¬∞ polydipsia
DI
<800 mOsm/d
Central DI
Nephrogenic DI
dDAVP

--- Fim da P√°gina 115 ---

POTASSIUM
4-10
POTASSIUM HOMEOSTASIS
Overview (Annals 2009;150:619)
‚Ä¢ Renal: potassium excretion regulated at distal nephron (collecting tubule)
distal Na delivery & urine flow: Na absorption S lumen electronegative S K secretion
aldosterone: increases Na absorption, K secretion
‚Ä¢ Transcellular shifts: most common cause of acute change in serum potassium
Acid-base disturbance: K/H exchange across cell membranes
Insulin S stimulates Na-K ATPase S hypokalemia (mitigates postprandial c K)
Catecholamines S stimulate Na-K ATPase S hypokalemia; reversed by -blockers
Digoxin S blocks Na-K ATPase S hyperkalemia
Massive necrosis (eg, tumor lysis, rhabdo, ischemic bowel) S release of intracellular K
Hypo- or hyperkalemic periodic paralysis: rare disorders due to channel mutations
HYPOKALEMIA
Transcellular shifts
‚Ä¢ Alkalemia, insulin, catecholamines, hypokalemic periodic paralysis, acute c in
hematopoiesis (megaloblastic anemia Rx w/ B12, AML crisis), hypothermia
GI potassium losses (UK 25 mEq/d or 15 mEq/L or TTKG 3)
‚Ä¢ GI losses plus metabolic acidosis: diarrhea, laxative abuse, villous adenoma
‚Ä¢ Vomiting & NGT drainage usually manifest as renal losses due to 2 hyperaldo & met. alk.
Renal potassium losses (UK 30 mEq/d or 15 mEq/L or TTKG 7)
‚Ä¢ Hypotensive or normotensive
acidosis: DKA, RTA [proximal RTA (type II) and some distal RTAs (type I)]
alkalosis
diuretics, vomiting/NGT drainage (via 2 hyperaldosteronism)
Bartter‚Äôs syndrome (loop of Henle dysfxn S furosemide-like effect; NEJM 1999;340:1177)
Gitelman‚Äôs syndrome (distal convoluted tubule dysfxn S thiazide-like effect)
Mg depletion: ? c distal K secretion (JASN 2007,18:2649)
‚Ä¢ Hypertensive: mineralocorticoid excess
1 hyperaldosteronism (eg, Conn‚Äôs syndrome)
2 hyperaldosteronism (eg, renovascular disease, renin-secreting tumor)
nonaldosterone mineralocorticoid (eg, Cushing‚Äôs, Liddle‚Äôs, exogenous mineralocort.,
licorice)
Clinical manifestations
‚Ä¢ Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, polyuria
‚Ä¢ ECG: U waves,  c QT interval, ventricular ectopy (PVCs, VT, VF)
Workup (NEJM 1998;339:451)
‚Ä¢ Rule-out transcellular shifts
‚Ä¢ ‚úì24-hr UK and transtubular potassium gradient (TTKG)  (UK/PK) / (Uosm/Posm)
UK 30 mEq/d or 15 mEq/L or TTKG 7 S renal loss
UK 25 mEq/d or 15 mEq/L or TTKG 3 S extrarenal loss
‚Ä¢ If renal losses, ‚úìBP, acid-base, UCl (UNa unreliable for volume status w/ alkalemia)
Figure 4-7 Approach to hypokalemia
Hypokalemia
GI Losses
Diarrhea
Laxatives
Villous adenoma
Renal Losses
DKA
RTA
Mg defic.
Diuretics
Bartter‚Äôs, Gitelman‚Äôs
Vomiting/NGT
acidemic
variable
alkalemic
hypertensive
 acid-base status
<20
1¬∞ hyperaldo
2¬∞ hyperaldo
Non-aldo mineralo
hypo- or normotensive
U  <25 mEq/d
TTKG <3
U  >30 mEq/d
TTKG >7
>20

--- Fim da P√°gina 116 ---

Treatment
‚Ä¢ If true potassium deficit: potassium repletion (T 1 mEq/L  200 mEq total body loss)
KCl 40 mEq PO q4‚Äì6h if nonurgent, KCl 10 mEq/h IV if urgent, recheck K freq
‚Ä¢ Beware of excessive potassium repletion if transcellular shift cause of hypokalemia
‚Ä¢ Treat underlying cause (if hydration needed, avoid dextrose-containing solutions as
dextrose S c insulin S intracellular potassium shifts)
‚Ä¢ Replete Mg as necessary
HYPERKALEMIA
Transcellular shifts
‚Ä¢ Acidemia, insulin defic. (DM), -blockers, dig intox., massive cellular necrosis (tumor
lysis, rhabdo, ischem. bowel, hemolysis), hyperkalemic periodic paralysis, succinylcholine
Decreased GFR
‚Ä¢ Any cause of oligouric or anuric AKI or any cause of end stage renal disease
Normal GFR but with T renal K excretion
‚Ä¢ Normal aldosterone function
T EAV (K excretion limited by T distal Na delivery & urine flow): CHF, cirrhosis
excessive K intake: in conjunction with impairment in K excretion or transcellular shift
‚Ä¢ Hypoaldosteronism: same as etiologies of hypoaldo RTA (type IV)
T renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, HIV
normal renin, T aldo synthesis: 1 adrenal disorders, ACEI, ARBs, heparin
T response to aldosterone
meds: K-sparing diuretics,TMP-SMX, pentamidine, calcineurin inhibitors
tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes
Clinical manifestations
‚Ä¢ Weakness, nausea, paresthesias, palpitations
‚Ä¢ ECG: peaked T waves, c PR interval, c QRS width, loss of P wave, sine wave pattern,
PEA/VF (ECG: low sensitivity, cardiac arrest can be first electrical manifestation!)
Workup (Crit Care Med 2008;36:3246)
‚Ä¢ Rule out pseudohyperkalemia (IVF with K, hemolysis during venipuncture, c plt or WBC)
‚Ä¢ Rule out transcellular shift
‚Ä¢ Assess GFR, if normal:
Consider T distal Na delivery and urine flow
‚úìtranstubular K gradient (TTKG)  (UK/PK)/(Uosm/Posm), 7 c/w hypoaldo 
Treatment of Hyperkalemia
Intervention
Dose
Onset
Comment
Calcium gluconate
1‚Äì2 amps IV
3 min
transient effect (30‚Äì60 min)
Calcium chloridea
stabilizes cell membrane
Insulin
reg. insulin 10 U IV
15‚Äì30
transient effect (30‚Äì60 min)
 1‚Äì2 amps D50W
min
drives K into cells
Bicarbonate
1‚Äì3 amps IV
15‚Äì30
transient effect (60 min)
(esp. if acidemic)
min
drives K into cells in
exchange for H
2 agonists
albuterol 10‚Äì20 mg inh.
30‚Äì90
transient effect (2 h)
or 0.5 mg IV
min
drives K into cells
Kayexalateb
30‚Äì90 g PO/PR
1‚Äì2 h
T total body K (over 6 h)
exchanges Na for K in gut
Diuretics
furosemide 40 mg IV
30 min
T total body K
Hemodialysis
T total body K
acalcium chloride contains more calcium and is typically reserved for use in codes (c risk of tissue necrosis)
bincreased risk of intestinal necrosis with postoperative ileus
‚Ä¢ Rate of onset important to note when establishing a treatment plan
‚Ä¢ Calcium helps prevent cardiac complications; ‚à¥should be initial Rx, esp. if ECG s
‚Ä¢ Insulin, bicarbonate (esp. if acidemic), and 2 agonists should follow to T plasma K
‚Ä¢ Treatments that eliminate total body K essential as other Rxs will wear off with time;
kayexalate 	 diuretics may be effective in many cases, but emergent hemodialysis 
should be considered in life-threatening situations
POTASSIUM
4-11

--- Fim da P√°gina 117 ---

AKI
4-12
RENAL FAILURE
ACUTE KIDNEY INJURY (AKI)
Definition (Crit Care 2007;11:R31)
‚Ä¢ AKI: an abrupt (48 h) c Cr 0.3 mg/dL, c Cr 50%, or UOP 0.5 mL/kg/hr for 6 h
Workup (JAMA 2003;289:747)
‚Ä¢ H&P: recent procedures & meds; VS & vol status; s/s of obstruction, vasc or systemic
dis.; ischemia (prerenal & ATN) accounts for 50% of in-hospital AKI
‚Ä¢ Urine evaluation: output, urinalysis, sediment, electrolytes, and osmolality
‚Ä¢ Fractional excretion of sodium (FENa)  (UNa/PNa)/(UCr/PCr)
1% S prerenal, contrast, or glomerulonephritis; 2% S ATN
In setting of diuretics, ‚úìFEUN  (UUN/PUN)/(UCr/PCr); 35% S prerenal
‚Ä¢ Renal U/S: r/o obstruction & eval kidney size to estimate chronicity of kidney disease
‚Ä¢ Serologies (if indicated): see ‚ÄúGlomerular Disease‚Äù
‚Ä¢ Renal bx: may be necessary if cause remains unclear
Etiologies and Diagnosis of Acute Kidney Injury (Lancet 2005;365:417)
Etiologies
U/A, Sediment, Indices
T Effective arterial volume (NEJM 2007;357:797)
Bland
Hypovolemia, T cardiac contractility (eg, CHF),
Transparent hyaline casts
systemic vasodilatation (eg, sepsis)
FENa 1%
Renal vasoconstriction
BUN/Cr 20
NSAIDs,ACEI/ARB, contrast
Uosm 500
calcineurin inhibitors, hepatorenal, hypercalcemia
Large vessel: RAS (bilateral  ACEI), thrombosis,
embolism, dissection, vasculitis, compression
Acute tubular necrosis (ATN)
Pigmented granular muddy
Ischemia: progression of prerenal disease
brown casts in 75%
Toxins
(	 in CIAKI)
Drugs:AG, amphotericin, cisplatin
	 RBCs & protein from tubular
Pigments: Hb, myoglobin (NEJM 2009;361:62)
damage
Proteins: Ig light chains
FENa 2% (except pigment &
Crystals: UA,ACV, MTX, indinavir, oral NaPO4
CIAKI)
Contrast-induced AKI (CIAKI): T RBF  toxin
Uosm 350
Acute interstitial nephritis (AIN)
WBCs,WBC casts, 	 RBCs
Allergic: -lactams, sulfa drugs, NSAIDs, PPIs
 urine eos in abx
Infection: pyelonephritis, legionella
 lymphs in NSAIDs
Infiltrative: sarcoid, lymphoma, leukemia
Autoimmune: Sj√∂gren‚Äôs,TINU syndrome, IgG4, SLE
Small vessel: cholesterol emboli, thrombotic
	 RBCs
microangiopathy (HUS/TTP, DIC, preeclampsia,
 urine eos in chol emboli
APS, malignant HTN, scleroderma renal crisis)
Glomerulonephritis (see ‚ÄúGlomerular Disease‚Äù)
Dysmorphic RBCs & RBC casts
Bladder neck: BPH, prostate cancer, neurogenic
Bland
bladder, anticholinergic meds
	 RBCs if nephrolithiasis
Ureteral (bilateral): malig, LAN, retroperitoneal
fibrosis, nephrolithiasis
Contrast-induced acute kidney injury (CIAKI)
‚Ä¢ Risk factors: CKD, DM, CHF, age, hypotension, c contrast volume (JACC 2004;44:1393)
‚Ä¢ Clinical: Cr c 25% or 0.5 mg/dL w/in 48 h, peaks in 3‚Äì5 d, resolves in 7‚Äì10 d
‚Ä¢ Prevention (NEJM 2006;354:379; JAMA 2006;295:2765; Circ 2006;113:1799)
N-acetylcysteine 1,200 mg PO bid on day prior to and day of contrast (NEJM 2006;354:2773)
Prehydration/posthydration (NEJM 1994;331:1416) unless contraindic. to IVF (eg, CHF)
isotonic NaHCO3: 3 mL/kg/h  1 h before, 1 mL/kg/h  6 h after (JAMA 2004;291:2328)
unclear if NaHCO3 more effective than saline, hydration is the key (Annals 2009;151:631)
benefit additive to N-acetylcysteine (Circ 2007;115:1211)
Hold ACEI/ARB, NSAIDs, diuretics
Minimize contrast volume and consider iso-osmolar contrast (JACC 2006;48:692)
? Hemofiltration (before & for 24 h after) if Cr 2.0 (NEJM 2003;349:1333)
‚Ä¢ Gadolinium: can cause AKI in stage IV CKD (Neph Dial Trans 2006;21:697), no effective ppx
Nephrogenic systemic fibrosis: fibrosis of skin, joints, eyes, and internal organs 2‚Äì4 wks
post exposure in Pts w/ moderate to severe CKD (JACC 2009;53:1621)
Post
Intrinsic
Prerenal

--- Fim da P√°gina 118 ---

Treatment
‚Ä¢ Treat underlying disorder (see relevant sections); ? steroids if AIN (KI 2008;73:940)
‚Ä¢ Avoid nephrotoxic insults; review dosing of renally cleared drugs
‚Ä¢ Optimize hemodynamics (both MAP & CO); may take 1‚Äì2 wks to recover from ATN 
‚Ä¢ Watch for and correct volume overload, electrolyte (c K, c PO4), & acid/base status
‚Ä¢ If obstruction is diagnosed and relieved, watch for:
Hypotonic diuresis (2 buildup of BUN, tubular damage); Rx w/ IVF (eg, 1‚ÅÑ2 NS)
Hemorrhagic cystitis (rapid  in size of bladder vessels); avoid by decompressing slowly
‚Ä¢ Indications for urgent dialysis (when condition refractory to conventional therapy)
Acid-base disturbance: acidemia
Electrolyte disorder: generally hyperkalemia; occasionally hypercalcemia, tumor lysis
Intoxication: methanol, ethylene glycol, lithium, salicylates
Overload of volume (CHF)
Uremia: pericarditis, encephalopathy, bleeding
‚Ä¢ No benefit to dopamine (Annals 2005;142:510), diuretics (JAMA 2002;288:2547), or mannitol
CHRONIC KIDNEY DISEASE (CKD)
Definition and Etiologies (Annals 2009;150:ITC2-1 & Lancet 2010;375:1296)
‚Ä¢ 3 mos of reduced GFR (60) and/or kidney damage (path, markers, imaging)
‚Ä¢ Prevalence 13% in U.S.; Cr poor estimate of GFR; ‚à¥use prediction equation,
eg, MDRD equation: www.kidney.org/professionals/KDOQI/gfr_calculator.cfm
nb, equation may underestimate GFR in Pts w/ normal renal fxn
‚Ä¢ Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%)
(NEJM 2008;359:1477), congenital, drugs, myeloma, progression of AKI (JAMA 2009;302:1179)
‚Ä¢ Rates of all-cause mortality and CV events increase with each stage of CKD and are
significantly higher than the rate of progression to kidney failure (NEJM 2004;351:1296)
Stages of CKD
Stage
GFR mL/min/1.73 m2
Goals
1 (nl or c GFR)
90
Dx/Rx of underlying condition & comorbidities,
slow progression; cardiovascular risk reduction
2 (mild)
60‚Äì89
Estimate progression
3 (moderate)
30‚Äì59
Evaluate and treat complications
4 (severe)
15‚Äì29
Prepare for renal replacement therapy (RRT)
5 (kidney failure)
15 or dialysis
Dialysis if uremic
Signs and Symptoms of Uremia (NEJM 2007;357:1316)
General
Nausea, anorexia, malaise, fetor uremicus, metallic taste, susceptibility 
to drug O/D, decreased temperature
Skin
Uremic frost (white crystals in & on skin), pruritis, calciphylaxis, NSF
Neurologic
Encephalopathy ( MS, T memory & attention), seizures, neuropathy,
impaired sleep, restless leg syndrome
Cardiovascular
Pericarditis, accelerated atherosclerosis, hypertension, hyperlipidemia,
volume overload, CHF, cardiomyopathy (especially LVH)
Hematologic
Anemia, bleeding (due to platelet dysfunction)
Metabolic
c K, c PO4, acidosis, T Ca, 2 hyperparathyroidism, osteodystrophy
Treatment (Annals 2009;150:ITC2-1, NEJM 2010;362:57)
‚Ä¢ General: nephrology referral when GFR 30 and access planning (avoid subclavian
lines; preserve an arm for access by avoiding blood draws, BP measurements, IVs)
‚Ä¢ Dietary restrictions: Na (if HTN), K (if oliguric or hyperkalemic), PO4, ? moderate
protein restriction, strict glc control in DM
‚Ä¢ BP Control: goal 130/80, start with ACEI (or ARB), effective in diabetic & nondiabetic
CKD (NEJM 2004;351:1952). ACEI  ARB unresolved (Annals 2008;148:30 & Lancet 2008;372:547).
For outPts, ‚úìCr & K in 1‚Äì2 wks, d/c if Cr c 30% or K 5.4 (after dietary  & loop diuretic).
ACEI may be effective & safe in advanced nondiabetic CKD (Cr 3‚Äì5) (NEJM 2006;354:131).
‚Ä¢ Metabolic acidosis: sodium bicarbonate or sodium citrate if HCO3 22 (JASN 2009;20:2075)
‚Ä¢ Anemia: goal Hb 11‚Äì12 g/dL; c death, HTN, stroke, & thromb w/ c Hb (NEJM 2006;
355:2085); no survival benefit w/ Hb 9 via epo if diabetic nephropathy (NEJM 2009;361:2019)
epoetin (start 80‚Äì120 U/kg SC, divided 3/wk) or darbepoetin (0.45 mcg/kg q wk)
iron supplementation to keep transferrin sat 20% (often given IV in HD Pts)
uremic bleeding: desmopressin (dDAVP) 0.3 g/kg IV or 3 g/kg intranasally
CKD
4-13

--- Fim da P√°gina 119 ---

‚Ä¢ 2 Hyperparathyroidism: c PO4, T Ca, T calcitriol S c PTH S renal osteodystrophy
CKD Stage
3
4
5
Target PTH (pg/mL)
35‚Äì70
70‚Äì110
150‚Äì300
phosphorus binders (take with meals!) (NEJM 2010;362:1312)
if c PO4 and T Ca S calcium acetate (PhosLo) or calcium carbonate
if refractory c PO4 or in setting of c Ca S sevelamer (Renagel), lanthanum (Fosrenol)
if severe c PO4 S aluminum hydroxide (Amphojel), short-term use only
calcitriol or paricalcitol if Ca-PO4 product 55 (? c survival in HD Pts, NEJM 2003;349:446)
cinacalcet (parathyroid calcium-sensing receptor agonist) if PTH remains elevated
despite phosphorus binders 	 vit D analogue (NEJM 2004;350:1516)
parathyroidectomy
‚Ä¢ Consider transplant evaluation
DIURESIS
General considerations 
‚Ä¢ Increases Na excretion for treatment of HTN or edema in CHF, renal failure and cirrhosis 
‚Ä¢ Daily wt most effective method of documenting successful diuresis
Loop diuretics (NEJM 1998;339:387)
‚Ä¢ Drugs: furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid
‚Ä¢ Mechanism: inhibit Na-K-2Cl transporter in thick ascending limb (ThAL)
Response is fxn of amt of drug excreted; ‚à¥c dose needed in renal insufficiency, CHF
Sigmoidal dose response curve; ‚à¥c dose until induce diuresis, cc dose beyond that
point yields diminishing returns compared with c frequency of dosing.
‚Ä¢ Dosing: PO bioavailability of furosemide 50%, ‚à¥IV dose 2 as potent as PO dose
torsemide & bumetanide 90% bioavailability; use ethacrynic acid if sulfa allergy
40 mg furosemide PO ‚âà20 mg furosemide IV ‚âà20 mg torsemide PO ‚âà1 mg bumetanide
dose furosemide bid-qid; qd dosing can lead to initial diuresis S antinatriuresis
? c diuresis w/ contin. infusion (bolus S titrate drip) vs. bolus alone (Annals 1991;115:360)
? c diuresis w/ co-administration of albumin if T serum albumin (Crit Care Med 2005;33:1681)
Thiazide diuretics (NEJM 2009;361:2153)
‚Ä¢ Drugs: hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)
‚Ä¢ Mechanism: inhibit Na-Cl cotransporter in the distal convoluted tubule (DCT)
synergistic with loop diuretic, esp. if chronic loop use
T effect when GFR 30, except metolazone which is still effective in renal insufficiency
‚Ä¢ Dosing: give prior to loop diuretic, typically 30 min before 
K-sparing diuretics
‚Ä¢ Drugs: spironolactone (Aldactone), amiloride, triamterene, eplerenone
‚Ä¢ Mechanism: T Na reabsorption in collecting duct (amiloride/triamterene inhibit principal
cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor).
Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.
Approach to Diuresis (if inadequate diuresis, go to next step)
Step
Action
1
Loop diuretic PO: ‚úìresponse at 3 h, redose at 2 prior dose if needed
2
Add thiazide diuretic PO (potentiates response to loop diuretic)
3
Loop diuretic IV: bolus bid-qid 	 thiazide (may start here if inPt)
c dose needed w/ c Cr; initial effective IV lasix dose ‚âà30  Cr
(ie, if Cr  4 S 120 mg IV lasix)
4
Loop diuretic infusion: bolus  continuous IV infusion 	 thiazide
5
RRT: consider ultrafiltration, CVVH, or HD
Disease state specific regimens
‚Ä¢ Renal insufficiency: loop diuretic (c dose to achieve effective delivery to ThAL) 	 thiazide
‚Ä¢ CHF: loop diuretic (c frequency over c dose)  thiazide (watch K & Mg)
‚Ä¢ Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2‚Äì3  normal dose
‚Ä¢ Cirrhosis: spironolactone (blocks 2 hyperaldosteronism)  lasix in 2.5:1 ratio
‚Ä¢ Severe metabolic alkalosis: acetazolamide & treat underlying cause
Adverse effects
‚Ä¢ Loop: T Na, T K, T Mg, T Ca, hyperuricemia, ototoxicity
‚Ä¢ Thiazide: T Na, T K, T Mg, c Ca, hyperlipidemia, pancreatitis
‚Ä¢ K-sparing: c K (especially w/ ACEI), metabolic acidosis
DIURESIS
4-14

--- Fim da P√°gina 120 ---

DIALYSIS
General
‚Ä¢ Substitutes for renal solute and fluid removal 
‚Ä¢ Acute: CVVH vs. HD (Chest 2007;132:1379); Chronic: PD vs. HD
Hemodialysis (HD) (NEJM 1998;338:1428; 339:1054)
‚Ä¢ Physiology: blood flows along one side of semipermeable membrane, dialysate along other
Fluid removal (ie, Na  H2O) via transmembrane pressure (TMP) gradient
Solute removal via transmembrane concentration gradient and inversely proportional
to size (‚à¥effective removal of K, urea, and Cr, but not PO4)
‚Ä¢ Typical orders: duration, volume removal goals, K and Ca in dialysate bath, anticoagulation
‚Ä¢ Complications: hypotension, arrhythmia, access complications, disequilibrium syndrome
Vascular Access
Advantages
Disadvantages
AV Fistula
Highest patency
Long maturation time (2‚Äì6 mo)
Lowest risk of bacteremia
Primary nonfunction (20%)
AV Graft
Easier to create than AVF
Poor 1 patency, often requiring
Maturation time (2‚Äì3 wks)
thrombectomy or angioplasty
Catheter
Immediate use
Highest risk of bacteremia
Use as bridge to AVF/AVG
T blood flow S T HD efficiency
Continuous Veno-Venous Hemofiltration (CVVH) (NEJM 1997;336:1303)
‚Ä¢ Physiology: based on hemofiltration rather than dialysis. Blood under pressure passes
down one side of a highly permeable membrane allowing water and solutes to pass
across the membrane via TMP gradient (convective clearance). Filtrate is discarded.
Replacement fluid is infused (solute concentrations similar to plasma, except no K,
urea, Cr, PO4). Fluid balance precisely controlled by adjusting amounts of filtrate
and replacement fluid.
‚Ä¢ Access: double-lumen central venous catheter
‚Ä¢ Typical orders: volume removal goals, replacement fluid buffer: HCO3 (requires heparin 
to prevent machine from clotting) vs. citrate (hepatically metabolized to HCO3;
provides anticoagulation w/ in machine via Ca chelation; ‚à¥need Ca infusion to
maintain serum Ca)
‚Ä¢ Complications: hypotension, T PO4, access complications; T ICa (citrate toxicity in Pts
with hepatic dysfunction S look for T ICa but normal/ c serum Ca and AG meta-
bolic acidosis)
‚Ä¢ Potential advantages over HD: less hypotension, better volume control, removal of
inflammatory mediators; however, no survival advantage (Lancet 2006;368:379)
‚Ä¢ No advantage for high intensity CVVH over standard intensity (NEJM 2008;359:7)
Peritoneal Dialysis (PD) (Perit Dial Int 2001;21:25)
‚Ä¢ Physiology: peritoneum acts as membrane. Fluid balance controlled by choosing
dialysate glucose concentration (higher concentrations pull more fluid into peri-
toneum); longer dwell times pull less fluid as glucose equilibrates across peritoneum
‚Ä¢ Access: permanent catheter inserted in OR
‚Ä¢ Typical orders for CAPD (continuous ambulatory peritoneal dialysis):
PD fluid  1.5%, 2.5%, or 4.25% dextrose
buffer (lactate), Na, K, Ca2, Mg2
infuse 10 min, dwell 30 min‚Äì5.5 h, drain 20 min
‚Ä¢ Can use overnight cycler device that infuses & drains more rapidly, with shorter dwells,
while Pt sleeps. Called automated or continuous cycling peritoneal dialysis (APD, CCPD).
‚Ä¢ Complications
Peritonitis (abdominal pain, tenderness, cloudy drainage)
diagnosis:WBC 100 and 50% PMNs
spectrum: 60‚Äì70% GPC, 15‚Äì20% GNR, remainder no bacteria or fungal
Rx: abx IV or in PD, catheter removal for certain pathogens (eg, yeast, Pseudomonas)
Hyperglycemia: exacerbated by inflammation, long dwell times, and higher [glc]
T albumin; right-sided pleural effusion
DIALYSIS
4-15

--- Fim da P√°gina 121 ---

NEPHRITIC
4-16
GLOMERULAR DISEASE
GLOMERULONEPHRITIS (GN)
Definition (NEJM 1998;339:888 & Lancet 2005;365:1797)
‚Ä¢ Pathologically: intraglomerular inflammation (ranging from focal proliferative [50% of
glomeruli] to diffuse proliferative to crescentic) (Lancet 2006;368:404)
‚Ä¢ Clinically: hematuria w/ dysmorphic RBCs or RBC casts, 	 subnephrotic proteinuria
often w/ renal failure, HTN, edema; spectrum of progression tempo:
acute GN  over days; rapidly progressive GN (RPGN)  wks; chronic GN  mos;
can simply have asx hematuria
ANCA Vasculitis (pauci-immune or minimal staining) 40‚Äì45% of total
Disease
Gran
Renal
Pulm
Asthma
ANCA Type*
ANCA 
Wegener‚Äôs

80%
90%
‚Äî
c-ANCA
90%
granulomatosis
( ENT)
(anti-PR3)
Microscopic
‚Äî
90%
50%
‚Äî
p-ANCA
70%
polyangiitis
(anti-MPO)
Churg-Strauss

45%
70%

p-ANCA
50%
syndrome
(anti-MPO)
*Predominant ANCA type; either p- or c-ANCA can be seen in all three diseases. (NEJM 1997;337:1512)
Anti-GBM Disease (linear staining) 15% of total
Disease
Glomerulonephritis
Pulm hemorrhage
Anti-GBM
Goodpasture‚Äôs



Anti-GBM disease

‚Äî

Immune Complex (IC) Disease (granular staining) 40‚Äì45% of total
Renal-limited diseases
Systemic diseases
Poststreptococcal GN
SLE
(PSGN, usually 10‚Äì14 d,  ASLO, T C3) ( ANA, anti-dsDNA, T C3, T C4)
Membranoproliferative GN
Cryoglobulinemia
(MPGN, T C3)
( cryocrit,  RF, HCV Ab, T C3, T C4)
Fibrillary glomerulonephritis
Endocarditis
(normal C3)
(fever,  BCx, valvular disease, T C3)
IgA nephropathy
Henoch-Sch√∂nlein purpura
(normal C3)
(IgA nephropathy  systemic vasculitis, normal C3)
Workup (Archives 2001;161:25)
‚Ä¢ AGN/RPGN 	 lung hemorrhage is an emergency S requires early Dx and Rx
‚Ä¢ ANCA (Lancet 2006;368:404), anti-GBM, complement levels
‚Ä¢ Depending on clinical hx:ANA,ASLO, BCx, cryocrit, hepatitis serologies, skin bx
‚Ä¢ Consider GN mimics
thrombotic microangiopathy: T Hct & Plts, schistocytes on smear, c LDH
cholesterol emboli (Lancet 2010;375:1650): purple toes, livedo, T C3/C4, eos, prior cath
AIN: rash, new drug exposure, urine WBCs (incl eos) 	 WBC casts
myeloma: anemia, hypercalcemia, lytic bone lesions, SPEP/UPEP
‚Ä¢ Renal biopsy with immunofluorescence (IF) 	 electron microscopy (EM)
Figure 4-8 Approach to glomerulonephritis
Glomerulonephritis
Wegener‚Äôs
c-ANCA
   granuloma
p-ANCA
Immune Complex Disease
(granular IF)
PSGN, MPGN
SLE, IE
Cryoglobulinemia
IgA/HSP
Fibrillary GN
‚Üì C3
nl C3
Anti-GBM Disease
(linear IF)
asthma
   gran
gran
Microscopic Polyangiitis
Churg-Strauss
Goodpasture‚Äôs
Anti-GBM
    lung
hemorrhage
   lung
hemorrhage
clinical history
ANCA
¬± ‚Üì complement
anti-GBM
ANCA      Vasculitis
(pauci-immune)
‚àí
‚àí
+
+
+
+
+
+

--- Fim da P√°gina 122 ---

Treatment
‚Ä¢ ANCA  or anti-GBM: steroids ASAP  cyclophos; 	 plasmapheresis (JASN 2007;18:2180)
‚Ä¢ SLE nephritis: IV cyclophosphamide  steroids S azathioprine or MMF (JAMA 2005;293:3053);
induction with MMF (no cyclophosphamide) may be as effective (NEJM 2005;353:2219)
‚Ä¢ Other IC disease: ? steroids 	 alkylating agents; treat underlying systemic disease
ASYMPTOMATIC GLOMERULAR HEMATURIA
Definition and Etiologies
‚Ä¢ Hematuria 	 proteinuria of glomerular origin w/o renal insufficiency or systemic 
disease (nonglomerular hematuria more common; see ‚ÄúHematuria‚Äù)
‚Ä¢ Ddx: any cause of GN, especially IgA; also consider Alport‚Äôs (X-linked, deafness, renal
failure) and thin basement membrane nephropathy (autosomal dominant, benign course)
IgA Nephropathy (NEJM 2002;347:738 & JASN 2005;16:2088)
‚Ä¢ Most common cause of GN; male predominance w/ peak incidence 20‚Äì30s
‚Ä¢ Wide range of clinical presentations: asx hematuria (30‚Äì40%), gross hematuria 1‚Äì3 d
after URI (30‚Äì40%), chronic GN (10%), nephrotic syndrome (5%), RPGN (5%)
‚Ä¢ Though clinical presentation can be highly suggestive, definitive dx only w/ bx
‚Ä¢ Prognosis: 25‚Äì30% will reach ESRD w/in 20‚Äì25 y of presentation
‚Ä¢ Treatment:ACEI/ARB, 	 fish oils (NEJM 1994;331:1194); steroids (JASN 2004;15:157) 	 cytotoxic
therapy for crescentic GN and nephrotic sx, consider for progressive chronic GN
NEPHROTIC SYNDROME
Definition
‚Ä¢ Proteinuria 3.5 g/d, albumin 3.5 mg/dL, edema, c cholesterol
Primary glomerular diseases (grouped by pathology)
‚Ä¢ Focal segmental glomerulosclerosis (40%)
idiopathic, HIV (collapsing variant), pamidronate, heroin, congenital, hyperfiltration due
to prior nephron loss, obesity, vesicoureteral reflux
‚Ä¢ Membranous nephropathy (30%)
idiopathic (phospholipase A2 receptor Abs; NEJM 2009;361:11), infxn (espec. HBV, also
HCV, syphilis), autoimmune (espec. SLE), carcinomas, drugs (NSAIDs, penicillamine)
‚Ä¢ Minimal change disease (20%, more common in children)
idiopathic, NSAIDs, Hodgkin‚Äôs disease & other lymphoproliferative disorders
‚Ä¢ Membranoproliferative GN (5%, mixed nephrotic/nephritic features)
Type I: infection (especially HCV 	 cryos; IE, HBV, other chronic infxns), immune
complex disease (SLE, cryos, Sj√∂gren‚Äôs), lymphoproliferative disorders, idiopathic
Type II: very rare; autoAb blocks inactivation of C3 convertase  C3 nephritic factor
‚Ä¢ Fibrillary-immunotactoid glomerulopathy (1%)
‚Ä¢ Mesangial proliferative GN (likely atypical forms of MCD or FSGS, 5%)
Systemic diseases
‚Ä¢ Diabetes mellitus: nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); large kidneys
hyperfiltration S microalbuminuria S dipstick  S nephrotic range (10‚Äì15 y)
concomitant proliferative retinopathy seen in 90% of type 1 and 60% of type 2
‚Ä¢ Amyloidosis:AL or light chain amyloid or AA amyloid secondary to inflammation
‚Ä¢ SLE: typically with membranous nephropathy (WHO class V)
‚Ä¢ Cryoglobulinemia: typically with membranoproliferative GN
Workup (Archives 2001;161:25 & BMJ 2008;336:1185)
‚Ä¢ Urine sediment: usually benign w/o concurrent nephritis; 	 oval fat bodies (‚ÄúMaltese
crosses,‚Äù NEJM 2007;357:806)
‚Ä¢ Measure proteinuria: 24-h urine collection or urine prot/Cr ratio (not accurate in AKI)
‚Ä¢ r/o secondary causes: c HbA1C  retinopathy S presumpt. dx of diabetic nephropathy;
‚úìANA, anti-dsDNA, C3, C4, SPEP/UPEP, fat pad bx, cryocrit, HBV, HCV, HIV, RPR,
phospholipase A2 receptor Ab
‚Ä¢ Renal biopsy
Treatment
‚Ä¢ General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (2 g/d)
‚Ä¢ ACEI/ARB: decrease proteinuria S slow nonimmunologic progression of renal disease
‚Ä¢ 1¬∫ glomerular dis: steroids 	 cytotoxic therapy; cancer screening if membranous neph.
‚Ä¢ Secondary causes: treat underlying disease
‚Ä¢ General: watch for malnutrition (protein loss), thrombosis (esp. renal vein, b/c loss of ATIII
& other endogenous anticoags), infection (esp. encapsulated organisms b/c loss of Ig) 
NEPHRITIC
4-17

--- Fim da P√°gina 123 ---

U/A
4-18
URINALYSIS
Urine Dipstick
Measurement
Significance and uses
Specific
estimate Uosm: each 0.001 above 1 30 osm (SG 1.010 S Uosm 300)
Gravity
SG and Uosm useful in evaluating AKI, dysnatremias, polyuria
heavy substances (glucose, contrast) increase SG more than Uosm
pH
range: 4.5‚Äì8.5; useful in evaluation of stones and RTAs, infection
Protein
detects albumin (marker for glomerular dysfxn); see ‚ÄúProteinuria‚Äù
RBC
see ‚ÄúHematuria‚Äù; also  with myoglobinuria (rhabdomyolysis)
WBC
suggests inflammation (UTI, interstitial nephritis, GN)
Ketones
detects acetoacetate (ie, ketoacidosis), but not -hydroxybutyrate
Nitrite
suggests presence of Enterobacteriaceae
Bilirubin
c in biliary or hepatic disease
Glucose
 in hyperglycemia (180 mg/dL), pregnancy, Fanconi‚Äôs syndrome
Urine Sediment (microscopic examination) (Am J Kidney Dis 2008;51:1052)
Method: centrifuge fresh sample  3‚Äì5 min at 1500‚Äì3000 RPM; pour off supernatant in
one motion; resuspend pellet by agitating base of tube; pour suspension onto slide, place
coverslip; view under ‚Äúhigh dry‚Äù power; phase contrast for RBC morphology.
Cells
RBCs: assess amount & morphology (many dysmorphic S glomerular)
WBCs: PMNs (UTI) vs. eosinophils (AIN; may require special stain)
Epithelial cells: tubular (ATN), transitional (bladder or ureters), squamous
Casts
Proteins molded in lumen of renal tubule 	 entrapped cellular elements
See Urinalysis Photo Inserts
RBC S GN
WBC S AIN, pyelonephritis, GN
Granular (‚Äúmuddy brown‚Äù): degenerating cellular casts S ATN
Tubular cell S ATN
Hyaline:Tamm-Horsfall protein (nonspecific)
Waxy and broad S advanced chronic kidney disease
Crystals
Calcium oxalate monohydrate: spindle, oval, or dumbbell shaped
Calcium oxalate dihydrate: envelope shaped or octahedral
Uric acid: variable shape; polychromatic under polarized light
Cystine: hexagon shaped
Struvite: coffin-lid shaped; seen in chronic UTI with urea-splitting organisms
PROTEINURIA
Etiologies of Proteinuria
Category
Description
Etiologies
Glomerular
Disruption of filtration
Glomerulonephritis
(can be 3 g/d)
barrier S lose albumin
Nephrotic syndrome
Tubulointerstitial
T reabsorption of freely
ATN
(usually 1‚Äì2 g/d)
filtered proteins S lose
AIN
globulins
Fanconi‚Äôs syndrome
Overflow
c production of freely
Multiple myeloma
filtered proteins
Myoglobinuria
Isolated
By def‚Äôn: asx, normal
Functional (fever, exercise, CHF)
renal fxn, sed, & imaging,
Orthostatic (only when upright)
no h/o renal disease
Idiopathic (transient or persistent)
‚Ä¢ Urine dipstick
1 30 mg/dL, 2 100 mg/dL, 3 300 mg/dL, 4 2 g/dL S interpretation depends
on SG; eg, 3 in very concentrated urine might not indicate heavy proteinuria
Insensitive for microalbuminuria and myeloma light chains; false  with contrast
‚Ä¢ Spot urine: protein (mg/dL)/creatinine (mg/dL) g/d of proteinuria (NEJM 1983;309:1543)
unlike urine dipstick, will accurately measure myeloma light chains
‚Ä¢ Orthostatic proteinuria: typically in adolescents; 90% of young  with isolated 
proteinuria have orthostatic proteinuria; typically resolves spontaneously

--- Fim da P√°gina 124 ---

HEMATURIA
Etiologies of Hematuria
Extrarenal (far more common)
Intrarenal
Nephrolithiasis
Nephrolithiasis or crystalluria
Neoplasm: transitional cell, prostate
Neoplasm
Infection: cystitis, urethritis, prostatitis
Trauma / exercise
Foley trauma
Vascular: renal infarcts, renal vein thromb.,
BPH
sickle cell disease and trait
Schistosoma haematobium
Glomerular disease (IgA, thin BM  others)
PKD (NEJM 2008;359:1477)
‚Ä¢ Wide, overlapping ages for various etiologies, but general guide for common causes:
20 y: GN, UTI, congenital; 20‚Äì60 y: UTI, nephrolithiasis, cancer
60 y : prostatitis, cancer, UTI; 60 : UTI, cancer
Workup (NEJM 2003;348:2330 & BMJ 2009;338:a3021)
‚Ä¢ Urine dipstick:  if 3 RBCs;  dipstick and  sediment S myo- or hemoglobinuria
‚Ä¢ Urine sediment: dysmorphic RBCs or RBC casts S GN S consider renal bx
‚Ä¢ If no evidence of glomerulonephritis:
r/o UTI
Urine cytology (Se 70%, Sp 95%; ‚à¥‚úìam void  3 to c yield)
Renal imaging: helical CT (r/o nephrolithiasis and neoplasia of upper tract), cystoscopy
(r/o bladder neoplasia, esp. 50 y), ? U/S (r/o obstruction or parenchymal disease)
NEPHROLITHIASIS
Types of stones and risk factors (Lancet 2006;367:333 & Annals 2009;151:ITC2)
‚Ä¢ Calcium (Ca oxalate  Ca phosphate): 70‚Äì90% of kidney stones
Urine characteristics: c Ca, c oxalate, c urate, c pH, T citrate, T volume
2 hypercalciuria: 1 hyperparathyroidism, type 1 RTA, sarcoid
2 hyperoxaluria: Crohn‚Äôs, ileal disease w/ intact colon, gastric bypass
Diet: c animal protein, c sucrose, c Na, T K, T fluid, T fruits/vegetables
‚Ä¢ Uric acid: 5‚Äì10% of kidney stones, radiolucent on plain film
Urine characteristics: c uric acid (eg, gout), T pH (eg, from chronic diarrhea)
‚Ä¢ Magnesium ammonium phosphate (‚Äústruvite‚Äù or ‚Äútriple phosphate‚Äù)
Chronic UTI w urea-splitting organisms (eg, Proteus, Klebs) S c urine NH3 and pH (7)
‚Ä¢ Cystine: inherited defects of tubular amino acid reabsorption
Clinical manifestations
‚Ä¢ Hematuria (absence does not exclude diagnosis), flank pain, N/V, dysuria, frequency
‚Ä¢ Ureteral obstruction (stones 5 mm unlikely to pass spont.) S AKI if solitary kidney
‚Ä¢ UTI: c risk of infection proximal to stone; urinalysis of distal urine may be normal
Workup
‚Ä¢ Noncontrast helical CT scan (ureteral dilation w/o stone suggests recent passage) 
‚Ä¢ Strain urine for stone to analyze; U/A & UCx, electrolytes, BUN/Cr, Ca, PO4, PTH, UA
‚Ä¢ 24-h urine  2 (6 wk after acute setting) for Ca, PO4, UA, oxalate, citrate, Na, Cr
Acute treatment (NEJM 2004;350:684)
‚Ä¢ Analgesia (narcotics 	 NSAIDs; combination superior, Ann Emerg Med 2006;48:173), aggressive
PO/IV hydration, antibiotics if UTI
‚Ä¢ Consider CCB or alpha blocker to promote ureteral relaxation (Lancet 2006;368:1171)
‚Ä¢ Indications for immediate urologic evaluation and/or hospitalization: obstruction
(especially solitary or transplant kidney), urosepsis, intractable pain or vomiting, AKI
‚Ä¢ Urologic Rx: lithotripsy, cystoscopic stent, percutaneous nephrostomy, stone removal
Chronic treatment
‚Ä¢ Increase fluid intake (2 L/d) for goal UOP 2 L/d
‚Ä¢ Calcium stones: 24-h urine identifies specific urinary risk factors to treat
T Na and meat intake (NEJM 2002;346:77), thiazides: decrease urine Ca
Depending on 24-h urine: K-citrate, dietary oxalate restriction, allopurinol
High dietary Ca is likely beneficial by T oxalate absorp., unclear role of Ca supplements
‚Ä¢ Uric acid: urine alkalinization (K-citrate), allopurinol
‚Ä¢ Magnesium ammonium phosphate: antibiotics to treat UTI, urologic intervention
‚Ä¢ Cystine: urine alkalinization (K-citrate), D-penicillamine, tiopronin, captopril
NEPHROLITH
4-19

--- Fim da P√°gina 125 ---

NOTES
NOTES
4-20

--- Fim da P√°gina 126 ---

ANEMIA
5-1
ANEMIA
T in RBC mass: Hct 41% or Hb 13.5 g/dL (men); Hct 36% or Hb 12 g/dL (women)
Clinical manifestations
‚Ä¢ Symptoms: T O2 delivery S fatigue, exertional dyspnea, angina (if CAD)
‚Ä¢ Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension
‚Ä¢ Other findings: jaundice (hemolysis), splenomegaly (thalassemia, neoplasm, chronic
hemolysis), petechiae/purpura (bleeding disorder), glossitis (iron, folate, vitamin B12
defic.), koilonychia (iron defic.), neurologic abnormalities (B12 defic.)
Diagnostic evaluation
‚Ä¢ History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including pica), FHx
‚Ä¢ CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can S nl MCV), RDW 
‚Ä¢ Reticulocyte index (RI)  [reticulocyte count  (Pt‚Äôs Hct/nl Hct)]/maturation factor
maturation factors for a given Hct: 45%  1, 35%  1.5, 25%  2, 20%  2.5
RI 2% S adequate marrow response; RI 2% S hypoproliferation
‚Ä¢ Peripheral smear: select area where RBCs evenly spaced and very few touch each
other; ‚úì RBC size, shape, inclusions (see Appendix & Peripheral Smear inserts),
WBC morphology, plt count 
‚Ä¢ Additional labs as indicated: hemolysis labs (if RI 2%), iron/TIBC, ferritin, folate, B12,
LFTs, BUN and Cr,TFTs, Hb electrophoresis, enzyme analyses, gene mutation screens
‚Ä¢ Bone marrow (BM) aspirate and biopsy (bx) with cytogenetics as indicated
Figure 5-1 Approach to anemia
Anemia
UNDERPRODUCTION
RI <2%
microcytic
anemia
normocytic
anemia
INCREASED DESTRUCTION or LOSS
recent acute
blood loss
hemolysis
‚Üë LDH
‚Üë bilirubin
‚Üì haptoglobin
macrocytic
anemia
s/s of
bleeding
low
MCV
normal
MCV
high
MCV
RI >2%
MICROCYTIC ANEMIAS
Iron deficiency (NEJM 1999;341:1986 & Hematology ASH Educ Prog 2003;40)
‚Ä¢ T marrow iron & depleted body iron stores S T heme synthesis S microcytosis S anemia
‚Ä¢ Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of
nonnutritive substances such as ice, clay), koilonychia (nail spooning)
Plummer-Vinson syndrome (iron deficiency anemia, esophageal web & atrophic glossitis)
‚Ä¢ Etiologies: chronic bleeding (GI‚Äîincluding cancer, menstrual, etc.), T supply (mal-
nutrition; T absorp. due to celiac sprue, Crohn‚Äôs, c gastric pH, subtotal gastrecto-
my), c demand (preg., epo). Rare Fe-refractory genetic disorder due to hepcidin
dysregulation (Nat Genet 2008;40:569).
‚Ä¢ Diagnosis: T Fe, c TIBC, T ferritin (espec. 15), T transferrin sat (Fe/TIBC; espec.
15%), c soluble transferrin receptor; c plt; unless hx c/w different etiology, initiate
workup for GIB; incl. H. pylori serology, ? celiac sprue labs (anti-TTG, antigliadin,
antiendomysial Ab)
‚Ä¢ Treatment (Fe supplementation): oral Fe tid (6 wk to correct anemia; 6 mo to
replete Fe stores); in cases of excessive/persistent GI losses or for dialysis or cancer
Pts prior to EPO Rx, IV iron (Fe-sucrose, -gluconate, -dextrose) should be considered  
Thalassemias (NEJM 2005;353:1135)
‚Ä¢ T synthesis of - or -globin chains of Hb S Z subunits S destruction of RBCs and
erythroid precursors; ‚à¥anemia from hemolysis and ineffective erythropoiesis
‚Ä¢ -thalassemia: deletions in -globin gene complex on chr. 16 (nl 4  genes)
3  S -thal-2 trait  silent carrier; 2  S -thal-1 trait or -thal minor  mild anemia
1  S HbH (4) disease  severe anemia, hemolysis, and splenomegaly
0  genes S Hb Barts (4)  intrauterine hypoxia and hydrops fetalis
‚Ä¢ -thalassemia: mutations in -globin gene on chr. 11 S absent or T gene product
1 mutated  gene S thal minor (or trait)  mild anemia (no transfusions)
2 mutated  genes S thal intermedia (occasional transfusions) or thal major (  Cooley‚Äôs
anemia; transfusion-dependent) depending on severity of mutations

--- Fim da P√°gina 127 ---

ANEMIA
5-2
‚Ä¢ Special clinical manifestations (in severe cases): chipmunk facies, pathologic fractures,
hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF,
bilirubin gallstones, iron overload syndromes (from chronic transfusions)
‚Ä¢ Diagnosis: MCV 70, normal Fe, MCV/RBC count 13, 	 c retics, basophilic
stippling; Hb electrophoresis: c HbA2 (2
2) in -thal; normal pattern in -thal trait
‚Ä¢ Treatment: folate; transfusions  deferoxamine, deferasirox (oral iron chelator);
splenectomy if 50% c in transfusions; consider allogeneic HSCT in children w/ severe
-thal major
Anemia of chronic inflammation (see below)
Sideroblastic anemia
‚Ä¢ Defective heme biosynthesis within RBC precursors 
‚Ä¢ Etiologies: hereditary/X-linked (ALAS2 mutations), idiopathic (MDS-RARS),
reversible (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)
‚Ä¢ Special clinical manifestations: hepatosplenomegaly, iron overload syndromes
‚Ä¢ Dx: review social, work, & TB hx; can be microcytic, normocytic, or macrocytic;
variable pop of hypochromic RBCs; c Fe, nl TIBC, c ferritin, basophilic stippling,
RBC Pappenheimer bodies (Fe-containing inclusions), ring sideroblasts
(w/ iron-laden mitochondria) in BM
‚Ä¢ Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for
severe anemia; high-dose pyridoxine for some hereditary cases
Figure 5-2 Approach to microcytic anemias
Microcytic Anemia
Iron deficiency
anemia
Thalassemia
Sideroblastic
anemia
‚Üì Fe, ‚Üë TIBC
‚Üì ferritin
Fe/TIBC <18%
MCV/RBC >13
‚Üì marrow Fe
normal iron studies
MCV/RBC <13
basophilic stippling
¬± ‚Üë retics
¬± abnl Hb electro.
‚Üì Fe, ‚Üì TIBC
‚Üë ferritin
Fe/TIBC >18%
‚Üë Fe, nl TIBC
‚Üë ferritin
basophilic stippling
ring sideroblasts in BM
Anemia of
chronic inflammation
NORMOCYTIC ANEMIAS
Pancytopenia (see below)
Anemia of chronic inflammation (ACI; NEJM 2005;352:1011; 2009;361:1904)
‚Ä¢ T RBC production due to impaired iron utilization and functional iron deficiency
from c hepcidin; cytokines (IL-6,TNF-) cause T epo responsiveness/production
‚Ä¢  Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy
‚Ä¢ Dx: T Fe, T TIBC (usually normal or low transferrin sat), 	 c ferritin; usually
normochromic, normocytic (70% of cases) but can be microcytic if prolonged.
‚Ä¢ Coexisting iron deficiency common. Dx clues include T serum ferritin levels, absence
of iron staining on BM bx,  response to a trial of oral iron, and/or c soluble
transferrin receptor/ferritin index (Blood 1997;89:1052).
‚Ä¢ Treatment: treat underlying disease 	 erythropoietin (? if Epo 500 mU/mL); for
cancer- or chemo-related ACI, use epo if Hb 10 g/dL. Iron if ferritin 100 or
Fe/TIBC 20%.
Anemias of chronic disorders
‚Ä¢ Anemia of chronic inflammation (see above)
‚Ä¢ Anemia of chronic kidney disease: T epo; may see burr cells; treat w/ epo (see
‚ÄúChronic Kidney Disease‚Äù)
‚Ä¢ Endocrine deficiencies: hypometabolism and T O2 demand with thyroid, pituitary, adrenal,
or parathyroid disease S T epo; can be normocytic or macrocytic
Sideroblastic anemia (see above)
Pure red cell aplasia
‚Ä¢ Destructive antibodies or lymphocytes S ineffective erythropoiesis
‚Ä¢ Associated with thymoma, CLL, and parvovirus infection
‚Ä¢ Diagnostic studies: lack of erythroid precursors on BM bx, other lines normal
‚Ä¢ Treatment: thymectomy if thymus enlarged; IVIg if parvovirus infection;
immunosuppression if CLL or idiopathic; supportive care with PRBC transfusions;
? erythropoietin receptor agonist if due to antierythropoietin Ab (NEJM 2009;361:1848)

--- Fim da P√°gina 128 ---

MACROCYTIC ANEMIAS
includes megaloblastic and nonmegaloblastic causes
Megaloblastic anemia
‚Ä¢ Impaired DNA synthesis S cytoplasm matures faster than nucleus S ineffective
erythropoiesis and macrocytosis; due to folate or B12 deficiency
‚Ä¢ ‚úìfolate and vitamin B12, c LDH & indirect bilirubin (due to ineffective erythropoiesis)
‚Ä¢ Smear: neutrophil hypersegmentation, macro-ovalocytes, anisocytosis, poikilocytosis
Folate deficiency
‚Ä¢ Folate present in leafy green vegetables and fruit; total body stores sufficient for 2‚Äì3 mo
‚Ä¢ Etiologies: malnutrition (alcoholics, anorectics, elderly), T absorption (sprue),
impaired metabolism (methotrexate, pyrimethamine, trimethoprim), c requirement
(chronic hemolytic anemia, pregnancy, malignancy, dialysis)
‚Ä¢ Diagnosis: T folate; T RBC folate, c homocyst. but nl methylmalonic acid (unlike B12 defic.)
‚Ä¢ Treatment: folate 1‚Äì5 mg PO qd for 1‚Äì4 mo or until complete hematologic recovery;
critical to r/o B12 deficiency first (see below)
Vitamin B12 deficiency
‚Ä¢ B12 present only in foods of animal origin; total body stores sufficient for 2‚Äì3 y
‚Ä¢ Binds to intrinsic factor (IF) secreted by gastric parietal cells; absorbed in terminal ileum
‚Ä¢ Etiologies: malnutrition (alcoholics, vegans), pernicious anemia (PA, autoimmune dis-
ease against gastric parietal cells, a/w polyglandular endocrine insufficiency and c
risk of gastric carcinoma), other causes of T absorption (gastrectomy, sprue, Crohn‚Äôs
disease), c competition (intestinal bacterial overgrowth, fish tapeworm)
‚Ä¢ Clinical manifestations: neurologic changes (subacute combined degeneration)
affecting peripheral nerves, posterior and lateral columns of the spinal cord, and cortex
S numbness, paresthesias, T vibratory and positional sense, ataxia, dementia
‚Ä¢ Dx: T B12; c homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; c gastrin in PA
‚Ä¢ Treatment: 1 mg B12 IM qd  7 d S q wk  4‚Äì8 wk S q month for life
neurologic abnormalities are reversible if treated w/in 6 mo
folate can reverse hematologic abnormalities of B12 deficiency but not neurologic
changes (and can lead to ‚Äústeal‚Äù of B12 stores S worsening of neuro complications)
oral supplementation (2 mg qd) appears feasible as well (Blood 1998;92:1191) even w/o IF
Nonmegaloblastic macrocytic anemias
‚Ä¢ Liver disease: often macrocytic, may see target cells
‚Ä¢ Alcoholism: BM suppression & macrocytosis independent of folate/B12 defic. or cirrhosis
‚Ä¢ Reticulocytosis
‚Ä¢ Other causes: hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine,
5-FU, hydroxyurea,Ara-C); hereditary orotic aciduria; Lesch-Nyhan synd.
PANCYTOPENIA
Etiologies
‚Ä¢ Hypocellular bone marrow (nl cellularity 100 ‚Äì age): aplastic anemia, hypoplastic MDS
‚Ä¢ Cellular bone marrow: MDS, aleukemic leukemia, PNH, severe megaloblastic anemia
‚Ä¢ Marrow replacement (myelophthisis): myelofibrosis, metastatic solid tumors, granulomas
‚Ä¢ Systemic diseases: hypersplenism, sepsis, alcohol, toxins
Clinical manifestations
‚Ä¢ Anemia S fatigue
‚Ä¢ Neutropenia S recurrent infections
‚Ä¢ Thrombocytopenia S mucosal bleeding & easy bruisability
Aplastic anemia  stem cell failure (Lancet 2005;365:1647)
‚Ä¢ Epidemiology: 2‚Äì5 cases/106/y; biphasic (major peak in adolescents, 2nd peak in elderly)
‚Ä¢ Diagnosis: pancytopenia w/ T retics, BM bx w/ cytogenetics showing hypocellularity
‚Ä¢ Etiologies: idiopathic (1‚ÅÑ2‚Äì2‚ÅÑ3 of cases)
stem cell destruction: radiation, chemotherapy, chemicals (eg, benzene)
idiosyncratic med rxn (eg, chloramphenicol, NSAIDs, sulfa drugs, gold,
carbamazepine, antithyroid)
viruses (HHV-6, HIV, EBV, parvovirus B19); also posthepatitis (non A, B, or C)
immune disorders (SLE, GVHD post HSCT, thymoma)
PNH (see below); Fanconi‚Äôs anemia (congenital disorder w/ pancytopenia, macrocytic
anemia, c risk of MDS,AML, & SCC of head & neck, and multiple physical anomalies);
telomerase (hTERT) mutation (NEJM 2005;352:1413)
ANEMIA
5-3

--- Fim da P√°gina 129 ---

‚Ä¢ Treatment and prognosis
allogeneic HSCT: for young Pts S 80% long-term survival and significantly T risk
of malignant evolution, but has risk of transplant-related morbidity & mortality; if
possible avoid transfusions (and alloimmunization) pretransplant
immunosuppression (CsA/tacrolimus,ATG): 70‚Äì80% respond, with 80‚Äì90% 5-y survival
in responders; 15‚Äì20% 10-y incidence of clonal disorders (mostly MDS, AML, PNH)
supportive care: transfusions, antibiotics, possible utility of G-CSF and epo
Myelodysplastic syndromes (MDS) (qv) 
Paroxysmal nocturnal hemoglobinuria (PNH)
‚Ä¢ Acquired clonal stem cell disorder  inactivating somatic mutation of PIG-A gene S
inability to form GPI-anchor for CD55 & CD59 (inhib of complement) S
complement-mediated RBC lysis, plt aggreg., & hypercoagulability
‚Ä¢ Clinical: intravascular hemolytic anemia, hypercoagulability (venous 
arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, deficient
hematopoiesis (cytopenias); a/w aplastic anemia, MDS, and evolution to AML
‚Ä¢ Dx: peripheral blood flow cytometry (T CD55 & CD59); urine hemosiderosis
‚Ä¢ Treatment: supportive care (iron, folate, transfusions)
allogeneic HSCT for hypoplasia or severe thrombosis
eculizumab (Ab inactivates terminal complement C5s): T hemolysis, improves QoL
& stabilizes Hb levels (NEJM 2004;350:552 & 2006;355:1233; Lancet 2009;373:759)
Myelophthisic anemia (see ‚ÄúPrimary Myelofibrosis‚Äù)
‚Ä¢ Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofi-
brosis), granulomas, lysosomal storage disorders
HEMOLYTIC ANEMIAS
Causes of Hemolytic Anemia by Mechanism
Location
Mechanism
Examples
Mode
Enzyme deficiency
G6PD deficiency
Intrinsic
Hemoglobinopathies
Sickle cell anemia, thalassemia
Hereditary
Membrane
Hereditary spherocytosis
abnormalities
PNH
Immune-mediated
Autoimmune; drug-induced, tx rxn
Traumatic
MAHA; prostheses (valves,TIPS)
Extrinsic
Direct infections,
Malaria, babesiosis; snake & spider
Acquired
toxins
venoms;Wilson‚Äôs; hypotonic infusions
Entrapment
Hypersplenism
(Lancet 2000;355:1169 & 1260)
Diagnostic evaluation
‚Ä¢ c reticulocyte count (RI 2%), c LDH, T haptoglobin (83% Se, 96% Sp), c indirect bili
‚Ä¢ Autoimmune hemolysis: Coombs‚Äô test  direct antiglobulin test (DAT) S  if
agglutination occurs when antisera against Ig or C3 are applied to patient RBCs
‚Ä¢ Intravascular: cc LDH, TT haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria
‚Ä¢ Extravascular: splenomegaly
‚Ä¢ Family h/o anemia; personal or family h/o cholelithiasis
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (Lancet 2008;371:64)
‚Ä¢ X-linked defect of metabolism (G6PD mutations) w/ c susceptibility to oxidative damage
‚Ä¢ Most common in males of African or Mediterranean descent (malaria-endemic areas)
‚Ä¢ Hemolysis precipitated by drugs (sulfonamides, dapsone, primaquine, doxorubicin,
methylene blue), infection, DKA, or foods (fava beans in children)
‚Ä¢ Diagnosis: smear may show RBC Heinz bodies (oxidized Hb) that result in bite cells
once removed by spleen; T G6PD levels (may be normal after acute hemolysis as older
RBCs have already lysed and young RBCs may still have near normal levels)
Sickle cell anemia (NEJM 1999;340:1021; Hematology ASH Educ Program 2004;35)
‚Ä¢ Recessive -globin mutation S structurally abnl hemoglobin (HbS);
8% of African Americans are heterozygotes (‚Äúsickle trait‚Äù; usually w/o sx)
1 in 400 are homozygotes (sickle cell disease)
‚Ä¢ Deoxygenated HbS polymerizes S RBC sickles and T RBC deformability S hemolysis and
microvascular occlusion
‚Ä¢ Anemia: chronic hemolysis 	 acute aplastic (parvo. B19) or splenic sequestration crises
‚Ä¢ Vaso-occlusion and infarction: painful crises, acute chest syndrome, CVA, splenic
sequestration, hand-foot syndrome, renal papillary necrosis, aseptic necrosis, priapism
ANEMIA
5-4

--- Fim da P√°gina 130 ---

‚Ä¢ Infection: splenic infarction S overwhelming infection by encapsulated organisms;
infarcted bone S osteomyelitis (Salmonella, Staph. aureus)
‚Ä¢ Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis
‚Ä¢ Treatment: hydroxyurea causes c HbF S T painful crises, acute chest episodes and
may T mortality (NEJM 2008;358:1362); allogeneic HSCT may have a role in young Pts
w/ severe disease (Blood 2000;95:1918) and adults (NEJM 2009;361:2309)
‚Ä¢ Supportive care: folic acid qd; pneumococcal, meningococcal, H. flu & HBV vaccination;
pain crises treated with hydration, oxygen, and analgesia; simple or exchange
transfusion for TIA or stroke, severe acute chest syndrome, and preop (goal Hb 10 g/dL)
Hereditary spherocytosis (HS) (Br J Hematol 2004;126:455)
‚Ä¢ Defect in a cytoskeletal protein of RBC membrane S membrane loss
mutations in ankyrin, - and -spectrin, band 3, and pallidin have been identified
‚Ä¢ Most common in N. European populations (1 in 5,000 births);  FHx (75% of Pts)
‚Ä¢ Anemia, jaundice, splenomegaly, pigmented gallstones
‚Ä¢ Diagnosis: spherocytes on smear,  osmotic fragility test (80% Se), T eosin-5-maleimide
(EMA) binding (92% Se; 99% Sp)
‚Ä¢ Treatment: folate, splenectomy for moderate and severe HS
Paroxysmal nocturnal hemoglobinuria (see above)
Autoimmune hemolytic anemia (AIHA)
‚Ä¢ Acquired, antibody-mediated RBC destruction
‚Ä¢ Warm AIHA: IgG Abs opsonize RBCs at body temp S removal by spleen
Etiologies: idiopathic, lymphoproliferative disorders (CLL, NHL), autoimmune diseases
(SLE), drugs (see below)
‚Ä¢ Cold AIHA: IgM Ab bind to RBCs at temp 37C S complement fixation
S intravascular hemolysis and acrocyanosis on exposure to cold
Etiologies: idiopathic, lymphoproliferative (eg,Waldenstr√∂m‚Äôs) disorders (monoclonal),
Mycoplasma pneumoniae infection and infectious mononucleosis (polyclonal)
‚Ä¢ Diagnosis: spherocytes on smear,  Coombs‚Äô; ‚úìcold agglutinin titer, splenomegaly
‚Ä¢ Treatment: treat underlying disease; warm AIHA: corticosteroids 	 splenectomy, IVIg,
cytotoxic agents, rituximab; cold AIHA: cold avoidance, steroids often ineffective,
rituximab (Blood 2004;103:2925)
Drug-induced hemolytic anemia
‚Ä¢ Acquired, antibody-mediated, RBC destruction precipitated by a medication:
abx: cephalosporins, sulfa drugs, rifampin, ribavirin
CV: methyldopa, procainamide, quinidine, thiazides
other:TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU
‚Ä¢ Diagnosis: Coombs‚Äô usually negative, c LDH
‚Ä¢  Treatment: discontinue offending agent
Microangiopathic hemolytic anemia (MAHA)
‚Ä¢ Intraarteriolar fibrin damages RBCs S acquired intravascular hemolysis
‚Ä¢ Etiologies: hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic 
purpura (TTP), disseminated intravascular coagulation (DIC), malignancy,
malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses
‚Ä¢ Diagnosis: schistocytes 	 thrombocytopenia 	 abnormalities associated with specific
disorders, eg, c PT in DIC, c Cr in HUS, c LFTs in HELLP
‚Ä¢ Treatment: treat underlying abnormality; urgent plasma exchange for TTP
Hypersplenism
‚Ä¢ Splenomegaly S stasis and trapping in the spleen S macrophagic attack and 
remodeling of RBC surface S spherocytosis S hemolysis
Causes of Splenomegaly
Etiology
Comments
RE* system hyperplasia
Hemolytic anemia, sickle cell disease, thalassemia major
Immune
Infection (HIV, EBV, CMV, TB, malaria, kala azar,
hyperplasia
Mycobacterium avium complex), autoimmune disorders (SLE,
RA with Felty‚Äôs syndrome), sarcoidosis, serum sickness
Congestion
Cirrhosis, CHF, portal/splenic vein thrombosis, schistosomiasis
Infiltration
Lysosomal storage disorders (Gaucher‚Äôs, Niemann-Pick),
(nonmalignant)
glycogen storage diseases, histiocytosis X, splenic cysts
Neoplasm
MPN (CML, PMF, PV, ET), CMML, acute leukemia,
lymphoma (NHL, HL, hairy cell leukemia, CLL, PLL,
Waldenstrom‚Äôs),T-LGL leukemia, multiple myeloma, amyloid 
boldface  causes of massive splenomegaly; *Reticuloendothelial
ANEMIA
5-5

--- Fim da P√°gina 131 ---

HEMOSTASIS
5-6
DISORDERS OF HEMOSTASIS
Clinical Characteristics of Bleeding Disorders
Feature
Platelet/Vascular Defect
Coagulation Defect
Site
Skin, mucous membranes
Deep in soft tissues (muscles, joints)
Lesions
Petechiae, ecchymoses
Hemarthroses, hematomas
Bleeding
After minor cuts: yes
After minor cuts: unusual
After surgery: immediate, mild
After surgery: delayed, severe
Purpura
‚Ä¢ Nonblanching purple/red lesions due to extravasation of RBCs into dermis
‚Ä¢ Nonpalpable (macular; 3 mm in diameter  petechiae; 3 mm  ecchymoses)
platelet disorder: thrombocytopenia, defect in platelet function
thromboemboli: DIC,TTP, cholesterol or fat emboli
trauma or vascular fragility (amyloidosis, Ehlers-Danlos, scurvy)
‚Ä¢ Palpable (papular)
vasculitis: leukocytoclastic, HSP, PAN, RMSF
infectious emboli: meningococcemia, bacterial endocarditis
Figure 5-3 Coagulation Cascade
XI
Intrinsic Pathway (PTT)
Extrinsic
Pathway
(PT)
Common Pathway 
I
XIIa
XI
XIa
IX
IXa
VIIIa
VIII
X
Xa
Va
V
Prothrombin (II)
Thrombin (IIa)
VII
TF:VIIa
Tissue Factor (TF)
PrS + APC
IIa
IIa
IIa
ATIII:Fondaparinux
Oral Xa inhibitors (eg, rivaroxaban)
Warfarin (inhibits synthesis
of II, VII, IX, X, PrC, PrS)
Thrombomodulin
TFPI
Fibrinogen (I)
Fibrin
Cross-linked Fibrin
XIIIa
Direct thrombin inhibitors (bivalirudin,
lepirudin, argatroban, dabigatran)
ATIII:UFH (anti-IIa‚âàanti-Xa) or LMWH (Xa>IIa)
PrC
Abnormal Hemostasis
PLATELET DISORDER
thrombocytopenia
COAGULOPATHY
acquired
(eg, meds, liver
disease, vitamin K
defic., DIC)
congenital
(eg, hemophilia,
vWD)
   personal
& family Hx
‚Üì platelet function
congenital
(eg, vWD)
acquired
(eg, meds,
uremia)
‚Üì production
(eg, aplastic
anemia)
‚Üë destruction
(eg, ITP,
DIC, TTP)
splenic
sequestration
   personal
& family Hx
mucocutaneous
bleeding
soft tissue
bleeding
Hx
Hx
Hx, CBC, smear, BMBx
‚Üì platelet
count
normal
platelet count
+
+
‚àí
‚àí
Coagulation factors shown by number.APC, activated protein C;AT, antithrombin; PrC, protein C; PrS,
protein S;TF, tissue factor;TFPI, tissue factor pathway inhibitor. (NEJM 2008;359:938)
Figure 5-4 Approach to abnormal hemostasis

--- Fim da P√°gina 132 ---

PLATELETS
5-7
PLATELET DISORDERS
THROMBOCYTOPENIA (Plt count 150,000/L)
Thrombocytopenia and Risk of Bleeding
Platelet count (cells/L)
Risk
100,000
No c risk
50,000‚Äì100,000
Risk with major trauma; can proceed with general surgery
20,000‚Äì50,000
Risk with minor trauma or surgery
20,000
Risk of spontaneous bleeding (less so with ITP)
10,000
Risk of severe, life-threatening bleeding
Etiologies
‚Ä¢ T production
hypocellular bone marrow: aplastic anemia (qv), rarely MDS, drugs (eg, thiazides,
antibiotics), alcohol, cirrhosis
hypercellular bone marrow: MDS, leukemia, severe megaloblastic anemia
marrow replacement: myelofibrosis, hematologic and solid malignancies, granulomas
‚Ä¢ c destruction
immune-mediated (distinguish primary from secondary; Blood 2009;113:2386)
Primary (idiopathic): immune thrombocytopenic purpura (ITP, see below)
Secondary: infections (HIV, herpes viruses, HCV), collagen vascular diseases (SLE),
antiphospholipid syndrome, lymphoproliferative disorders (CLL, lymphoma), drugs
(many, including heparin, abciximab, quinidine, sulfonamides, vancomycin),
alloimmune (posttransfusion)
non‚Äìimmune-mediated: MAHA (DIC, HUS,TTP), ticlopidine/clopidogrel, vasculitis,
preeclampsia/HELLP syndrome, cardiopulmonary bypass, CVVH, IABP, cavernous
hemangioma
‚Ä¢ Abnormal distribution or pooling: splenic sequestration, dilutional, hypothermia
‚Ä¢ Unknown: ehrlichiosis, babesiosis, RMSF
Diagnostic evaluation
‚Ä¢ H&P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, bleeding
‚Ä¢ CBC with differential: isolated thrombocytopenia vs. multilineage involvement
‚Ä¢ Peripheral smear
c destruction S look for large plts, schistocytes (see Peripheral Smear inserts)
T production S rarely limited to platelets S look for blasts, hypersegmented PMNs,
leukoerythroblastic s
rule out pseudothrombocytopenia due to platelet clumping (‚úìplatelet count in
non‚ÄìEDTA-containing tube, eg, citrate-containing yellow top tube)
Figure 5-5 Approach to thrombocytopenia
Thrombocytopenia
isolated thrombocytopenia
otherwise normal CBC & smear
ITP
autoimmune diseases?
medications? 
infections?
2¬∞ immune
medications
infections
Evan‚Äôs synd.
hypersplenism
DIC
HUS/TTP
aplastic anemia
MDS
leukemia
myelophthisis
culprits
culprits
spherocytes
schistocytes
pancytopenia
and/or blasts
leuko-
erythroblastic
abnormal CBC and/or smear
+
‚àí
‚Ä¢ Additional laboratory evaluations as indicated
if anemia: ‚úìreticulocyte count, LDH, haptoglobin, bilirubin to detect hemolysis
if hemolytic anemia: ‚úìPT, PTT, fibrinogen, D-dimer, Coombs, ANA 
BM bx for unexplained thrombocytopenia, esp. if associated with splenomegaly 
Primary Immune Thrombocytopenic Purpura (ITP) (Blood 2010;115:168)
‚Ä¢ Primary ITP: isolated thrombocytopenia due to immune platelet destruction
(secondary ITP a/w disease or drug exposure; Rx underlying disorder)

--- Fim da P√°gina 133 ---

‚Ä¢ Primary ITP is diagnosis of exclusion; no robust clinical or lab parameters, but typically:
CBC: isolated T plt (100,000/L); 10% have ITP  AIHA  Evans syndrome
Peripheral smear: large platelets
BM bx: c megakaryocytes; perform in adults 60 y to r/o myelodysplasia
Rule out other etiologies: viral serologies (HIV, HCV, HBV, EBV), H. pylori Ab, ANA,
pregnancy test,APLA,TSH, parvovirus, & CMV PCR. Anti-plt Ab tests not useful.
‚Ä¢ Clinical manifestations: insidious onset of mucocutaneous bleeding; :  3:1
‚Ä¢ Treatment: goals based on individual Pt
rarely indicated if plt 50,000/L unless bleeding, trauma/surgery, anticoag, comorbidities
steroids, IVIg and splenectomy mainstay of initial Rx, but TPO-receptor agonists
(eg, romiplostim and eltrombopag) likely to play increasing role
Treatment of Primary ITP in Adults
Approach
Treatment
Notes
Steroids: prednisone 
70‚Äì90% initial response
0.5‚Äì2 mg/kg/d PO tapered 4 wk 
20% sustained remission
vs. dexamethasone 40 mg PO  4 d
T M FcR & T anti-plt Ab
First-line
For Rh(D)  Pts w/ spleen
Anti-Rh(D) Ig 75 g/kg/d IV
Ab-coated RBCs overwhelm 
M FcR
IVIg (1 g/kg/d IV  2‚Äì3 d)
Up to 80% initial response
consider if need rapid c in plt
Blocks M FcR, T anti-plt Ab
Splenectomy
Persistent disease 6 mo 
65% long-term remission
Rituximab (anti-CD20) 	 dex
anti‚ÄìB-cell Ab
Second-line
Romiplostim or eltrombopag
TPO-R agonists S c plt prod
Azathioprine, cyclophosphamide
Immunosuppressants
Danazol, vincristine
T plt clearance
Aminocaproic acid
Inhibits plasmin activation
Methylprednisolone 1g/d IV  3 d
See above
Bleeding
IVIg
See above
Platelet transfusion
Given w/ IVIg or anti-Rh(D)
Refractory
Romiplostim or eltrombopag
See above
Autologous HSCT
Limited data, investigational
(NEJM 2006;355:1672 & 2007;357:2237; Lancet 2008;371:395 &  2009;373:641; Blood 2010;115:168)
Overview of Heparin-Induced Thrombocytopenias
Feature
Type I
Type II
Mechanism
Direct effect of heparin 
Immune (Ab)-mediated
(nonimmune)
IgG against plt factor 4‚Äîheparin complex
Incidence
10‚Äì20%
1‚Äì3% with UFH, 0‚Äì0.8% LMWH
Onset
After 1‚Äì4 d of
After 4‚Äì10 d; but can occur in 24 h if prior 
heparin therapy
exposure w/in 100 d (persistent Ab).
Postop highest risk. Can occur after 
heparin d/c
Platelet nadir
100,000/L
60,000/L, T 50%
Sequelae
None
Thrombotic events (HITT) in 30‚Äì50%
Rare hemorrhagic complications
Management
Can continue heparin
Discontinue heparin
and observe
Alternative anticoagulation
(NEJM 2001;344:1286; Chest 2008;133:340S & 2009;135:1651)
‚Ä¢ Pathophysiology (type II):Ab binds heparin-PF4 S immune complex binds to plt
S plt activation, further PF4 release S plt aggregates removed from circulation S
thrombocytopenia; procoagulants released by plts and tissue factor released by 
endothelial cells damaged by HIT Abs S prothrombotic state
‚Ä¢ Diagnosis: need to meet clinical and pathologic criteria ( HIT Ab alone Z HIT)
Clinical: plt 100,000 or T 50% from baseline; or venous (DVT, PE) or arterial
(limb ischemia, CVA, MI) thrombosis (4:1 ratio); or heparin-induced skin lesions
(may also manifest c heparin resistance)
Pathologic:  HIT Ab using PF4-heparin ELISA (90% Se, re ‚úìif high suspicion),
may confirm w/ fxnal plt aggregation (serotonin-release) assay (90% Sp)
PLATELETS
5-8

--- Fim da P√°gina 134 ---

‚Ä¢ Treatment of type II (NEJM 2006;355:809; Chest 2008;133:340S)
Discontinue heparin (including flushes, LMWH prophylaxis, heparin-impregnated lines)
Avoid plt transfusions if not actively bleeding (anecdotally linked w/ thrombotic events)
Nonheparin anticoag. (argatroban, lepirudin, bivalirudin) regardless if thrombosis; initiate
warfarin when plt 150,000, overlap 5 days (‚úìchromogenic Xa to titrate)
 thrombosis (HITT):  anticoagulate for  3‚Äì6 mo
 thrombosis (isolated HIT): screen for LE DVT; no consensus on duration of subse-
quent anticoag. (at least until plt count recovers, more often 2‚Äì3 mo if no clot)
‚Ä¢ Heparin use if h/o HIT: if PF4 Ab  (typically 100 d after dx) S re-exposure to UFH
reasonable (eg, for surgery); HIT recurrence low (NEJM 2001;344:1286; Chest 2008;133:340S)
Hemolytic-uremic syndrome (HUS) & thrombotic thrombocytopenic purpura (TTP)
‚Ä¢ Definition: vascular occlusive disorders w/ systemic (TTP) or intrarenal (HUS) plt aggreg.
S thrombocytopenia & mechanical injury to RBCs (MAHA) (NEJM 2002;347:589)
HUS triad  thrombocytopenia  MAHA  renal failure
TTP pentad  thrombocytopenia  MAHA 	  MS 	 renal failure 	 fever
‚Ä¢ Pathophysiology: mechanism in most HUS cases is distinct from TTP (NEJM 1998;339:1578)
HUS: Shiga toxin binds & activates renal endothelial cells & plts S intrarenal thrombi
TTP: T ADAMTS13 protease activity S persistence of large vWF multimers on endothelial
surface S adhesion and aggregation of passing platelets S thrombosis
‚Ä¢ Clinical manifestations and associations
HUS: usually in children; prodrome of bloody diarrhea due to enterohemorrhagic E. coli
TTP: usually in adults; idiopathic, drugs (CsA, gemcitabine, mitomycin C, ticlopidine,
clopidogrel, quinine), HIV, pregnancy, HSCT, autoimmune disease, familial
‚Ä¢ Diagnosis: unexplained thrombocytopenia (typically 20 k)  MAHA S sufficient for dx
 schistocytes (2‚Äì3/hpf),  Coombs, normal PT/PTT & fibrinogen, TT ADAMTS13
cc LDH (tissue ischemia  hemolysis), c indirect bili., cc haptoglobin, c Cr (esp. in HUS)
Biopsy: arterioles filled with platelet hyaline thrombi
Ddx: DIC, vasculitis, malignant hypertension, preeclampsia/HELLP syndrome
‚Ä¢ Treatment: urgent plasma exchange 	 glucocorticoids in all adults w/ suspected
TTP-HUS; FFP if delay to plasma exchange
platelet transfusions contraindicated S c microvascular thrombosis (NEJM 2006;354:1927)
Disseminated intravascular coagulation (DIC): see ‚ÄúDisorders of Coagulation‚Äù
DISORDERS OF PLATELET FUNCTION
Mechanisms and Etiologies of Platelet Function Abnormalities
Function
Inherited
Acquired
Adhesion
Bernard-Soulier; vWD
Uremia; acquired vWD
Aggregation
Afibrinogenemia
Ticlopidine, clopidogrel, GP IIb/IIIa
Glanzmann‚Äôs thrombasthenia
Dysproteinemias (myeloma)
Granule
Chediak-Higashi syndrome
Drugs (ASA, NSAIDs); liver disease;
release
Hermansky-Pudlak syndrome
MPN; cardiopulmonary bypass
Tests of platelet function
‚Ä¢ Bleeding time: global screen of platelet function; not reliable and rarely used
‚Ä¢ Platelet aggregation tests: measure aggregation in response to agonists (eg,ADP)
von Willebrand‚Äôs disease (vWD) (NEJM 2004;351:683)
‚Ä¢ von Willebrand‚Äôs factor (vWF) function  platelet glue & plasma carrier of factor VIII
‚Ä¢ vWD is the most common inherited bleeding disorder.
Type 1 (autosomal dominant; 85% of cases): partial quantitative deficiency in vWF
Type 2 (autosomal dominant; 15% of cases): qualitative deficiency of vWF
Type 3 (autosomal recessive; rare): near complete deficiency of vWF
‚Ä¢ Acquired vWD: associated with many disorders (malignancy, autoimmune, hypothyroidism,
drugs) and caused by different mechanisms (anti-vWF Abs, c clearance, T synthesis)
‚Ä¢ Diagnosis: T vWF:Ag, T vWF activity (measured by ristocetin cofactor assay), T factor
VIII, 	 c PTT, 	 T platelets; confirm with vWF multimer analysis
‚Ä¢ Clinical condition, factor VIII levels and ristocetin cofactor assay useful to guide Rx decision
‚Ä¢ Treatment: desmopressin (dDAVP, IV/IN) S c endothelial cell release of vWF; variable
efficacy depending on type, ‚à¥‚úìresponse before use w/ subseq. bleeding or procedures;
vWF replacement: cryoprecipitate, factor VIII concentrates rich in vWF, recomb. vWF
Uremic Bleeding
‚Ä¢ Uremia S platelet dysfunction including T aggregation, impaired adhesiveness
‚Ä¢ Treatment: dDAVP, cryoprecipitate, correct anemia (improves plt aggregation and
adhesion by increasing plt interactions with endothelium),consider holding anti-plt agents
PLATELETS
5-9

--- Fim da P√°gina 135 ---

COAGULOPATHIES
5-10
COAGULOPATHIES
Screening Test Abnormalities in Inherited and Acquired Coagulopathies
PT
PTT
Factors
Inherited
Acquired
c
4
VII
FVII defic.
Vit. K defic.; liver dis.; factor inhib.
4
c
VIII or IX
Hemophilias, vWD
Antiphospholipid Ab; factor inhib.
c
c
I, II, V, or X
Fbgn, FII, or FV defic.
DIC; liver dis.; factor inhib.
Further coagulation tests
‚Ä¢ Mixing study: useful if c PT or PTT; mix Pt‚Äôs plasma 1:1 w/ normal plasma and retest
PT/PTT normalizes S factor deficiency; PT/PTT remains elevated S factor inhibitor
‚Ä¢ Coagulation factor levels: useful if mixing study suggests factor deficiency
DIC S all factors consumed; ‚à¥T factor V and VIII
liver disease S T all factors except VIII; ‚à¥T factor V, normal factor VIII
vitamin K deficiency S T factors II,VII, IX, X (and protein C, S); ‚à¥normal V and VIII
‚Ä¢ DIC screen: fibrinogen (consumed), fibrin degradation products (FDPs,  due to intense
fibrinolysis), D-dimer (more specific FDP test that detects degradation of X-linked fibrin)
Hemophilias (NEJM 2001;344:1773)
‚Ä¢ X-linked factor VIII (hemophilia A) or factor IX (hemophilia B) deficiency
‚Ä¢ Classification: mild (5‚Äì25% normal factor activity), moderate (1‚Äì5%), or severe (1%)
‚Ä¢ Clinical manifestations: hematomas, hemarthroses, bruising, bleeding (mucosal, GI, GU)
‚Ä¢ Diagnosis: c PTT (normalizes w/mixing study), normal PT & vWF, T factor VIII or IX
‚Ä¢ Treatment: purified/recomb. factor VIII or IX concentrate, desmopressin (mild disease),
aminocaproic acid; recomb. factor VIIa if factor inhib., cryo (only has factor VIII)
Coagulation factor inhibitors
‚Ä¢ Etiologies: hemophilia (treated with factor replacement); postpartum; lymphoproliferative
disorders and other malignancies; autoimmune diseases; most commonly anti‚Äìfactor VIII
‚Ä¢ Diagnosis: c PTT (does not normalize w/mixing study); Bethesda assay quantitates titer
‚Ä¢ Treatment: high titer S recomb. factor VIIa, porcine factor concentrates, activated
prothrombin complex; others S high-purity human factor, plasmapheresis, immuno-
supp. w/ steroids, cyclophosphamide, and/or rituximab (Curr Opin Hematol 2008;15:451)
Disseminated intravascular coagulation (DIC) (NEJM 1999;341:586)
‚Ä¢ Etiologies: trauma, shock, infection, malignancy (esp.APL), obstetric complications
‚Ä¢ Pathogenesis: massive activation of coagulation that overwhelms control mechanisms
thrombosis in microvasculature S ischemia  microangiopathic hemolytic anemia
acute consumption of coagulation factors and platelets S bleeding
chronic DIC S able to replete factors and platelets S thrombosis
‚Ä¢ Diagnosis: c PT, c PTT, T fibrinogen (may be nl b/c acute phase),  FDP/D-dimer, T
plts,  schisto, c LDH, T hapto; chronic DIC:  FDP/D-dimer, variable plts, other labs nl
‚Ä¢ Treatment: treat underlying process; support with FFP, cryoprecipitate (goal fibrinogen
100 mg/dL), and platelets; consider activated protein C in severe sepsis
Vitamin K deficiency
‚Ä¢ Etiologies: malnutrition, T absorption (antibiotic suppression of vitamin K-producing
intestinal flora or malabsorption), liver disease (T stores), warfarin
Properties and Antidotes for Anticoagulants & Fibrinolytics
Anticoag.
t1/2
Labs
Rx for O/D w/ serious bleeding*
UFH
60‚Äì90,
c PTT
Protamine IV 1 mg/100 U UFH (max 50 mg). For
RES
infusions, dose to reverse 2 UFH given per h
Bivalirudin
25, K
c PTT
Dialysis
Lepirudin
80, K
c PTT
Dialysis
Argatroban
45, L
c PTT
? Dialysis
Enoxaparin,
2‚Äì7, K
(anti-Xa)
? Protamine (reversal incomplete)
Dalteparin
Fondaparinux
24, K
(anti-Xa)
? Dialysis
Warfarin
36, L
c PT
No bleeding: if INR 6‚Äì10 give vit. K 2.5 mg PO 
(superior to SC, ‚âàIV at 24 h) or ‚àÖRx; if INR 10 
give 5 mg (Archives 2003;163:2469; Annals 2009;150:293)
Bleeding: vit. K 10 mg IV  FFP 2‚Äì4 units IV q 6‚Äì8
Fibrinolytic
20‚Äì90,
T fbgn
Cryoprecipitate, FFP, 	 aminocaproic acid
LK
c FDP
*Initial step should be immediate d/c of anticoag. K, kidney; L, liver; RES, reticuloendothelial system.

--- Fim da P√°gina 136 ---

HYPERCOAG
5-11
HYPERCOAGULABLE STATES
Suspect in Pts with venous or arterial thrombosis at young age or unusual locations,
recurrent thromboses or pregnancy loss, or  FHx
Inherited Hypercoagulable States
Risk factor
Prevalence
VTE
Comments
Factor V Leiden 
3‚Äì7%
4.3
Activated protein C (APC) resist.
Prothrombin mutation
2%
2.8
G20210A S c prothrombin level
Hyperhomocysteinemia
5‚Äì10%
2.5
Inherited or acquired
Protein C deficiency
0.02‚Äì0.05%
11
Warfarin-induced skin necrosis risk
Protein S deficiency
0.01‚Äì1%
32
Antithrombin III def.
0.04%
17.5
May be relatively heparin-resistant
Prevalence is in Caucasians. (NEJM 2001;344:1222; Hematology ASH Educ Prog 2007;127)
Vascular Beds Affected by Inherited and Acquired Hypercoagulable States
Venous
Venous and Arterial
Factor V Leiden
? factor V Leiden  smoking
Prothrombin mutation
Hyperhomocysteinemia (inherited or acquired)
T protein C, S, or AT III
Dysfibrinogenemia
Stasis: immobilization,
Platelet defects: myeloproliferative disorders, HIT, PNH 
surgery, CHF
(although venous  arterial)
Malignancy
Hyperviscosity: polycythemia vera,Waldenstr√∂m‚Äôs
Hormonal: OCPs, HRT,
macroglobulinemia, sickle cell, acute leukemia
tamoxifen, pregnancy
Vessel wall defects: vasculitis, trauma, foreign bodies
Nephrotic syndrome
Others: antiphospholipid syndrome, IBD
Diagnostic evaluation
‚Ä¢ APC resistance screen; prothrombin PCR test; functional assays for protein C and S,
ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant
Ab. Also consider nephrotic syndrome, PNH (especially if mesenteric thrombus).
‚Ä¢ Consider JAK2 mutation screen if suspect myeloprolif disorder, especially if Budd-Chiari.
‚Ä¢ Proteins C & S and ATIII levels are affected by acute thrombosis and anticoagulation
‚à¥levels best assessed 2 wk after completing anticoagulation course
‚Ä¢ Age-appropriate malignancy screening ( in 12% with ‚Äúidiopathic‚Äù DVT; Annals 1996;125:785)
Treatment
‚Ä¢ Asx w/ inherited risk factor: consider prophylactic anticoag. if develops acquired risk factor
‚Ä¢ Thrombosis w/ inherited risk factor: see ‚ÄúVenous Thromboembolism‚Äù
Antiphospholipid syndrome (APS) (NEJM 2002;346:752)
‚Ä¢ Definition: dx requires 1 clinical & 1 laboratory criteria
Clinical: thrombosis (any) or complication of pregnancy (3 spont. abortions before 
10 wk or 1 fetal loss after 10 wk or premature birth before 34 wk)
Laboratory:  moderate-high titer anticardiolipin (ACL), lupus anticoagulant (LA)
or 2-glycoprotein-I (2-GP-I) Ab on 2 occasions at least 12 wk apart
‚Ä¢ Clinical manifestations: DVT/PE/CVA, recurrent fetal loss, thrombocytopenia,
hemolytic anemia, livedo reticularis; ‚Äúcatastrophic APS‚Äù  widespread acute
thrombotic microangiopathy with multiorgan visceral damage S high mortality
‚Ä¢ Antiphospholipid antibodies (APLA)
‚úì if: SLE, age 40 y & arterial thromb, recurrent venous thromb, spontaneous abortion 
ACL: Ab against cardiolipin, a mitochondrial phospholipid; IgG more specific than IgM
LA: Ab that prolongs phospholipid-dependent coagulation reactions; ‚à¥c PTT that
does not correct with mixing study but does correct with excess phospholipids
or platelets; PT not affected b/c the reaction contains much more phospholipid
2-GP-I:  Ab against 2-glycoprotein-I, IgG or IgM
False VDRL: nontreponemal test for syphilis in which cardiolipin is part of Ag complex
Clinical significance of different Abs in pathogenesis uncertain
Risk of thromboembolic phenomena may increase with titer of APLs
‚Ä¢ Etiologies: primary (idiopathic) or secondary due to autoimmune syndromes
(eg, SLE), malignancy, infections, drug reactions
‚Ä¢ Treatment: UFH/LMWH S warfarin after thromboembolic event (lifelong for most Pts)
Intensity of anticoagulation controversial (Arthritis Rheum 2007;57:1487)
INR 2‚Äì3 for an initial venous thrombosis (NEJM 2003;349:1133; J Thromb Haemost 2005;3:848)
INR 3‚Äì4 for an initial arterial thrombosis or for recurrent venous thrombosis on warfarin
Consider ASA prophylaxis for high-risk asx Pt (eg, SLE)
Acquired
Inher.

--- Fim da P√°gina 137 ---

LEUKOCYTES
5-12
DISORDERS OF LEUKOCYTES
Neutrophilia (7500‚Äì10,000/L)
Infection
Usually bacterial; 	 toxic granulations, D√∂hle bodies
Inflammation
Burn, tissue necrosis, MI, PE, collagen vascular disease
Drugs and toxins
Corticosteroids, -agonists, lithium, G-CSF; cigarette smoking
Stress
Release of endogenous glucocorticoids and catecholamines
Marrow stimulation
Hemolytic anemia, immune thrombocytopenia
Asplenia
Surgical, acquired (sickle cell), congenital (dextrocardia)
Neoplasm
Can be 1 (MPN) or paraneoplastic (eg, carcinomas of lung, GI)
Leukemoid reaction
50,000/L  left shift, not due to leukemia; unlike CML, c LAP
Lymphocytosis (4000‚Äì5000/L)
Infection
Usually viral;‚Äúatypical lymphocytes‚Äù with mononucleosis syndromes
Other: pertussis, toxoplasmosis
Hypersensitivity
Drug-induced, serum sickness
Stress
Cardiac emergencies, trauma, status epilepticus, postsplenectomy
Autoimmune
Rheumatoid arthritis (large granular lymphocytes), malignant thymoma
Neoplasm
Leukemia (ALL, CLL, others), lymphoma
Monocytosis (500/L)
Infection
Usually TB, SBE, Listeria, Brucella, rickettsiae, fungi, parasites
Inflammation
IBD, sarcoidosis, collagen vascular diseases
Neoplasm
Hodgkin‚Äôs disease, leukemias, MPD, carcinomas
Eosinophilia (500/L)
Infection
Usually parasitic (helminths)
Allergic
Drugs; asthma, hay fever, eczema;ABPA
Collagen vascular disease
RA, Churg-Strauss syndrome, eosinophilic fasciitis, PAN
Endocrine
Adrenal insufficiency
Neoplasm
Hodgkin‚Äôs lymphoma, CML, mycosis fungoides,
carcinomas, mastocytosis
Atheroembolic disease
Cholesterol emboli syndrome
Hypereosinophilic syndrome
Multiorgan system involvement including heart and CNS,
associated with FIP1L1-PDGFRA fusion (NEJM 2003;348:1201)
D816kit-positive systemic mastocytosis (Lancet 2003;362:535)
Basophilia (150/L)
Neoplasm
MPD, Hodgkin‚Äôs disease
Alteration in BM or reticuloendothelial compartment
Hemolytic anemia, splenectomy
Inflammation or allergy
IBD, chronic airway inflammation
Lymphadenopathy
Viral
HIV, EBV, CMV, HSV,VZV, hepatitis, measles, rubella
Bacterial
Generalized (brucellosis, leptospirosis,TB, atypical mycobacteria, syphilis)
Localized (streptococci, staphylococci, cat-scratch disease, tularemia)
Fungal and
Histoplasmosis, coccidioidomycosis, paracoccidioidomycosis
parasitic
Toxoplasmosis
Immunologic
Collagen vascular disease, drug hypersensitivity (eg, phenytoin), serum
sickness, histiocytosis X, Castleman‚Äôs and Kawasaki disease
Neoplasm
Lymphoma, leukemia, amyloidosis, metastatic carcinoma
Other
Sarcoidosis; lipid storage diseases
Factors that
Age (40 y), size (2 cm), location (supraclavicular is always
favor biopsy
abnormal), duration (1 m).
Consistency (hard vs. rubbery vs. soft) & tenderness are not reliable.

--- Fim da P√°gina 138 ---

TRANSFUSION
5-13
TRANSFUSION THERAPY
Blood Products and Indications
For acute blood loss or to c O2-carrying capacity if end organ
ischemia. In critical illness, Hb goal 7‚Äì9 g/dL adequate; consider 
Packed red blood
10‚Äì12 g/dL if coronary ischemia (NEJM 1999;340:409 & 2001;345:1230).
cells (PRBCs)
1 U PRBC S c Hb by 1 g/dL. Large-volume transfusion PRBC S T
Ca, c K, T plt, ccoags (may need concurrent transfusion plt & FFP).
Plts 10,000/L or 20,000/L with infection or c bleeding risk or
50,000/L with active bleeding or preprocedure. 6 U pooled donor plts
 1 single donor plt apheresis unit (reduces alloimmunization) S c plt
Platelets (plts)
count by 30‚Äì60,000/L. Contraindicated in TTP/HUS, HELLP, HIT.
Refractory: c 5000/L 30‚Äì60 min posttransfusion. Suggests 
alloimmunization S trial ABO-matched plts. If still refractory ‚úìpanel
reactive Abs (PRA) to assess utility HLA-matched plts.
Fresh frozen
Contains all coagulation factors. For bleeding due to deficiency of
plasma (FFP)
multiple coagulation factors (eg, DIC,TTP/HUS, liver disease,
warfarin excess, dilution) or PT 17 sec preprocedure.
Cryoprecipitate
Enriched for fibrinogen, vWF,VIII, and XIII. For bleeding in vWD,
factor XIII deficiency or fibrinogen 100 mg/dL.
Irradiated
Prevents donor T-cell proliferation. Use if risk of transfusion-assoc 
GVHD (HSCT, heme malig, congenital immunodef).
CMV-negative
From CMV-negative donors. For CMV-seronegative pregnant women,
transplant candidates/recipients, SCID,AIDS Pts.
WBCs cause HLA alloimmunization and fever (cytokine release) and
carry CMV. For chronically transfused Pts, potential transplant
Leukoreduced
recipients, h/o febrile nonhemolytic transfusion reaction, cases in
which CMV-negative products are desired but unavailable.
Intravenous
Polyvalent IgG from 1000 donors. For postexposure prophylaxis
immune globulin
(eg, HAV), certain autoimmune disorders (eg, ITP, Guillain-Barr√©, MG
(IVIg)
? CIDP), congenital or acquired hypogammaglobulinemia (CVID, CLL).
Plasmapheresis
Removes lg molec wt subst. (eg, cryoglobulinemia, Goodpasture‚Äôs,
and
Guillain-Barr√©, hyperviscosity syndrome,TTP) or cells (eg, leukemia
cytapheresis
w/ hyperleukocytosis, sx thrombocytosis, sickle cell) from plasma.
Transfusion Complications
Noninfectious
Risk (per unit)
Infectious
Risk (per unit)
Febrile
1:100
CMV
common
Allergic
1:100
Hepatitis B
1:220,000
Delayed hemolytic
1:1000
Hepatitis C
1:1,600,000
Acute hemolytic
1:250,000
HIV
1:1,800,000
Fatal hemolytic
1:100,000
Bacteria (PRBCs)
1:500,000
TRALI
1:5000
Bacteria (platelets)
1:12,000
(NEJM 1999;340:438; JAMA 2003;289:959)
Transfusion reactions
‚Ä¢ For all reactions (except minor allergic): stop transfusion; send remaining blood
product and fresh blood sample to blood bank
‚Ä¢ Acute hemolytic: fever, hypotension, flank pain, renal failure 24 h after transfusion
Due to ABO incompatibility S preformed Abs against donor RBCs
Treatment: vigorous IVF, maintain UOP with diuretics, mannitol, or dopamine
‚Ä¢ Delayed hemolytic: generally less severe than acute hemolytic; 5‚Äì7 d after transfusion
Due to undetected allo-Abs against minor antigens S anamnestic response
Treatment: usually no specific therapy required; dx is important for future transfusion
‚Ä¢ Febrile nonhemolytic: fever and rigors 0‚Äì6 h after transfusion
Due to Abs against donor WBCs and cytokines released from cells in blood product
Treatment: acetaminophen 	 meperidine; rule out infection and hemolysis
‚Ä¢ Allergic: urticaria; rarely, anaphylaxis: bronchospasm, laryngeal edema, hypotension
Reaction to transfused proteins; anaphylaxis seen in IgA-deficient Pts w/ anti-IgA Abs
Treatment: urticaria S diphenhydramine; anaphylaxis S epinephrine 	 glucocorticoids
‚Ä¢ Transfusion-related acute lung injury (TRALI): noncardiogenic pulmonary edema
Due to donor Abs that bind recipient WBCs, which then aggregate in pulmonary
vasculature and release mediators causing c capillary permeability. Rx: see ‚ÄúARDS.‚Äù

--- Fim da P√°gina 139 ---

MDS
5-14
MYELODYSPLASTIC SYNDROMES (MDS)
Myeloid neoplasm overview (Blood 2009;114:937)
‚Ä¢ Myeloid neoplasms are classified into 5 categories based on bone marrow morphology,
clinical characteristics and genetics (WHO 2008 system)
WHO 2008 Myeloid Neoplasm Categories
Acute myeloid leukemia
Dysplastic clonal myeloid stem cell (SC) disorder w/ 20% 
blasts in the bone marrow or peripheral blood
Myelodysplastic syndromes
Dysplastic clonal myeloid SC disorder S cytopenias;
20% blasts, but risk of leukemic transformation
Myeloproliferative neoplasms
Clonal expansion of nondysplastic multipotent myeloid SC
MDS/MPN
Features of both MDS & MPN (eg, CMML, atypical CML)
Myeloid/lymphoid malig. a/w 
Consider imatinib Rx for PDGFR rearrangement
eos and PDGFR or FGFR1 
Myelodysplastic syndromes (MDS) overview (NEJM 2009;361:1872)
‚Ä¢ Acquired clonal stem cell disorder S ineffective hematopoiesis S cytopenias,
dysmorphic blood cells and precursors, variable risk of leukemic transformation
‚Ä¢ Epidemiology: 100 cases/106/y; median age 65 y; male predominance (1.8x)
‚Ä¢ Idiopathic or 2 to chemo w/ alkylating agents, topo II inhib.; c risk w/ radiation, benzene
‚Ä¢ Clinical manifestations: anemia (85%), neutropenia (50%), thrombocytopenia (25%)
‚Ä¢ Diagnosis: dysplasia (usually multilineage) in peripheral smear (ovalomacrocytes,
pseudo-Pelger-Hu√´t anomaly) and bone marrow (10% dysplasia with blasts 	 RS) 
‚Ä¢ Cytogenetic abnormalities: several are characteristic of MDS and have prognostic
significance [eg, del(5q), monosomy 7, del(7q), trisomy 8, del(20q)]
‚Ä¢ Prior to dx MDS: exclude AML (20% blasts) and CMML (monocyte count 1  109/L);
r/o 2 BM s due to defic. of B12, folate, copper; viral infections (eg, HIV);
chemotherapy; alcohol abuse; lead or arsenic toxicity
WHO 2008 Classification Systems for MDS
Classification
Bone Marrow Features
Refractory cytopenias with unilineage dysplasia (RCUD):
10% dysplastic cells in one 
including refractory anemia, refractory neutropenia, or 
myeloid lineage
refractory thrombocytopenia
5% blasts; 15% RS
Refractory anemia with ring sideroblasts (RARS)
5% blasts, 15% RS 
Refractory cytopenias with multilineage dysplasia (RCMD)
10% dysplasia 2 lines
5% blasts, w/ or w/o RS
MDS with isolated del(5q)
5% blasts, del(5q)
Refractory anemia with excess blasts ‚Äì 1 (RAEB-1)
5‚Äì9% blasts, no Auer rods
Refractory anemia with excess blasts ‚Äì 2 (RAEB-2)
10‚Äì19% blasts, 	 Auer rods
MDS, unclassifiable (MDS-U)
10% dysplasia  5%
blasts  cytogen. abnl.
FAB classification no longer used clinically. RAEB-T reclassified as AML with multilineage dysplasia and
CMML as MDS/MPN. Presence of cytogenetic anomalies, such as t(15;17), t(8;21), inv16, t(16;16) or MLL
rearrangement, warrant classification as AML, regardless of BM blast count. RS, ring sideroblasts.
‚Ä¢ Treatment: intensity based on risk category (see below), age, performance status (PS)
Poor PS, any risk S supportive care  transfusions, G-CSF, epo, abx if needed
Low/intermediate risk S Epo (esp if Epo level 500); lenalidomide (esp for 5q- syndrome;
NEJM 2005;352:549); DNA demethylating agents (azacitidine or decitabine)
Intermediate/high risk S DNA demethylating agents, combination chemo (akin
to AML therapy) or allogeneic HSCT (HLA-matched sibling donor preferred)
if age 55 (consider reduced-intensity transplant for ages 55‚Äì75)
Hypoplastic MDS (rare) S can consider immunosuppression (CsA, ATG, prednisone)
‚Ä¢ Prognosis: IPSS correlates with survival and progression to AML
International Prognostic Scoring System (IPSS)
Risk
Total
Median
Score
group score
survival
0
0.5
1
1.5
2
Low
0
5.7 y
Blasts (%)
5
5‚Äì10
‚Äì
11‚Äì20
21‚Äì30
Int-1
0.5‚Äì1
3.5 y
Karyotype
Good
Int.
Poor
‚Äì
‚Äì
Int-2
1.5‚Äì2
1.2 y
Cytopenias
0 or 1
2 or 3
‚Äì
‚Äì
‚Äì
High
2.5
0.4 y
(Blood 1997;89:2079) LDH may add further prognostic value to traditional IPSS score (Leukemia 2005;19:2223)

--- Fim da P√°gina 140 ---

MPN
5-15
MYELOPROLIFERATIVE NEOPLASMS (MPN)
General (NEJM 2006;355:2452; Nat Rev Clin Oncol 2009;6:627)
‚Ä¢ Results from clonal expansion of multipotent hematopoietic stem cell
‚Ä¢ A type of myeloid neoplasm (see MDS for classification)
‚Ä¢ Different from MDS in that the cells are not dysplastic (ie, normally developed)
‚Ä¢ 8 categories of MPN: polycythemia vera (PV); essential thrombocythemia (ET); primary
myelofibrosis (PM); chronic myelogenous leukemia (CML), BCR-ABL1‚Äì; chronic
neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; masto-
cytosis; myeloproliferative neoplasms, unclassifiable
‚Ä¢ Gain of fxn mutations in JAK2 (Janus kinase) present in most cases of MPN (PV 100%,
ET 50%, PMF 50%; NEJM 2005;352:1779) and BCR-ABL fusion in all cases of CML;
KIT mutations in virtually all mastocytosis; MPL and TET2 mutations w/ lower 
frequency; genetic lesions are useful as a clonal marker and dx tool
POLYCYTHEMIA VERA (PV)
Definition
‚Ä¢ c in RBC mass 	 c granulocytes and platelets in the absence of physiologic stimulus
Etiologies of erythrocytosis
‚Ä¢ Relative c RBC (T plasma): dehydration;‚Äústress‚Äù erythrocytosis (Gaisb√∂ck‚Äôs syndrome)
‚Ä¢ Absolute c RBC: 1 (PV, other MPD) or 2 due to hypoxia; carboxyhemoglobinemia;
inappropriate erythropoietin (renal, hepatic, cerebellar tumors); Cushing‚Äôs syndrome
Clinical manifestations (common between PV and ET)
‚Ä¢ Symptoms S often termed ‚Äúvasomotor symptoms‚Äù
hyperviscosity (erythrocytosis): headache, dizziness, tinnitus, blurred vision
thrombosis (hyperviscosity, thrombocytosis): transient visual disturbances (amaurosis,
ocular migraine); Budd-Chiari syndrome; erythromelalgia  intense burning, pain, and
erythema of extremities due to microvascular thrombi; c risk of DVT, MI, stroke.
Risk of thrombosis is highly correlated with elevated WBC in PV and ET (see below).
bleeding (abnormal platelet function): easy bruising, epistaxis, GI bleeding
c histamine from basophils S pruritus, peptic ulcers; c uric acid (cell turnover) S gout
‚Ä¢ Signs: plethora, splenomegaly, hypertension, engorged retinal veins
Diagnostic evaluation
‚Ä¢ Hb 18.5 g/dL (men), 16.5 g/dL (women)
‚Ä¢ ‚úìEpo to rule out secondary causes of erythrocytosis; if Epo T, PV likely
If Epo c, then ‚úìSaO2 or PaO2, carboxyhemoglobin
‚Ä¢ JAK2 V617F mutation screen on peripheral blood is positive in 95% of PV and
JAK2 exon 12 mutations are present in the remainder of Pts
‚Ä¢ 	 c WBC, platelets, basophils; c uric acid, leukocyte alkaline phosphatase, vitamin B12
‚Ä¢ Peripheral smear S no morphologic abnormalities
‚Ä¢ BM bx S hypercellular, megakaryocytic hyperplasia, T iron, absence of Ph chromosome
Treatment
‚Ä¢ Phlebotomy (espec if sx) to moderate degree of Fe defic. S Hct 45% () or
42% ()
‚Ä¢ Low-dose ASA in all Pts (NEJM 2004;350:114)
‚Ä¢ Hydroxyurea if high risk of thrombosis (age 60, prior thrombosis) or sx throm-
bocytosis (plt 1.5  106/L)
‚Ä¢ Supportive: allopurinol (gout), H2-blockers/antihistamines (pruritus)
Prognosis
‚Ä¢ Median survival if treated is 9‚Äì12 y
‚Ä¢ Risk of transformation into acute leukemia (2% for untreated Pts, higher if previous chemo)
‚Ä¢ Post-PV myelofibrosis (spent phase) occurs in 15% of cases, usually after 10 y
ESSENTIAL THROMBOCYTHEMIA (ET)
Definition
‚Ä¢ c in platelets (450,000/L) 	 c RBC and granulocytes
Etiologies of thrombocytosis
‚Ä¢ 1  ET or other MPN; myelodysplastic syndromes (5q-syndrome)
‚Ä¢ 2  reactive thrombocytosis: inflammation (RA, IBD, vasculitis), infection, acute
bleeding, iron deficiency, postsplenectomy, neoplasms (particularly Hodgkin‚Äôs disease)
‚Ä¢ Of Pts w/ plt 106/L, 1 in 6 will have ET

--- Fim da P√°gina 141 ---

Clinical manifestations (see ‚ÄúPolycythemia Vera‚Äù)
‚Ä¢ Thrombosis with erythromelalgia (risk of thrombosis highest in Pts with WBC 8700),
bleeding, pruritus; mild splenomegaly; migraine,TIA
Diagnostic evaluation
‚Ä¢ Peripheral smear: large hypogranular platelets
‚Ä¢ BM bx: megakaryocytic hyperplasia; absence of Philadelphia chromosome and lack of
collagen fibrosis; normal iron stores
‚Ä¢ JAK2 V617F present in 50% of ET
‚Ä¢ Does not meet WHO criteria for diagnosis of CML, PV, PMF or MDS
Treatment of ET
Risk
Features
ASA 81 mg qd
Cytoreduction
Age 60 and
Consider for
no h/o thrombosis and
vasomotor
No
Low
plt 1.5 x 106/L and
symptoms
no CV risk factors
Int.
Neither low nor high 

Consider if plt 1.5  06/L
Age 60 or
Hydroxyurea superior to
High
h/o thrombosis or

anagrelide (NEJM 2005;353:33)
plt 1.5  106/L
Goal plt 400,000/L
Prognosis
‚Ä¢ Overall survival similar to control population with low rate of transformation into PV,
PMF or acute leukemia; ‚à¥low-risk Pts (see above) do not need treatment
PRIMARY MYELOFIBROSIS (PMF)
Definition
‚Ä¢ Clonal myeloproliferation with reactive marrow fibrosis & extramedullary hematopoiesis
‚Ä¢ Formerly known as agnogenic myeloid metaplasia with myelofibrosis
Etiologies of myelophthisis (marrow replacement)
‚Ä¢ 1 	 primary myelofibrosis; post-PV/ET myelofibrosis
‚Ä¢ 2 	 hematologic (eg, leukemia, MDS) or metastatic malignancies (eg, breast, prostate)
collagen vascular disorders (eg, SLE)
toxins (eg, benzene, radiation)
granulomas from infection (eg,TB, fungal) or sarcoid
deposition diseases (eg, Gaucher‚Äôs disease)
Clinical manifestations (NEJM 2000;342:1255)
‚Ä¢ Ineffective erythropoiesis S anemia; extramedullary hematopoiesis S massive
splenomegaly (abdominal pain, early satiety)  hepatomegaly
‚Ä¢ Tumor bulk and c cell turnover S fatigue, weight loss, fever, sweats
Diagnostic evaluation ( JAMA 2010;303:2513)
‚Ä¢ Anemia with variable WBC and platelet counts
‚Ä¢ Peripheral smear S ‚Äúleukoerythroblastic‚Äù (teardrop cells, nucleated RBCs,
immature WBCs); large abnormal platelets
‚Ä¢ BM aspirate S ‚Äúdry‚Äù tap; BM bx S severe fibrosis, replacement by reticulin & collagen
‚Ä¢ JAK2 V617F present in 50% of PMF; MPL mutations in 11% of JAK2-negative pts
‚Ä¢ Does not meet WHO criteria for CML (absence of BCR-ABL translocation), PV, MDS
Treatment
‚Ä¢ In absence of adverse prognostic factors (eg, anemia or sx) S no treatment
‚Ä¢ Allogeneic HSCT only potential cure S consider in young Pts with poor prognosis
‚Ä¢ Supportive care: transfusions; inconsistent benefit from androgens or epo;
splenectomy for blood counts refractory to transfusion or painful splenomegaly
‚Ä¢ Hydroxyurea for significant leukocytosis or thrombocytosis
Complications and prognosis
‚Ä¢ Median survival 5 y; transformation into AML occurs at a rate of 8%/y
‚Ä¢ Worse prognosis with Hb 10 g/dL or with either WBC 30,000/L or WBC 4000/L
CHRONIC MYELOGENOUS LEUKEMIA
(see ‚ÄúLeukemia‚Äù)
MPN
5-16

--- Fim da P√°gina 142 ---

LEUKEMIA
5-17
LEUKEMIA
ACUTE LEUKEMIA
Definition
‚Ä¢ Clonal proliferation of hematopoietic progenitor with T ability to differentiate into mature
elements S c blasts in bone marrow and periphery S T RBCs, platelets, and neutrophils
Epidemiology and risk factors
‚Ä¢ Acute myelogenous leukemia (AML): 12,000 cases/y; median age 65 y; 80% of
adult acute leukemia cases
‚Ä¢ Acute lymphocytic leukemia (ALL): 4000 cases/y; median age 10 y; bimodal with
2nd peak in elderly
‚Ä¢ Risk factors: radiation, chemo (alkylating agents, topo II inhib), benzene, smoking
‚Ä¢ Acquired hematopoietic diseases: MDS, MPN (especially CML), aplastic anemia, PNH
‚Ä¢ Inherited: Down‚Äôs & Klinefelter‚Äôs, Fanconi‚Äôs anemia, Bloom syndrome, ataxia telangiectasia
Clinical manifestations
‚Ä¢ Cytopenias S fatigue (anemia), infection (neutropenia), bleeding (thrombocytopenia)
‚Ä¢ More common in AML:
leukostasis (when blast count 50,000/L): occluded microcirculation S local
hypoxemia and hemorrhage S headache, blurred vision,TIA/CVA, dyspnea, hypoxia;
look for hyperviscosity retinopathy (vascular engorgement, exudates, hemorrhage)
DIC (especially with APL)
leukemic infiltration of skin, gingiva (especially with monocytic subtypes)
chloroma: extramedullary tumor of leukemic cells, virtually any location
‚Ä¢ More common in ALL:
bone pain, lymphadenopathy, hepatosplenomegaly (also seen in monocytic AML)
CNS involvement (15%): cranial neuropathies, nausea and vomiting, headache
anterior mediastinal mass (especially in T-cell); tumor lysis syndrome (qv)
Diagnostic evaluation (Blood 2009;114:937)
‚Ä¢ Peripheral smear: anemia, thrombocytopenia, variable WBC (50% p/w c WBC,
50% p/w normal or T WBC)  circulating blasts (seen in 95%;  Auer Rods in AML)
‚Ä¢ Bone marrow: hypercellular with 20% blasts; cytogenetics, flow cytometry
‚Ä¢ Presence of certain cytogenetic anomalies, ie, t(15;17), t(8;21), inv(16) or
t(16;16), are sufficient for dx of AML regardless of the blast count
‚Ä¢ ‚úìfor tumor lysis syndrome (rapid cell turnover): c UA, c LDH, c K, c PO4, T Ca
‚Ä¢ Coagulation studies to r/o DIC: PT, PTT, fibrinogen, D-dimer
‚Ä¢ LP (w/ co-admin of intrathecal chemotherapy to avoid seeding CSF w/ circulating
blasts) for ALL Pts (CNS is sanctuary site) and for AML w/ CNS sx
‚Ä¢ TTE if prior cardiac history or before use of anthracyclines
‚Ä¢ HLA typing of Pt, siblings, and parents for potential allogeneic HSCT candidates
ACUTE MYELOGENOUS LEUKEMIA (AML)
Classification (FAB no longer used clinically; Blood 2009;114:937)
‚Ä¢ Features used to confirm myeloid lineage and subclassify AML to guide treatment:
morphology: blasts,  granules,  Auer rods (eosinophilic needle-like inclusions)
cytochemistry:  myeloperoxidase and/or nonspecific esterase
immunophenotype: CD13 & CD33 are myeloid antigens;  CD41 associated with M7
cytogenetics: important for prognosis, see below.
WHO 2008 Classification of AML (Blood 2009;114:937)
4 Major Subtypes
Examples
With recurrent genetic abnormalities
t(8;21); inv(16); t(15;17); 11q23 anomalies
With myelodysplasia-related change
w/ or w/o antecedent MDS or MPN
Therapy-related
eg, alkylating agents or topoisomerase inhibitors
Not otherwise specified
w/ min differentiation; w/o maturation; w/ 
maturation; myelomonocytic; monoblastic/monocytic;
erythroid; megakaryoblastic
AML Genetics (JCO 2005;23:6285; Blood 2007;109:431 & Grimwade, Blood 2010;epub)
Favorable Prognosis
Unfavorable Prognosis
Karytope
t(15;17) in APL; t(8;21);
‚Äì5; ‚Äì7; 3q26 aberrations, t(6;9); 11q23
inv(16); t(16;16)
aberrations; complex karyotype
Gene mutations
NPM1; CEBPA
FLT3 ITD; MLL partial tandem dup; c BAALC

--- Fim da P√°gina 143 ---

Treatment (Blood 2009;113:1875 & 2010;115:453)
‚Ä¢ Induction chemo followed by consolidation Rx
‚Ä¢ Induction chemo:‚Äú3  7‚Äù  ida/daunorubicin  3 d  cytarabine  7 d; daunorubicin
high-dose (90 mg/m2) superior to standard dose (45 mg/m2) (NEJM 2009;361:1235 & 1249)
‚Ä¢ ‚úìfor complete remission (CR)  normal peripheral counts, 5% BM blasts
CR Z cure ‚à¥must always f/u induction with consolidation Rx
‚Ä¢ If  CR: consolidation Rx based on risk stratification (age, genetics, PS): chemo or
allogeneic HSCT or autologous HSCT (JAMA 2009;301:2349)
‚Ä¢ If  CR: reinduction with similar chemotherapy (25) or alternative regimen
‚Ä¢ If relapse after CR: salvage chemotherapy followed by allogeneic or autologous HSCT
‚Ä¢ Supportive care: hydration  allopurinol or rasburicase for tumor lysis prophylaxis;
transfusions 	 G-CSF; antibiotics for fever and neutropenia; antifungals
for prolonged fever & neutropenia; hydroxyurea 	 leukophoresis for leukostasis
Prognosis
‚Ä¢ CR achieved in 70‚Äì80% of Pts 60 y and in 40‚Äì50% for Pts 60 y
‚Ä¢ Overall survival depends on prognostic factors: ranges from 50% for Pts 60 y w/o 
poor prognostic factors to 10% for Pts 60 y w/ poor prognostic factors
‚Ä¢ Poor prognostic factors: age 60, unfavorable cytogenetics (see above), poor
performance score, antecedent MDS/MPN, therapy-related AML
‚Ä¢ Gene expression profiling may be useful (NEJM 2004;330:1605, 1617; JCO 2005;23:6296)
Acute Promyelocytic Leukemia (APL) (Blood 2009;113:1875)
‚Ä¢ Rare disease w/ only 600‚Äì800 cases/y in US, but biologically and clinically distinct
‚Ä¢ Atypical promyelocytes (large, granular cells; creased nuclei) in blood and bone marrow
‚Ä¢ Defined by translocation of retinoic acid receptor: t(15;17); PML-RAR (95% of cases)
‚Ä¢ Medical emergency with DIC and bleeding common; supportive care measures crucial
‚Ä¢ Remarkable responses to all-trans-retinoic acid (ATRA), which induces differentiation,
and arsenic trioxide (ATO); early initiation of ATRA is critical as soon as APL suspected
‚Ä¢ Induction chemo typically anthracycline  ATRA 	 cytarabine S CR in 90% of Pts
‚Ä¢ Consolidation Rx (eg,ATO S anthracycline  ATRA) followed by prolonged mainte-
nance Rx (eg,ATRA  6MP  MTX); ATO highly active in induction and consolida-
tion and is promising as 1st-line Rx or for treatment of refractory disease
‚Ä¢ Overall best prognosis of all AMLs w/ 80% cure rate; WBC 10,000/L 
is adverse prognostic factor (Blood 2000;96:1247)
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Classification
‚Ä¢ Lymphoblastic neoplasms may present as acute leukemia (ALL) with 20% BM
blasts, or as lymphoblastic lymphoma (LBL) w/ mass lesion & 20% BM blasts.
ALL and LBL are considered the same disease with different clinical presentations.
‚Ä¢ Morphology: no granules (granules seen in myeloid lineage)
‚Ä¢ Cytochemistry:  terminal deoxynucleotidyl transferase (TdT) in 95% of ALL
‚Ä¢ Cytogenetics (JCO 2005;23:6306): t(9;22)  Philadelphia chrom (Ph) 25% of adults w/ ALL
‚Ä¢ Immunohistochemistry: 3 major phenotypes (Burkitt‚Äôs usually treated differently)
WHO Immunophenotype Classification of ALL
WHO Type
Adult Freq
Immunohistochemistry
Precursor B-cell
75%
 TdT,  CD19; variable CD10, CD20
Precursor T-cell
20%
 TdT,  T-cell Ag (CD2, 3, 5, 7)
 CD10,  mature T-cell Ag (CD4, 8)
Burkitt‚Äôs Lymphoma*
5%
 TdT,  surface Ig
*Burkitt‚Äôs lymphoma may present as an acute leukemia, with circulating tumor cells (see ‚ÄúLymphoma‚Äù)
Treatment (NEJM 2006;354:166)
‚Ä¢ Induction chemo: multiple acceptable regimens including combination of anthra-
cycline, vincristine, steroids, cyclophosphamide, 	 asparaginase
‚Ä¢ CNS prophylaxis: intrathecal MTX/cytarabine 	 cranial irradiation or systemic MTX
‚Ä¢ Postremission therapy options:
consolidation/intensification chemo (7 mos) followed by maintenance chemo (2‚Äì3 y)
high-dose chemo w/ allo HSCT considered for all Pts in CR1 w/ available donor
‚Ä¢ If relapse S salvage chemo followed by allogeneic HSCT if able
‚Ä¢ Ph  t(9;22) S add imatinib or dasatinib & consider for allogeneic HSCT
‚Ä¢ MLL-AF4 t(4;11) S consider for allogeneic HSCT
LEUKEMIA
5-18

--- Fim da P√°gina 144 ---

Prognosis
‚Ä¢ CR achieved in 80% of adults
‚Ä¢ Cure achieved in 50-70% if good prog. factors vs. in 10‚Äì30% w/ poor prog. factors
‚Ä¢ Good prognostic factors: younger age,WBC 30,000/L,T-cell immunophenotype,
absence of Ph chromosome or t(4;11), early attainment of CR
‚Ä¢ Gene expression patterns may be useful in predicting chemo resistance (NEJM 2004;351:533)
CHRONIC MYELOGENOUS LEUKEMIA (CML)
Definition (Blood 2009;114:937)
‚Ä¢ Myeloproliferative neoplasm with clonal overproduction of hematopoietic
myeloid stem cells that can differentiate
‚Ä¢ Philadelphia chromosome (Ph) 	 t(9;22) S BCR-ABL fusion S c Abl kinase activity
BCR-ABL required for Dx of CML
‚Ä¢ ‚ÄúAtypical CML‚Äù (BCR-ABL ) now considered a separate disease and reclassified as
MDS/MPN (see ‚ÄúMyelodysplastic Syndromes‚Äù)
Epidemiology and risk factors
‚Ä¢ 4300 new cases/y in U.S.; median age 50 at presentation; 15% of adult leukemias
‚Ä¢ c risk with irradiation; no clear relation to cytotoxic drugs
Clinical manifestations
‚Ä¢ Triphasic clinical course; 85% present in the chronic phase
‚Ä¢ Chronic phase: often asymptomatic but common features are fatigue, malaise, weight
loss, night sweats, abdominal fullness (splenomegaly 50%)
‚Ä¢ Accelerated phase: refractory leukocytosis and worsening symptoms S fever, weight
loss, progressive splenomegaly, bone pain, bleeding, infections, pruritus (basophilia)
‚Ä¢ Blastic phase  acute leukemia S severe constitutional symptoms, infection, bleeding
and possible leukostasis (see ‚ÄúAcute Leukemia‚Äù)
Diagnostic evaluation
‚Ä¢ Peripheral smear: leukocytosis (often 100,000/L), left-shifted with all stages of
myeloid maturation; anemia, thrombocytosis, basophilia
‚Ä¢ Bone marrow: hypercellular, c myeloid to erythroid ratio, T leuk alkaline phosphatase
‚Ä¢ Chronic: 10% blasts (peripheral or BM)
‚Ä¢ Accelerated: 10‚Äì20% blasts, 20% basos, plts 100K, c spleen size, karyotypic prog.
‚Ä¢ Blastic: 20% blasts (2/3 myeloid, 1/3 lymphoid), may see extramedullary leukemia
Treatment (NEJM 2006;355:2408; Lancet 2007;370:342; NEJM 2007;357:258)
‚Ä¢ Tyrosine kinase inhib: 1st line Rx chronic phase; continued indef in responders
imatinib, dasatinib & nilotinib are selective inhib of BCR-ABL (Blood 2008;112:4808)
imatinib active in chronic, accelerated, blastic phases (but less as disease advances)
imatinib resistance is associated with BCR-ABL mutation or amplification 
dasatanib and nilotinib are more potent BCR-ABL inhibitors and yield higher
response rates than imatinib as initial therapy (NEJM 2010:362:2251 & 2260); both are effec-
tive against most imatinib resistance mutations except T315I (NEJM 2006:354:2531 & 2542)
side effects include nausea, diarrhea, muscle cramps, cytopenias, T PO4, rarely CHF;
dasatinib also a/w pericardial & pleural effusions, nilotinib w/ c bili & lipase
‚Ä¢ Allogeneic HSCT: consider for Pts w/ available donor who present in accelerated or
blastic phase; reasonable option for Pts with relapsed/refractory disease to imatinib
(especially Pts w/ BCR-ABL T315I mutation)
Goals of Imatinib Therapy
Response
Definition
Goal time
WBC 10K, Plt 450, 5% myelocytes &
Hematologic
metamyelocytes, 20% basos, no immature cells in
3 mo
blood, no extramedullary involvement
Cytogenetic
Absence of the Ph chromosome in metaphase cells
12 mo
Molecular
3-log reduction by quantitative PCR
12‚Äì18 mo
Prognosis
‚Ä¢ Natural hx (untreated) of chronic phase CML is prog. to blast phase and death w/in 4‚Äì6 y
‚Ä¢ Chronic phase CML Rx‚Äôd w/ imatinib: 89% overall survival, 95% survival free of CML-
related deaths, 7% progression to blast phase at 5 y (NEJM 2006;355:2408)
‚Ä¢ Accelerated phase CML Rx‚Äôd w/ imatinib: 50% overall survival at 4 y (Cancer 2005;103:2099)
‚Ä¢ Poor prognostic factors: c age, c platelet count, c spleen size, c percentage of blasts
LEUKEMIA
5-19

--- Fim da P√°gina 145 ---

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Definition (NEJM 2005;352:804; Br J Haematol 2007;139:672)
‚Ä¢ Monoclonal accumulation of functionally incompetent mature B-lymphocytes
‚Ä¢ CLL & small lymphocytic lymphoma (SLL) now classified as same disease
Epidemiology and risk factors
‚Ä¢ 10,000 new cases/y; median age at dx is 65 y; most common adult leukemia
‚Ä¢ c incidence in 1st-degree relatives; no known association with radiation, chemicals, drugs
Clinical manifestations
‚Ä¢ Symptoms: often asx & identified when CBC reveals lymphocytosis; 10‚Äì20% p/w fatigue,
malaise, night sweats, weight loss (ie, lymphoma ‚ÄúB‚Äù sx)
‚Ä¢ Signs: lymphadenopathy (80%) and hepatosplenomegaly (50%)
‚Ä¢ Autoimmune hemolytic anemia (AIHA) or thrombocytopenia (ITP)
‚Ä¢ Hypogammaglobulinemia 	 neutropenia S c susceptibility to infections
‚Ä¢ Bone marrow failure
‚Ä¢ Monoclonal gammopathy in 5%
‚Ä¢ Aggressive transformation: 5% develop Richter‚Äôs syndrome  transformation into
high-grade lymphoma (usually DLBCL) and sudden clinical deterioration
Diagnostic evaluation (see ‚ÄúLymphoma‚Äù for general approach)
‚Ä¢ Peripheral smear: lymphocytosis (5000/L, mature-appearing small cells)
‚Äúsmudge‚Äù cells from damage to abnl lymphs from shear stress of making blood smear
‚Ä¢ Flow cytometry: clonality with dim surface Ig (sIg); CD5, CD19, CD20, CD23.
CD38 or ZAP70 a/w unmutated Ig variable heavy chain region & worse prognosis
‚Ä¢ Bone marrow: normo- or hypercellular; infiltrated w/ small B-cell lymphocytes (30%)
‚Ä¢ Lymph nodes: infiltrated w/ small lymphocytic or diffuse small cleaved cells  SLL
‚Ä¢ Cytogenetics: 11q22-23 & 17p13 unfavorable; trisomy 12 neutral; 13q14 favorable
CLL Staging
Rai System
Median
Binet System
Stage
Description
survival
Description
Stage
0
Lymphocytosis only
10 y
3 node areas
A
I
 lymphadenopathy
7 y
3 node areas
B
II
 hepatosplenomegaly
III
 anemia (not AIHA)
1‚Äì2 y
Anemia or
C
IV
 thrombocytopenia (not ITP)
thrombocytopenia
Treatment
‚Ä¢ Treatment is palliative S early stage disease can be followed w/o Rx
‚Ä¢ Indications for treatment: Rai stages III/IV, Binet stage C, disease-related sx,
progressive disease,AIHA or ITP refractory to steroids, recurrent infections
‚Ä¢ Options for treatment
purine analogs: fludarabine (‚ÄúF‚Äù), pentostatin (‚ÄúP‚Äù)
alkylating agents: cyclophosphamide (‚ÄúC‚Äù), CVP, CHOP; chlorambucil for elderly
monoclonal Ab against CD20 (rituximab,‚ÄúR‚Äù) or CD52 (alemtuzumab)
 survival w/ single agents, although higher response rate w/ F (NEJM 2000;343:1750)
combination regimens (ie, FR, FC, FCR, PCR) superior to monoRx (Lancet 2007;370:230)
‚Ä¢ Role of autologous and allogeneic HSCT being studied
‚Ä¢ Localized SLL can be treated with involved-field radiation therapy alone, rather than chemo
‚Ä¢ Supportive care: PCP, HZV,VZV prophylaxis; CMV monitoring for Pts receiving CD52;
AIHA/ITP S steroids; recurrent infections S IVIg; bulky disease with compressive
symptoms S XRT; splenomegaly with refractory cytopenias S splenectomy
Prognostic Factors & Median Survival in CLL
Factor
Years
Factor
Years
Cytogenetics
CD38 expression
17p-
2.5
Low (20‚Äì30%)
8
11q-
6.6
High (20‚Äì30%)
Unclear
Trisomy 12 or Normal
9
Zap-70 expression
13q-
11
Low (20‚Äì30%)
24.3
IgVH gene status
High (20‚Äì30%)
9.3
Mutated (2%)*
24
2-microglobulin: higher levels correlate with
Unmutated (2%)*
8
disease stage, tumor burden and a poorer prognosis.
*% difference c/w germline. NEJM 2004;351:893 & 2005;353:1793; Blood 2007;109:4679; JCO 2009;27:1637.
LEUKEMIA
5-20

--- Fim da P√°gina 146 ---

LYMPHOMA
5-21
LYMPHOMA
Definition
‚Ä¢ Malignant disorder of lymphoid cells that reside predominantly in lymphoid tissues
‚Ä¢ Hodgkin lymphoma (HL) is distinguished from non-Hodgkin‚Äôs lymphoma (NHL) by
the presence of Reed-Sternberg (RS) cells
Clinical manifestations
‚Ä¢ Lymphadenopathy (nontender)
HL: superficial (usually cervical/supraclavicular) 	 mediastinal lymphadenopathy;
nodal disease with orderly, anatomic spread to adjacent nodes
NHL: diffuse; nodal and extranodal disease with noncontiguous spread;
symptoms reflect involved sites (abdominal fullness, bone pain)
‚Ä¢ Constitutional (‚ÄúB‚Äù) symptoms: fever (38), sweats, weight loss (10% over 6 mos)
HL: periodic, recurrent ‚ÄúPel-Ebstein‚Äù fever; 10‚Äì15% have pruritus
NHL: ‚ÄúB‚Äù symptoms less common than in HL
Diagnostic and staging evaluation
‚Ä¢ Physical exam: lymph nodes, liver/spleen size, Waldeyer‚Äôs ring, testes (1% of NHL), skin
‚Ä¢ Pathology: excisional lymph node bx (not FNA, need surrounding architecture) with
immunophenotyping and cytogenetics; BM bx (except in HL clinical stage IA/IIA with
favorable features); LP if CNS involvement is clinically suspected
‚Ä¢ Lab tests: CBC, BUN/Cr, LFTs, ESR, LDH, UA, Ca, alb; ‚úìHBV & HCV (and must 
‚úìHBsAg & anti-HBc if planning rituximab Rx as can lead to HBV reactivation); 
consider HIV, HTLV, & EBV serologies and connective tissue diseases autoAbs
‚Ä¢ Imaging: chest/abd/pelvic CT (but don‚Äôt reliably detect spleen/liver involvement)
‚à¥also need PET scans
head CT/MRI if neurological symptoms; bone scan if bony pain or if A elevated
Ann Arbor Staging System with Cotswolds Modifications
Stage
Features
I
Single lymph node (LN) region
II
2 LN regions on the same side of the diaphragm
III
LN regions on both sides of the diaphragm
IV
Disseminated involvement of one or more extralymphatic organs
Modifiers:A  no symptoms; B  fever, night sweats or weight loss; X  bulky disease 
greatest transverse diam. of mediastinal mass / max diam. of chest wall 1/3 on CXR or
10 cm if in abd; E  involves single contiguous extranodal site; H  hepatic; S  splenic
HODGKIN LYMPHOMA (HL)
Epidemiology and risk factors
‚Ä¢ 8,500 cases/y; bimodal distribution (15‚Äì35 & 50 y); c male; ? role for EBV
Pathology
‚Ä¢ Affected nodes show RS cells (1%) in background of non-neoplastic inflammatory cells
‚Ä¢ Classic RS cells: bilobed nucleus & prominent nucleoli with surrounding clear space (‚Äúowl‚Äôs
eyes‚Äù). RS cells are clonal B-cells: CD15, CD30, CD20 by flow cytometry.
WHO Histologic Classification of Classical HL
Lymphocyte
5%
Abundant normal-appearing lymphocytes; mediastinal LAN
rich
uncommon; male predominance; good prognosis
Nodular
60‚Äì
Collagen bands; frequent mediastinal LAN; young adults;
sclerosis
80%
female predominance; usually stage I/II at dx
Mixed
15‚Äì
Pleomorphic; older age; male predominance; 50% stage
cellularity
30%
III/VI at presentation; intermediate prognosis
Lymphocyte
1%
Diffuse fibrosis and large numbers of RS cells; older, male
depletion
patients; disseminated at dx; seen in HIV; worst prognosis
‚Ä¢ Nonclassical (5%): nodular lymphocyte predominant (NLP); involves peripheral LN
80% present in stage I‚ÄìII and Rx can be RT alone or combination chemo  RT w/ 80%
10-y progression-free survival, 93% overall survival (JCO 1997;15;3060)
Consider rituximab as most NLP RS cells are CD20 
Stage III-IV treated with combination chemo (see below)

--- Fim da P√°gina 147 ---

Treatment
‚Ä¢ Stage I-II classical HL: consider ABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine)  RT (or ABVD  6 cycles alone in select cases) 
‚Ä¢ Stage III-IV: ABVD  6 cycles or BEACOPP (bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone) in high-risk advanced Pts
‚Ä¢ Refractory/relapsed disease: salvage chemo, high-dose chemo  auto HSCT, allo HSCT
‚Ä¢ Late effects: c risk for second malignancies including lung cancer (XRT and
chemo), breast cancer (XRT), acute leukemia/MDS, NHL; cardiac disease (XRT
and anthracycline); pulmonary toxicity (bleomycin); hypothyroidism (XRT) 
International Prognostic Score (IPS)
Negative Prognostic Indicators
Total # of 
5-y PFS
Indicators
Albumin 4 g/dL
0
84%
Hb 10.5 g/dL
1
77%
Male
2
67%
Age 45 y
3
60%
Stage IV
4
51%
WBC  15k/L
5
42%
Lymphocytes 600/L or 8% of differential
(NEJM 1998;339:1506)
NON-HODGKIN‚Äôs LYMPHOMA (NHL)
Epidemiology and risk factors
‚Ä¢ 66,000 new cases/y; median age at diagnosis 65 y;  predominance; 85% B cell origin
‚Ä¢ Associated conditions: immunodeficiency (eg, HIV, posttransplant); autoimmune
disorders (eg, Sj√∂gren‚Äôs, RA, SLE); infection (eg, EBV, HTLV-I, H. pylori)
‚Ä¢ Burkitt‚Äôs lymphoma: (1) endemic or African (jaw mass, 80‚Äì90% EBV-related);
(2) sporadic or American (20% EBV-related); (3) HIV-related
WHO Classification of Lymphoid Malignancies
Type
Examples 
Associated genetic abnl
Mature
Diffuse large B-cell lymphoma (DLBCL)
B Cell
Follicular lymphoma
IGH-BCL2
CLL/small lymphocytic lymphoma
Mantle cell
t(11;14) BCL1-IgH S cyclin D1 dysreg
Marginal zone lymphoma (nodal,
AP12-MALT1 & BCL-10-Ig enhancer
extranodal (MALT), splenic)
Burkitt‚Äôs lymphoma
8q24, c-MYC
Hairy cell leukemia (p/w fatigue, T monos,
massive splenomegaly;  TRAP)
Mature
Peripheral T cell lymphoma
T Cell 
Mycosis fungoides (cutaneous 
& NK 
lymphoma) / S√©zary syndrome ( LAN)
Cell
Anaplastic large cell lymphoma 
Some ALK1 
Angioimmunoblastic T cell lymphoma
(Blood 2007;110:695; NEJM 2010; 362:1417)
Treatment
‚Ä¢ Treatment and prognosis determined by histopathologic classification rather than stage
‚Ä¢ Indolent: goal is sx management (bulky dis., cytopenias,‚ÄúB‚Äù sx); not curable w/o allo HSCT
Options include radiation for localized disease, rituximab 	 chemo (CVP, fludara-
bine, bendamustine), single-agent chemo (chlorambucil, cyclophosphamide, flu-
darabine). Newer rituximab radioimmunotherapy (RIT) conjugates include I131
tositumomab and Y90 ibritumomab tiuxetan. 
Rituximab maintenance c survival in relapsed disease (JNCI 2009:101:248); growing role
for rituximab maintenance in indolent and aggressive disease (trials pending)
‚Ä¢ Aggressive (DLBCL, 30‚Äì40% of NHL): goal is cure (JCO 2005;23:6387)
CHOP-R (cyclophosphamide, doxorubicin  hydroxydaunorubicin, vincristine  Oncovorin,
prednisone, rituximab) (NEJM 2002;346:235 & 2008;359:613); 
5-y progression-free survival  54%; overall survival  58% (JCO 2005;23:4117)
 Radiation for localized or bulky disease
LYMPHOMA
5-22

--- Fim da P√°gina 148 ---

Consider CNS prophylaxis w/ intrathecal or systemic high-dose methotrexate if
paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; 
2 extranodal site  c LDH may also warrant
Refractory/relapsed disease: salvage chemo; high-dose chemo  auto-HSCT (NEJM
1995;333:1540); allo-HSCT if beyond 2nd relapse
‚Ä¢ Highly Aggressive
Burkitt‚Äôs: intensive short-course chemotherapy (Blood 2004;104:3009)
Low risk defined as nl LDH & single focus of disease 10 cm; all others high risk
Low risk Rx  CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose
methotrexate 	 rituximab) (Leuk Lymph 2004;45:761)
High risk Rx  CODOX-M/IVAC (above w/ ifosfamide, etoposide, high-dose cytarabine)
All Pts receive CNS prophylaxis and tumor lysis syndrome prophylaxis
Lymphoblastic lymphoma (B- or T-cell): treated like ALL (see ‚ÄúAcute Leukemia‚Äù)
Prognosis
‚Ä¢ Indolent: T response to chemotherapy, but long median survival
Follicular Lymphoma International Prognostic Index (FLIPI)
Factors: age 60, stage III/IV, Hb 12 g/dL, 4 nodal areas, LDH nl
# Factors
5-y Overall Survival
10-y Overall Survival
0‚Äì1
90%
71%
2
78%
51%
3
52%
35%
(Blood 2004;104:1258)
‚Ä¢ Aggressive: c chance of cure, but overall worse prognosis
International Prognostic Index (IPI) for Aggressive NHL
Factors: age 60, stage III/IV, 2 extranodal sites, performance status 2, LDH nl
# Factors
Complete Response
5-y Overall Survival
0‚Äì1
87%
73%
2
67%
51%
3
55%
43%
4‚Äì5
44%
26%
Revised IPI Prognosis in Patients Rx‚Äôd with CHOP-R
Factors
% at dx
4-y Overall Survival
0
10%
94%
1‚Äì2
45%
79%
3‚Äì5
45%
55%
(NEJM 1993;329:987; Blood 2007;109:1857).
HIV-associated NHL (Blood 2006;107:13; www.nccn.org)
‚Ä¢ HIV  imparts 60‚Äì100 relative risk
‚Ä¢ NHL is an AIDS-defining malignancy along with Kaposi‚Äôs, cervical CA, anal CA
‚Ä¢ Concurrent HAART & chemotherapy likely provides survival benefit
‚Ä¢ DLBCL & immunoblastic lymphoma (67%): CD4 100, EBV-associated
Treat as immunocompetent (CHOP-R), but avoid rituximab if CD4 100
‚Ä¢ Burkitt‚Äôs and Burkitt‚Äôs-like (20%): can occur with CD4 200
Treat as immunocompetent, though prognosis is significantly worse
‚Ä¢ Primary CNS lymphoma (16%): CD4 50, EBV-associated (also seen in Pts w/o HIV) 
Treat with high-dose methotrexate  steroids 	 RT
‚Ä¢ Primary effusion lymphoma (5%): HHV8 driven; also can be seen in other immuno-
supp. Pts such as s/p solid organ transplant or w/ chronic HBV. Treat with standard
CHOP (often CD20-), but poor prognosis.
LYMPHOMA
5-23

--- Fim da P√°gina 149 ---

MM
5-24
PLASMA CELL DYSCRASIAS
MULTIPLE MYELOMA (MM)
Definition and epidemiology
‚Ä¢ Malignant neoplasm of plasma cells producing a monoclonal Ig  ‚ÄúM protein‚Äù
‚Ä¢ 20,580 new cases and 10,580 deaths/y in U.S. (2009); median age at diagnosis 66 y
‚Ä¢ African American:Caucasian ratio 2:1
Clinical manifestations
‚Ä¢ Anemia (normocytic) due to bone marrow involvement and autoimmune Ab
‚Ä¢ Bone pain and hypercalcemia due to c osteoclast activity S lytic lesions, pathologic fx
‚Ä¢ Recurrent infections due to relative hypogammaglobulinemia as clonal plasma cells
suppress nl immunoglobulin
‚Ä¢ Renal disease: multiple mechanisms include toxic effect of filtered light chains S renal
failure (cast nephropathy) or type II RTA; amyloidosis or light chain deposition disease S
nephrotic syndrome: hypercalcemia, urate nephropathy, type I cryoglobulinemia
‚Ä¢ Neurologic: cord compression; POEMS (polyneuropathy, organomegaly, endocrinopa-
thy, M protein, skin changes) syndrome
‚Ä¢ Hyperviscosity: usually when IgM 4 g/dL, IgG 5 g/dL, or IgA 7 g/dL
‚Ä¢ Coagulopathy: inhibition of or Ab against clotting factor; Ab-coated platelets
‚Ä¢ Amyloidosis (see ‚ÄúAmyloidosis‚Äù)
Diagnostic and staging evaluation (NCCN Version 3.2010)
‚Ä¢ Sx MM criteria  M protein in serum (usually 3 g/dL) or urine, marrow plasmacyto-
sis (usually 90%) or presence of a plasmacytoma, and myeloma-related organ or tis-
sue impairment (ROTI)  lytic bone lesions, Ca 11.5 g/dL, Cr 2 mg/dL, or Hb 10
‚Ä¢ Variants
smoldering MM: M protein 3 g/dL and/or plasmacytosis 10%, but asx & no ROTI
risk of progression related to level of plasmacytosis and M protein (NEJM 2007;356:2582)
solitary bone plasmacytoma: 1 lytic lesion w/o M protein, plasmacytosis, or other ROTI
extramedullary plasmacytoma: usually upper respiratory tract
plasma cell leukemia: plasma cell count 2000/L
nonsecretory MM: no M protein, but marrow plasmacytosis & ROTI
‚Ä¢ Ddx of M component: MM, MGUS (see below), CLL, lymphoma, cirrhosis, sarcoidosis, RA
‚Ä¢ Peripheral smear S rouleaux (see Peripheral Smear insert); ‚úìCa, alb, Cr; T anion gap,
c globulin, c ESR
‚Ä¢ Protein electrophoresis and immunofixation
serum protein electrophoresis (SPEP): quantitates M component;  in 80% of Pts
urine protein electrophoresis (UPEP): detects the 20% of Pts who secrete only light
chains (  Bence Jones proteins), which are filtered rapidly from the blood
immunofixation: shows component is monoclonal and identifies Ig type S IgG (50%),
IgA (20%), IgD (2%), IgM (0.5%), light chain only (20%), nonsecretors (5%)
serum-free light chain assay: important test for dx and to follow treatment response
‚Ä¢ 2-microglobulin and LDH levels reflect tumor burden 
‚Ä¢ Bone marrow bx: better prognosis  hyperdiploidy; worse prognosis  del. of
chromosome 17p13 (10% of Pts) & certain translocations
‚Ä¢ Skeletal survey (plain radiographs) to identify lytic bone lesions and areas at risk for
pathologic fracture; bone scan is not useful for detecting lytic lesions
Multiple Myeloma Staging Systems
Stage
ISS Criteria
Durie-Salmon Criteria
Median survival
2-microglobulin
all of the following:
3.5 mg/L
Hb 10 g/dL; Ca 12 mg/dL;
I
and
0‚Äì1 lytic bone lesions; IgG 
61 mo
albumin 3.5g/dL
5 g/dL or IgA 3 g/dL or 
urine light chain 4 g/24 h
II
fulfilling criteria for neither I nor III
55 mo
any of the following:
Hb 8.5 g/dL; Ca 12 mg/dL; 
III
2-microglobulin
5 lytic bone lesions; IgG 
30 mo for IIIA
5.5 mg/L
7 g/dL or IgA 5 g/dL or  
15 mo for IIIB
urine light chain 12 g/24 h
Subclassification by serum Cr:A 2 mg/dL; B 2 mg/dL

--- Fim da P√°gina 150 ---

Treatment (NEJM 2004;351:1860; Lancet 2009;374:324; NEJM 2009;360:2645)
‚Ä¢ Treatment not indicated for smoldering MM or asx stage I disease
‚Ä¢ In general, Pts divided into two groups: transplant eligible vs. not eligible
‚Ä¢ If not transplant eligible: systemic chemotherapy (c median survival, but not curative)
regimens include melphalan  prednisone  either thalidomide/lenalidomide (Lancet
2007;370:1209) or proteasome inhibitor if high risk (bortezomib; NEJM 2008;359:906)     
lenalidomide  dexamethasone for relapsing/refractory MM (NEJM 2007;357:2123, 2133)
‚Ä¢ If transplant eligible: high-dose chemo  auto-HSCT. Not curative, but c survival
c/w conv. chemo (NEJM 2009;360:2645). Offer if 70 y w/ good performance status.  
Many chemo regimens used incl. thalidomide or lenalidomide  dex, bortezomib 
dex, vincristine/doxorubicin/dex, etc.
Double auto-HSCT c survival (NEJM 2003;349:2495),  thalidomide S c response
rate but no  in overall survival (NEJM 2006;354:1021)
‚Ä¢ Local radiation for solitary or extramedullary plasmacytoma
‚Ä¢ Adjunctive Rx
bone: bisphosphonates (NEJM 1996;334:488; & JCO 2007;25:2464); XRT for sx bony lesions
renal: avoid NSAIDs & IV contrast; consider plasmapheresis for acute renal failure
hyperviscosity syndrome: plasmapheresis
infections: consider IVIg for recurrent infections
‚Ä¢ Common toxicities of Rx: melphalan  prednisone S infxn, myelosuppression;
thalidomide S thromboembolism, bradycardia, periph. neuropathy, neutropenia, rash
(Blood 2008;111:3968); bortezomib S periph. neuropathy
MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)
Definition and epidemiology (NEJM 2006;355:2765)
‚Ä¢ M protein 3 g/dL, no urinary Bence Jones proteins, marrow plasmacytosis 10%, no ROTI
‚Ä¢ Prevalence 3% in population 50 y of age, 5% in population 70 y of age, and
7.5% in population 85 y of age (NEJM 2006;354:1362)
Management
‚Ä¢ ‚úìCBC, Ca, Cr, SPEP and UPEP with immunofixation to exclude MM
‚Ä¢ Close observation: repeat SPEP in 6 mos and then yearly thereafter if stable
Prognosis (NEJM 2002:346:564)
‚Ä¢ 1%/y or 25% lifetime risk S MM, WM, amyloidosis, or malign. lymphoproliferative dis.
‚Ä¢ Abnormal serum-free light chain ratio: c risk of progression to MM (Blood 2005;105:812)
WALDENSTR√ñM‚ÄôS MACROGLOBULINEMIA (WM)
Definition (JCO 2005;23:1564; Blood 2007;109:5096)
‚Ä¢ B-cell neoplasm (lymphoplasmacytic lymphoma) that secretes monoclonal IgM
‚Ä¢ No evidence of bone lesions (IgM M component  lytic bone lesions  ‚ÄúIgM myeloma‚Äù)
Clinical manifestations
‚Ä¢ Fatigue from anemia is most common sx
‚Ä¢ Tumor infiltration: BM (cytopenias), hepatomegaly, splenomegaly, lymphadenopathy
‚Ä¢ Circulating monoclonal IgM
hyperviscosity syndrome (15%)
neurologic: blurred vision (‚Äúsausage‚Äù retinal veins on funduscopy), HA, dizziness,  MS
cardiopulmonary: congestive heart failure, pulmonary infiltrates
type I cryoglobulinemia S Raynaud‚Äôs phenomenon
platelet dysfxn S mucosal bleeding
‚Ä¢ IgM deposition (skin, intestine, kidney); amyloidosis and glomerulopathy
‚Ä¢ Autoantibody activity of IgM
chronic AIHA (prominent rouleaux; 10% Coombs‚Äô   AIHA)
peripheral neuropathy: may be due to IgM against myelin-associated glycoprotein
Diagnostic evaluation
‚Ä¢ SPEP  immunofixation with IgM 3 g/dL; 24-h urine for UPEP (only 20% have  UPEP)
‚Ä¢ Bone marrow biopsy: c plasmacytoid lymphocytes; 2-microglobulin for prognostic eval
‚Ä¢ Relative serum viscosity: defined as ratio of viscosity of serum to H2O (nl ratio
1.8) hyperviscosity syndrome when relative serum viscosity 5‚Äì6
Treatment (NCCN Version 3.2010)
‚Ä¢ Hyperviscosity: plasmapheresis
‚Ä¢ Symptoms (eg, progressive anemia): systemic chemotherapy w/ chlorambucil, fludarabine,
cladribine, rituximab, bortezomib or combination therapy
‚Ä¢ Thalidomide and HSCT are investigational modalities
WM
5-25

--- Fim da P√°gina 151 ---

HSCT
5-26
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages
Categories of Stem Cell Transplantation
Feature
Allogeneic (Allo)
Autologous (Auto)
Donor-recipient relationship
Immunologically distinct
Donor is also recipient
Graft-versus-host disease
Yes
No
Graft-versus-tumor effect
Yes
No
Risk of graft contam. w/ tumor
No
Yes
Relapse risk (leukemia)
Lower
Higher
Transplant-related mortality
Higher
Lower
‚Ä¢ Types of Allo HSCT: based on donor/recipient matching of major HLA antigens on
Chr. 6 (3 principal genes for serotyping: HLA-A, -B, & -DR; each w/ 2 alleles ‚à¥6 major Ag)
Matched related (sibling matched at 6/6 major Ag): lowest risk of GVHD; preferred donor
Mismatched related (eg, 1/6 Ag mismatch) or haploidentical (mismatch at 3/6 Ag):
easiest to find, but c risk of GVHD; ‚à¥need to deplete T cells first
Matched unrelated: c risk of GVHD; ‚à¥adv. molecular matching of 8 HLA alleles to T risk
Umbilical cord blood: HSC processed at birth & stored; T risk of GVHD; tolerate mismatch
‚Ä¢ Graft-versus-host disease (GVHD): undesirable side effect of allo HSCT
allogeneic T cells view host cells as foreign; c incid. w/ mismatch or unrelated donors
‚Ä¢ Graft-versus-tumor (GVT) effect: desirable consequence of allo HSCT;
allogeneic T cells attack host tumor cells
Indications (NEJM 2006;354:1813)
‚Ä¢ Malignant disease:
Auto HSCT allows higher doses of chemo by rescuing hematopoietic system
(used for lymphoma, multiple myeloma, testicular cancer)
Allo HSCT produces graft-versus-tumor (GVT) effect, in addition to
hematopoietic rescue (used for AML, ALL, CML, CLL, MDS, lymphoma)
‚Ä¢ Nonmalignant disease: allo HSCT replaces abnl lymphohematopoietic system w/ one
from nl donor (eg, immunodef., aplastic anemia, hemoglobinopathies, ? autoimmune dis.)
Transplantation procedure
‚Ä¢ Preparative regimen: chemotherapy and/or immunosuppression prior to transplantation
myeloablative (traditional): chemotherapy and/or total body irradiation. Goal is
eradication of underlying disease for which transplant is being performed.
nonmyeloablative (‚Äúmini‚Äù): reduced-intensity conditioning regimens S T toxicity to
allow Pts w/ comorbidities or c age to tolerate HSCT. Goal to proceed w/
transplant when in disease remission, harnessing GVT effect while tolerating GVHD.
‚Ä¢ Sources of stem cells:
bone marrow (BM): original source of HSCT but now less common than PBSC
peripheral blood stem cells (PBSC): easier collection, most commonly used source
umbilical cord blood (UCB): less stringent HLA-matching requirements, though fewer
available cells from single donor (‚à¥2 donors typically combined), slower engraftment
‚Ä¢ Engraftment: absolute neutrophil count (ANC) recovers to 500/L w/in 2 wk w/ PBSC,
3 wk w/ BM, 4 wk w/ UCB. G-CSF accelerates recovery by 3‚Äì5 d in all scenarios.
Engraftment syndrome: fever, rash, noncardiogenic pulm edema, abnl LFTs, AKI, wt gain.
Dx of exclusion, r/o infection, GVHD; Rx w/ IV steroids.
Complications
‚Ä¢ Either direct chemoradiotoxicites associated with preparative regimen or consequences
of interaction between donor and recipient immune systems
Timing and Mechanism of Noninfectious Complications of HSCT
Timing
30 d
30‚Äì90 d
90 d
Regimen-
Pancytopenia
Growth failure
related
Mucositis, rash, alopecia
Hypogonadism/infertility
Nausea, vomiting, diarrhea
Hypothyroidism
Peripheral neuropathies
Cataracts
Hemorrhagic cystitis
Avascular necrosis of bone
Veno-occlusive disease
2nd malignancy
Interstitial pneumonitis
Immune-
Acute GVHD
Chronic GVHD
mediated
Primary graft failure
Secondary graft failure

--- Fim da P√°gina 152 ---

‚Ä¢ Sinusoidal obstruction syndrome (SOS; incidence 10%, mortality 30%)
Previously known as veno-occlusive disease (VOD)
Mechanism: direct cytotoxic injury to hepatic venules S in situ thrombosis
Symptoms: tender hepatomegaly, ascites, jaundice, fluid retention
with severe disease S liver failure, encephalopathy, hepatorenal syndrome
Diagnosis: c ALT/AST, c bilirubin; c PT with severe disease; Doppler U/S may show
reversal of portal vein flow; c hepatic wedge pressure; abnl liver bx
Treatment: supportive; prophylaxis with ursodiol; defibrotide
‚Ä¢ Idiopathic interstitial pneumonitis (IIP, up to 70% mortality; Curr Opin Oncol 2008;20:227)
Mech: alveolar injury due to direct toxicity S fever, hypoxia, diffuse pulmonary infiltrates
Diffuse alveolar hemorrhage (DAH): subset of IIP
Diagnosis: bronchoscopy to exclude infection; c bloody lavage fluid seen with DAH
Treatment: high-dose corticosteroids (limited data)
‚Ä¢ Acute GVHD (within 3 mos of transplant; Lancet 2009;373:1550)
Clinical grade I-IV based on scores for skin (severity of maculopapular rash), liver
(bilirubin level), and GI (volume of diarrhea); bx supports diagnosis
Prevention: immunosuppression (MTX  CsA or tacrolimus) or T-cell depletion of graft
Treatment: grade I S none; grade II‚ÄìIV  S associated with T survival and ‚à¥treated with
immunosuppressants (corticosteroids, CsA, tacrolimus, rapamycin, rituximab, MMF)
‚Ä¢ Chronic GVHD (developing or persisting beyond 3 mos posttransplant)
Clinical: malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, bile duct
degeneration and cholestasis. More common w/ PBSC than BM.
Treatment: immunosuppressants as above; photopheresis
‚Ä¢ Graft failure
Primary  persistent neutropenia without evidence of engraftment
Secondary  delayed pancytopenia after initial engraftment; either immune mediated due
to attack by immunocompetent host cells in the allogeneic setting (termed graft
rejection) or non‚Äìimmune mediated (eg, CMV infection)
‚Ä¢ Infectious complications
due to regimen-induced pancytopenia and immunosuppression
auto HSCT recipients do not require immunosuppression and ‚à¥remain at c risk only
during the pre-engraftment and immediate postengraftment phases
both primary infections and reactivation events occur (eg, CMV, HSV, VZV)
Infectious Complications Following Allogeneic HSCT
Time after transplant and associated risk factors
Days 0‚Äì30
Days 30‚Äì90
90 days
Class of pathogen and
Mucositis
Acute GVHD
Chronic GVHD
associated prophylaxis
Organ dysfunction
T cellular
T cellular &
Neutropenia
immunity
humoral
immunity
Viral
Respiratory and enteral viruses
acyclovir to d 365 (HSV/VZV);
HSV*
CMV*, HHV 6 & 7
valganciclovir or ganciclovir if
EBV-related lymphoma
CMV  (monitor until d 100 or
VZV*, BK/JC
until no longer immunesupp.)
Bacterial
Gram  cocci (coagulase-negative
Encapsulated 
antibiotics (eg,
staph., S. aureus, S. viridans)
bacteria
fluoroquinolone) while
GNRs (Enterobacteriaceae,
neutropenic
Pseudomonas, Legionella,
S. maltophilia)
Fungal
Candida spp.
fluconazole or posaconazole 
(NEJM 2007;356:335) to d 75 for
Candida
Aspergillus spp.
Parasitic
T. gondii
T. gondii
TMP-SMX to d 180 (or off
P. carinii
P. carinii
immunosuppression) for PCP
S. stercoralis
*Primarily among persons who are seropositive before transplant
HSCT
5-27

--- Fim da P√°gina 153 ---

LUNG
5-28
LUNG CANCER
Pathology and genetics (NEJM 2008;359:1367)
‚Ä¢ Non‚Äìsmall cell lung cancer (NSCLC, 85%)
Adenocarcinoma: typically peripheral; tumor cells can have mutations in KRAS,
EGFR, p53, & LKB1, and EML4-ALK fusion protein
Squamous cell: typically central; tumor cells can have mutations in p53, MET, &
LKB1, and/or amplifications in EGFR, MET, & PIK3CA
Large cell: typically peripheral
Bronchioalveolar carcinoma: track along airways, can be multifocal
‚Ä¢ Small cell lung cancer (SCLC, 15%): typically central; mutations in p53 & MET
Epidemiology and risk factors
‚Ä¢ Most common cause of cancer-related death for both men and women in U.S.
‚Ä¢ Cigarette smoking: 85% of lung cancers occur in smokers; risk  total pack-yrs, 
T risk after quitting/reducing, but not to baseline (JAMA 2005;294:1505)
squamous & small cell almost exclusively in smokers
adenocarcinoma most common type in nonsmokers
bronchioalveolar carcinoma associated with females, nonsmokers, EGFR mutations
‚Ä¢ Asbestos: when combined with smoking, synergistic c in risk of lung cancer
‚Ä¢ Radon: risk to general population unclear
Clinical manifestations
‚Ä¢ 10% are asx at presentation and are detected incidentally by imaging
‚Ä¢ Endobronchial growth of 1 tumor: cough, hemoptysis, dyspnea, wheezing, post‚Äì
obstructive pneumonia; more common with squamous or small cell (central location)
‚Ä¢ Regional spread
pleural effusion, pericardial effusion, hoarseness (recurrent laryngeal nerve palsy),
dysphagia (esophageal compression), stridor (tracheal obstruction)
Pancoast‚Äôs syndrome: apical tumor S brachial plexus involvement (C8, T1, T2) S
Horner‚Äôs syndrome, shoulder pain, rib destruction, atrophy of hand muscles
SVC syndrome (NEJM 2007;356:1862): central tumor S SVC compression S face or
arm swelling (80%), venous distention of neck & chest wall (60%),
dyspnea/cough (50%), HA (10%); Rx  steroids & diuretics, XRT 	 chemo
after tissue dx, SVC stent for severe sx, fibrinolytic  anticoag if thrombus  
‚Ä¢ Extrathoracic metastases: brain, bone, liver, adrenal, skin
‚Ä¢ Paraneoplastic syndromes
Endocrine
ACTH (SCLC) S Cushing‚Äôs syndrome; ADH (SCLC) S SIADH
PTH-rP (squamous cell) S hypercalcemia
Skeletal: digital clubbing (non‚Äìsmall cell), hypertrophic pulmonary
osteoarthropathy (adenocarcinoma)  symmetric polyarthritis and proliferative
periostitis of long bones
Neurologic (usually small cell): Eaton-Lambert, periph. neuropathy, cerebellar degen.
Cutaneous: acanthosis nigricans, dermatomyositis
Hematologic: hypercoagulable state (adenocarcinoma), DIC, marantic endocarditis
Screening (NEJM 2005;352:2714)
‚Ä¢ No proven survival benefit to screening CXR or sputum cytology, even in high-risk Pts
‚Ä¢ Survival benefit of screening chest CT in observational studies controversial (NEJM
2006;355:1763; JAMA 2007;297:953); await RCTs
Diagnostic and staging evaluation (AJCC Cancer Staging Manual, 7th ed, 2010)
‚Ä¢ Imaging: CXR, chest CT (include liver and adrenal glands)
‚Ä¢ Tissue
bronchoscopy (for central lesions) or CT-guided needle bx (for peripheral
lesions or accessible sites of suspected metastasis)
mediastinoscopy (lymph node bx), VATS (eval. of pleura peripheral lesions),
thoracentesis (cell block for cytology), or sputum cytology (for central lesions)
‚Ä¢ Staging
Intrathoracic: mediastinoscopy or VATS; thoracentesis if pleural effusion
Extrathoracic:
PET scan or integrated PET-CT more Se than CT alone for detecting mediastinal
and distant mets as well as bone mets (NEJM 2000;343:254; 2003;348:2500; 2009;361:32)
brain MRI for all Pts and bone scan for those w/ localizing sx or lab abnormalities
BM bx for SCLC if peripheral smear abnl
‚Ä¢ PFTs with quantitative V/Q if planned treatment includes surgical resection; need to
have 30% of normal, predicted lung fxn after resection

--- Fim da P√°gina 154 ---

TNM Staging System for NSCLC
N stage
N0
N1
N2
N3
T/M
Definition
no 
ipsilat.
ipsilat.
contralat. or
stage
nodes
hilar
mediast.
supraclav.
T1
T 2 cm (T1a) or T 2‚Äì3 cm (T1b)
IA
IIA
T2
T 5 cm (T2a) or T 5‚Äì7 cm (T2b)
IB/IIA
IIA/B
T3
T 7 cm or invasion of chest wall,
diaph., mediast. pleura, pericard.
IIB
IIIA
Invasion of mediast., heart, great 
T4
vessels, trachea, esoph, vertebrae;
IIIB
separate tumor nodule ipsilat lobe
M1a
Nodules contralat lobe; pleural 
nodules or malignant effusion
IV
M1b
Distant metastasis
NSCLC treatment (NCCN Clinical Practice Guidelines in Oncology, www.nccn.org)
‚Ä¢ Stages I & II: surgical resection  adjuvant chemo for stage IB-II (NEJM
2004;350:351 & 2005;352:2589); gene expression data identify early NSCLC w/ c risk of
recurrence that may benefit from more aggressive chemo (NEJM 2006;355:570)
‚Ä¢ Stage III: chemoradiation is main treatment modality
IIIA viewed as potentially resectable (Lancet 2009;374:379) and IIIB as unresectable
neoadjuvant chemoradiation may convert unresectable S resectable
‚Ä¢ Stage IV: chemotherapy c survival c/w best supportive care
standard is a platinum-based doublet (eg, carboplatin  paclitaxel)
no single regimen proven superior (NEJM 2002;346:92)
palliative radiation used to control local symptoms caused by tumor or metastasis
solitary brain metastasis: surgical resection  whole brain irradiation may c survival
‚Ä¢ Biologic therapy (for stage IIIB/IV)
anti-VEGF mAb (bevacizumab) added to chemo S c median survival by 2 mo; c risk of
bleeding, ‚à¥do not use if brain mets or squamous cell (hemoptysis) (NEJM 2006;355:2542)
EGFR inhibitor (gefitinib, erlotinib, cetuximab) c survival as 1st line Rx and if progress
after chemo (NEJM 2005;353:123; 2009;361:947 & 2010;362:2380; Lancet 2009;373:1525); target to
Pts w/ EGFR mutations (more common in Asians, , nonsmokers, bronchioalveolar
histology)
ALK inhibitors in clinical trials for EML4-ALK  NSCLC
NSCLC Simplified Staging Schema,Treatment, and 5-y Survival
Stage % at dx
Definition
Treatment
5-y (%)
I
10-20
Isolated lesion
Surgery  chemo
60
II
10‚Äì20
Hilar node spread
Surgery 	 radiation 	 chemo
40‚Äì50
IIIA
15
Mediast. spread
Chemoradiation
but resectable
	 surgical resection
25‚Äì30
IIIB
15
Unresectable
Chemoradiation 	 biologic
	 surgery (selected cases)
10‚Äì20
IV
40
Metastatic
Chemo 	 biologic and/or supportive care
Palliative radiation
1
NSCLC prognosis
‚Ä¢ Gene expression data may aid in prognosis (NEJM 2006;355:570 & 2007;356:11)
‚Ä¢ EGFR mutations are associated with an improved prognosis in NSCLC (Lancet 2008;372:1809)
SCLC Treatment (NCCN Clinical Practice Guidelines in Oncology, www.nccn.org)
‚Ä¢ SCLC usually disseminated at presentation, but can be very responsive to chemoradiation
‚Ä¢ Chemotherapy (platinum  etoposide) is primary treatment modality
‚Ä¢ Thoracic radiation added to chemotherapy improves survival in limited stage disease
‚Ä¢ Prophylactic cranial irradiation (PCI) improves survival for limited stage disease in
complete remission (NEJM 1999;341:476)
SCLC Staging Schema and Treatment
Stage
% at dx
Definition
Treatment
Median
survival
Limited
30‚Äì40
Confined to ipsilat. hemithorax
Radiation 
1‚Äì2 y
w/in one radiation port
chemotherapy 	 PCI
Extensive
60‚Äì70
Beyond one radiation port
Chemotherapy 	 PCI
1 y
LUNG
5-29

--- Fim da P√°gina 155 ---

BREAST
5-30
BREAST CANCER
Epidemiology and genetics (Risk assessment tool: www.cancer.gov/bcrisktool/)
‚Ä¢ Most common cancer in U.S. women; 2nd leading cause of cancer death in women
‚Ä¢ Age: incidence rates c with age, with decrease in slope at age of menopause
‚Ä¢ Genetics (NEJM 2007;357:154 & 2008;359:2143): 15‚Äì20% have  FHx. Risk depends on # of
affected 1 relatives and their age at dx. 45% of familial cases a/w known germline mut.
BRCA1/2: 35‚Äì85% lifetime risk of breast cancer & c risk of ovarian cancer; ? c colon &
prostate cancer; prog not worse than in non-carriers w/ breast cancer (NEJM
2007;357:115); BRCA2: a/w c male breast cancer & pancreatic cancer; rare muta-
tions in CHEK2 or TP53 a/w c risk in familial breast cancer (JAMA 2006;295:1379)
‚Ä¢ Estrogen: c risk with early menarche, late menopause, late parity, or nulliparity (NEJM
2006;354:270); c risk with prolonged HRT (RR  1.24 after 5.6 y, JAMA 2003;289:3243);
no c risk shown with OCP use (NEJM 2002;346:2025)
‚Ä¢ Benign breast conditions: c risk w/ atypia (atypical ductal or lobular hyperplasia) &
proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features;
no c risk w/ cysts, fibroadenoma, or columnar changes (NEJM 2005;352:229)
‚Ä¢ c risk with h/o ionizing radiation to chest for treatment of Hodgkin‚Äôs lymphoma 
Clinical manifestations
‚Ä¢ Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral,
limited to one duct, bloody, associated with mass)
‚Ä¢ Special types: Paget‚Äôs disease S unilateral nipple eczema  nipple discharge;
inflammatory breast cancer S skin erythema and edema (peau d‚Äôorange)
‚Ä¢ Metastases: lymph nodes, bone, liver, lung, brain
Screening
‚Ä¢ Self breast exam (SBE): no proven mortality benefit (JNCI 2002;94:1445); not recommended 
‚Ä¢ Clinical breast exam (CBE): benefit independent of mammography not established
‚Ä¢ Mammography: 20‚Äì30% T in breast cancer mortality (smaller absolute benefit
in women 50 y) (Lancet 2001;358:1340 & 2002;359:909; Annals 2002;137:347; Lancet 2006;368:2053);
75% of all abnl finding benign; suspicious: clustered microcalc., spiculated, enlarging;
adding U/S c Se, but T PPV (JAMA 2008;299:3151)
‚Ä¢ ACS/NCI recommend annual mammo  CBE beginning at age 40; USPSTF recommends
begin at 50 and biennially (Annals 2009;151:716), controversial (NEJM 2009;361:2499)
‚Ä¢ c risk: screen earlier w/ CBE and mammo (age 25 in BRCA1/2 carrier, 5‚Äì10 y before
earliest FHx case, 8‚Äì10 y after thoracic XRT, upon dx of c risk benign disease)
‚Ä¢ MRI: superior to mammo in high-risk Pts; consider annually if 20% lifetime risk (eg, 
FHx, BRCA 1 or 2, prior chest XRT) (NEJM 2004;351:427; Lancet 2005;365:1769 & 2007;370:485)
‚Ä¢ Genetic testing should be considered in women with strong FHx
Diagnostic evaluation
‚Ä¢ Palpable breast mass:
Age 30 y S observe for resolution over 1‚Äì2 menstrual cycles
Age 30 y, unchanging mass S U/S S aspiration if mass not simple cyst
Age 30 y or solid mass on U/S or bloody aspirate or recurrence after aspiration S
mammo (detect other lesions) and either fine-needle aspir. or core-needle bx
Clearly cancerous on exam or indeter. read/atypia on needle bx S excisional bx
‚Ä¢ Suspicious mammogram with normal exam: stereotactically-guided bx
‚Ä¢ MRI: detects contralateral cancer in 3% of women w/ recently dx breast cancer &
negative contralateral mammogram (but PPV only 21%) (NEJM 2007;356:1295);
whether to use routinely remains unclear
Staging
‚Ä¢ Anatomic: tumor size, chest wall invasion, axillary LN mets (strongest prognostic factor)
‚Ä¢ Histopathologic: type (little prognostic relevance) & grade; lymphatic/vascular invasion
In situ carcinoma: no invasion of surrounding stroma
Ductal (DCIS): c risk of invasive cancer in ipsilateral breast (30%/10 y)
Lobular (LCIS): marker of c risk of invasive cancer in either breast (1%/y)
Invasive carcinoma: infiltrating ductal (70‚Äì80%); invasive lobular (5‚Äì10%); tubular, 
medullary, and mucinous (10%, better prognosis); papillary (1‚Äì2%); other (1‚Äì2%)
Inflammatory breast cancer (see above): not a histologic type but a clinical reflection
of tumor invasion of dermal lymphatics; very poor prognosis
Paget disease: ductal cancer invading nipple epidermis 	 associated mass
‚Ä¢ Biomarkers: determine estrogen, progesterone receptor (ER/PR) and HER2/neu
status for all invasive breast cancers
‚Ä¢ Recurrence score and risk with Oncotype DX 21-gene assay in ER , node  Pts
(NEJM 2004;351:2817; 2006:355:560)

--- Fim da P√°gina 156 ---

Simplified Staging System for Breast Cancer
Stage
Characteristics
Description
5-y surv
I
Tumor 2 cm
Operable
90%
IIA
Tumor 2 cm or mobile axillary nodes
locoregional
80%
IIB
Tumor 5 cm
65%
IIIA
Internal mammary or fixed axillary nodes
Locally advanced
50%
IIIB
Direct extension to chest wall or skin
Inoperable
45%
IIIC
Infraclavicular or supraclavicular nodes
locoregional
40%
IV
Distant metastases
Metastatic
15%
Treatment
‚Ä¢ Local control: surgery and radiation therapy (RT)
Breast-conserving  lumpectomy  breast RT  axillary node dissection (ALND) is
equivalent to mastectomy  ALND (NEJM 2002;347:1227, 1233); contraindications:
multicentric disease, diffuse microcalcifications, prior RT, pregnancy, ? tumor 5 cm
Sentinel lymph node bx prior to ALND preferred if w/o palpable axillary LNs
Radiation therapy (RT) after mastectomy for 4  LN, tumor 5 cm or  surgical
margins S T locoregional recurrence and c survival (Lancet 2005;366:2087)
‚Ä¢ Systemic therapy: for stage I-III except tumors 1 cm (complex risk assessment needed).
http://www.adjuvantonline.com/index.jsp can guide use of chemo and/or hormonal Rx.
Chemotherapy (Lancet 2008;371:29): in adjuvant setting usually anthracycline-based (eg,
adriamycin  cyclophosphamide). Sequential Rx w/ taxane (eg, docetaxel) S small
c survival, ? related to length of amenorrhea (NEJM 2007;357:1496 & 2010;362:2053).
Biologics
trastuzumab (Herceptin; anti-HER2/neu mAb) c survival in HER2 tumors (15‚Äì20%),
but c cardiotoxicity w/ anthracyclines (NEJM 2007;357:39, 1673; Lancet 2007;369:29).
Usually used after anthracyline regimens or concurrently w/ taxane regimens.
lapatinib (tyrosine kinase inhib. of HER2 & EGFR): if mets, delays progression if 
failed trastuzumab (NEJM 2006;355:2733)
bevacizumab (anti-VEGF): if mets, delays progression (NEJM 2007;357:2666)
Hormonal (in ER/PR  or unknown status)
tamoxifen: 41% T recurrence and 34% T breast cancer mortality in postmenopausal
Pts (Lancet 2005;365:1687)
aromatase inhibitors (AI) (anastrozole, letrozole, exemestane): 18% T recurrence
c/w tamoxifen in postmenopausal Pts (Lancet 2005;365:60; NEJM 2005;353:2747)
2nd-line: ovarian ablation with LHRH agonists (goserelin) or oophorectomy if
premenopausal; pure antiestrogens (fulvestrant) if postmenopausal
ovarian ablation  AI or tamoxifen for premenopausal women is under study
PARP1 (poly(adenosine diphosphate [ADP]‚Äìribose) polymerase 1) inhib. against
BRCA1 or BRCA2 defective breast cancers (NEJM 2009;361:189)
Treatment of Carcinoma in situ and Invasive Carcinoma of the Breast
LCIS
Close surveillance 	 chemoprevention; ? prophylactic bilat. mastectomy
DCIS
Mastectomy or lumpectomy  RT; ALND not indicated; 	 chemoprevention
(NEJM 2004;350:1430)
Surgery  RT
I
 Adjuvant chemo if c risk: tumor 1 cm or  LN or ER/PR  (Lancet 1998;352:930)
II
 Hormonal therapy if ER/PR  (or unknown status) (Lancet 2009;374:2055)
 Trastuzumab if HER2 and tumor 1 cm or  LN
Neoadjuvant chemo S surgery  RT 	 adjuvant chemotherapy
III
 Hormonal therapy for ER/PR  (or unknown status) tumors
 Trastuzumab if HER2
ER/PR : hormonal therapy 	 chemotherapy
IV
ER/PR : HER2 S chemo  trastuzumab; HER2  S chemotherapy
Bony mets: bisphosphonates T skeletal complic. (NEJM 1998;339:357)
Prevention
‚Ä¢ Selective estrogen receptor modulators (SERMs)
Tamoxifen: T risk contralat breast CA as adjuvant Rx; approved for 1 prevent. if c risk:
T invasive breast CA, but c DVT & uterine CA; ? c in mortality (Lancet 2002;360:817)
Raloxifene: T risk of invasive breast cancer & vertebral fx, c risk of stroke & DVT/PE 
(NEJM 2006;355:125);  tamoxifen in prevention of breast cancer w/ T risk of
DVT/PE & cataracts, trend towards T uterine cancer (JAMA 2006;295:2727)
‚Ä¢ BRCA1/2 carriers: intensified surveillance as described above. Prophylactic bilat. mastecto-
my S 90% T risk & bilat. salpingo-oophorectomy T risk of ovarian and breast cancer.
BREAST
5-31

--- Fim da P√°gina 157 ---

PROSTATE
5-32
PROSTATE CANCER
Epidemiology and risk factors (NEJM 2003;349:366)
‚Ä¢ Most common cancer in U.S. men; 2nd most common cause of cancer death in men
‚Ä¢ Lifetime risk of prostate cancer dx 16%; lifetime risk of dying of prostate cancer 3%
‚Ä¢ More common with c age (rare if 45 y), in African Americans, and if  FHx
Clinical manifestations (usually asymptomatic at presentation)
‚Ä¢ Obstructive sx (more common with BPH): hesitancy, T stream, retention, nocturia
‚Ä¢ Irritative sx (also seen with prostatitis): frequency, dysuria, urgency
‚Ä¢ Periprostatic spread: hematuria, hematospermia, new-onset erectile dysfunction
‚Ä¢ Metastatic disease: bone pain, spinal cord compression, cytopenias
Screening (NEJM 2009;360:1351)
‚Ä¢ Mortality benefit from screening has not been established, with one recent trial
showing a 20% T mortality, but another no benefit (NEJM 2009;360:1310 & 1320)
‚Ä¢ Digital rectal exam (DRE): size, consistency, lesions
‚Ä¢ PSA: 4 ng/mL cutpoint neither Se nor Sp; can c with BPH, prostatitis, acute retention, after
bx or TURP, and ejaculation (no significant c after DRE, cystoscopy);
15% of men 62 y w/ PSA 4 & nl DRE have bx-proven T1 cancer (NEJM 2004;350:2239)
‚Ä¢ Per American Cancer Soc., offer PSA  DRE screening to men age 50 (45 if high risk)
with life expectancy 10 y; USPSTF has no rec. for PSA if 75 y, rec. against if 75 y
Diagnostic and staging evaluation
‚Ä¢ Transrectal ultrasound (TRUS) guided biopsy, with 6‚Äì12 core specimens
‚Ä¢ Histology: Gleason grade (2‚Äì10; low grade 6)  sum of the differentiation score (1 
best, 5  worst) of the two most prevalent patterns in the bx; correlates with prognosis
‚Ä¢ Imaging: to evaluate extraprostatic spread
bone scan: for PSA 10 ng/mL, high Gleason grade, or clinically advanced tumor
abdomen-pelvis CT: inaccurate for detecting extracapsular spread and lymph node mets
endorectal coil MRI: improves assessment of extracapsular spread
TNM Staging & Treatment of Prostate Cancer
Nodes,
Stage
Tumor
Mets
Treatment
T1a 
N0, M0,
Active surveillance (consider if life expect. 10 y)
non-palp.,
Gleason
Radiation (external or brachy; NEJM 2006;355:1583)
I
not visible
2‚Äì4
Radical prostatectomy (	 radiation and/or
on imaging
hormonal Rx if high-risk features found at 
II
T1/T2 
N0, M0
surgery). Min. invasive RP a/w T hospital stay,
w/ in prostate
but c risk of salvage Rx (JCO 2008;26:2278).
III
T3  extends
Radiation  androgen deprivation (see below)
thru capsule
N0, M0
(Lancet 2009;373:301)
T4  invades
Radiation (for M0 disease)
adjacent
N0, M0
Androgen deprivation (NEJM 2009;360:2516)
structures
GnRH analogues (leuprolide, goserelin)
IV
Any T
N1, M0
antiandrogens (flutamide, bicalutamide)
2nd-line: androgen synthesis inhibitor
Any T
Any N,
(ketoconazole, aminoglutethimide),
M1*
antiandrogen withdrawal (see below)
Chemo (docetaxel  prednisone) if refractory
*Bisphosphonates (alendronate, zolendronate) & palliative radiation for bone mets
Prognosis
‚Ä¢ PSA level, Gleason grade, and age are predictors of metastatic disease
‚Ä¢ In surgically treated Pts, 5-y relapse-free survival 90% if disease confined to organ,
75% if extension through capsule, and 40% if seminal vesicle invasion
‚Ä¢ Compared to active surveillance surgery T prostate cancer mortality & overall mortality
in Pts 75 y (NEJM 2005;352:1977); comparisons of surgery and radiation are underway
‚Ä¢ PSA doubling time, Gleason, & time to biochemical recurrence predict mortality following
recurrence. For local recurrence following RP, salvage RT may be beneficial if low PSA.
‚Ä¢ Metastatic disease: median survival 24‚Äì30 mos; all progress to androgen indepen-
dence (in 15‚Äì20% discontinuation of anti-androgens results in paradoxical T in PSA)
‚Ä¢ Long-term consequences of anti-androgen therapy include osteoporosis 
Prevention
‚Ä¢ Finasteride and dutasteride T total prostate cancers detected by bx, but c number of
high Gleason grade tumors (NEJM 2003;349:215 & 2010;362:1192)

--- Fim da P√°gina 158 ---

COLORECTAL
5-33
COLORECTAL CANCER (CRC)
Epidemiology and risk factors
‚Ä¢ 4th most common cancer in U.S men and women; 2nd leading cause of cancer death
overall
‚Ä¢ Rare before age 40, w/ 90% of cases occurring after age 50. 70% are sporadic.
‚Ä¢ Family History: up to 25% of Pts have  FHx. Risk depends on # of 1st degree rela-
tives (w/ CRC or polyp) and their age at dx; 5% have an identifiable germline mutation
Familial adenomatous polyposis (FAP): mutation of APC tumor suppressor S 1000s
of polyps at young age S 100% lifetime risk; c risk of thyroid, stomach, SI cancers
Hereditary nonpolyposis colorectal cancer (HNPCC): mutations in DNA mis-
match repair genes S c tumor progression S 80% lifetime risk; predom. right-sided
tumors; c risk of endometrial, ovarian, stomach, small bowel cancers.
Amsterdam criteria: 3 family members w/ HNPCC-related cancer, one of
which dx before age 50, affecting 2 successive generations.
‚Ä¢ Inflammatory bowel disease: c risk with c extent and duration of disease
‚Ä¢ Other factors a/w c risk of CRC: diet rich in animal fat, ? smoking, ? diabetes/obesity
‚Ä¢ T risk of adenomas w/ ASA & NSAIDs, incl. COX-2 (NEJM 2006;355:873, 885), but c bleeding
and c CV events w/ COX-2; T COX-2-expressing CRC after prolonged ASA (NEJM
2007;356:2131 & Lancet 2007;369:1603); currently not recommended (Annals 2007;146:361)
Pathology and Genetics (Hematol Oncol Clin North Am 2002;16:127)
‚Ä¢ Adenoma S carcinoma sequence reflects accumulation of multiple genetic mutations
c risk of malignancy with large (2.5 cm), villous, sessile adenomatous polyps
Adenomas typically observed 10 y prior to onset of cancer (both sporadic and familial)
‚Ä¢ Genetic profile in sporadic CRC: APC (80%), KRAS (50%), TP53 (50‚Äì70%), DCC or
SMAD4, chromosomal instability (majority) or mismatch repair deficiency (10‚Äì15%)
‚Ä¢ Upfront genotyping at dx may guide Rx (eg, KRAS, see below)
Clinical manifestations
‚Ä¢ Distal colon:  bowel habits, obstruction, colicky abdominal pain, hematochezia
‚Ä¢ Proximal colon: iron defic. anemia, dull vague abd pain; obstruction atypical
due to larger lumen, liquid stool, and polypoid tumors (vs. annular distal tumors)
‚Ä¢ Metastases: nodes, liver, lung, peritoneum S RUQ tenderness, ascites, supraclavicular LN
‚Ä¢ Associated with Streptococcus bovis bacteremia and Clostridium septicum sepsis
Screening (NEJM 2009;361:1179)
‚Ä¢ Average risk: colonoscopy starting at age 50 & repeat q10y strongly preferred method
‚Ä¢ c risk: earlier and/or more frequent screening.  FHx: age 40 or 10 y before index
dx, then q5y. IBD: 8‚Äì10 y after dx, then q1‚Äì2y. Known or suspected familial syn-
drome: genetic counseling & very early screening (eg, age 20-25), then q1‚Äì2y.
‚Ä¢ Colonoscopy: test of choice as examines entire colon; 90% Se for lesions 1 cm. Flex
sig less Se but better than no endoscopy (NEJM 1992;326:653). If polyp found, re ‚úìin 3‚Äì5 y.
‚Ä¢ Fecal occult blood test (FOBT): T mortality (NEJM 1993;328:1365 & 2000;343:1603); 3 card
home testing more Se (24% vs. 5%) than DRE/FOBT (Annals 2005;142:81). Repeat q1y.
‚Ä¢ Fecal DNA: c Se,  Sp c/w FOBT, but less Se than colonoscopy (NEJM 2004;351:2704)
‚Ä¢ CT colonography (CTC): c/w colonoscopy, 90% Se for lesions 1 cm but consid-
erably less for smaller lesions (NEJM 2008;359:1207). Strategy of CTC followed by
colonoscopy for lesions 6 mm diagnoses similar # of advanced neoplasms as
colonoscopy alone, but with only 8% needing colonoscopy (NEJM 2007;357:1403).
However, in high-risk Pts, Se only 85% for advanced neoplasia 6 mm (JAMA
2009;301;2453). ‚à¥? consider CTC if avg risk (w/o personal or FH of polyps/CRC)
(Gastro 2008;134:1578) or if cannot obtain colonoscopy.
Staging (AJCC Cancer Staging Manual, 7th ed, 2010)
‚Ä¢ TNM staging: Size/depth of primary (T), locoregional nodes (N), distant metastases (M).
Staging is complex and based on pathologic correlation with observed survival data.
‚Ä¢ Colonoscopy  biopsy/polypectomy  intraoperative and pathologic staging
essential for evaluating extracolonic spread
‚Ä¢ CT scans of chest and abdomen/pelvis (inaccurate for depth of invasion & malignant LN) 
‚Ä¢ Baseline CEA in Pt with known CRC has prognostic significance and is useful to fol-
low response to therapy and detect recurrence; not a screening tool

--- Fim da P√°gina 159 ---

Treatment Based on TNM and Modified Dukes Staging of Colorectal Cancer
TNM
Dukes
Path. Criteria
5-y surv.
Treatment
I
A
Into submucosa 
Surgery alone (resection and 
or muscularis
94‚Äì97%
analysis of  12 LN)
IIA
B
Into serosa
83%
Surgery; no established role for 
IIB
B
Into peritoneum
74%
adjuvant chemo for colon cancer*
Preop XRT or 5FU/XRT added for
IIC
B
Direct invasion
56%
rectal cancer followed by postop 
chemo (FOLFOX)
IIIA
C
6  LNs
86%
Surgery  chemotherapy*
IIIB
C
Varying degrees
51‚Äì77%
5-FU  leucovorin  oxaliplatin 	
of  LNs and
FOLFOX (NEJM 2004;350:2343)
IIIC
C
local invasion
15‚Äì47%
Preop XRT or chemorad added for 
rectal cancer (NEJM 2006;355:1114)
Chemotherapy (NEJM 2005;352:476):
FOLFOX, FOLFIRI or CapeOX 	
bevacizumab or cetuximab 
(benefit limited to Pts w/o KRAS
Distant
mutation)
IV
D
metastases
5%
	 surgical resection isolated mets 
(a/w 30% 5-y survival)
Consider resection of primary 
tumor if perf, obstruction, or 
bleeding
NCCN Clinical Practice Guidelines in Oncology, www.nccn.org. 5-y survival data shown are approximately
equivalent for colon and rectal cancers, shown as average, w/ ranges for TNM substaging, adapted from
relative survival in SEER data (JCO 2010;28:256,264). * Consider adjuvant chemo for high-risk stage II
(obstruction, perforation, adherence to adjacent structures, inadequate nodal sampling, lymphovascular
invasion, poorly differentiated). Bevacizumab is an anti-VEGFA mAb (NEJM 2004;350:2335); cetuximab is an
anti-EGFR mAb (NEJM 2004:351:337).
COLORECTAL
5-34

--- Fim da P√°gina 160 ---

PANCREATIC
5-35
PANCREATIC TUMORS
Pathology and genetics (Annu Rev Pathol 2008;3:157; Genes Dev 2006;20:1218)
‚Ä¢ Histologic types:  adenocarcinoma (85%), acinar cell carcinoma, endocrine tumors, cys-
tic neoplasms (eg, IPMN, see below), rare mets to pancreas (eg, lung, breast, renal cell)
‚Ä¢ Pancreatic adenocarcinoma accounts for majority of pancreatic cancer (85%)
‚Ä¢ Location: 60% in head, 15% in body, 5% in tail; in 20% diffuse infiltration of pancreas
‚Ä¢ Mutations in adenocarc.: KRAS (90%), p16 (80‚Äì95%), p53 (50‚Äì75%), SMAD4 (55%)
Epidemiology and risk factors (Lancet 2004;363:1049)
‚Ä¢ Pancreatic adenocarcinoma is 4th leading cause of cancer death in U.S. men and women
‚Ä¢ 80% of pancreatic adenocarcinomas occur in Pts 60‚Äì80 y
‚Ä¢ Acquired risk factors: smoking (RR 1.5), obesity, chronic pancreatitis, ? diabetes
‚Ä¢ Hereditary risk factors: genetic susceptibility may play a role in 5‚Äì10% of cases
Hereditary chronic pancreatitis: mutation in cationic trypsinogen gene (PRSS1)
Familial cancer syndromes and gene mutations with c risk: familial atypical multiple mole
melanoma (CDKN2A/p16), familial breast and ovarian cancer (BRCA2), Peutz-Jeghers
(LKB1), ataxia-telangiectasia (ATM), ? hereditary colorectal cancer (HNPCC and FAP) 
Clinical manifestations
‚Ä¢ Painless jaundice (w/ pancreatic head mass), pain (radiating to back), weight loss
‚Ä¢ New-onset atypical diabetes mellitus; unexplained malabsorption; unexplained pancreatitis
‚Ä¢ Migratory thrombophlebitis (Trousseau‚Äôs sign)
‚Ä¢ Exam: abdominal mass; nontender, palpable gallbladder (Courvoisier‚Äôs sign, but more often
seen with biliary tract cancers); hepatomegaly; ascites; left supraclavicular (Virchow‚Äôs)
node & palpable rectal shelf (both nonspecific signs of carcinomatosis)
‚Ä¢ Laboratory tests may show c bilirubin, c A, anemia
Diagnostic and staging evaluation
‚Ä¢ Pancreatic protocol CT scan (I w/ arterial & venous phase imaging)
‚Ä¢ If no lesion seen S EUS, ERCP, MRI/MRCP may reveal mass or malignant ductal strictures
‚Ä¢ Biopsy pancreatic lesion via EUS-guided FNA (preferred in potential surgical candidates)
or CT-guided (potential risk of seeding) or biopsy metastasis
‚Ä¢ Tumor markers: c CA 19-9 (nb, falsely c in liver failure); may be useful to follow dis. postop
Clinical (Radiologic) Staging & Prognosis of Pancreatic Adenocarcinoma
Stage, % at dx
Criteria
Median Survival
Resectable,
No extrapanc. dis. or bulky LAN
10‚Äì20 mo (favorable: tumor 3
15‚Äì20%
Patent SMV & portal vein; celiac
cm,  marg., well-differen.)
axis & SMA not involved
5-y 30% node  vs. 10% if 
Locally advanced Extensive PV/SMV, celiac axis,
8‚Äì12 mo
(unresect.), 40%
or SMA involvement
Metastatic, 40%
Usually liver & periton.; occ lung
3‚Äì6 mo
Treatment of pancreatic adenocarcinoma (NEJM 2010;362:1605)
‚Ä¢ Resectable: surgery 	 adjuvant (neoadjuvant or postoperative) therapy
pancreaticoduodenectomy  Whipple procedure  resection of pancreatic head,
duodenum, CBD and gallbladder 	 partial gastrectomy
adjuvant therapy: c survival but choice of regimen controversial (chemo vs. chemo/XRT
and gemcitabine vs. 5FU; NEJM 2004;350:2713; JCO 2005;23:4532; JAMA 2007;297:267)
‚Ä¢ Locally advanced: optimal strategy controversial. Gemcitabine alone (Ann Oncol
2008;19:1592; Br J Cancer 2007;96:1183; JCO 2009;27:2269); ? gemcitabine  XRT (JCO 2008;26:214s). 
‚Ä¢ Metastatic: gemcitabine (JCO 1997;15:2403); adding erlotinib (JCO 2005;23:16S,1) or
capecitabine (JCO 2009;27:5513) may give modest benefit. Offer clinical trials.
‚Ä¢ Palliative and supportive care
obstructive jaundice or gastric outlet obstruction: endoscopic stenting or surgical bypass
pain: opiates, celiac plexus neurolysis, radiation therapy
weight loss: pancreatic enzyme replacement, nutrition consult, end-of-life discussions
Cystic lesions of the pancreas (NEJM 2004;351:1218; The Oncologist 2009;14:125)
‚Ä¢ 10% of pancreatic neoplasms. Dx w/ CT, ERCP, MRCP or EUS.
‚Ä¢ Serous cystadenoma: usually benign; central scar or honeycomb appearance on imaging
‚Ä¢ Mucinous cystic neoplasm (MCN): predominantly young females; multiloculated tumors
in body or tail w/ ovarian-type stroma and mucin-rich fluid w/ c CEA levels; precancerous
‚Ä¢ Intraductal papillary mucinous neoplasm (IPMN): neoplasm arising in main pan-
creatic duct or a branch; a/w ductal dilation w/ extrusion of mucinous material.
Uncertain progression to cancer (? 5‚Äì20 y). Surgery based on size, location, dysplasia.  

--- Fim da P√°gina 161 ---

ONC EMERG
5-36
ONCOLOGIC EMERGENCIES
FEVER AND NEUTROPENIA (FN)
Definition
‚Ä¢ Fever: single oral temp 38.3C (101F) or 38C (100.4F) for 1 h
‚Ä¢ Neutropenia: ANC 500 cells/L or 1,000 cells/L with predicted nadir 500 cells/L
Pathophysiology and microbiology
‚Ä¢ Predisposing factors: catheters, skin breakdown, GI mucositis, obstruction (lymphat-
ics, biliary tract, GI, urinary tract), immune defect a/w malignancy
‚Ä¢ Most episodes thought to result from seeding of bloodstream by GI flora
‚Ä¢ Neutropenic enterocolitis (typhlitis): RLQ pain, watery/bloody diarrhea, cecal wall thickening
‚Ä¢ GNRs (especially P. aeruginosa) were historically most common
‚Ä¢ Gram  infections have recently become more common (60‚Äì70% of identified organisms)
‚Ä¢ Fungal superinfection often results from prolonged neutropenia & antibiotic use
‚Ä¢ Infection with atypical organisms and bacterial meningitis is rare
Prevention
‚Ä¢ Levofloxacin (500 mg qd) T febrile episodes & bacterial infections in chemo-related
high-risk neutropenic patients; no difference in mortality (NEJM 2005;353:977, 988)
Diagnostic evaluation
‚Ä¢ Exam: skin, oropharynx, lung, perirectal area, surgical & catheter sites; avoid DRE
‚Ä¢ Labs: CBC with differential, electrolytes, BUN/Cr, LFTs, U/A
‚Ä¢ Micro: blood (peripheral & through each indwelling catheter port), urine, & sputum cx;
for localizing s/s S ‚úìstool (C. difficile, cx), peritoneal fluid, CSF (rare source)
‚Ä¢ Imaging: CXR; for localizing s/s S CNS, sinus, chest, or abdomen/pelvis imaging
‚Ä¢ Caveats: neutropenia S impaired inflammatory response S exam and radiographic
findings may be subtle; absence of neutrophils by Gram stain does not r/o infection
Risk stratification (factors that predict lower risk)
‚Ä¢ History: age 60 y, no symptoms, no major comorbidities, cancer in remission, solid
tumor, no h/o fungal infection or recent antifungal Rx
‚Ä¢ Exam: temp 39 C, no tachypnea, no hypotension, no  MS, no dehydration
‚Ä¢ Studies: ANC 100 cells/L, anticipated duration of neutropenia 10 d, normal CXR
Initial antibiotic therapy (Clin Infect Dis 2002;34:730)
‚Ä¢ Empiric regimens should include a drug with antipseudomonal activity
‚Ä¢ PO abx may be used in low-risk Pts: cipro  amoxicillin-clavulanate (NEJM 1999;341:305)
‚Ä¢ IV antibiotics: no clearly superior regimen; monotherapy or 2-drug regimens can be used
Monotherapy: ceftazidime, cefepime, imipenem, or meropenem
2-drug therapy: aminoglycoside  antipseudomonal -lactam
PCN-allergic: levofloxacin  aztreonam or aminoglycoside
‚Ä¢ Vancomycin added in select cases (hypotension, indwelling catheter, severe mucositis,
MRSA colonization, h/o quinolone prophylaxis), discontinue when cultures   48 h
Modification to initial antibiotic regimen
‚Ä¢ Low-risk Pts who become afebrile w/in 3‚Äì5 d can be switched to PO antibiotics
‚Ä¢ Empiric antibiotics changed for fever 3‚Äì5 d or progressive disease (eg, add vancomycin)
‚Ä¢ Antifungal therapy is added for neutropenic fever 5 d
liposomal amphotericin B, caspofungin, micafungin, anidulafungin, voriconazole,
posaconazole all options (NEJM 2002;346:225 & 2007;356:348)
Duration of therapy
‚Ä¢ Known source: complete standard course (eg, 14 d for bacteremia)
‚Ä¢ Unknown source: continue antibiotics until afebrile and ANC 500 cells/L
‚Ä¢ Less clear when to d/c abx when Pt is afebrile but prolonged neutropenia
Role of hematopoietic growth factors (JCO 2005;23:4198 & 2006;24:3187)
‚Ä¢ Granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF) colony-stimulating fac-
tors can be used as 1 prophylaxis when expected FN incidence 20% or as 2 pro-
phylaxis after FN has occurred in a previous cycle (to maintain dose-intensity for
curable tumors). CSF T rate of FN but have not been shown to impact mortality.
‚Ä¢ Colony-stimulating factors can be considered as adjuvant therapy in high-risk FN Pts
SPINAL CORD COMPRESSION
Clinical manifestations
‚Ä¢ Metastases located in vertebral body extend and cause epidural spinal cord compression

--- Fim da P√°gina 162 ---

‚Ä¢ Prostate, breast, and lung cancer are the most common causes, followed by renal cell
carcinoma, NHL, and myeloma
‚Ä¢ Site of involvement: thoracic (70%), lumbar (20%), cervical (10%)
‚Ä¢ Signs and symptoms: pain (96%, precedes neuro s), weakness, autonomic
dysfunction (urinary retention, T anal sphincter tone), sensory loss
Diagnostic evaluation
‚Ä¢ Always take back pain in Pts with solid tumors very seriously
‚Ä¢ Do not wait for neurologic signs to develop before initiating evaluation b/c duration &
severity of neurologic dysfunction before Rx are best predictors of neurologic outcome
‚Ä¢ Urgent whole-spine MRI is study of choice. Consider CT myelogram if unable to get MRI.
Treatment
‚Ä¢ Dexamethasone (10 mg IV S 4 mg IV or PO q6h)
initiate immediately while awaiting imaging if back pain  neurologic deficits
‚Ä¢ Emergent XRT or surgical decompression if confirmed compression / neuro deficits
‚Ä¢ Surgery  XRT superior to XRT alone for neuro recovery in solid tumors (Lancet 2005;366:643)
‚Ä¢ If pathologic fracture causing compression S surgery; if not surgical candidate S XRT
TUMOR LYSIS SYNDROME
Clinical manifestations
‚Ä¢ Large tumor burden or a rapidly proliferating tumor S spontaneous or chemotherapy-
induced release of intracellular electrolytes and nucleic acids
‚Ä¢ Most common w/ Rx of high-grade lymphomas (Burkitt‚Äôs) and leukemias (ALL, AML,
CML in blast crisis); rare with solid tumors; rarely due to spontaneous necrosis
‚Ä¢ Electrolyte abnormalities: c K, c uric acid, c PO4 S T Ca
‚Ä¢ Renal failure (urate nephropathy)
Prophylaxis
‚Ä¢ Allopurinol 300 mg qd to bid PO or 200‚Äì400 mg/m2 IV (adjusted for renal fxn) &
aggressive hydration prior to beginning chemotherapy or XRT
‚Ä¢ Rasburicase (recombinant urate oxidase) 0.15 mg/kg or 6 mg fixed dose (except in obese
Pts) & aggressive hydration prior to beginning chemotherapy or XRT (see below)
Treatment
‚Ä¢ Avoid IV contrast and NSAIDs
‚Ä¢ Allopurinol  aggressive IV hydration 	 diuretics to c UOP
‚Ä¢ Consider alkalinization of urine w/ isotonic NaHCO3 to c UA solubility & T risk of urate
nephropathy (controversial: may cause metabolic alkalosis or Ca3(PO4)2 precipitation).
‚Ä¢ Rasburicase (0.15‚Äì0.2 mg/kg/d  3‚Äì7 d) for severe c UA, espec in aggressive malig;
UA level must be drawn on ice to quench ex vivo enzyme activity ( JCO 2003;21:4402;
Acta Haematol 2006;115:35)
‚Ä¢ Treat hyperkalemia, hyperphosphatemia, and symptomatic hypocalcemia
‚Ä¢ Hemodialysis may be necessary; early renal consultation for Pts w/ renal insuffic. or ARF
ONC EMERG
5-37
CANCER OF UNKNOWN PRIMARY SITE
Evaluation of Cancer of Unknown Primary
Path
Possible Sources
Markers
Imaging
Additional Path
Colon, upper GI, panc.
CEA, CA19-9
Endoscopy/EUS
CDX1, CK7/20
HCC
AFP
Abd/Pelvic CT
Breast
CA-15-3
Mammography
ER/PR, GCDFP
Ovarian, prostate
CA125, PSA
Pelvic U/S
CA-125, PSAP
Lung
Chest CT
TTF1, CK7
Lung
None
Chest CT
TTF1, CK7
Head & Neck
Laryngoscopy
Esophageal
Endoscopy
Cervix,Anus
Germ cell
hCG,AFP
Testicular U/S
PLAP, isochrom 12p
Lymphoma
LDH
PET
LCA, flow, cytogenetics
Thyroid
Thyroglob.
Thyroid U/S
Thyroglobulin
GIST, Sarcoma
Abd/Pelvic CT
c-KIT, desmin, vimentin
Neuroendocrine
NSE, chromogranin
Consider EM for all
Additional studies for each possible source listed in same row.
‚Ä¢ Bony mets: breast, lung, thyroid, kidney, prostate
Poorly
Differen.
Squam.
Adeno.

--- Fim da P√°gina 163 ---

NOTES
5-38
NOTES

--- Fim da P√°gina 164 ---

PNEUMONIA
6-1
PNEUMONIA
Microbiology of Pneumonia
Clinical Setting
Etiologies
Community-
S. pneumoniae
acquired
Mycoplasma, Chlamydia, viral (espec. in young & healthy)
(CID 2007;44:527)
H. influenzae, M. catarrhalis (espec. in COPD‚Äôers)
Legionella (espec. in elderly, smokers, T immunity)
Klebsiella & other GNR (espec. in alcoholics & aspirators)
S. aureus (espec. post-viral infection)
Influenza A & B et al. (see ‚ÄúViral Respiratory Infections‚Äù)
(no organism identified in 40‚Äì60% cases)
Hospital-
GNR including Pseudomonas, Klebsiella, E. coli, Enterobacter,
acquired
Serratia, Acinetobacter, & S. aureus (including MRSA)
Acid suppression may c risk of acquiring PNA (JAMA 2009;301:2120)
Immunosuppressed
Above  PCP, fungi, Nocardia, atypical mycobacteria, CMV, HSV
Aspiration
Chemical pneumonitis due to aspiration of gastric contents
(NEJM 2001;334:665)
Bacterial pneumonia 24‚Äì72 h later, due to aspiration of 
oropharyngeal microbes
outpatients: typical oral flora (Strep, S. aureus, anaerobes)
inpatients or chronically ill: GNR and S. aureus
Clinical manifestations
‚Ä¢ ‚ÄúTypical‚Äù: acute onset of fever, cough w/ purulent sputum, dyspnea, consolidation on CXR
‚Ä¢ ‚ÄúAtypical‚Äù (originally described as culture ): tends to p/w insidious onset of dry
cough, extrapulm sx (N/V, diarrhea, headache, myalgias, sore throat), patchy inter-
stitial pattern on CXR, and c transaminases & T Na w/ Legionella
‚Ä¢ S/s & imaging do not reliably distinguish between ‚Äútypical‚Äù (S. pneumo, H. flu) and ‚Äúatypical‚Äù
(Mycoplasma, Chlamydia, Legionella, viral) 
Diagnostic studies
‚Ä¢ Sputum Gram stain: utility debated. Is it a good sample (ie, sputum or spit) ? S
should be 10 squamous cells/lpf. Is it a purulent sample? S should be 25 PMNs/lpf
‚Ä¢ Sputum bacterial culture: should be transported to lab w/in 1‚Äì2 h of collection.
In select situations, consider respiratory viral testing (DFA or PCR), rarely viral cx.
‚Ä¢ Blood cultures (before antibiotics!):  in 10% of inPts, depending on pathogen
‚Ä¢ CXR (PA & lateral; see Radiology inserts) S tap effusions if 5 cm or severe PNA
‚Ä¢ Other labs: SaO2 or PaO2, CBC w/ diff, lytes, BUN/Cr, glc, LFTs; arterial pH (if severe)
‚Ä¢ Other microbiologic studies (paired serologies available for most atypicals):
Mycoplasma: PCR of throat or sputum/BAL before first dose abx
Legionella: urine Ag (detects L. pneumophila L1 serotype, 60‚Äì70% of clinical disease)
S. pneumoniae urinary Ag (Se 50‚Äì80%, Sp 90%)
MTb: induced sputum for AFB stain and mycobact. cx (empiric respiratory isolation while
pending); avoid quinolones if considering TB; request rapid DNA probe if stain 
Induced sputum for PCP if HIV  or known T cell-mediated immunity; HIV test if 15‚Äì54 y
‚Ä¢ Bronchoscopy: consider if Pt immunosupp., critically ill, failing to respond, or has
chronic pneumonia.Also in suspected TB if no adequate sputum and in suspected
PCP if induced sputum unavailable or  but clinical suspicion high.
‚Ä¢ Reasons for failure to improve on initial Rx:
Insufficient time: may take 72 h to see clinical improvement
Insufficient drug levels: eg, vanco trough 15‚Äì20 g/mL (needed for lung penetration)
Resistant organisms (or superinfxn): eg, MRSA, Pseudomonas; consider bronchoscopy
Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; consider CT
Parapneumonic effusion/empyema: esp. seen w/ Strep pneumo, GrpA Strep; if CXR neg,
consider CT (dx tap  chest tube if effusion present, particularly if loculated)
Metastatic infection (endocarditis, meningitis, arthritis), abscess
Prognosis (also see PORT score, next page)
‚Ä¢ Pneumonia and influenza are the 8th leading cause of death in the U.S.
‚Ä¢ For low-risk Pts, can discharge immediately after switching to PO abx (CID 2007;44:527)
‚Ä¢ CXR resolves in most by 6 wks; consider f/u to r/o underlying malignancy or other dx
‚Ä¢ Newer metrics proposed to replace Pneumonia Severity Index (PSI, aka PORT score);
simpler parameters, similar performance characteristics, but not as well validated
CURB-65 (Thorax 2003;58:377): Confusion, Uremia, RR 30, BP 90/60, age 65
SMART-COP (CID 2008;47:375): SBP 90, Multilobar infiltrates, Alb 3.5 g/dL, RR 30,
Tachycardia (HR 125 bpm), Confusion, O2 sat 90%, pH 7.35 (arterial)

--- Fim da P√°gina 165 ---

PNEUMONIA
6-2
PORT Score, Prognosis, and Recommended Triage
Class
Score
Mortality
Suggested Triage
I
Age 50, no comorbidities
1%
Outpatient
II
70
1%
Outpatient
III
71‚Äì90
2.8%
? Brief inpatient
IV
91‚Äì130
8.2%
Inpatient
V
130
29.2%
ICU
Variables
Points
Demograph.
Men (age in y), women (age ‚Äì 10), nursing home resident (10)
Coexist. probs
Neoplasm (30), liver dis. (20), CHF (10), CVA (10), renal dis. (10)
Exam
	 MS (20),RR 30 (20),SBP 90 (20),T 35
/40
 (15),HR 125 (10)
Laboratory
pH 7.35 (30), BUN 30 (20), Na 130 (20), glc 250 (10),
Hct 30 (10), PaO2 60 or SaO2 90 (10), pleural effusion (10)
(NEJM 1997;336:243)
Treatment
Clinical scenario
Empiric treatment guidelines*
Outpatient
No recent abx: macrolide or doxycycline
Recent abx: (macrolide  [high-dose amox  clav or 2nd-gen.
ceph.]) or respiratory FQ
Community-acquired,
(3rd-gen. ceph.  macrolide) or respiratory FQ
hospitalized
Community-acquired,
(3rd-gen. ceph. or amp-sulbactam)  (macrolide or FQ)
hospitalized, ICU
(assuming no risk for Pseudomonas)
Hosp-acquired & risk 
(Antipseudomonal PCN or ceph. or carbapenem)  (FQ or
for MDR pathogens
[gentamicin  azithromycin])  vancomycin
Immunosuppressed
As above  TMP-SMX  steroids to cover PCP
Aspiration
(3rd-gen. ceph. or FQ)  (clindamycin or metronidazole)
Route of therapy
InPts should initially be treated w/ IV abx
	 to PO when clinically responding and able to take POs
*When possible, organism-directed therapy, guided by in vitro susceptibilities or local patterns of drug
resistance should be used. For ventilator-associated pneumonia, 8  15 d of Rx, except for Pseudomonas
and other non-fermenting GNR (JAMA 2003;290:2588; AJRCCM 2005;171:388; CID 2007;44:527)
Prevention
‚Ä¢ Pneumococcal polysaccharide vaccine: persons 65 y of age or high-risk medical illness
‚Ä¢ VAP precautions: HOB 30
, chlorhexidine rinse; aspiration precautions in high-risk Pts
VIRAL RESPIRATORY INFECTIONS
Microbiology and Epidemiology
‚Ä¢ Typical pathogens: short, mild  rhinovirus, coronavirus; longer, more severe or com-
plicated  influenza, parainfluenza, respiratory syncytial virus (RSV), adenovirus
‚Ä¢ Seasonal flu: 365,000 hosp., 51,000 deaths per y in U.S.; most 65 y (NEJM 2008;359:2579)
‚Ä¢ Pandemic 2009 H1N1: more severe disease in younger Pts (JAMA 2009;302:1896)
Diagnosis
‚Ä¢
Primarily clinical: cough, fever, myalgias, arthralgias, rhinorrhea, pharyngitis
(in contrast, viral bronchitis p/w cough  low-grade temp; usually benign & self-limited)
‚Ä¢
Respiratory viral panel (flu, paraflu, RSV, adeno) on nasal washing or sputum/BAL 
‚Ä¢
Rapid influenza test on nasal swab: Se 50‚Äì70% (? lower for pandemic flu), Sp 95%
‚Ä¢
DFA (Se 85%), RT-PCR (gold standard) avail. for influenza (PCR distinguishes type)
Treatment
‚Ä¢
Seasonal influenza: M2 inhib. (amantadine, rimantadine) effective only against some type A;
neuraminidase inhib. (oseltamivir, zanamivir) effective vs.A & B, but resistance emerging
‚Ä¢
Pandemic H1N1 influenza: nearly 100% sensitive to oseltamivir, consider IV peramivir for
critically ill Pts unable to take PO (currently emergency use in U.S.); resistant to amantidine
‚Ä¢
Oseltamivir dosed 75 mg PO bid  5 d, effective only if started w/in 48 h of sx, but used
anytime in immunosupp. & considered in all Pts w/ or predisposed to severe influenza
‚Ä¢
Consider inhaled ribavirin for RSV in immunosupp. (eg, BMT, lung tx); limited adult data
Prevention
‚Ä¢ Inactivated influenza vaccine: available for seasonal and select pandemic flu, incl. H1N1
rec if 50 y, at risk for complic., HCW, caretakers of high-risk Pts; for all if surplus
‚Ä¢ Isolation, droplet precautions for inPts strongly recommended
‚Ä¢ Prophylaxis for high-risk contacts of confirmed influenza: oseltamivir 75 mg PO daily  10 d

--- Fim da P√°gina 166 ---

FUNGAL
6-3
FUNGAL INFECTIONS
Candida species
‚Ä¢ Microbiology: normal GI flora; C. albicans & nonalbicans spp. (consider azole resistance
if prior Rx or nonalbicans; C. parapsilosis more likely to be echinocandin resistant)
‚Ä¢ Risk factors: neutropenia, immunosupp., broad-spectrum abx, intravascular
catheters (esp. if TPN), IVDU, abd surgery, DM, renal failure
‚Ä¢ Clinical manifestations
Mucocutaneous: cutaneous (eg, red, macerated lesions in intertriginous zones); oral
thrush (exudative, erythematous, or atrophic; if unexplained, r/o HIV); esophageal
(odynophagia;  oral thrush); vulvovaginal, balanitis
Candiduria: typically colonization due to broad-spectrum abx and/or indwelling catheter
Candidemia (#4 cause of nosocomial bloodstream infxn): r/o retinal involvement
(req c Rx); endocarditis rare but serious (esp. w/ nonalbicans & prosthetic valve)
Hepatosplenic: intestinal seeding of portal & venous circulation; seen in acute leukemics
Hematogenous dissemination S lung, brain, meninges, etc
Empiric Treatment
Mucocutaneous
Clotrimazole, nystatin, fluconazole, itraconazole
Candiduria
Fluconazole or intravesical ampho B if sx, severely 
immunosupp., or will undergo GU procedure
Candidemia w/o neutropenia
Echinocandin or fluconazole or ampho B
Febrile neutropenia
Echinocandin (eg, micafungin) or Ampho B 
Remove intravascular catheters (CID 2009;48:503)
Histoplasmosis
‚Ä¢ Epidemiology: hyperendemic in central & SE U.S. (esp. in areas w/ bird & bat 
droppings), present in river banks elsewhere including northeast
‚Ä¢ Clinical manifestations
Acute pulmonary: often subclinical, but may see mild to severe  cavitary 
Chronic pulmonary: c productive cough, wt loss, night sweats, infiltrates, cavitation
Disseminated (immunosupp.): fever, wt loss, HSM, LAN, oral ulcers, skin lesion
‚Ä¢ Treatment: itraconazole; amphotericin  steroids if severe or disseminated (CID 2007;45;807)
Coccidioidomycosis
‚Ä¢ Epidemiology: SW U.S. (San Joaquin or ‚ÄúValley‚Äù fever)
‚Ä¢ Clinical manifestations
Acute pulmonary: often subclinical; chest pain, cough, fever, arthralgias
Chronic pulmonary: cough, hemoptysis, fever, night sweats, wt loss
Chronic disseminated (in immunosupp., pregnant, & DM): fever, malaise, diffuse 
pulmonary process, bone, skin, & meningeal involvement 
‚Ä¢ Treatment for disseminated or high-risk 1
 pulmonary: fluconazole or itraconazole, or
amphotericin if severe (CID 2005;41:1217)
Blastomycosis
‚Ä¢ Epidemiology: south central, SE, and midwest U.S.
‚Ä¢ Clinical manifestations: often asx, acute PNA, chronic pneumonia;
extrapulmonary: verrucous & ulcerated skin lesions, bone & GU involvement, CNS
‚Ä¢ Treatment: itraconazole; ampho B if severe or immunosupp. (CID 2008;46:1801)
Aspergillus (Chest 2002;121:1988; CID 2008;46:327; NEJM 2009;360:1870)
‚Ä¢ ABPA; hypersensitivity pneumonitis: see ‚ÄúInterstitial Lung Disease‚Äù
‚Ä¢ Aspergilloma: usually in pre-existing cavity (from TB, etc.); most asx, but can lead
to hemoptysis; sputum cx  in 50%; CT S mobile intracavitary mass with air crescent
Rx: antifungals w/o benefit; embolization or surgery for persistent hemoptysis
‚Ä¢ Necrotizing tracheitis: white necrotic pseudomembranes in Pts w/ AIDS or lung Tx
‚Ä¢ Chronic necrotizing: seen in COPD, mild immunosupp; subacute sputum, fever, wt loss;
CT: infiltrate  nodule  thick pleura; lung bx S invasion; Rx  voriconazole  ampho B
‚Ä¢ Invasive/disseminated: seen if immunosupp. (neutropenia, s/p transplant, steroid Rx,
AIDS esp. w/ steroids or neutropenia); s/s PNA w/ chest pain & hemoptysis; CT: nodules,
halo sign, air crescent sign; lung bx if dx inconclusive; Rx  voriconazole  ampho B
Zygomycetes (eg, Mucor, Rhizopus)
‚Ä¢ Epidemiology: diabetes mellitus (70%), heme malignancy, s/p transplant, chronic
steroids, deferoxamine or iron overload
‚Ä¢ Clinical manifestations: rhinocerebral  periorbital/forehead pain (more extensive than
orbital cellulitis),  fever (may appear nontoxic at first), exophthalmos, decreased EOM,
may involve CNs (V VII); nasal turbinates  black eschar; Dx: careful ENT exam  bx
‚Ä¢ Treatment: Serial debridements, ampho.Very high mortality even if treated.

--- Fim da P√°gina 167 ---

Cryptococcus (CID 2010;50:291)
‚Ä¢ Epidemiology: immunosupp. (esp.AIDS) most susceptible, but may occur in healthy host
‚Ä¢ Clinical manifestations 
CNS (meningitis)  HA, fever, meningismus, high ICP,  stupor. Dx: LP w/ CSF CrAg,
India ink stain, fungal cx (cell counts vary); serum CrAg 1:8 highly Se/Sp in AIDS.
Other forms: pulmonary, urinary, cutaneous, CNS cryptococcoma.With any evi-
dence of cryptococcal disease, exonerate CNS infxn w/ LP.
‚Ä¢ Treatment:
CNS disease (or non-CNS disease in immunosupp. Pts):
HIV : Induction: ampho (Ampho B 0.7‚Äì1.0 mg/kg/d, liposomal ampho B 3‚Äì4 mg/kg/d
or ABLC 5 mg/kg/d) and if bone marrow allows, flucytosine (100 mg/kg/d in 
4 divided doses)  2 wk; Consolidation: fluconazole 800 mg/d  8 wk;
Maintenance: 12 mo antifungal Rx and until immune recovery on ARVs
Transplant: Induction: liposomal ampho B and flucytosine  2 wks; Consolidation:
fluconazole 400 mg/d  8 wk; Maintenance: fluconazole  6‚Äì12 mo if able to 
reduce immunosuppressive Rx, o/w longer
Treat high ICP w/ repeat large-volume LPs or temp. lumbar drain; few require VP shunt
Non-CNS disease in healthy Pts: fluconazole vs. observation, based on clinical setting
Fungal diagnostics
‚Ä¢ Culture: Candida grows well in blood/urine cx, others (eg, Crypto, Histo) grow better
in fungal isolator BCx. Cx insensitive for Coccidioides.
‚Ä¢ Antibody detection: Histo, Blasto, Coccidio, Aspergillus. Se variable.
‚Ä¢ Antigen detection
Histo urine/serum Ag: Se of urine Ag 90% (serum Ag 80%) for disseminated
disease; Sp limited by cross-reactivity with other fungal infxns
1,3--D-glucan: Se for many fungal infxns (Candida, Aspergillus, Histo, Coccidio,
Fusarium, Pneumocystis, Sporothrix; but not Crypto, Blasto, Mucor, Rhizopus); not Sp
Galactomannan (GM): more specific for Aspergillus, but Se 50%
Crypto Ag (serum, CSF): serum Ag 90% Se & Sp in invasive infxn, lower for pulm only
‚Ä¢ Histopathologic exam (nb, no grinding of tissue if Zygomycetes suspected)
INFECTIONS IN SUSCEPTIBLE HOSTS
Overview
‚Ä¢ Many immunophenotypes, meds, or systemic diseases may predispose to infection
‚Ä¢ The following is not an exhaustive list, but a delineation of common or classic etiologies
‚Ä¢ Many Pts will fit into more than one category (eg, DM, ESRD, extremes of age)
Predisposition
Classic infectious etiologies 
Humoral immune 
Encapsulated bacteria: S. pneumo, H. flu, N. meningitidis
dysfunction (eg,
Other bacteria: E. coli and other GNRs
CVID, myeloma)
Granulocytopenia 
Bacteria: Gram positive: coag neg Staph, S. aureus, viridans Strep,
or neutropenia
S. pneumo, other Strep; Corynebacterium spp., Bacillus spp.
(includes DM,
Gram negative: E. coli, Klebsiella, Pseudomonas
ESRD S functional 
Fungi: Yeast: Candida albicans and other Candida spp.; Molds:
impairment)
Aspergillus, Mucor spp., and others (these also require CMI)
Impaired cell-
Bacteria: Salmonella spp., Campylobacter, Listeria, Yersinia, Legionella,
mediated 
Rhodococcus, Nocardia,TB, other mycobacteria
immunity (CMI)
Fungi: Candida, Crypto, Histo, Coccidio, Aspergillus, and other 
(eg, HIV, chronic 
molds, Pneumocystis
steroids,
Viruses: HSV, VZV, CMV, EBV, JC virus, BK virus
posttransplant,
Parasites: Protozoa: Toxoplasma, Cryptosporidium, Isospora,
DM, ESRD)
Babesia; Helminths: Strongyloides
Organ 
Splenectomy: S. pneumo, H. flu, N. meningitidis (vaccinate against
dysfunction
these 3, ideally prior to splenectomy); Capnocytophaga, Babesia
Liver (esp. cirrhosis): Vibrio spp., encapsulated bacteria
ESRD: impaired granulocyte fxn and CMI as above
Iron overload (or deferoxamine Rx): Yersinia, Mucor
Biologics (eg,
Bacteria: sepsis,TB, other mycobacteria
TNF inhibitors,
Fungi: Pneumocystis, Histo, Coccidio, other endemic fungi
anti-B-cell Rx)
Viruses: JC virus (PML), EBV, HSV, VZV, HBV
Parasites: Strongyloides reactivation 
INFXN SUSCEPT
6-4

--- Fim da P√°gina 168 ---

UTI
6-5
URINARY TRACT INFECTIONS (UTI)
Definitions
‚Ä¢ Anatomic
lower: urethritis, cystitis (superficial infection of bladder)
upper: pyelonephritis (inflammatory process of the renal parenchyma), renal or
perinephric abscess, prostatitis
‚Ä¢ Clinical
uncomplicated: cystitis in immunocompetent nonpregnant women w/o underly-
ing structural or neurologic disease
complicated: upper tract infection in women or any UTI in men or pregnant women
or UTI with underlying structural disease or immunosuppression
Microbiology
‚Ä¢ Uncomplicated UTI: E. coli (80%), Proteus, Klebsiella, S. saprophyticus (CID 2004;39:75)
‚Ä¢ Complicated UTI: E. coli (30%), enterococci (20%), Pseudomonas (20%), S. epidermidis
(15%), other GNR
‚Ä¢ Catheter-associated UTI: yeast (30%), E. coli (25%), other GNR, enterococci, S. epi
‚Ä¢ Urethritis: Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum,
Trichomonas vaginalis, Mycoplasma genitalium, HSV
‚Ä¢ S. aureus: uncommon primary urinary pathogen in absence of catheter or recent
instrumentation; ‚à¥consider bacteremia w/ hematogenous seeding
Clinical manifestations
‚Ä¢ Cystitis: dysuria, urgency, frequency, hematuria, 	 in urine color/odor, suprapu-
bic pain; fever generally absent
‚Ä¢ Urethritis: may be identical to cystitis except urethral discharge may be present
‚Ä¢ Prostatitis
chronic: similar to cystitis except symptoms of obstruction (hesitancy, weak stream)
acute: perineal pain, fever, tenderness on prostate exam
‚Ä¢ Pyelonephritis: fever, shaking chills, flank or back pain, nausea, vomiting, diarrhea
‚Ä¢ Renal abscess (intrarenal or perinephric): identical to pyelonephritis except persistent
fever despite appropriate antibiotics
Diagnostic studies
‚Ä¢ Urinalysis: pyuria  bacteriuria  hematuria  nitrites
‚Ä¢ Urine Cx (from clean-catch midstream or straight-cath specimen)
significant bacterial counts: 105 CFU/mL in asx women, 103 CFU/mL in men,
102 CFU/mL in sx or catheterized Pts (hydration may falsely dilute counts)
pyuria &  UCx  sterile pyuria S urethritis, nephritis, renal tuberculosis, foreign body
‚Ä¢ Pregnant women & those undergoing urologic surgery: screen for asx bacteriuria
‚Ä¢ Blood cultures: in febrile and possibly complicated UTIs
‚Ä¢ DNA detection/cx for C. trachomatis/N. gonorrhoeae in high-risk Pts or sterile pyuria
‚Ä¢ 1st-void and midstream urine specimens, prostatic expressage, and post‚Äìprostatic
massage urine specimens in cases of suspected prostatitis
‚Ä¢ Abdominal CT to r/o abscess in Pts with pyelo who fail to defervesce after 72 h
‚Ä¢ Urologic workup (renal U/S w/ PVR, abd CT, voiding cystography) if recurrent UTIs in men
Treatment of UTIs
Clinical scenario
Empiric treatment guidelines*
Cystitis
FQ or TMP-SMX PO  3 d (uncomp.) or  10‚Äì14 d (complicated)
Asx bacteriuria in pregnancy or prior to urologic surgery S abx  3 d
Catheterized Pts
Abx as above and remove or exchange catheter
Urethritis
Treat for both Neisseria and Chlamydia
Neisseria: ceftriaxone 125 mg IM  1
Chlamydia: doxy 100 mg PO bid  7 d or azithromycin 1 g PO  1
Prostatitis
FQ or TMP-SMX PO  14‚Äì28 d (acute) or 6‚Äì12 wks (chronic)
Pyelonephritis
Outpatient: FQ or oral ceph. PO  14 d
Inpatient: ceftriaxone IV or FQ PO or aminoglycoside or 
ampicillin/sulbactam  14 d
(	 IV S PO when Pt improved clinically and afebrile  24‚Äì48 h and 
then complete 14-d course)
Renal abscess
Drainage  antibiotics as for pyelonephritis
*When possible, use organism-directed therapy, guided by in vitro susceptibilities, Pt‚Äôs past microbiology
data and recent antibiotic exposure, or local patterns of drug resistance.

--- Fim da P√°gina 169 ---

SOFT TISSUE
6-6
SOFT TISSUE AND BONE INFECTIONS
CELLULITIS
Infection of superficial and deep dermis and subcutaneous fat
Microbiology (NEJM 2004;350:904; CID 2005;41:1373)
‚Ä¢ Primarily Strep and Staph, including MRSA; may include GNRs in diabetics/immunosupp.
‚Ä¢ Community-acquired MRSA (CA-MRSA, NEJM 2005;352:1485 & 2006;355:666):
Up to 75% of purulent skin/soft tissue infxns, depending on location (rapidly increasing)
Clinically indistinguishable from MSSA, though may be more aggressive/abscess-forming
High-risk groups: athletic teams, military, prison, MSM, communities w/ MRSA infxns
Often TMP-SMX sensitive; variably clindamycin sensitive (may falsely appear sus-
ceptible on lab testing, requires confirmation w/ D-test; NEJM 2007;357:380)
‚Ä¢ Special cases: cat bite S P. multocida; dog bite S P. multocida, C. canimorsus; penetrating
injury S Pseudomonas; gardening S Sporothrix; salt water S V. vulnificus (classically
from raw oysters), Erysipelothrix; fresh water S Aeromonas
Clinical manifestations
‚Ä¢ Erythema, edema, warmth, pain (rubor, tumor, calor, dolor)
‚Ä¢  Lymphangitis (proximal red streaking) and regional lymphadenopathy
‚Ä¢ P. multocida S rapid onset; C. canimorsus S sepsis w/ symmetric, peripheral gangrene
in splenectomized and other immunosupp. Pts; V. vulnificus S hemorrhagic bullae &
sepsis (especially in cirrhotics); Sporothrix S ulcerating nodules
‚Ä¢ Toxic shock syndrome can be seen w/ Staph or Strep infxn. Fever, HA, vomiting,
myalgias, pharyngitis, diarrhea, diffuse rash w/ desquamation. Hypotension, shock.
BCx may be .
Diagnosis
‚Ä¢ Largely clinical diagnosis; BCx low yield (Se 5% in simple cellulitis) but useful if 
‚Ä¢ Aspirate of bulla or pus from furuncle or pustule may provide dx
Treatment
‚Ä¢ Abx: PCNase-resist PCN or 1st-gen. ceph.; if MRSA risk: inPt S vanco; outPt S TMP-
SMX  agent for strep (eg, PCN, amox, clinda) or doxy (active against MRSA  strep) 
‚Ä¢ Limb elevation (erythema may worsen after starting abx b/c bacterial killing S inflamm.)
‚Ä¢ Worse outcomes if vasc. insuff., edema, immunosupp., resistant orgs., or deeper infxn
OTHER CUTANEOUS INFECTIONS
Definitions
‚Ä¢ Impetigo: superficial purulent lesions, usually on face/extrem,  bullae,  gold crust
‚Ä¢ Erisypelas: raised erythematous lesion with clear demarcation from normal skin
‚Ä¢ Folliculitis: superficial inflammation of hair follicles, limited to epidermis
‚Ä¢ Furunculosis: infxn of follicle extending to dermis (mult. coalescent furuncles  carbuncle)
Microbiology and treatment (CID 2005;41:1373)
‚Ä¢ Impetigo: Strep or Staph; Rx  topical mupirocin or other top. antibacterial usually sufficient
‚Ä¢ Erisypelas: mainly Grp A Strep; Rx  PCN unless Staph suspected
‚Ä¢ Folliculitis/furunculosis: S. aureus, Pseud. (‚Äúhot tub folliculitis‚Äù); Rx  warm compress
 I&D; abx controversial, give if assoc. cellulitis, lyphangitis, systemic sx, immunsosupp.
‚ÄúDIABETIC FOOT‚Äù
Infected neuropathic foot ulcer
Microbiology
‚Ä¢ Mild (superficial, no bone or joint involvement): usually S. aureus or aerobic streptococci
‚Ä¢ Limb- or life-threatening  deep, bone/joint involvement, systemic tox., limb ischemia
monomicrobial or polymicrobial with aerobes  anaerobes
aerobes  staphylococci, streptococci, enterococci, and GNR (including Pseudomonas)
anaerobes  anaerobic streptococci, Bacteroides, Clostridium (rare)
Clinical manifestations
‚Ä¢ Ulcer with surrounding erythema and warmth  purulent drainage
‚Ä¢ Tenderness may be absent due to neuropathy
‚Ä¢  Crepitus (indicating gas and ‚à¥mixed infection w/ GNR & anaerobes or Clostridium)
‚Ä¢  Underlying osteomyelitis
‚Ä¢  Systemic toxicity (fever, chills, leukocytosis, hyperglycemia)
‚Ä¢ #1 cause of DM-related hosp. days; #1 proximal cause of non-traumatic amputations in U.S.

--- Fim da P√°gina 170 ---

Diagnostic studies
‚Ä¢ Superficial swabs from ulcers not helpful (only yield superficial colonizing organisms)
‚Ä¢ Wound cx (eg, curettage at base of ulcer after d√©bridement) has c Se
‚Ä¢ Blood cx should be obtained in all Pts,  in 10‚Äì15%
‚Ä¢ Osteomyelitis should always be ruled out (see below for specific imaging tests)
probing to bone via ulcer/tract has high Sp but low Se; bone bx most reliable
Treatment (NEJM 1994;331:854, CID 2004;39:885)
‚Ä¢ Bedrest, elevation, non‚Äìweight-bearing status, wound care, antibiotics
Severity of infection
Empiric antibiotics
Mild
PCNase-resistant PCN or 1st-gen. ceph. (TMP-SMX if
MRSA suspected)
Chronic non-limb &
(FQ  clindamycin) or ampicillin-sulbactam or
non-life-threatening
ticarcillin-clavulanate or (ceftriaxone  clinda) or ertapenem;
add vanco or TMP-SMX or doxycycline if suspect MRSA
Life-threatening
Vanco  one of the following: imipenem or
(piperacillin/tazobactam) or (aztreonam  metronidazole)
‚Ä¢ Surgery: early, aggressive, and repeated surgical d√©bridement; revascularization or
amputation may be necessary
NECROTIZING FASCIITIS
Definition
‚Ä¢ Infection and necrosis of superficial fascia, subcutaneous fat, and deep fascia (necrosis
of arteries and nerves in subcutaneous fat S gangrene)
‚Ä¢ Fournier‚Äôs gangrene: necrotizing fasciitis of the male genitalia (used by some to describe
involvement of male or female perineum)
Epidemiology
‚Ä¢ c risk in diabetes, PVD, alcohol abuse, IVDU, immunosuppression, cirrhosis
‚Ä¢ Can also affect healthy individuals
Microbiology
‚Ä¢ Group I (often after abd/perineal surgery or trauma): polymicrobial (anaerobe 
facultative anaerobe  GNR); often with DM, PVD and other comorbidities.
‚Ä¢ Group II (usually extrem): Strep pyogenes  Staph; often healthy w/o obvious portal
of entry; up to 1‚ÅÑ2 have toxic shock syndrome (TSS). CA-MRSA can rarely cause
monomicrobial necrotizing fasciitis.
Clinical manifestations
‚Ä¢ Most common sites: extremities, abdominal wall, and perineum, but can occur anywhere
‚Ä¢ Cellulitic skin 	s with poorly defined margins  rapid spread  systemic toxicity
‚Ä¢ Pain out of proportion to apparent cellulitis; skin hyperesthetic and later anesthetic
‚Ä¢ Bullae (serous S hemorrhagic); darkening of skin to bluish-gray S cutaneous 
gangrene  crepitus or radiographically visible gas
Diagnostic signs
‚Ä¢ Need high degree of clinical suspicion because of nonspecific physical exam
‚Ä¢ Aspiration of necrotic center; blood cultures; Gram stain; ‚úìCK for tissue necrosis
‚Ä¢ Imaging studies: MRI S best tissue contrast; plain radiographs S soft tissue gas;
CT S extent of infection, soft tissue gas 
‚Ä¢ Clinical diagnosis enough to initiate urgent surgical exploration
‚Ä¢ Microbiologic diagnosis from Gram stain and culture of surgical specimens
Treatment
‚Ä¢ Definitive treatment is surgical d√©bridement of necrotic tissue and fasciotomy
‚Ä¢ Type I: breadth of GNR coverage determined by host, prev hosp, prev Rx and initial
Gram stain; eg, carbapenem or (3rd-gen ceph  amp  [clinda or metronidazole])
‚Ä¢ Type II: PCN  clindamycin. If community-acquired MRSA a consideration,  vanco.
If TSS, add high dose IVIG.
‚Ä¢ Hyperbaric oxygen: adjunct, but should not delay definitive surgical treatment
Prognosis
‚Ä¢ Generally fatal if untreated; reported mortality 20‚Äì50%
CLOSTRIDIAL MYONECROSIS (GAS GANGRENE)
Definition
‚Ä¢ Life-threatening, fulminant clostridial infection of skeletal muscle
‚Ä¢ Usually muscle trauma (penetrating wound or crush injury)  wound contami-
nation w/ clostridial spores
‚Ä¢ Most commonly C. perfringens; C. septicum assoc w/ cancer (GI, heme), even w/o trauma
SOFT TISSUE
6-7

--- Fim da P√°gina 171 ---

Clinical manifestations
‚Ä¢ Incubation period 6 h to 2‚Äì3 d
‚Ä¢ Acute onset with sense of heaviness or pain, often at site of trauma or surgery, that
rapidly worsens with marked systemic toxicity
‚Ä¢ Bronze skin discoloration, tense bullae, serosanguineous or dark fluid and necrotic areas
‚Ä¢ Crepitus present but not prominent (gas is in muscle), may be obscured by edema
Diagnostic studies
‚Ä¢ Gram stain of discharge: lg, Gram  bacilli w/ blunt ends, few polys, bacteremia in 15%
‚Ä¢ Plain radiographs: gas dissecting into muscle
Treatment
‚Ä¢ Surgical exploration with d√©bridement, fasciotomies, and amputation if necessary
‚Ä¢ Antibiotics: high-dose penicillin G 24 MU IV divided q2‚Äì3h  clinda 900 mg IV q8h
‚Ä¢ ? Hyperbaric oxygen
OSTEOMYELITIS
Infection of bone due to hematogenous seeding or direct spread from contiguous focus
Microbiology (NEJM 1997;336:999)
‚Ä¢ Hematogenous: S. aureus; mycobacterial infection of vertebral body  Pott‚Äôs disease
‚Ä¢ Contiguous focus (may be acute or chronic)
open fracture, orthopedic surgery, etc.: S. aureus and S. epi
 vasc. insuffic. (eg, diabetic foot): polymicrobial (aerobic  anaerobic GPC & GNR)
Clinical manifestations
‚Ä¢ Surrounding soft-tissue compromise  fistula to superficial skin
‚Ä¢  Fever, malaise, and night sweats (more common in hematogenous than contiguous)
‚Ä¢ Vertebral osteomyelitis (seen in Pts over 50 y): unremitting, focal back pain, usually
fever (NEJM 2010;362:1022)
Diagnostic studies (JAMA 2008;299:806)
‚Ä¢ Identification of the causative organism is key
‚Ä¢ Culture data from tissue (surgical sampling/needle bx), not swabs of ulcers/fistulae
‚Ä¢ Blood cultures (more often  with acute hematogenous osteomyelitis)
‚Ä¢ ESR 70 greatly increases likelihood of osteo (JAMA 2008;299:806)
‚Ä¢ Imaging
plain radiographs: normal early in disease; lytic lesions seen after 2‚Äì6 wks
MRI: can detect very early changes (overall Se 90%, Sp 82%; Archives 2007;167:125)
CT: can demonstrate periosteal reaction and cortical and medullary destruction
CT & MRI very Se but not completely Sp; false  if contiguous focus w/ periosteal
reaction, Charcot changes
radionuclide imaging: very Se but non-Sp (false  if soft-tissue inflammation)
Treatment
‚Ä¢ Antibiotics (based on cx data)  4‚Äì6 wks
‚Ä¢ Surgery should be considered for any of the following: acute osteo that fails to respond
to medical Rx, chronic osteo, complications of pyogenic vertebral osteo (eg, early signs
of cord compression, spinal instability, epidural abscess), or infected prosthesis
EPIDURAL ABSCESS
Etiology
‚Ä¢ Hematogenous spread (2/3): skin infection, soft tissue (dental abscess), or endocarditis
‚Ä¢ Direct extension (1/3): vertebral osteomyelitis, sacral decubitus ulcer, spinal anesthesia
or surgery, lumbar puncture
‚Ä¢ Risk factors: diabetes, renal failure, alcoholism, IVDU, immunosuppression
‚Ä¢ S. aureus most common pathogen
Clinical manifestations
‚Ä¢ Back pain (unremitting including midline)  often fever  nerve root or cord signs
Diagnostic studies
‚Ä¢ MRI
‚Ä¢ Aspiration of abscess fluid for Gram stain & cx or operative Gram stain & cx 
‚Ä¢ Blood cx (frequently )
Treatment
‚Ä¢ Antibiotics  surgery (decompressive laminectomy and d√©bridement) for failure
to improve on medical Rx or early s/s of cord compression (w/ vertebral osteo
and epidural abscess, may see paraplegia 48‚Äì72 h after first signs)
OSTEO
6-8

--- Fim da P√°gina 172 ---

MENINGITIS
6-9
INFECTIONS OF THE NERVOUS SYSTEM
ACUTE BACTERIAL MENINGITIS
Definition
‚Ä¢ Bacterial infection of the subarachnoid space
Microbiology in Adult Meningitis
Etiology
Comments
S. pneumoniae
Look for distant infection (eg, Osler‚Äôs triad  meningitis,
(30‚Äì60%)
pneumonia, endocarditis).
Drug-resistant S. pneumoniae (DRSP):
40% PCN-resistant (even intermed resist problematic for Rx)
10% 3rd-gen. ceph.-resistant
Vaccine reduces rate of invasive disease
N. meningitidis
Primarily in children and young adults; may be associated with 
(10‚Äì35%)
petechiae or purpura. Deficiencies in terminal complement 
predispose to recurrent meningococcemia & rarely, meningitis.
Vaccine rec for all adolescents, college freshmen living in dorm,
military recruits, s/p splenectomy, or C5‚Äì9 deficiency.
H. influenzae
T Incidence in children because of H. influenzae type b vaccine.
(5%)
Look for predisposing factors in adults (eg, CSF leak, recent
neurosurgical procedure, trauma, mastoiditis).
L. monocytogenes
Seen in elderly, alcoholics, or patients with malignancy,
(5‚Äì10%)
immunosuppression, or iron overload. Outbreaks associated with
contaminated milk, cheese, coleslaw, raw vegetables. Despite
name, often associated with poly-predominant pleocytosis.
GNRs
Usually nosocomial or postprocedure or in elderly or 
(1‚Äì10%)
immunosuppressed
Staphylococci
Seen with indwelling CSF shunt (S. epidermidis) or following
(5%)
neurosurgery or head trauma (S. aureus)
Mixed infection
Suspect parameningeal focus or CSF leak
Clinical manifestations (NEJM 2006;354:44)
‚Ä¢ Fever (77%)
‚Ä¢ Headache (87%), stiff neck (83%), and photosensitivity
‚Ä¢ 	 MS (69%) (defined as GCS 14), seizures (5%)
‚Ä¢ 2 of 4 (fever, HA, stiff neck, 	 MS) present in 95%
‚Ä¢ Presentation may be atypical (eg, lethargy w/o fever) in elderly and immunosupp.
Recurrent meningitis
‚Ä¢ Bacterial: consider CSF leak, dermal sinus, or other congenital/acquired anatomic defects
‚Ä¢ Viral: HSV-2 (causes majority of Mollaret‚Äôs meningitis)
‚Ä¢ Aseptic (see below): leak from cyst/tumor/lesion with dermoid/epidermoid elements,
autoimmune (eg, SLE, Beh√ßet‚Äôs), medications 
Physical exam
‚Ä¢ Nuchal rigidity (Se 30%), Kernig‚Äôs sign (Pt supine, hip flexed at 90
, knee flexed at 90
;
 if passive extension of knee results in resistance), Brudzinski‚Äôs sign (Pt supine and
limbs supine;  if passive neck flexion S involuntary hip and/or knee flexion)
nb, Kernig‚Äôs and Brudzinski‚Äôs signs  in only 5% of Pts (CID 2002;35:46)
‚Ä¢  Focal neuro findings (30%; hemiparesis, aphasia, visual field cuts, CN palsies)
‚Ä¢  Funduscopic findings: papilledema, absent venous pulsations
‚Ä¢  Rash: maculopapular, petechial, or purpuric
Diagnostic studies
‚Ä¢ Blood cultures before abx
‚Ä¢ WBC count: 10,000 in 83% of bacterial meningitis 
‚Ä¢ Consider head CT to r/o mass effect before LP if presence of high-risk feature (age
60 y, immunosupp., h/o CNS disease, new-onset seizure, 	 MS, focal neuro
findings, papilledema); absence of all these has NPV 97%; however, in Pts w/ mass effect,
herniation may occur w/o LP and may not occur even w/ LP (NEJM 2001;345:1727)
‚Ä¢ Lumbar puncture (NEJM 2006;355:e12)
CSF Gram stain has 60‚Äì90% Se; cx 70‚Äì85% Se if LP done prior to abx
repeat LP only if no clinical response after 48 h of appropriate abx, or CSF shunt present
‚Ä¢ Rule of 2s: CSF WBC 2k, glc 20, & TP 200 has 98% Sp for bacterial meningitis

--- Fim da P√°gina 173 ---

Typical CSF Findings in Meningitis
Condition
Appearance
Pressure
WBC/mm3
Glc
TP
(cm H2O)
Predom type
(mg/dL)
(mg/dL)
Normal
Clear
9‚Äì18
0‚Äì5
50‚Äì75
15‚Äì40
lymphs
Bacterial
Cloudy
18‚Äì30
100‚Äì10,000
45
100‚Äì1000
polys
TB
Cloudy
18‚Äì30
500
45
100‚Äì200
lymphs
Fungal
Cloudy
18‚Äì30
300
45
40‚Äì300
lymphs
Aseptic
Clear
9‚Äì18
300
50‚Äì100
50‚Äì100
polys S lymphs
‚Ä¢ Additional CSF studies depending on clinical suspicion: acid-fast smear and cx, India ink
prep, cryptococcal Ag, fungal cx,VDRL, PCR (eg, of HSV,VZV, enteroviral), cytology
Treatment of Meningitis
Clinical scenario
Empiric treatment guidelines*
Normal adult
Ceftriaxone 2 g IV q12h Vancomycin 15‚Äì20 mg/kg IV q12h
(nb, Cftx in case PCN-resistant S. pneumo; Vanco, which has
poorer CSF penetration, in case Cftx-resistant S. Pneumo)
If 50 y old or alcoholic:  ampicillin 2 g IV q4h for Listeria
TMP/SMX  vancomycin if -lactam allergic
Immunosuppressed
Ampicillin  ceftazidime 2 g IV q8h  vancomycin  acyclovir
CSF shunts, recent
Vancomycin  ceftazidime 2 g IV q8h (NEJM 2010;362:146)
neurosurgery, or
head trauma
Empiric antibiotics should be started as soon as possible. If concerned about c ICP,
obtain BCx S start empiric abx S obtain head CT S LP (if not contraindicated); yield of
CSF fluid unlikely to be changed if obtained w/in 4 h of initiation of abx.
Corticosteroids: Dexamethasone 10 mg IV q6h  4 d S T neuro disability & mort. by
50% w/ S. pneumo & GCS 8‚Äì11. Consider steroids in all bacterial meningitis prior to
organism identification. Must start before or w/ 1st dose of abx (NEJM 2002;347:1549).
Prophylaxis: rifampin (600 mg PO bid  2 d) or ciprofloxacin (500 mg PO  1) or 
ceftriaxone (250 mg IM  1) for close contacts of Pt w/ meningococcal meningitis
Precautions: droplet precautions until N. meningitidis is ruled out
*When possible, organism-directed Rx, guided by suscept. or local patterns of drug resistance should be used.
Prognosis
‚Ä¢ For community-acquired S. pneumo mort. 19‚Äì37%; 30% have long-term neuro sequelae
ASEPTIC MENINGITIS
Definition
‚Ä¢ Negative bacterial microbiologic data, CSF pleocytosis with  appropriate
blood and CSF cultures (aseptic meningitis can be neutrophilic, though less common)
‚Ä¢ Aseptic  less likely to be bacterial, but can be infectious or noninfectious
Etiologies (Neurology 2006;66:75)
‚Ä¢ Viral: enteroviruses (most common), HIV, HSV (type 2  1),VZV, mumps, lymphocytic
choriomeningitis virus, encephalitis viruses, adenovirus, polio, CMV, EBV
‚Ä¢ Parameningeal focus of infection (eg, brain abscess, epidural abscess, septic
thrombophlebitis of dural venous sinuses, or subdural empyema)
‚Ä¢ TB, fungal, spirochetal (Lyme, syphilis, leptospirosis), rickettsial, Coxiella, Ehrlichia
‚Ä¢ Partially treated bacterial meningitis
‚Ä¢ Medications: TMP/SMX, NSAIDs, IVIg and antilymphocyte globulins, penicillin, isoniazid
‚Ä¢ Systemic illness: SLE, sarcoidosis, Beh√ßet‚Äôs, Sj√∂gren‚Äôs syndrome, rheumatoid arthritis
‚Ä¢ Neoplasms: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis
(CSF cytology or flow may be reactive and dx may require meningeal bx)
Empiric treatment
‚Ä¢ No abx if suspect viral (cell count 500 w/ 50% lymphs, TP 80‚Äì100 mg/dL, normal glc,
 Gram stain, not elderly/immunosupp.); o/w start empiric abx, wait for cx data
‚Ä¢ MTb: antimycobacterial Rx  dexamethasone (NEJM 2004;351:1741)
‚Ä¢ Fungal: amphotericin B or lipid formulation,  5-fluorouracil
MENINGITIS
6-10

--- Fim da P√°gina 174 ---

VIRAL ENCEPHALITIS
Definition
‚Ä¢ Viral infection of the brain parenchyma with evidence of neurologic dysfunction
Etiologies (Lancet 2002;359:507; Neurology 2006;66:75; CID 2008;47:303)
‚Ä¢ HSV-1 (9%): all ages/seasons; MRI: temporal lobe lesions/edema; EEG: temporal focus
‚Ä¢ VZV (9%): 1
 or reactivation;  vesicular rash; all ages (favors elderly), all seasons
‚Ä¢ Arboviruses (9%): Eastern/Western equine,West Nile, St. Louis, Japanese, Powassan
W Nile (NEJM 2005;353:287): mosquito vector, bird reservoir; fever, HA, flaccid paralysis, rash
‚Ä¢ Enteroviruses (Coxsackie, echo): viral syndrome; peaks in late summer/early fall
‚Ä¢ Others: CMV, EBV, HIV, JC virus (PML), measles, mumps, rubella, rabies, flu, adenovirus
‚Ä¢ Nonviral mimics: bacterial endocarditis, brain abscess, toxoplasmosis,TB, toxins, vas-
culitis, hematologic malignancies, subdural hematoma, encephalomyelitis (eg,
ADEM), paraneoplastic syndromes, seizure, mitochondrial disorders
Clinical manifestations
‚Ä¢ Fever, HA, 	 MS,  seizures and focal neuro findings (latter atypical for viral meningitis)
Diagnostic studies (etiologic dx made in only about 25% of cases)
‚Ä¢ Lumbar puncture: lymphocytic pleocytosis; PCR for HSV (95% Se & Sp at 2‚Äì3 d),VZV,
CMV, EBV, HIV, JC, adeno/enterovirus, W Nile (60% Se); W Nile CSF IgM 80% Se
‚Ä¢ MRI (CT if MRI unavailable);W Nile w/ thalamic hyperintensity
‚Ä¢ EEG (to r/o seizure; findings in encephalitis are non-specific)
‚Ä¢ Dilated retinal exam
‚Ä¢ Serologies; vaccine history, ELISA or DFA of nasal or resp swabs for respiratory viruses
Treatment
‚Ä¢ HSV, VZV: acyclovir 10 mg/kg IV q8h (often empiric Rx given frequency of HSV/VZV)
‚Ä¢ CMV: ganciclovir  foscarnet; supportive care for most other etiologies
BELL‚Äôs PALSY
Definition & Etiology
‚Ä¢ Acute, idiopathic, unilateral facial nerve palsy (peripheral CN VII)
‚Ä¢ Postulated to be due to reactivation of HSV-1 in cranial nerve VII
Clinical manifestations
‚Ä¢ Unilateral facial muscle weakness, hyperacusis, decreased taste/lacrimation/salivation
Diagnosis
‚Ä¢ Dx of exclusion: r/o brainstem lesion, Lyme, zoster (incl sine herpete), HIV/AIDS, sarcoid
Treatment (NEJM 2007;357:1598 & JAMA 2009;302:985)
‚Ä¢ 80% recover spontaneously by 9 mos (much lower rate in diabetics)
‚Ä¢ Corticosteroids (prednisolone 25 mg PO bid  10 d) started w/in 72 h of sx onset
improve odds of recovery (note: no conclusive data for diabetics, immunosuppressed)
‚Ä¢ No conclusive data to support the use of acyclovir or valacyclovir, though often given
ZOSTER
Definition & Etiology
‚Ä¢ Zoster  herpes zoster  shingles: acute, unilateral, painful dermatomal skin eruption
‚Ä¢ VZV reactivation in peripheral nerve distribution from latency in dorsal root ganglion
Clinical manifestations
‚Ä¢ Neuritic pain in a dermatomal distribution, then acute dermatomal eruption of
clustered rash (vesicles  papules/pustules  macules) in varying stages of evolution
‚Ä¢ Consecutive dermatomes may be seen in all Pts; more widespread in immunosupp.
‚Ä¢ Lesions in V1 distribution of facial nerve require urgent ophthalmologic evaluation
‚Ä¢ Post-herpetic neuralgia (PHN)  severe pain lasting 90 d after episode; may last
mos to y, more frequent w/ c age and w/ delay of antiviral Rx
Diagnosis
‚Ä¢ Physical appearance of rash; most sensitive is DFA from scraping of unroofed vesicle,
Tzanck does not distinguish HSV or VZV, culture insensitive for VZV (unlike HSV)
Treatment
‚Ä¢ Rx if can initiate w/in 72 h of skin lesions in normal host or at any time dx in immunosupp.
‚Ä¢ Valacyclovir or famciclovir  7 d in normal host; acyclovir 10 mg/kg IV q8h if dissemi-
nated or high-risk Pt (medically ill, immunosupp.,V1 zoster w/ any ophthalmic s/s, etc).
‚Ä¢ Prevention: vaccine approved for Pts 60 y (T lifetime risk from 20% to 10%, also T PHN)
ENCEPHALITIS
6-11

--- Fim da P√°gina 175 ---

ENDOCARDITIS
6-12
BACTERIAL ENDOCARDITIS
Definition
‚Ä¢ Infection of endothelium of heart (including but not limited to the valves) 
‚Ä¢ Acute (ABE): infection of normal valves with a virulent organism (eg, S. aureus, group
A or other beta-hemolytic strep, Strep pneumo)
‚Ä¢ Subacute (SBE): indolent infection of abnl valves w/ less virulent organism (eg, S. viridans)
Predisposing conditions
‚Ä¢ Abnormal valve
high-risk: prior endocarditis, rheumatic valvular disease,AoV disease (incl. bicuspid),
complex cyanotic lesions, prosthesis (annual risk 0.3‚Äì1%)
medium-risk: MV disease (including MVP w/ MR or leaflet thickening), HCMP
‚Ä¢ Abnormal risk of bacteremia: IVDU, indwelling venous catheters, poor dentition,
hemodialysis, DM, intracardiac devices (eg, pacemaker, ICD)
Modified Duke Criteria
Major
Minor
‚Ä¢ Sustained bacteremia by an organism 
‚Ä¢ Predisposing condition (see above)
known to cause endocarditis (or 1 BCx
‚Ä¢ Fever
or  serology for Coxiella)*
‚Ä¢ Vascular phenomena: septic arterial
‚Ä¢ Endocardial involvement document by
or pulmonary emboli, mycotic
either  echocardiogram (vegetation,
aneurysms, ICH, Janeway lesions
abscess, prosthetic dehiscence)
‚Ä¢ Immune phenomena:  RF, GN,
or new valvular regurgitation
Osler‚Äôs nodes, Roth spots
‚Ä¢  blood cx not meeting major criteria
Definitive (ie, highly probable): 2 major or 1 major  3 minor or 5 minor criteria
Possible: 1 major  1 minor or 3 minor criteria
Se 90%, Sp 95%. NPV 92% (CID 2000;30:633). *Serologic or molecular tests for other known agents
of culture  endocarditis (see below) not yet included as major criterion, but may be dx.
Microbiology of Endocarditis
Native valve endocarditis
Prosthetic valve
(NVE)
endocarditis (PVE)
Early
Late
Etiology
Non-IVDA
IVDA
(60 d post)
(60 d post)
S. viridans et al.
36%
13%
5%
20%
Enterococcus
11%
5%
8%
13%
S. aureus
28%
68%
36%
20%
S. epidermidis
9%
5%
17%
20%
GNR
5%
5%
6%
5%
Other
5%
5%
10%
10%
Culture 
11%
5%
17%
12%
Culture   nutritionally-deficient streptococci,HACEK (Haemophilus parainfluenzae & aphrophilus,
Actinobacillus,Cardiobacterium,Eikenella,and Kingella),Bartonella,Coxiella,Chlamydia,Legionella,Brucella
(JAMA 2007;297:1354; Annals 2007;147:829; Archives 2009;169:463)
Clinical manifestations (Archives 2009;169:463)
‚Ä¢ Persistent bacteremia: fever (80‚Äì90%), chills, night sweats, anorexia, wt loss, fatigue
‚Ä¢ Valvular or perivalvular infection: CHF, conduction abnormalities
‚Ä¢ Septic emboli: systemic emboli (eg, to periphery, CNS, kidneys, spleen, or joints), stroke,
pulmonary emboli (if right-sided), mycotic aneurysm, MI (coronary artery embolism)
‚Ä¢ Immune complex phenomena: arthritis, glomerulonephritis,  RF, c ESR
Physical exam
‚Ä¢ HEENT: Roth spots (retinal hemorrhage  pale center), petechiae (conjunctivae, palate)
‚Ä¢ Cardiac: murmur (85%), new valvular regurgitation (40‚Äì85%)  thrill (fenestrated valve
or ruptured chordae), muffled prosthetic valve sounds. Frequent exams for 	 murmurs.
‚Ä¢ Abdomen: tender splenomegaly
‚Ä¢ Musculoskeletal: arthritis, vertebral tenderness
‚Ä¢ Extremities (typically seen in SBE, not ABE)
Janeway lesions (septic emboli S nontender, hemorrhagic macules on palms or soles)
Osler‚Äôs nodes (immune complexes S tender nodules on pads of digits)
proximal nail bed splinter hemorrhages (8‚Äì15%); petechiae (33%); clubbing
‚Ä¢ Neuro: 	 MS or focal deficits
‚Ä¢ Devices: erythema, tenderness, or drainage at catheter site, PM/ICD pocket tenderness

--- Fim da P√°gina 176 ---

Diagnostic studies
‚Ä¢ Blood cultures (before abx): at least 3 sets (aerobic & anaerobic bottles) from dif-
ferent sites, ideally spaced 1 h apart. ‚úìBCx (at least 2 sets) after appropriate abx
have been initiated to document clearance; repeat q24‚Äì48h until .
‚Ä¢ CBC w/ diff (cWBC common in ABE; anemia in 90% SBE), ESR, RF, BUN/Cr, U/A & UCx
‚Ä¢ ECG (on admission and at regular intervals) to assess for new conduction abnormalities
‚Ä¢ Echocardiogram: obtain TTE if low clinical suspicion, expect good image quality;
TEE if (i) mod-to-high clinical suspicion, (ii) high-risk Pt (prosthetic valve, prior IE,
CHD), (iii) TTE nondx, (iv) TTE  but endocarditis strongly suspected, or (v) sus-
pect progressive or invasive infection (eg, persistent bacteremia or fever, new con-
duction abnl, intracardiac shunt, etc.) (Circ 2005;111:e394)
Method
Sensitivity
NVE
PVE
Abscess
Transthoracic (TTE)
50‚Äì65%
36‚Äì69%
28‚Äì36%
Transesophageal (TEE)
90%
90%
80‚Äì87%
(EHJ 1999;20:232; J Am Soc Echo 2003;16:67; Heart 2004;90:614)
‚Ä¢ Culture  endocarditis: may be due to abx prior to BCx. Detailed hx: animal expo-
sure, travel, unpasteurized dairy, etc. Seek ID eval (Med 2005;84:162; NEJM 2007;356:715).
Treatment
‚Ä¢ Obtain culture data first
ABE S abx should be started promptly after culture data obtained
SBE S if Pt hemodynamically stable, abx may be delayed to properly obtain adequate
BCx data, especially in the case of prior abx Rx
‚Ä¢ Suggested empiric therapy (Circ 2005;111:394)
native valve ABE: vanco  gent 
native valve SBE: ceftriaxone (or amp if ? enterococcus; eg, older  or ob/gyn)  gent
PVE: early (60 d): vanco  cefepime  gent; intermediate (60‚Äì365 d): vanco 
gent; late (1 y): vanco  ceftriaxone  gent
native or prosthetic valve, culture : depends on host & epi, seek ID consultation
‚Ä¢ Adjust abx regimen and duration based on valve (NVE vs. PVE), organism, & sensitivities 
‚Ä¢ Repeat BCx qd until Pt defervesces and BCx ; usually 2‚Äì3 d
‚Ä¢ Fever may persist up to 1 wk after appropriate abx therapy instituted or in setting of
metastatic sites of infection
‚Ä¢ Systemic anticoagulation relatively contraindicated given risk of hemorrhagic
transformation of cerebral embolic strokes (however, in absence of cerebral emboli, can
continue anticoagulation for pre-existing indication)
‚Ä¢ Monitor for complications of endocarditis (CHF, conduction block, new emboli, etc.)
and complications of abx therapy (interstitial nephritis, renal failure, neutropenia, etc.)
‚Ä¢ Duration of Rx: usually 4‚Äì6 wks. With NVE & sx 3 mos S 4 wks of abx; sx 3
mos S 6 wks. Uncomplicated right-sided NVE S 2 wks may be comparable. 2‚Äì3
wks of aminoglycoside ? ‚âà4 wks for native valve enterococcus (CID 2002;34:159).
Indications for surgery (EHJ 2009;30:2369; Circ 2010;121:1005 & 1141)
‚Ä¢ Try for as many days of abx as possible, in hopes of T incidence of recurrent infec-
tion in prosthesis, as well as to improve structural integrity of tissue that will
receive prosthesis
‚Ä¢ Severe valvular dysfunction S refractory CHF: emergent if refractory cardio-
genic shock (ie, despite ICU-level Rx); urgent (w/in days) if persistent refractory
HF; elective (w/in wks) if asx severe AI or MR or PVE w/ dehiscence
‚Ä¢ Uncontrolled infxn (urgent surgery w/in days indicated): periannular abscess
(10‚Äì40% NVE, 60‚Äì100% PVE), fistula, worsening conduction, c veg. size, or persis-
tent sepsis (eg,  BCx (? or fever) after 1 wk of appropriate IV abx and no
drainable metastatic focus or other identifiable cause); also consider for S. aureus,
fungal or multiresistant organisms
‚Ä¢ Systemic embolism (20‚Äì50%): L-sided w/ despite approp. abx, either recurrent emboli,
10 mm veg. & prior embolic event, or 15 mm veg.; risk of embolism 4.8/1000 Pt
days in 1st wk, 1.7/1000 Pt days thereafter; cerebral emboli no longer considered 
contraindic to surgery unless hemorrhage (then ideally wait 1 mo) or severe stroke 
‚Ä¢ PVE, especially with valve dysfunction or dehiscence or S. aureus or GNR infection
Prognosis
‚Ä¢ NVE: non-IVDU S. aureus S 30‚Äì45% mortality; IVDU S. aureus (typically right-sided)
S 10‚Äì15% mortality; SBE S 10‚Äì15% mortality 
‚Ä¢ PVE S 23% mortality
‚Ä¢ Aortic valve worse prognosis than mitral valve
ENDOCARDITIS
6-13

--- Fim da P√°gina 177 ---

Endocarditis Prophylaxis
Cardiac
Prosthetic valve; previous NVE; congenital heart disease (CHD) 
conditions*
including unrepaired or incompletely repaired cyanotic CHD (palliative 
shunts or conduits), 1st 6 mos after completely repaired CHD using 
prosthetic material; cardiac transplant recipients w/ valvulopathy
(Prophylaxis no longer rec. in acquired valvular dysfxn,
bicuspid AoV, MVP with leaflet thickening or regurgitation, HCMP)
Procedures*
Dental: that involve manipulation of gingival tissue or periapical region
of teeth or perforation of oral mucosa (eg, extractions, periodontal
procedures, implants, root canal, cleanings)
Respiratory: incision or biopsy of respiratory mucosa
(Prophylaxis no longer rec. for GI or GU procedures)
Regimens
Oral: amoxicillin 2 g 30‚Äì60 min before
Unable to take PO: amp 2 g IM/IV or cefazolin or cftx 1 g IM/IV
PCN-allergic: clindamycin 600 mg PO/IM/IV
*Pts should meet both indications (conditions and procedure) to qualify for prophylaxis. (Circ 2007;116:1736)
BACTEREMIA
Etiologies
‚Ä¢ 1
 infxn due to direct inoculation of the blood, frequently assoc. w/ intravascular catheters.
Catheter-related bloodstream infection  same org from peripheral cx and (cath
tip cx or cx drawn from catheter) (CID 2009;49:1).
‚Ä¢ 2
 infxn due to infection in another site (eg, UTI, lung, biliary tree, skin) spreading to blood
Microbiology
‚Ä¢ 1
 infxn/indwelling catheters (CID 2004;39:309): coagulase-neg staphylococci (includes 
S. epidermidis and others) 31%, Staphylococcus aureus 20%, enterococci 9%, Candida
species 9%, E. coli 6%, Klebsiella species 5%
‚Ä¢ 2
 infxn: dependent on source
Risk factors for true bacteremia (JAMA 1992;267:1962)
‚Ä¢ Pt: fever, shaking chills, IVDU, major comorbidities, immunosupp, indwelling catheter
‚Ä¢ Organism
higher risk: S. aureus, -hemolytic strep, enterococci, GNR, S. pneumonia, Neisseria
lower risk: coag-neg staph (10%), diphtheroids, & Propionibacterium (0%)
‚Ä¢ Time to growth: 24 h S higher risk, 72 h S lower risk (except for slow-
growing organisms such as HACEK group)
‚Ä¢ Confirmatory cultures: draw prior to first abx dose in stable Pts if possible
‚Ä¢ Factors favoring endocarditis: bacteremia that is high-grade w/o identifiable source, per-
sisting after line removal or drainage of focal source, in hosts at risk for endocarditis, or
w/ organisms known to cause IE (Duke criteria); emboli
Treatment
‚Ä¢ 1
 infxn: antibiotics based on Gram stain/culture results; tailor abx to sensitivities
empiric therapy for GPC: vanco to cover coag-neg staph and MRSA while awaiting sensi
Short-Term Central Venous Catheter-Related Blood Stream Infections* (CID 2009;49:1)
S. aureus
Risk of endocarditis in bacteremia: 25% (JACC 1997;30:1072)
D/c catheter,TEE to r/o endocarditis; if echo  and not immunosupp 
and no intravasc prosthesis, Rx  2 wks from first  BCx. If no echo 
obtained, Rx  4‚Äì6 wks.
Preferred abx: MSSA S nafcillin or oxacillin; MRSA S vancomycin
Coag-neg
May consider keeping catheter. Catheter retention does not T rate of 
staphylococci
bacteremia resolution, but a/w c rate of recurrence (CID 2009;49:1187).
If catheter left in place, Rx  10‚Äì14 d and consider antibiotic lock Rx 
(instill high-concentration abx into catheter lumen for hrs to days)
If catheter d/c, Rx  5‚Äì7 d
Enterococcus
D/c catheter & Rx  7‚Äì14 d 
GNR
D/c catheter & Rx  7‚Äì14 d.Abx based on suscept.
Fungi
D/c catheter & Rx  14 d from first  BCx
*Complicated infections w/ suppurative thrombophlebitis, osteomyelitis, or endocarditis require longer treatment 
‚Ä¢ 2
 infxn: assess for primary source of infection and treat underlying infection. Source
control essential when possible for cure and preventing recurrent infection.
‚Ä¢ Persistently  BCx: d/c indwelling catheters, consider metastatic infxn, infected
thrombosis or infected prosthetic material (joint, vascular graft, pacemaker, etc.)
ENDOCARDITIS
6-14

--- Fim da P√°gina 178 ---

TB
6-15
TUBERCULOSIS
Epidemiology
‚Ä¢ U.S.: 10‚Äì15 million infected (10 c risk if foreign-born or minority); worldwide: 2 billion 
‚Ä¢ After resurgence in U.S. 1984‚Äì1992, rates have declined, though slower than CDC goals
‚Ä¢ Pt is more likely to develop TB disease if:
High-prevalence populations (more likely to be exposed to & infected w/ bacillus):
immigrant from high-prevalence area, homeless or medically underserved, resident or
worker in jail or long-term facility, HCW at facility w/ TB, close contact to Pt w/ active TB
High-risk populations (more likely to progress from infxn S active disease): HIV 
or other immunosupp, chronic renal failure, DM, organ Tx, IVDU, EtOH, mal-
nourished, malignancy, gastrectomy, on biologics (eg,TNF inhibitors, rituximab)
Microbiology and natural history
‚Ä¢ Transmission of Mycobacterium tuberculosis via small-particle aerosols (ie, droplet nuclei)
‚Ä¢ 90% of infected normal hosts will never develop clinically evident disease, 10% will 
‚Ä¢ Localized disease: healing & calcification or progressive 1
 TB (at site of infection)
‚Ä¢ Hematogenous spread: latent infection  reactivation TB or progressive disseminated TB
‚Ä¢ Two-thirds of clinically evident disease in U.S. due to reactivation
Screening for prior infection
‚Ä¢ Whom to screen: high-prevalence and high-risk populations (HIV  Pts should
have PPD testing as part of initial evaluation and annually thereafter)
‚Ä¢ How to screen: Mantoux tuberculin test (ie, purified protein derivative or PPD)
inject 5-TU (0.1 mL) intermed. strength PPD intradermally S wheal; examine 48‚Äì72 h
‚Ä¢ How to interpret PPD: determine max diameter of induration by palpation
Size of reaction
Persons considered to have  test
5 mm
HIV  or immunosupp (eg, prednisone 15 mg/d  1 mo)
Close contacts with Pt w/ active TB; CXR w/ apical fibrosis c/w TB
10 mm
All other high-risk or high-prevalence populations
Recent conversion (c in induration by 10 mm in last 2 y)
15 mm
Everyone else
False 
Faulty application, anergy (including from active TB), acute TB 
(2‚Äì10 wk to convert), acute non-TB infections, malignancy
False 
Improper reading, cross-reaction with nontuberculous mycobacteria
(NTM), BCG vaccination (although usually 10 mm by adulthood)
Booster effect
c induration due to immunologic boost by prior skin test in previously
sensitized individual (by TB or NTM, or BCG).Test goes from  S 
but does not represent true conversion due to recent infection. 2nd 
test is Pt‚Äôs true baseline. Can be 1 y after initial test.
(NEJM 2002;347:1860)
‚Ä¢ IFN- release assays (IGRA): (Ag-stimulated IFN- release from Pt‚Äôs T-cells): may
be used for screening where you would use PPD; may have c Sp, esp in BCG Rx‚Äôd
Pts (Annals 2008;149:177). Relies on host immune fxn, so Se still limited in immuno-
supp. Lack of gold standard for latent TB infxn compromises Se/Sp estimates (J Clin
Epi 2010;63:257). One-step test, but more expensive than PPD.
Clinical manifestations
‚Ä¢ Primary TB pneumonia: middle or lower lobe consolidation,  effusion,  cavitation
‚Ä¢ TB pleurisy: can occur w/ primary or reactivation. Due to breakdown of granuloma
w/ spilling of contents into pleural cavity and local inflammation. Pulmonary
effusion  pericardial and peritoneal effusions (tuberculous polyserositis).
‚Ä¢ Reactivation TB pulmonary dis.: apical infiltrate  volume loss  cavitation
‚Ä¢ Miliary TB: acute or insidious; due to widespread hematogenous dissemination; usu-
ally in immunosupp, DM, EtOH, elderly or malnourished. Constitutional sx
(fever, night sweats, weight loss) usually prominent. Pulm disease w/ small millet
seed‚Äìlike lesions (2‚Äì4 mm) on CXR or chest CT (latter more Se), present in
60‚Äì80% of those w/ miliary TB.
‚Ä¢ Extrapulmonary TB: lymphadenitis, pericarditis, peritonitis, meningitis, nephritis  sterile
pyuria, osteomyelitis (vertebral  Pott‚Äôs disease), hepatitis, splenitis, cutaneous, arthritis
‚Ä¢ TB and HIV: HIV-infected & other immunosupp Pts at c risk for infxn, progressive 1
infxn, and reactivation. Risk of progression from infxn to disease 8‚Äì10%/y. Can occur at
any CD4 count, but more likely to disseminate at lower CD4 counts. Reinfection (includ-
ing w/ drug-resistant strains) is clinically significant, particularly in hyperendemic areas.
‚Ä¢ Multi-drug resistant (MDR) TB: resistant to isoniazid (INH) and rifampin (RIF)
‚Ä¢ Extensively drug resistant (XDR) TB: resistant to INH, RIF, quinolone, & 2nd-line injectables

--- Fim da P√°gina 179 ---

Diagnostic studies for active TB (high index of suspicion is key!)
‚Ä¢ Acid-fast smear (rapid dx) and culture (c Se and allows susceptibility testing) of
sputum, bronchoscopic alveolar lavage, pleura, or other clinical specimens; avoid FQ
if considering dx of TB, as they can compromise dx yield
‚Ä¢ PCR: 94‚Äì97% Se c/w smear; 40‚Äì77% Se c/w culture (JAMA 2009;301:1014)
‚Ä¢ CXR: classically fibrocavitary apical disease in reactivation vs. middle & lower lobe
consolidation in 1
 TB, but distinction imperfect and HIV  strongly assoc. with non-
apical disease, regardless of timing (JAMA 2005;293:2740)
‚Ä¢ Adenosine deaminase (ADA): useful in extrapulmonary sites, best validated for ascites
Preventive therapy (JAMA 2005;293:2776; Annals 2009;150:ITC6-1)
‚Ä¢ Appropriate prophylaxis reduces incidence of subsequent disease by 65‚Äì75%
‚Ä¢ Treat Pts who are  based on screening guidelines listed above, or any exposed HIV  Pt
‚Ä¢ R/O active disease in any Pt w/ suggestive s/s before starting INH. If HIV , routinely ask
if cough, fever, or night sweats; if yes S ‚úìsputum smear, CXR, CD4 (NEJM 2010;362:707).
Scenario
Regimen
Likely INH-sensitive
INH 300 mg PO qd  pyridoxine 25 mg PO qd  6‚Äì9 mo
HIV 
INH 300 mg PO qd  pyridoxine 25 mg PO qd  9 mo
Contact case INH-resistant
RIF  4 mo
Contact case known or
No proven regimen: ? PZA  EMB, ? PZA  FQ
suspected to have MDR TB
(INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; FQ, fluoroquinolone)
‚Ä¢ Monitor for hepatitis: if aminotransferases 5 normal (risk c w/ age; Chest 2005;128:116)
or symptomatic S d/c current anti-TB meds and reevaluate
Treatment of active tuberculosis (JAMA 2005;293:2776; Annals 2009;150:ITC6-1)
‚Ä¢ Isolate Pt
‚Ä¢ Use multiple drugs to which organism susceptible (see below); consult ID specialist before
empiric Rx for possible MDR-TB (suspect if prior TB Rx, from or travel to area w/ high
rates of MDR-TB, exposure to person w/ likely MDR-TB, poor Rx adherence, ? HIV)
‚Ä¢ Promote adherence to Rx; directly observed Rx cost effective if high risk for nonadherence
‚Ä¢ Obtain monthly smears/cx on treatment until 2 consecutive are  for TB
‚Ä¢ Monthly clinical evaluation to monitor for Rx response and adverse drug rxns
‚Ä¢ Screen for HIV in all Pts in whom initiating anti-TB Rx; if indicated, should initiate
HIV Rx concurrently (NEJM 2010;362:697)
‚Ä¢ Paradoxical worsening of sx can occur after starting Rx. More common w/ extrapulm TB 
(eg, tuberculoma, LAN), likely due to hypersensitivity response to killing of bacilli. More
frequent/severe w/ concurrent immune reconstitution (eg, HIV  Pts started on ARVs,
Pts taken off immunosuppressants, etc). Must r/o treatment failure (repeat Cx, imaging, etc).
Antituberculous Medications
Drug
Dose
Adverse effects*
Isoniazid (INH)
300 mg PO qd
Hepatitis, periph neuropathy (risk T by 
concomitant vit B6), lupus-like synd.
Rifampin (RIF)
600 mg PO qd
Orange discoloration of urine/tears, GI 
upset, hepatitis, hypersensitivity, fever
Pyrazinamide (PZA)
25 mg/kg PO qd
Hepatitis, hyperuricemia, arthritis
Ethambutol (EMB)
15‚Äì25 mg/kg PO qd
Optic neuritis
Streptomycin (SM)
15 mg/kg IM qd
Ototoxicity, nephrotoxicity
Amikacin (AMK)
15 mg/kg IM qd
Ototoxicity, nephrotoxicity
Quinolone (moxifloxacin)
400 mg PO qd
GI upset
*Risk of hepatitis c w/ pre-existing liver disease. Consult ID specialist if moderate to severe liver disease,
and consider withholding or replacing PZA or INH.
Antituberculous Regimens*
Scenario
Regimen
Pulmonary TB
INH  RIF  PZA  (EMB) until suscept. known
4% INH-resist. in
If sensitive to INH & RIF S INH  RIF  PZA  2 mos,
community
then S INH  RIF  4 mos
(includes most of U.S.)
If resistant, see next row
Drug-resistant TB
Consult ID specialist
(INH-R, RIF-R, or MDR/XDR)
(NEJM 2008;359:636)
Extrapulmonary TB
Consult ID specialist
TB in HIV  patient
Consult ID specialist
*Individualize duration based on host, disease form, and rate of clinical/microbiologic improvement.
TB
6-16

--- Fim da P√°gina 180 ---

HIV/AIDS
6-17
HIV/AIDS
Definition
‚Ä¢ AIDS: HIV  CD4 count 200/mm3 or opportunistic infection (OI) or malignancy
Epidemiology
‚Ä¢ 1 million Americans infected w/ HIV; 6th leading cause of death in 25‚Äì44 y-old age group 
‚Ä¢ 33.4 million individuals infected worldwide
‚Ä¢ Routes: sexual (risk is 0.3% for male-to-male, 0.2% for male-to-female, 0.1% for female-to-
male transmission), IVDA, transfusions, needle sticks (0.3%), vertical (15‚Äì40% w/o ARV)
‚Ä¢ Postexposure (risk infxn 0.3%) ppx: 2 NRTIs ( PI or NNRTI if high-risk)  4 wks 
Acute retroviral syndrome (ARS)
‚Ä¢ Occurs in 40‚Äì90% of Pts 2‚Äì6 wks after infxn;  ELISA,  viral load (2 wks after infxn)
‚Ä¢ Mononucleosis-like syndrome (c incid mucocut. & neuro manifestations c/w EBV or CMV)
Diagnostic studies
‚Ä¢ ELISA for HIV-1 Ab:  1‚Äì12 wks after acute infection; 99% Se; 1
 screen test
‚Ä¢ Western blot:  if 2 bands from diff regions of HIV genome; 99% Sp; confirmatory
after  ELISA
‚Ä¢ Rapid preliminary tests: 4 Ab tests; use saliva, plasma, blood, or serum; 99% Se &
96‚Äì99% Sp (Annals 2008;149:153); PPV in low prev populations as low as 50% 
‚Ä¢ PCR (viral load): detects HIV-1 RNA in plasma; assay range is 48‚Äì10 million copies/mL
2% false , but usually low # copies; in contrast, should be very high (750 k) in 1
 infxn
‚Ä¢ When testing, obtain informed consent for ELISA,Western, and PCR
‚Ä¢ HIV screening is recommended for all Pts in all health care settings (MMWR Sept 22, 2006)
‚Ä¢ CD4 count: not a dx test per se, as may be HIV  and have a normal CD4 count or
may have a low CD4 count and not be HIV ; many other illnesses impact CD4 count
Initial approach to HIV  Pt
‚Ä¢ Document HIV infection (if adequate documentation is not available, repeat dx studies)
‚Ä¢ H&P (mucocutaneous, neurocognitive issues, OIs, malignancies, STDs); review all
ARVs and other meds
‚Ä¢ Lab evaluation: CD4 count, viral load, HIV genotype, CBC w/ diff., Cr, lytes, LFTs, fasting
glc and lipids; PPD or IGRA, syphilis serology; toxoplasmosis & CMV IgG; HAV, HBV, &
HCV serologies; Chlamydia & gonorrhea screening; baseline CXR; Pap smear in 
Antiretrovirals (ARVs)
Drugs
Side Effects
abacavir (ABC; Ziagen)
Class: GI intol. common (less w/ 3TC,ABC,TDF)
didanosine (ddI;Videx)
lipoatrophy (less w/ 3TC,ABC, FTC,TDF)
emtricitabine (FTC; Emtriva)
lactic acidosis (less w/ 3TC,ABC, FTC,TDF)
lamivudine (3TC; Epivir)
ABC: hypersensitivity (3%), ‚úìHLA-B*5701
stavudine (d4T; Zerit)
AZT: BM suppression (esp macrocytic anemia)
tenofovir (TDF;Viread)
ddI & d4T: peripheral neuropathy & pancreatitis
zidovudine (AZT; Retrovir)
ddI & ABC: MI (Lancet 2008;371:1417)
TDF: acute or chronic renal insufficiency
delaverdine (DLV; Rescriptor)
Class: rash, hepatitis, mixed CYP450 inducer/inhib 
efavirenz (EFV; Sustiva)
EFV: CNS effects (incl depression)
etravirine (ETR; Intelence)
ETR: rare hypersensitivity
nevirapine (NVP;Viramune)
NVP: rash and hypersensitivity [risk factors are
female, CD4 250, pregnancy (‚à¥avoid)]
amprenavir (APV;Agenerase)
Class: GI intolerance
atazanavir (ATV; Reyataz)
inhibit CYP450 (‚à¥caution w/ simva & lovastatin)
darunavir (DRV; Prezista)
type II DM
fosamprenavir (FPV; Lexiva)
hepatotoxicity
indinavir (IDV; Crixivan)
truncal obesity; hyperlipidemia (less w/ ATV)
lopinavir/riton. (LPV/r; Kaletra)
MI (NEJM 2007;356:1723)
nelfinavir (NFV;Viracept)
IDV,ATV: crystalluria S nephrolithiasis
ritonavir (RTV; Norvir)
DRV: rash (10%)
saquinavir (SQV; Invirase)
DRV & TPV: possible sulfa cross-reactivity
tipranavir (TPV;Aptivus)
enfurvitide (T20; Fuzeon)
injection site reaction
maraviroc (MVC; Selzentry)
dizziness, hepatotoxicity
raltegravir (RAL; Isentress)
GI intol, CPK elevation
NRTI, nucleoside/tide reverse transcriptase inhibitor; NNRTI, nonnucleoside RTI; PI, protease inhibitor;
FI, fusion inhibitor; EI, entry inhibitor (CCR5 antagonist); II, integrase inhibitor
II EI FI
PI
NNRTI
NRTI

--- Fim da P√°gina 181 ---

‚Ä¢ ARVs should be given in consultation w/ HIV specialist as recommendations continue
to be in flux, and drug resistance and adverse reactions can be complicated to manage 
‚Ä¢ Indications for initiation of ARVs (DHHS guidelines Dec 1, 2009; http://aidsinfo.nih.gov)
AIDS-defining illness or CD4 350/mm3 (also gen rec. at 350‚Äì500/mm3, 
NEJM 2009;360:1815) or pregnancy, HIV-assoc. nephropathy, HBV co-infxn requiring Rx,
or HIV-assoc. sx (systemic, neurocognitive, mucocutaneous, etc.) 
‚Ä¢ Genotypic resistance testing recommended for all Pts in U.S. starting ARV
‚Ä¢ Regimens for treatment-na√Øve Pts (DHHS guidelines Dec 1, 2009; http://aidsinfo.nih.gov)
[NNRTI  2 NRTI] or [PI ( low-dose ritonavir)  2 NRTI] or [II  2 NRTI]
efavirenz  tenofovir  emtricitabine (NEJM 2006;354:251; 2008;358:2095; 2009;361:2230)
ritonavir-boosted atazanavir  tenofovir  emtricitabine
ritonavir-boosted darunavir  tenofovir  emtricitabine
raltegravir  tenofovir  emtricitabine (NEJM 2008;359:339; Lancet 2009;374:796)
‚Ä¢ Maraviroc (EI) under study in na√Øve & Rx‚Äôd Pts, ‚úìCCR5 tropism assay (NEJM 2008;359:1429)
‚Ä¢ Viral load should T 1 log copies/mL 2‚Äì8 wks after starting and be undetectable by
12‚Äì24 wks
‚Ä¢ Initiation of ARVs may transiently worsen existing OIs for several wks b/c c
immune response (immune reconstitution inflammatory syndrome or IRIS)
‚Ä¢ If Rx needs to be interrupted, stop all ARVs to minimize development of resistance
‚Ä¢ Failing regimen  unable to achieve undetectable viral load, c viral load, T CD4 count, or
clinical deterioration (with detectable viral load consider genotypic or phenotypic assay)
OI Prophylaxis (MMWR March 24, 2009)
OI
Indication
1 Prophylaxis
Tuberculosis
 PPD (5 mm) or IGRA
INH  vitamin B6  9 mo
or high-risk exposure
Pneumocystis
CD4 count 200/mm3 or
TMP-SMX DS or SS qd or DS tiw or
jiroveci
CD4% 14% or thrush
dapsone 100 mg qd or
atovaquone 1500 mg qd or
pentamidine 300 mg inh q4wk
Toxoplasmosis
CD4 count 100/mm3 and
TMP-SMX DS qd or
 Toxoplasma serology
dapsone 50 mg qd  pyrimethamine
50 mg qwk  leucovorin 25 qwk
MAC
CD4 count 50/mm3
azithro 1200 mg qwk or
clarithro 500 mg bid
Stop 1
 prophylaxis if CD4 initiation threshold 3‚Äì6 mo on ARVs
Stop 2
 prophylaxis (maintenance therapy of existing OI; drugs and doses differ for
different OIs) if there has been clinical resolution or stabilization and CD4 thresholds
have been exceeded  3‚Äì6 mo
COMPLICATIONS OF HIV/AIDS
CD4 count
Complications
500
Constitutional symptoms
Mucocutaneous: Kaposi‚Äôs sarcoma; seborrheic dermatitis; oral hairy 
leukoplakia; lymphoma; oral, esophageal, & recurrent vaginal 
candidiasis; HSV;VZV
Recurrent bacterial infections
TB (pulmonary and extrapulmonary)
200
Pneumocystis jiroveci pneumonia (PCP), Toxoplasma, Bartonella
Cryptococcus, Histoplasma, Coccidioides
50‚Äì100
CMV, MAC
Invasive aspergillosis, bacillary angiomatosis (disseminated Bartonella)
CNS lymphoma, PML
Fever
‚Ä¢ Etiologies (Infect Dis Clin North Am 2007;21:1013)
infxn (82‚Äì90%): MAC, TB, CMV, early PCP, histoplasmosis, cryptococcosis,
coccidioidomycosis, toxoplasmosis, endocarditis
noninfectious: lymphoma, drug reaction
‚Ä¢ Workup: guided by CD4 count, s/s, epi, & exposures
CBC, chem, LFTs, BCx, CXR, UA, mycobact. & fungal cx, ‚úìmeds, ? ‚úìchest & abd CT
CD4 100‚Äì200 S serum cryptococcal Ag, LP, urinary Histo Ag, CMV PCR or antigenemia
pulmonary s/s S CXR;ABG; sputum for bacterial cx, PCP,AFB; bronchoscopy
diarrhea S stool for fecal leuks, culture, O&P, AFB; endoscopy
abnormal LFTs S abd CT, liver bx
cytopenias S BM bx (include aspirate for culture)
HIV/AIDS
6-18

--- Fim da P√°gina 182 ---

Cutaneous
‚Ä¢ Seborrheic dermatitis; eosinophilic folliculitis; HSV & VZV infections; prurigo nodu-
laris; scabies; cutaneous candidiasis; eczema; psoriasis; cutaneous drug eruptions
‚Ä¢ Dermatophyte infections: proximal subungual onychomycosis (onychomycosis starting at
nail bed) virtually pathognomonic for HIV
‚Ä¢ Molluscum contagiosum (poxvirus): 2‚Äì5 mm pearly papules w/ central umbilication
‚Ä¢ Kaposi‚Äôs sarcoma (KSHV or HHV8): red-purple nonblanching nodular lesions
‚Ä¢ Bacillary angiomatosis (disseminated Bartonella): friable violaceous vascular papules
‚Ä¢ Warts (HPV infection)
‚Ä¢ c rates of MRSA skin & soft tissue infections
Ophthalmologic
‚Ä¢ CMV retinitis (CD4 count usually 50); Rx: ganciclovir, valganciclovir, ganciclovir
ocular insert, foscarnet, or cidofovir (also HZV,VZV)
Oral
‚Ä¢ Aphthous ulcers
‚Ä¢ Thrush (oral candidiasis): typically associated with burning or pain.Types:
exudative (curdlike patches that reveal raw surface when scraped off),
erythematous (erythema without exudates),
atrophic
‚Ä¢ Oral hairy leukoplakia: painless proliferation of papillae. Caused by EBV but not
precancerous; adherent white coating usually on lateral tongue.
‚Ä¢ Kaposi‚Äôs sarcoma
Cardiac
‚Ä¢ Dilated CMP; PHT; PI S c risk of MI (NEJM 2007;356:1723; JID 2010;201:318)
Pulmonary
Radiographic pattern
Common causes
Normal
Early P. jiroveci (PCP)
Diffuse interstitial infiltrates
P. jiroveci, TB, viral or disseminated fungal PNA
Focal consolidation or masses
Bacterial or fungal PNA,TB, Kaposi‚Äôs sarcoma
Cavitary lesions
TB, aspergillosis, and other fungal PNA
Bacterial PNA (including MRSA, Nocardia, and
Rhodococcus)
Pleural effusion
TB, bacterial or fungal PNA
Kaposi‚Äôs sarcoma, lymphoma
‚Ä¢ Pneumocystis jiroveci (PCP) pneumonia (CD4 200)
constitutional sx, fever, night sweats, dyspnea on exertion, nonproductive cough
CXR w/ interstitial pattern, T PaO2, c A-a ‚àá, c LDH,  PCP sputum stain,  beta-glucan
Rx if PaO2 70: TMP-SMX 15‚Äì20 mg of TMP/kg, divided tid, avg dose  DS 2
tabs PO tid or [TMP 5 mg/kg PO tid  dapsone 100 mg PO qd] or [clindamycin 
primaquine] or atovaquone
Rx if PaO2 70 or A-a gradient 35: prednisone (40 mg PO bid, then T after 5 d; start
before TMP/SMX; NEJM 1990;323:1444); TMP-SMX 15‚Äì20 mg of TMP/kg IV divided q8h
or [clindamycin  primaquine] or pentamidine or [trimetrexate  leucovorin]
Gastrointestinal
‚Ä¢ Esophagitis: Candida, CMV, HSV, aphthous ulcers, pill-induced
upper endoscopy if no thrush or unresponsive to empiric antifungal therapy
‚Ä¢ Enterocolitis
bacterial (usually acute): Salmonella, Shigella, Campylobacter, Yersinia, C. difficile
protozoal (usually chronic): Giardia, Entamoeba, Cryptosporidium, Isospora,
Microsporidium, Cyclospora
viral (CMV, adenovirus); fungal (histoplasmosis); MAC; AIDS enteropathy
‚Ä¢ GI bleeding: CMV, Kaposi‚Äôs sarcoma, lymphoma, histo
‚Ä¢ Proctitis: HSV, CMV, Chlamydia (lymphogranuloma venereum), N. gonorrhoeae
Hepatobiliary
‚Ä¢ Hepatitis: HBV, HCV, CMV, MAC, drug-induced
‚Ä¢ AIDS cholangiopathy: often in a/w CMV or Cryptosporidium or Microsporidium
Renal
‚Ä¢ HIV-associated nephropathy (collapsing FSGS); nephrotoxic drugs
HIV/AIDS
6-19

--- Fim da P√°gina 183 ---

Hematologic
‚Ä¢ Anemia:ACD, BM infiltration by infxn or tumor, drug toxicity, hemolysis
‚Ä¢ Leukopenia
‚Ä¢ Thrombocytopenia: bone marrow involvement, ITP
‚Ä¢ c Globulin
Oncologic
‚Ä¢ Non-Hodgkin‚Äôs lymphoma: c frequency regardless of CD4 count, but incidence c
as CD4 count T
‚Ä¢ CNS lymphoma: CD4 count 50, EBV-associated
‚Ä¢ Kaposi‚Äôs sarcoma (HHV-8): can occur at any CD4 count, but incidence c as CD4 count T
usually occurs in MSM
mucocutaneous: red-purple nodular lesions
pulmonary: nodules, infiltrates, effusions, LAN
GI: GI bleeding, obstruction, obstructive jaundice
Rx: limited disease S alitretinoin gel, XRT, cryo, or intralesional vinblastine;
systemic S chemotherapy
‚Ä¢ Cervical cancer 
‚Ä¢ Anal cancer
‚Ä¢ c Rates of liver (a/w HBV, HCV), gastric, and lung cancer (Lancet 2007;370:59; CID 2007;45:103)
Endocrine/metabolic
‚Ä¢ Hypogonadism
‚Ä¢ Adrenal insufficiency (CMV, MAC, or HIV-associated)
‚Ä¢ Wasting syndrome
‚Ä¢ Lipodystrophy and metabolic syndrome: central obesity, lipoatrophy of extrem-
ities, dyslipidemia, hyperglycemia (insulin resistance)
‚Ä¢ Lactic acidosis: N/V, abdominal pain; ? mitochondrial toxicity of AZT, d4T, ddI, and, less
commonly, other NRTI
Neurologic
‚Ä¢ Meningitis: Cryptococcus (p/w HA, 	?MS, CN palsy  other classic meningeal s/s; dx
w/ CSF; serum CRAg 90% Se; Rx w/ fluconazole; if opening pressure high, repeat
LP qd), bacterial (incl. Listeria), viral (HSV, CMV, HIV seroconversion), tuberculosis,
lymphomatous, histoplasmosis, coccidioidomycosis
‚Ä¢ Neurosyphilis: meningitis, cranial nerve palsies, dementia
‚Ä¢ Space-occupying lesions: may present as headache, focal deficits, or 	 MS
workup:MRI,stereotactic brain bx if suspect non-Toxoplasma etiology (toxoplasma sero )
or if Pt fails to respond to 2-wk trial of empiric toxoplasmosis Rx (of those who 
ultimately respond, 50% do so by d 3, 86% by d 7, 91% by d 14; NEJM 1993;329:995)
Etiology
Imaging Appearance
Diagnostic studies
Toxoplasmosis
enhancing lesions,
 Toxoplasma serology 
typically in basal ganglia
(Se 85%)
(can be multiple)
CNS lymphoma
enhancing ring lesion
 CSF PCR for EBV
(single 60% of the time)
 SPECT or PET scan
Progressive multifocal
Multiple nonenhancing
 CSF PCR for JC virus
leukencephalopathy (PML)
lesions in white matter
Other: bacterial abscess,
Variable
Biopsy
nocardiosis, cryptococcoma,
tuberculoma, CMV, HIV
‚Ä¢ AIDS dementia complex: memory loss, gait disorder, spasticity
‚Ä¢ Myelopathy: infection (CMV, HSV), cord compression (epidural abscess, lymphoma),
vacuolar (HIV)
‚Ä¢ Peripheral neuropathy: meds, HIV, CMV, demyelinating
Disseminated Mycobacterium avium complex (DMAC)
‚Ä¢ Clinical manifestations: fever, night sweats, wt loss, hepatosplenomegaly, diarrhea,
pancytopenia. May see enteritis and mesenteric lymphadentitis with CD4
100‚Äì150, bacteremia usually when CD4 50
‚Ä¢ Treatment: clarithromycin  ethambutol  rifabutin
Cytomegalovirus (CMV)
‚Ä¢ Usually reactivation
‚Ä¢ Clinical manifestations: retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis
‚Ä¢ Treatment: valganciclovir, ganciclovir, foscarnet, or cidofovir
HIV/AIDS
6-20

--- Fim da P√°gina 184 ---

LYME
6-21
TICK-BORNE DISEASES
Distinguishing Features of Tick-Borne Illnesses
Disease
Rash
T WBC
Anemia
T Plts
c LFTs
Lyme
Erythema migrans




RMSF
Petechiae, palms/soles


 (late)

Ehrlichia





Babesia


 (hemolytic)


LYME DISEASE
Microbiology
‚Ä¢ Infection with spirochete Borrelia burgdorferi (consider coinfection w/ Ehrlichia, Babesia)
‚Ä¢ Transmitted by ticks (Ixodes, deer tick); animal hosts include deer and mice
‚Ä¢ Infection usually requires tick attachment 36‚Äì48 h
Epidemiology
‚Ä¢ Most common vector-borne illness in U.S.; peak incidence in summer (May‚ÄìAug)
‚Ä¢ Majority of cases in NY, NJ, CT, RI,WI, PA, MA, ME, NH, MI, MD, DE, northern CA
‚Ä¢ Humans contact ticks usually in fields with low brush near wooded areas
Clinical Manifestations
Stage
Manifestations
Stage 1
Due to local effects of spirochete. General: flu-like illness
(early localized)
Derm (80%): erythema migrans (EM)  erythematous patches w/
wks after infection
central clearing, size 6‚Äì38 cm; lymphocytomas; regional LAN
Stage 2
Due to spirochetemia and immune response
(early dissem.)
General: fatigue, malaise, LAN, HA; fever uncommon
wks to mos after
Derm: multiple (1‚Äì100) annular lesions  EM
infection
Rheum (10%): migratory arthralgias (knee & hip) & myalgias
Neurologic (15%): cranial neuropathies (esp. CN VII), aseptic 
meningitis, mononeuritis multiplex ( pain), transverse myelitis
Cardiac (8%): heart block, myopericarditis
Stage 3
Due to chronic infection or autoimmune response
(late persistent)
Derm: acrodermatitis chronica atrophicans, panniculitis
mos to y after
Rheum (60%): joint pain, recurrent mono- or oligoarthritis of
infection
large joints (classically knee), synovitis
Neurologic: subacute encephalomyelitis, polyneuropathy, dementia
(Lancet 2003;362:1639; CID 2006;43:1089; NEJM 2007;357:1422)
Diagnostic studies
‚Ä¢ In general, a clinical diagnosis, but rigorous dx requires confirmatory testing (per IDSA)
‚Ä¢ Serology (in right clinical setting): screen w/ ELISA, but false  due to other spirochetal
diseases, SLE, RA, EBV, HIV, etc.; false  due to early abx therapy or w/in 6 wks of infxn
confirm  ELISA results w/ Western blot (c Sp)
‚Ä¢ ‚úìCSF if suspected neuro disease:  intrathecal Ab if (IgGCSF/IgGserum)/(albCSF/albserum) 1
Treatment (NEJM 2006;354:2794)
‚Ä¢ Prophylaxis (best prevention is tick avoidance): protective clothing, tick ‚úìq24h, DEET
Chemoprophylaxis w/ doxycycline 200 mg PO  1 only if all of the following:
1. Ixodes scapularis tick attached 36 h
2. Local Lyme carriage in ticks 20% (peak season in New England, mid-Atl, MN,WI)
3. Abx can be given w/in 72 h 
4. No contraindic to doxy (eg, preg, allergy, age 8 y)
If all the above met, NNT still 40‚Äì150 to prevent 1 case of Lyme (NEJM 2001;345:79)
Regardless of ppx, monitor for fever, flu-like sx, rash (erythema migrans)  30 d
‚Ä¢ Antibiotics: if clin. manifestations and  serology (? and h/o tick bite if nonendemic area)
local or early dissem. w/o neuro or cardiac involvement: doxycycline 100 mg PO
bid  2 wks (range: 10‚Äì21 d); alternative (eg, pregnancy, doxy allergy): amox 
500 mg PO tid or cefuroxime 500 mg PO bid  14‚Äì21 d
neuro (other than isolated CN VII palsy), cardiac, chronic arthritis: ceftriaxone
2 g IV daily  2‚Äì4 wks; alternative (eg, severe -lactam allergy): doxy 100‚Äì200 mg
PO bid x 2‚Äì4 wks
‚Ä¢ Consider coinfection if severe/refractory sx, persistent fever, cytopenias

--- Fim da P√°gina 185 ---

ROCKY MOUNTAIN SPOTTED FEVER (RMSF)
Microbiology & Epidemiology
‚Ä¢ Infection with Rickettsia rickettsii (Gram  obligate intracellular bacterium)
‚Ä¢ Transmitted by Dermacentor variabilis, Dermacentor andersoni
‚Ä¢ Coastal mid-Atl, New Engl, midwest, northwest, southeast, Canada, Mexico, Central &
South America
‚Ä¢ Peak incidence spring and early summer
Clinical manifestations (typically w/in 1 week of tick exposure)
‚Ä¢ Fever, HA, 	MS, myalgias, N/V, occasionally abdominal pain
‚Ä¢ Rash (2‚Äì5 d after onset)  centripetal: starts on ankles and wrists S trunk, palms &
soles; progresses from macular to maculopapular to petechial
‚Ä¢ Severe cases progress to vasculitis, hypoperfusion/shock, end-organ damage
‚Ä¢ Up to 75% mortality if untreated, 5‚Äì10% even w/ Rx (esp. if delayed) (NEJM 2005;353:551)
Diagnosis
‚Ä¢ Usually a clinical diagnosis; requires early clinical suspicion given risks of delayed Rx
‚Ä¢ During acute illness can dx by examining skin bx for rickettsiae (Se 70%)
‚Ä¢ 7‚Äì10 d after onset of sx, serology (indirect fluorescent antibody test) turns 
Treatment
‚Ä¢ Doxycycline 100 mg PO bid (give empirically if clinical suspicion)
EHRLICHIOSIS/ANAPLASMOSIS
Microbiology
‚Ä¢ Infection with Gram  obligate intracellular bacterium
‚Ä¢ Human monocytic ehrlichiosis (Ehrlichiosis chaffeensis) (HME)
‚Ä¢ Human granulocytic anaplasmosis (Anaplama phagocytophilum) (HGA)
‚Ä¢ Transmission: HME by Amblyomma americanum, Dermacentor variabilis; HGA by Ixodes
Epidemiology
‚Ä¢ Majority of HGA cases found in RI, MN, CT, NY, MD
‚Ä¢ Majority of cases of HME found in SE, southcentral, and mid-Atlantic regions of U.S.
‚Ä¢ Peak incidence spring and early summer
Clinical manifestations (typically w/in 3 wks of tick exposure)
‚Ä¢ Fever, myalgias, malaise, HA, occasional cough, dyspnea; onset often acute
‚Ä¢ Laboratory: leukopenia, thrombocytopenia, renal failure, c aminotransferases, LDH, A
Diagnosis
‚Ä¢ Start Rx based on clinical suspicion; however, definitive dx requires confirmation
‚Ä¢ Acute illness: intraleukocytic morulae on peripheral blood smear (rare); PCR; later: serology
Treatment
‚Ä¢ Doxycycline 100 mg PO bid (often  10 d); should defervesce in 48 h, else reconsider dx
BABESIOSIS
Microbiology & Epidemiology
‚Ä¢ Infection with parasite Babesia microti (U.S.), Babesia divergens (Europe)
‚Ä¢ Transmitted by Ixodes
‚Ä¢ Europe & U.S. (more commonly coastal areas & islands off of MA, NY, RI, CT)
‚Ä¢ Peak incidence spring and summer
Clinical manifestations
‚Ä¢ Range from asx to fevers, sweats, myalgias, & HA to severe hemolytic anemia,
hemoglobinuria, & death (degree of parasitemia correlates roughly with severity)
‚Ä¢ Risk factors for severe disease include asplenia, T cellular immunity, c age, pregnancy
Diagnosis
‚Ä¢ Clinical syndrome  blood smear with intraerythrocytic parasites; PCR; serology (late)
Treatment
‚Ä¢ [Atovaquone  azithromycin] (1st line) or [clindamycin  quinine] (for more severe cases)
‚Ä¢ Exchange transfusion if parasitemia 10%, severe hemolysis, or SIRS
TULAREMIA
Microbiology
‚Ä¢ Infxn w/ Francisella tularensis via contact w/ animal tissue, tick/insect bite, ? aerosol
Clinical manifestations (typically w/in 2‚Äì10 d of infxn)
‚Ä¢ Acute onset of fever, HA, nausea; ulcer w/ black eschar at site of entry; LAN; PNA
Diagnosis & Treatment
‚Ä¢ Hazardous to cx. Serology  by 2nd week.
‚Ä¢ Streptomycin or gentamicin  7‚Äì14 d
TICK INFXNS
6-22

--- Fim da P√°gina 186 ---

FUO
6-23
FEVER OF UNKNOWN ORIGIN (FUO)
Definition
‚Ä¢ Fever 101
F or 38.3
C on more than one occasion
‚Ä¢ Duration 3 wks
‚Ä¢ No diagnosis despite 1 wk of intensive evaluation
Etiologies
‚Ä¢ Differential extensive, but following are some common causes in immunocompetent hosts
‚Ä¢ More likely to be subtle manifestation of common disease than an uncommon disease
‚Ä¢ In Pts with HIV: 75% infectious, rarely due to HIV itself
‚Ä¢ Up to 30% of cases undiagnosed, most spontaneously defervesce
Category
Etiologies of Classic FUO
Infection
Tuberculosis: disseminated or extrapulmonary disease can have
30%
normal CXR, PPD, sputum AFB; biopsy (lung, liver, bone marrow)
for granulomas has 80‚Äì90% yield in miliary disease
Intra-abdominal abscess: hepatic, splenic, subphrenic, pancreatic,
perinephric, pelvic, prostatic abscess or prostatitis, appendicitis
Endocarditis: consider HACEK orgs, Bartonella, Legionella, Coxiella
Osteomyelitis, dental abscess, sinusitis, paraspinal abscess
CMV, EBV, Lyme, malaria, Babesia, ameba, fungus, typhoid
Connective
Giant cell arteritis: headache, scalp pain, jaw claudication, visual
tissue disease
disturbances, myalgias, arthralgias, c ESR
30%
Adult-onset Still‚Äôs disease (juvenile RA): fevers w/ evanescent 
truncal rash, pharyngitis, LAN, very high ferritin
Polyarteritis nodosa, other vasculitides
RA, SLE, PMR, psoriatic arthritis, reactive arthritis
Neoplasm
Lymphoma: LAN, HSM, T Hct or plt, c LDH; leukemia, myelodysplasia
20%
Renal cell carcinoma: microscopic hematuria, c Hct
Hepatocellular, pancreatic, and colon cancers, sarcomas
Atrial myxomas: obstruction, embolism, constitutional symptoms
Miscellaneous
Drugs, factitious
20%
DVT, PE, hematoma
Thyroiditis or thyroid storm, adrenal insufficiency, pheochromocytoma
Granulomatous hepatitis (many causes), sarcoidosis
Familial Mediterranean fever (mutation in pyrin in myeloid cells;
episodic fever, peritonitis, pleuritis; c WBC & ESR during attacks);
other defects in innate immunity
(Archives 2003;163:545; Medicine 2007;86:26)
Workup
‚Ä¢ History: thorough hx, ROS, PMHx and PSHx, fever curve (consider holding antipyretics),
infectious contacts, travel, pets, occupation, meds,TB hx
‚Ä¢ Careful physical exam w/ attention to skin/mucous memb., LAN, murmurs, HSM, arthritis
‚Ä¢ Laboratory evaluation
CBC with diff, lytes, BUN, Cr, LFTs, ESR, CRP, ANA, RF, cryoglobulin, LDH, CK, SPEP
BCx  3 sets (off abx; hold for HACEK, RMSF, Q fever, Brucella), U/A, UCx, PPD or
IGRA, HIV Ab  PCR, heterophile Ab (specific EBV serologies if neg), CMV 
antigenemia, Hep serologies if LFTs abnl
‚Ä¢ Discontinue unnecessary meds (only 20% w/ med-induced FUO have eos or rash),
reassess 1‚Äì3 wks after meds d/c‚Äôd
‚Ä¢ Imaging studies: CXR, chest & abd CT (oral & IV contrast), ? tagged WBC or
gallium scan, ? FDG PET, ? echo, ? lower extremity Doppler U/S
‚Ä¢ Pursue abnormalities raised by above w/u (eg, bx, MRI, etc., for dx, not screening)
‚Ä¢ Duke‚Äôs criteria for endocarditis (qv) have good Se & Sp in Pts with FUO
‚Ä¢ Consider temporal artery bx if c ESR and age 60, particularly if other s/s
‚Ä¢ ? Bone marrow aspirate & bx (esp if signs of marrow infiltration) or liver bx (espec. if c A):
even w/o localizing s/s, yield may be up to 24% (path and culture) (Archives 2009;169:2018)
‚Ä¢ More likely to make a dx if: continuous fever, duration 180 d, c ESR/CRP/LDH,
leukopenia, thrombocytosis, abnl chest CT, or abnl FDG-PET
Treatment
‚Ä¢ Empiric antibiotics are not indicated (unless Pt neutropenic)
‚Ä¢ Empiric glucocorticoids not indicated unless strong suspicion for specific rheumatologic dx
‚Ä¢ 5‚Äì15% of FUO resolve on their own (wks to mos) w/o dx

--- Fim da P√°gina 187 ---

NOTES
NOTES
6-24

--- Fim da P√°gina 188 ---

PITUITARY
7-1
PITUITARY DISORDERS
HYPOPITUITARY SYNDROMES
Panhypopituitarism
‚Ä¢ Etiologies
Primary: surgery, radiation, tumors (primary or metastatic), infection, infiltration
(sarcoid, hemochromatosis), autoimmune, ischemia (including Sheehan‚Äôs syndrome
caused by pituitary infarction intrapartum), carotid aneurysms, cavernous sinus
thrombosis, trauma
Secondary (hypothalamic dysfunction or stalk interruption): tumors (including
craniopharyngioma), infection, infiltration, radiation, surgery, trauma
‚Ä¢ Clinical manifestations
Hormonal: acute S weakness, easy fatigability, hypotension, polyuria and polydipsia;
chronic S bradycardia, sexual dysfxn, loss of axillary & pubic hair, wt loss, amenorrhea
Mass effect: headache, visual field s, cranial nerve palsies, galactorrhea
Apoplexy (pituitary hemorrhage or infarction, usually w/ underlying pituitary adenoma):
sudden headache, N/V, visual field s, cranial nerve palsies, meningismus,  MS,
hypoglycemia, hypotension
‚Ä¢ Diagnostic studies
Hormonal studies
chronic: T target gland hormone  T or normal trophic pituitary hormone
acute: target gland hormonal studies may be normal
partial hypopituitarism is more common than panhypopituitarism
Pituitary MRI
‚Ä¢ Treatment
Replace deficient target gland hormones
Most important deficiencies to recognize and treat in inpatients are adrenal insufficiency
and hypothyroidism; if both present, treat with glucocorticoids first, then replace
thyroid hormone so as not to precipitate adrenal crisis
T ACTH
‚Ä¢ Adrenal insufficiency similar to 1 (see ‚ÄúAdrenal Disorders‚Äù) except:
no salt cravings or hypokalemia (b/c aldo preserved)
no hyperpigmentation (b/c ACTH/MSH is not c)
T TSH
‚Ä¢ Central hypothyroidism similar to 1 (see ‚ÄúThyroid Disorders‚Äù) except absence of goiter
‚Ä¢ Dx with free T4 in addition to TSH, as TSH may be low or inappropriately normal
T PRL
‚Ä¢ Inability to lactate
T GH
‚Ä¢ c chronic risk for osteoporosis, fatigue, weight gain
‚Ä¢ Dx with failure to c GH w/ appropriate stimulus (eg, insulin tolerance test, glucagon
stimulation)
‚Ä¢ GH replacement in adults controversial
T FSH & LH
‚Ä¢ Clinical manifestations: T libido, impotence, oligomenorrhea or amenorrhea, infertility
‚Ä¢ Physical examination: T testicular size; loss of axillary, pubic, and body hair
‚Ä¢ Dx with: T a.m. testosterone or estradiol and  T or normal FSH/LH (all levels
T in acute illness, ‚à¥do not measure in hospitalized Pts)
‚Ä¢ Treatment: testosterone or estrogen replacement vs. correction of the underlying cause
T ADH (hypothalamic or stalk disease): diabetes insipidus
‚Ä¢ Clinical manifestations: severe polyuria, mild hypernatremia (severe if T access to H2O)
‚Ä¢ Diagnostic studies: see ‚ÄúDisorders of Sodium Homeostasis‚Äù

--- Fim da P√°gina 189 ---

HYPERPITUITARY SYNDROMES
Pituitary tumors
‚Ä¢ Pathophysiology: adenoma S excess of trophic hormone (if tumor fxnal, but 30‚Äì40%
not) and potentially deficiencies in other trophic hormones due to compression;
cosecretion of PRL and growth hormone in 10% of prolactinomas
‚Ä¢ Clinical manifestations: syndromes due to oversecretion of hormones (see below)
 mass effect: headache, visual s, diplopia, cranial neuropathies
‚Ä¢ Workup: MRI, hormone levels,  visual field testing, consider MEN1 (see below)
if 10 mm, ‚àÖmass effect, no hormonal effects, can f/up q 3‚Äì6 mos
Hyperprolactinemia (NEJM 2010;362:1219)
‚Ä¢ Etiology
prolactinoma (50% of pituitary adenomas)
stalk compression due to nonprolactinoma S T inhibitory dopamine S c PRL (mild)
‚Ä¢ Physiology: PRL induces lactation and inhibits GnRH S T FSH & LH
‚Ä¢ Clinical manifestations: amenorrhea, galactorrhea, infertility, T libido, impotence
‚Ä¢ Diagnostic studies: c PRL, but elevated in many situations, ‚à¥r/o pregnancy or
exogenous estrogens, hypothyroidism, dopamine agonists (psych meds, antiemetics),
renal failure (T clearance), cirrhosis, stress, c carb diet. MRI to evaluate for tumor,
visual field testing if MRI shows compression of optic chiasm.
‚Ä¢ Treatment
If asx (no HA or hypogonadal sx) and microadenoma (10 mm), follow with MRI
If sx or macroadenoma (10 mm) options include:
medical with dopamine agonist such as bromocriptine (70‚Äì100% success rate) or
cabergoline (better tolerated); side effects include N/V, orthostasis, nasal congestion
surgical: transsphenoidal surgery (main indications: failed medical Rx, GH co-secretion,
or neurologic sx not improving); 10‚Äì20% recurrence rate
radiation: if medical or surgical therapy have failed or are not tolerated
Acromegaly (c GH; 10% of adenomas; NEJM 2006;355:2558)
‚Ä¢ Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1)
‚Ä¢ Clinical manifestations: c soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel
syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes
mellitus, acanthosis/skin tags, c sweating, HTN/CMP, colonic polyps
‚Ä¢ Diagnostic studies: no utility in checking random GH levels because of pulsatile secretion
c IGF-1 (somatomedin C);  c PRL; pituitary MRI to evaluate for tumor
oral glc tolerance test S GH not suppressed to 1 (0.3 if newer assay) ng/mL by 2 h
‚Ä¢ Treatment: surgery, octreotide (long- and short-acting preparations), dopamine 
agonists (if PRL co-secretion), pegvisomant (GH receptor antagonist), radiation
‚Ä¢ Prognosis: w/o Rx there is 2‚Äì3 c mortality, risk of pituitary insufficiency, colon cancer
Cushing‚Äôs disease (c ACTH): 10‚Äì15% of adenomas; see ‚ÄúAdrenal Disorders‚Äù
Central hyperthyroidism (c TSH, c -subunit): extremely rare; see ‚ÄúThyroid Disorders‚Äù
c FSH & LH: usually non-fxn, presents as hypopituitarism b/c of compression effects
DISORDERS OF MULTIPLE ENDOCRINE SYSTEMS
Multiple Endocrine Neoplasia (MEN) Syndromes
Type
Features
1
Parathyroid hyperplasia/adenomas S hypercalcemia (100% penetrance)
(MENIN
Pancreatic islet cell neoplasia (gastrin,VIP, insulin, glucagon)
inactiv.)
Pituitary adenomas (fxn or non-fxn)
2A
Medullary thyroid carcinoma (MTC)
(RET proto-
Pheochromocytoma (50%)
oncogene)
Parathyroid hyperplasia S hypercalcemia (15‚Äì20%)
2B
Medullary thyroid carcinoma (MTC)
(RET proto-
Pheochromocytoma (50%)
oncogene)
Mucosal and gastrointestinal neuromas
Polyglandular Autoimmune (PGA) Syndromes
Type
Features
I (children)
Mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency
II (adults)
Adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1
PITUITARY
7-2

--- Fim da P√°gina 190 ---

THYROID
7-3
THYROID DISORDERS
Diagnostic Studies in Thyroid Disorders
Test
Comments
Thyroid-stimulating
Most sensitive test to detect 1 hypo- and hyperthyroidism
hormone (TSH)
May be inappropriately normal in central etiologies
T‚Äôd by dopamine, steroids, severe illness
T3 and T4 immunoassays
Measure total serum concentrations (‚à¥influenced by TBG)
Free T4 immunoassay
Free T4, not influenced by TBG, increasingly popular
(FT4)
Thyroxine-binding
c TBG (‚à¥c T4): estrogens, OCP, pregnancy, hepatitis, opioids,
globulin (TBG)
hereditary
T TBG (‚à¥T T4): androgens, glucocorticoids, nephritic 
syndrome, cirrhosis, acromegaly, nicotinic acid, hereditary
Reverse T3
Inactive, c‚Äôd in sick euthyroid syndrome
Thyroid antibodies
Antithyroid peroxidase (TPO) seen in Hashimoto‚Äôs (high titer),
painless thyroiditis and Graves‚Äô disease (low titer)
Thyroid-stimulating Ig (TSI) and thyrotropin-binding inhibitory
immunoglobulin (TBII) seen in Graves‚Äô disease
Thyroglobulin
c‚Äôd in goiter, hyperthyroidism and thyroiditis
T‚Äôd in factitious ingestion of thyroid hormone
Tumor marker for thyroid cancer only after total 
thyroidectomy and radioiodine therapy
Radioactive iodine uptake
Useful to differentiate causes of hyperthyroidism
(RAIU) scan
c uptake
homogeneous 	 Graves‚Äô disease
heterogeneous 	 multinodular goiter
1 focus of uptake w/ suppression of rest of gland 	 hot 
nodule
no uptake 	 subacute painful or silent thyroiditis,
exogenous thyroid hormone, struma ovarii, recent iodine
load, or antithyroid drugs
Figure 7-1 Approach to thyroid disorders
TSH
Free T
Free T
Central
Hypothyroidism
Subclinical
hyperthyroidism
Primary
hyperthyroidism
Subclinical
hypo-
thyroidism
TSH-secreting
adenoma
(central hyper-
thyroidism)
or
Thyroid
hormone
resistance
normal
decreased
increased
decreased
normal
increased
decreased
increased
Primary
hypothyroidism
RAIU
Graves‚Äô
disease
Toxic
multinodular
goiter
Functioning
adenoma
Thyrotoxicosis
factitia
homogeneous
diffuse
focal
Thyroiditis
Struma ovarii
or Iodine load
serum thyroglobulin
none
heterogeneous
normal
‚Üì
‚Üë
? secondary
(central) disease

--- Fim da P√°gina 191 ---

HYPOTHYROIDISM
Etiologies
‚Ä¢ Primary (
90% of cases of hypothyroidism; T free T4, c TSH)
Goitrous: Hashimoto‚Äôs thyroiditis, recovery after thyroiditis, iodine defic., Li, amiodarone
Nongoitrous: surgical destruction, s/p radioactive iodine or XRT, amiodarone
‚Ä¢ Central (T free T4,low/nl or slightly high TSH):hypothalamic or pituitary failure (TSH levels T or
‚Äúnormal,‚Äù can be slightly c although functionally inactive due to abnormal glycosylation)
Hashimoto‚Äôs thyroiditis
‚Ä¢ Autoimmune destruction with patchy lymphocytic infiltration
‚Ä¢ Associated with other autoimmune disease and may be part of PGA syndrome type II
‚Ä¢  antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) Abs in 
90%
Clinical manifestations (Lancet 2004;363:793)
‚Ä¢ Early: weakness, fatigue, arthralgias, myalgias, headache, depression, cold intolerance,
weight gain, constipation, menorrhagia, dry skin, coarse brittle hair, brittle nails, carpal
tunnel syndrome, delayed DTRs (‚Äúhung up‚Äù reflexes), diastolic HTN, hyperlipidemia
‚Ä¢ Late: slow speech, hoarseness, loss of outer third of eyebrows, myxedema
(nonpitting skin thickening due to c glycosaminoglycans), periorbital puffiness,
bradycardia, pleural, pericardial, & peritoneal effusions, atherosclerosis
‚Ä¢ Myxedema coma: hypothermia, hypotension, hypoventilation,  MS
Diagnostic studies
‚Ä¢ T FT4; c TSH in primary hypothyroidism;  antithyroid Ab in Hashimoto‚Äôs thyroiditis
‚Ä¢ May see hyponatremia, hypoglycemia, anemia, c LDL, T HDL, and c CK
‚Ä¢ Screening recommended for pregnant women
Treatment of overt hypothyroidism
‚Ä¢ Levothyroxine (1.5‚Äì1.7 g/kg/d), re ‚úìTSH q5‚Äì6wks and titrate until euthyroid;
sx can take mos to resolve; lower starting dose (0.3‚Äì0.5 g/kg/d) if at risk for
ischemic heart disease; advise Pt to keep same formulation of levothyroxine;
c dose typically needed if: pregnancy (30% c by wk 8), initiation of estrogen 
replacement, poor GI absorption (concomitant Fe or Ca suppl., PPI, sucralfate,
celiac disease, IBD)
‚Ä¢ Myxedema coma: load 5‚Äì8 g/kg T4 IV, then 50‚Äì100 g IV qd; b/c peripheral 
conversion impaired, may also give 5‚Äì10 g T3 IV q8h if unstable w/ bradycardia 
and/or hypothermia (T3 more arrhythmogenic); must give empiric adrenal replace-
ment therapy first as T adrenal reserves in myxedema coma
Subclinical hypothyroidism (NEJM 2001;345:260)
‚Ä¢ Mild c TSH and normal free T4 with only subtle or no sx
‚Ä¢ If c titers of antithyroid Abs, progression to overt hypothyroidism is 4%/y
‚Ä¢ Rx controversial: follow expectantly or treat to improve mild sx or dyslipidemia
most initiate Rx if TSH 
10 mU/L, goiter, pregnancy, or infertility
HYPERTHYROIDISM
Etiologies (Lancet 2003;362:459)
‚Ä¢ Graves‚Äô disease (60‚Äì80% of thyrotoxicosis)
‚Ä¢ Thyroiditis: thyrotoxic phase of subacute (granulomatous) thyroiditis or painless
(lymphocytic) thryoiditis
‚Ä¢ Toxic adenomas (single or multinodular goiter) 
‚Ä¢ TSH-secreting pituitary tumor or pituitary resistance to thyroid hormone (cTSH, c free T4)
‚Ä¢ Misc: amiodarone, iodine-induced, thyrotoxicosis factitia, struma ovarii (3% of ovarian
dermoid tumors and teratomas), hCG-secreting tumors (eg, choriocarcinoma),
large deposits of metastatic follicular thyroid cancer
Graves‚Äô disease (NEJM 2008;358:2594)
‚Ä¢ Female:male ratio is 5‚Äì10:1, most Pts between 40 and 60 y at dx
‚Ä¢  thyroid antibodies: TSI or TBII ( in 80%), anti-TPO, antithyroglobulin; ANA
‚Ä¢ Clinical manifestations in addition to those of hyperthyroidism (see below):
goiter: diffuse, nontender, w/ thyroid bruit
ophthalmopathy (NEJM 2009;360:994): Seen in 50%; up to 90% if formally tested.
Periorbital edema, lid retraction, proptosis, conjunctivitis, diplopia (EOM infiltration);
associated w/ smoking. Stare and lid lag seen in any type of hyperthyroidism.
pretibial myxedema (3%): infiltrative dermopathy
THYROID
7-4

--- Fim da P√°gina 192 ---

Clinical manifestations of hyperthyroidism
‚Ä¢ Restlessness, sweating, tremor, moist warm skin, fine hair, tachycardia, AF, weight loss,
c frequency of stools, menstrual irregularities, hyperreflexia, osteoporosis, stare and
lid lag (due sympathetic overactivity)
‚Ä¢ Apathetic thyrotoxicosis: seen in elderly who can present with lethargy as only sx
‚Ä¢ Thyroid storm (extremely rare): delirium, fever, tachycardia, systolic hypertension but
wide pulse pressure and T MAP, GI symptoms; 20‚Äì50% mortality
Laboratory testing
‚Ä¢ c FT4 and FT3; T TSH (except in TSH-secreting tumors)
‚Ä¢ RAIU scan is very useful study to differentiate causes (see table on page 7-3)
‚Ä¢ Rarely need to ‚úìfor autoantibodies except in pregnancy (to assess risk of fetal Graves‚Äô)
‚Ä¢ May see hypercalciuria  hypercalcemia, c A, anemia
Treatment
‚Ä¢ -blockers: control tachycardia (propranolol also T T4 S T3 conversion)
‚Ä¢ Graves‚Äô disease: either antithyroid drugs or radioactive iodine (NEJM 2005;352:905)
methimazole: 70% chance of recurrence after 1 y; side effects include pruritus,
rash, arthralgia, fever, N/V, and agranulocytosis in 0.5%. PTU: 2nd line (risk of
hepatocellular necrosis; TID dosing; slower effect). For both, need to ‚úìLFTs,
WBC, TSH at baseline and in follow-up.
radioactive iodine (RAI): preRx selected Pts w/ cardiovascular disease or elderly
w/ antithyroid drugs to prevent c thyrotoxicosis, stop 3 d before to allow RAI
uptake; 
75% of treated Pts become hypothyroid
surgery: less commonly chosen for Graves‚Äô, usually for Pts w/ obstructive goiter
or ophthalmopathy
‚Ä¢ Toxic adenoma or toxic multinodular goiter: RAI or surgery (methimazole preRx for
surgery, in selected patients before RAI)
‚Ä¢ Thyroid storm: -blocker, PTU, iopanoic acid or iodide (for Wolff-Chaikoff effect) 
1 h
after PTU,  steroids (T T4 S T3)
‚Ä¢ Ophthalmopathy: can worsen after RAI, prevented by prophylactic Rx w/ prednisone in
high-risk patients; can be Rx‚Äôd w/ radiation and/or surgical decompression of the orbits
Subclinical hyperthyroidism (NEJM 2001;345:512)
‚Ä¢ Mild T TSH and normal free T4 with only subtle or no sx
‚Ä¢ 15% will develop overt hyperthyroidism in 2 y; c risk of AF & osteoporosis
‚Ä¢ Rx controversial: consider if TSH 0.1 mU/L and c risk for CV disease or osteopenic
THYROIDITIS (NEJM 2003;348:2646)
‚Ä¢ Acute: bacterial infection (very rare in U.S. except postsurgical)
‚Ä¢ Subacute: transient thyrotoxicosis S transient hypothyroidism S normal thyroid fxn
painful (viral, granulomatous, or de Quervain‚Äôs): fever, c ESR; Rx 	 NSAIDs,ASA, steroids
silent (postpartum, autoimmune, or lymphocytic): painless,  TPO Abs; if 
postpartum, can recur with subsequent pregnancies
other: amiodarone, palpation thyroiditis, after radiation
‚Ä¢ Chronic: Hashimoto‚Äôs (hypothyroidism), Riedel‚Äôs (idiopathic fibrosis)
NONTHYROIDAL ILLNESS (SICK EUTHYROID SYNDROME)
‚Ä¢ TFT abnormalities in Pts w/ severe nonthyroidal illness (‚à¥in acute illness, ‚úìTFTs only
if c concern for thyroid disease); may have acquired transient central hypothyroidism
‚Ä¢ If thyroid dysfxn suspected in critically ill Pt, TSH alone not reliable; must measure total
T4, FT4, & T3
‚Ä¢ Mild illness: T T4 S T3 conversion, c rT3 ‚áíT T3; in severe illness: T TBG & albumin, cc rT3
‚áíTT T3, c degradation of T4, central T TSH ‚áíTT T3, TT T4, T FT4, T TSH
‚Ä¢ Recovery phase: c TSH followed by recovery of T4 and then T3
‚Ä¢ Replacement thyroxine not helpful or recommended for critically ill Pts w/ T T3 and T4
unless other s/s of hypothyroidism
AMIODARONE AND THYROID DISEASE
Risk of thyroid dysfunction is lower with lower doses
‚úìTSH prior to therapy, at 4-mo intervals on amio, and for 1 y after if amio d/c‚Äôd
Hypothyroidism (occurs in 10%; more common in iodine-replete areas)
‚Ä¢ Pathophysiology
(1) Wolff-Chaikoff effect: iodine load T I uptake, organification, and release of T4 & T3
(2) inhibits T4 S T3 conversion
(3) ? direct/immune-mediated thyroid destruction
THYROID
7-5

--- Fim da P√°gina 193 ---

‚Ä¢ Normal individuals: T T4; then escape Wolff-Chaikoff effect and have c T4, T T3, c TSH;
then TSH normalizes (after 1‚Äì3 mos)
‚Ä¢ Susceptible individuals (eg, subclinical Hashimoto‚Äôs, ‚à¥‚úìanti-TPO) do not escape effects
‚Ä¢ Treatment: thyroxine to normalize TSH; may need larger than usual dose
Hyperthyroidism (3% of Pts on amio; 10‚Äì20% of Pts in iodine-deficient areas)
‚Ä¢ Type 1 	 underlying multinodular goiter or autonomous thyroid tissue
pathophysiology: Jod-Basedow effect (iodine load S c synthesis of T4 and T3 in
autonomous tissue)
diagnostic studies: c thyroid blood flow on Doppler U/S; treatment: methimazole
‚Ä¢ Type 2 	 destructive thyroiditis
pathophysiology: c release of preformed T4 & T3 S hyperthyroidism
S hypothyroidism S recovery
diagnostic studies: T flow on Doppler U/S; treatment: steroids
‚Ä¢ Type 1 vs. 2 often difficult to distinguish and Rx for both initiated (JCEM 2001;86:3)
THYROID NODULES
‚Ä¢ Prevalence 5‚Äì10% (50‚Äì60% if screen with U/S), 5% malignant
‚Ä¢ Features associated w/ c risk of malignancy: age 20 or 
70 y, male sex, h/o neck XRT,
hard and immobile mass, cold nodule on RAIU, large size, worrisome U/S findings
(hypoechoic, solid, irregular borders, microcalcifications, central blood flow),
cervical LAN
‚Ä¢ Features associated w/ benign dx: FHx of autoimmune thyroid disease or goiter, presence
of hypothyroidism or hyperthyroidism, nodule tenderness
‚Ä¢ Screening U/S recommended for those with FHx of MEN2 or medullary thyroid cancer,
personal h/o neck XRT, palpable nodules, or multinodular goiter
‚Ä¢ FNA for nodules 
10 mm (
8 mm if irregular borders), microcalcifications, or central
vasculature; FNA any nodules in Pts with h/o neck XRT or FHx of MEN2 or MTC
Figure 7-2 Approach to thyroid nodules (Endocr Pract 2006;12:63)
Observe
or
Suppressive Rx
Thyroid nodule
FNA
(¬± U/S guidance)
Benign
(70%)
or
Likely benign
toxic adenoma:
ablate, resect, or med Rx
cold
Indeterminate
(15%)
Suspicious
(10%)
Malignant
(5%)
RAIU
Suppressive
Rx
Surgery
Surgery
Observe
resolves
does not
resolve
hot
hot
RAIU
Surgery
cold
or
or
TSH
RAIU
Likely benign
toxic adenoma:
ablate, resect, or med Rx
hot
low
or
normal
meeting criteria
outlined in the text
cold or
non-specific
THYROID
7-6

--- Fim da P√°gina 194 ---

ADRENAL
7-7
ADRENAL DISORDERS
Cushing‚Äôs Syndrome (Hypercortisolism)
Definitions
‚Ä¢ Cushing‚Äôs syndrome  cortisol excess
‚Ä¢ Cushing‚Äôs disease  Cushing‚Äôs syndrome 2 to pituitary ACTH hypersecretion
Etiologies of hypercortisolism
‚Ä¢ Most common cause is iatrogenic Cushing‚Äôs syndrome caused by exogenous glucocorticoids
‚Ä¢ Cushing‚Äôs disease (60‚Äì70%): pituitary adenoma (usually microadenoma) or hyperplasia
‚Ä¢ Adrenal tumor (15‚Äì25%): adenoma or (rarely) carcinoma
‚Ä¢ Ectopic ACTH (5‚Äì10%): SCLC, carcinoid, islet cell tumors, medullary thyroid cancer, pheo
Clinical manifestations
‚Ä¢ Nonspecific: glucose intolerance or DM, HTN, obesity, oligomenorrhea, osteoporosis
‚Ä¢ More specific: central obesity w/ extremity wasting, dorsocervical fat pads, rounded facies
‚Ä¢ Most specific: spontaneous bruising, proximal myopathy, wide striae, hypokalemia
‚Ä¢ Other: depression, insomnia, psychosis, impaired cognition, facial plethora, acne,
hirsutism, hyperpigmentation (if c ACTH), fungal skin infxns, nephrolithiasis, polyuria
Figure 7-3 Approach to suspected Cushing‚Äôs syndrome
CRH, corticotropin-releasing hormone; DST, dexamethasone suppression test; UFC, urinary free cortisol
Overnight 1 mg DST  give 1 mg at 11 pm; ‚úì8 am serum cortisol (suppression if 1.8 g/dL); 1‚Äì2% false 
(primarily used to evaluate subclinical Cushing‚Äôs in adrenal ‚Äúincidentalomas‚Äù) (JCEM 2008;93:1526)
11 pm salivary cortisol  abnl if level c; 24-h UFC  abnl if level c,  4  ULN virtually diagnostic
48-h LD DST  CRH  0.5 mg q6h  2 d,then IV CRH 2 h later; ‚úìserum cortisol 15 min later (  1.4 g/dL)
48-h LD DST  0.5 mg q6h  2 d; ‚úì24-h UFC at base. & during last 24 h of dex (suppress if 10% of base)
48-h HD DST  2 mg q6h  2 d; ‚úì24-h UFC as per LD DST
O/N HD DST  8 mg at 11 pm; ‚úì9 am serum cortisol (suppression if 32% of baseline)
CRH test  1 g/kg IV; ‚úìcortisol and ACTH ( stim if  35% c in ACTH or 20% c in cortisol above baseline)
BIPSS, bilat. inferior petrosal sinus vein sampling; ‚úìpetrosal:peripheral ACTH ratio (  2 basal, 3 after CRH)
(Endo & Metab Clin North Am 2005;34:385)
Suspect Cushing‚Äôs Syndrome Clinically
Ectopic ACTH
Differentiate level of defect by checking serum ACTH
Cushing‚Äôs disease
Adrenal tumor
adrenal CT or MRI
pituitary MRI
ACTH-independent
ACTH-dependent
48-h or O/N high-dose DST
(or CRH test)
Will not suppress
(or     stim)
chest/abd MRI
somatostatin scan
BIPSS
Will suppress
(or     stim)
search
normal
or high
low
re  after resolution of
illness or  combined
48-h LD DST + CRH
3 Options for Screening for Hypercortisolism:
24-h UFC or Overnight 1 mg DST or 11 pm Salivary Cortisol
Not Cushing‚Äôs
 (or repeat) 24-h UFC
   or     but high
clinical suspicion
    but in Pt w/
acute illness, EtOH, depression
   and low
clinical suspicion
? Pseudo-
Cushing‚Äôs
‚àí
‚àí
‚àí
+
+
‚àí
+
+
+
+
+
+
‚àí
‚àí
‚àí

--- Fim da P√°gina 195 ---

Treatment of Cushing‚Äôs syndrome
‚Ä¢ Surgical resection of pituitary adenoma, adrenal tumor, or ectopic ACTH-secreting tumor
‚Ä¢ If transsphenoidal surgery (TSS) not successful S pituitary XRT, medical adrenalectomy
w/ mitotane, or bilat surgical adrenalectomy; ketoconazole ( metyrapone) to T cortisol
‚Ä¢ Glucocorticoid replacement therapy  6‚Äì36 mos after TSS (lifelong glucocorticoid 
mineralocorticoid replacement if medical or surgical adrenalectomy)
HYPERALDOSTERONISM
Etiologies
‚Ä¢ Primary (adrenal disorders, renin independent increase in aldosterone)
adrenal hyperplasia (70%), adenoma (Conn‚Äôs syndrome, 25%), carcinoma (5%)
glucocorticoid-remediable aldosteronism (GRA; ACTH-dep. rearranged promoter)
‚Ä¢ Secondary (extra-adrenal disorders, c aldosterone is renin dependent)
Primary reninism: renin-secreting tumor (rare)
Secondary reninism
renovascular disease: RAS, malignant hypertension
edematous states w/ T effective arterial volume: CHF, cirrhosis, nephrotic syndrome
hypovolemia, diuretics,T2D, Bartter‚Äôs (defective Na/K/2Cl transporter  receiving loop
diuretic), Gitelman‚Äôs (defective renal Na/Cl transporter  receiving thiazide diuretic)
‚Ä¢ Nonaldosterone mineralocorticoid excess mimics hyperaldosteronism
11-HSD deficiency (S lack of inactivation of cortisol, which binds to otherwise
nonselective mineralocorticoid receptor)
Black licorice (glycyrrhizinic acid inhibits 11-HSD), extreme hypercortisolism
(overwhelming 11-HSD), exogenous mineralocorticoids
Liddle‚Äôs syndrome (constitutively activated/overexpressed distal tubular renal Na channel)
Clinical manifestations
‚Ä¢ Mild to moderate HTN (11% of Pts w/ HTN refractory to 3 drugs; Lancet
2008;371:1921), headache, muscle weakness, polyuria, polydipsia; no peripheral edema
because of ‚Äúescape‚Äù from Na retention; malignant HTN is rare
‚Ä¢ Classically hypokalemia (but often normal), metabolic alkalosis, mild hypernatremia
Diagnostic studies
‚Ä¢ 5‚Äì10% of Pts w/ HTN; ‚à¥screen if HTN  hypokalemia, adrenal mass, or refractory HTN
‚Ä¢ Screening: aldosterone (
15‚Äì20 ng/dL) and plasma aldosterone:renin ratio (
20 if 1)
obtain 8 a.m. paired values (off spironolactone & eplerenone for 6 wks); Se & Sp 
85%
‚Ä¢ ACEI/ARB, diuretics, CCB can c renin activity S T PAC/PRA ratio and Bs may c
PAC/PRA ratio; ‚à¥avoid. -blockers generally best to control HTN during dx testing.
‚Ä¢ Confirm with sodium suppression test (fail to suppress aldo after sodium load)
oral salt load ( KCl)  3 d, ‚úì24-h urine ( if aldo 
12 g/d while Na 
200 mEq/d)
or 2L NS over 4 h, measure aldo at end of infusion ( if aldo 
5 ng/dL)
Figure 7-4 Approach to suspected hyperaldosteronism
(Adapted from Trends in Endocrine Metabolism 1999;5:97)
Suspect Hyperaldosteronism
Non-aldosterone
mineralocorticoid excess
Plasma renin & aldosterone a.m. collection
Cushing‚Äôs syndrome
CAH (some forms)
11Œ≤-OHSD deficiency
Licorice (chronic ingestion)
Liddle‚Äôs syndrome
Exogenous mineralocorticoids
salt suppression test
1¬∞ Hyperaldosteronism
‚Üì renin
‚Üë aldosterone (>15)
aldo:renin >20
‚Üì renin
‚Üì aldosterone
‚Üë renin
‚Üë aldosterone
aldo:renin‚â§10
2¬∞ Hyperaldosteronism
Renin-secreting tumor
Renovascular disease
CHF, cirrhosis, nephrotic
Hypovolemia & diuretic use
Bartter‚Äôs syndrome
Gitelman‚Äôs syndrome
Adrenal CT or MRI
unilateral lesion
Adrenal vein
sampling
Adenoma or
Carcinoma
localize
Hyperplasia
or GRA
no localization
no or bilateral lesions
+
ADRENAL
7-8

--- Fim da P√°gina 196 ---

Treatment
‚Ä¢ Adenoma or carcinoma S surgery
‚Ä¢ Hyperplasia S spironolactone or eplerenone; GRA S glucocorticoids  spironolactone
ADRENAL INSUFFICIENCY
Etiologies
‚Ä¢ Primary 	 adrenocortical disease 	 Addison‚Äôs disease
autoimmune: isolated or in assoc w/ PGA syndromes (see table on page 7-2)
infection: TB, CMV, histoplasmosis
vascular: hemorrhage (usually in setting of sepsis), thrombosis, and trauma
metastatic disease: (90% of adrenals must be destroyed to cause insufficiency)
deposition diseases: hemochromatosis, amyloidosis, sarcoidosis
drugs: ketoconazole, etomidate (even after single dose), rifampin, anticonvulsants
‚Ä¢ Secondary 	 pituitary failure of ACTH secretion (but aldosterone intact b/c RAA axis)
any cause of primary or secondary hypopituitarism (see ‚ÄúPituitary Disorders‚Äù)
glucocorticoid therapy (can occur after 2 wks of ‚Äúsuppressive doses‚Äù; dose effect
variable; 10 mg prednisone daily chronically can be suppressive) 
megestrol (a progestin with some glucocorticoid activity)
Clinical manifestations (NEJM 1996;335:1206)
‚Ä¢ Primary or secondary: weakness and fatigability (99%), anorexia (99%),
orthostatic hypotension (90%), nausea (86%), vomiting (75%), hyponatremia (88%)
‚Ä¢ Primary only (extra s/s due to lack of aldosterone and c ACTH): marked orthostatic
hypotension (because volume-depleted), hyperpigmentation (seen in creases, mucous
membranes, pressure areas, nipples), hyperkalemia
‚Ä¢ Secondary only:  other manifestations of hypopituitarism (see ‚ÄúPituitary Disorders‚Äù)
Diagnostic studies
‚Ä¢ Early a.m. serum cortisol: 3 g/dL virtually diagnostic; 18 g/dL rules it out
(except in severe septic shock‚Äîsee below)
‚Ä¢ Standard (250 g) cosyntropin stimulation test (testing ability of ACTH S c cortisol)
normal 	 60-min post-ACTH cortisol 18 g/dL
abnormal in primary b/c adrenal gland diseased and unable to give adequate output
abnormal in chronic secondary b/c adrenals atrophied and unable to respond
(very rarely, may be normal in acute secondary b/c adrenals still able to respond;
early a.m. cortisol can be used rather than post-stim value in these cases)
‚Ä¢ Low-dose (1 g) cort stim: ? more Se than high-dose test (controversial)
‚Ä¢ Other tests to evaluate HPA axis (w/ guidance by endocrinologist): insulin-induced
hypoglycemia (measure serum cortisol response); metyrapone (blocks cortisol synthesis
and therefore stimulates ACTH, measure plasma 11-deoxycortisol and urinary 
17-hydroxycorticosteroid levels)
‚Ä¢ Other lab abnormalities: hypoglycemia, eosinophilia, lymphocytosis,  neutropenia
‚Ä¢ ACTH: c in 1, T or low-normal in 2
‚Ä¢ Imaging studies to consider
pituitary MRI to detect anatomical abnormalities
adrenal CT: small, noncalcified adrenals in autoimmune, enlarged in metastatic disease,
hemorrhage, infection, or deposition (although they may be normal-appearing)
Adrenal insufficiency & critical illness (NEJM 2003;348:727; JAMA 2009;301:2362)
‚Ä¢ Perform ACTH stim ASAP in hypotensive Pt suspected to have absolute adrenal insuffic. 
‚Ä¢ Initiate corticosteroids early: use dexamethasone 2‚Äì4 mg IV q6h  fludrocortisone 50 g
daily prior to ACTH stim; change to hydrocortisone 50‚Äì100 mg IV q6‚Äì8h once
test completed.
‚Ä¢ Rx of relative adrenal insufficiency controversial (see ‚ÄúSepsis‚Äù).
Treatment
‚Ä¢ Acute insufficiency: volume resuscitation w/ normal saline  hydrocortisone IV as above 
‚Ä¢ Chronic insufficiency
Hydrocortisone: 20‚Äì30 mg PO qd (2‚ÅÑ3 a.m. 1‚ÅÑ3 early p.m.) or prednisone 5 mg PO qam
Fludrocortisone (not needed in 2 adrenal insufficiency): 0.05‚Äì0.1 mg PO qam
back-up dexamethasone 4 mg IM prefilled syringe given to Pt for emergency situations
ADRENAL
7-9

--- Fim da P√°gina 197 ---

PHEOCHROMOCYTOMA
Clinical manifestations (five Ps)
‚Ä¢ Pressure (hypertension, paroxysmal in 50%, severe and resistant to therapy)
‚Ä¢ Pain (headache, chest pain)
‚Ä¢ Palpitations (tachycardia, tremor, wt loss, fever)
‚Ä¢ Perspiration (profuse)
‚Ä¢ Pallor (vasoconstrictive spell)
‚Ä¢ ‚ÄúRule of 10‚Äù: 10% extra-adrenal (known as paraganglioma), 10% in children,
10% multiple or bilateral, 10% recur (c in paraganglioma), 10% malignant (c in
paraganglioma), 10% familial, 10% incidentaloma
‚Ä¢ Emotional stress does not trigger paroxysms, but abdominal manipulation can trigger
catecholamine release; some reports of IV contrast causing paroxysms
‚Ä¢ Associated with MEN 2A/2B, Von Hippel Lindau, neurofibromatosis type 1, familial
paraganglioma (mutations in succinate dehydrogenase gene, B, C and D)
Diagnostic studies
‚Ä¢ 24 urinary fractionated metanephrines & catechols: 90% Se, 98% Sp ( JCEM 2003;88:553).
Screening test of choice if low-risk (as false  with severe illness, renal failure, OSA,
labetalol due to assay interference, TCAs, medications containing sympathomimetics)
‚Ä¢ Plasma free metanephrines: 99% Se, 89% Sp (JAMA 2002;287:1427). Screening test of choice
if high-risk, but c rate of false  in low-preval. population.
‚Ä¢ Adrenal CT or MRI; consider MIBG scintigraphy if CT/MRI , PET can be used to
localize nonadrenal mass, but usually easy to find
‚Ä¢ Consider genetic testing in appropriate circumstances (bilateral, young Pt,  FHx,
extra-adrenal)
Treatment
‚Ä¢ -blockade first (usually phenoxybenzamine)  -blockade (often propranolol) S surgery
ADRENAL INCIDENTALOMAS
Epidemiology
‚Ä¢ 4% of Pts undergoing abdominal CT scan have incidentally discovered adrenal mass;
prevalence c with age
Differential diagnosis
‚Ä¢ Nonfunctioning mass: adenoma, cysts, abscesses, granuloma, hemorrhage, lipoma,
myelolipoma, primary or metastatic malignancy
‚Ä¢ Functioning mass: pheochromocytoma, adenoma (cortisol, aldosterone, sex hormones),
nonclassical CAH, other endocrine tumor, carcinoma
‚Ä¢ Nonadrenal mass: renal, pancreatic, gastric, artifact
Workup (NEJM 2007;356:601)
‚Ä¢ Rule out subclinical Cushing‚Äôs syndrome in all Pts using 1 mg overnight DST 
(Sp 91%). Abnormal results require confirmatory testing.
‚Ä¢ Rule out hyperaldosteronism if hypertensive w/ plasma aldo & renin (see above).
‚Ä¢ Rule out pheochromocytoma in all Pts (b/c of morbidity unRx‚Äôd pheo) using 24-h
urine fractionated metanephrines and catecholamines or plasma free metanephrines.
‚Ä¢ Rule out metastatic cancer and infection by history or CT-guided biopsy if suspicious
(in Pts w/ h/o cancer, 50% of adrenal incidentalomas are malignant)
‚Ä¢ CT and MRI characteristics may suggest adenoma vs. carcinoma
Benign features: size 4 cm; smooth margins, homogenous and hypodense appearance;
unenhanced CT 10 Hounsfield units or CT contrast-medium washout 
50% at
10 min. Can follow such incidentalomas w/ periodic scans.
Suspicious features: size 
4 cm or c size on repeat scan; irregular margins,
heterogeneous, dense, or vascular appearance; h/o malignancy or young age
(incidentaloma less common). Such incidentalomas warrant FNA biopsy, repeat
scan in 3 mos, or resection.
ADRENAL
7-10

--- Fim da P√°gina 198 ---

CALCIUM
7-11
CALCIUM DISORDERS
Laboratory Findings in Calcium Disorders
Ca
PTH
Disease
PO4
c
cc
Hyperparathyroidism (1 and 3)
T
c or nl
Familial hypocalciuric hypercalcemia
T
Malignancy
var.
Vitamin D excess
c
T
Milk-alkali syndrome, thiazides
T
c Bone turnover
c
T
cc
Pseudohypoparathyroidism
c
c
Vitamin D deficiency
T
Chronic renal failure (2 hyperpara)
c
var.
Acute calcium sequestration
var.
T
Hypoparathyroidism
c
Pitfalls in measuring calcium
‚Ä¢ Physiologically active Ca is free or ionized (ICa). Serum Ca reflects total calcium
(bound  unbound) and ‚à¥influenced by albumin (main Ca-binding protein)
‚Ä¢ Corrected Ca (mg/dL) 	 measured Ca (mg/dL)  {0.8  [4 - albumin (gm/dL)]}
‚Ä¢ Alkalosis will cause more Ca to be bound to albumin (‚à¥total Ca may be normal but T ICa)
‚Ä¢ Best to measure ionized Ca directly
HYPERCALCEMIA
Etiologies of Hypercalcemia
Category
Etiologies
Hyperparathyroidism
1: adenoma (85%), hyperplasia (15‚Äì20%; spont. vs. MEN
(HPT)
1/2A), carcinoma (1%)
3: after long-standing 2 hyperparathyroidism (as in renal
failure) S autonomous nodule develops, requires surgery
Lithium S c PTH
Familial hypocalciuric
Inact. mut. in Ca-sensing receptor in parathyroid and kidney
hypercalcemia (FHH)
S c Ca set point;  c PTH (and less c than in 1 hyperpara.)
Acquired form due to autoAb vs. Ca-sensing receptor (rare)
FECa [(24h UCa/serum Ca) / (24h UCr/serum Cr)] 0.01
Malignancy
PTH-related peptide (PTHrP) S humoral c Ca of malignancy
(e.g., squamous cell cancers, renal, breast, bladder)
Cytokines & c 1,25-(OH)2D3 (eg, hematologic malignancies)
Local osteolysis (eg, breast cancer, myeloma)
Vitamin D excess
Granulomas (sarcoid,TB, histo,Wegener‚Äôs) S c 1-OH S
c 1,25-(OH)2D.Vitamin D intoxication.
c Bone turnover
Hyperthyroidism, immobilization  Paget‚Äôs disease, vitamin A
Miscellaneous
Thiazides; Ca-based antacids or massive dairy 
consumption (milk-alkali syndrome); adrenal insufficiency
Among inPts w/ hypercalcemia: 45% have cancer, 25% 1 HPT, 10% CKD S 3 HPT
(JCEM 2005;90:6316)
Clinical manifestations (‚Äúbones, stones, abdominal groans, and psychic moans‚Äù)
‚Ä¢ Hypercalcemic crisis (usually when Ca 
13‚Äì15): polyuria, dehydration, mental
status s
Ca toxic to renal tubules S blocks ADH activity, causes vasoconstriction, and T GFR
S polyuria but c Ca reabsorption S c serum Ca S c nephrotoxicity and CNS sx
‚Ä¢ Osteopenia, fractures, and osteitis fibrosa cystica (latter seen in severe hyperpara. only S
c osteoclast activity S cysts, fibrous nodules, salt & pepper appearance on X-ray)
‚Ä¢ Nephrolithiasis, nephrocalcinosis, nephrogenic DI
‚Ä¢ Abdominal pain, anorexia, nausea, vomiting, constipation, pancreatitis, PUD
‚Ä¢ Fatigue, weakness, depression, confusion, coma, T DTRs, short QT interval
‚Ä¢ 1 HPT: 80% asx, 20% nephrolithiasis, osteoporosis, etc.
‚Ä¢ Calciphylaxis (calcific uremic arteriopathy): calcification of media of small- to med-sized
blood vessels of dermis & SC fat S ischemia and skin necrosis (NEJM 2007;356:1049).
Associated w/ uremia, c PTH, c Ca, c PO4, and c (Ca  PO4) product. Dx by biopsy.
Rx: aggressive wound care, keep Ca & PO4 nl (goal 55), avoid vitamin D & Ca suppl.
IV Na thiosulfate & parathyroidectomy controversial.
Overall portends a poor prognosis

--- Fim da P√°gina 199 ---

Diagnostic studies
‚Ä¢ Hyperparathyroidism and malignancy account for 90% of cases of hypercalcemia
hyperparathyroidism more likely if asx or chronic hypercalcemia
malignancy more likely if acute or sx; malignancy usually overt or becomes so in mos
‚Ä¢ Ca, alb, ICa, PTH (may be inappropriately normal in 1 hyperparathyroidism & FHH), PO4;
based on results consider checking PTHrP, 25-(OH)D, 1,25-(OH)2D, A, UCa, SPEP,
UPEP, ACE, CXR/CT, mammogram
Acute Treatment of Hypercalcemia
Treatment
Onset Duration Comments
Normal saline
h
during Rx Natriuresis S c renal Ca excretion
(4‚Äì6 L/d)
 Furosemide
h
during Rx Use only if volume overloaded.
Bisphosphonates
1‚Äì2 d
var.
Inhibit osteoclasts, useful in malignancy; caution
in renal failure; risk of jaw osteonecrosis
Calcitonin
h
2‚Äì3 d
Quickly develop tachyphylaxis
Glucocorticoids
days
days
? Useful in some malig, granulomatous disorders 
& vitamin D intox.
(NEJM 2005;352:373)
Treatment of asymptomatic 1 HPT (JCEM 2009;94:335)
‚Ä¢ Surgery if: age 50 y; serum Ca 
1 mg/dL 
ULN; CrCl 60 mL/min, DEXA T score ‚àí2.5
‚Ä¢ If not yet candidate for surgery: ‚úìserum Ca & Cr annually and BMD q1‚Äì2y
no data yet to support use of bisphosphonates, estrogen, SERMs, or calcimimetic
HYPOCALCEMIA
Etiologies of Hypocalcemia
Category
Etiologies
Hypoparathyroidism
Sporadic; familial (PGA 1, activating Ca-sensing receptor
(NEJM 2008;359:391)
mutations; see 7-2); iatrogenic (s/p thyroid, cancer surgery,
neck irradiation);Wilson‚Äôs, hemochromatosis; hypoMg (T
secretion and effect); activating Ca-sensing receptor autoAb
Pseudo-
Ia and Ib: PTH end organ resistance (‚à¥c serum PTH)
hypoparathyroidism
Ia:  skeletal abnormalities, short stature, & retardation
Pseudopseudohypoparathyroidism 	 Ia syndrome but nl Ca & PTH
Vitamin D deficiency
Nutritional/sunlight deprivation; GI disease/fat malabs.; drugs
or resistance
(anticonvulsants, rifampin, ketoconazole, 5-FU/leucovorin);
genetic (1-hydroxylase,VDR mutations)
Chronic renal failure
T 1,25-(OH)2D production, c PO4 from T clearance
Accelerated net bone
Postparathyroidectomy, Rx of severe vit D deficiency or
Formation
Paget‚Äôs disease (NEJM 2006;355:593), osteoblastic metastases
Calcium
Pancreatitis, citrate excess (after blood transfusions),
sequestration
acute cc PO4 (ARF, rhabdomyolysis, tumor lysis), bisphosphonates
Clinical manifestations
‚Ä¢ Neuromuscular irritability: perioral paresthesias, cramps,  Chvostek‚Äôs (tapping
facial nerve S contraction of facial muscles),  Trousseau‚Äôs (inflation of BP cuff S
carpal spasm), laryngospasm; irritability, depression, psychosis, c ICP, seizures, c QT
‚Ä¢ Rickets and/or osteomalacia: chronic T vit D S T Ca, T PO4 S T bone/cartilage
mineralization, growth failure, bone pain, muscle weakness
‚Ä¢ Renal osteodystrophy (T vit D & c PTH in renal failure): osteomalacia (T mineralization
of bone due to T Ca and 1,25-(OH)2D) & osteitis fibrosa cystica (due to c PTH)
Diagnostic studies
‚Ä¢ Ca, alb, ICa, PTH, 25-(OH)D, 1,25-(OH)2D (if renal failure or rickets), Cr, Mg, PO4, A, UCa
Treatment (also treat concomitant vitamin D deficiency)
‚Ä¢ Symptomatic: intravenous Ca gluconate (1‚Äì2 g IV over 20 mins)  calcitriol (most
effective in acute hypocalcemia, but takes hrs to work)  Mg (50‚Äì100 mEq/d)
‚Ä¢ Asymptomatic and/or chronic: oral Ca (1‚Äì3 g/d) & vitamin D (eg, ergocalciferol 50,000 IU
PO q wk  8‚Äì10 wks). In chronic hypopara., calcitriol is needed, consider also thiazide
‚Ä¢ Chronic renal failure: phosphate binder(s), oral Ca, calcitriol or analog (calcimimetic
may be needed later to prevent hypercalcemia)
CALCIUM
7-12

--- Fim da P√°gina 200 ---

DIABETES
7-13
DIABETES MELLITUS
Definition (Diabetes Care 2003;26:S33 & 2009;32:1327)
‚Ä¢ Fasting glc 126 mg/dL  2; random glc 200 mg/dL  2 or  1 if severe 
hyperglycemia and acute metabolic decompensation; or 75 g OGTT w/ 2-h glc
200 mg/dL (routine OGTT not recommended)
‚Ä¢ Blood glc higher than normal, but not frank DM (‚Äúprediabetics,‚Äù 40% U.S. population)
Impaired fasting glc (IFG): 100‚Äì125 mg/dL
Impaired glc tolerance (IGT): 140‚Äì199 mg/dL 2 h after 75 g OGTT
Preventing progression to DM: diet & exercise (58% T), metformin (31% T), TZD (60% T)
‚Ä¢ c HbA1C (no accepted criterion yet, 6.5% recommended by intl expert cmte)
Categories
‚Ä¢ Type 1: islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin
prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; c risk
if  FHx; HLA associations; anti-GAD, anti-islet cell & anti-insulin autoantibodies 
‚Ä¢ Type 2: insulin resistance  relative insulin deficiency
prevalence 8%; onset generally later in life; cc risk if  FHx; no HLA associations
risk factors: age,  FHx, obesity, sedentary lifestyle
‚Ä¢ Type 2 DM p/w DKA (‚Äúketosis-prone type 2 diabetes‚Äù): most often seen in nonwhite,
 anti-GAD Ab, eventually may not require insulin (Endo Rev 2008;29:292)
‚Ä¢ Mature-Onset Diabetes of the Young (MODY): autosomal dom. forms of DM due to
defects in insulin secretion genes; genetically and clinically heterogeneous (NEJM 2001;345:971)
‚Ä¢ Secondary causes of diabetes: exogenous glucocorticoids, glucagonoma (3 Ds 	
DM, DVT, diarrhea), pancreatic (pancreatitis, hemochromatosis, CF, resection),
endocrinopathies (Cushing‚Äôs disease, acromegaly), gestational, drugs (protease
inhibitors, atypical antipsychotics)
Clinical manifestations
‚Ä¢ Polyuria, polydipsia, polyphagia with unexplained weight loss; can also be asymptomatic
Diabetes Treatment Options
Diet
Type 1: carb counting;Type 2: wt reduction diet  exercise
Metformin
T hepatic gluconeogenesis, T HbA1C 1.5%
Wt neutral, N/V & diarrhea, rare lactic acidosis
Contraindic. in renal (eg, Cr 
1.5) or liver failure
Consider first-line Rx w/ lifestyle mod. for all T2D w/ HbA1C 7%
Sulfonylureas (SU)
c insulin secretion, T HbA1C 1.5%. Hypoglycemia, wt gain.
Thiazolidinediones (TZD)
c insulin sens. in adipose & muscle. T HbA1C 1%
(PPAR agonists)
Wt gain, hepatotoxicity, fluid retention & CHF, bone fractures
? c MI w/ rosiglitazone (NEJM 2007;356:2457; Lancet 2009;373:2125)
but not w/ pioglitazone (JAMA 2007;298:1180)
Contraindic. in liver disease and NYHA III‚ÄìIV, monitor LFTs
Glinides
c insulin secretion, T HbA1C 1.5%
Hypoglycemia (but less than w/ SU), wt gain
Exenatide
c glc-depend insulin secretion (GLP-1 agonist), T HbA1C 0.5%
Wt loss, N/V & diarrhea (30‚Äì45%), pancreatitis (rare)
-glucosidase inhibitor
T intestinal CHO absorption, T HbA1C 0.5‚Äì0.8%. GI distress (gas).
Pramlintide
Delays gastric emptying & T glucagon, T HbA1C 0.5%
To be used as adjunctive Rx w/ insulin in T1D or T2D
DPP-4 inhibitor
Blocks degrad. of GLP-1 & GIP S c insulin. T HbA1C 0.5%.
Insulin
Hypoglycemia, wt gain
Generally combine intermed./long-acting (NPH or glargine) and
(Additional T1D options:
short/rapid-acting (regular or lispro) insulin for all T1D.
insulin pump, pancreatic
In T2D, consider starting if mono oral Rx not adequate (espec if 
or islet cell transplant)
c HbA1c high) and definitely start if combo oral Rx not adequate.
( JAMA 2002;287:360, 373; Diabetes Care 2009;32:193)
Insulin Preparations
Preparation
Onset
Peak
Duration
Side effects/Comments
Lispro, aspart
5‚Äì15 min
60‚Äì90 min
2‚Äì4 h
Give immediately before meal
Regular
30‚Äì60 min
2‚Äì4 h
5‚Äì8 h
Give 30 min before meal
NPH
1‚Äì2 h
4‚Äì8 h
12‚Äì18 h
Can cause protamine Ab prod
Glargine
2 h
No peak
20‚Äì24 h
Once daily (AM or PM)
(NEJM 2005;352:174)

--- Fim da P√°gina 201 ---

Complications
‚Ä¢ Retinopathy
non-proliferative: ‚Äúdot & blot‚Äù and retinal hemorrhages, cotton-wool/protein exudates
proliferative: neovascularization, vitreous hemorrhage, retinal detachment, blindness
treatment: photocoagulation, surgery
‚Ä¢ Nephropathy: microalbuminuria S proteinuria 	 nephrotic syndrome S renal failure
diffuse glomerular basement membrane thickening/nodular pattern (Kimmelstiel-Wilson)
usually accompanied by retinopathy; lack of retinopathy suggests another cause
treatment: strict BP control using ACE inhibitors (NEJM 1993;329:1456 & 35:1941; Lancet
1997;349:1787) or ARBs (NEJM 2001;345:851, 861), low-protein diet, dialysis, or transplant
‚Ä¢ Neuropathy
symmetric peripheral: symmetric distal sensory loss, paresthesias, 	 motor loss
autonomic: gastroparesis, constipation, neurogenic bladder, erectile dysfxn, orthostasis
mononeuropathy: sudden-onset peripheral or CN deficit (footdrop, CN III VI  IV)
‚Ä¢ Accelerated atherosclerosis: coronary, cerebral, and peripheral arterial beds
‚Ä¢ Infections: UTI, osteomyelitis of foot, candidiasis, mucormycosis, necrotizing external otitis
‚Ä¢ Dermatologic: necrobiosis lipoidica diabeticorum, lipodystrophy, acanthosis nigricans
Outpatient screening and treatment goals (Diabetes Care 2009;32:193 & S1:S13)
‚Ä¢ ‚úìHbA1C q3‚Äì6mo, goal 7% for most Pts (NEJM 2008;358:2545, 2560); microvascular &
macrovascular complications T by strict glycemic control in T1D (NEJM 1993;329:997 &
2005;353:2643) & T2D (Lancet 1998;352:837; NEJM 2008;359:1577; Lancet 2009;373:1765; Annals 2009;151:394)
‚Ä¢ Microalbuminuria screening yearly with spot microalbumin/Cr ratio, goal 30 mg/g
‚Ä¢ BP 130/80; LDL 100,TG 150, HDL 40; benefit of statins even w/o overt CAD
(Lancet 2003;361:2005 & 2004;364:685);ASA if age 50 () or 60 () or other cardiac risk
factors (Circ 2010;121:2694)
‚Ä¢ Dilated retinal exam yearly; comprehensive foot exam qy (Diabetes Care 2009;32:51, 513)
Management of hyperglycemia in inpatients 
‚Ä¢ Identify reversible causes/exacerbaters (dextrose IVF, glucocorticoids, postop, c carb diet)
‚Ä¢ Dx studies: BG fingersticks (fasting, qAC, qHS; or Q6h if NPO), HbA1C
‚Ä¢ Treatment goals: avoid hypoglycemia, extreme hyperglycemia (180 mg/dL)
‚Ä¢ Modification of outPt treatment regimen: In T1D, do not stop basal insulin (can cause DKA).
In T2D: stopping oral DM meds generally preferred to avoid hypoglycemia or med
interaction (except if short stay, excellent outPt cntl, no plan for IV contrast, nl diet) 
‚Ä¢ InPt insulin: can use outPt regimen as guide; if insulin na√Øve:
total daily insulin  wt (kg) 
 2, to start; adjust as needed
give 1‚ÅÑ2 of total daily insulin as basal insulin in long-acting form to target fasting glc  
give other 1‚ÅÑ2 as short-acting boluses (standing premeal & sliding scale corrective insulin)
‚Ä¢ Discharge regimen: similar to admission regimen unless poor outPt cntl or strong
reason for .Arrange early insulin and glucometer teaching, prompt outPt follow-up.
DIABETIC KETOACIDOSIS (DKA)
Precipitants (the Is)
‚Ä¢ Insulin defic. (ie, failure to take enough insulin); Iatrogenesis (glucocorticoids)
‚Ä¢ Infection (pneumonia, UTI) or Inflammation (pancreatitis, cholecystitis)
‚Ä¢ Ischemia or Infarction (myocardial, cerebral, gut); Intoxication (alcohol, drugs)
Pathophysiology
‚Ä¢ Occurs in T1D (and in ketosis-prone T2D); c glucagon and T insulin
‚Ä¢ Hyperglycemia due to: c gluconeogenesis, c glycogenolysis, T glucose uptake into cells
‚Ä¢ Ketosis due to: insulin deficiency S mobilization and oxidation of fatty acids,
c substrate for ketogenesis, c ketogenic state of the liver, T ketone clearance
Clinical manifestations (Diabetes Care 2003;26:S109)
‚Ä¢ Polyuria, polydipsia, & dehydration S c HR, HoTN, dry mucous membranes, T skin turgor 
‚Ä¢ Nausea, vomiting, abdominal pain (either due to intra-abdominal process or DKA), ileus
‚Ä¢ Kussmaul‚Äôs respirations (deep) to compensate for metabolic acidosis with odor of acetone
‚Ä¢  MS S somnolence, stupor, coma; mortality 1% even at tertiary care centers
Diagnostic studies
‚Ä¢ c anion gap metabolic acidosis: can later develop nonanion gap acidosis due to
urinary loss of ketones (HCO3 equivalents) and fluid resuscitation with chloride
‚Ä¢ Ketosis:  urine and serum ketones (acetoacetate measured by nitroprusside, but
predominant ketone is -OH-butyrate; urine ketones may be  in fasting normal Pts)
‚Ä¢ c serum glc; c BUN & Cr (dehydration 	 artifact due to ketones interfering w/ some assays)
‚Ä¢ Pseudohyponatremia: corrected Na  measured Na  [2.4  (measured glc ‚Äì100)/100]
‚Ä¢ T or c K (but even if serum K is elevated, usually total body K depleted); T total body phos
‚Ä¢ Leukocytosis, c amylase (even if no pancreatitis)
DIABETES
7-14

--- Fim da P√°gina 202 ---

DIABETES
7-15
Typical DKA ‚ÄúFlow sheet‚Äù Setup
VS
UOP
pH
HCO3
AG
Ketones
Glc
K
PO4
IVF
Insulin
Note: Main ketone produced is -OH-butyrate (OHB), but ketone measured by nitroprusside is acetoacetate
(Ac-Ac). As DKA is treated, OHB S Ac-Ac, ‚à¥AG can decrease while measured ketones can increase.
Treatment of DKA
Rule out possible precipitants
Infection, intra-abdominal process, MI, etc.
Aggressive hydration
NS 10‚Äì14 mL/kg/h, tailor to dehydration & CV status
Insulin
10 U IV push followed by 0.1 U/kg/h
Continue insulin drip until AG normal
If glc 250 and AG still high S add dextrose to IVF
and continue insulin to metabolize ketones
AG normal S SC insulin (overlap IV & SC 2‚Äì3 h)
Electrolyte repletion
K: add 20‚Äì40 mEq/L IVF if serum K 4.5
insulin promotes K entry into cells S T serum K
careful K repletion in Pts with renal failure
HCO3: ? replete if pH 7 or if cardiac instability
PO4: replete if 1
HYPEROSMOLAR HYPERGLYCEMIC STATE
Definition, Precipitants, Pathophysiology (Diabetes Care 2003;26:S33)
‚Ä¢ Extreme hyperglycemia (w/o ketoacidosis)  hyperosm.   MS in T2D (typically elderly)
‚Ä¢ Precip same as for DKA, but also include dehydration and renal failure
‚Ä¢ Hyperglycemia S osmotic diuresis S vol depletion S prerenal azotemia S c glc, etc.
Clinical manifestations & dx studies (Diabetes Care 2006;29[12]:2739)
‚Ä¢ Volume depletion and  MS
‚Ä¢ c serum glc (usually 
600 mg/dL) and c meas. serum osmolality (
320 mOsm/L)
effective Osm 	 2  Na (mEq/L)  glc (mg/dL)/18 
‚Ä¢ No ketoacidosis; usually c BUN & Cr; [Na] depends on hyperglycemia & dehydration
Treatment (r/o possible precipitants; 15% mortality due to precipitating factors)
‚Ä¢ Aggressive hydration: initially NS, then 1/2 NS, average fluid loss up to 8‚Äì10 L
‚Ä¢ Insulin (eg, 10 U IV followed by 0.05‚Äì0.1 U/kg/h)
HYPOGLYCEMIA
Etiologies in diabetics
‚Ä¢ Excess insulin, oral hypoglycemics, missed meals, renal failure (T insulin & SU clearance)
‚Ä¢ -blockers can mask symptoms of hypoglycemia
Etiologies in nondiabetics
‚Ä¢ c insulin: exogenous insulin, sulfonylureas, insulinoma, anti‚Äìinsulin antibodies
‚Ä¢ T glucose production: hypopituitarism, adrenal insufficiency, glucagon deficiency,
hepatic failure, renal failure, CHF, alcoholism, sepsis
‚Ä¢ c IGF-II: non‚Äìislet tumor
‚Ä¢ Postprandial, esp. postgastrectomy or gastric bypass: excessive response to glc load
‚Ä¢ Low glc w/o sx can be normal
Clinical manifestations (glucose 55 mg/dL)
‚Ä¢ CNS: headache, visual s,  MS, weakness, seizure, LOC (neuroglycopenic sx)
‚Ä¢ Autonomic: diaphoresis, palpitations, tremor (adrenergic sx)
Evaluation in nondiabetics (J Clin Endocrinol Metab 2009;94:709)
‚Ä¢ If clinically ill: take measures to avoid recurrent hypoglycemia; ‚úìBUN, Cr, LFTs,TFTs;
IGF-I/IGF-II ratio when appropriate
‚Ä¢ If otherwise healthy: 72-h fast w/ monitored blood glc; stop for neuroglycopenic sx
‚Ä¢ At time of hypoglycemia: insulin, C peptide (c w/ insulinoma and sulfonylureas, T w/
exogenous insulin), -OH-butyrate, sulfonylurea levels
‚Ä¢ At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding
Treatment
‚Ä¢ Glucose tablets, paste, fruit juice are first-line Rx for Pts who can take POs
‚Ä¢ If IV access available, give 25‚Äì50 g of D50 (50% dextrose)
‚Ä¢ If no IV, can give glucagon 0.5‚Äì1 mg IM or SC (side effect: N/V)

--- Fim da P√°gina 203 ---

LIPID
7-16
LIPID DISORDERS
Measurements
‚Ä¢ Lipoproteins 	 lipids (cholesteryl esters & triglycerides)  phospholipids  proteins
include: chylomicrons,VLDL, IDL, LDL, HDL, Lp(a)
‚Ä¢ Measure after 12-h fast; LDL is calculated 	 TC - HDL - (TG/5) (if TG 
400, order
direct LDL measurement as calc. LDL inaccurate). Lipid levels stable up to 24 h
after ACS and other acute illnesses, then T and may take 6 wks to return to nl.
‚Ä¢ Metabolic syndrome (3 of following):waist 40‚Äù () or 35‚Äù ();TG 150;HDL 40 mg/dL
() or 50 mg/dL (); BP 130/85 mm Hg; fasting glc 100 mg/dL (Circ 2009;120:1640)
Secondary Dyslipidemias
Category
Disorders
Endocrinopathies
Type 2 diabetes (c TG, T HDL)
Hypothyroidism (c LDL, c TG); hyperthyroidism (T LDL)
Cushing‚Äôs syndrome & exogenous steroids (c TG)
Renal diseases
Renal failure (c TG); nephrotic syndrome (c LDL)
Hepatic diseases
Cholestasis, PBC (c LDL); liver failure (T LDL); acute hepatitis (c TG)
Lifestyle
Obesity (c TG, T HDL); sedentary lifestyle (T HDL);
alcohol (c TG, c HDL); tobacco (T HDL)
Medications
Thiazides (c LDL); -blockers (c TG, T HDL)
Estrogens (c TG, c HDL); protease inhibitors (c TG)
Primary dyslipidemias
‚Ä¢ Familial hypercholesterolemia (FH, 1:500): defective LDL receptor; cc chol, nl TG; c CAD
‚Ä¢ Familial defective apoB100 (FDB, 1:1000): similar to FH
‚Ä¢ Familial combined hyperlipidemia (FCH, 1:200): polygenic; c chol, c TG, T HDL; c CAD
‚Ä¢ Familial dysbetalipoproteinemia (FDBL, 1:10,000): apoE 2/2  DM, obesity, renal disease,
etc.; c chol and TG; tuberoeruptive and palmar striated xanthomas; c CAD
‚Ä¢ Familial hypertriglyceridemia (FHTG, 1:500): c TG,  c chol, T HDL, pancreatitis
Physical examination findings
‚Ä¢ Tendon xanthomas: seen on Achilles, elbows, and hands; imply LDL 
300 mg/dL
‚Ä¢ Eruptive xanthomas: pimplelike lesions on extensor surfaces; imply TG 
1000 mg/dL
‚Ä¢ Xanthelasma: yellowish streaks on eyelids seen in various dyslipidemias
‚Ä¢ Corneal arcus: common in older adults, imply hyperlipidemia in young Pts
Treatment
‚Ä¢ Every 1 mmol (39 mg/dL) T LDL S 21% T major vascular events (CV death, MI, stroke,
revasc) in individuals w/ & w/o CAD (Lancet 2005;366:1267); in healthy individuals w/
LDL 130 mg/dL & hs-CRP 
2, rosuvastatin S 47% T CVD/MI/stroke (NEJM 2008;359:2195)
‚Ä¢ Fewer clinical data, but TG 400 and HDL 
40 are additional reasonable targets
NCEP Guidelines
Clinical risk
LDL Goal
High: CHD, CVD, PAD,AAA, DM,
100 mg/dL
or 2 RFs & 10-y risk 
20%
or 70 if very high risk
(ACS, CAD  multiple RFs or  met syndrome)
Mod high: 2 RFs & 10-y risk 10‚Äì20%
130 mg/dL (optional 100 mg/dL)
Mod: 2 RFs & 10-y risk 10%
130 mg/dL
Lower: 0‚Äì1 RFs
160 mg/dL
RFs: male 45 y or female 55 y, smoking, HTN,  FHx, HDL 40. If HDL 
60, subtract 1 RF. Framingham
10-y CHD risk score at www.nhlbi.nih.gov/guidelines/cholesterol. (JAMA 2001;285:2486; Circulation 2004;110:227)
Drug Treatment
Drug
T LDL
c HDL
TTG
Side effects/comments
Statins
20‚Äì60%
5‚Äì10%
10‚Äì25%
c aminotransferases in 0.5‚Äì3%; ‚úìLFTs before, at 
8‚Äì12 wks, and then q6mos; risk dose-depend.
Myalgias 10% (not always c CK), myositis 0.5%,
rhabdo 0.1%, risk dose-depend.
Doubling of dose S 6% further T LDL.
Ezetimibe
15‚Äì20%
‚Äî
‚Äî
Well tolerated; typically w/ statin
Fibrates
5‚Äì15%
5‚Äì15%
35‚Äì50%
Myopathy risk c w/ statin. Dyspepsia, gallstones
Niacin
10‚Äì25%
30%
40%
Flushing (Rx w/ ASA), pruritis, c glc, gout,
nausea, severe hepatitis (rare)
Resins
20%
3‚Äì5%
? c
Bloating, binds other meds
-3 FA
5% c
3%
25‚Äì30%
Dyspepsia, diarrhea

--- Fim da P√°gina 204 ---

ARTHRITIS
8-1
ARTHRITIS‚ÄîOVERVIEW
Approach to patient with joint pain
‚Ä¢ Hx: distinguish joint vs. soft tissue pain, inflammatory vs. noninflammatory pain
Features suggestive of inflammatory pain: swelling in specific joint (w/o h/o trauma),
persistence over days to weeks, morning stiffness, improvement of pain and stiffness
w/ motion & exercise, improvement w/ NSAIDs or steroids
‚Ä¢ Physical exam (see later): localize complaint and determine if there are objective
signs of inflammation (arthritis, bursitis, tendinitis) or noninflammatory pain
(arthralgia, myofascial pain)
‚Ä¢ Osteoarthritis can p/w bony enlargement or crepitus, w/ or w/o noninflammatory
effusion
Key Physical Exam Findings in Joint Pain
Joint
Soft tissues
Physical exam
Inflammatory
Arthralgia
Bursitis
Tendonitis
Myofascial
Arthritis
Inspection
Swelling
yes
no
yes
yes
no
Erythema
varies
no
yes
usually
no
Palpation
Warmth
yes
no
yes
usually
no
Tenderness
varies
varies
over bursa
over tendon
yes
ROM*
ROM
limited
full or 
full
full, often 
full
limited
limited by 
pain
Pain w/ active or
both
usually both
varies
active 
usually both
passive ROM
passive
*Range of motion (ROM) of joint or joint associated with bursa or tendon
Approach to arthritis
# Joints involved
acute
chronic
Inflammation?
Infection
Trauma/Hemarthrosis
Crystal deposition
Reactive
Early chronic cause
Yes
Osteoarthritis
Internal derangement
Osteonecrosis
Tumor
Duration?
Indolent infection
Early oligo/poly
Indolent infection
Spondyloarthritis
Early poly
Rheumatoid
Lupus
Myositis
Systemic Sclerosis
CPPD disease
mono
oligo
poly
No
Figure 8-1 Approach to arthritis
Etiologies of Arthritis by Joint
Shoulder
OA, calcific (Milwaukee shoulder), septic, CPPD
Elbow
Septic, spondyloarthritis, juvenile idiopathic arthritis (common nonarthritic
causes of pain incl. olecranon bursitis and lateral epicondylitis)
Wrist
RA, CPPD, septic, gout, adult-onset Still‚Äôs disease
1st CMC
OA
MCP
RA, CPPD, psoriatic, gout
PIP
OA, RA, psoriatic, gout
DIP
OA, psoriatic, gout
Hip
OA, septic, spondyloarthritis, osteonecrosis
Knee/ankle
OA, RA, gout, CPPD, psoriatic, septic, Lyme, spondyloarthritis, sarcoidosis
Toes
Gout, OA, spondyloarthritis, psoriatic

--- Fim da P√°gina 205 ---

ARTHRITIS
8-2
Comparison of Major Arthritides
Feature
OA
RA
Gout
Spondylo-
arthritis
Onset
gradual
gradual
acute
variable
Inflammation




Pathology
degeneration
pannus
microtophi
enthesitis
# of joints
poly
poly
mono to poly
oligo or poly
Type of joints
small or large
small
small or large
large
Locations
hips, knees, spine
MCP, PIP
MTP
sacroiliac
typically
1st CMC
wrists
feet, ankles
spine
involved
DIP, PIP
feet, ankles
knees
large peripheral
Special
Bouchard‚Äôs nodes
ulnar dev.
urate
en bloc spine
articular
Heberden‚Äôs nodes
swan neck
crystals
enthesopathy
findings
boutonni√®re
(eg,Achilles)
Bone
osteophytes
osteopenia
erosions
erosions
changes
erosions
ankylosis
Extra-
SC nodules
tophi
uveitis
articular
pulmonary
olec. bursitis
conjunctivitis
features
cardiac
renal stones
aortic insuff.
splenomegaly
psoriasis
IBD
Lab data
normal
 RF,
c UA
anti-CCP
Analysis of Joint Fluid
Test
Normal
Noninflammatory
Inflammatory
Septic
Appearance
clear
clear, yellow
clear to opaque
opaque
yellow-white
WBC/mm3
200
2000
2000
2000
usually 50K
Polys
25%
25%
50%
75%
Culture




Conditions
OA, internal
RA, crystal
infection
derangement
CTD
spondyloarth.

--- Fim da P√°gina 206 ---

RA
8-3
RHEUMATOID ARTHRITIS (RA)
Definition and epidemiology
‚Ä¢ Chronic, symmetric, debilitating, and destructive polyarthritis caused by inflammatory,
proliferative synovial tissue (pannus) formation in affected joints
‚Ä¢ Genetic factors: c incidence in Pts w/ shared epitope on class II MHC DRB1 and DR4
‚Ä¢ Environmental factors: smoking, silica dust exposure
‚Ä¢ c risk w/ shared epitope & smoke b/c gene‚Äìenvironment interaction (Ann Rheum Dis 2010;69:70)
‚Ä¢ Prevalence  1% of adults; female:male  3:1; onset 35‚Äì50 y; worldwide
Clinical manifestations (Lancet 2001;358:903)
‚Ä¢ Pain, swelling, and impaired function of joints (typically PIPs, MCPs, wrists, knees,
ankles, MTPs, and cervical spine) with morning stiffness for 1 h
‚Ä¢ Polyarticular in 75% (60% small joints, 30% large joints, 10% both), monoarticular in
25% (knee, shoulder, wrist)
‚Ä¢ Joint immobilization, muscle shortening, bone & cartilage destruction, joint deformities:
ulnar deviation, swan neck (MCP flexion, PIP hyperextension, DIP flexion),
boutonni√®re (PIP flexion, DIP hyperextension), cock-up deformities (toes)
‚Ä¢ C1‚ÄìC2 instability S myelopathy, ‚à¥‚úìC-spine flex/ext films prior to elective intubation
‚Ä¢ Rheumatoid nodules (20‚Äì30%; usually in sero- Pts): SC nodules on extensor 
surfaces along tendon sheaths and in bursae; also occur in lung, heart, and sclera
‚Ä¢ Constitutional symptoms: fever, weight loss, malaise
‚Ä¢ Ocular: scleritis, episcleritis, keratoconjunctivitis sicca (associated Sj√∂gren‚Äôs)
‚Ä¢ Pulmonary (20% of the time precedes joint manifestations)
ILD: COP, fibrosis, nodules, Caplan‚Äôs syndrome (pneumoconiosis  rheumatoid nodules)
pleural disease: pleuritis, pleural effusions (classically low glucose)
pulmonary hypertension
airway disease: obstruction (cricoarytenoid arthritis), bronchiolitis, bronchiectasis
‚Ä¢ Cardiac: pericarditis (effusion in 13 of sero-), myocarditis, nodules can cause valvular
and/or conduction disease. Associated with c risk of cardiovascular death com-
pared with that of general population (Rheum 2009;48:1309).
‚Ä¢ Heme: anemia of chronic inflammation, leukemia, lymphoma
‚Ä¢ Vascular: small nail fold infarcts, palpable purpura, leukocytoclastic vasculitis
‚Ä¢ Renal: glomerulonephritis (membranous, mesganigal, MPGN); nephrotic syndrome
due to AA amyloidosis; Rx-induced, including NSAIDs (AIN, membranous GN),
gold, MTX 
‚Ä¢ Longstanding seropositive, erosive RA:
Felty‚Äôs syndrome (1%): neutropenia, RF , splenomegaly; c risk of NHL
large granular lymphocyte syndrome: neutropenia, lymphocytosis blood/marrow
‚Ä¢ Remember that rheumatoid joints can become superinfected
Laboratory and radiologic studies
‚Ä¢ RF (IgM anti-IgG Ab) in 85% of Pts; nonspecific as also seen in other rheumatic 
diseases (SLE, Sj√∂gren‚Äôs), chronic inflammation (SBE, hepatitis,TB), type II cryoglob-
ulinemia, 5% of healthy population
‚Ä¢ ACPA (anti‚Äìcitrullinated peptide Ab) or anti-CCP (Ab to cyclic citrullinated peptide): simi-
lar Se (80%), more Sp (90%) than RF particularly for early RA (Arth Rheum 2009;61:1472)
‚Ä¢ c ESR and CRP;  ANA in 15%; c globulin during periods of active disease; anemia
‚Ä¢ Radiographs of hands and wrists: periarticular osteopenia, bone erosions, and deformities
ACR/EULAR Classification Criteria (Arth Rheum 2010; in press)
‚Ä¢ Use for Pts with 1 joint with synovitis not better explained by another disease 
‚Ä¢ Summed score of 6 c/w RA
Joint involvement
Score
Acute phase reactants
Score
1 med-large
0
Normal ESR & CRP
0
2‚Äì10 med-large
1
Abnormal ESR or CRP
1
1‚Äì3 small
2
Duration of sx
Score
4‚Äì10 small
3
6 wk
0
10 (1 small)
5
6 wk
1
Serology
Score
RF & ACPA 
0
Low- RF or ACPA
2
High- RF or ACPA
3
Choose highest number from each category and add for
total score. Small joints exclude 1st MTP & 1st CMC;
med-large joints  elbows, shoulders, hips, knees, ankles.
Low- serology 3 ULN.

--- Fim da P√°gina 207 ---

Management (Lancet 2009;373:659)
‚Ä¢ Early dx and Rx w/ frequent follow-up and escalation of Rx as needed S T disease
activity and radiographic progression, c physical fxn and quality of life 
‚Ä¢ Initial therapy:nonselective NSAIDs (? c CV adverse events) or COX-2 inhibitors (c CV
adverse events w/ some): sx control as indicated; glucocorticoids (joint injection
or low-dose oral): acutely T inflammation; physical and occupational therapy
‚Ä¢ Start Disease-Modifying Anti-Rheumatic Drug (DMARD) w/in 3 mo if established
disease and ongoing inflammation (Annals 2007;146:406); all take 1 mo to have an effect
DMARDs
Class
Drug
Side effects
Methotrexate (MTX) 
Antimetab Leflunomide
Azathioprine (AZA)
Anti-TNF: etanercept, infliximab,
adalimumab, certolizumab, golimumab
IL-1RA: anakinra
Biologic
CTLA4-Ig: abatacept
IL-6R Ab: tocilizumab
Anti-CD20: rituximab
Hydroxychloroquine (HCQ)
Retinopathy, maculopapular rash
Sulfasalazine (SAS)
Allergic rxn. Need folate suppl.
Other
Gold
Minocycline
Cyclosporine
Nephrotox, HTN, gum hyperplasia
(NEJM 2005;353:1114 & 2006;350:2572; Arth Rheum 2008;11:3319; Lancet 2008;371:987 & 2009;374:210)
‚Ä¢ Treatment strategies (Lancet 2008;372:375 & 374:459; Ann Rheum Dis 2010;69;976 & 987)
monotherapy with MTX (a/w lower mortality; Lancet 2007;359:1173), sulfasalazine,
leflunomide, or hydroxychloroquine, or
combination of DMARD  glucocorticoid or anti-TNF (Arth Rheum 2005;52:3360 & 3371)
eg, MTX  anti-TNF c remission rate vs. MTX alone (Lancet 2008;372:375)
escalation Rx S add medication (usually biologic) or change DMARD, eg, if
suboptimal response to MTX, addition of anti-TNF superior to SAS & HCQ
biologics: never use 2 biologics concurrently in the same Pt
RELAPSING POLYCHONDRITIS
Definition & Epidemiology
‚Ä¢ Inflammatory destruction of cartilaginous structures
‚Ä¢ Defined by chondritis in 2 of the following sites: auricular, nasal, or laryngotracheal;
or chondritis in 1 of these sites  2 other manifestations (below) (Annals 1986;104:74)
‚Ä¢ 40% of cases a/w immunologic disorder (eg, RA, SLE, vasc., Sj√∂gren‚Äôs), cancer, or MDS  
‚Ä¢ Mean age at diagnosis is 47 y, men  women
Clinical manifestations (Curr Opin Rheumatol 2004;16:56)
‚Ä¢ Subacute onset of red, painful, and swollen cartilage; ultimately atrophic & deformed
‚Ä¢ Relapsing-remitting pattern
‚Ä¢ Frequency of involved cartilage: external ear (89%), migratory asymmetric nonerosive
arthropathy (72%), episcleritis/scleritis (59%), laryngotracheal sx (55%), inner ear
(28%), nasal cartilage, saddle deformity (25%), skin (25%), laryngotracheal stricture
(23%), kidney (22%), heart valves (12%), AI  MR
‚Ä¢ Ddx: Infxn (eg, Pseudomonal external otitis),Wegener‚Äôs, IBD chondritis, trauma
Diagnosis
‚Ä¢ Clinical diagnosis based on exam with multiple sites of cartilaginous inflammation
‚Ä¢ Labs: c ESR & CRP, leukocytosis, eosinophilia, anemia of chronic inflammation
‚Ä¢ Bx (not req for dx): proteoglycan depletion, perichondrial inflammation and replacement
with granulation tissue and fibrosis; immunofluorescence with Ig and C3 deposits
Evaluation and Treatment
‚Ä¢ Screen for pulm (PFTs, CXR/CT,  bronch) and cardiac (ECG,TTE) involvement
‚Ä¢ Therapy guided by disease activity and severity: steroids first line; NSAIDs, dapsone
for sx control of arthralgias and mild disease; MTX or AZA for steroid-sparing;
cyclophosphamide for organ-threatening disease
RA/RP
8-4
GI distress, myelosupression,
hepatotoxicity. Supplement MTX
w/ folate.
TB, zoster, & other infxns. ‚à¥screen 
for TB prior to starting Rx.
? tumors.
? CHF & demyelinating CNS 
disease for anti-TNF. 

--- Fim da P√°gina 208 ---

GOUT
8-5
CRYSTAL DEPOSITION ARTHRITIDES
GOUT
Definition & Pathobiology (Lancet 2010;375:318)
‚Ä¢ Monosodium urate (MSU) crystal deposition in joints and other tissues  
‚Ä¢ Activate cryopyrin inflammasome S IL-1	 S inflammation (Nature 2006;440:237)
Epidemiology
‚Ä¢ More common in men than in women (9:1); peak incidence 5th decade
‚Ä¢ Most common cause of inflammatory arthritis in men over 30 y
‚Ä¢ Rare in premenopausal women (estrogens promote renal urate excretion)
‚Ä¢ Risk factors: c serum uric acid (UA) related to metabolic syndrome; HTN; chronic kid-
ney disease; c intake of meat, seafood, and EtOH (Lancet 2004;363:1277; NEJM 2004;350:1093) 
Etiologies
‚Ä¢ Uric acid (UA) is end product of purine catabolism and is renally excreted
UA Overproduction
UA Underexcretion
Primary
Idiopathic
Idiopathic
hyperuricemia
Rare inherited enzyme (HGPRT, PRPP) defic.
Common genetic variants (Lancet 2008;372:1953)
Secondary
c meat, seafood, EtOH intake
Dehydration
hyperuricemia
Myelo- & lymphoproliferative dis.
T renal function
Chronic hemolytic anemia
Drugs: diuretics, PZA,
Cytotoxic drugs, psoriasis
EMB, salicylates, CsA
Severe muscle exertion
Keto- or lactic acidosis
(Lancet 2004;363:1277; NEJM 2004;350:1093; Annals 2005;143:499)
Clinical manifestations
‚Ä¢ Acute arthritis: sudden onset (freq. nocturnal) of painful monoarticular arthritis
location: MTP of great toe (‚Äúpodagra‚Äù), feet, ankles, knees; occasionally polyarticular
overlying skin is warm, tense, dusky red; Pt may be febrile
precipitants: rapid 
 UA; c dietary purine; surgery; infection; diuretics, dehydration
‚à¥frequent in hospitalized Pts
recovery: subsides in 3‚Äì10 d; intercritical period  remission of joint pain between attacks
‚Ä¢ Tophi: deposits of urate crystals in SC tissue & joints; commonly in joints of fingers, wrists,
knees; also on pinna,Achilles tendon, and pressure areas, eg, ulnar aspect of forearm
‚Ä¢ Bursitis: olecranon, patellar (must be differentiated from intra-articular effusion)
‚Ä¢ Chronic tophaceous gout: deforming arthritis from tophus formation S pain, joint erosion
‚Ä¢ Renal: uric acid stones; urate nephropathy (interstitial deposits)
‚Ä¢ Asymptomatic hyperuricemia: serum UA 6.8 mg/dL w/o disease manifestations
Diagnostic studies
‚Ä¢ c UA does not make dx: 25% of measurements nl during acute attack, though 
7.5 mg/dL in 95% at some time during an attack; c WBC count & ESR
‚Ä¢ Arthrocentesis
take care not to tap through an infected area thus introducing infections into joint space
polarized microscopy S needle-shaped, negatively birefringent crystals (yellow
parallel to axis marked on polarizer), intracellular or extracellular (less specific)
WBC 20,000‚Äì100,000/mm3, 50% polys
infection can coexist with acute attacks, ‚à¥always check Gram stain and culture
‚Ä¢ Radiographs
early S show soft tissue swelling; useful to exclude chondrocalcinosis or septic changes
late S bony erosions with overhanging edge, soft tissue calcifications within tophi
Acute Treatment for Gout
Drug
Mechanism
Comments
NSAIDs
T inflammation
Gastritis; T dose in renal insufficiency
Colchicine
inhibits polymerization of
Nausea, vomiting, and diarrhea
(PO or IV)
microtubules S
IV and high PO doses S bone marrow
prevention of chemotaxis
suppression, myopathy, neuropathy
and phagocytosis
T dose in renal insufficiency
Corticosteroids
For initial Rx, efficacy ‚âàNSAIDs
(PO, IA, or IV)
Highly effective for recalcitrant cases
or Corticotropin
T inflammation
Rule out joint infection first
(SC, IM, or IV)
(NEJM 2003;349:1647; Lancet 2008;371:1854)

--- Fim da P√°gina 209 ---

Chronic treatment
‚Ä¢
T urate production by T intake of meat and seafood (note: high-purine vegetables a/w 
c risk); c intake low-fat dairy products; T alcohol (esp. beer); wt control
‚Ä¢ Avoid dehydration and hyperuricemia-promoting drugs (eg, thiazide and loop diuretics)
‚Ä¢ Prophylaxis if frequent attacks and when starting antihyperuricemic therapy:
daily low-dose colchicine (50% T risk of acute flare; J Rheum 2004;31:2429) 
or NSAIDs (less evidence of effectiveness; Ann Rheum Dis 2006;65:1312)
‚Ä¢ Antihyperuricemic therapy for tophi, frequent attacks, nephrolithiasis; goal UA 6 mg/dL
however, do not start w/o prophylaxis and until 2‚Äì4 wk after acute attack as 
 T in serum
UA concentration can precipitate an attack
allopurinol (xanthine oxidase inhibitor); side effects: hypersensitivity, rash, diarrhea,
dyspepsia, headache, renal failure, BM suppression, and hepatitis; monitor CBC &
LFTs; dose adjustment necessary in Pts concurrently taking AZA
febuxostat (nonpurine xanthine oxidase inhibitor): consider if allopurinol intolerance/
failure or CKD; side effects: liver abnl, rash, arthralgias, nausea; monitor LFTs
(Arth Rheum 2008;59:1540); dose adjustment also necessary for AZA
probenecid (uricosuric) for underexcreters (urine UA 600 mg/24 h)
CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD)
DEPOSITION DISEASE
Definition
‚Ä¢ Deposition of CPPD crystals w/in tendons, ligaments, articular capsules, synovium,
cartilage
‚Ä¢ Acute inflammation due to CPPD crystals in a joint is termed pseudogout
‚Ä¢ Chondrocalcinosis: calcification of cartilage visible on radiographs, resulting from
CPPD deposition in articular cartilage, fibrocartilage, or menisci
Epidemiology
‚Ä¢ More common in elderly: 20% over age 60 y have knee chondrocalcinosis in autopsy studies
Etiologies
‚Ä¢ Most cases idiopathic, but consider search for underlying cause, especially in the young
‚Ä¢ Metabolic: the 3 Hs: hemochromatosis, hypothyroidism, hyperparathyroidism;
diabetes, hypomagnesemia, alkaline phosphatase deficiency, familial hypocalciuric
hypercalcemia, gout, Gitelman‚Äôs syndrome, X-linked hypophosphatemic rickets
‚Ä¢ Joint trauma (incl. previous surgery); joint injections with hyaluronate can precipitate attacks
‚Ä¢ Familial chondrocalcinosis (autosomal dominant disorder)
Pathogenesis
‚Ä¢ c synovial & joint fluid levels of inorganic pyrophosphate produced by articular chon-
drocytes from ATP hydrolysis in response to various insults or inherited defects
favors CPPD crystallogenesis and deposition in the cartilage matrix
‚Ä¢ Crystals activate cryopyrin inflammasome S IL-1	 S inflammation (Nature 2006;440:237) 
Clinical manifestations
‚Ä¢ Pseudogout: acute mono- or asymmetric oligoarticular arthritis, indistinguishable from
gout except through synovial fluid exam for crystals
location: knees, wrists, and MCP joints
precipitants: surgery, trauma, or severe illness
‚Ä¢ ‚ÄúPseudo-RA‚Äù: chronic polyarticular arthritis with morning stiffness;  RF
‚Ä¢ Premature OA: destruction of articular cartilage and bony overgrowths S degen. of joints
Diagnostic studies
‚Ä¢ Arthrocentesis
take care not to tap through an infected area thus introducing infxn into joint space
polarized microscopy S rhomboid-shaped, weakly positively birefringent crystals
(yellow perpendicular and blue parallel to axis marked on polarizer)
WBC 2000‚Äì100,000/mm3, 50% polys
infection can coexist with acute attacks, ‚à¥always check Gram stain and culture
‚Ä¢ Screen for associated metabolic diseases when dx a new case: ‚úìCa, Mg,TSH, Fe, glc, UA
‚Ä¢ Radiographs: though not a prerequisite for the diagnosis of CPPD disease,
chondrocalcinosis appears as punctate and linear densities in articular cartilage, menisci,
triangular fibrocartilage of the wrist, small joints of fingers, and symphysis pubis
Treatment
‚Ä¢ Acute therapy for pseudogout: same as for gout, though colchicine not as effective
‚Ä¢ Chronic therapy: treat predisposing disease
‚Ä¢ Low-dose daily colchicine may be effective prophylaxis in some Pts
CPPD
8-6

--- Fim da P√°gina 210 ---

SERONEG
8-7
SERONEGATIVE SPONDYLOARTHRITIS
GENERAL
Definition (Annals 2002;136:896)
‚Ä¢ A spectrum of systemic inflammatory arthritides w/ predilection for the spine,
entheses, sacroiliac, and peripheral joints; affects 0.5‚Äì2% of population
‚Ä¢ 5 subtypes: ankylosing spondylitis, reactive, psoriatic, IBD-associated, and
undifferentiated (does not meet criteria for other subtypes, wide clinical spectrum)
‚Ä¢ Notable for absence of rheumatoid factor or autoantibodies;  c ESR
‚Ä¢ Synovial fluid of affected joints shows an inflammatory, nonseptic picture
Pathogenesis (Semin Arthritis Rheum 2008;38:83)
‚Ä¢ c prevalence of HLA-B27:  in 50‚Äì90% of Pts, but common in general pop. (6‚Äì8%) 
‚Ä¢ HLA-B27 accounts for 30% of attributable genetic risk, but not used for dx
‚Ä¢ Other gene associations: IL23R (26% of attributable risk) and ARTS1 (9%)
‚Ä¢ Environmental factors likely critical for disease, esp. reactive arthritis (eg, infection)
ANKYLOSING SPONDYLITIS
Epidemiology
‚Ä¢ Onset in teens or mid-20s; onset after age 40 y very unusual; male:female ratio 
3:1; HLA-B27  in 90%
Clinical manifestations
‚Ä¢ Gradual onset of chronic, intermittent bouts of lower back pain and stiffness
‚Ä¢ Morning stiffness that improves with hot shower and exercise
‚Ä¢ Progressive limitation of motion in cervical, thoracic, and/or lumbar spine over time
Severity of lumbar flexion deformity assessed by  modified Wright-Schober
test (4 cm c in distance between a point at lumbosacral jxn and another point
10 cm above, when going from standing to maximum forward flexion)
T-spine mobility (extension) and kyphosis severity measured by occiput-to-wall distance 
‚Ä¢ Enthesitis: inflammation at site of tendon/ligament insertion into bone, eg,Achilles
tendinitis, plantar fasciitis, rigidity of spine (bamboo spine by x-ray) 
‚Ä¢ Arthritis in peripheral joints can occur, eg, hips, shoulders, knees
‚Ä¢ Acute anterior uveitis (25‚Äì40% at some time during disease): presents with unilateral 
blurred vision, lacrimation, and photophobia
‚Ä¢ Cardiovascular disease (5%): ascending aortitis,AI, conduction system abnormalities
‚Ä¢ Neurologic complications: spinal fractures, C1/2 subluxation, or cauda equina syndrome
Imaging studies
‚Ä¢ Radiographs of spine to assess progression of disease:
Sacroiliac joint disease with erosions and sclerosis
Calcification of spinal ligaments with bridging syndesmophytes (‚Äúbamboo spine‚Äù)
Squaring and generalized demineralization of vertebral bodies,‚Äúshiny corners‚Äù
‚Ä¢ MRI spine to assess inflammation in sacroiliac joint, esp. early in disease course
Treatment (Lancet 2007;369:1379; Curr Opin Rheumatol 2009;21:324)
‚Ä¢ Supportive: physical therapy, NSAIDs, steroid injection
‚Ä¢ Anti-TNF shown to improve symptoms and function (Ann Rheum Dis 2006;65:423)
‚Ä¢ MTX: somewhat effective for peripheral arthritis, but little or no effect on spinal sx;
SAS may provide benefit in Pts w/o peripheral arthritis (Ann Rheum Dis 2006;65:1147)
REACTIVE ARTHRITIS
Epidemiology
‚Ä¢ Ages 20‚Äì40 y; male:female ratio  5:1; more common in Caucasians
Pathogenesis
‚Ä¢ Immune-mediated aseptic synovitis in a genetically susceptible host post-GU or GI infxn
‚Ä¢ Bacteria associated with disease
GU: Chlamydia and Ureaplasma urealyticum
GI: Shigella, Salmonella, Yersinia, Campylobacter, C. difficile
Clinical presentation
‚Ä¢ Originally described as a triad of seronegative arthritis, nongonococcal
urethritis, and noninfectious conjunctivitis (Reiter‚Äôs syndrome)
‚Ä¢ Arthritis: 10‚Äì30 d post‚Äìinciting infection S mild constitutional sx, low back pain, asym-
metric, mono- or oligoarticular arthritis of primarily large joints (knees, ankles, feet),
enthesopathy, and sacroiliitis. Can develop sausage digits (dactylitis) of extremities.

--- Fim da P√°gina 211 ---

‚Ä¢ Urethritis/cervicitis: usually Chlamydia infection preceding arthritis, but also can see
sterile urethritis in postdysenteric reactive arthritis
‚Ä¢ Conjunctivitis: noninfectious, unilateral or bilateral and  uveitis, iritis, and keratitis
‚Ä¢ Cutaneous manifestations (may go unnoticed by Pt)
circinate balanitis: shallow, painless ulcers of glans penis and urethral meatus
keratoderma blenorrhagica: hyperkeratotic skin lesions on soles of feet, scrotum,
palms, trunk, scalp
stomatitis and superficial oral ulcers
‚Ä¢ GI: diarrhea and abdominal pain either w/ or w/o infectious agent
‚Ä¢ CV:AI from inflammation and scarring of aorta and valve; conduction defects
Radiographs
‚Ä¢ Early: soft tissue swelling and effusions around affected joints
‚Ä¢ Late: asymmetric proliferation of bone at site of inflammation
‚Ä¢ Asymmetric sacroiliitis in 70%
Diagnostic studies
‚Ä¢ PCR of urine or genital swab for Chlamydia, stool cultures, C. difficile toxin, etc., but 
studies do not rule out
Treatment and prognosis
‚Ä¢ NSAIDs, steroid injection for mono- or oligoarthritis, SAS if inflammation persists
‚Ä¢ Antibiotics if evidence of active or antecedent infection, as cx may be 
‚Ä¢ Arthritis may persist for months to years, and recurrences are common
PSORIATIC ARTHRITIS
Epidemiology
‚Ä¢ Seen in 20‚Äì30% of Pts w/ psoriasis (and not necessarily those with severe skin disease)
‚Ä¢ Arthritis may precede onset of skin disease, even by years; a/w nail changes
‚Ä¢ 20‚Äì40% of Pts with psoriatic arthritis have spinal or sacroiliac involvement
‚Ä¢  Men and women are affected equally and most Pts in 30s and 40s
Clinical manifestations
‚Ä¢ Several clinical patterns of arthritis:
monoarticular/oligoarticular (eg, large joint, DIP joint, dactylitic digit): most
common initial manifestation
polyarthritis (small joints of the hands and feet, wrists, ankles, knees, elbows):
indistinguishable from RA, but often asymmetric
arthritis mutilans: severe destructive arthritis with bone resorption, esp. hands
axial disease: similar to ankylosing spondylitis  peripheral arthritis
‚Ä¢ Enthesopathies, tendinitis
‚Ä¢ Fingernails: pitting, transverse depressions, onycholysis, subungal hyperkeratosis
‚Ä¢ Eye inflammation (30%): conjunctivitis, iritis, episcleritis, and keratoconjunctivitis sicca
‚Ä¢ Psoriatic skin lesions
Radiographs
‚Ä¢ ‚ÄúPencil-in-cup‚Äù deformity seen at DIP joints, erosive changes
‚Ä¢ Spinal involvement, sacroiliitis
Treatment
‚Ä¢ Symptom control: NSAIDs; intra-articular glucocorticoid injections
‚Ä¢ Anti-TNF (etanercept, infliximab, adalimumab) T progression of disease
‚Ä¢ Sulfasalazine: only DMARD shown to improve sx, but not progression of disease
‚Ä¢ Other: MTX, leflunomide, CsA,AZA, PUVA, antimalarials, gold
ENTEROPATHIC (IBD-ASSOCIATED)
Epidemiology
‚Ä¢ Seen in 20% of Pts w/ IBD; more frequently seen in Crohn‚Äôs than UC
Clinical manifestations
‚Ä¢ Peripheral, migratory, asymmetric, nondeforming oligoarthritis: abrupt
onset, large joints, course parallels GI disease
‚Ä¢ Spondylitis: associated more strongly with HLA-B27, course does not parallel GI disease
‚Ä¢ Sacroiliitis
‚Ä¢ Erythema nodosum, pyoderma gangrenosum ( neutrophilic dermatosis S painful ulcers w/
violaceous border; Ddx incl. idiopathic, IBD, RA, myelogenous leukemia), anterior uveitis
Treatment
‚Ä¢ 5-ASA compounds, etc., for underlying IBD (see IBD)
SERONEG
8-8

--- Fim da P√°gina 212 ---

INFXN ARTH
8-9
INFECTIOUS ARTHRITIS & BURSITIS
DIAGNOSIS AND EMPIRIC TREATMENT OF INFECTIOUS ARTHRITIS
Diagnosis
‚Ä¢ Arthrocentesis should be performed as soon as suspected
‚Ä¢ Take care not to tap through an infected area thus introducing infxn into joint space
‚Ä¢ Send fluid for cell count, gram stain, bacterial culture, crystals
WBC 50,000 with poly predominance suspicious for bacterial infection
(crystals do not rule out septic arthritis!)
Initial therapy
‚Ä¢ Prompt empiric antibiotics guided by gram stain
‚Ä¢ If gram stain negative, empiric Rx w/ cefazolin (eg, low risk of MRSA and gonorrhea)
or vancomycin (IVDU, MRSA risk factors); add cefepime if elderly, immunosupp.
‚Ä¢ Modify antibiotics based on culture results and clinical course
Common microbes
Population
Initial antibiotic regimen
S. aureus
Normal joints
Nafcillin or
(most common)
Prosthetic joints
Vancomycin if suspect MRSA (eg,
Damaged joints
hospitalized Pt)
S. epidermidis
Prosthetic joints
Nafcillin or
GPC
Post‚Äìjoint procedure
Vancomycin if suspect MRSA (eg,
hospitalized Pt)
Streptococci
Healthy adults
Penicillin G or ampicillin
Splenic dysfunction
Diplococci:
Sexually active young
Ceftriaxone or cefotaxime
N. gonorrhea
adults
GN
Rods: E. coli,
IVDU
Cefepime or piperacillin/tazobactam
Pseudomonas,
GI infection
 antipseudomonal aminoglycoside
Serratia
Immunocompromised
if suspect IVDU
BACTERIAL (NONGONOCOCCAL) ARTHRITIS
Epidemiology and risk factors
‚Ä¢ Immunocompromised host (eg, diabetics, HIV, elderly, SLE)
‚Ä¢ Damaged joints: RA, OA, gout, trauma, prior surgery/prosthetic, prior arthrocentesis (rare)
‚Ä¢ Bacterial seeding
bacteremia secondary to IVDU, endocarditis, or skin infection
direct inoculation or spread from contiguous focus (eg, cellulitis, septic bursitis, osteo)
Clinical manifestations (Lancet 2010;375:846)
‚Ä¢ Acute onset of monoarticular arthritis (80%) with pain, swelling, and warmth
‚Ä¢ Location: knee (most common), hip, wrist, shoulder, ankle. In IVDA, tends to involve
other areas, eg, sacroiliac joint, symphysis pubis, sternoclavicular and manubrial joints
‚Ä¢ Constitutional symptoms: fevers, chills, sweats, malaise, myalgias, pain
‚Ä¢ Infection can track from initial site to form fistulae, abscesses, or osteomyelitis
‚Ä¢ Septic bursitis must be differentiated from septic intra-articular effusion
Additional diagnostic studies
‚Ä¢ Synovial fluid: WBC usually 50,000 (but can be as low as 1,000), 90% polys
gram stain  in 75% of Staph, 50% of GNR; culture  in 90% of cases
‚Ä¢ Leukocytosis with neutrophilic predominance  bandemia
‚Ä¢ Blood cultures  in 50% of cases
‚Ä¢ Conventional radiographs usually normal until after 2 wk of infection when bony
erosions, joint space narrowing, osteomyelitis, periostitis can be seen
‚Ä¢ CT and MRI useful especially for suspected hip infection or epidural abscess
Definitive treatment (for nonprosthetic joints)
‚Ä¢ Antibiotics (as earlier)
‚Ä¢ Surgical drainage/lavage indicated in many cases, especially for larger joints
‚Ä¢ Prognosis: 10‚Äì50% mortality depending on virulence of organism, time to Rx, host

--- Fim da P√°gina 213 ---

DISSEMINATED GONOCOCCAL INFECTION (DGI)
Epidemiology
‚Ä¢ Most frequent type of infectious arthritis in sexually active young adults
‚Ä¢ Caused by Neisseria gonorrhea
‚Ä¢ Normal host as well as Pts w/ deficiencies of terminal components of complement
‚Ä¢ Female:male ratio  4:1. c incidence during menses, pregnancy, and postpartum period.
c incidence in homosexual males. Rare after age 40 y.
Clinical manifestations
‚Ä¢ Preceded by mucosal infection (eg, endocervix, urethra, or pharynx) that is often asx
‚Ä¢ Usually presents as two distinct syndromes:
Joint localized: purulent arthritis (40%) usually of knees, wrists, hands, or ankles
Bacteremia: triad of polyarthritis, tenosynovitis, skin lesions
prodrome: fever, malaise, migratory polyarthralgias (wrist, knees, ankles, elbows)
acute onset of tenosynovitis (60%) in wrists, fingers, ankles, toes
rash (50%): gunmetal gray pustules with erythematous base on extremities & trunk
‚Ä¢ Rare complications: Fitz-Hugh-Curtis syndrome (perihepatitis), pericarditis, meningitis,
myocarditis, osteomyelitis
Additional diagnostic studies
‚Ä¢ Leukocytosis with increased neutrophils; c ESR
‚Ä¢ Synovial fluid: WBC 50,000 (but can be 10,000), poly predominant
Gram stain  in 25% of cases
culture  in up to 50% of cases if culture anaerobically on Thayer-Martin media
PCR for gonococcal DNA can improve Se (not widely available or standardized)
‚Ä¢ Blood culture: more likely  in tenosynovitis; rarely in joint localized disease
‚Ä¢ Gram stain and culture of skin lesions occasionally 
‚Ä¢ Cervical, urethral, pharyngeal, rectal cultures on Thayer-Martin media indicated; check for
Chlamydia
Treatment
‚Ä¢ Ceftriaxone or cefotaxime  7 d w/ empiric doxycycline for possible concur-
rent Chlamydia (fluoroquinolones no longer recommended due to resistance)
‚Ä¢ Joint aspiration or arthroscopy/lavage may be required for Pts with purulent arthritis
OLECRANON AND PREPATELLAR BURSITIS
Epidemiology and risk factors (Infect Dis North Am 2005;19:991)
‚Ä¢ 150 bursae in the body; two most commonly infected are olecranon and prepatellar
‚Ä¢ Most commonly due to direct trauma, percutaneous inoculation, or contiguous
spread from adjacent infection (eg, cellulitis)
‚Ä¢ Other risk factors: recurrent noninfectious inflammation (eg, gout, RA, CPPD), diabetes
‚Ä¢ S. aureus (80%) most common, followed by streptococci
Diagnosis
‚Ä¢ Physical exam: discrete bursal swelling, erythema, maximal tenderness at center of
bursa with preserved joint range of motion
‚Ä¢ Aspirate bursa if concern for infxn, ‚úìcell count, gram stain, bacterial cx, crystals
WBC 20,000 with poly predominance suspicious for bacterial infection, but
lower counts common (crystals do not rule out septic bursitis!)
‚Ä¢ Assess for adjacent joint effusion, which can also be septic
‚Ä¢ Take care not to tap through infected skin thus introducing infxn into bursa
Initial therapy
‚Ä¢ Prompt empiric coverage for staphylococci and streptococci: cefazolin or oxacillin,
vancomycin if concern for MRSA, broaden spectrum based on other risk factors
‚Ä¢ PO antibiotics acceptable for mild presentation
‚Ä¢ Modify antibiotics based on gram stain, culture results, and clinical course
‚Ä¢ Duration of therapy is 1‚Äì4 wk
‚Ä¢ Serial aspirations every 1‚Äì3 d until sterile or no reaccumulation of fluid
‚Ä¢ Surgical intervention if unable to drain bursa through aspiration, evidence of foreign
body or necrosis, recurrent or refractory bursitis with concern for infection of
adjacent structures
INFXN ARTH
8-10

--- Fim da P√°gina 214 ---

CTD
8-11
CONNECTIVE TISSUE DISEASES
% Autoantibodies in Patients with Rheumatic Diseases
Disease
ANA &
RF
dsDNA
Sm
Ro
La
Scl-70
Cent
Jo
RNP
Pattern
SLE
95‚Äì99
20
50‚Äì70
30
35
15
0
0
0
30‚Äì50
D, S, N
RA
15‚Äì35
85
5
0
10
5
0
0
0
10
D
Sj√∂gren‚Äôs
90
75
5
0
55
40
0
0
0
15
D, S
Diffuse
90
30
0
0
5
1
40
5
0
30
SSc
N, S, D
Limited
90
30
0
0
5
1
5
70
0
30
SSc
S, N, D
PM-DM
75‚Äì95
33
0
0
0
0
10
0
25
0
MCTD
95‚Äì99
50
0
0
5
5
0
0
0
100
S, D
(D  diffuse or homogeneous, S  speckled, N  nucleolar; Primer on the Rheumatic Diseases, 12th ed., 2001)
‚Ä¢ Autoantibody testing is directed by clinical findings, as autoantibodies themselves do
not define a particular connective tissue disease
‚Ä¢ Overlap syndromes encompassing more than one connective tissue disorder may be
reflected serologically by the presence of multiple autoantibodies
see ‚ÄúSystemic Lupus Erythematosus‚Äù and ‚ÄúRheumatoid Arthritis‚Äù for those diseases
SYSTEMIC SCLEROSIS AND SCLERODERMA DISORDERS
Definition and epidemiology
‚Ä¢ Scleroderma refers to the presence of tight, thickened skin
‚Ä¢ Localized scleroderma  morphea (plaques of fibrotic skin), linear (fibrotic bands),
‚Äúen coup de saber‚Äù (linear scleroderma on one side of scalp and forehead ‚âàsaber scar)
‚Ä¢ Systemic sclerosis (SSc)  scleroderma  internal organ involvement. Subgroups:
SSc w/ limited cutaneous disease (hands, arms, face): CREST syndrome, pulm HTN;
renal and cardiac manifestations rare
SSc w/ diffuse cutaneous disease (incl. proximal extremities & trunk): rapidly pro-
gressing disorder affecting skin, one or more internal organs
SSc sine scleroderma (visceral disease without skin involvement, rare)
‚Ä¢ Peak onset of SSc between ages 30‚Äì50; more common in women than men
‚Ä¢ 1‚Äì2/100,000 annual incidence of systemic disease in the U.S.
‚Ä¢ Pathogenesis: immune damage to endothelial cells and reactive O2 species produc-
tion S persistent oxidative stress S perivascular inflammation S fibroblast activa-
tion and fibrosis. Cytokines, growth factors, and autoantibodies (against PDGF
receptor, endothelial cells, and fibroblasts) all contribute (NEJM 2009;360:1989).
Classification criteria (1 major or 2 minor; 97% Se, 98% Sp; Arth Rheum 1980;23:581)
‚Ä¢ Major: skin findings extend proximal to MCP or MTP joints
‚Ä¢ Minor: sclerodactyly (skin findings limited to the fingers)
digital pitting scars from loss of substance on the finger pad
bibasilar pulmonary fibrosis
‚Ä¢ Other causes of thickened skin: diabetes (scleredema ‚â†scleroderma), hypothyroidism,
nephrogenic systemic fibrosis, eosinophilic fasciitis, amyloidosis, GVHD, drug or toxin
Diagnostic studies
‚Ä¢ Autoantibodies
 anti-Scl-70 (anti-topoisomerase 1): 40% of diffuse, 15% of limited
 anti-centromere: 60‚Äì80% of limited, 5% of diffuse
 ANA (90%),  RF (30%)
‚Ä¢ If renal involvement S c BUN and Cr, proteinuria
‚Ä¢ If pulmonary involvement S interstitial pattern on CXR/chest CT, restriction and/or
T DLCO on PFTs; PHT revealed by echocardiography
‚Ä¢ Skin bx not routine, but helpful to assess other possible causes for skin thickening

--- Fim da P√°gina 215 ---

Clinical Manifestations of Systemic Sclerosis
Skin
Tightening and thickening of extremities, face, trunk (bx not req for dx)
‚ÄúPuffy‚Äù hands, carpal tunnel syndrome, sclerodactyly
Nailfold capillary dilatation & dropout
Immobile, pinched, ‚Äúmouselike‚Äù facies and ‚Äúpurse-string‚Äù mouth
Calcinosis cutis (subcutaneous calcification)
Telangiectasias
Arteries
Raynaud‚Äôs phenomenon (80%); digital or visceral ischemia
Renal
Scleroderma renal crisis  sudden onset severe HTN, RPGN, MAHA
Crescentic GN (rare) with  p-ANCA (J Rheum 2006;33:1886)
GI
GERD and erosive esophagitis
Esophageal dysmotility S dysphagia, odynophagia, aspiration
Gastric dysmotility S early satiety and gastric outlet obstruction
Small intestinal dysmotility S bloating, diarrhea, malabsorption
Musculoskel
Polyarthralgias & joint stiffness; muscle weakness, tendon friction rubs
Cardiac
Myocardial fibrosis, pericarditis; conduction abnormalities
Pulmonary
Pulmonary fibrosis (typically develops w/in 4 y); pulmonary arterial 
hypertension (typically develops after many yrs). #1 cause of mortality.
Endocrine
Amenorrhea and infertility common; thyroid fibrosis  hypothyroidism
Systemic Sclerosis
Limited
Diffuse
General
Fatigue, weight loss
Skin
Thickening on distal extremities
Thickening on extremities
and face only
(incl. digits), face, and trunk
Nails
Capillary dropout  dilatation
Capillary dropout & dilatation
Pulmonary
PAH  fibrosis
Fibrosis  PAH
GI
GERD, hypomotility, PBC
GERD, hypomotility
Renal
Renovascular HTN
Cardiac
Restrictive cardiomyopathy
Other
CREST syndrome 
Raynaud‚Äôs
Calcinosis, Raynaud‚Äôs
Esophageal dysmotility
Sclerodactyly, Telangiectasias
Antibodies
Anticentromere (70%)
Anti-Scl 70 (40%)
Prognosis
Survival 70% at 10 y
Survival 40‚Äì60% at 10 y
Treatment (organ-based approach)
‚Ä¢ Pulmonary
fibrosis: cyclophosphamide (NEJM 2006;354:2653), steroids
PAH: pulmonary vasodilators (see ‚ÄúPulmonary Hypertension‚Äù)
‚Ä¢ Renal: monitor BP monthly, intervene early to avoid HTN crisis; dipstick for protein
ACE inhibitors (not ARB) for HTN crisis (poor prognosis w/ 50% mortality)
‚Ä¢ GI: PPI and/or H2-blockers for GERD; antibiotics for malabsorption
hypomotility: metoclopramide or erythromycin; nonoperative Rx of pseudoobstruction
‚Ä¢ Cardiac: NSAIDs or steroids for pericarditis
‚Ä¢ Arthritis: acetaminophen, NSAIDs, PT
‚Ä¢ Myositis: MTX, AZA, steroids
‚Ä¢ Skin: PUVA for morphea. For pruritis: emollients, topical or oral steroids (use w/ cau-
tion, can precip HTN renal crisis, Arthritis Rheum 1998;41:1613). Immunosuppressives
offer only minimal to modest benefit for skin fibrosis.
INFLAMMATORY MYOPATHIES
Definition and epidemiology (Lancet 2003;362:971)
‚Ä¢ Polymyositis (PM): T cell-mediated muscle injury S skeletal muscle inflam. & weakness
‚Ä¢ Dermatomyositis (DM): immune complex deposition in blood vessels with complement
activation S skeletal muscle inflam. & weakness  skin manifestations 
‚Ä¢ Inclusion body myositis (IBM): T cell-mediated muscle injury, vacuole formation with
amyloid deposition S skeletal muscle inflam. & weakness
‚Ä¢ 10% of PM and 15% of DM associated with malignancy (NEJM 1992; 326:363)
‚Ä¢ PM/DM: onset typically 40s and 50s; more common in women than men
‚Ä¢ IBM: onset after age 50; men  women; often misdiagnosed as polymyositis
CTD
8-12

--- Fim da P√°gina 216 ---

Clinical manifestations
‚Ä¢ Muscle weakness: gradual, progressive, often painless, symmetric, and proximal;
typically difficulty climbing stairs, arising from chairs, brushing hair;  tenderness of
affected areas; asymmetry and distal weakness more common in IBM than PM/DM
‚Ä¢ Dermatologic
erythematous rash on sun-exposed skin: neck & shoulders (shawl sign), face, chest
heliotrope rash (purplish discoloration) over upper eyelids  periorbital edema
Gottron‚Äôs papules (pathognomonic): violaceous often scaly areas symmetrically over
dorsum of PIP and MCP joints, elbows, patellae, medial malleoli
subungal erythema, dilation and dropout of nailbed capillaries, cuticular telangiec-
tases,‚Äúmechanic‚Äôs hands‚Äù (skin cracks on digits)
dermatologic features without muscle disease  DM sine myositis
‚Ä¢ Polyarthralgias or polyarthritis
‚Ä¢ Vasculitis of skin, muscle, GI tract and eyes; Raynaud‚Äôs (30%, usu. DM and overlap CTD)
‚Ä¢ Visceral involvement
pulmonary: acute alveolitis, chronic ILD, weakness of respiratory muscles
cardiac (33%): myocarditis, pericarditis, arrhythmias; HF uncommon; c CK-MB & Tn
(J Rheumatol 2009;36:2711)
GI: dysphagia, aspiration
‚Ä¢ Ddx: drug-induced myopathy (statins, cocaine, steroids, colchicine); infxn (HIV, EBV,
CMV); metabolic (hypothyroid, hypo K, hypo Ca); neuromuscular disease (eg, myas-
thenia gravis); glycogen storage disease; mitochondrial myopathy; muscular dystrophy
Diagnostic studies
‚Ä¢ c CK, aldolase, SGOT, and LDH;  c ESR & CRP
‚Ä¢ Autoantibodies:  ANA (75%),  RF (33%)
 anti-Jo-1 (25%), a/w nonerosive polyarthritis, Raynaud‚Äôs, ILD, mechanic‚Äôs hands
 anti-Mi-2 (5-10%), more common with DM, may have better prognosis
 anti-SRP (signal recognition peptide), seen in PM, indicates more aggressive disease
‚Ä¢ EMG: c spontaneous activity, T amplitude, polyphasic potentials with contraction
‚Ä¢ Muscle biopsy: all with muscle fiber necrosis, degeneration & regeneration
PM: endomysial inflam. (CD8 T cells) surrounds non-necrotic fibers, c MHC class I
DM: perimysial, perivascular inflam. (B & CD4 T cells), complement in vessels
IBM: same as PM with eosinophilic inclusions and rimmed vacuoles (EM)
Treatment (PM and DM, no effective treatment for IBM)
‚Ä¢ High-dose steroids, add MTX or AZA if tapering fails at 2‚Äì3 mo
‚Ä¢ For resistant disease: IVIg (DM  PM), MMF, rituximab, CsA, tacrolimus,
cyclophosphamide (esp. if ILD or vasculitis) 
‚Ä¢ IVIg for life-threatening esophageal or respiratory muscle involvement
‚Ä¢
‚úì for occult malignancy; monitor respiratory muscle strength with spirometry
Myositides, Myopathies, and Myalgias
Disease
Weakness
Pain
c CK
c ESR
Biopsy
DM/PM




as above
IBM




as above
mild necrosis
Hypothyroidism




inflammation
atrophy
Steroid-induced




atrophy
PMR




normal
(limited by pain)
Fibromyalgia




normal
(limited by pain)
(tender points)
SJ√ñGREN‚ÄôS SYNDROME
Definition and epidemiology
‚Ä¢ Chronic dysfunction of exocrine glands due to lymphoplasmacytic infiltration
‚Ä¢ Can be primary or secondary (a/w RA, scleroderma, SLE, PM, hypothyroidism, HIV)
‚Ä¢ More prevalent in women than in men; typically presents between 40 and 60 y of age
Clinical manifestations
‚Ä¢ Dry eyes (keratoconjunctivitis sicca): T tear production; burning, scratchy sensation
‚Ä¢ Dry mouth (xerostomia): difficulty speaking/swallowing; dental caries; xerotrachea; thrush
‚Ä¢ Parotid gland enlargement or intermittent swelling (bilateral)
CTD
8-13

--- Fim da P√°gina 217 ---

‚Ä¢ Other manifestations: chronic arthritis; interstitial nephritis (40%), type I RTA (20%);
vasculitis (25%); vaginal dryness/dyspareunia; pleuritis; pancreatitis
‚Ä¢ c risk of lymphoproliferative disorders (50 c risk of lymphoma and WM in 1 Sj√∂gren‚Äôs)
Diagnostic studies
‚Ä¢ Autoantibodies:  ANA (95%),  RF (75%)
Primary Sj√∂gren‚Äôs:  anti-Ro (anti-SS-A, 56%) and  anti-La (anti-SS-B, 30%)
‚Ä¢ Schirmer test: filter paper in palpebral fissures to assess tear production
‚Ä¢ Rose-Bengal staining: dye that reveals devitalized epithelium of cornea/conjunctiva
‚Ä¢ Biopsy (minor salivary, labial, lacrimal, or parotid gland): lymphoplasmacytic infiltration
Classification criteria (4 of 6 has 94% Se & 94% Sp; Arthritis Rheum 1993;36:340)
1. Dry eyes
5. Objective T in salivary gland function
2. Dry mouth
6. Ab to Ro/SS-A or La/SS-B
3.  Schirmer test or Rose-Bengal staining
4. Inflammatory foci on minor salivary gland bx
Treatment
‚Ä¢ Ocular: artificial tears, cyclosporine eyedrops
‚Ä¢ Oral: sugarfree gum, lemondrops, saliva substitute, hydration, cholinergic Rx
‚Ä¢ Systemic: NSAIDs, steroids, DMARDs; treat underlying disease (secondary Sj√∂gren‚Äôs)
MIXED CONNECTIVE TISSUE DISEASE (MCTD)
Definition
‚Ä¢ MCTD pts have features of SLE, systemic sclerosis, and/or polymyositis, often
evolving a dominant phenotype of SLE or systemic sclerosis
Clinical manifestations
‚Ä¢ Raynaud‚Äôs phenomenon typical presenting symptom
‚Ä¢ Hand edema:‚Äúpuffy hands,‚Äù sclerodactyly, RA-like arthritis without erosions
‚Ä¢ Pulmonary involvement (85%) with pulmonary hypertension, fibrosis
‚Ä¢ GI dysmotility (70%)
‚Ä¢ Low risk for renal HTN crisis or glomerulonephritis; if either, reconsider diagnosis of MCTD
Diagnostic studies
‚Ä¢  ANA (95‚Äì99%),  RF (50%)
‚Ä¢ Anti-U1-RNP present by definition in MCTD, but not specific (seen in up to 50%
SLE Pts)
Treatment
‚Ä¢ As per specific rheumatic diseases detailed above
RAYNAUD‚ÄôS PHENOMENON
Clinical manifestations (NEJM 2002;347:1001)
‚Ä¢ Episodic, reversible digital ischemia, in response to cold or stress, classically: blanching
(ischemia) S cyanosis (venule dilatation) S rubor (resolution with reactive
hyperemia); color change usually well demarcated; affects fingers, toes, ears, nose
‚Ä¢ Associated sx include cold, numbness, & paresthesias S throbbing & pain
Primary  Raynaud‚Äôs disease (50%; excluded all secondary causes)
‚Ä¢ Onset age 20‚Äì40 y, female:male  5:1
‚Ä¢ Clinical: mild, symmetric episodic attacks; no evidence of peripheral vascular disease, no
tissue injury, normal nailfold capillary examination,  ANA, normal ESR
Secondary  Raynaud‚Äôs phenomenon (50%)
‚Ä¢ Typically, Pts 35 y of age
‚Ä¢ Collagen vascular disease: SSc, SLE, RA, PM-DM, MCTD, Sj√∂gren‚Äôs (abnl nailfold exam)
exaggerated vascular reactivity ultimately leads to tissue ischemia & injury
‚Ä¢ Arterial disease: peripheral atherosclerosis, thromboangiitis obliterans (abnormal pulses)
‚Ä¢ Hematologic: cryoglobulinemia,Waldenstr√∂m‚Äôs, antiphospholipid syndrome
‚Ä¢ Trauma (vibration or repetitive motion injury) & drugs (ergot alkaloids)
Treatment
‚Ä¢ All: avoid cold, maintain warmth of digits & body; avoid cigarettes, drugs, and trauma
‚Ä¢ Mild to moderate: long-acting CCB, -blockers, topical nitrates, low-dose ASA
‚Ä¢ Moderate to severe: sildenafil, bosentan (esp. w/ PHT); consider digital sympathectomy 
‚Ä¢ Digit-threatening: IV prostaglandins, digital sympathectomy
‚Ä¢ Others:ARBs, fish oil (primary RP only; Am J Med 1989;86:158)
CTD
8-14

--- Fim da P√°gina 218 ---

SLE
8-15
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Multisystem inflammatory autoimmune disease with a broad spectrum of clinical 
manifestations in association with antinuclear antibody (ANA) production
Epidemiology
‚Ä¢ Prevalence 15‚Äì50/100,000; predominantly affects women 2nd to 4th decade
‚Ä¢ Female:male ratio  8:1;African American:Caucasian ratio  4:1
‚Ä¢ Complex genetics; some HLA assoc.; rare c1q & c2 defic.
Classification Criteria and Other Clinical Manifestations of SLE
Organ System
Am. Coll. Rheum. Criteria
Other Features
Constitutional
Fever, malaise, anorexia,
(84%)
weight loss
Cutaneous
1. Malar rash (spares nasolabial folds)
Alopecia
(81%)
2. Discoid rash (erythematous
Vasculitis
papules w/ keratosis & plugging)
Subacute cutaneous lupus
3. Photosensitivity (rash, fever, N/V) Panniculitis (lupus profundus)
4. Oral/nasopharyngeal
Urticaria
ulcers
Musculoskeletal
5. Nonerosive arthritis:
Arthralgias and myalgias
(85‚Äì95%)
episodic, oligoarticular,
Avascular necrosis of bone
symmetrical, migratory
Cardiopulmonary
6. Serositis: pleuritis (37%) or
Pneumonitis, IPF, shrinking
(33%)
pleural effusion, pericarditis
lung, PAH, DAH
(29%) or pericardial effusion
Myocarditis, CAD (NEJM
2003;349:2399, 2407)
Libman-Sacks endocarditis
Renal
7. Proteinuria (>500 mg/dL or
Nephrotic syndrome
(77%)
3 on dipstick) or urinary
Lupus nephritis (ISN/RPS):
cellular casts
I  min. mesangial
II  mesangial prolif
III  focal (active/chronic) prolif
IV  diffuse prolif
V  membranous
VI  advanced sclerotic
Neurologic
8. Seizures or psychosis
Organic brain syndrome, PML
(54%)
without other cause
Cranial or periph. neuropathies
Gastrointestinal
Serositis (peritonitis, ascites)
(~30%)
Vasculitis (bleeding, perf.)
Abdominal pain
Hepatitis, pancreatitis
Hematologic
9. Hemolytic anemia (DAT )
Anemia of chronic disease
or leukopenia (4000/mm3),
Antiphospholipid syndrome
or lymphopenia (1500/mm3),
(VTE w/  ACL Ab or  LAC)
or thrombocytopenia
Splenomegaly
(100,000/mm3)
Lymphadenopathy
Other
Sicca syndrome
Conjunctivitis or episcleritis
Raynaud‚Äôs (20%)
Nailfold capillary changes
Serologies
10.  ANA
‚Üìcomplement (during flare),
11.  anti-ds-DNA, anti-Sm,
‚ÜëESR, ‚ÜëCRP,  anti-Ro or
or antiphospholipid Abs
anti-RNP,  RF,  anti-CCP
If 4 of 11 criteria met, Se & Sp for SLE 95%. However, Pt may have SLE but not have 4 criteria at a
given point in time. (Lancet 2007;369:587)
Workup
‚Ä¢ Detailed history and exam to assess for signs and symptoms of disease
‚Ä¢ Autoantibodies:ANA, if  ‚Üí‚úìanti-ds-DNA, anti-Sm, anti-Ro, anti-La, anti-U1-RNP
‚Ä¢ Electrolytes, BUN, Cr, U/A, urine sediment, 24-h urine for CrCl and protein
‚Ä¢ CBC, Coombs‚Äô test, PTT, APLA (anticardiolipin or lupus anticoagulant  in 20‚Äì40%),
C3, C4

--- Fim da P√°gina 219 ---

Autoantibodies in SLE
AutoAb
Frequency (approx)
Clinical Associations
Timeline
ANA
95‚Äì99% if active disease
Any or all of the broad spectrum
90% if in remission
of clinical manifestations
Homogeneous or speckled
Sensitive but not specific
May appear
Ro
15‚Äì35%
Sj√∂gren‚Äôs/SLE overlap
yrs before
La
 anti-Ro in ANA  SLE
Neonatal lupus
overt disease 
Photosensitivity
Subacute cutaneous lupus
ds-DNA
70%; very specific for SLE
Lupus nephritis
Titers parallel disease activity,
Vasculitis
Appears mos
especially renal disease
before or at
Sm
30%; very specific for SLE
Lupus nephritis
diagnosis
U1-RNP
40%
MCTD; Raynaud‚Äôs
Tend not to have nephritis
histone
SLE 80%, c/w 90% in DLE
Mild arthritis and serositis
At diagnosis
(NEJM 2003;349:1526)
Treatment of SLE
Drug
Indication
Adverse Effects
NSAIDs
Arthralgias/arthritis,
Gastritis, UGIB
myalgias, mild serositis
Renal failure
Hydroxychloroquine
Mild disease complicated by
Retinal damage
serositis, arthritis, skin 
s
Stevens-Johnson synd.
Myopathy
Corticosteroids
Low doses for mild disease
Adrenal suppression,
High doses for major
osteopenia, avascular
manifestations including
necrosis of bone, myopathy
renal, hematologic, CNS
Mycophenolate
Nephritis (induction and/or
Myelosuppression
maintenance; NEJM
Immunosuppression/infxn,
2004;350:971 & 2005;353:2219)
teratogen
Cyclophosphamide
Severe nephritis, vasculitis 
Myelosuppression
or CNS disease (induction 
Myeloproliferative disorders
maintenance)
Immunosuppression/infxn
Hemorrhagic cystitis,
bladder cancer
Infertility, teratogen
Azathioprine (AZA)
Mild nephritis (2nd line)
Myelosuppression
Steroid-sparing agent
Hepatotoxicity
Lymphoproliferative disorders
Methotrexate (MTX)
Skin and joint disease
Myelosuppression
Serositis
Hepatotoxicity
Pneumonitis  fibrosis
Alopecia, stomatitis
Cyclosporine (CsA)
Renal disease
Hyperplastic gums, HTN
Hirsutism
Renal impairment, anemia
Rituximab
? Refractory ITP or AIHA
B-cell depletion; PML (?)
Belimumab
Refractory SLE;
B-cell depletion
compassionate use only 
(Arth Rheum 2010;62:201)
Prognosis
‚Ä¢ 5-y survival rate 90%, 10-y survival rate 80%
‚Ä¢ Leading causes of morbidity and mortality: infection, renal failure, neurologic and
cardiovascular events; thrombotic complications (Medicine 2003;82:299)
Drug-induced lupus (DLE)
‚Ä¢ Drugs: procainamide, hydralazine, penicillamine, minocycline, INH, methyldopa, quinidine,
chlorpromazine, diltiazem, anti-TNF
‚Ä¢ Clinical: generally milder disease with predominantly arthritis and serositis
‚Ä¢ Laboratory:  anti-histone (95%);  anti-ds-DNA & anti-Sm; normal complement levels
‚Ä¢ Course: usually reversible w/in 4‚Äì6 wk after stopping medication
SLE
8-16

--- Fim da P√°gina 220 ---

VASCULITIS
8-17
VASCULITIS
LARGE-VESSEL VASCULITIS
Takayasu‚Äôs arteritis (‚Äúpulseless disease‚Äù)
‚Ä¢ Systemic granulomatous vasculitis involving Ao and branches; most often subclavian
and innominate arteries (90%), as well as carotid, renal, pulmonary (~50%)
‚Ä¢ Most common in Asia and in young women of reproductive age
‚Ä¢ Clinical manifestations
Phase I: inflammatory period with fever, arthralgias, weight loss
Phase II: vessel pain and tenderness, ‚Üìand unequal pulses in extremities, bruits,
limb claudication, renovascular hypertension (50%), neurogenic syncope. Ao
aneurysm and AI may accompany aortic involvement.
Phase III: burnt out, fibrotic period
‚Ä¢ Dx studies: ‚ÜëESR (75%), CRP; arteriography ‚Üíocclusion, stenosis, irregularity and
aneurysms; carotid Doppler studies; MRI/MRA; pathology ‚Üífocal panarteritis,
cellular infiltrate with granulomas and giant cells. MRI useful for monitoring.
‚Ä¢ Classification criteria (3 of 6 is 90.5% Se & 97.8% Sp; Arth Rheum 1990;33:1129)
1. age 40 y at dis. onset
4. systolic BP difference 10 mmHg between arms
2. claudication of extremities
5. bruit over subclavian arteries or aorta
3. ‚Üìbrachial artery pulse     
6. arteriogram abnormality (Ao, primary branches,
or prox. large arteries in extremities)
‚Ä¢ Treatment: steroids, MTX, antiplatelet Rx, surgical/endovascular revasc (Circ 2008;69:70)
Giant cell arteritis (GCA) (NEJM 2003;349:160)
‚Ä¢ Vasculitis affecting cranial branches of aortic arch, especially temporal artery 
(thus also called temporal arteritis), but can cause aortitis as well
‚Ä¢
90% of Pts 60 y, rare 50 y; female:male ratio  2:1
‚Ä¢ Clinical manifestations (JAMA 2002;287:92)
constitutional sx: low-grade fevers, fatigue, weight loss, myalgias, anorexia
headache, tender temporal arteries and scalp and absent temporal artery pulsation
ophthalmic artery (20%) ‚Üíoptic neuritis, diplopia, amaurosis fugax, and blindness
facial arteries ‚Üíjaw claudication 
Raynaud‚Äôs phenomenon; intermittent claudication of extremities; thoracic Ao aneurysm
‚Ä¢ Dx studies: ‚ÜëESR (though in ~5% ESR <40 even before Rx); ‚ÜëCRP, anemia
(ESR related to fgbn & Ig in blood; Ddx for 100: malignancy esp. multiple myeloma,
lymphoma; GCA or other vasculitis; ESRD; endocarditis,TB, osteomyelitis)
temporal artery bx: 3‚Äì5 cm, bilat. ‚Üëyield (J Rheum 2009;36:794); look for vasculitis, granul.
if suspect Ao involvement: MRI/MRA or CT-PET to identify stenoses, aneurysms, inflam.
‚Ä¢ Classification criteria (3 of 5 is 93.5% Se & 91.2% Sp; Arth Rheum 1990;33:1122)
1. age 50 y
4. ‚ÜëESR 50 mm/h
2. new headache
5. biopsy ‚Üívasculitis & granulomas
3. temp artery tenderness or ‚Üìpulsation
‚Ä¢ Polymyalgia rheumatica (seen in 50% GCA Pts; 15% of Pts w/ PMR develop GCA)
no universal or validated diagnostic criteria exist; instead follow general guidelines:
age 50 y; ESR 40 mm/h (and/or elevated CRP)
bilateral aching and morning stiffness (30 min  1 mo), involving 2 of following 3
areas: neck or torso, shoulders or prox. arms, hips or prox. thighs; nighttime pain
exclude other causes of sx (eg, RA); CK should be normal
‚Ä¢ Treatment: steroids (if vision threatened do not await path results before starting Rx);
40‚Äì60 mg/d for GCA; 10‚Äì20 mg/d for PMR; follow clinical status and ESR  CRP
MEDIUM-VESSEL VASCULITIS
Polyarteritis nodosa (‚Äúclassic‚Äù PAN) ( JAMA 2002;288:1632)
‚Ä¢ Acute or chronic systemic necrotizing vasculitis, typically of renal and other visceral
arteries, without granuloma formation
‚Ä¢ More common in men; average age of onset ~50 y; strongly associated with HBV
‚Ä¢ Clinical manifestations (Cupps and Fauci. The Vasculitides. Philadelphia:WB Saunders, 1981)
constitutional sx: weight loss, fevers, fatigue
musculoskeletal (64%): myalgias, arthralgias, arthritis
renal involvement (60%) with active urinary sediment, hypertension, renal failure
nervous system (51%): peripheral neuropathies, mononeuritis multiplex, stroke
GI (44%): abd pain, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain
cutaneous lesions (43%): livedo reticularis, purpura, nodules, Raynaud‚Äôs
cardiac (36%): coronary arteritis, cardiomyopathy, pericarditis
if lung involvement, suspect other vasculitis

--- Fim da P√°gina 221 ---

‚Ä¢ Dx studies: ‚ÜëESR & CRP, ‚ÜëWBC, rare eosinophilia, HBsAg ( in ~30%),  ‚ÜìC,  ANCA
angiogram (mesenteric or renal vessels) ‚Üímicroaneurysms and focal vessel narrowing
CTA may be adequate to make the dx; MRA is not as sensitive as angio or CTA
biopsy (sural nerve, skin or affected organ) ‚Üívasculitis of small and medium vessel
arteries with fibrinoid necrosis without granulomas
‚Ä¢ Classification criteria (3 of 10 criteria is 82% Se & 87% Sp; Arth Rheum 1990;33:1088)
1. weight loss 4 kg
2. livedo reticularis
3. testicular pain/tenderness
4. myalgias, weakness, leg tenderness
5. mononeuropathy or polyneuropathy
6. diastolic BP 90 mmHg
7. elevated BUN 40 mg/dL or Cr 1.5 mg/dL
8. Hepatitis B virus
9. Arteriographic abnormality (aneurysms, occlusion of visceral arteries)
10. Biopsy ‚Üívasculitis of small or medium-sized vessel
‚Ä¢ Treatment: steroids, cyclophosphamide; antiviral therapy for HBV-related PAN
ANCA-ASSOCIATED SMALL-VESSEL VASCULITIS
Disease
Gran.
Renal
Pulm.
Asthma
ANCA Type*
ANCA 
Wegener‚Äôs

80%
90%
‚Äî
c-ANCA
90%
granulomatosis
(anti-PR3)
Microscopic
‚Äî
90%
50%
‚Äî
p-ANCA
70%
polyangiitis
(anti-MPO)
Churg-Strauss

45%
70%

p-ANCA
50%
syndrome
(anti-MPO)
*Predominant ANCA type; either p- or c-ANCA can be seen in all three diseases. (NEJM 1997;337:1512)
Differential diagnosis of ANCA
‚Ä¢ c-ANCA (anti-PR3): Wegener‚Äôs granulomatosis, Churg-Strauss, microscopic polyangiitis
‚Ä¢ p-ANCA (anti-MPO): microscopic polyangiitis, Churg-Strauss,Wegener‚Äôs
granulomatosis, drug-induced vasculitis, nonvasculitic rheumatic diseases
‚Ä¢ atypical ANCA patterns: drug-induced vasculitis, nonvasculitic rheumatic diseases,
ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis
Wegener‚Äôs granulomatosis
‚Ä¢ Necrotizing granulomatous inflammatory disease with systemic vasculitis, particularly
involving the upper and lower respiratory tract, and kidney
‚Ä¢ Can occur at any age, but ‚Üëincidence in young and middle-aged adults
‚Ä¢ Clinical manifestations
pulmonary (90%)
upper: sinusitis, otitis (rare in adults), rhinitis, nasal mucosal ulceration, saddle-
nose deformity
lower: pleurisy, pulmonary infiltrate, nodules, hemorrhage, hemoptysis
renal (80%): hematuria, RPGN (pauci-immune)
ocular (50%): episcleritis, uveitis, & proptosis from orbital granulomas, corneal ulcer
neurologic: cranial and peripheral neuropathies, mononeuritis multiplex
hematologic: ‚Üëincidence DVT/PE (20) when disease active (Annals 2005;142:620)
‚Ä¢ Dx studies: 90%  ANCA (80‚Äì95% c-ANCA, remainder p-ANCA)
CXR or CT ‚Üínodules, infiltrates, cavities; sinus CT ‚Üísinusitis
‚ÜëBUN & Cr, proteinuria, hematuria; sediment w/ RBC casts, dysmorphic RBCs
biopsy ‚Üínecrotizing granulomatous inflammation of arterioles, capillaries, veins
‚Ä¢ Classification criteria (2 of 4 criteria is 88% Se & 92% Sp; Arth Rheum 1990;33:1101)
1. nasal or oral inflammation: oral ulcers, purulent or bloody nasal discharge
2. CXR showing nodules, fixed infiltrates, or cavities
3. microscopic hematuria or urinary red cell casts
4. granulomatous inflammation on biopsy
‚Ä¢ Treatment (NEJM 2003;349:36; Annals 2009;150:670)
Induction: cyclophosphamide PO (2 mg/kg/d  3‚Äì6 mo or pulse 15 mg/kg/d q2‚Äì3 wk)
& prednisone (1‚Äì2 mg/kg/d taper over 6‚Äì18 mo)
RPGN: consider adding plasma exchange to regimen (J Am Soc Nephrol 2007;18:2180)
VASCULITIS
8-18

--- Fim da P√°gina 222 ---

Maintenance: MTX or AZA for 2 y 
for mild disease MTX/prednisone may be adequate for induction
disease relapses: match aggressive disease with aggressive Rx as needed
‚ÜëANCA w/o clinical evidence of flare should not prompt  Rx (Annals 2007;147:611)
TMP-SMX may prevent upper airway disease relapse incited by respiratory infections
Microscopic polyangiitis (MPA)
‚Ä¢ Necrotizing small-vessel vasculitis ‚Üíglomerulonephritis, pulmonary capillary
alveolitis, & dermal leukocytoclastic venulitis 
‚Ä¢ Not associated with HBV (unlike classic PAN)
‚Ä¢ Clinical manifestations: similar to Wegener‚Äôs but renal  respiratory involvement;
constitutional and neuro sx as per Wegener‚Äôs, lower rate of relapse
‚Ä¢ Dx studies: 70%  ANCA (almost all p-ANCA), biopsy ‚Üínecrotizing,
pauci-immune inflammation of arterioles, capillaries, & venules;
urine sediment and CXR findings similar to those seen in Wegener‚Äôs
‚Ä¢ Treatment: as for Wegener‚Äôs ‚Üícyclophosphamide; high-dose corticosteroids;
AZA for maintenance; plasmapheresis 
Churg-Strauss syndrome
‚Ä¢ Eosinophil-rich granulomatous inflammation involving lung, peripheral nerves,
heart, kidneys, and skin
‚Ä¢ Rare condition that can present at any age, but typically 30‚Äì40 y; a/w HLA-DRB4
‚Ä¢ Clinical manifestations
asthma and allergic rhinitis (new asthma in an adult raises suspicion)
eosinophilic infiltrative disease or eosinophilic pneumonia
systemic small-vessel vasculitis with granulomas
neuropathy (incl. mononeuritis multiplex), glomerulonephritis
cardiac involvement: coronary arteritis, myocarditis, CHF, valvular insufficiency
(Medicine 2009;88:236)
dermatologic: palpable purpura, petechiae, subcutaneous nodules
‚Ä¢ Dx studies: 50%  ANCA (c-ANCA or p-ANCA), eosinophilia (5‚Äì10 k/L, 80%),
biopsy ‚Üímicrogranulomas, fibrinoid necrosis, and thrombosis of small arteries and
veins with eosinophilic infiltrates; CXR may show shifting pulmonary infiltrates
‚Ä¢ Classification criteria (4 of 6 criteria is 85% Se & 99.7% Sp; Arth Rheum 1990;33:1094)
1. asthma
4. migratory or transitory pulm. infiltrates
2. eosinophilia 10%
5. paranasal sinus abnormality
3. mono- or polyneuropathy
6. extravascular eosinophils on biopsy
‚Ä¢ Treatment: high-dose corticosteroids ( cyclophosphamide or other DMARDs if nec.)
IMMUNE COMPLEX‚ÄìASSOCIATED SMALL-VESSEL VASCULITIS
Henoch-Sch√∂nlein purpura (HSP)
‚Ä¢  Systemic vasculitis characterized by palpable purpura, arthralgia, abd pain, hematuria
‚Ä¢ Epidemiology: male  female, children  adults, onset in winter  summer 
‚Ä¢ Begins after upper respiratory tract infection (esp. Strep) or drug exposure; IgA-mediated
‚Ä¢ Clinical manifestations: palpable purpura on extensor surfaces & buttocks; nondeforming
polyarthralgias especially involving hips, knees, and ankles; colicky
abdominal pain  GIB or intussusception; nephritis ranging from microscopic
hematuria and proteinuria to ESRD; many have fever
‚Ä¢ Diagnostic studies: normal plt count; skin bx ‚Üíleukocytoclastic vasculitis with IgA
and C3 deposition in vessel wall; renal bx ‚Üímesangial IgA deposition
‚Ä¢ Criteria for classification (2 of 4 is 87% Se and 88% Sp; Arth Rheum 1990;33:1114)
1. palpable purpura
2. age 	20 y at disease onset
3. bowel angina
4. biopsy showing granulocytes in the walls of arterioles or venules
‚Ä¢ Treatment: supportive; steroids  DMARDs for renal or severe disease
Cryoglobulinemic vasculitis: see ‚ÄúCryoglobulinemia‚Äù
Connective tissue disease‚Äìassociated vasculitis
‚Ä¢ Vasculitis associated with RA, SLE, or Sj√∂gren‚Äôs syndrome
‚Ä¢ Clinical manifestations
distal arteritis: digital ischemia, livedo reticularis, palpable purpura, cutaneous ulceration
visceral arteritis: pericarditis and mesenteric ischemia 
peripheral neuropathy
‚Ä¢ Diagnostic studies: skin & sural nerve bx, angiography, EMG; ‚ÜìC
 in SLE;  RF in RA
‚Ä¢ Treatment: steroids, cyclophosphamide, MTX (other DMARDs)
VASCULITIS
8-19

--- Fim da P√°gina 223 ---

Cutaneous leukocytoclastic angiitis
‚Ä¢ Heterogeneous group of clinical syndromes due to immune complex deposition
in capillaries, venules, and arterioles; includes hypersensitivity vasculitis
‚Ä¢ Overall the most common type of vasculitis
‚Ä¢ Etiologies
drugs: penicillin, aspirin, amphetamines, thiazides, chemicals, immunizations
infections: strep throat, bacterial endocarditis,TB, hepatitis, staphylococcal infections
tumor antigens
foreign proteins (serum sickness)
‚Ä¢ Clinical manifestations: abrupt onset of palpable purpura, cutaneous ulceration, and
transient arthralgias after exposure to the offending agent, variably accompanied by
fever, arthralgias, and other organ involvement; peripheral neuropathy
‚Ä¢ Dx studies: ‚ÜëESR, ‚Üìcomplement levels, eosinophilia; skin biopsy ‚Üí
leukocytoclastic vasculitis with neutrophils, nuclear fragments 2 to karyorrhexis,
Ig  complement deposition on direct immunofluorescence 
perivascular hemorrhage and fibrinoid deposits 
distinguished from HSP by absence of IgA deposition in skin, and from cryoglobulinemic
vasculitis by absence of cryoglobulins
‚Ä¢ Classification criteria (3 of 5 criteria is 71% Se & 84% Sp; Arth Rheum 1990;33:1108)
1. age 16 y
2. medication taken at disease onset
3. palpable purpura
4. maculopapular rash
5. biopsy showing granulocytes in a perivascular or extravascular location
‚Ä¢ Treatment: withdrawal of offending agent  rapid prednisone taper
Beh√ßet‚Äôs syndrome
‚Ä¢ Multisystem vasculitis that may involve small-, medium- and large-sized vessels,
characterized by recurrent oral and genital ulcers with variable manifestations
affecting the skin, eye, CNS, and musculoskeletal system
‚Ä¢ Associated with HLA B51, highest prevalence on the old Silk Road (Turkey) and
other Asian countries
‚Ä¢ Classification criteria (#1  2 others is 91% Se & 96% Sp; Lancet 1990;335:1078)
1. recurrent oral aphthous ulceration (at least 3 times in one year)
2. recurrent genital ulceration
3. eye lesions: uveitis (with hypopyon), scleritis, retinal vasculitis, optic neuritis
4. skin lesions: pustules, papules, folliculitis, erythema nodosum
5.  pathergy test (prick forearm with sterile needle ‚Üípustule)
‚Ä¢ Other clinical manifestations
arthritis: mild, symmetric, chronic and nondestructive, involving knees and ankles
neurologic: focal deficits, pleocytosis, inflammatory infiltrates w/o vasculitis
vascular: superficial or deep vein thrombosis (25%); arterial stenosis, occlusion, and
aneurysm can also occur
‚Ä¢ Evaluation: ulcer bx, cerebral angio (rarely necessary); slitlamp exam and funduscopy
‚Ä¢ Treatment (Rheumatology 2007;46:736; Ann Rheum Dis 2009;68:1528)
mucocutaneous
mild: colchicine, topical steroids, dapsone
severe: oral steroids,AZA, thalidomide (males), MTX, CsA, anti-TNF
arthritis: NSAIDs, colchicine, steroids,AZA, anti-TNF, IFN-2a
ocular: steroids, AZA, infliximab, IFN-2a, CsA, cyclophosphamide, chlorambucil
vascular: large artery (esp pulmonary), high-dose steroids  cyclophosphamide then
AZA maintenance; for venous thrombosis, control inflammation  anticoagulation
CNS
parenchymal: steroids, MTX,AZA, infliximab, adalimumab, cyclophosphamide,
chlorambucil 
dural sinus thrombosis: steroids and anticoagulation
AZA early helps prevent ocular disease and ulcerations, and improves prognosis
VASCULITIS
8-20

--- Fim da P√°gina 224 ---

CRYO
8-21
CRYOGLOBULINEMIA
Definition & Types (Blood Reviews 2007;21:183)
‚Ä¢ Proteins that precipitate on exposure to the cold, characterized by their com-
position
Types of Cryoglobulinemia
Feature
Type I 
Type II
Type III
(monoclonal)
(mixed)
(polyclonal)
Proportion 
10‚Äì15%
50‚Äì60%
25‚Äì30%
of cases
Cryoglobulin
monoclonal Ig 
monoclonal IgM usually
polyclonal Ig
(usually IgM, or IgG)
w/ RF activity  polyclonal
IgG
Common 
MM,Waldenstrom‚Äôs
HCV infection ( 80% are
Autoimmune
etiologies
HCV RNA )
syndromes 
Primary 
Hyperviscosity
IC-mediated vasculitis, w/ multiorgan
manifestations
 thrombosis
involvement.Type III can be asymptomatic
Etiologies
‚Ä¢ Infections (type II & III): viral (HCV, HBV, HAV, EBV, CMV, HIV), bacterial (endocarditis,
Lyme, syphilis), fungal (coccidiomycosis), and parasitic (malaria, schistosomiasis)
‚Ä¢  Hematologic diseases (type I): MM, NHL, HL, CLL, CML,TTP, myelodysplasia 
‚Ä¢  Autoimmune syndromes (type III predominant, also type II): SLE, Sj√∂gren‚Äôs syndrome,
PAN, RA, sarcoid, IBD
‚Ä¢ Essential (idiopathic)
‚Ä¢ Renal transplant recipients
Pathophysiology
‚Ä¢ Chronic immune stimulation and/or lymphoproliferation S immune complex 
(IC) formation
‚Ä¢ Defective/insufficient IC clearance S IC deposition with complement activation
‚Ä¢ Promotes: platelet aggregation S small vessel thromboses, inflammation S vasculitis
Clinical manifestations (systemic sx usually due to type II  III)  
‚Ä¢ General: weakness, low-grade fever
‚Ä¢ Dermatologic (can also be seen in type I): lower extremity purpura, livedo reticu-
laris, leg ulcers, Raynaud‚Äôs phenomenon, leukocytoclastic vasculitis
‚Ä¢ Rheumatologic: symmetric, migratory arthralgias of small or medium joints
‚Ä¢ Renal (50%): glomerulonephritis (proteinuria, hematuria, ARF, hypertension, edema)
‚Ä¢ Hematologic: anemia, thrombocytopenia
‚Ä¢ GI: abdominal pain, hepatosplenomegaly, abnormal LFTs
‚Ä¢ Neurologic: peripheral neuropathy and mononeuritis multiplex
Diagnostic studies
‚Ä¢ Cryoglobulins  proteins that precipitate from serum or plasma when cooled
cryocrit is quantitation of cryoprotein, does not nec. correlate w/ disease activity
‚Ä¢ Must distinguish from cryofibrinogenemia  proteins that precipitate from plasma only
(eg, fibrin, fibrinogen). Separate disorder that can be seen in CTD, infection, malig-
nancy. Usually asx or may promote thrombosis.
‚Ä¢  rheumatoid factor (RF)
‚Ä¢ False elevations in WBC or plt count on automated CBC, due to cryoprecipitation
‚Ä¢ T C4 levels, variable C3 levels, c ESR
‚Ä¢ Must keep blood warmed to 37C at all times en route to lab; early cooling causes
false  cryoglobulin, loss of RF and TT complement
‚Ä¢ In HCV-associated type 2 cryoglobulinemia:  HCV RNA,  anti-HCV Ab
‚Ä¢ Biopsy of affected tissue (skin, kidney)
Treatment
‚Ä¢ Treat underlying disorder:
chemotherapy and/or radiation for lymphoproliferative disorders
antiviral therapy and/or rituximab for HCV (Arth Rheum 2009;60:2531)
DMARDs for rheumatic disease
‚Ä¢ NSAIDs for control of mild symptoms for Pts with normal renal function
‚Ä¢ Prednisone  other immunosuppressants (eg, cyclophosphamide) for major organ
involvement
‚Ä¢ Plasmapheresis in severe disease

--- Fim da P√°gina 225 ---

AMYLOID
8-22
AMYLOIDOSIS
Accumulation of insoluble fibrillar proteins that form -pleated sheets
Classification of Amyloidosis
Type
Precursor
Causative diseases
Organ systems
AL
Ig light chain
MM
Renal, cardiac, GI,
(Primary)
(monoclonal)
Light chain disease ( )
neuro, cutaneous,
Most common
MGUS,WM
hepatic, pulmonary,
2000 cases/y
musculoskel, heme
AA
Serum amyloid
Inflam: RA, IBD, FMF
Renal, GI, hepatic,
(Secondary)
(SAA)
Chronic infxns: osteo,TB
neuro, cutaneous
Neoplasms: renal, HD
Hereditary
Transthyretin, et al.
Mutant proteins
Neurologic, cardiac
Senile
TTR,ANP
Normal proteins; 2 aging
Cardiac, aorta, GI
A2M
	2-microglobulin
Dialysis-associated 	2m
Musculoskeletal
(normally renally excreted)
Organ-
	-amyloid protein
Localized production and
Neurologic
specific
Peptide hormones
processing
Endocrine
(Adapted from NEJM 1997;337:898; 2003;349:583; 2007;356:2361)
Clinical Manifestations of Amyloidosis
System
Manifestations
Amyloid
Renal
Proteinuria or nephrotic syndrome
AL,AA
Cardiac
Cardiomyopathy (restrictive & dilated)
AL, hereditary,
T QRS amplitude, conduction abnormalities, AF
senile,
Orthostatic hypotension
organ-specific
GI
Diarrhea, malabsorption, protein loss
all systemic
Ulceration, hemorrhage, obstruction
Macroglossia S dysphonia and dysphagia
Neurologic
Peripheral neuropathy with painful paresthesias
hereditary,AL,
Autonomic neuro S impotence, dysmotility, T BP
organ-specific,
Carpal tunnel syndrome
A	2m
Cutaneous
Waxy, nonpruritic papules; periorbital ecchymoses
AL
‚ÄúPinch purpura‚Äù  skin bleeds with minimal trauma
Hepatic &
Hepatomegaly, usually without dysfunction
all systemic
Splenic
Splenomegaly, usually without leukopenia or anemia
Endocrine
Deposition with rare hormonal insufficiency
organ-specific
Musculoskel
Arthralgias and arthritis
AL,A	2m
Pulmonary
Airway obstruction
AL,AA
Hematologic
Factor X deficiency
AL
Diagnostic studies
‚Ä¢ If suspect AL S ‚úìSIEP (not SPEP or UPEP) & free light chains,  BM bx
‚Ä¢ If suspect renal involvement ‚úìU/A (proteinuria)
‚Ä¢ If suspect cardiac involvement: ‚úì ECG (T voltage, conduction abnl), echo (biventricular
thickening with ‚Äúgranular sparkling‚Äù appearance; c wall w/o c volt 75% Se, 95% Sp), MRI
‚Ä¢ Serum amyloid P scintigraphy (NEJM 1990;323:508)
‚Ä¢ Biopsy (abdominal SC fat pad, rectal, or affected tissue [eg, heart]) S apple-green
birefringence on Congo red stain
‚Ä¢ Genetic testing for hereditary forms
Treatment
‚Ä¢ AL: melphalan  dex, ? autologous SCT if limited organ involvement (NEJM 2007;357:1083)
‚Ä¢ AA: Rx underlying disease; colchicine for FMF (NEJM 2007;356:23); eprodisate promising
for renal disease (NEJM 2007;356:2349)
‚Ä¢ For hereditary amyloidoses in which amyloid precursor protein is produced by the
liver (eg,TTR), liver transplantation may prevent further deposition
‚Ä¢ If cardiac involvement: diuretics; avoid digoxin & CCB; may not tolerate vasodilators
‚Ä¢ Heart, kidney, and liver transplantation may be considered in those with advanced
disease
Prognosis
‚Ä¢ AL amyloid: median survival 12‚Äì18 mo; if cardiac involvement, median survival 6 mo
‚Ä¢ AA amyloid: median survival 11 y (NEJM 2007;356:2361)

--- Fim da P√°gina 226 ---

ŒîMS
9-1
CHANGE IN MENTAL STATUS
Definitions (nb, description of state better than imprecise use of terms)
‚Ä¢ Confusion (encephalopathy): unable to maintain coherent thought process
‚Ä¢ Delirium: waxing & waning confusional state w/ additional sympathetic signs
‚Ä¢ Drowsiness: T level of consciousness, but rapid arousal to verbal or noxious stimuli
‚Ä¢ Stupor: impaired arousal to noxious stimuli, but some preserved purposeful movements
‚Ä¢ Coma: sleeplike state of unresponsiveness, with no purposeful response to stimuli
Etiologies
Primary Neurologic
Systemic
(usually with focal signs)
(especially in elderly)
Stroke
Cardiac: severe CHF, HTN encephalopathy
Seizure (postictal, status, nonconvulsive)
Pulmonary: T PaO2, c PaCO2
Infection: meningoencephalitis, abscess
GI: liver failure, constipation, Wilson‚Äôs
Epidural/subdural hematoma
Renal: uremia, hyponatremia and 
Concussion
hypernatremia
Hydrocephalus
Endocrine: T glc, DKA, HHNS, c Ca,
Complicated migraine
hypothyroidism or hyperthyroidism,
Venous thrombosis
Addisonian crisis
Transient global amnesia
ID: pneumonia, UTI, sepsis
CNS vasculitis
Hypothermia and hyperthermia
TTP
Medications (espec. opiates & sedatives)
Alcohol & toxins
Initial evaluation
‚Ä¢ History (typically from others): previous or recent illnesses, including underlying
dementia or psychiatric disorders; head trauma; meds, drug or alcohol use
‚Ä¢ General physical examination: evaluate for asterixis, signs of trauma, stigmata of
liver disease, embolic phenomena, signs of drug use, nuchal rigidity (may be present
in meningitis or subarachnoid hemorrhage, but do not test if question of
trauma/cervical spine fracture)
‚Ä¢ Neurologic examination (if possible, off sedatives/paralytics)
Observation for response to stimuli, papilledema, spontaneous movements
Pupil size & reactivity: pinpoint S opiates; midposition & fixed S midbrain lesion;
fixed & dilated S severe anoxic encephalopathy, herniation
Intact oculocephalic (‚Äúdoll‚Äôs eyes,‚Äù eyes move opposite head movement) or
oculovestibular (‚Äúcold calorics,‚Äù eyes move slowly toward lavaged ear and then
quick horizontal nystagmus away) imply brainstem intact
Other cranial nerves: eye position at rest, response to visual threat, corneal reflex,
facial grimace to nasal tickle, cough/gag (with ET tube manipulation if necessary)
Look for s/s of c ICP: HA, vomiting, HTN, T HR, papilledema, unilateral dilated pupil
Motor response in the extremities to noxious stimuli, noting purposeful vs. posturing;
decerebrate  arms extended; decorticate  arms flexed; both with legs extended
Deep tendon reflexes, Babinski response
Glasgow Coma Scale
Eye opening
Best verbal response
Best motor response
Points
Follows commands
6
Oriented
Localizes pain
5
Spontaneous
Confused
Withdraws from pain
4
To voice
Inappropriate words
Decorticate posturing
3
To painful stimuli
Unintelligible sounds
Decerebrate posturing
2
None
None
None
1
Sum points from each of the 3 categories to calculate the score
Initial treatment
‚Ä¢ Control airway, monitor vital signs, IV access
‚Ä¢ Immobilization of C-spine if concern for cervical trauma
‚Ä¢ Thiamine (100 mg IV) prior to dextrose to prevent exacerb. of Wernicke‚Äôs encephalopathy
‚Ä¢ Dextrose (50 g IV push)
‚Ä¢ Naloxone 0.01 mg/kg if opiates suspected; flumazenil 0.2 mg IV if benzos suspected
‚Ä¢ If concern for c ICP and herniation: c head of bed; osmotherapy with mannitol;
hyperventilation; dexamethasone; consider emergent surgical decompression

--- Fim da P√°gina 227 ---

ŒîMS
9-2
Diagnostic studies
‚Ä¢ Head CT; radiographs to r/o C-spine fracture; CXR to r/o PNA (in elderly)
‚Ä¢ Laboratory: electrolytes, BUN, Cr, ABG, LFTs, CBC, PT, PTT, NH3, tox screen,TSH, U/A
‚Ä¢ Lumbar puncture to r/o meningitis
‚Ä¢ EEG to r/o nonconvulsive seizures
ANOXIC BRAIN INJURY
Prevalence
‚Ä¢ Pts w/ at least 5 min of cerebral hypoxia at risk
‚Ä¢ 1.5 million cardiac arrests per year in U.S.; 30% survive, but only 10‚Äì20% return to
independence
Initial evaluation
‚Ä¢ Neuro exam: focus on coma exam S cranial nerves, motor response to pain
‚Ä¢ Imaging: usually not informative w/in first day after arrest, but should be done prior
to initiating hypothermia if patient found down or witnessed to hit head
Coma Exam Checklist
Cranial nerves 
Pupillary response, extraocular movements, corneal reflex 
Motor 
Spontaneous limb movements, posturing 
Sensory
Response to painful stimuli
Reflexes
Deep tendon reflexes, Babinski
Induced hypothermia (NEJM 2002;346:549, 559)
‚Ä¢ Indications: comatose w/in 6 h following cardiac arrest (not isolated resp. arrest).
Fully studied only in VT/VF, but acceptable to perform after asystole or PEA arrest.
‚Ä¢ Contraindications: active bleeding, including cerebral; known sepsis; recent surgery or
trauma (relative); CV instability; clear improvement in neurologic exam (purposeful
movements, vocalizations)
‚Ä¢ Method: target temperature 32‚Äì34C  24 h (from time of initiation of cooling)
cold saline infusions; ice packs to the head, neck, and torso; cooling blankets
may use cooling vest or endovascular catheter if available
‚Ä¢ Complications
cardiac dysrhythmias (bradycardia most common): if significant dysrhythmia or
hemodynamic instability, d/c cooling and actively rewarm patient (this is only cir-
cumstance in which active rewarming should be performed; o/w rewarm no
faster than 0.5C per h)
coagulopathy: Pts can receive fibrinolytics, GP IIb/IIIa inhibitors, etc., and still
undergo cooling. ‚úìPT and PTT.
infection: ‚úìsurveillance blood cultures during cooling
hyperglycemia
hypokalemia during cooling, hyperkalemia w/ rewarming; keep K 4‚Äì5 mEq/L
Ongoing evaluation
‚Ä¢ Neuro exam: daily focus on coma exam, cranial nerves, GCS score. Pt needs to be
off sedation for adequate time to evaluate (depends on doses used, duration of
Rx, metabolic processes in the individual Pt).
‚Ä¢ Labs: daily CBC, PT/PTT, electrolytes. Serum neuron-specific enolase (NSE) on day 1‚Äì3
‚Ä¢ Imaging: noncontrast CT 24 h after arrest; if unrevealing, MRI around day 3‚Äì5
‚Ä¢ EEG: should be performed in any Pt w/ seizures or myoclonus (to r/o status epilepti-
cus); should be considered in all unresponsive Pts (to r/o nonconvulsive seizures)
‚Ä¢ Somatosensory evoked potentials (SSEP): helpful for prediction of poor outcome if
absent cortical responses bilaterally; should not be performed earlier than 48 h
after arrest (72 h if cooled)
Prognosis (Neuro 2006;67:203; NEJM 2009;361:605)
‚Ä¢ Uniformly poor prognosis can be predicted at 72 h only in Pts who have absent
pupillary and corneal reflexes, and no motor response to pain; also with absent
SSEPs at 48 h
‚Ä¢ Otherwise, requires multifactorial approach, considering neuro exam, age and
comorbid diseases, and ancillary data (serum NSE, neuroimaging, EEG, SSEP)
‚Ä¢ When in doubt, err on the side of giving more time (especially in younger Pts and
induced hypothermia Pts)

--- Fim da P√°gina 228 ---

SEIZURES
9-3
SEIZURES
Definitions (NEJM 2003;349:1257)
‚Ä¢ Seizure  abnormal, paroxysmal, excessive discharge of CNS neurons; occurs in
5‚Äì10% of the population; clinical manifestations can range from dramatic to subtle
‚Ä¢ Epilepsy  recurrent seizures due to an underlying cause; 0.5‚Äì1.0% of population
‚Ä¢ Generalized seizures (involves brain diffusely)
Tonic-clonic (grand mal): tonic phase (10‚Äì20 sec) with contraction of muscles (caus-
ing expiratory moan, cyanosis, pooling of secretions, tongue biting) S clonic
phase (30 sec) with intermittent relaxing and tensing of muscles
Absence (petit mal): transient lapse of consciousness w/o loss of postural tone
Myoclonic (infantile spasms & juvenile myoclonic epilepsy): sudden, brief contraction
‚Ä¢ Partial or focal seizures (involves discrete areas, implies a focal, structural lesion)
Simple: without impairment of consciousness; may be motor, sensory, or autonomic
Complex: with impairment of consciousness  automatisms
Partial with secondary generalization: starts focal, becomes diffuse
Ddx
‚Ä¢ Syncope
Feature
Seizure
Syncope
Aura
Unusual behavior/automatisms
Diaphoresis, nausea, tunnel vision
Convulsions
Variable duration
Usually 10 sec
Post-ictal state
Yes 
No
Other clues
Tongue biting, incontinence
Skin pallor, clamminess
‚Ä¢ Nonepileptic seizure (NES, aka ‚Äúpsychogenic‚Äù): may see side-to-side head turning,
asymmetric large-amplitude limb movements, diffuse twitching w/o LOC, and crying
or talking during event
‚Ä¢ Other: metabolic disorders (eg, alcoholic blackouts, hypoglycemia); migraines; TIAs;
narcolepsy; nonepileptic myoclonus; tics; asterixis
Etiologies
‚Ä¢ Alcohol withdrawal, illicit drugs, meds (eg, -lactams, bupropion, tramadol, metro-
nidazole, meperidine, CsA, antidep., clozapine can lower seizure threshold)
‚Ä¢ Brain tumor or penetrating trauma
‚Ä¢ Cerebrovascular disease, including subdural hematomas, hypertensive encephalopathy
‚Ä¢ Degenerative disorders of the CNS (eg, Alzheimer‚Äôs)
‚Ä¢ Electrolyte (hyponatremia) & other metabolic (eg, uremia, liver failure, hypoglycemia)
Clinical manifestations
‚Ä¢ Aura (sec to mins): premonition consisting of abnormal smells/tastes, unusual behav-
ior, oral or appendicular automatisms
‚Ä¢ Ictal period (sec to mins): tonic and/or clonic movements of head, eyes, trunk, or extrem.
‚Ä¢ Postictal period (mins to h): slowly resolving period of confusion, disorientation,
and lethargy. May be accompanied by focal neurologic deficits (Todd‚Äôs paralysis).
‚Ä¢ Status epilepticus: continuous tonic-clonic seizure 30 min, or repeated seizures
such that there is no resolution of postictal periods. Complications include neu-
ronal death, rhabdomyolysis, and lactic acidosis.
‚Ä¢ Nonconvulsive status epilepticus alteration of awareness (ranging from confu-
sion to coma) w/o motor manifestations. Dx with EEG.
Clinical evaluation
‚Ä¢ Seizure: patient usually w/o recollection, must talk to witnesses
unusual behavior before seizure (ie, an aura)
type & pattern of abnl movements, incl. head turning & eye deviation (gaze prefer-
ence usually away from seizure focus)
loss of responsiveness
‚Ä¢ HPI: recent illnesses/fevers, head trauma, sleep deprivation, medication compliance
‚Ä¢ PMH: prior seizures or  FHx, prior meningitis/encephalitis, prior stroke or head trauma
‚Ä¢ Medications, alcohol, and illicit drug use
‚Ä¢ General physical exam should include the skin, looking for neuroectodermal disorders
(eg, neurofibromatosis, tuberous sclerosis) that are a/w seizures
‚Ä¢ Neurologic exam should look for focal abnormalities S underlying structural abnormality
Diagnostic studies
‚Ä¢ Laboratory: full electrolytes, BUN, Cr, glc, LFTs, tox screen, medication levels
‚Ä¢ EEG: if frequent, can capture repetitive rhythmic activity (nb, generalized seizures will
always have abnl EEG; partial may not); eval for interictal epileptiform activity 

--- Fim da P√°gina 229 ---

SEIZURES
9-4
(eg, spikes or sharp waves), but seen in up to 2% of normal population; sleep
deprivation c dx yield of EEG; video monitoring may help w/ nonepileptic seizures
‚Ä¢ MRI to r/o structural abnormalities; c Se w/ fine coronal cuts of frontal & temporal lobes
‚Ä¢ LP (after r/o space-occupying lesion): if suspect meningitis (eg, fever, c WBC, nuchal
rigidity) or encephalitis and in all HIV  Pts
Treatment (Lancet 2006;367:1087 & 2007;369:1000, 1016; NEJM 2008;359:166)
‚Ä¢ Treat any underlying causes, including CNS infections, intoxication, or withdrawal, etc.
‚Ä¢ Antiepileptic drug (AED) therapy is usually reserved for Pts w/ underlying structural
abnormality or an idiopathic seizure plus (i) status epilepticus on presentation, (ii)
focal neurologic exam, (iii) postictal Todd‚Äôs paralysis, or (iv) abnormal EEG
‚Ä¢ For Pts w/ infrequent seizures, early (vs. delayed) intervention w/ AED c time to seizure
recurrence, but has no effect on long-term seizure-free status (Lancet 2005;365:2007)
‚Ä¢ AED choice dependent on type of seizure, side effects, cost, and drug interactions
‚Ä¢ Introduce gradually, monitor carefully
‚Ä¢ May consider withdrawal if seizure-free (typically for at least 1 y) and normal EEG
‚Ä¢ Individual state laws mandate seizure-free duration before being allowed to drive
Antiepileptic Drugs and Side Effects
Medication
Avg daily dose
Common Side Effects
Systemic 
Neurologic
Phenytoin
300‚Äì400 mg
Gum hyperplasia
Dizziness, ataxia,
Carbamazepine
600‚Äì1800 mg
Aplastic anemia, T WBC,
diplopia, confusion,
rash, hepatotoxicity, T Na
drowsiness
Valproic acid
750‚Äì2000 mg
Hepatotoxicity, c NH3, c wt,
Tremor, drowsiness
hair loss
Phenobarbital
60‚Äì180 mg
Rash
Drowsiness
Ethosuximide
750‚Äì1250 mg
Rash, bone marrow 
Drowsiness,
suppression
behavioral 	s
Gabapentin
900‚Äì2400 mg
GI upset, wt gain
Nystagmus,
drowsiness
Lamotrigine
200‚Äì400 mg
Rash (Stevens-Johnson 
Tremor, HA,
syndrome)
insomnia
Leviteracitam
1500‚Äì3000 mg
GI upset (rare)
Drowsiness,
emotional lability
Oxcarbazepine
1200‚Äì2400 mg
Hyponatremia, rash
Drowsiness
Topiramate
100‚Äì400 mg
T wt, hypohidrosis, kidney 
Cognitive slowing,
stones, glaucoma
fatigue
Zonisamide
200‚Äì400 mg
T wt, hypohidrosis, kidney 
Abnormal thinking,
stones
fatigue
(JAMA 2004;291:605, 615)
Status epilepticus (consult neurology)
‚Ä¢ Place Pt in semiprone position to T risk of aspiration
‚Ä¢ Oral airway or, if prolonged, endotracheal intubation
‚Ä¢ IV access, start normal saline infusion
‚Ä¢ STAT labs including glc, Na, Ca, serum & urine toxicology screen, anticonvulsant levels
‚Ä¢ Thiamine (100 mg IV) prior to dextrose to prevent exacerb. of Wernicke‚Äôs encephalopathy
‚Ä¢ Dextrose (50 g IV push)
Treatment of Status Epilepticus
(Proceed to next step if seizures continue)
Step
Antiepileptic
Dosing regimen
Typical adult dose
1
Lorazepam or
0.1 mg/kg at 2 mg/min
Successive 2‚Äì4 mg IV pushes
Diazepam
0.2 mg/kg at 5 mg/min
Successive 5‚Äì10 mg IV pushes
Lorazepam marginally slower onset of action (3 vs. 2 min) but at least as efficacious
(success 65%) & longer duration of effect (12‚Äì24 h vs. 15‚Äì30 min)
2
Phenytoin or
20 mg/kg at 50 mg/min
1.0‚Äì1.5 g IV over 20 min
Fosphenytoin
20 mg PE/kg at 150 mg/min
1.0‚Äì1.5 g PE IV over 5‚Äì10 min

 5‚Äì10 mg/kg if still seizing

 500 mg IV if still seizing
Subsequent steps typically mandate intubation, EEG monitoring, and ICU admission
3
Phenobarbital
20 mg/kg at 50‚Äì75 mg/min
1.0‚Äì1.5 g IV over 30 min

 5‚Äì10 mg/kg if still seizing

 500 g IV if still seizing
4
General anesthesia with midazolam, pentobarbital, or propofol
PE, phenytoin equivalents. (JAMA 1983;249:1452; NEJM 1998;338:970 & 339:792)

--- Fim da P√°gina 230 ---

ALCOHOL WITHDRAWAL
Pathophysiology
‚Ä¢ Alcohol is CNS depressant
‚Ä¢ Chronic use S insensitivity to inhibitory neurotransmitter -aminobutyric acid (GABA)
‚Ä¢ Abrupt alcohol cessation S CNS overactivity
Clinical manifestations
‚Ä¢ Minor withdrawal sx (6‚Äì48 h after last drink): mild anxiety, tremulousness, HA
‚Ä¢ Withdrawal seizures: typically w/in 48 h after last drink; if unRx‚Äôd, 1‚ÅÑ3 S delirium tremens
‚Ä¢ Alcoholic hallucinosis: isolated hallucinations (typically visual) 12‚Äì48 h after last drink
‚Ä¢ Delirium tremens (DT): disorientation, agitation, hallucinations, c HR & BP, fever,
diaphoresis; begins 48‚Äì96 h after last drink, lasts 5‚Äì7 d
‚Ä¢ Need to consider other dx: CNS infxn, CNS bleed, drug O/D, acute liver failure, GIB
Clinical Institute Withdrawal Assessment scale for alcohol (CIWA-Ar)
‚Ä¢ Assign points for each of the 10 criteria; add points to calculate score
CIWA-Ar Scale
Points
Anxiety
Agitation
Tremor
HA
Orientation
0
None
None
None
None
Oriented
1
Somewhat
Not visible, but
Very mild
Cannot do serial
felt at fingertips
additions
2
Mild
Disorient. by 2 d
3
Moderate
Disorient. by 2 d
4
Guarded
Restless
Moderate w/ 
Mod severe
Disoriented to
hands extended
person or place
5
Severe
n/a
6
Very severe
n/a
7
Panic
Pacing or 
Severe
Extremely
n/a
thrashing
severe
Points
N/V
Sweats
Auditory 
Visual 
Tactile disturb
halluc.
halluc.
0
None
None
None
None
None
1
Moist palms
Very mild
Very mild 
Very mild 
photosens.
paresthesias
2
Mild
Mild 
Mild paresth.
photosens.
3
Moderate
Mod 
Mod paresth.
photosens.
4
Intermit. w/ 
Beads
Mod severe
Mod severe 
Mod severe 
dry heaves
visual halluc.
hallucinations
5
Severe
Severe 
Severe
6
Very severe
Very severe
Very severe
7
Constant
Drenching
Cont.
Continuous
Continuous
SCORE: 8 none to minimal withdrawal; 8‚Äì15 mild; 16‚Äì20 moderate, 20 severe
(Each criterion is a continuum that ranges from 0‚Äì7 points [except 0‚Äì4 for Orientation]; selected cells
have text to provide guidance for assigning points.)
Treatment (NEJM 2003;348:1786)
‚Ä¢ Benzodiazepines (BDZ)
Drug: diazepam (long-acting w/ active metab; T risk of recurrent withdrawal), lorazepam
(short half-life), chlordiazepoxide, oxazepam (no active metabs; good if cirrhosis)
Route: start IV, transition to PO
Dosing: typically start w/ diazepam 10‚Äì15 mg IV q10‚Äì15 min (or lorazepam 2‚Äì4 mg IV
q15‚Äì20 min) until appropriate sedation achieved, then titrate to CIWA-Ar scale, eval-
uating q1h until score 8  8h, then q2h  8h, and if stable then q4h (JAMA 1994;272:519)
‚Ä¢ If refractory to BDZ prn, consider BDZ gtt, phenobarbital or propofol (& intubation)
‚Ä¢ Do not give haloperidol (T seizure threshold) or B / central 2-agonists (mask sx)
‚Ä¢ Mechanical restraints as needed until chemical sedation achieved
‚Ä¢ Volume resuscitation as needed; thiamine then glc to prevent Wernicke‚Äôs encephalopathy
(ataxia, ophthalmoplegia, short-term memory loss); replete K, Mg, PO4
‚Ä¢ Prophylaxis: if min sx or asx (ie, CIWA score 8) but prolonged heavy EtOH con-
sumption or h/o withdrawal seizures or DTs S chlordiazepoxide 25‚Äì100 mg
(based on severity of EtOH use) q6h  24h, then 25‚Äì50 mg q6h  2d
ETOH
9-5

--- Fim da P√°gina 231 ---

STROKE
9-6
STROKE
ISCHEMIC (70%)
Etiologies
‚Ä¢ Embolic (75%): artery S artery, cardioembolic, paradoxical (NEJM 2007;357:2262), cryptogenic
‚Ä¢ Thrombotic (25%): lacunar (arteriolar, seen in HTN & DM) or large vessel
‚Ä¢ Other: dissection, vasculitis, vasospasm, hyperviscosity, watershed
Clinical Manifestations
Embolic: rapid onset, sx maximum at onset
Thrombotic: progression of sx over hrs to days possibly with stuttering course
Artery
Deficits
ICA/Ophth
Amaurosis fugax (transient monocular blindness)
ACA
Hemiplegia (leg  arm)
Confusion, abulia, urinary incontinence, primitive reflexes
MCA
Hemiplegia (arm & face  leg); hemianesthesia; homonymous hemianopia
Aphasia if dom. hemisphere: sup. div. S expressive; inf. S receptive
Apraxia and neglect if nondominant hemisphere
Drowsiness & stupor seen later (due to brain swelling)
PCA
Thalamic syndromes with contralateral hemisensory disturbance, aphasia
Macular-sparing homonymous hemianopia
Vertebral
Wallenberg syndrome  numbness of ipsilateral face and contralateral 
limbs, diplopia, dysarthria, ipsilateral Horner‚Äôs
Basilar
Pinpoint pupils, long tract signs (quadriplegia and sensory loss), cranial 
nerve abnormalities, cerebellar dysfunction
Cerebellar
Vertigo, nausea/vomiting, diplopia, nystagmus, ipsilateral limb ataxia
Lacunar
Pure hemiplegia, pure hemianesthesia, ataxic hemiparesis, or
dysarthria 
 clumsy hand
Transient ischemia attacks (TIAs) are sudden neurologic deficits caused by cerebral
ischemia w/o evidence of infarction on imaging; sx typically resolve w/in 24 h (usually w/in 1 h);
a harbinger of stroke.
Ddx: seizure, migraine, syncope, hypoglycemia, anxiety
Physical examination
‚Ä¢ General including rhythm, murmurs, carotid & subclavian bruits, signs of peripheral emboli
‚Ä¢ Neurologic including NIH stroke scale (NIHSS)
Diagnostic studies
‚Ä¢ Laboratory: electrolytes, Cr, glc, CBC, PT, PTT, LFTs, ESR, tox screen, BCx (if suspicion for
endocarditis); once stable, lipids, HbA1c,TSH, homocysteine, Lp(a), hypercoag w/u (if
65 y or in those w/ cryptogenic strokes; ideally drawn before anticoagulation initiated)
‚Ä¢ ECG
‚Ä¢ Urgent CT is usually the initial imaging study because of its rapidity and availability
first, noncontrast CT to r/o hemorrhage (Se for ischemic 	s is 20% w/in 12 h)
then, CT angio/perfusion to evaluate cerebrovascular patency and areas of reversible
ischemia (if intra-arterial/catheter-based interventions are being considered)
‚Ä¢ MRI offers superior imaging but may not identify acute hemorrhage (although data sug-
gest may be equivalent; JAMA 2004;292:1823) and may be falsely  for small brainstem
strokes w/in 1st 3 h; should be delayed if Pt is unstable or will delay therapy
‚Ä¢ Carotid Doppler U/S, transcranial Doppler (TCD)
‚Ä¢ Holter monitoring to assess for paroxysmal AF
‚Ä¢ Echocardiography w/ bubble study to r/o PFO or atrial septal aneurysm (confer 4
c risk of stroke; NEJM 2001;345:1740), cardiac thrombus, valvular vegetations
Treatment of TIA (NEJM 2002;347:1687)
‚Ä¢ Immediate evaluation and treatment as clinically indicated (Lancet 2007;370:1432)
‚Ä¢ Consider heparin IV S warfarin if: known or presumptive cardioembolic TIAs or if
bridging to mechanical intervention (CEA, stenting) for large vessel atherothrombotic dis.
‚Ä¢ Antiplatelet therapy with ASA, clopidogrel, or ASA 
 dipyridamole
‚Ä¢ Carotid revascularization if sx 70% ipsilateral stenosis (see later)
Risk of progression of TIA to stroke (Lancet 2007;369:283)
‚Ä¢ ABCD2: Age 60 y (
1); BP 140/90 (
1); Clin. features: unilateral weakness (
2), speech
impairment w/o weakness (
1); Duration 60 (
2) or 10‚Äì59 min (
1); Diabetes (
1)
‚Ä¢ Risk of stroke at 2 d: low risk (0‚Äì3)  1.0%; moderate (4‚Äì5)  4.1%; high (6‚Äì7)  8.1%
‚Ä¢ Risk of progression higher for TIAs due to large artery/lacunar dis. (vs. cardioembolic)

--- Fim da P√°gina 232 ---

Treatment of ischemic stroke (NEJM 2008;359:1317; Lancet 2010;375:1695)
‚Ä¢ Thrombolysis (IV): 0.9 mg/kg (max 90 mg), w/ 10% as bolus over 1 min, rest over 1 h
consider if onset w/in 4.5 h, large deficit, ‚àÖhemorrhage, and ‚àÖcontraindication to lysis.
For Pts Rx‚Äôd w/in 3 h, 12% absolute c in excellent functional outcome, 5.8%
absolute c ICH, trend toward 4% absolute T mortality (NEJM 1995;333:1381)
‚Ä¢ Intra-arterial therapy with thrombolysis (JAMA 1999;282:2003) or catheter-based tech-
niques promising (66% rate of recanalization) but still experimental;
currently reserved for occlusion of a major vessel (ICA, MCA, basilar)
‚Ä¢ Anticoag w/ UFH of no proven benefit w/ c risk of hemorrhagic transformation 
consider infusion w/o bolus if Pt not thrombolysed and having progressive sx
long-term warfarin if embolic stroke; no role in nonembolic stroke (NEJM 2001;345:1444)
‚Ä¢ Antiplatelet therapy
ASA T death & recurrent stroke (Stroke 2000;31:1240) and is superior to warfarin
alone (NEJM 2005;352:1305)
dipyridamole  ASA superior to ASA alone (Lancet 2006;367:1665)
clopidogrel  ASA not more effective than ASA alone and c bleeding (Lancet 2004;364:331)
dipyridamole  ASA ‚âàclopidogrel alone in risk of recurrent stroke, and T bleeding
w/ clopidogrel, but study limited by preponderance of small-vessel subtype (NEJM
2008;359:1238)
‚Ä¢ BP should not be lowered acutely unless severe (SBP 200) or evidence of MI or CHF
if considering thrombolysis, then lower to 180/110 with nitrates or labetalol
‚Ä¢ DVT prophylaxis: enoxaparin more efficacious than UFH (Lancet 2007;369:1347)
‚Ä¢ Cerebral edema peaks at 3‚Äì4 d poststroke S c ICP requiring elevated head of bed
30; intubation & hyperventilation to PaCO2 30 (transient benefit);
osmotherapy with mannitol IV 1 gm/kg S 0.25 g/kg q6h;  hypertonic saline
surgical decompression
‚Ä¢ Statin S T in recurrent stroke & T MACE (Lancet 2002;360:7; NEJM 2006;355:549)
Carotid revascularization
‚Ä¢ Carotid endarterectomy (if institutional morbidity & mortality 6%) indicated for:
sx stenosis 70% (? 50‚Äì69% if male, age 75 y, or recent sx) S 65% T
stroke (NEJM 1991;325:445; Lancet 2004;363:915)
asx stenosis 70% & 75 y S 50% T stroke (Lancet 2004;363:1491)
‚Ä¢ Superiority and even noninferiority of carotid stenting remains controversial (NEJM
2004;351:1493; Lancet 2006;368:1239; NEJM 2006;355:1660 & 2008;358:1572; Lancet 2010;375:985)
Patent foramen ovale (PFO) (NEJM 2005;353:2361)
‚Ä¢ Present in 27% of population; may be a/w stroke, but yearly risk 0.1% in healthy pop.
‚Ä¢ Features a/w c risk of stroke: 4 mm separation, R S L shunting at rest, c septal mobility
‚Ä¢ If PFO & stroke/TIA: no evidence to favor warfarin over ASA (Circ 2002;105:2625); con-
sider anticoagulation if Pt is at high risk or has DVT/PE; closure trials ongoing
HEMORRHAGIC (30%)
Etiologies
‚Ä¢ Intracerebral (90%): HTN (brainstem/cerebellum, basal ganglia), AVM, amyloid
angiopathy (lobar), anticoagulation/thrombolysis, venous thrombosis, tumors
‚Ä¢ Subarachnoid (SAH, 10%; Lancet 2007;369:306): ruptured aneurysm, trauma
Clinical manifestations
‚Ä¢ Impairment in level of consciousness, vomiting  headache, may cause progressive focal
neurologic deficit depending on site of hemorrhage, nuchal rigidity if SAH present
Diagnostic studies
‚Ä¢ CT or ? MRI (JAMA 2004;292:1823)
‚Ä¢ Angiography (CT or conventional) to determine the source of bleeding (aneurysm, AVM)
‚Ä¢ LP to ‚úìfor xanthochromia if no evidence of hemorrhage on CT and suspicious for SAH
Treatment
‚Ä¢ Reverse any coagulopathies
‚Ä¢ Platelets: keep 100k; unclear if transfusions necessary for patients on ASA
‚Ä¢ Recombinant activated factor VII is currently investigational, but may T hematoma
expansion and mortality at the expense of c risk of adverse thromboembolic events
(NEJM 2005;352:777)
‚Ä¢ Strict BP control w/ goal SBP 140, unless risk for hypoperfusion b/c critical carotid sten.
‚Ä¢ ICH: surgical decompression for large hemorrhage with clinical deterioration
‚Ä¢ SAH: nimodipine to T risk of vasospasm, phenytoin for seizure prophylaxis, endovascu-
lar (Lancet 2005;366:783) or surgical correction of aneurysm/AVM to prevent rebleeding
‚Ä¢ Cerebral venous thrombosis: paradoxically, requires anticoagulation with IV heparin
STROKE
9-7

--- Fim da P√°gina 233 ---

NEUROMUSC
9-8
WEAKNESS & NEUROMUSCULAR DYSFUNCTION
Feature
Upper Motor 
Lower Motor 
Myopathy
Neuron
Neuron
Distribution of 
Regional
Distal, segmental
Proximal,
weakness
symmetric
Atrophy
None
Severe
Mild
Fasciculations
None
Common
None
Tone
c
T
Normal or T
Reflexes (DTRs)

 
 
 
0/ 

 / 
 
Babinski
Present
Absent
Absent
PERIPHERAL NEUROPATHIES
Etiologies
‚Ä¢ Mononeuropathy (one nerve): entrapment, compression, trauma, DM, Lyme
‚Ä¢ Mononeuropathy multiplex (axonal loss of multiple, separate, noncontiguous nerves):
vasculitides, sarcoid, DM, Lyme, Sj√∂gren, hereditary neuropathy with pressure palsies
‚Ä¢ Polyneuropathy (multiple symmetric nerves, generally length dependent)
Demyelinating
acute: acute inflammatory demyelinating polyneuropathy (AIDP)  Guillain-Barr√©
subacute: meds (paclitaxel), paraneoplastic
chronic: DM, CIDP, hypothyroidism, toxins, paraproteinemia, hereditary
Axonal
acute: porphyria, vasculitis, uremia
subacute: meds (cisplatin, paclitaxel, vincristine, INH, ddI), EtOH, sepsis, paraneo.
chronic: DM, uremia, lead, arsenic, Lyme, HIV, paraproteinemia, B12 defic
Clinical manifestations
‚Ä¢ Weakness, fasciculations, numbness, dysesthesias (burning/tingling)
‚Ä¢  Autonomic dysfxn (orthostasis, bowel/bladder retention/incontinence, impotence)
‚Ä¢ Depressed or absent DTRs (may be normal in small fiber neuropathy)
Diagnostic studies
‚Ä¢ Distal symmetric polyneuropathy: start w/ glc or HbA1C, B12, SPEP 
 SIEP
‚Ä¢ Electrolytes, BUN/Cr, CBC,TSH, LFTs, ANA, ESR, HIV, Cu, Lyme titers, genetic testing,
and heavy metal screening as indicated by clinical history and exam
‚Ä¢ EMG & NCS (often no change in first 10‚Äì14 d or in small fiber neuropathy) 
‚Ä¢ Autonomic testing / skin bx (polyneuropathy), nerve bx (mononeuropathy multiplex)
‚Ä¢ MRI if possible radiculopathy or plexopathy
GUILLAIN-BARR√â Syndrome (GBS)
Definition and epidemiology
‚Ä¢ Acute inflammatory demyelinating polyneuropathy (AIDP)
‚Ä¢ Incidence 1‚Äì2 per 100,000; most common acute / subacute paralysis
‚Ä¢ Precipitants: viral illness (EBV, CMV, HSV, HIV), URI (Mycoplasma), gastroenteritis
(Campylobacter), Lyme, surgery, older immunizations
Clinical manifestations
‚Ä¢ Ascending paralysis over hours to days
‚Ä¢ Hypoactive then absent reflexes
‚Ä¢ Sensory dysesthesias and numbness often first symptoms, back pain also common
‚Ä¢ Respiratory failure requiring ventilatory assistance occurs in 30%;
autonomic instability and arrhythmias occur in 50%
‚Ä¢ Fisher variant: ophthalmoplegia, ataxia, areflexia; associated with anti-GQ1b antibodies
Diagnostic studies (results may be normal in first several days)
‚Ä¢ LP: albuminocytologic dissociation  c protein w/o pleocytosis (20 lymphs)
‚Ä¢ EMG & NCS: T nerve conduction velocity and conduction block
‚Ä¢ FVC & NIF: to assess for risk of respiratory failure (cannot rely on PaO2 or SaO2)
Treatment
‚Ä¢ Plasma exchange (Neuro 1985;35:1096) or IVIg (NEJM 1992;326:1123)
no additional benefit with both (Lancet 1997;349:225)
‚Ä¢ Supportive care with monitoring in ICU setting if rapid progression or resp. failure
‚Ä¢ Watch for autonomic dysfunction: labile BP, dysrhythmias (telemetry)
‚Ä¢ Most recover near baseline; axonal variant (5%) with incomplete recovery; 3‚Äì5% mortality

--- Fim da P√°gina 234 ---

MYASTHENIA GRAVIS
Definition and epidemiology
‚Ä¢ Autoimmune disorder with Ab directed against acetylcholine receptor (AChR) in NMJ
‚Ä¢ Prevalence: 1 in 7,500; affects all ages, peak incidence 20s‚Äì30s (women), 60s‚Äì70s (men)
Clinical manifestations
‚Ä¢ Fluctuating weakness w/ fatigability (worse w/ repetitive use, relieved by rest)
‚Ä¢ Cranial muscles involved early S ocular (ptosis, diplopia) in 50%; bulbar (difficulty
chewing, dysarthria, dysphagia) in 15%. Often later progresses to generalized weakness.
‚Ä¢ Limb weakness proximal  distal; DTRs preserved; minimal / no atrophy
‚Ä¢ Exacerbations triggered by stressors such as URI, surgery, pregnancy or postpartum,
meds (eg, aminoglycosides, procainamide, phenytoin); prednisone can worsen acutely
‚Ä¢ Myasthenic crisis  exacerbation S need for respiratory assistance
‚Ä¢ Cholinergic crisis  weakness due to overtreatment with anticholinesterase medications;
may have excessive salivation, abdominal cramping, and diarrhea; rare at normal doses
Diagnostic studies
‚Ä¢ Bedside: ptosis after 30 seconds of sustained upgaze, improved with ice pack over eyes
‚Ä¢ Neostigmine test: temporary c strength; false  &  occur; premedicate w/ atropine
‚Ä¢ EMG: T response with repetitive nerve stimulation (vs. c response in Lambert-Eaton)
‚Ä¢ Anti-AChR Ab: Se 80%, 50% if ocular disease only; Sp 90%; muscle specific receptor
tyrosine kinase (MuSK) Ab account for most AchR Ab  cases
‚Ä¢ CT or MRI of thorax to evaluate thymus (65% hyperplasia, 10% thymoma)
Treatment
‚Ä¢ Anticholinesterase medications (eg, pyridostigmine)
‚Ä¢ Thymectomy if thymoma; may lead to improvement in up to 85% Pts w/o thymoma
‚Ä¢ Immunosuppression: prednisone  azathioprine, cyclophosphamide
‚Ä¢ Myasthenic crisis: treat precipitant
consider d/c anticholinesterase if suspect cholinergic crisis
aggressive immunosuppression with glucocorticoids (but watch for initial worsening)
IVIg, plasmapheresis
ICU if rapid or severe (follow FVC, NIF)
MYOPATHIES
Etiologies
‚Ä¢ Hereditary: Duchenne, Becker, limb-girdle, myotonic, metabolic, mitochondrial
‚Ä¢ Endocrine: hypothyroidism, hyperparathyroidism, Cushing syndrome
‚Ä¢ Toxic: statins, fibrates, glucocorticoids (critical illness myopathy), zidovudine, alcohol,
cocaine, antimalarials, colchicine, penicillamine
‚Ä¢ Infectious: HIV, HTLV-1, trichinosis, toxoplasmosis 
‚Ä¢ Inflammatory (see Rheumatology): polymyositis, dermatomyositis, inclusion body myositis
Clinical manifestations
‚Ä¢ Progressive or episodic weakness (not fatigue)
‚Ä¢ Weakness most often symmetric, proximal  distal (stairs, rising from sitting, etc.)
‚Ä¢  Myalgias (though not prominent or frequent)
‚Ä¢ May develop either pseudohypertrophy (dystrophies) or mild muscle atrophy
Diagnostic studies
‚Ä¢ CK, aldolase, LDH, electrolytes,ALT/AST, PTH,TSH, ESR, HIV
‚Ä¢ Autoantibodies (anti-Jo1, antisynthetase, anti-Mi-2, anti-SRP,ANA, RF)
‚Ä¢ EMG/NCS: low-amplitude, polyphasic units with early recruitment,  fibrillation
potentials
‚Ä¢ Muscle biopsy, molecular genetic testing (where indicated)
NEUROMUSC
9-9

--- Fim da P√°gina 235 ---

HEADACHE
9-10
HEADACHE
Primary headache syndromes
‚Ä¢ Tension: associated with muscle contraction in neck or lower head; treat with NSAIDs
‚Ä¢ Migraine: see later
‚Ä¢ Cluster: periodic, paroxysmal, brief, sharp, orbital headache that may awaken from sleep
 lacrimation, rhinorrhea, conjunctival injection, or unilateral Horner‚Äôs syndrome.
Acute treatments: oxygen, triptans; chronic prophylaxis: calcium-channel blocker.
Secondary causes of headaches
‚Ä¢ Vascular: stroke, intracerebral hemorrhage, SAH, subdural hematoma,AVM, unruptured
aneurysm, arterial hypertension, venous thrombosis
‚Ä¢ Infection: meningitis, encephalitis, abscess
‚Ä¢ Brain tumor
‚Ä¢ Pseudotumor cerebri (idiopathic intracranial hypertension)
‚Ä¢ CSF disorder: c (hydrocephalus) or T (s/p LP)
‚Ä¢ Trigeminal neuralgia
‚Ä¢ Extracranial: sinusitis,TMJ syndrome, temporal arteritis
‚Ä¢ Medication (analgesic) overuse
Clinical evaluation (JAMA 2006;296:1274)
‚Ä¢ History: quality, severity, location, duration, time of onset, precipitants/relieving factors
‚Ä¢ Associated symptoms (visual 	s, nausea, vomiting, photophobia)
‚Ä¢ Focal neurologic symptoms
‚Ä¢ Head or neck trauma, constitutional symptoms
‚Ä¢ Medications, substance abuse
‚Ä¢ General and neurologic examination
‚Ä¢ Warning signs that should prompt neuroimaging:
worst ever, worsening over days, wakes from sleep
vomiting, aggravated by exertion or Valsalva
age 50 y, fever, abnl neurologic exam, aura, cluster-type headache, unilateral
MIGRAINE
Epidemiology
‚Ä¢ Affects 15% of women and 6% of men; onset usually by 30 y
Clinical manifestations (Lancet 2004;363:381; JAMA 2006;296:1274)
‚Ä¢ Unilateral or bilateral, retro-orbital, throbbing or pulsatile headache; lasts 4‚Äì72 h
‚Ä¢ Often accompanied by nausea, vomiting, photophobia
‚Ä¢ ‚ÄúPOUNDing‚Äù: Pulsatile; duration 4‚Äì72 hOurs; Unilateral; Nausea & vomiting; Disabling
LR 3.5 if 3 criteria are met, LR 24 if 4 criteria are met
‚Ä¢ Classic (18%)  visual aura (scotomata with jagged or colored edge) precedes
headache
‚Ä¢ Common (64%)  headache without aura
‚Ä¢ Complicated  accompanied by stereotypical neurologic deficit that may last hrs
‚Ä¢ Precipitants: stress, hunger, foods (cheese, chocolate) and food additives (MSG),
fatigue, alcohol, menstruation, exercise
Treatment (NEJM 2002;346:257)
‚Ä¢ Eliminate precipitants
‚Ä¢ Prophylaxis:TCA, B, CCB, valproic acid, topiramate (JAMA 2004;291:965)
‚Ä¢ Abortive therapy
ASA, acetaminophen, caffeine, high-dose NSAIDs
metoclopramide IV, prochlorperazine IM or IV
5-HT1 agonists (‚Äútriptans‚Äù); contraindic. if complicated migraine, CAD, prior stroke
combo of triptan 
 NSAID more efficacious than either alone (JAMA 2007;297:1443)
ergotamine, dihydroergotamine; use with caution in Pts with CAD

--- Fim da P√°gina 236 ---

SPINE
9-11
BACK AND SPINAL CORD DISEASE
Ddx of back pain
‚Ä¢ Musculoskeletal: musculoligamentous ‚Äústrain‚Äù (experienced by up to 80% of popula-
tion at some time), OA, RA, spondylolisthesis, vertebral compression fx, inflamma-
tory spondyloarthritis (ankylosing spondylitis, reactive, psoriatic)
‚Ä¢ Spinal cord (myelopathy) / nerve root (radiculopathy):
Degenerative/traumatic: disc herniation, spondylosis, fracture
Neoplastic: lung, breast, prostate, multiple myeloma, lymphoma
Infectious (also see ID section): osteomyelitis, epidural abscess, zoster, Lyme, CMV, HIV
‚Ä¢ Referred pain from visceral disease: (quality of pain can be important to distinguish)
GI: PUD, cholelithiasis, pancreatitis, pancreatic cancer
GU: pyelonephritis, nephrolithiasis, uterine or ovarian cancer, salpingitis
Vascular: aortic dissection, leaking aortic aneurysm
Initial evaluation
‚Ä¢ History: location, radiation, neurologic symptoms, infection, malignancy
‚Ä¢ General physical examination: local tenderness, ROM, signs of infection or malignancy,
signs of radiculopathy (experienced as sharp/lancinating pain radiating into limb):
Spurling sign (radicular pain w/ downward force to extended & ipsilaterally rotated head)
straight leg raise (radicular pain at 30‚Äì70): ipsilateral: 95% Se, 40% Sp; crossed 
(contralateral leg raised): 25% Se, 90% Sp
‚Ä¢ Neurologic examination: full motor (including sphincter tone), sensory (including
perineal region), and reflexes including anal (S4) and cremasteric (L2)
‚Ä¢ Laboratory (depending on suspicion): CBC, ESR, Ca, PO4, A, CSF
‚Ä¢ Neuroimaging: low yield if nonradiating pain, high false  rate (incidental spondylosis)
depending on suspicion: x-rays, CT or CT myelography, MRI, bone scan
‚Ä¢ EMG/NCS may be useful to distinguish root/plexopathies from peripheral neuropathies
SPINAL CORD COMPRESSION
Clinical manifestations
‚Ä¢ Acute: flaccid paraparesis and absent reflexes (‚Äúspinal shock‚Äù)
‚Ä¢ Subacute-chronic: spastic paraparesis and hyperactive reflexes
‚Ä¢ Posterior column dysfunction in legs (loss of vibratory sense or proprioception)
‚Ä¢ Sensory loss below level of lesion
‚Ä¢ Bilateral prominent Babinski responses  ankle clonus
Evaluation and treatment
‚Ä¢ Empiric spine immobilization (collar, board) for all trauma patients
‚Ä¢ STAT MRI (at and above clinical spinal level, pre- and postgadolinium) or CT myelogram
‚Ä¢  Emergent neurosurgical and/or neurology consultation
‚Ä¢ Urgent radiation therapy  surgery for compression if due to metastatic disease
‚Ä¢ High-dose steroids depending on cause:
Tumor: dexamethasone 10‚Äì100 mg IV  1 then 4‚Äì24 mg every 6 hr  
Trauma: controversial (may have slight benefit but c risk of infection, poor healing)
? methylprednisolone 30 mg/kg IV over 15 min then 45 min later: 5.4 mg/kg/h  23 h
Conus Medullaris vs. Cauda Equina Syndromes
Features
Conus Medullaris
Cauda Equina
Localization
Cord (UMN) 
 nerve roots (LMN)
Nerve roots (LMN)
Bilateral
Unilateral
Pain
Mild, back  radicular
Severe, radicular  back
Sensory loss
Symmetric perianal
Asymmetric saddle/leg
Motor dysfxn
Mild symmetric weakness
Marked asymmetric weakness
Reflexes
T ankle but knee preserved
T ankle, T knee
May have T reflexes, Babinski
Babinski absent
Bowel-Bladder
Early retention, incontinence,
sxs less frequent / occur late
-Sexual dysfxn
T anal tone, & impotence
NERVE ROOT COMPRESSION
Clinical manifestations
‚Ä¢ Radicular pain aggravated by activity (esp. bending, straining, coughing), relieved by lying 
‚Ä¢ Sciatica  radicular pain radiating from buttocks down lateral aspect of leg, often to
knee or lateral calf  numbness and paresthesias radiating to lateral foot

--- Fim da P√°gina 237 ---

SPINE
9-12
Disc Herniation: Cervical and Lumbar Radiculopathy
Disc
Root
Pain / 
Sensory loss
Motor loss
Reflex 
Paresthesias
Loss
C4‚ÄìC5
C5
Neck, shoulder,
Shoulder
Deltoid, biceps,
Biceps
upper arm
infraspinatus
C5‚ÄìC6
C6
Neck, shoulder, lat.
Lat. arm, radial 
Biceps,
Biceps,
arm, radial forearm,
forearm, thumb 
brachioradialis
brachio-
thumb & index 
& index finger
radialis,
finger
supinator
C6‚ÄìC7
C7
Neck, lat. arm, ring 
Radial forearm,
Triceps,
Triceps,
& index fingers
index & middle 
extensor carpi
supinator
fingers
ulnaris
C7‚ÄìT1
C8
Ulnar forearm
Ulnar half of ring
Intrinsic hand 
Finger 
and hand
finger, little finger
muscles, wrist 
flexion
extensors, flexor 
dig profundus
L3‚ÄìL4
L4
Anterior thigh, inner
Anteromedial 
Quadriceps
Patella
shin
thigh and shin,
inner foot
L4‚ÄìL5
L5
Lat. thigh and calf,
Lat. calf and 
Extensor 
None
dorsum of foot,
great toe
hallucis longus,
great toe
 foot 
dorsiflexion,
invers. & evers.
L5‚ÄìS1
S1
Back of thigh,
Posterolat. calf,
Gastrocnemius 
Achilles
lateral posterior 
lat. and sole of 
 foot eversion
calf, lat. foot
foot, smaller 
toes
(Nb, lumbar disc protrusion tends to compress the nerve root that exits one vertebral level below the protrusion.)
Neurogenic vs.Vascular Claudication
Features
Neurogenic Claudication
Vascular Claudication
Cause
Lumbar spinal stenosis
Peripheral artery disease 
(with nerve root compression)
(with limb ischemia)
Pain
Radicular back / buttock pain
Cramping leg pain
Maximal anterior thighs 
Most common in calves
Radiating down legs
Radiating up legs
Worse with
Walking & standing 
Walking
Hyperextension / lying prone
Biking 
Better with
Bending forward, sitting
Rest (standing or sitting)
Other Sx
Numbness / paresthesias
Pale, cool extremity
Exam
 Focal weakness, T reflexes
Diminished/absent pulses
T Lumbar extension
(dorsalis pedis / posterior tibialis)
Preserved pulses
Pallor
Diagnostic 
MRI lumbar spine
Arterial Doppler studies
studies
CT myelogram (if no MRI)
Ankle-brachial index (ABI) 0.90
EMG/NCS
Arteriography
Treatment
PT (flexion exercise), NSAIDs,
Modify vascular risk factors,
steroid injections (ESI)
exercise rehab, antiplatelet Rx,
Surgery (if other Rx fails)
revascularization
(Nb, diagnosis complicated by overlap between presentations & possibility of both diagnoses in the same
patient. NEJM 2007;356:1241 & 2008;358:818.)
Treatment of nerve root compression
‚Ä¢ Conservative: avoid bending/lifting; NSAIDs
‚Ä¢ Spinal epidural steroid injections (ESI): limited short-term relief of refractory radicular pain 
‚Ä¢ Surgery: cord compression or cauda equina syndrome; progressive motor dysfunction;
bowel / bladder dysfunction; failure to respond to conservative Rx (NEJM 2007;356:2245)

--- Fim da P√°gina 238 ---

ACLS
10-1
ACLS ALGORITHMS
Figure 10-1 ACLS VF/pulseless VT, asystole & PEA algorithms
Pulseless Arrest
VF or VT
Primary ABCD Survey
Airway: open airway (head tilt-chin lift or jaw thrust)
Breathing: ‚äï pressure ventilation (give 2 breaths)
Circulation: chest compressions (1      ‚Äì2 inches, ~100/min; 30:2 comp-vent ratio)
Defibrillation:  rhythm ASAP
Defib √ó 1
(200 J biphasic or 360 J monophasic)
Defib √ó 1
Defib √ó 1
(before or after shock)
Epinephrine or Vasopressin
Treatment of reversible causes of PEA & asystole
Hypovolemia: volume infusion
Hypoxia: oxygenate
Hydrogen ions (acidosis): NaHCO3
Hypokalemia: KCl
Hyperkalemia: Ca, NaHCO3, insulin/glc
Hyoglycemia: glucose
Hypothermia: warming
Toxins/Tablets: med-specific
Tamponade: pericardiocentesis
Tension PTX: needle decompression
Thrombosis (ACS): PCI (or lysis), IABP
Thrombosis (PE): lysis, thrombectomy
Trauma (hypovol, ‚Üë ICP): per ATLS
ASYSTOLE or PEA
CPR √ó 5 cycles ( ‚âà 2 mins)
&
Secondary ABCD Survey
Airway: remove obstructions; insert airway; ? advanced airway
Breathing:  placement of airway (clinical & CO2 detector); O2;
     1 breath q6‚Äì8sec (8‚Äì10 breaths per min) w/o stopping CPR 
Circulation: IV access
Differential dx: consider causes (H‚Äôs & T‚Äôs, see below)
= Intubate
= Ventilate
= IV access
confirm asystole in >1 lead (r/o fine VF)
 rhythm
 rhythm
shockable
not shockable
Vasopressor q3‚Äì5min
Vasopressor q3‚Äì5min
Epinephrine or Vasopressin
Antiarrhythmic
(before or after shock)
Amiodarone, Lidocaine, or Mg
shockable
(VT/VF)
not shockable
(asystole/PEA)
Atropine
for asystole or slow PEA rate
MEDICATIONS
epinephrine: 1mg IV (10 mL of 1:10,000 solution)
    or 2 mg ETT q3‚Äì5min
vasopressin: 40 U IV to replace 1st or 2nd epi dose
amiodarone: 300 mg IVP ¬± 150 mg IVP in 3-5 min
lidocaine: 1.0‚Äì1.5 mg/kg IVP (~100 mg)
  then 0.5‚Äì0.75 mg/kg (~50 mg) q5‚Äì10min, max 3 mg/kg
atropine: 1 mg IV q3‚Äì5min √ó 3
magnesium: 1‚Äì2 g IV for TdP
C
P
R
2 min
2 min
C
P
R
(Adapted from ACLS 2005 Guidelines, Circ 2005;112(Suppl I):IV-58)

--- Fim da P√°gina 239 ---

ACLS
10-2
Figure 10-2 ACLS tachycardia algorithm
Tachycardia
unstable
r/o sinus tach
Synch cardioversion
(rarely needed for HR <150)
or
defibrillation for PMVT
vagal
maneuvers
adenosine
MEDICATIONS
adenosine: 6 mg rapid IVP then 20 cc NS bolus,
12 mg IVP q2min √ó 2 if needed
amiodarone 150 mg IV over 10 min
diltiazem: 15‚Äì20 mg IV over 2 min,
20‚Äì25 mg 15 min later if needed, 5‚Äì15 mg/h
ibutilide: 1 mg over 10 min, repeat √ó 1 if needed
lidocaine 1‚Äì1.5 mg/kg IVP, repeat in 5‚Äì10 min
metoprolol 5 mg IV q5min √ó 3
procainamide 17 mg/kg at 50 mg/min (avoid if EF    )
verapamil 2.5‚Äì5 mg IV over 2 min,
5‚Äì10 mg 15‚Äì30 min later if needed
CARDIOVERSION
Ancillary equipment
O   sat monitor
suction device
IV line
intubation equipment
Premedicate
call anesthesia service
midazolam 1‚Äì5 mg
fentanyl 100‚Äì300 Œºg
titrate to effect
Synchronized cardioversion
100, 200, 300, 360 J
or biphasic equivalent
IV Access, O ,12-lead ECG, focused H & P for reversible causes
NARROW COMPLEX
WIDE COMPLEX
Likely
AVNRTor AVRT
Rx recurrence w/
adenosine or
long-acting AV
nodal agent such
as diltiazem or
metoprolol
Possibly
AFL, ATAC, NPJT
Control rate w/
diltiazem or
metoprolol
AF, AFL, or MAT
Control rate w/
diltiazem or
metoprolol
VT or ? WCT
amiodarone
or
procainamide
or
lidocaine
& prepare for
synch
cardioversion
SVT w/ aber.
adenosine
AF w/ aber.
Control rate w/
diltiazem or
metoprolol
AF + WPW
amiodarone,
procainamide,
or
avoid adenosine,
digoxin, CCB & B
PMVT (nl QT)
treat ischemia
amiodarone
& prepare for
or lidocaine
defibrillation
Torsades (‚Üë QT)
correct abnl lytes
& other precip.
Mg 2 g IV
overdrive pacing
or isoproterenol
? lidocaine
regular
regular
irregular
irregular
converts
does not convert
QRS <120 msec
QRS ‚â•120 msec
unstable = hypotension or other
s/s shock, Œî MS, chest pain
ibutilide
‚Üë 
(Adapted from ACLS 2005 Guidelines, Circ 2005;112(Suppl I):IV-67)

--- Fim da P√°gina 240 ---

Figure 10-3 ACLS bradycardia algorithms
ACLS
10-3
Bradycardia (HR <60 & inadequate for clinical condition)
observe
atropine 0.5 mg IV q3‚Äì5min, max 3 mg
transcutaneous pacing
dopamine 2‚Äì10 Œºg/kg/min or epinephrine 2‚Äì10 Œºg/min
while awaiting pacer or if pacer ineffective
transvenous pacing
prep for transcutaneous pacing
use w/o delay for Type II 2¬∞ AVB or 3¬∞ AVB
Unstable?
(eg, hypotension or other
s/s shock, Œî MS, chest pain)
Yes
No
ABCs, IV Access, O ,12-lead ECG, focused H&P for reversible causes
(Adapted from ACLS 2005 Guidelines, Circ 2005;112(Suppl I):IV‚Äì67)
Figure 10-4 ACLS pulmonary edema, hypotension, or shock algorithm
Acute Pulmonary Edema, Hypotension, or Shock
Volume
problem
Pump
problem
Rate
problem
Fluids and/or blood
Consider vasopressors
ABCs, IV Access, O , 12-lead ECG, focused H&P, CXR
What is BP?
(after empiric 250‚Äì500 cc NS
bolus unless in CHF)
Go to tachycardia or
bradycardia algorithm
SBP <70
cardiogenic
shock
Norepinephrine
1‚Äì30 Œºg/min
or
Dopamine
5‚Äì20 Œºg/kg/min
Dopamine
2‚Äì20 Œºg/kg/min
add
Norepinephrine
if dopamine
>20 Œºg/kg/min
SBP 70‚Äì100
cardiogenic
shock
SBP 70‚Äì100
no shock
Dobutamine
2‚Äì20 Œºg/kg/min
SBP >100
CHF
Nitroglycerin
10‚Äì1000 Œºg/min
and/or
Nitroprusside
0.1‚Äì5 Œºg/kg/min
Furosemide 0.5‚Äì1 mg/kg IV
Morphine 2‚Äì4 mg IV
Oxygen/noninvasive vent./intub.
further interventions based on etiology
If in pulmonary edema, consider:
What is the nature of the problem?
(Adapted from ACLS 2005 Guidelines)

--- Fim da P√°gina 241 ---

ICU MEDS
10-4
ICU MEDICATIONS
Drug
Class
Dose
per kg
average
Pressors, Inotropes, and Chronotropes
Phenylephrine
1
10‚Äì300 g/min
Norepinephrine
1  1
1‚Äì40 g/min
Vasopressin
V1
0.01‚Äì0.1 U/min (usually 0.04)
Epinephrine
1, 2, 1, 2
2‚Äì20 g/min
Isoproterenol
1, 2
0.1‚Äì10 g/min
D
0.5‚Äì2 g/kg/min
50‚Äì200 g/min
Dopamine
, D
2‚Äì10 g/kg/min
200‚Äì500 g/min
, , D
10 g/kg/min
500‚Äì1000 g/min
Dobutamine
1  2
2‚Äì20 g/kg/min
50‚Äì1000 g/min
Milrinone
PDE
50 g/kg over 10 min then
3‚Äì4 mg over 10 min
0.375‚Äì0.75 g/kg/min
then 20‚Äì50 g/min
Inamrinone
PDE
0.75 mg/kg over 3 min
40‚Äì50 mg over 3 min
then 5‚Äì15 g/kg/min
then 250‚Äì900 g/min
Vasodilators
Nitroglycerin
NO
10‚Äì1000 g/min
Nitroprusside
NO
0.1‚Äì10 g/kg/min
5‚Äì800 g/min
Nesiritide
BNP
2 g/kg IVB then
0.01 g/kg/min
Labetalol
1, 1, and
20 mg over 2 min then 20‚Äì80 mg q10min
2 blocker
or 10‚Äì120 mg/h
Fenoldopam
D
0.1‚Äì1.6 g/kg/min
10‚Äì120 g/min
Epoprostenol
vasodilator
2‚Äì20 ng/kg/min
Enalaprilat
ACE
0.625‚Äì2.5 mg over 5 min then 0.625‚Äì5 mg q6h
Hydralazine
vasodilator
5‚Äì20 mg q20‚Äì30min
Antiarrhythmics
Amiodarone
K et al.
150 mg over 10 min, then
(Class III)
1 mg/min  6h, then 0.5 mg/min  18h
Lidocaine
Na channel
1‚Äì1.5 mg/kg then
100 mg then
(Class IB)
1‚Äì4 mg/min
1‚Äì4 mg/min
Procainamide
Na channel
17 mg/kg over 60 min
1 g over 60 min then
(Class IA)
then 1‚Äì4 mg/min
1‚Äì4 mg/min
Ibutilide
K channel
1 mg over 10 min,
(Class III)
may repeat  1
Propranolol
 blocker
0.5‚Äì1 mg q5min
then 1‚Äì10 mg/h
Esmolol
1  2
500 g/kg then
20‚Äì40 mg over 1 min
blocker
25‚Äì300 g/kg/min
then 2‚Äì20 mg/min
2.5‚Äì5 mg over 1‚Äì2 min
Verapamil
CCB
repeat 5‚Äì10 mg in 15‚Äì30 min prn
5‚Äì20 mg/h
0.25 mg/kg over 2 min
20 mg over 2 min
Diltiazem
CCB
reload 0.35 mg/kg  1 prn
reload 25 mg  1 prn
then 5‚Äì15 mg/h
then 5‚Äì15 mg/h
Adenosine
purinergic
6 mg rapid push
if no response: 12 mg S 12‚Äì18 mg

--- Fim da P√°gina 242 ---

ICU MEDS
10-5
Drug
Class
Dose
per kg
average
Sedation
Morphine
opioid
1-unlimited mg/h
Fentanyl
opioid
50‚Äì100 g then 50-unlimited g/h
Thiopental
barbiturate
3‚Äì5 mg/kg over 2 min
200‚Äì400 mg over 2 min
Etomidate
anesthetic
0.2‚Äì0.5 mg/kg
100‚Äì300 mg
Propofol
anesthetic
1‚Äì3 mg/kg then
50‚Äì200 mg then
0.3‚Äì5 mg/kg/h
20‚Äì400 mg/h
Diazepam
BDZ
1‚Äì5 mg q1‚Äì2h then q6h prn
Midazolam
BDZ
0.5‚Äì2 mg q5min prn or
0.5‚Äì4 mg then 1‚Äì10 mg/h
Ketamine
anesthetic
1‚Äì2 mg/kg
60‚Äì150 mg
Haloperidol
antipsychotic
2‚Äì5 mg q20‚Äì30min
Naloxone
opioid antag.
0.4‚Äì2 mg q2‚Äì3min to total of 10 mg
0.2 mg over 30 sec then
Flumazenil
BDZ antag.
0.3 mg over 30 sec if still lethargic
may repeat 0.5 mg over 30 sec to total of 3 mg
Paralysis
Succinylcholine
depolar.
paralytic
0.6‚Äì1.1 mg/kg
70‚Äì100 mg
Tubocurare
nACh
10 mg then 6‚Äì20 mg/h
Pancuronium
nACh
0.08 mg/kg
2‚Äì4 mg q30‚Äì90‚Äô
Vecuronium
nACh
0.08 mg/kg then
5‚Äì10 mg over 1‚Äì3 min
0.05‚Äì0.1 mg/kg/h
then 2‚Äì8 mg/h
Cisatracurium
nACh
5‚Äì10 g/kg/min
Miscellaneous
Aminophylline
PDE
5.5 mg/kg over 20 min
250‚Äì500 mg
then 0.5‚Äì1 mg/kg/h
then 10‚Äì80 mg/h
Insulin
10 U then 0.1 U/kg/h
Glucagon
5‚Äì10 mg then 1‚Äì5 mg/h
Octreotide
somatostatin
analog
50 g then 50 g/h
Phenytoin
antiepileptic
20 mg/kg at 50 mg/min
1‚Äì1.5 g over 20‚Äì30 min
Fosphenytoin
antiepileptic
20 mg/kg at 150 mg/min
1‚Äì1.5 g over 10 min
Phenobarbital
barbiturate
20 mg/kg at 50‚Äì75 mg/min
1‚Äì1.5 g over 20 min
Mannitol
osmole
1.5‚Äì2 g/kg over 30‚Äì60 min
repeat q6‚Äì12h to keep osm 310‚Äì320

--- Fim da P√°gina 243 ---

ANTIBIOTICS
10-6
ANTIBIOTICS
The following tables of spectra of activity for different antibiotics are generalizations.
Sensitivity data at your own institution should be used to guide therapy.
Penicillins
Generation
Properties
Spectrum
Natural
Some GPC, GPR, GNC, most
Group A streptococci
(eg, penicillin)
anaerobes (except Bacteroides)
Enterococci, Listeria, Pasteurella
Actinomyces, Syphilis
Anti-Staph
Active vs PCNase-producing Staph
Staphylococci (except MRSA)
(eg, nafcillin)
Little activity vs. Gram 
Streptococci
Amino
Penetrate porin channel of Gram 
E. coli, Proteus, H. influenzae
(eg, ampicillin)
Not stable against PCNases
Salmonella, Shigella
Enterococci, Listeria
Extended
Penetrate porin channel of Gram 
Most GNR incl. Enterobacter,
(eg, piperacillin)
More resistant to PCNases
Pseudomonas, Serratia
Carbapenem
Resistant to most -lactamases
Most Gram  and  bacteria 
(eg, imipenem)
including anaerobes, but not
MRSA or VRE
Monobactams
Active vs. Gram  but not Gram 
Gram  bacterial infxn in Pt
(aztreonam)
w/ PCN or Ceph allergy
-lact. Inhib.
Inhibit plasma-mediated -lactamases
Adds Staph, B. fragilis and
(eg, sulbactam)
some GNR (H. influenzae,
M. catarrhalis, some Klebsiella);
intrinsic activity against 
Acinetobacter (sulbactam only)
Cephalosporins
Resistant to most -lactamases. No activity vs. MRSA or enterococci.
Gen.
Spectrum
Indications
First
Most GPC (incl. Staph & Strep, not MRSA)
Used for surgical ppx & 
(eg, cefazolin)
Some GNR (incl. E. coli, Proteus, Klebsiella)
skin infxns
Second (eg,
T activity vs. GPC, c vs. GNR. 2 subgroups:
cefuroxime,
Respiratory: H. influenzae & M. catarrhalis
PNA/COPD flare
cefotetan)
GI/GU: c activity vs. B. fragilis
Abdominal infxns
Third (eg,
Broad activity vs. GNR & some anaerobes
PNA, sepsis, meningitis
ceftriaxone)
Ceftazidime active vs. Pseudomonas
Fourth
c resistance to -lactamases (incl. of Staph
Similar to 3rd gen.
(eg, cefepime)
and Enterobacter)
MonoRx for nonlocalizing
febrile neutropenia
Other Antibiotics
Antibiotic
Spectrum
Vancomycin
Gram  bacteria incl. MRSA, PCNase-producing pneumococci and
enterococci (except VRE)
Linezolid
Daptomycin
GPC incl. MRSA & VRE (check susceptibility for VRE) 
Quinopristin/
Dalfopristin
Quinolones
Enteric GNR & atypicals. 3rd & 4th gen. c activity vs. Gram .
Aminoglycosides
GNR. Synergy w/ cell-wall active abx (-lactam, vanco) vs. GPC.
T activity in low pH (eg, abscess). No activity vs. anaerobes.
Macrolides
GPC, some respiratory Gram , atypicals
TMP/SMX
Some enteric GNR, PCP, Nocardia,Toxoplasma, most community-
acquired MRSA
Clindamycin
Most Gram  (except enterococci) & anaerobes (incl. B. fragilis)
Metronidazole
Almost all anaerobic Gram , most anaerobic Gram 
Doxycycline
Rickettsia, Ehrlichia, Chlamydia, Mycoplasma, Nocardia, Lyme
Tigecycline
Many GPC incl. MRSA & VRE; some GNR incl. ESBL but not 
Pseudomonas or Proteus.Approved for abdominal or skin/soft tissue 
infections. Check susceptibility if organism isolated.

--- Fim da P√°gina 244 ---

FORMULAE
10-7
FORMULAE AND QUICK REFERENCE
CARDIOLOGY
Hemodynamic parameters
Normal value
Mean arterial pressure (MAP) 
70‚Äì100 mmHg
Heart rate (HR)
60‚Äì100 bpm
Right atrial pressure (RA)
6 mmHg
Right ventricular (RV)
systolic 15‚Äì30 mmHg
diastolic 1‚Äì8 mmHg
systolic 15‚Äì30 mmHg
Pulmonary artery (PA)
mean 9‚Äì18 mmHg
diastolic 6‚Äì12 mmHg
Pulmonary capillary wedge pressure (PCWP)
12 mmHg
Cardiac output (CO)
4‚Äì8 L/min
Cardiac index (CI)
2.6‚Äì4.2 L/min/m2
Stroke volume (SV)
60‚Äì120 mL/contraction
Stroke volume index (SVI)
40‚Äì50 mL/contraction/m2
Systemic vascular resistance (SVR)
800‚Äì1200 dynes  sec/cm5
Pulmonary vascular resistance (PVR)
120‚Äì250 dynes  sec/cm5
‚ÄúRule of 6s‚Äù for PAC: RA 6, RV 30/6, PA 30/12,WP 12. 1 mmHg 	 1.36 cm water or blood.
Fick cardiac output
Oxygen consumption (L/min) 	 CO (L/min)  arteriovenous (AV) oxygen difference
CO 	 oxygen consumption / AV oxygen difference
Oxygen consumption must be measured (can estimate w/ 125 mL/min/m2, but inaccurate)
AV oxygen difference 	 Hb (g/dl)  10 (dl/L)  1.36 (mL O2/g of Hb)  (SaO2‚ÄìSvO2)
SaO2 is measured in any arterial sample (usually 93‚Äì98%)
SvO2 (mixed venous O2) is measured in RA, RV, or PA (assuming no shunt) (normal 75%)
‚à¥Cardiac output (L/min)
Shunts
Qp
(if no R S L shunt, PV O2 sat  SaO2)
Qs
(MVO2 drawn proximal to potential L S R shunt)
(if only L S R and no R S L shunt)
Valve equations
Simplified Bernoulli equation: Pressure gradient (
P) 	 4  v2 (where v 	 peak flow velocity)
Continuity eq.,(conservation of flow):Area1 Velocity1 	 A2 V2 (where 1 & 2 different points)
or AVA (unknown) 	 ALV outflow tract 
(all of which can be measured on echo)
Gorlin equation: Valve area
(constant 	 1 for AS, 0.85 for MS)
Hakki equation: Valve area  CO
1
P
	
CO(DEP or SEP)  HR
44.3  constant  1
P
a
VLVOT
VAoV
b
Qp
Qs
	
SaO2  MV O2 sat
PV O2 sat  PA O2 sat 
SaO2  MV O2 sat
SaO2  PA O2 sat
	
Oxygen consumption
SaO2  mixed venous O2 sat
	
Oxygen consumption
Pulm. vein O2 sat  Pulm. artery O2 sat
	
Oxygen consumption
Hb (gdl)  13.6  (SaO2  SvO2)
	 mean PA  mean PCWP
CO
 80
	 MAP  mean RA
CO
  80
	 CI
HR
	 CO
HR
	 CO
BSA
	
SBP  (DBP  2)
3

--- Fim da P√°gina 245 ---

FORMULAE
10-8
PULMONARY
Chest Imaging (CXR & CT) Patterns
Pattern
Pathophysiology
Ddx
Consolidation Radiopaque material in air
Acute: water (pulm edema), pus (PNA), blood
space & interstitium
Chronic: neoplasm (BAC, lymphoma), aspiration,
patent airway S
inflammatory (BOOP, eosinophilic PNA), PAP,
‚Äúair bronchograms‚Äù
granuloma (TB/fungal, alveolar sarcoid)
Ground glass
Interstitial thickening or
Acute: pulm edema, infxn (PCP, viral, resolving
(CT easier 
partial filling of alveoli
bact. PNA)
than CXR)
(but vessels visible)
Chronic: ILD
w/o fibrosis: acute hypersens., DIP/RB, PAP
w/ fibrosis: IPF
Septal lines
Radiopaque material in
Cardiogenic pulm edema, interstitial PNA
Kerley A & B
septae
viral, mycoplasma), lymphangitic tumor
Reticular
Lace-like net (ILD)
ILD (espec. IPF, CVD, bleomycin, asbestos)
Nodules
Tumor
Cavitary: Primary or metastatic cancer,
Granulomas
TB (react. or miliary), fungus,Wegener‚Äôs, RA
Abscess
septic emboli, PNA
Noncavitary: any of above  sarcoid,
hypersens. pneum., HIV, Kaposi‚Äôs sarcoma
Wedge opac.
Peripheral infarct
PE, cocaine, angioinv. aspergillus,Wegener‚Äôs
Tree-in-bud
Inflammation of small
Bronchopneumonia, endobronchial TB/MAI,
(best on CT)
airways
viral PNA, aspiration,ABPA, CF, asthma, BOOP
Hilar fullness
c LN or pulm arteries
Neoplasm (lung, mets, lymphoma)
Infxn (AIDS); Granuloma (sarcoid/TB/fungal)
Pulmonary hypertension
Upper lobe
n/a
TB, fungal, sarcoid, hypersens. pneum., CF, XRT
Lower lobe
n/a
Aspiration, bronchiect., IPF, RA, SLE, asbestos
Peripheral
n/a
BOOP, IPF & DIP, eos PNA, asbestosis
CXR in heart failure
‚Ä¢ c cardiac silhouette (in systolic dysfxn, not in diastolic)
‚Ä¢ Pulmonary venous hypertension: cephalization of vessels (vessels size  bronchi in
upper lobes), peribronchial cuffing (fluid around bronchi seen on end S small circles),
Kerley B lines (horizontal 1‚Äì2 cm lines at bases), c vascular pedicle width, loss of sharp
vascular margins, pleural effusions (75% bilateral)
‚Ä¢ Pulmonary edema: ranges from ground glass to consolidation; often dependent
and central, sparing outer third (‚Äúbat wing‚Äù appearance)
Dead space 	 lung units that are ventilated but not perfused
Intrapulmonary shunt 	 lung units that are perfused but not ventilated
Alveolar gas equation:
PAO2
(where R  0.8)
PAO2
(on room air)
A-a gradient 	 PAO2 ‚Äì PaO2 [normal A-a gradient  4  (age/4)]
Minute ventilation (VE) 	 tidal volume (VT)  respiratory rate (RR) (normal 4‚Äì6 L/min)
Tidal volume (VT) 	 alveolar space (VA)  dead space (VD)
Fraction of tidal volume that is dead space 
PaCO2 	 k 	 
CO2 Production
alveolar ventilation 	 k 
#
VCO2
RR  VT  a1 
VD
VT
b
a
VD
VT
b 	
PaCO2  PexpiredCO2
PaCO2
	 150 
PaCO2
0.8
	 3F1O2  (760  47)4 
PaCO2
R

--- Fim da P√°gina 246 ---

FORMULAE
10-9
Hours post-ingestion
1
0
Acetaminophen
plasma concentration (Œºg/mL)
4
8
12
16
20
24
28
32
10
100
TREATMENT LINE
Possible
Risk
Probable Risk
Rumack-Matthew Line
No Risk
GASTROENTEROLOGY
Figure 10-5 Acetaminophen toxicity nomogram
(Adapted Archives 1981;141:382 & Guidelines for Management of Acute Acetaminophen Overdose. McNeil, 1999.)
NEPHROLOGY
Anion gap (AG) 	 Na ‚Äì (Cl  HCO3) (normal 	 [alb]  2.5; typically 12  2 mEq)
Delta-delta (

) 	 [
 AG (ie, calc. AG - expected) / 
 HCO3 (ie, 24 - measured HCO3)]
Urine anion gap (UAG) 	 (UNa  UK) ‚Äì UCl
Calculated osmoles 
Osmolal gap (OG) 	 measured osmoles ‚Äì calculated osmoles (normal  10)
Estimated creatinine clearance
( 0.85 in women)
Fractional excretion of Na (FENa, %) 	
	
Corrected Na in hyperglycemia
estimate in all Pts: corrected Na 	 measured Na 
however, 
 in Na depends on glc (Am J Med 1999;106:399)

 is 1.6 mEq per each 100 mg/dl c in glc ranging from 100‚Äì440

 is 4 mEq per each 100 mg/dl c in glc beyond 440
Total body water (TBW) 	 0.60  IBW ( 0.85 if female and  0.85 if elderly)
Free H2O deficit
(in 70 kg Pt)
Trans-tubular potassium gradient (TTKG) 	
	 TBW  a
3Na4serum  140
140
b  a
3Na4serum  140
3
b
c2.4 
(measured glc  100)
100
d
‚â•
UNa(mEqL)
PNa(mEqL)  100%
UCr(mg mL)
PCr (mgdl)  100 (mL dl)
¬•
	
3140  age (yrs)4  wt (kg)
serum Cr (mgdl)  72
(2  Na)  a
glc
18b  aBUN
2.8 b  aEtOH
4.6 b
UNa
PNa
UCr
PCr
UK
PK
UOsm
POsm

--- Fim da P√°gina 247 ---

FORMULAE
10-10
Heparin for Thromboembolism
80 U/kg bolus
18 U/kg/h
PTT
Adjustment
40
bolus 5000 U, c rate 300 U/h
40‚Äì49
bolus 3000 U, c rate 200 U/h
50‚Äì59
c rate 150 U/h
60‚Äì85
no 
86‚Äì95
T rate 100 U/h
96‚Äì120
hold 30 min, T rate 100 U/h
120
hold 60 min, T rate 150 U/h
(Modified from Chest 2008;133:141S)
Heparin for ACS
60 U/kg bolus (max 4000 U)
12 U/kg/h (max 1000 U/h)
PTT
Adjustment
40
bolus 3000 U, c rate 100 U/h
40‚Äì49
c rate 100 U/h
50‚Äì75
no 
76‚Äì85
T rate 100 U/h
86‚Äì100
hold 30 min, T rate 100 U/h
100
hold 60 min, T rate 200 U/h
(Modified from Circ 2007;116:e148 & Chest
2008;133:670)
‚úìPTT q6h after every change (half-life of heparin is 90 min)
‚úìPTT qd or bid once PTT is therapeutic
‚úìCBC qd (to ensure Hct and plt counts are stable)
Warfarin Loading Nomogram
Day
INR
1.5
1.5‚Äì1.9
2‚Äì2.5
2.6‚Äì3
3
1‚Äì3
5 mg (7.5 mg if  80 kg)
2.5‚Äì5 mg
0‚Äì2.5 mg
0 mg
4‚Äì5
10 mg
5‚Äì10 mg
0‚Äì5 mg
0‚Äì2.5 mg
6
Dose based on requirements over preceding 5 days
(Annals 1997;126:133; Archives 1999;159:46)
or, go to www.warfarindosing.org
HEMATOLOGY
Peripheral Smear Findings (also see Photo Inserts)
Feature
Abnormalities and diagnoses
Size
normocytic vs. microcytic vs. macrocytic S see below
Shape
anisocytosis S unequal RBC size; poikilocytosis S irregular RBC shape
acanthocytes  spur cells (irregular sharp projections) S liver disease 
bite cells (removal of Heinz bodies by phagocytes) S G6PD deficiency
echinocytes  burr cells (even, regular projections) S uremia, artifact 
pencil cell S long, thin, hypochromic - very common in adv. iron deficiency
rouleaux S hyperglobulinemia (eg, multiple myeloma)
schistocytes, helmet cells S MAHA (eg, DIC,TTP/HUS), mechanical valve
spherocytes S HS,AIHA; sickle cells S sickle cell anemia
stomatocyte S central pallor appears as curved slit S liver disease, EtOH
target cells S liver disease, hemoglobinopathies, splenectomy
tear drop cells  dacryocytes S myelofibrosis, myelophthisic anemia,
megaloblastic anemia, thalassemia
Intra-
basophilic stippling (ribosomes) S abnl Hb, sideroblastic, megaloblastic
RBC
Heinz bodies (denatured Hb) S G6PD deficiency, thalassemia
findings
Howell-Jolly bodies (nuclear fragments) S splenectomy or functional 
asplenia (eg advanced sickle cell) 
nucleated RBCs S hemolysis, extramedullary hematopoiesis
WBC
blasts S leukemia, lymphoma; Auer rods S acute myelogenous leukemia
findings
hypersegmented (5 lobes) PMNs: megaloblastic anemia (B12/folate def.)
pseudo-Pelger-Hu√´t anomaly (bilobed nucleus,‚Äúpince-nez‚Äù) S MDS
toxic granules (coarse, dark blue) and D√∂hle bodies (blue patches of 
dilated endoplasmic reticulum) S (sepsis, severe inflammation
Platelet
clumping S artifact, repeat plt count
number S periph blood plt count approximately 10,000 plt for every one 
plt seen at hpf (100)
size S MPV (mean platelet volume) enlarged in ITP
(NEJM 2005;353:498)

--- Fim da P√°gina 248 ---

FORMULAE
10-11
Warfarin-heparin overlap therapy
‚Ä¢ Indications: when failure to anticoagulate carries c risk of morbidity or mortality
(eg, DVT/PE, intracardiac thrombus)
‚Ä¢ Rationale: (1) Half-life of factor VII (3‚Äì6 h) is shorter than half-life of factor II (60‚Äì72 h);
‚à¥warfarin can elevate PT before achieving a true antithrombotic state
(2) Protein C also has half-life less than that of factor II;
‚à¥theoretical concern of hypercoagulable state before antithrombotic state
‚Ä¢ Method: (1) Therapeutic PTT is achieved using heparin
(2) Warfarin therapy is initiated
(3) Heparin continued until INR therapeutic for 2 d and 4‚Äì5 d of warfarin
(roughly corresponds to 2 half-lives of factor II or a reduction to 25%)
OTHER
Ideal body weight (IBW)  [50 kg (men) or 45.5 kg (women)]  2.3 kg/inch over 5 feet
Body surface area (BSA, m2) 
Disease
present
absent

a
b
Test
(true )
(false )

c
d
(false )
(true )
Prevalence
Sensitivity
Specificity
 Predictive value
 Predictive value
Accuracy
 Likelihood ratio
 Likelihood ratio
Odds
Probability
Posttest odds  pretest odds  LR

odds
odds  1

probability
1  probability

false negative rate
true negative rate  1  Se
Sp

true positive rate
false positive rate 
Se
1  Sp

true positives  true negatives
all patients

a  d
a  b  c  d

true negatives
all negatives 
d
cd

true positives
all positives

a
a  b

true negatives
all healthy

d
b  d

true positives
all diseased

a
a  c
 all diseased
all patients 
a  b
a  b  c  d
B
height (cm)  weight (kg)
3600

--- Fim da P√°gina 249 ---

NOTES
10-12
NOTES

--- Fim da P√°gina 250 ---

5-NT
5-nucleotidase
6-MP
6-mercaptopurine
a/w
associated with
AAA
abdominal aortic aneurysm
AAD
antiarrhythmic drug
Ab
antibody
ABE
acute bacterial endocarditis
ABG
arterial blood gas
abnl
abnormal
ABPA
allergic bronchopulmonary
aspergillosis
abx
antibiotics
AC
assist control
ACE
angiotensin converting enzyme
ACEI
ACE inhibitor
ACI
anemia of chronic inflammation
ACL
anticardiolipin antibody
ACLS
advanced cardiac life support
ACS
acute coronary syndrome
ACTH
adrenocorticotrophic hormone
ACV
acyclovir
ADA
adenosine deaminase
ADH
antidiuretic hormone
ADL
activities of daily living
AF
atrial fibrillation
AFB
acid-fast bacilli
AFL
atrial flutter
AFP
-fetoprotein
AFTP
ascites fluid total protein
AG
aminoglycoside
anion gap
Ag
antigen
AGN
acute glomerulonephritis
AI
aortic insufficiency
AIDS
acquired immunodeficiency
syndrome
AIH
autoimmune hepatitis
AIHA
autoimmune hemolytic anemia
AIN
acute interstitial nephritis
AIP
acute interstitial pneumonia
AKI
acute kidney injury
ALF
acute liver failure
ALL
acute lymphoblastic leukemia
ALS
amyotrophic lateral sclerosis
ALT
alanine aminotransferase
AMA
anti-mitochondrial antibody
AMI
anterior myocardial infarction
AML
acute myelogenous leukemia
ANA
antinuclear antibody
ANCA
antineutrophilic cytoplasmic
antibody
angio
angiogr
ogram
AoD
aortic dissection
AoV
aortic valve
APC
activated protein C
APL
acute promyelocytic leukemia
APLA
antiphospholipid antibody
APS
antiphospholipid antibody
syndrome
ARB
angiotensin receptor blocker
ARDS
acute respiratory distress
syndrome
ARV
antiretroviral
ARVC
arrhythmogenic RV
cardiomyopathy
AS
aortic stenosis
ASA
aspirin
ASD
atrial septal defect
AST
aspartate aminotransferase
asx
asymptomatic
AT
atrial tachycardia
ATII
angiotensin II
ATIII
antithrombin III
ATN
acute tubular necrosis
ATRA
all-trans-retinoic acid
AV
atrioventricular
AVA
aortic valve area
AVB
atrioventricular block
AVNRT
AV nodal reentrant tachycardia
AVR
aortic valve replacement
AVRT
AV reciprocating tachycardia
AZA
azathioprine
A
alkaline phosphatase
b/c
because
BAL
bronchoalveolar lavage
B
beta-blocker
BBB
bundle branch block
BCx
blood culture
BD
bile duct
BDZ
benzodiazepines
bili.
bilirubin
BiPAP
bilevel positive airway pressure
BiV
biventricular
BM
bone marrow
bowel movement
BMD
bone mineral density
BMI
body mass index
BMS
bare metal stent
BNP
B-type natriuretic peptide
BOOP
bronchiolitis obliterans with
organizing pneumonia
BP
blood pressure
BPH
benign prostatic hypertrophy
BRBPR
bright red blood per rectum
BS
breath sounds
BT
bleeding time
BUN
blood urea nitrogen
bx
biopsy
C
complement
c/w
compared with
consistent with
CABG
coronary artery bypass grafting
CAD
coronary artery disease
CALLA
common ALL antigen
CAPD
chronic ambulatory peritoneal
dialysis
CBC
complete blood count
CBD
common bile duct
CCB
calcium channel blocker
CCl4
carbon tetrachloride
CCP
cyclic citrullinated peptide
CCS
Canadian Cardiovascular
Society
CCY
cholecystectomy
CD
Crohn‚Äôs disease
CEA
carcinoembryonic antigen
carotid endarterectomy
ceph.
cephalosporin
CF
cystic fibrosis
Cftx
ceftriaxone
CFU
colony forming units
CHB
complete heart block
CHD
congenital heart disease
CHF
congestive heart failure
ABBREVIATIONS
ABBREV
11-1

--- Fim da P√°gina 251 ---

ABBREV
11-2
CI
cardiac index
CIAKI
contrast-induced acute kidney
injury
CIDP
chronic inflammatory
demyelinating polyneuropathy
CK
creatine kinase
CKD
chronic kidney disease
CLL
chronic lymphocytic leukemia
CMC
carpalmetacarpal (joint)
CML
chronic myelogenous leukemia
CMML
chronic myelomonocytic
leukemia
CMP
cardiomyopathy
CMV
cytomegalovirus
CN
cranial nerve
CO
carbon monoxide
cardiac output
COP
cryptogenic organizing 
pneumonia
COPD
chronic obstructive pulmonary
disease
COX
cyclooxygenase
CP
chest pain
CPAP
continuous positive airway
pressure
CPP
cerebral perfusion pressure
CPPD
calcium pyrophosphate 
dihydrate
Cr
creatinine
CRC
colorectal cancer
CrCl
creatinine clearance
CRP
C-reactive protein
CRT
cardiac resynchronization therapy
CsA
cyclosporine A
CSF
cerebrospinal fluid
CSM
carotid sinus massage
CT
computed tomogram
CTA
CT angiogram
CTD
connective tissue disease
CV
cardiovascular
CVA
cerebrovascular accident
CVD
cerebrovascular disease
collagen vascular disease
CVID
common variable 
immunodeficiency
CVP
central venous pressure
CVVH
continuous veno-venous
hemofiltration
CW
chest wall
cx
culture
CXR
chest radiograph
d
day
D
death
d/c
discharge
discontinue
MS
change in mental status
DA
dopamine
DAD
diffuse alveolar damage
DAH
diffuse alveolar hemorrhage 
DAT
direct antiglobulin test
DBP
diastolic blood pressure
DCIS
ductal carcinoma in situ
DCMP
dilated cardiomyopathy
Ddx
differential diagnosis
DES
drug-eluting stent
DFA
direct fluorescent antigen
detection
DI
diabetes insipidus
DIC
disseminated intravascular
coagulation
diff.
differential
DIP
desquamative interstitial
pneumonitis
distal interphalangeal (joint)
DKA
diabetic ketoacidosis
DLCO
diffusion capacity of the lung
DLE
drug induced lupus
DM
dermatomyositis
diabetes mellitus
DMARD
disease-modifying anti-rheumatic
drug
DOE
dyspnea on exertion
DRE
digital rectal exam
DSE
dobutamine stress echo
DTRs
deep tendon reflexes
DU
duodenal ulcer
DVT
deep vein thrombosis
dx
diagnosis
EAD
extreme axis deviation
EAV
effective arterial volume
EBV
Epstein-Barr virus
ECG
electrocardiogram
echo
echocardiogram
ECMO
extracorporeal membrane
oxygenation
ED
emergency department
EDP
end-diastolic pressure
EDV
end-diastolic volume
EEG
electroencephalogram
EF
ejection fraction
EGD
esophagogastroduodenoscopy
EGFR
epidermal growth factor receptor
EI
entry inhibitor
EIA
enzyme-linked immunoassay
ELISA
enzyme-linked immunosorbent
assay
EM
electron microscopy
EMB
ethambutol
ENT
ears, nose, & throat
EOM
extraocular movement/muscles
EP
electrophysiology
Epo
erythropoietin
EPS
electrophysiology study
ERCP
endoscopic retrograde
cholangiopancreatography
ERV
expiratory reserve volume
ESP
end-systolic pressure
ESR
erythrocyte sedimentation rate
ESRD
end-stage renal disease
ESV
end-systolic volume
ET
endotracheal tube
essential thrombocythemia
EtOH
alcohol
ETT
endotracheal tube
exercise tolerance test
EUS
endoscopic ultrasound
EVAR
endovascular aneurysm repair
FDP
fibrin degradation product
FEV1
forced expiratory volume in 
1 second
FFP
fresh frozen plasma
FHx
family history
FI
fusion inhibitor
FMD
fibromuscular dysplasia
FMF
familial Mediterranean fever
FNA
fine needle aspiration
FOB
fecal occult blood
FOBT
fecal occult blood testing
FQ
fluoroquinolone

--- Fim da P√°gina 252 ---

ABBREV
11-3
FRC
functional residual capacity
FSGS
focal segmental 
glomerulosclerosis
FSH
follicle stimulating hormone
FTI
free thyroxine index
FUO
fever of unknown origin
FVC
forced vital capacity
G6PD
glucose-6-phosphate 
dehydrogenase
GB
gallbladder
GBM
glomerular basement membrane
GBS
Guillain-Barr√© syndrome
GCA
giant cell arteritis
GCS
Glasgow coma scale
G-CSF
granulocyte colony stimulating
factor
GE
gastroesophageal
gen.
generation
GERD
gastroesophageal reflux disease
GFR
glomerular filtration rate
GGT
-glutamyl transpeptidase
GH
growth hormone
GIB
gastrointestinal bleed
GIST
gastrointestinal stromal tumor
glc
glucose
GN
glomerulonephritis
GNR
gram-negative rods
GnRH
gonadotropin-releasing hormone
GPC
gram-positive cocci
GPI
glycoprotein IIb/IIIa inhibitor
GRA
glucocorticoid-remediable
aldosteronism
GU
gastric ulcer
GVHD
graft-versus-host disease
h
hour
H2RA
H2-receptor antagonist
h/o
history of
HA
headache
HAV
hepatitis A virus
Hb
hemoglobin
HBIG
hepatitis B immunoglobulin
HBV
hepatitis B virus
HCC
hepatocellular carcinoma
HCMP
hypertrophic cardiomyopathy
Hct
hematocrit
HCV
hepatitis C virus
HCW
health care worker
HD
hemodialysis
HDL
high-density lipoprotein
HDV
hepatitis D virus
HELLP
hemolysis, abnormal LFTs, low
platelets
HEV
hepatitis E virus
HF
heart failure
HGPRT
hypoxanthine-guanine 
phosphoribosyl transferase
HHS
hyperosmolar hyperglycemic state
HIT
heparin-induced 
thrombocytopenia
HK
hypokinesis
HL
Hodgkin lymphoma
HoTN
hypotension
hpf
high power field
HPT
hyperparathyroidism
HR
heart rate
HRT
hormone replacement therapy
HS
hereditary spherocytosis
HSCT
hematopoietic stem cell
transplantation
HSM
hepatosplenomegaly
HSP
Henoch-Sch√∂nlein purpura
HSV
herpes simplex virus
HTN
hypertension
HUS
hemolytic uremic syndrome
I&D
incision & drainage
IABP
intraaortic balloon pump
IBD
inflammatory bowel disease
IC
inspiratory capacity
ICa
ionized calcium
ICD
implantable cardiac defibrillator
ICH
intracranial hemorrhage
ICP
intracranial pressure
ICU
intensive care unit
IE
infective endocarditis
IGF
insulin-like growth factor
IGRA
interferon- release assay
II
integrase inhibitor
IIP
idiopathic interstitial pneumonia
ILD
interstitial lung disease
IMI
inferior myocardial infarction
infxn
infection
inh
inhaled
INH
isoniazid
INR
international normalized ratio
IPF
idiopathic pulmonary fibrosis
ITP
idiopathic thrombocytopenic
purpura
IVB
intravenous bolus
IVC
inferior vena cava
IVDU
intravenous drug use(r)
IVF
intravenous fluids
IVIg
intravenous immunoglobulin
JVD
jugular venous distention
JVP
jugular venous pulse
LA
left atrium
long-acting
lupus anticoagulant
LABA
long-acting 2-agonist
LAD
left anterior descending 
coronary artery
left axis deviation
LAE
left atrial enlargement
LAN
lymphadenopathy
LAP
leukocyte alkaline phosphatase
LAP
left atrial pressure
LBBB
left bundle branch block
LCA
left coronary artery
LCIS
lobular carcinoma in situ
LCx
left circumflex coronary artery
LDH
lactate dehydrogenase
LDL
low-density lipoprotein
LE
lower extremity
LES
lower esophageal sphincter
LFTs
liver function tests
LGIB
lower gastrointestinal bleed
LH
luteinizing hormone
LLQ
left lower quadrant
LM
left main coronary artery
LMWH
low-molecular-weight heparin
LN
lymph node
LOC
loss of consciousness
LOS
length of stay
LP
lumbar puncture
lpf
low power field
LR
lactated Ringer‚Äôs
LQTS
long QT syndrome
LUSB
left upper sternal border

--- Fim da P√°gina 253 ---

ABBREV
11-4
LV
left ventricle
LVAD
LV assist device
LVEDP
LV end-diastolic pressure
LVEDV
LV end-diastolic volume
LVH
left ventricular hypertrophy
LVOT
left ventricular outflow tract
LVSD
LV systolic dimension
MAC
mitral annular calcification
Mycobacterium avium complex
MAHA
microangiopathic hemolytic
anemia
MAO
monoamine oxidase
MAP
mean arterial pressure
MAT
multifocal atrial tachycardia
MCD
minimal change disease
MCP
metacarpal phalangeal (joint)
MCTD
mixed connective tissue disease
MCV
mean corpuscular volume
MDI
metered dose inhaler
MDMA
3,4-methylenedioxymetham-
phetamine (Ecstasy)
MDS
myelodysplastic syndrome
MEN
multiple endocrine neoplasia
MG
myasthenia gravis
MGUS
monoclonal gammopathy of
uncertain significance
MI
myocardial infarction
min
minute
min.
minimal
MM
multiple myeloma
MMEFR
maximal mid-expiratory flow
rate
MMF
mycophenolate mofetil
MN
membranous nephropathy
MNZ
metronidazole
mod.
moderate
MODS
multiple organ dysfunction
syndrome
mos
months
MPN
myeloproliferative neoplasm
MPGN
membranoproliferative
glomerulonephritis
MR
magnetic resonance
mitral regurgitation
MRA
magnetic resonance angiography
MRCP
magnetic resonance cholan-
giopancreatography
MRI
magnetic resonance imaging
MRSA
methicillin-resistant S. aureus
MS
mitral stenosis
MTb
Mycobacterium tuberculosis
MTP
metatarsal phalangeal (joint)
MTX
methotrexate
MV
mitral valve
MVA
mitral valve area
MVP
mitral valve prolapse
MVR
mitral valve replacement
M
macrophage
N/V
nausea and/or vomiting
NAC
N-acetylcysteine
NAFLD
non-alcoholic fatty liver disease
NASH
non-alcoholic steatohepatitis
NG
nasogastric
NGT
nasogastric tube
NHL
Non-Hodgkin lymphoma
NIF
negative inspiratory force
NJ
nasojejunal
nl
normal
NM
neuromuscular
NMJ
neuromuscular junction
NNRTI
non-nucleoside reverse 
transcriptase inhibitor
NNT
number needed to treat
NO
nitric oxide
NPJT
nonparoxysmal junctional
tachycardia
NPO
nothing by mouth
NPV
negative predictive value
NS
normal saline
NSAID
nonsteroidal anti-inflammatory
drug
NSCLC
non-small cell lung cancer
NYHA
New York Heart Association
NPPV
noninvasive positive pressure
ventilation
NRTI
nucleoside reverse transcriptase
inhibitor
NSF
nephrogenic systemic fibrosis
NTG
nitroglycerin
NUD
nonulcer dyspepsia
NVE
native valve endocarditis
O/D
overdose
o/w
otherwise
OA
osteoarthritis
OCP
oral contraceptive pill
OG
osmolal gap
OGT
orogastric tube
OGTT
oral glucose tolerance test
OI
opportunistic infection
OM
obtuse marginal coronary artery
OSA
obstructive sleep apnea
OTC
over-the-counter
p/w
present(s) with
PA
pulmonary artery
PAC
pulmonary artery catheter
PAD
peripheral arterial disease
PAN
polyarteritis nodosa
PASP
pulmonary artery systolic
pressure
PAV
percutaneous aortic valvuloplasty
pb
problem
PBC
primary biliary cirrhosis
PCI
percutaneous coronary 
intervention
PCN
penicillin
PCP
Pneumocystis jiroveci pneumonia
PCR
polymerase chain reaction
PCT
porphyria cutanea tarda
PCWP
pulmonary capillary wedge
pressure
PD
Parkinson‚Äôs disease
peritoneal dialysis
PDA
patent ductus arteriosus
posterior descending coronary
artery
PE
pulmonary embolism
PEA
pulseless electrical activity
PEEP
positive end-expiratory pressure
PEF
peak expiratory flow 
PET
positron emission 
tomography
PEx
physical examination
PFO
patent foramen ovale
PFT
pulmonary function test
PGA
polyglandular autoimmune
syndrome
PHT
pulmonary hypertension
PI
protease inhibitor

--- Fim da P√°gina 254 ---

ABBREV
11-5
PID
pelvic inflammatory disease
PIF
prolactin inhibitory factor
PIP
peak inspiratory pressure
proximal interphalangeal (joint)
PKD
polycystic kidney disease
PM
polymyositis
PMF
primary myelofibrosis
PMHx
past medical history
PMI
point of maximal impulse
PML
progressive multifocal
leukoencephalopathy
PMN
polymorphonuclear leukocyte
PMV
percutaneous mitral 
valvuloplasty
PMVT
polymorphic ventricular
tachycardia
PNA
pneumonia
PND
paroxysmal nocturnal dyspnea
PNH
paroxysmal nocturnal 
hemoglobinuria
PMR
polymyalgia rheumatica
PO
oral intake
POBA
plain old balloon angioplasty
POTS
postural orthostatic 
tachycardia syndrome
PPD
purified protein derivative
PPH
primary pulmonary 
hypertension
PPI
proton pump inhibitors
Pplat
plateau pressure
PPM
permanent pacemaker
PPV
positive predictive value
Ppx
prophylaxis
PR
PR segment on ECG
pulmonary regurgitation
PRBCs
packed red blood cells
PRL
prolactin
PRPP
phosphoribosyl-1- 
pyrophosphate
PRWP
poor R wave progression
PS
pressure support
pulmonic stenosis
PSA
prostate specific antigen
PSC
primary sclerosing cholangitis
PSGN
post streptococcal 
glomerulonephritis
PSHx
past surgical history
PSV
pressure support ventilation
Pt
patient
PT
prothrombin time
PTA
percutaneous transluminal
angioplasty
PTH
parathyroid hormone
PTH-rP
parathyroid hormone-related
peptide
PTT
partial thromboplastin time
PTU
propylthiouracil
PTX
pneumothorax
PUD
peptic ulcer disease
PUVA
psoralen + ultraviolet A 
PV
polycythemia vera
portal vein
PVD
peripheral vascular disease
PVE
prosthetic valve endocarditis
PVR
pulmonary vascular resistance
PZA
pyrazinamide
qac
before every meal
qhs
every bedtime
QoL
quality of life
Qw
Q wave
r/i
rule in
r/o
rule out
RA
refractory anemia
rheumatoid arthritis
right atrium
RAD
right axis deviation
RAE
right atrial enlargement
RAI
radioactive iodine
RAIU
radioactive iodine uptake
RAS
renal artery stenosis
RBBB
right bundle branch block
RBC
red blood cell
RBF
renal blood flow
RCA
right coronary artery
RCMP
restrictive cardiomyopathy
RCT
randomized controlled trial
RDW
red cell distribution width
RE
reticuloendothelial
RF
rheumatoid factor
risk factor
RHD
rheumatic heart disease
RI
reticulocyte index
RIBA
recombinant immunoblot assay
RMSF
Rocky Mountain spotted fever
ROS
review of systems
RPGN
rapidly progressive
glomerulonephritis
RR
respiratory rate
RRT
renal replacement therapy
RT
radiation therapy
RTA
renal tubular acidosis
RUQ
right upper quadrant
RUSB
right upper sternal border
RV
residual volume
right ventricle
RVAD
RV assist device
RVH
right ventricular hypertrophy
RVOT
RV outflow tract
RVSP
RV systolic pressure
Rx
therapy
s/e
side effect
s/p
status post
s/s
signs and symptoms
SA
sinoatrial
SAAG
serum-ascites albumin gradient
SAH
subarachnoid hemorrhage
SAS
sulfasalazine
SBE
subacute bacterial endocarditis
SBP
spontaneous bacterial 
peritonitis
systolic blood pressure
SBT
spontaneous breathing trial
SC
subcutaneous
SCD
sudden cardiac death
SCID
severe combined 
immunodeficiency
SCLC
small cell lung cancer
Se
sensitivity
sec
second
SERM
selective estrogen receptor
modulator
sev.
severe
SIADH
syndrome of inappropriate
antidiuretic hormone
SIEP
serum immunoelectrophoresis
SIMV
synchronized intermittent
mandatory ventilation
SLE
systemic lupus erythematosus
SMA
superior mesenteric artery
SMV
superior mesenteric vein

--- Fim da P√°gina 255 ---

ABBREV
11-6
SOS
sinusoidal obstructive syndrome
Sp
specificity
SPEP
serum protein electrophoresis
SR
sinus rhythm
SSCY
Salmonella, Shigella,
Campylobacter, Yersinia
SSRI
selective serotonin reuptake
inhibitor
SSS
sick sinus syndrome
ST
sinus tachycardia
STD
sexually transmitted disease
ST-segment depression
STE
ST-segment elevation
SV
stroke volume
SVC
superior vena cava
SVR
systemic vascular resistance
SVT
supraventricular tachycardia
sx
symptom(s) or symptomatic
T1D
type 1 diabetes mellitus
T2D
type 2 diabetes mellitus
T3RU
T3 resin uptake
TAA
thoracic aortic aneurysm
TB
tuberculosis
TBG
thyroid binding globulin
TCA
tricyclic antidepressant
TCD
transcranial Doppler
TCN
tetracycline
TdP
torsades de pointes
TdT
terminal deoxynucleotidyl
transferase
TEE
transesophageal echo
TFTs
thyroid function tests
TG
triglycerides
TGA
transposition of the great
arteries
TIA
transient ischemic attack
TIBC
total iron binding capacity
TINU
tubulointerstitial nephritis and
uveitis
TIPS
transjugular intrahepatic 
portosystemic shunt
TLC
total lung capacity
Tn
troponin
TP
total protein
TPN
total parenteral nutrition
Tpo
thrombopoietin
TPO
thyroid peroxidase
TR
tricuspid regurgitation
TRALI
transfusion-related acute lung
injury
TRH
thyrotropin releasing hormone
TRS
TIMI risk score
TRUS
transrectal ultrasound
TS
tricuspid stenosis
TSH
thyroid stimulating hormone
TSI
thyroid-stimulating
immunoglobulin
TSS
toxic shock syndrome
transsphenoidal surgery
TTE
transthoracic echo
TTKG
transtubular potassium gradient
TTP
thrombotic thrombocy-topenic
purpura
TV
tricuspid valve
Tw
T wave
TWF
T-wave flattening
TWI
T-wave inversion
Tx
transplant
TZD
thiazolidinediones
U/A
urinalysis
U/S
ultrasound
UA
unstable angina
uric acid
UAG
urine anion gap
UC
ulcerative colitis
UCx
urine culture
UES
upper esophageal sphincter
UFH
unfractionated heparin
UGIB
upper gastrointestinal bleed
UIP
usual interstitial pneumonitis
ULN
upper limit of normal
UOP
urine output
UPEP
urine protein electrophoresis
UR
urgent revascularization
URI
upper respiratory tract 
infection
UTI
urinary tract infection
V/Q
ventilation-perfusion
VAD
ventricular assist device
VAP
ventilator-associated pneumonia
VATS
video-assisted thoracoscopic
surgery
VBI
vertebrobasilar insufficiency
VC
vital capacity
VD
vessel disease
VDRL
venereal disease research
laboratory (test for syphilis)
VEGF
vascular endothelial growth
factor
VF
ventricular fibrillation
VLDL
very-low-density 
lipoproteins
VOD
veno-occlusive disease
VSD
ventricular septal defect
VT
tidal volume
VT
ventricular tachycardia
VTE
venous thromboembolus
vWD
von Willebrand‚Äôs disease
vWF
von Willebrand‚Äôs factor
VZV
varicella zoster virus
w/
with
w/o
without
w/u
workup
WBC
white blood cell (count)
WCT
wide-complex tachycardia
WHO
World Health Organization
wk
week
WM
Waldenstr√∂m‚Äôs
macroglobulinemia
WMA
wall motion abnormality
WPW
Wolff-Parkinson-White 
syndrome
XRT
radiation therapy

--- Fim da P√°gina 256 ---

A
A-a gradient, 2-18, 10-8
abdominal CT scan, P-7
alpha1-antitrypsin deficiency
as cause of cirrhosis, 3-24
as cause of COPD, 2-5
acanthosis nigricans, 5-28
accessory pathway, 1-33
acetaminophen
hepatotoxicity, 3-19, 10-9
as cause of metabolic acidosis, 4-2
achalasia, 3-1
acid-base disturbances, 4-1
acquired immunodeficiency syndrome
(AIDS), 6-17
acromegaly, 7-2
activated protein C
resistance, 5-11
therapy, 2-23
acute coronary syndromes, 1-6
acute interstitial nephritis, 4-12
acute interstitial pneumonia, 2-10
acute kidney injury, 4-12
acute respiratory distress syndrome
(ARDS), 2-22
acute tubular necrosis, 4-12
Addison‚Äôs disease, 7-9
adrenal disorders, 7-7
adrenal incidentalomas, 7-10
adrenal insufficiency, 7-9
adrenal mass, 7-10
advanced cardiac life support, 10-1
alcohol withdrawal, 9-5
allergic bronchopulmonary aspergillosis,
2-10
alveolar gas equation, 10-8
amaurosis fugax, 9-6
amiodarone and thyroid disease, 7-5
amyloidosis, 8-22
cardiac manifestations, 1-19
anaplasmosis, 6-22
anemia, 5-1
aplastic, 5-3
autoimmune hemolytic, 5-5, P-13
of chronic inflammation, 5-2
Cooley‚Äôs, 5-1
Fanconi‚Äôs, 5-3
folate deficiency, 5-3
hemolytic, 5-4
iron deficiency, 5-1, P-13
macrocytic, 5-3, P-13
megaloblastic, 5-3
microangiopathic hemolytic, 5-5
microcytic, 5-1
myelophthisic, 5-4
normocytic, 5-2
pernicious, 5-3
sickle cell, 5-4, P-14
sideroblastic, 5-2
angina, 1-6
angiodysplasia, 3-3
angioplasty, 1-5
anion gap, 4-2, 10-9
ankylosing spondylitis, 8-7
anoxic brain injury, 9-2
antibiotics, 10-6
antibodies
anticardiolipin, 5-11, 8-15
anti-CCP, 8-3
anti-centromere, 8-11
anti-citrullinated peptide (ACPA), 8-3
anti-ds-DNA, 8-15
anti-GBM, 4-16
antihistone, 8-16
anti-Jo-1, 8-13
anti-La, 8-14, 8-16
anti-Mi-2, 8-13
anti-mitochondrial, 3-24
anti-MPO, 8-18, 4-16
antineutrophil cytoplasmic (ANCA),
8-18, 4-16
antinuclear (ANA), 8-16
antiphospholipid, 5-11
anti-PR3, 4-16, 8-18
anti-Ro, 8-14, 8-16
anti-saccharomyces cerevisiae
(ASCA), 3-11
anti-Scl-70, 8-11
anti-Sm, 8-16
anti-smooth muscle, 3-19
anti-TPO, 7-15
anti-U1-RNP, 8-14, 8-16
in connective tissue diseases, 8-11
anticoagulants, 5-10, 5-6
anti-GBM disease, as cause of
glomerulonephritis, 4-16
antiphospholipid syndrome, 5-11
aortic aneurysm, 1-30
aortic dissection, 1-31
aortic insufficiency, 1-21
aortic stenosis, 1-20
aortoenteric fistula, 3-3
arrhythmogenic RV cardiomyopathy, 1-34
arthritis, 8-1
enteropathic, 8-8
infectious, 8-9
mutilans, 8-8
osteoarthritis, 8-2
psoriatic, 8-8
reactive, 8-7
rheumatoid, 8-3
asbestosis, 2-10
ascites, 3-26
treatment of in cirrhotics, 3-21
aspergillus, 6-3
asthma, 2-2
atrial fibrillation, 1-32, 1-35
atrial flutter, 1-32
auto-PEEP, 2-20
AV block, 1-32
AV dissociation, 1-32
B
babesiosis, 6-22
back pain, 9-11
bacteremia, 6-14
INDEX
INDEX
I-1

--- Fim da P√°gina 257 ---

INDEX
I-2
Barrett‚Äôs esophagitis, 3-2
Bartter‚Äôs syndrome, 4-5, 4-10, 7-8
basophilia, 5-12
basophilic stippling, 10-10
Beck‚Äôs triad, 1-26
Behcet‚Äôs syndrome, 8-20
Bell‚Äôs palsy, 6-11
Bernard-Soulier disease, 5-9
berylliosis, 2-10
bilevel positive airway pressure (BiPAP),
2-20
biliary tract disease, 3-27
bite cells, 5-4, 10-10
biventricular pacing, 1-16, 1-39
blastomycosis, 6-3
body surface area, 10-11
Boerhaave syndrome, 1-3
bone infections, 6-6
bone marrow transplantation, 5-26
bradycardia, 1-32, 10-3
breast cancer, 5-30
Brockenbrough sign, 1-18
bronchiectasis, 2-1
bronchiolitis obliterans with organizing
pneumonia, 2-10
bronchitis, chronic, 2-5
Brudzinski‚Äôs sign, 6-9
Brugada syndrome, 1-34
B-type natriuretic peptide, 2-1, 1-14
Budd-Chiari syndrome, 3-25
bundle branch blocks, 1-1
burr cells, 10-10
bursitis, 8-1, 8-10
C
calciphylaxis, 7-11
calcium disorders, 7-11
calcium pyrophosphate dihydrate
deposition disease, 8-6
cancer of unknown primary site, 5-38
Candida infections, 6-3
Caplan‚Äôs syndrome, 8-3
carbon monoxide poisoning, 2-18
cardiac output, 1-12, 10-7
cardiac resynchronization therapy,
1-16, 1-39
cardiomyopathy, 1-17
dilated, 1-17
hypertrophic, 1-18
restrictive, 1-19
vs constrictive pericarditis, 1-27
Takotsubo, 1-17
cardioversion, 10-2
carotid revascularization, 9-7
cauda equina syndrome, 9-11
celiac disease, 3-6
cellulitis, 6-6
cerebrovascular disease, 9-6
Chagas, 1-17
Charcot‚Äôs triad, 3-28
Chediak-Higashi syndrome, 5-9
chest pain, 1-3
Child-Turcotte-Pugh scoring system,
3-23
cholangitis, 3-28
cholecystitis, 3-27
choledocholithiasis, 3-28
cholelithiasis, 3-27
cholestasis, 3-15
cholesterol emboli syndrome, 1-5
chronic kidney disease, 4-13
chronic obstructive pulmonary disease
(COPD), 2-5, P-1
Churg-Strauss syndrome, 8-19
as cause of asthma, 2-2
as cause of glomerulonephritis, 4-16
as cause of interstitial lung disease,
2-10
Chvostek‚Äôs sign, 7-12
cirrhosis, 3-21
claudication, neurogenic vs. vascular, 9-12
clostridial myonecrosis, 6-7
Clostridium difficile diarrhea, 3-6
coagulation cascade, 5-6
coagulopathies, 5-10
coarctation of aorta, 1-28
coccidioidomycosis, 6-3
cold calorics, 9-1
colonoscopy, screening, 5-33
colorectal cancer, 5-33
coma, 9-1
computed tomography angiography,
1-4
confusion, 9-1
connective tissue diseases, 8-11
Conn‚Äôs syndrome, 7-8
constipation, 3-8
constrictive pericarditis, 1-27
continuous positive airway pressure
(CPAP), 2-19, 2-20
continuous veno-venous hemofiltration,
4-15
contrast-induced acute kidney injury,
4-12
conus medullaris syndrome, 9-11
cord compression, 5-36, 9-11
corneal acrus, 7-16
coronary angiography, 1-5
coronary arteries, P-13
coronary artery bypass grafting
(CABG), 1-5
coronary artery calcium score, 1-4
coronary revascularization, 1-5
Courvoisier‚Äôs sign, 5-35
creatinine clearance, 10-9
CREST syndrome, 8-12
Crohn‚Äôs disease, 3-10
cryoglobulinemia, 8-21
Cryptococcus, 6-4
cryptogenic organizing pneumonia,
2-10
crystal deposition arthritides, 8-5
Cullen‚Äôs sign, 3-13
Cushing‚Äôs reflex, 3-20
Cushing‚Äôs syndrome, 7-7
cutaneous leukocytoclastic angiitis,
8-20
CXR/chest CT, 10-8, P-1
cyanide poisoning, 2-18
cystic fibrosis, 2-1
cystitis, 6-5
cytomegalovirus, 6-20

--- Fim da P√°gina 258 ---

INDEX
I-3
D
dactylitis, 8-7
decerebrate posturing, 9-1
decorticate posturing, 9-1
deep venous thrombosis, 2-13
delirium, 9-1
delirium tremens, 9-5
delta-delta, 4-2, 10-9
dermatomyositis, 8-12
desquamative interstitial pneumonia, 2-10
diabetes insipidus, 4-8, 4-9
diabetes mellitus, 7-13
diabetic foot, 6-6
diabetic ketoacidosis (DKA), 7-14
dialysis, 4-15
diarrhea, 3-5
Dieulafoy‚Äôs lesion, 3-3
diffuse alveolar damage, 2-22
diffuse alveolar hemorrhage, 2-10, 5-27
disc herniation, 9-12
discriminant function, 3-19
disseminated gonococcal arthritis
(DGI), 8-10
disseminated intravascular coagulation
(DIC), 5-10
diuresis, 4-14
diverticular disease, 3-9
Dohle bodies, 10-10
doll‚Äôs eyes, 9-1
Dressler‚Äôs syndrome, 1-11, 1-25
Duke treadmill score, 1-4
duodenal ulcer, 3-2
dyslipidemias, 7-16
dyspepsia, 3-2
dysphagia, 3-1
dyspnea, 2-1
dysuria, 6-5
E
Eaton-Lambert syndrome, 5-28, 9-9
echocardiography, P-9
Ehlers-Danlos syndrome, 1-31
ehrlichiosis, 6-22
electrocardiography, 1-1
encephalitis, viral, 6-11
endocarditis, 6-12
endomyocardial fibrosis, 1-19
enthesitis, 8-7
eosinophilia, 5-12
eosinophilic pneumonias, 2-10
epidural abscess, 6-8
epilepsy, 9-3
erisypelas, 6-6
erythema migrans, 6-21
erythema nodosum, 2-9, 8-20
erythrocyte sedimentation rate,
8-17
erythromelalgia, 5-15
esophageal reflux, 3-1
esophageal ring, 3-1
esophageal spasm, 1-3
esophageal web, 3-1
esophagitis, 3-1, 3-3
essential thrombocythemia, 5-15
ethylene glycol intoxication, 4-2
exercise tolerance test, 1-4
F
factor V Leiden, 5-11
familial adenomatous polyposis, 5-33
familial hypocalciuric hypercalcemia,
7-11
familial Mediterranean fever, 6-23
Fanconi‚Äôs syndrome, 4-3
Felty‚Äôs syndrome, 8-3
fever
neutropenia and, 5-36
of unknown origin (FUO), 6-23
Pel-Ebstein, 5-21
fibromyalgia, 8-13
Fitz-Hugh-Curtis syndrome, 8-10
focal segmental glomerulosclerosis,
4-17
folate deficiency, 5-3
folliculitis, 6-6
Forrester class, 1-11
Fournier‚Äôs gangrene, 6-7
fractional excretion of Na, 4-12, 10-9
free H2O deficit, 4-8, 10-9
fungal infections, 6-3
furunculosis, 6-6
G
Gaisb√∂ck‚Äôs syndrome, 5-15
Gallavardin effect, 1-20
gallstone ileus, 3-27
gallstones, 3-27
gas gangrene, 6-7
gastric antral vascular ectasia, 3-3
gastric ulcer, 3-2
gastritis, 3-3
gastroesophageal reflux disease
(GERD), 3-1
gastrointestinal bleeding, 3-3
giant cell arteritis, 8-17
Gitelman‚Äôs syndrome, 4-5, 4-10, 7-8
Glanzmann‚Äôs thromboasthenia, 5-9
Glasgow Coma Scale, 9-1
glomerulonephritis, 4-16
glucagonoma
as cause of diabetes mellitus, 7-13
as cause of diarrhea, 3-7
glucose-6-phosphate dehydrogenase
(G6PD) deficiency, 5-4
glycemic control, in critical care, 2-23
goiter, 7-4
Goodpasture‚Äôs syndrome
as cause of alveolar hemorrhage, 2-10
as cause of glomerulonephritis, 4-16
Gottron‚Äôs papules, 8-13
gout, 8-5
graft-versus-host disease (GVHD), 5-27
Graves‚Äô disease, 7-4
Grey Turner‚Äôs sign, 3-13
Guillain-Barr√© syndrome, 9-8
H
Hamman-Rich syndrome, 2-10
Hashimoto‚Äôs thyroiditis, 7-4
headache, 9-10
heart failure, 1-14
with preserved EF, 1-16
heart valve anatomy, 1-24

--- Fim da P√°gina 259 ---

INDEX
I-4
Heinz bodies, 5-4, 10-10
Helicobacter pylori infection, 3-2
heliotrope rash, 8-13
hematemesis, 3-3
hematochezia, 3-3
hematopoietic stem cell transplantation,
5-26
hematuria, 4-19
hemochromatosis
as cause of cirrhosis, 3-23
as cause of DCMP, 1-17
as cause of RCMP, 1-19
hemodialysis, 4-15
hemolytic-uremic syndrome, 5-9
hemophilia, 5-10
hemoptysis, 2-7
Henoch-Sch√∂nlein purpura, 8-19
as cause of glomerulonephritis, 4-16
heparin-induced thrombocytopenia, 5-8
heparin nomograms, 10-10
hepatic encephalopathy, 3-22
hepatic hydrothorax, 2-11, 3-21
hepatitis, 3-17
alcoholic, 3-19
autoimmune, 3-19
ischemic, 3-19
viral, 3-17
hepatocellular carcinoma, 3-22
hepatopulmonary syndrome, 3-22
hepatorenal syndrome, 3-22
hereditary nonpolyposis colorectal
cancer, 5-33
hereditary spherocytosis, 5-5
Hermansky-Pudlak syndrome, 5-9
herpes zoster, 6-11
histoplasmosis, 6-3
homeostasis disorders, 5-7
Howell-Jolly bodies, 10-10
human immunodeficiency virus (HIV),
6-17
hyperaldosteronism, 7-8
as cause of hypokalemia, 4-10
as cause of metabolic alkalosis, 4-4
hyperbilirubinemia, 3-16
hypercalcemia, 7-11
hypercapnia, 2-18
hypercholesterolemia, 7-16
hypercoagulable states, 5-11
hypercortisolism, 7-7
hyperhomocysteinemia, 5-11
hyperkalemia, 4-11
hypernatremia, 4-8
hyperosmolar hyperglycemic state, 7-15
hyperparathyroidism, 7-11
secondary, 4-14
hyperpituitary syndrome, 7-2
hyperprolactinemia, 7-2
hypersensitivity pneumonia, 2-10
hypersensitivity vasculitis, 8-20
hypersplenism, 5-5
hypertension, 1-28
hypertensive crisis, 1-29
hyperthyroidism, 7-4
hypertriglyceridemia, 7-16
hypertrophic pulmonary
osteoarthropathy, 5-28
hypoaldosteronism, 7-9
as cause of hyperkalemia, 4-11
as cause of metabolic acidosis, 4-3
hypocalcemia, 7-12
hypoglycemia, 7-15
hypokalemia, 4-10
hyponatremia, 4-6
hypoparathyroidism, 7-12
hypopituitary syndromes, 7-1
hypothermia, induced, 9-2
hypothyroidism, 7-4
hypoxemia, 2-18
I
ICU medications, 10-4
ideal body weight, 10-11
idiopathic interstitial pneumonia, 2-10
idiopathic pulmonary fibrosis, 2-10
idiopathic pulmonary hemosiderosis, 2-10
IgA nephropathy, 4-17
ileus, 3-8
immune thrombocytopenic purpura, 5-7
impetigo, 6-6
implantable cardiac defibrillator, 1-16,
1-39
inclusion body myositis, 8-12
infections in susceptible hosts, 6-4
inflammatory bowel disease, 3-10
influenza, 6-2
interstitial lung disease, 2-9
intracerebral hemorrhage, 9-7
intraductal papillary mucinous
neoplasm, 5-35
intramural hematoma (aortic), 1-31
iron deficiency, 5-1
irritable bowel syndrome (IBS), 3-7
ischemic colitis, 3-12
isopropyl glycol intoxication, 4-3
J
Janeway lesions, 6-12
jaundice, 3-15
Jod-Basedow effect, 7-6
K
Kaposi‚Äôs sarcoma, 6-20
Kernig‚Äôs sign, 6-9
ketoacidosis, 4-2
Killip class, 1-11
koilonychia, 5-2
Kussmaul‚Äôs sign, 1-27
L
lactic acidosis, 4-2
lactose intolerance, 3-6
Langerhans cell granulomatosis, 2-10
left ventricular thrombus, 1-11
leukemia, 5-17, P-14
acute lymphoblastic, 5-18
acute myelogenous, 5-17
acute promyelocytic, 5-18
chronic lymphocytic, 5-20
chronic myelogenous, 5-19
hairy cell, 5-22
leukostasis, 5-17
Libman-Sacks endocarditis, 8-15

--- Fim da P√°gina 260 ---

INDEX
I-5
Liddle‚Äôs syndrome, 4-5, 4-10, 7-8
Light‚Äôs criteria, 2-11
lipodystrophy, 6-20
liver failure, 3-20
liver tests, abnormal, 3-15
liver transplantation, 3-23
Loeys-Dietz syndrome, 1-31
L√∂ffler‚Äôs endocarditis, 1-19
L√∂ffler‚Äôs syndrome, 2-10
L√∂fgren‚Äôs syndrome, 2-9
long QT syndrome, 1-34
lung cancer, 5-28
lupus anticoagulant, 5-11
lupus pernio, 2-9
Lyme disease, 6-21
lymphadenopathy, 5-12
lymphocytic interstitial pneumonia,
2-10
lymphocytosis, 5-12
lymphoma, 5-21
CNS, 6-20
Hodgkin, 5-21
non-Hodgkin‚Äôs, 5-21
M
macro-ovalocytes, 5-3
malabsorption, 3-6
Mallory-Weiss tear, 3-3
mammography, 5-30
Marfan syndrome, 1-31
mechanical ventilation, 2-19
mechanic‚Äôs hands, 8-13
Meckel‚Äôs diverticulum, 3-4
Meig‚Äôs syndrome, 2-11, 3-26
MELD score, 3-23
melena, 3-3
membranous nephropathy, 4-17
meningitis
acute bacterial, 6-9
aseptic, 6-10
mental status, change in, 9-1
mesenteric ischemia, 3-12
metabolic acidosis, 4-2
metabolic alkalosis, 4-4
metabolic syndrome, 7-16
methanol intoxication, 4-2
methemoglobinemia, 2-18
microangiopathic hemolytic anemia,
5-5
microscopic polyangiitis, 8-19
as cause of interstitial lung disease,
2-10
as cause of glomerulonephritis, 4-16
migraine headache, 9-10
milk-alkali syndrome, 7-11
minimal change disease, 4-17
Mirizzi‚Äôs syndrome, 3-27
mitral regurgitation, 1-22
mitral stenosis, 1-22
mitral valve prolapse, 1-23
mixed connective tissue disease
(MCTD), 8-14
molluscum contagiosum, 6-19
monoclonal gammopathy of uncertain
significance, 5-25
monocytosis, 5-12
mucinous cystic neoplasm of pancreas,
5-35
Mucor infection, 6-3
multiple endocrine neoplasia (MEN)
syndromes, 7-2
multiple myeloma, 5-24
murmurs, eponymous
Austin Flint, 1-21
Graham Steel, 2-14
Murphy‚Äôs sign, 3-27
myalgias, 8-13
myasthenia gravis, 9-9
Mycobacterium avium complex,
disseminated, 6-20
mycosis fungoides, 5-22
myelodysplastic syndromes, 5-14
myelofibrosis, primary, 5-16
myeloid neoplasms, 5-14
myeloproliferative neoplasms, 5-15
myocardial infarction (MI)
non ST elevation, 1-7
ST elevation, 1-9
myocardial viability, 1-4
myocarditis, 1-17, 1-3
myopathies, 8-12, 9-9
myositides, 8-13
myxedema, 7-4
N
necrotizing fasciitis, 6-7
nephrogenic systemic fibrosis, 4-12
nephrolithiasis, 4-19
nephrotic syndrome, 4-17
nerve root compression, 9-11
neuropathies, 9-8
neutropenia, 5-36, 6-4
neutropenic enterocolitis, 5-36
neutrophilia, 5-12
New York Heart Association
classification, 1-14
nonalcoholic fatty liver disease
(NAFLD), 3-19
noninvasive ventilation, 2-20
nonspecific interstitial pneumonia,
2-10
nonulcer dyspepsia, 3-2
O
obstructive sleep apnea, 2-8
Ogilvie‚Äôs syndrome, 3-8
omega-3 fatty acids, 1-16, 7-16
oral hairy leukoplakia, 6-19
orthostatic hypotension, 1-37
Osler‚Äôs nodes, 6-12
osmolal gap, 4-3, 10-9
osteoarthritis, 8-2
osteomyelitis, 6-8
P
pacemakers, 1-39
Paget‚Äôs disease
of bone, 7-11
of breast, 5-30
Pancoast‚Äôs syndrome, 5-28
pancreatic cancer, 5-35
pancreatic insufficiency, 3-7

--- Fim da P√°gina 261 ---

INDEX
I-6
pancreatitis, 3-13
pancytopenia, 5-3
panhypopituitarism, 7-1
papillary muscle rupture, 1-10
Pappenheimer bodies, 5-2
paracentesis, 3-26
paroxysmal nocturnal syndromes, 5-4
patent foramen ovale, 9-7
Pel-Ebstein fever, 5-10
peptic ulcer disease (PUD), 1-3, 3-2
percutaneous coronary intervention
(PCI), 1-5
pericardial effusion, 1-25
pericardial tamponade, 1-26
pericarditis, 1-25
period paralysis
hyperkalemic, 4-11
hypokalemic, 4-10
peripheral smear, findings in, 10-10
peritoneal dialysis, 4-15
peritonitis, 3-26
petechiae, 5-6
pheochromocytoma, 7-10
phlegmasia cerulean dolens, 2-13
pica, 5-1
pituitary disorders, 7-1
pituitary tumors, 7-2
plasma cell dyscrasias, 5-24
platelet disorders, 5-7
pleural effusion, 2-11, P-4
pleuritis, 1-3
Plummer-Vinson syndrome, 5-1
pneumoconioses, 2-10
Pneumocystis jiroveci pneumonia, 6-19
pneumocystis, 2-10
pneumonia, 6-1, P-2
pneumothorax, P-4
POEMS syndrome, 5-24
polyarteritis nodosa, 8-17
polycythemia vera, 5-15
polydipsia, 4-9
polyglandular autoimmune (PGA)
syndromes, 7-2
polymyalgia rheumatica, 8-17, 8-13
polymyositis, 8-12
polyuria, 4-9
porphyria cutanea tarda, 3-18
portal hypertension, 3-21
portal vein thrombosis (PVT), 3-25
portopulmonary hypertension, 3-22, 2-16
portosystemic encephalopathy, 3-22
Pott‚Äôs disease, 6-8, 6-15
preexcitation, 1-33
preoperative risk assessment, 1-40
prerenal azotemia, 4-12
primary biliary cirrhosis, 3-24
primary sclerosing cholangitis, 3-24
Prinzmetal‚Äôs angina, 1-6
progressive multifocal
leukencephalopathy, 6-20
prolactinoma, 7-2
propylene glycol intoxication, 4-2
prostate cancer, 5-32
prostatitis, 6-5
prostate-specific antigen (PSA) testing,
5-32 
prosthetic heart valves, 1-24
proteinuria, 4-18
prothrombin mutation, 5-11
pseudogout, 8-6
pseudo-hypoparathyroidism, 7-12
pseudo-Pelger-Hu√´t cells, 5-14, 10-10
pseudotumor cerebri, 9-10
pulmonary alveolar proteinosis, 2-10
pulmonary artery catheter, 1-12, 10-7
pulmonary edema
CXR pattern in, 10-8, P-2
treatment of, 1-15, 10-3
pulmonary embolism, 2-13, P-6
pulmonary function tests, 2-1
pulmonary hypertension, 2-16
pulsus paradoxus, 1-26
pure red cell aplasia, 5-2
purified protein derivative (PPD) test,
6-15
purpura, 5-6
pyelonephritis, 6-5
pyoderma gangrenosum, 8-8, 3-10
Q
QT interval, 1-1
R
radiculopathies, 9-11
radioactive iodine uptake scan, 7-3
Raynaud‚Äôs phenomenon, 8-14
Reed-Sternberg cells, 5-21
Reiter‚Äôs syndrome, 8-7
relapsing polychondritis, 8-4
renal abscess, 6-5
renal artery stenosis, 1-28
renal failure, 4-12
renal osteodystrophy, 7-12
renal tubular acidosis, 4-3
respiratory acidosis, 4-5
respiratory alkalosis, 4-5
respiratory bronchiolitis-associated
interstitial lung disease, 2-10
respiratory failure, 2-18
reticulocyte index, 5-1
Reynold‚Äôs pentad, 3-28
rheumatoid factor, 8-3
Rhizopus infection, 6-3
Richter‚Äôs syndrome, 5-20
Rocky Mountain spotted tick fever, 6-22
Roth spots, 6-12
S
salicylate intoxication, 4-2
Samter‚Äôs syndrome, 2-2
sarcoidosis, 2-19, P-6
cardiac manifestations of, 1-19
schistocytes, 5-5, 10-10, P-14
sciatica, 9-12
scleroderma, 8-11
seizures, 9-3
sepsis, 2-23
seronegative spondyloarthritis, 8-7
serum-ascites albumin gradient,
3-26
S√©zary syndrome, 5-22
Sheehan‚Äôs syndrome, 7-1

--- Fim da P√°gina 262 ---

INDEX
I-7
shock, 1-13, 10-4
cardiogenic, 1-13
septic, 2-23
sicca syndrome, 8-13
sick euthyroid syndrome, 7-5
sick sinus syndrome, 1-32
silicosis, 2-10
sinusoidal obstruction syndrome, 3-25,
5-27
Sj√∂grens‚Äôs syndrome, 8-13
smudge cells, 5-20
soft tissue infections, 6-6
solitary pulmonary nodule, 2-7
spinal cord compression, 5-36, 9-11
spinal stenosis, 9-12
splenomegaly, 5-5
spontaneous bacterial peritonitis,
3-26
treatment of in cirrhosis, 3-22
spur cells, 10-10, P-14
statistics, 10-11
status epilepticus, 9-4
stent thrombosis, 1-5
steroids, in critical care, 2-23
Still‚Äôs disease, 6-23
stool osmotic gap, 3-7
stress test, 1-4
stroke, 9-6
struma ovarii, 7-4
subarachnoid hemorrhage, 9-7
superior vena cava syndrome, 5-28
syncope, 1-37
syndrome of inappropriate antidiuretic
hormone (SIADH), 4-7
systemic lupus erythematosus (SLE),
8-15
systemic sclerosis, 8-11
T
tachycardias, 1-32, 10-2
atrial, 1-32
atrioventricular reciprocating, 1-32,
1-34
AV nodal reentrant, 1-32
multifocal atrial, 1-32
nonparoxysmal junctional, 1-32
SA node reentrant, 1-32
sinus, 1-32
supraventricular, 1-32
ventricular, 1-34
wide-complex, 1-34
Takayasu‚Äôs arteritis, 8-17
target cells, 10-10
tear drop cells, 5-16, 10-10, P-14
temporal arteritis, 8-17
thalassemias, 5-1
thrombocytopenia, 5-7
thrombotic thrombocytopenic purpura,
5-9
thrush, 6-19
thyroid disorders, 7-3
thyroid function tests, 7-3
thyroiditis, 7-4, 7-5
thyroid nodules, 7-6
thyroid storm, 7-5
Todd‚Äôs paralysis, 9-3
torsades de pointes, 1-34
total body water, 10-9
toxic shock syndrome, 6-6
toxoplasmosis, 6-20
transfusion-related acute lung injury,
2-22, 5-13
transfusion therapy, 5-13
transient ischemic attack (TIA), 9-6
trans-tubular potassium gradient, 4-10,
10-9
tropical sprue, 3-7
troponin, 1-3, 1-6
Trousseau‚Äôs sign
of hypocalcemia, 7-12
of malignancy, 7-12
tuberculosis, 6-15
tularemia, 6-22
tumor lysis syndrome, 5-37
T wave inversion, 1-2
typhilitis, 5-36
U
ulcerative colitis, 3-10
ulcers, 3-2
unstable angina, 1-7
uremia, 4-13
uremic bleeding, 5-9
urethritis, 6-5
uric acid kidney stones, 4-19
urinalysis, 4-18
urinary tract infection (UTI), 6-5
urine anion gap, 4-3
urine dipstick, 4-18
urine osmolality, 4-6
urine sediment, 4-18, P-15
usual interstitial pneumonia, 2-10
uveitis, 8-7
V
varices, 3-3, 3-22
vasculitis, 8-17
veno-occlusive disease
hepatic, 3-25, 5-27
pulmonary, 2-16
venous thromboembolism (VTE), 2-13
ventricular aneurysm, 1-11
ventricular pseudoaneurysm, 1-11
ventricular septal defect, 1-10
Verner-Morrison syndrome, 3-7
Virchow‚Äôs node, 5-35
Vitamin B12 deficiency, 5-3
vitamin D deficiency, 7-12
vitamin K deficiency, 5-10
von Willebrand‚Äôs disease, 5-9
W
Waldenstr√∂m‚Äôs macroglobulinemia,
5-25
warfarin loading nomogram, 10-10
warfarin overdose, 5-10
Wegener‚Äôs granulomatosis, 8-18
as cause of interstitial lung disease,
2-10
as cause of glomerulonephritis, 4-16
Wernicke‚Äôs encephalopathy, 9-5
Whipple‚Äôs disease, 3-7

--- Fim da P√°gina 263 ---

INDEX
I-8
Wilson‚Äôs disease, 3-23
Wolff-Chaikoff effect, 7-5
Wolff-Parkinson-White syndrome,
1-33
X
xanthelasma, 7-16
xanthomas, 7-16
Y
yellow-nail syndrome, 2-11
Z
Zenker‚Äôs diverticulum, 3-1
Zollinger-Ellison syndrome, 3-2, 3-7
zoster, 6-11
zygomycetes, 6-3

--- Fim da P√°gina 264 ---

NOTES

--- Fim da P√°gina 265 ---

NOTES

--- Fim da P√°gina 266 ---

PHOTO INSERT
P-1
Radiology
2 Normal lateral CXR. (Radiology 101, 3rd ed, 2009.)
3 COPD: with hyperlucent,overinflated lungs and flat diaphragms. (Radiology 101, 3rd ed, 2009.)
1 Normal PA CXR. The convex right cardiac border is formed by the right atrium
(straight arrows), and the curved arrows indicated the location of the superior vena cava.
The left cardiac and great vessels border what might be considered as four skiing moguls.
From cephalad to caudad, the moguls are the aortic arch, the main and left pulmonary arter-
ies, the left atrial appendage, and the left ventricle. (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 267 ---

PHOTO INSERT
P-2
4 Interstitial pulmonary edema: with Kerley A, B, and C lines and cephalization of
the vascular markings. (Fund. Diag. Radiology 3rd ed, 2006.)
5 Alveolar pulmonary edema. (Fund. Diag. Radiology 3rd ed, 2006.)
6 Right upper lobe pneumonia. (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 268 ---

PHOTO INSERT
P-3
7 Right middle lobe pneumonia. (Radiology 101, 3rd ed, 2009.)
8 Right lower lobe pneumonia (PA). (Radiology 101, 3rd ed, 2009.)
9 Right lower lobe pneumonia (lateral). (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 269 ---

PHOTO INSERT
P-4
10 Bilateral pleural effusions (curved arrows) and enlarged azygous vein (straight
arrow) (PA). (Radiology 101, 3rd ed, 2009.)
11 Bilateral pleural effusions (curved arrows) (lateral). (Radiology 101, 3rd ed, 2009.)
12 Pneumothorax. (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 270 ---

PHOTO INSERT
P-5
13 Normal chest CT at level of pulmonary arteries (parenchymal windows).
(Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 271 ---

PHOTO INSERT
P-6
14 Bilateral PE (mediastinal windows). (Radiology 101, 3rd ed, 2009.)
15 Sarcoidosis with perilymphatic nodules. (Fund. Diag. Radiology 3rd ed, 2006.)
16 Idiopathic pulmonary fibrosis. (Fund. Diag. Radiology 3rd ed, 2006.)

--- Fim da P√°gina 272 ---

PHOTO INSERT
P-7
17 Normal abdomen CT at level of liver & spleen. (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 273 ---

PHOTO INSERT
P-8
18 Normal abdomen CT at level of pancreas. (Radiology 101, 3rd ed, 2009.)

--- Fim da P√°gina 274 ---

PHOTO INSERT
P-9
Echocardiography
1 Parasternal long-axis view allows visualization of the right ventricle (RV), ven-
tricular septum (VS), posterior wall (PW) aortic valve cusps, left ventricle (LV), mitral
valve, left atrium (LA), and ascending thoracic aorta (Ao). *Pulmonary artery. (Top: From
Mayo Clinic Proceedings. [Tajik AJ, Seward JB, Hagler DJ, et al.Two-dimensional real-time ultrasonic imaging of the
heart and great vessels:Technique, image orientation, structure identification, and validation. Mayo Clinic
Proceedings, 1978;53:271‚Äì303], with permission. Bottom: From Oh JK, Seward JB,Tajik AJ. The Echo Manual, 3rd ed.
Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and
Research. All rights reserved.)
Ventricular septum
Left ventricular
outflow tract
Anterior mitral
leaflet
Posterior mitral
leaflet
Left atrium
Coronary sinus
Posteromedial papillary
muscle
Right ventricle
Right coronary
cusp
Noncoronary
cusp

--- Fim da P√°gina 275 ---

PHOTO INSERT
P-10
2 Parasternal short-axis view at the level of the aorta: LA, left atrium; PV, pul-
monary valve; RA, right atrium; RVOT, right ventricular outflow tract. (Top: From Mayo Clinic
Proceedings. [Tajik AJ, Seward JB, Hagler DJ, et al.Two-dimensional real-time ultrasonic imaging of the heart and
great vessels:Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings,
1978;53:271‚Äì303], with permission. Bottom: From Oh JK, Seward JB,Tajik AJ. The Echo Manual, 3rd ed.
Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and
Research. All rights reserved.)
Anterior
tricuspid
leaflet
Right
coronary
cusp
Left coronary
artery
Left atrial
appendage
Left coronary
cusp
Left atrium
Coronary sinus
Atrial septum
Inferior
vena cava
Right coronary
artery
Right atrium
Noncoronary
cusp
Right ventricular
outflow tract
Pulmonary
valve

--- Fim da P√°gina 276 ---

PHOTO INSERT
P-11
3 Parasternal short-axis view at the level of the papillary muscles: AL, an-
terolateral papillary muscle; PM, posteromedial papillary muscle; RV, right ventricle;
VS, ventricular septum; LV, left ventricle. (Top: From Mayo Clinic Proceedings. [Tajik AJ, Seward JB,
Hagler DJ, et al.Two-dimensional real-time ultrasonic imaging of the heart and great vessels:Technique, image
orientation, structure identification, and validation. Mayo Clinic Proceedings, 1978;53:271‚Äì303], with permission.
Bottom: From Oh JK, Seward JB,Tajik AJ. The Echo Manual, 3rd ed. Philadelphia: Lippincott Williams & Wilkins,
2006. By permission of Mayo Foundation for Medical Education and Research. All rights reserved.)
Anterolateral
free wall
Left ventricle
Anterolateral
papillary
muscle
Posteromedial papillary
muscle
Posterolateral
wall
Ventricular
septum
Right ventricle

--- Fim da P√°gina 277 ---

PHOTO INSERT
P-12
4 Apical four-chamber view: Note that at some institutions the image is re-
versed so that the left side of the heart appears on the right side of the screen. LA,
left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (Top: From Mayo Clinic
Proceedings. [Tajik AJ, Seward JB, Hagler DJ, et al.Two-dimensional real-time ultrasonic imaging of the heart and
great vessels:Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings,
1978;53:271‚Äì303], with permission. Bottom: From Oh JK, Seward JB,Tajik AJ. The Echo Manual, 3rd ed. Philadelphia:
Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and Research.
All rights reserved.)
Papillary muscles: Left ventricle
Posteromedial
Anterolateral
Posterolateral
wall
Anterior
Posterior
Left atrium
Pulmonary veins
Atrial
septum
Inferior
vena cava
Right atrium
Posterior
Anterior
Septal
Tricuspid valve
leaflets:
Right ventricle
Ventricular septum
Right ventricular
wall
Mitral valve leaflets:

--- Fim da P√°gina 278 ---

PHOTO INSERT
P-13
Peripheral Blood Smears
1 Normal smear.
2 Hypochromic, microcytic anemia due
to iron-deficiency.
Coronary Angiography
LEFT CORONARY ARTERY
LAO
1. Left anterior descending artery (LAD)
2. Ramus medianus artery
3. Diagonal branches
4. Septal branches
5. Left circumflex artery (LCx)
6. Left atrial circumflex artery
7. Obtuse marginal branches
1. Conus artery
2. SA node artery
3. Acute marginal branches
4. Posterior descending artery (PDA)
5. AV node artery
6. Posterior left ventricular artery (PLV)
LAO
RAO
RAO
1
1
2
1
2
2
2
3
3
3
3
4
4
4
4
5
5
5
6
6
6
6
6
6
6
7
7
RIGHT CORONARY ARTERY
Coronary arteries. (From Grossman WG. Cardiac Catheterization and Angiography,
4th ed. Philadelphia: Lea & Febiger, 1991, with permission.)
3 Macrocytic anemia due to pernicious
anemia; note macro-ovalocytes 
and hypersegmented neutrophils.
4 Spherocytes due to 
autoimmune hemolytic anemia.

--- Fim da P√°gina 279 ---

PHOTO INSERT
P-14
9 Nucleated RBC.
10 Rouleaux.
5 Sickle cell anemia.
6 Schistocytes.
7 Teardrop shaped RBC (dacrocyte).
8 Acanthocytes.
1 AML with Auer rod.
2 ALL.
Leukemias

--- Fim da P√°gina 280 ---

PHOTO INSERT
P-15
3 CML.
4 CLL.
All photos excluding Leukemias Fig. 4: From Wintrobe‚Äôs Clin. Hematol. 12th ed, 2009:
Leukemias Fig. 4 From Devita, Hellman, and Rosenberg‚Äôs Cancer: Princip. & Prac. of
Oncol. 8th ed, 2008.
3 RBC cast. (Dis. of Kidney & Urinary Tract,
8th ed, 2006.)
4 WBC cast. (Clin. Lab. Medicine, 2nd ed,
2002.)
Urinalysis
1 Granular cast. (College of Am. Pathologist,
with permission.)
2 Hyaline cast. (Clin.Lab.Medicine,2nd ed,
2002.)

--- Fim da P√°gina 281 ---


--- Fim da P√°gina 282 ---

